--
-- PostgreSQL database dump
--

SET statement_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = off;
SET check_function_bodies = false;
SET client_min_messages = warning;
SET escape_string_warning = off;

SET search_path = drugs, pg_catalog;

--
-- Name: clinical_effects_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('clinical_effects_pk_seq', 16, true);


--
-- Name: disease_code_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('disease_code_pk_seq', 1, false);


--
-- Name: evidence_levels_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('evidence_levels_pk_seq', 7, true);


--
-- Name: flags_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('flags_pk_seq', 5, true);


--
-- Name: info_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('info_pk_seq', 1, false);


--
-- Name: manufacturer_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('manufacturer_pk_seq', 187, true);


--
-- Name: patient_categories_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('patient_categories_pk_seq', 9, true);


--
-- Name: pharmacologic_mechanisms_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('pharmacologic_mechanisms_pk_seq', 8, true);


--
-- Name: product_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('product_pk_seq', 2342, true);


--
-- Name: severity_level_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('severity_level_pk_seq', 5, true);


--
-- Name: sources_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('sources_pk_seq', 5, true);


--
-- Name: topic_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('topic_pk_seq', 9, true);


--
-- Name: units_pk_seq; Type: SEQUENCE SET; Schema: drugs; Owner: ian
--

SELECT pg_catalog.setval('units_pk_seq', 19, true);


--
-- Data for Name: atc; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY atc (atccode, name) FROM stdin;
C04AF	Enzymes
C10AB	Fibrates
D08AL30	Silver
G01AX02	Inosine
J07CA10	Typhoid - hepatitis A
N02BE	Anilides
N05AN	Lithium
V08AA10	Diodone
A	Alimentary tract and metabolism
A01	Stomatological preparations
A01A	Stomatological preparations
A01AA	Caries prophylactic agents
A01AA01	Sodium fluoride
A01AA02	Sodium monofluorophosphate
A01AA03	Olaflur
A01AA04	Stannous fluoride
A01AA30	Combinations
A01AA51	Sodium fluoride, combinations
A01AB	Antiinfectives and antiseptics for local oral treatment
A01AB02	Hydrogen peroxide
A01AB03	Chlorhexidine
A01AB04	Amphotericin
A01AB05	Polynoxylin
A01AB06	Domiphen
A01AB07	Oxyquinoline
A01AB08	Neomycin
A01AB09	Miconazole
A01AB10	Natamycin
A01AB11	Various
A01AB12	Hexetidine
A01AB13	Tetracycline
A01AB14	Benzoxonium chloride
A01AB15	Tibezonium iodide
A01AB16	Mepartricin
A01AB17	Metronidazole
A01AB18	Clotrimazole
A01AB19	Sodium perborate
A01AB21	Chlortetracycline
A01AB22	Doxycycline
A01AB23	Minocycline
A01AC	Corticosteroids for local oral treatment
A01AC01	Triamcinolone
A01AC02	Dexamethasone
A01AC03	Hydrocortisone
A01AC54	Prednisolone, combinations
A01AD	Other agents for local oral treatment
A01AD01	Epinephrine
A01AD02	Benzydamine
A01AD05	Acetylsalicylic acid
A01AD06	Adrenalone
A01AD07	Amlexanox
A01AD08	Becaplermin
A01AD11	Various
A02	Drugs for acid related disorders
A02A	Antacids
A02AA	Magnesium compounds
A02AA01	Magnesium carbonate
A02AA02	Magnesium oxide
A02AA03	Magnesium peroxide
A02AA04	Magnesium hydroxide
A02AA05	Magnesium silicate
A02AA10	Combinations
A02AB	Aluminium compounds
A02AB01	Aluminium hydroxide
A02AB02	Algeldrate
A02AB03	Aluminium phosphate
A02AB04	Dihydroxialumini sodium carbonate
A02AB05	Aluminium acetoacetate
A02AB06	Aloglutamol
A02AB07	Aluminium glycinate
A02AB10	Combinations
A02AC	Calcium compounds
A02AC01	Calcium carbonate
A02AC02	Calcium silicate
A02AC10	Combinations
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds
A02AD01	Ordinary salt combinations
A02AD02	Magaldrate
A02AD03	Almagate
A02AD04	Hydrotalcite
A02AD05	Almasilate
A02AF	Antacids with antiflatulents
A02AF01	Magaldrate and antiflatulents
A02AF02	Ordinary salt combinations and antiflatulents
A02AG	Antacids with antispasmodics
A02AH	Antacids with sodium bicarbonate
A02AX	Antacids, other combinations
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BA	H<v>2<D>-receptor antagonists
A02BA01	Cimetidine
A02BA02	Ranitidine
A02BA03	Famotidine
A02BA04	Nizatidine
A02BA05	Niperotidine
A02BA06	Roxatidine
A02BA07	Ranitidine bismuth citrate
A02BA08	Lafutidine
A02BA51	Cimetidine, combinations
A02BA53	Famotidine, combinations
A02BB	Prostaglandins
A02BB01	Misoprostol
A02BB02	Enprostil
A02BC	Proton pump inhibitors
A02BC01	Omeprazole
A02BC02	Pantoprazole
A02BC03	Lansoprazole
A02BC04	Rabeprazole
A02BC05	Esomeprazole
A02BD	Combinations for eradication of Helicobacter pylori
A02BD01	Omeprazole, amoxicillin and metronidazole
A02BD02	Lansoprazole, tetracycline and metronidazole
A02BD03	Lansoprazole, amoxicillin and metronidazole
A02BD04	Pantoprazole, amoxicillin and clarithromycin
A02BD05	Omeprazole, amoxicillin and clarithromycin
A02BD06	Esomeprazole, amoxicillin and clarithromycin
A02BD07	Lansoprazole, amoxicillin and clarithromycin
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BX01	Carbenoxolone
A02BX02	Sucralfate
A02BX03	Pirenzepine
A02BX04	Methiosulfonium chloride
A02BX05	Bismuth subcitrate
A02BX06	Proglumide
A02BX07	Gefarnate
A02BX08	Sulglicotide
A02BX09	Acetoxolone
A02BX10	Zolimidine
A02BX11	Troxipide
A02BX12	Bismuth subnitrate
A02BX13	Alginic acid
A02BX51	Carbenoxolone, combinations excl. psycholeptics
A02BX71	Carbenoxolone, combinations with psycholeptics
A02BX77	Gefarnate, combinations with psycholeptics
A02DA	Antiflatulents
A02X	Other drugs for acid related disorders
A03	Drugs for functional gastrointestinal disorders
A03A	Drugs for functional bowel disorders
A03AA	Synthetic anticholinergics, esters with tertiary amino group
A03AA01	Oxyphencyclimine
A03AA03	Camylofin
A03AA04	Mebeverine
A03AA05	Trimebutine
A03AA06	Rociverine
A03AA07	Dicycloverine
A03AA08	Dihexyverine
A03AA09	Difemerine
A03AA30	Piperidolate
A03AB	Synthetic anticholinergics, quaternary ammonium compounds
A03AB01	Benzilone
A03AB02	Glycopyrronium
A03AB03	Oxyphenonium
A03AB04	Penthienate
A03AB05	Propantheline
A03AB06	Otilonium bromide
A03AB07	Methantheline
A03AB08	Tridihexethyl
A03AB09	Isopropamide
A03AB10	Hexocyclium
A03AB11	Poldine
A03AB12	Mepenzolate
A03AB13	Bevonium
A03AB14	Pipenzolate
A03AB15	Diphemanil
A03AB16	(2-benzhydryloxyethyl)diethylmethylammonium iodide
A03AB17	Tiemonium iodide
A03AB18	Prifinium bromide
A03AB19	Timepidium bromide
A03AB21	Fenpiverinium
A03AB53	Oxyphenonium, combinations
A03AC	Synthetic antispasmodics, amides with tertiary amines
A03AC02	Dimethylaminopropionylphenothiazine
A03AC04	Nicofetamide
A03AC05	Tiropramide
A03AD	Papaverine and derivatives
A03AD01	Papaverine
A03AD02	Drotaverine
A03AD30	Moxaverine
A03AE	Drugs acting on serotonin receptors
A03AE01	Alosetron
A03AE02	Tegaserod
A03AE03	Cilansetron
A03AE04	Prucalopride
A03AX	Other drugs for functional bowel disorders
A03AX01	Fenpiprane
A03AX02	Diisopromine
A03AX03	Chlorbenzoxamine
A03AX04	Pinaverium
A03AX05	Fenoverine
A03AX06	Idanpramine
A03AX07	Proxazole
A03AX08	Alverine
A03AX09	Trepibutone
A03AX10	Isometheptene
A03AX11	Caroverine
A03AX12	Phloroglucinol
A03AX13	Silicones
A03AX30	Trimethyldiphenylpropylamine
A03AX58	Alverine, combinations
A03B	Belladonna and derivatives, plain
A03BA	Belladonna alkaloids, tertiary amines
A03BA01	Atropine
A03BA03	Hyoscyamine
A03BA04	Belladonna total alkaloids
A03BB	Belladonna alkaloids semisynthetic, quaternary ammonium compounds
A03BB01	Butylscopolamine
A03BB02	Methylatropine
A03BB03	Methylscopolamine
A03BB04	Fentonium
A03BB05	Cimetropium bromide
A03C	Antispasmodics in combination with psycholeptics
A03CA	Synthetic anticholinergic agents in combination with psycholeptics
A03CA01	Isopropamide and psycholeptics
A03CA02	Clidinium and psycholeptics
A03CA03	Oxyphencyclimine and psycholeptics
A03CA04	Otilonium bromide and psycholeptics
A03CA05	Glycopyrronium and psycholeptics
A03CA06	Bevonium and psycholeptics
A03CA07	Ambutonium and psycholeptics
A03CA08	Diphemanil and psycholeptics
A03CA30	Emepronium and psycholeptics
A03CA34	Propantheline and psycholeptics
A03CB	Belladonna and derivatives in combination with psycholeptics
A03CB01	Methylscopolamine and psycholeptics
A03CB02	Belladonna total alkaloids and psycholeptics
A03CB03	Atropine and psycholeptics
A03CB04	Methylhomatropine and psycholeptics
A03CB31	Hyoscyamine and psycholeptics
A03CC	Other antispasmodics in combination with psycholeptics
A03D	Antispasmodics in combination with analgesics
A03DA	Synthetic anticholinergic agents in combination with analgesics
A03DA01	Tropenzilone and analgesics
A03DA02	Pitofenone and analgesics
A03DA03	Bevonium and analgesics
A03DA04	Ciclonium and analgesics
A03DA05	Camylofin and analgesics
A03DA06	Trospium and analgesics
A03DA07	Tiemonium iodide and analgesics
A03DB	Belladonna and derivatives in combination with analgesics
A03DB04	Butylscopolamine and analgesics
A03DC	Other antispasmodics in combination with analgesics
A03E	Antispasmodics and anticholinergics in combination with other drugs
A03EA	Antispasmodics, psycholeptics and analgesics in combination
A03ED	Antispasmodics in combination with other drugs
A03F	Propulsives
A03FA	Propulsives
A03FA01	Metoclopramide
A03FA02	Cisapride
A03FA03	Domperidone
A03FA04	Bromopride
A03FA05	Alizapride
A03FA06	Clebopride
A04	Antiemetics and antinauseants
A04A	Antiemetics and antinauseants
A04AA	Serotonin (5HT<v>3<D>) antagonists
A04AA01	Ondansetron
A04AA02	Granisetron
A04AA03	Tropisetron
A04AA04	Dolasetron
A04AA05	Palonosetron
A04AD	Other antiemetics
A04AD01	Scopolamine
A04AD02	Cerium oxalate
A04AD04	Chlorobutanol
A04AD05	Metopimazine
A04AD10	Dronabinol
A04AD11	Nabilone
A04AD12	Aprepitant
A04AD13	Casopitant
A04AD51	Scopolamine, combinations
A04AD54	Chlorobutanol, combinations
A05	Bile and liver Therapy
A05A	Bile therapy
A05AA	Bile acid preparations
A05AA01	Chenodeoxycholic acid
A05AA02	Ursodeoxycholic acid
A05AA03	Cholic acid
A05AB	Preparations for biliary tract therapy
A05AB01	Nicotinyl methylamide
A05AX	Other drugs for bile therapy
A05AX01	Piprozolin
A05AX02	Hymecromone
A05AX03	Cyclobutyrol
A05B	Liver therapy, lipotropics
A05BA	Liver therapy
A05BA01	Arginine glutamate
A05BA03	Silymarin
A05BA04	Citiolone
A05BA05	Epomediol
A05BA06	Ornithine oxoglurate
A05BA07	Tidiacic arginine
A05BA08	Glycyrrhizic acid
A05C	Drugs for bile therapy and lipotropics in combination
A06	Laxatives
A06A	Laxatives
A06AA	Softeners, emollients
A06AA01	Liquid paraffin
A06AA02	Docusate sodium
A06AA51	Liquid paraffin, combinations
A06AB	Contact laxatives
A06AB01	Oxyphenisatine
A06AB02	Bisacodyl
A06AB03	Dantron
A06AB04	Phenolphthalein
A06AB05	Castor oil
A06AB06	Senna glycosides
A06AB07	Cascara
A06AB08	Sodium picosulfate
A06AB09	Bisoxatin
A06AB20	Contact laxatives in combination
A06AB30	Contact laxatives in combination with belladonna alkaloids
A06AB52	Bisacodyl, combinations
A06AB53	Dantron, combinations
A06AB56	Senna glycosides, combinations
A06AB57	Cascara, combinations
A06AB58	Sodium picosulfate, combinations
A06AC	Bulk producers
A06AC01	Ispaghula (psylla seeds)
A06AC02	Ethulose
A06AC03	Sterculia
A06AC05	Linseed
A06AC06	Methylcellulose
A06AC07	Triticum (wheat fibre)
A06AC08	Polycarbophil calcium
A06AC51	Ispaghula, combinations
A06AC53	Sterculia, combinations
A06AC55	Linseed, combinations
A06AD	Osmotically acting laxatives
A06AD01	Magnesium carbonate
A06AD02	Magnesium oxide
A06AD03	Magnesium peroxide
A06AD04	Magnesium sulfate
A06AD10	Mineral salts in combination
A06AD11	Lactulose
A06AD12	Lactitol
A06AD13	Sodium sulfate
A06AD14	Pentaerythrityl
A06AD15	Macrogol
A06AD16	Mannitol
A06AD17	Sodium phosphate
A06AD18	Sorbitol
A06AD19	Magnesium citrate
A06AD21	Sodium tartrate
A06AD61	Lactulose, combinations
A06AD65	Macrogol, combinations
A06AG	Enemas
A06AG01	Sodium phosphate
A06AG02	Bisacodyl
A06AG03	Dantron, incl. combinations
A06AG04	Glycerol
A06AG06	Oil
A06AG07	Sorbitol
A06AG10	Docusate sodium, incl. combinations
A06AG11	Laurilsulfate, incl. combinations
A06AG20	Combinations
A06AH	Peripheral opioid receptor antagonists
A06AH01	Methylnaltrexone bromide
A06AH02	Alvimopan
A06AX	Other laxatives
A06AX01	Glycerol
A06AX02	Carbon dioxide producing drugs
A06AX03	Lubiprostone
A07	Antidiarrheals, intestinal antiinflammatory/ antiinfective agents
A07A	Intestinal antiinfectives
A07AA	Antibiotics
A07AA01	Neomycin
A07AA02	Nystatin
A07AA03	Natamycin
A07AA04	Streptomycin
A07AA05	Polymyxin B
A07AA06	Paromomycin
A07AA07	Amphotericin
A07AA08	Kanamycin
A07AA09	Vancomycin
A07AA10	Colistin
A07AA11	Rifaximin
A07AA51	Neomycin, combinations
A07AA54	Streptomycin, combinations
A07AB	Sulfonamides
A07AB02	Phthalylsulfathiazole
A07AB03	Sulfaguanidine
A07AB04	Succinylsulfathiazole
A07AC	Imidazole derivatives
A07AC01	Miconazole
A07AX	Other intestinal antiinfectives
A07AX01	Broxyquinoline
A07AX02	Acetarsol
A07AX03	Nifuroxazide
A07AX04	Nifurzide
A07B	Intestinal adsorbents
A07BA	Charcoal preparations
A07BA01	Medicinal charcoal
A07BA51	Medicinal charcoal, combinations
A07BB	Bismuth preparations
A07BC	Other intestinal adsorbents
A07BC01	Pectin
A07BC02	Kaolin
A07BC03	Crospovidone
A07BC04	Attapulgite
A07BC05	Diosmectite
A07BC30	Combinations
A07BC54	Attapulgite, combinations
A07C	Electrolytes with carbohydrates
A07CA	Oral rehydration salt formulations
A07D	Antipropulsives
A07DA	Antipropulsives
A07DA01	Diphenoxylate
A07DA02	Opium
A07DA03	Loperamide
A07DA04	Difenoxin
A07DA05	Loperamide oxide
A07DA52	Morphine, combinations
A07DA53	Loperamide, combinations
A07E	Intestinal antiinflammatory agents
A07EA	Corticosteroids acting locally
A07EA01	Prednisolone
A07EA02	Hydrocortisone
A07EA03	Prednisone
A07EA04	Betamethasone
A07EA05	Tixocortol
A07EA06	Budesonide
A07EA07	Beclometasone
A07EB	Antiallergic agents, excl. corticosteroids
A07EB01	Cromoglicic acid
A07EC	Aminosalicylic acid and similar agents
A07EC01	Sulfasalazine
A07EC02	Mesalazine
A07EC03	Olsalazine
A07EC04	Balsalazide
A07F	Antidiarrheal microorganisms
A07FA	Antidiarrheal microorganisms
A07FA01	Lactic acid producing organisms
A07FA02	Saccharmomyces boulardii
A07FA51	Lactic acid producing organisms, combinations
A07X	Other antidiarrheals
A07XA	Other antidiarrheals
A07XA01	Albumin tannate
A07XA02	Ceratonia
A07XA03	Calcium compounds
A07XA04	Acetorphan
A07XA51	Albumin tannate, combinations
A08	Antiobesity preparations, excl. diet products
A08A	Antiobesity preparations, excl. diet products
A08AA	Centrally acting antiobesity products
A08AA01	Phentermine
A08AA02	Fenfluramine
A08AA03	Amfepramone
A08AA04	Dexfenfluramine
A08AA05	Mazindol
A08AA06	Etilamfetamine
A08AA07	Cathine
A08AA08	Clobenzorex
A08AA09	Mefenorex
A08AA10	Sibutramine
A08AA56	Ephedrine, combinations
A08AB	Peripherally acting antiobesity products
A08AB01	Orlistat
A08AX	Other antiobesity drugs
A08AX01	Rimonabant
A09	Digestives, incl. enzymes
A09A	Digestives, incl. enzymes
A09AA	Enzyme preparations
A09AA01	Diastase
A09AA02	Multienzymes (lipase, protease etc.)
A09AA03	Pepsin
A09AA04	Tilactase
A09AB	Acid preparations
A09AB01	Glutamic acid hydrochloride
A09AB02	Betaine hydrochloride
A09AB03	Hydrochloric acid
A09AB04	Citric acid
A09AC	Enzyme and acid preparations, combinations
A09AC01	Pepsin and acid preparations
A09AC02	Multienzymes and acid preparations
A10	Drugs used in diabetes
A10A	Insulins and analogues
A10AB	Insulins and analogues for injection, fast-acting
A10AB01	Insulin (human)
A10AB02	Insulin (beef)
A10AB03	Insulin (pork)
A10AB04	Insulin lispro
A10AB05	Insulin aspart
A10AB06	Insulin glulisine
A10AB30	Combinations
A10AC	Insulins and analogues for injection, intermediate-acting
A10AC01	Insulin (human)
A10AC02	Insulin (beef)
A10AC03	Insulin (pork)
A10AC04	Insulin lispro
A10AC30	Combinations
A10AD	Insulins and analogues for injection, intermediate-acting combined with fast-acting
A10AD01	Insulin (human)
A10AD02	Insulin (beef)
A10AD03	Insulin (pork)
A10AD04	Insulin lispro
A10AD05	Insulin aspart
A10AD30	Combinations
A10AE	Insulins and analogues for injection, long-acting
A10AE01	Insulin (human)
A10AE02	Insulin (beef)
A10AE03	Insulin (pork)
A10AE04	Insulin glargine
A10AE05	Insulin detemir
A10AE30	Combinations
A10AF	Insulins and analogues, for inhalation
A10AF01	Insulin (human)
A10B	Blood glucose lowering drugs, excl. insulins
A10B E01	
A10BA	Biguanides
A10BA01	Phenformin
A10BA02	Metformin
A10BA03	Buformin
A10BB	Sulfonamides, urea derivatives
A10BB01	Glibenclamide
A10BB02	Chlorpropamide
A10BB03	Tolbutamide
A10BB04	Glibornuride
A10BB05	Tolazamide
A10BB06	Carbutamide
A10BB07	Glipizide
A10BB08	Gliquidone
A10BB09	Gliclazide
A10BB10	Metahexamide
A10BB11	Glisoxepide
A10BB12	Glimepiride
A10BB31	Acetohexamide
A10BC	Sulfonamides (heterocyclic)
A10BC01	Glymidine
A10BD	Combinations of oral blood glucose lowering drugs
A10BD01	Phenformin and sulfonamides
A10BD02	Metformin and sulfonamides
A10BD03	Metformin and rosiglitazone
A10BD04	Glimepiride and rosiglitazone
A10BD05	Metformin and pioglitazone
A10BD06	Glimepiride and pioglitazone
A10BD07	Metformin and sitagliptin
A10BD08	Metformin and vildagliptin
A10BD09	Pioglitazone and alogliptin
A10BF	Alpha glucosidase inhibitors
A10BF01	Acarbose
A10BF02	Miglitol
A10BF03	Voglibose
A10BG	Thiazolidinediones
A10BG01	Troglitazone
A10BG02	Rosiglitazone
A10BG03	Pioglitazone
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH01	Sitagliptin
A10BH02	Vildagliptin
A10BH03	Saxagliptin
A10BH04	Alogliptin
A10BX	Other blood glucose lowering drugs, excl. insulins
A10BX01	Guar gum
A10BX02	Repaglinide
A10BX03	Nateglinide
A10BX04	Exenatide
A10BX05	Pramlintide
A10BX06	Benfluorex
A10BX07	Liraglutide
A10BX08	Mitiglinide
A10X	Other drugs used in diabetes
A10XA	Aldose reductase inhibitors
A10XA01	Tolrestat
A11	Vitamins
A11A	Multivitamins, combinations
A11AA	Multivitamins with minerals
A11AA01	Multivitamins and iron
A11AA02	Multivitamins and calcium
A11AA03	Multivitamins and other minerals, incl. combinations
A11AA04	Multivitamins and trace elements
A11AB	Multivitamins, other combinations
A11B	Multivitamins, plain
A11BA	Multivitamins, plain
A11C	Vitamin A and D, incl. combinations of the two
A11CA	Vitamin A, plain
A11CA01	Retinol (vitamin A)
A11CA02	Betacarotene
A11CB	Vitamin A and D in combination
A11CC	Vitamin D and analogues
A11CC01	Ergocalciferol
A11CC02	Dihydrotachysterol
A11CC03	Alfacalcidol
A11CC04	Calcitriol
A11CC05	Colecalciferol
A11CC06	Calcifediol
A11CC20	Combinations
A11D	Vitamin B<v>1<D>, plain and in combination with vitamin B<v>6<D> and vitamin B<v>12<D>
A11DA	Vitamin B<v>1<D>, plain
A11DA01	Thiamine (vitamin B1)
A11DA02	Sulbutiamine
A11DA03	Benfotiamine
A11DB	Vitamin B<v>1<D> in comb. with vitamin B<v>6<D> and/or vitamin B<v>12<D>
A11E	Vitamin B-complex, incl. combinations
A11EA	Vitamin B-complex, plain
A11EB	Vitamin B-complex with vitamin C
A11EC	Vitamin B-complex with minerals
A11ED	Vitamin B-complex with anabolic steroids
A11EX	Vitamin B-complex, other combinations
A11G	Ascorbic acid (vitamin C), incl. combinations
A11GA	Ascorbic acid (vitamin C), plain
A11GA01	Ascorbic acid (vitamin C)
A11GB	Ascorbic acid (vitamin C), combinations
A11GB01	Ascorbic acid (vitamin C) and calcium
A11H	Other plain vitamin preparations
A11HA	Other plain vitamin preparations
A11HA01	Nicotinamide
A11HA02	Pyridoxine (vitamin B<v>6<D>)
A11HA03	Tocopherol (vitamin E)
A11HA04	Riboflavin (vitamin B<v>2<D>)
A11HA05	Biotin
A11HA06	Pyridoxal phosphate
A11HA07	Inositol
A11HA08	Tocofersolan
A11HA30	Dexpanthenol
A11HA31	Calcium pantothenate
A11HA32	Pantethine
A11J	Other vitamin products, combinations
A11JA	Combinations of vitamins
A11JB	Vitamins with minerals
A11JC	Vitamins, other combinations
A12	Mineral supplements
A12A	Calcium
A12AA	Calcium
A12AA01	Calcium phosphate
A12AA02	Calcium glubionate
A12AA03	Calcium gluconate
A12AA04	Calcium carbonate
A12AA05	Calcium lactate
A12AA06	Calcium lactate gluconate
A12AA07	Calcium chloride
A12AA08	Calcium glycerylphosphate
A12AA09	Calcium citrate lysine complex
A12AA10	Calcium glucoheptonate
A12AA11	Calcium pangamate
A12AA12	Calcium acetate anhydrous
A12AA20	Calcium (different salts in combination)
A12AA30	Calcium laevulate
A12AX	Calcium, combinations with other drugs
A12B	Potassium
A12BA	Potassium
A12BA01	Potassium chloride
A12BA02	Potassium citrate
A12BA03	Potassium hydrogentartrate
A12BA04	Potassium hydrogencarbonate
A12BA05	Potassium gluconate
A12BA30	Combinations
A12BA51	Potassium chloride, combinations
A12C	Other mineral supplements
A12CA	Sodium
A12CA01	Sodium chloride
A12CA02	Sodium sulfate
A12CB	Zinc
A12CB01	Zinc sulfate
A12CB02	Zinc gluconate
A12CB03	Zinc protein complex
A12CC	Magnesium
A12CC01	Magnesium chloride
A12CC02	Magnesium sulfate
A12CC03	Magnesium gluconate
A12CC04	Magnesium citrate
A12CC05	Magnesium aspartate
A12CC06	Magnesium lactate
A12CC07	Magnesium levulinate
A12CC08	Magnesium pidolate
A12CC09	Magnesium orotate
A12CC10	Magnesium oxide
A12CC30	Magnesium (different salts in combination)
A12CD	Fluoride
A12CD01	Sodium fluoride
A12CD02	Sodium monofluorophosphate
A12CD51	Fluoride, combinations
A12CE	Selenium
A12CE01	Sodium selenate
A12CE02	Sodium selenite
A12CX	Other mineral products
A13	Tonics
A13A	Tonics
A14	Anabolic agents for systemic use
A14A	Anabolic steroids
A14AA	Androstan derivatives
A14AA01	Androstanolone
A14AA02	Stanozolol
A14AA03	Metandienone
A14AA04	Metenolone
A14AA05	Oxymetholone
A14AA06	Quinbolone
A14AA07	Prasterone
A14AA08	Oxandrolone
A14AA09	Norethandrolone
A14AB	Estren derivatives
A14AB01	Nandrolone
A14AB02	Ethylestrenol
A14AB03	Oxabolone cipionate
A14B	Other anabolic agents
A15	Appetite stimulants
A16	Other alimentary tract and metabolism products
A16A	Other alimentary tract and metabolism products
A16AA	Amino acids and derivatives
A16AA01	Levocarnitine
A16AA02	Ademetionine
A16AA03	Levoglutamide
A16AA04	Mercaptamine
A16AA05	Carglumic acid
A16AA06	Betaine
A16AB	Enzymes
A16AB01	Alglucerase
A16AB02	Imiglucerase
A16AB03	Agalsidase alfa
A16AB04	Agalsidase beta
A16AB05	Laronidase
A16AB06	Sacrosidase
A16AB07	Alglucosidase alfa
A16AB08	Galsulfase
A16AB09	Idursulfase
A16AX	Various alimentary tract and metabolism products
A16AX01	Tioctic acid
A16AX02	Anethole trithione
A16AX03	Sodium phenylbutyrate
A16AX04	Nitisinone
A16AX05	Zinc acetate
A16AX06	Miglustat
A16AX07	Sapropterin
B	Blood and blood forming organs
B01	Antithrombotic agents
B01A	Antithrombotic agents
B01AA	Vitamin K antagonists
B01AA01	Dicoumarol
B01AA02	Phenindione
B01AA03	Warfarin
B01AA04	Phenprocoumon
B01AA07	Acenocoumarol
B01AA08	Ethyl biscoumacetate
B01AA09	Clorindione
B01AA10	Diphenadione
B01AA11	Tioclomarol
B01AB	Heparin group
B01AB01	Heparin
B01AB02	Antithrombin III
B01AB04	Dalteparin
B01AB05	Enoxaparin
B01AB06	Nadroparin
B01AB07	Parnaparin
B01AB08	Reviparin
B01AB09	Danaparoid
B01AB10	Tinzaparin
B01AB11	Sulodexide
B01AB12	Bemiparin
B01AB51	Heparin, combinations
B01AC	Platelet aggregation inhibitors excl. heparin
B01AC01	Ditazole
B01AC02	Cloricromen
B01AC03	Picotamide
B01AC04	Clopidogrel
B01AC05	Ticlopidine
B01AC06	Acetylsalicylic acid
B01AC07	Dipyridamole
B01AC08	Carbasalate calcium
B01AC09	Epoprostenol
B01AC10	Indobufen
B01AC11	Iloprost
B01AC13	Abciximab
B01AC15	Aloxiprin
B01AC16	Eptifibatide
B01AC17	Tirofiban
B01AC18	Triflusal
B01AC19	Beraprost
B01AC21	Treprostinil
B01AC22	Prasugrel
B01AC30	Combinations
B01AD	Enzymes
B01AD01	Streptokinase
B01AD02	Alteplase
B01AD03	Anistreplase
B01AD04	Urokinase
B01AD05	Fibrinolysin
B01AD06	Brinase
B01AD07	Reteplase
B01AD08	Saruplase
B01AD09	Ancrod
B01AD10	Drotrecogin alfa
B01AD11	Tenecteplase
B01AD12	Protein C
B01AE	Direct thrombin inhibitors
B01AE01	Desirudin
B01AE02	Lepirudin
B01AE03	Argatroban
B01AE04	Melagatran
B01AE05	Ximelagatran
B01AE06	Bivalirudin
B01AE07	Dabigatran etexilate
B01AX	Other antithrombotic agents
B01AX01	Defibrotide
B01AX04	Dermatan sulfate
B01AX05	Fondaparinux
B01AX06	Rivaroxaban
B02	Antihemorrhagics
B02A	Antifibrinolytics
B02AA	Amino acids
B02AA01	Aminocaproic acid
B02AA02	Tranexamic acid
B02AA03	Aminomethylbenzoic acid
B02AB	Proteinase inhibitors
B02AB01	Aprotinin
B02AB02	Alfa<v>1<D> antitrypsin
B02AB03	C1-inhibitor
B02AB04	Camostat
B02B	Vitamin K and other hemostatics
B02BA	Vitamin K
B02BA01	Phytomenadione
B02BA02	Menadione
B02BB	Fibrinogen
B02BB01	Human fibrinogen
B02BC	Local hemostatics
B02BC01	Absorbable gelatin sponge
B02BC02	Oxidized cellulose
B02BC03	Tetragalacturonic acid hydroxymethylester
B02BC05	Adrenalone
B02BC06	Thrombin
B02BC07	Collagen
B02BC08	Calcium alginate
B02BC09	Epinephrine
B02BC10	Fibrinogen, human
B02BC30	Combinations
B02BD	Blood coagulation factors
B02BD01	Coagulation factor IX, II, VII and X in combination
B02BD02	Coagulation factor VIII
B02BD03	Factor VIII inhibitor bypassing activity
B02BD04	Coagulation factor IX
B02BD05	Coagulation factor VII
B02BD06	Von Willebrand factor and coagulation factor VIII in combination
B02BD07	Coagulation factor XIII
B02BD08	Eptacog alfa (activated)
B02BD09	Nonacog alfa
B02BD30	Thrombin
B02BX	Other systemic hemostatics
B02BX01	Etamsylate
B02BX02	Carbazochrome
B02BX03	Batroxobin
B02BX04	Romiplostim
B02BX05	Eltrombopag
B03	Antianemic preparations
B03A	Iron preparations
B03AA	Iron bivalent, oral preparations
B03AA01	Ferrous glycine sulfate
B03AA02	Ferrous fumarate
B03AA03	Ferrous gluconate
B03AA04	Ferrous carbonate
B03AA05	Ferrous chloride
B03AA06	Ferrous succinate
B03AA07	Ferrous sulfate
B03AA08	Ferrous tartrate
B03AA09	Ferrous aspartate
B03AA10	Ferrous ascorbate
B03AA11	Ferrous iodine
B03AB	Iron trivalent, oral preparations
B03AB01	Ferric sodium citrate
B03AB02	Saccharated iron oxide
B03AB03	Sodium feredetate
B03AB04	Ferric hydroxide
B03AB05	Dextriferron
B03AB06	Ferric citrate
B03AB07	Chondroitin sulfate-iron complex
B03AB08	Ferric acetyl transferrin
B03AB09	Ferric proteinsuccinylate
B03AC	Iron trivalent, parenteral preparations
B03AC01	Dextriferron
B03AC02	Saccharated iron oxide
B03AC03	Iron-sorbitol-citric acid complex
B03AC05	Ferric sorbitol gluconic acid complex
B03AC06	Ferric oxide dextran complex
B03AC07	Ferric sodium gluconate complex
B03AD	Iron in combination with folic acid
B03AD01	Ferrous amino acid complex
B03AD02	Ferrous fumarate
B03AD03	Ferrous sulfate
B03AD04	Dextriferron
B03AE	Iron in other combinations
B03AE01	Iron, vitamin B<v>12<D> and folic acid
B03AE02	Iron, multivitamins and folic acid
B03AE03	Iron and multivitamins
B03AE04	Iron, multivitamins and minerals
B03AE10	Various combinations
B03B	Vitamin B<v>12<D> and folic acid
B03BA	Vitamin B<v>12<D> (cyanocobalamin and derivatives)
B03BA01	Cyanocobalamin
B03BA02	Cyanocobalamin tannin complex
B03BA03	Hydroxocobalamin
B03BA04	Cobamamide
B03BA05	Mecobalamin
B03BA51	Cyanocobalamin, combinations
B03BA53	Hydroxocobalamin, combinations
B03BB	Folic acid and derivatives
B03BB01	Folic acid
B03BB51	Folic acid, combinations
B03X	Other antianemic preparations
B03XA	Other antianemic preparations
B03XA01	Erythropoietin
B03XA02	Darbepoetin alfa
B03XA03	Methoxy polyethylene glycol-epoetin beta
B05	Blood substitutes and perfusion solutions
B05A	Blood and related products
B05AA	Blood substitutes and plasma protein fractions
B05AA01	Albumin
B05AA02	Other plasma protein fractions
B05AA03	Fluorocarbon blood substitutes
B05AA05	Dextran
B05AA06	Gelatin agents
B05AA07	Hydroxyethylstarch
B05AA08	Hemoglobin crosfumaril
B05AA09	Hemoglobin raffimer
B05AA10	Hemoglobin glutamer (bovine)
B05AX	Other blood products
B05AX01	Erythrocytes
B05AX02	Thrombocytes
B05AX03	Blood plasma
B05AX04	Stem cells from umbilical cord blood
B05B	I.V. solutions
B05BA	Solutions for parenteral nutrition
B05BA01	Amino acids
B05BA02	Fat emulsions
B05BA03	Carbohydrates
B05BA04	Protein hydrolysates
B05BA10	Combinations
B05BB	Solutions affecting the electrolyte balance
B05BB01	Electrolytes
B05BB02	Electrolytes with carbohydrates
B05BB03	Trometamol
B05BC	Solutions producing osmotic diuresis
B05BC01	Mannitol
B05BC02	Carbamide
B05C	Irrigating solutions
B05CA	Antiinfectives
B05CA01	Cetylpyridinium
B05CA02	Chlorhexidine
B05CA03	Nitrofural
B05CA04	Sulfamethizole
B05CA05	Taurolidine
B05CA06	Mandelic acid
B05CA07	Noxytiolin
B05CA08	Ethacridine lactate
B05CA09	Neomycin
B05CA10	Combinations
B05CB	Salt solutions
B05CB01	Sodium chloride
B05CB02	Sodium citrate
B05CB03	Magnesium citrate
B05CB04	Sodium bicarbonate
B05CB10	Combinations
B05CX	Other irrigating solutions
B05CX01	Glucose
B05CX02	Sorbitol
B05CX03	Glycine
B05CX04	Mannitol
B05CX10	Combinations
B05D	Peritoneal dialytics
B05DA	Isotonic solutions
B05DB	Hypertonic solutions
B05X	I.V. solution additives
B05XA	Electrolyte solutions
B05XA01	Potassium chloride
B05XA02	Sodium bicarbonate
B05XA03	Sodium chloride
B05XA04	Ammonium chloride
B05XA05	Magnesium sulfate
B05XA06	Potassium phosphate, incl. comb. with other potassium salts
B05XA07	Calcium chloride
B05XA08	Sodium acetate
B05XA09	Sodium phosphate
B05XA10	Magnesium phosphate
B05XA11	Magnesium chloride
B05XA12	Zinc chloride
B05XA13	Hydrochloric acid
B05XA14	Sodium glycerophosphate
B05XA15	Potassium lactate
B05XA16	Cardioplegia solutions
B05XA17	Potassium acetate
B05XA30	Combinations of electrolytes
B05XA31	Electrolytes in combination with other drugs
B05XB	Amino acids
B05XB01	Arginine hydrochloride
B05XB02	Alanyl glutamine
B05XB03	Lysine
B05XC	Vitamins
B05XX	Other I.V. solution additives
B05XX02	Trometamol
B05Z	Hemodialytics and hemofiltrates
B05ZA	Hemodialytics, concentrates
B05ZB	Hemofiltrates
B06	Other hematological agents
B06A	Other hematological agents
B06AA	Enzymes
B06AA02	Fibrinolysin and desoxyribonuclease
B06AA03	Hyaluronidase
B06AA04	Chymotrypsin
B06AA07	Trypsin
B06AA10	Desoxyribonuclease
B06AA11	Bromelains
B06AA55	Streptokinase, combinations
B06AB	Other hem products
B06AB01	Hematin
C	Cardiovascular system
C01	Cardiac therapy
C01A	Cardiac glycosides
C01AA	Digitalis glycosides
C01AA01	Acetyldigitoxin
C01AA02	Acetyldigoxin
C01AA03	Digitalis leaves
C01AA04	Digitoxin
C01AA05	Digoxin
C01AA06	Lanatoside C
C01AA07	Deslanoside
C01AA08	Metildigoxin
C01AA09	Gitoformate
C01AA52	Acetyldigoxin, combinations
C01AB	Scilla glycosides
C01AB01	Proscillaridin
C01AB51	Proscillaridin, combinations
C01AC	Strophantus glycosides
C01AC01	G-strophanthin
C01AC03	Cymarin
C01AX	Other cardiac glycosides
C01AX02	Peruvoside
C01B	Antiarrhythmics, class I and III
C01BA	Antiarrhythmics, class IA
C01BA01	Quinidine
C01BA02	Procainamide
C01BA03	Disopyramide
C01BA04	Sparteine
C01BA05	Ajmaline
C01BA08	Prajmaline
C01BA12	Lorajmine
C01BA51	Quinidine, combinations excl. psycholeptics
C01BA71	Quinidine, combinations with psycholeptics
C01BB	Antiarrhythmics, class IB
C01BB01	Lidocaine
C01BB02	Mexiletine
C01BB03	Tocainide
C01BB04	Aprindine
C01BC	Antiarrhythmics, class IC
C01BC03	Propafenone
C01BC04	Flecainide
C01BC07	Lorcainide
C01BC08	Encainide
C01BD	Antiarrhythmics, class III
C01BD01	Amiodarone
C01BD02	Bretylium tosilate
C01BD03	Bunaftine
C01BD04	Dofetilide
C01BD05	Ibutilide
C01BD06	Tedisamil
C01BG	Other class I antiarrhythmics
C01BG01	Moracizine
C01BG07	Cibenzoline
C01C	Cardiac stimulants excl. cardiac glycosides
C01CA	Adrenergic and dopaminergic agents
C01CA01	Etilefrine
C01CA02	Isoprenaline
C01CA03	Norepinephrine
C01CA04	Dopamine
C01CA05	Norfenefrine
C01CA06	Phenylephrine
C01CA07	Dobutamine
C01CA08	Oxedrine
C01CA09	Metaraminol
C01CA10	Methoxamine
C01CA11	Mephentermine
C01CA12	Dimetofrine
C01CA13	Prenalterol
C01CA14	Dopexamine
C01CA15	Gepefrine
C01CA16	Ibopamine
C01CA17	Midodrine
C01CA18	Octopamine
C01CA19	Fenoldopam
C01CA21	Cafedrine
C01CA22	Arbutamine
C01CA23	Theodrenaline
C01CA24	Epinephrine
C01CA30	Combinations
C01CA51	Etilefrine, combinations
C01CE	Phosphodiesterase inhibitors
C01CE01	Amrinone
C01CE02	Milrinone
C01CE03	Enoximone
C01CE04	Bucladesine
C01CX	Other cardiac stimulants
C01CX06	Angiotensinamide
C01CX07	Xamoterol
C01CX08	Levosimendan
C01D	Vasodilators used in cardiac diseases
C01DA	Organic nitrates
C01DA02	Glyceryl trinitrate
C01DA04	Methylpropylpropanediol dinitrate
C01DA05	Pentaerithrityl tetranitrate
C01DA07	Propatylnitrate
C01DA08	Isosorbide dinitrate
C01DA09	Trolnitrate
C01DA13	Eritrityl tetranitrate
C01DA14	Isosorbide mononitrate
C01DA20	Organic nitrates in combination
C01DA38	Tenitramine
C01DA52	Glyceryl trinitrate, combinations
C01DA54	Methylpropylpropanediol dinitrate, combinations
C01DA55	Pentaerithrityl tetranitrate, combinations
C01DA57	Propatylnitrate, combinations
C01DA58	Isosorbide dinitrate, combinations
C01DA59	Trolnitrate, combinations
C01DA63	Eritrityl tetranitrate, combinations
C01DA70	Organic nitrates in combination with psycholeptics
C01DB	Quinolone vasodilators
C01DB01	Flosequinan
C01DX	Other vasodilators used in cardiac diseases
C01DX01	Itramin tosilate
C01DX02	Prenylamine
C01DX03	Oxyfedrine
C01DX04	Benziodarone
C01DX05	Carbocromen
C01DX06	Hexobendine
C01DX07	Etafenone
C01DX08	Heptaminol
C01DX09	Imolamine
C01DX10	Dilazep
C01DX11	Trapidil
C01DX12	Molsidomine
C01DX13	Efloxate
C01DX14	Cinepazet
C01DX15	Cloridarol
C01DX16	Nicorandil
C01DX18	Linsidomine
C01DX19	Nesiritide
C01DX51	Itramin tosilate, combinations
C01DX52	Prenylamine, combinations
C01DX53	Oxyfedrine, combinations
C01DX54	Benziodarone, combinations
C01E	Other cardiac preparations
C01EA	Prostaglandins
C01EA01	Alprostadil
C01EB	Other cardiac preparations
C01EB02	Camphora
C01EB03	Indometacin
C01EB04	Crataegus glycosides
C01EB05	Creatinolfosfate
C01EB06	Fosfocreatine
C01EB07	Fructose 1,6-diphosphate
C01EB09	Ubidecarenone
C01EB10	Adenosine
C01EB11	Tiracizine
C01EB13	Acadesine
C01EB15	Trimetazidine
C01EB16	Ibuprofen
C01EB17	Ivabradine
C01EB18	Ranolazine
C01EB19	Icatibant
C01EB21	Regadenoson
C01EX	Other cardiac combination products
C02	Antihypertensives
C02A	Antiadrenergic agents, centrally acting
C02AA	Rauwolfia alkaloids
C02AA01	Rescinnamine
C02AA02	Reserpine
C02AA03	Combinations of rauwolfia alkaloids
C02AA04	Rauwolfia alkaloids, whole root
C02AA05	Deserpidine
C02AA06	Methoserpidine
C02AA07	Bietaserpine
C02AA52	Reserpine, combinations
C02AA53	Combinations of rauwolfia alkaloids, combinations
C02AA57	Bietaserpine, combinations
C02AB	Methyldopa
C02AB01	Methyldopa (levorotatory)
C02AB02	Methyldopa (racemic)
C02AC	Imidazoline receptor agonists
C02AC01	Clonidine
C02AC02	Guanfacine
C02AC04	Tolonidine
C02AC05	Moxonidine
C02AC06	Rilmenidine
C02B	Antiadrenergic agents, ganglion-blocking
C02BA	Sulfonium derivatives
C02BA01	Trimetaphan
C02BB	Secondary and tertiary amines
C02BB01	Mecamylamine
C02BC	Bisquaternary ammonium compounds
C02C	Antiadrenergic agents, peripherally acting
C02CA	Alpha-adrenoceptor antagonists
C02CA01	Prazosin
C02CA02	Indoramin
C02CA03	Trimazosin
C02CA04	Doxazosin
C02CA06	Urapidil
C02CC	Guanidine derivatives
C02CC01	Betanidine
C02CC02	Guanethidine
C02CC03	Guanoxan
C02CC04	Debrisoquine
C02CC05	Guanoclor
C02CC06	Guanazodine
C02CC07	Guanoxabenz
C02D	Arteriolar smooth muscle, agents acting on
C02DA	Thiazide derivatives
C02DA01	Diazoxide
C02DB	Hydrazinophthalazine derivatives
C02DB01	Dihydralazine
C02DB02	Hydralazine
C02DB03	Endralazine
C02DB04	Cadralazine
C02DC	Pyrimidine derivatives
C02DC01	Minoxidil
C02DD	Nitroferricyanide derivatives
C02DD01	Nitroprusside
C02DG	Guanidine derivatives
C02DG01	Pinacidil
C02K	Other antihypertensives
C02KA	Alkaloids, excl. rauwolfia
C02KA01	Veratrum
C02KB	Tyrosine hydroxylase inhibitors
C02KB01	Metirosine
C02KC	MAO inhibitors
C02KC01	Pargyline
C02KD	Serotinin antagonists
C02KD01	Ketanserin
C02KX	Other antihypertensives
C02KX01	Bosentan
C02KX02	Ambrisentan
C02KX03	Sitaxentan
C02L	Antihypertensives and diuretics in combination
C02LA	Rauwolfia alkaloids and diuretics in combination
C02LA01	Reserpine and diuretics
C02LA02	Rescinnamine and diuretics
C02LA03	Deserpidine and diuretics
C02LA04	Methoserpidine and diuretics
C02LA07	Bietaserpine and diuretics
C02LA08	Rauwolfia alkaloids, whole root and diuretics
C02LA09	Syrosingopine and diuretics
C02LA50	Comb. of rauwolfia alkaloids and diuretics incl. other combinations
C02LA51	Reserpine and diuretics, combinations with other drugs
C02LA52	Rescinnamine and diuretics, combinations with other drugs
C02LA71	Reserpine and diuretics, combinations with psycholeptics
C02LB	Methyldopa and diuretics in combination
C02LB01	Methyldopa (levorotatory) and diuretics
C02LC	Imidazoline receptor agonists in combination with diuretics
C02LC01	Clonidine and diuretics
C02LC05	Moxonidine and diuretics
C02LC51	Clonidine and diuretics, combinations with other drugs
C02LE	Alpha-adrenoceptor blocking agents and diuretics
C02LE01	Prazosin and diuretics
C02LF	Guanidine derivatives and diuretics
C02LF01	Guanethidine and diuretics
C02LG	Hydrazinophthalazine derivatives and diuretics
C02LG01	Dihydralazine and diuretics
C02LG02	Hydralazine and diuretics
C02LG03	Picodralazine and diuretics
C02LG51	Dihydralazine and diuretics, combinations with other drugs
C02LG73	Picodralazine and diuretics, combinations with psycholeptics
C02LK	Alkaloids, excl. rauwolfia, in combination with diuretics
C02LK01	Veratrum and diuretics
C02LL	MAO inhibitors and diuretics
C02LL01	Pargyline and diuretics
C02LN	Serotonin antagonists and diuretics
C02LX	Other antihypertensives and diuretics
C02LX01	Pinacidil and diuretics
C02N	Combinations of antihypertensives
C03	Diuretics
C03A	Low-ceiling diuretics, thiazides
C03AA	Thiazides, plain
C03AA01	Bendroflumethiazide
C03AA02	Hydroflumethiazide
C03AA03	Hydrochlorothiazide
C03AA04	Chlorothiazide
C03AA05	Polythiazide
C03AA06	Trichlormethiazide
C03AA07	Cyclopenthiazide
C03AA08	Methyclothiazide
C03AA09	Cyclothiazide
C03AA13	Mebutizide
C03AB	Thiazides and potassium in combination
C03AB01	Bendroflumethiazide and potassium
C03AB02	Hydroflumethiazide and potassium
C03AB03	Hydrochlorothiazide and potassium
C03AB04	Chlorothiazide and potassium
C03AB05	Polythiazide and potassium
C03AB06	Trichlormethiazide and potassium
C03AB07	Cyclopenthiazide and potassium
C03AB08	Methyclothiazide and potassium
C03AB09	Cyclothiazide and potassium
C03AH	Thiazides, combinations with psycholeptics and/or analgesics
C03AH01	Chlorothiazide, combinations
C03AH02	Hydroflumethiazide, combinations
C03AX	Thiazides, combinations with other drugs
C03AX01	Hydrochlorothiazide, combinations
C03B	Low-ceiling diuretics, excl. thiazides
C03BA	Sulfonamides, plain
C03BA02	Quinethazone
C03BA03	Clopamide
C03BA04	Chlortalidone
C03BA05	Mefruside
C03BA07	Clofenamide
C03BA08	Metolazone
C03BA09	Meticrane
C03BA10	Xipamide
C03BA11	Indapamide
C03BA12	Clorexolone
C03BA13	Fenquizone
C03BA82	Clorexolone, comb. with psycholeptics
C03BB	Sulfonamides and potassium in combination
C03BB02	Quinethazone and potassium
C03BB03	Clopamide and potassium
C03BB04	Chlortalidone and potassium
C03BB05	Mefruside and potassium
C03BB07	Clofenamide and potassium
C03BC	Mercurial diuretics
C03BC01	Mersalyl
C03BD	Xanthine derivatives
C03BD01	Theobromine
C03BK	Sulfonamides, combinations with other drugs
C03BX	Other low-ceiling diuretics
C03BX03	Cicletanine
C03C	High-ceiling diuretics
C03CA	Sulfonamides, plain
C03CA01	Furosemide
C03CA02	Bumetanide
C03CA03	Piretanide
C03CA04	Torasemide
C03CB	Sulfonamides and potassium in combination
C03CB01	Furosemide and potassium
C03CB02	Bumetanide and potassium
C03CC	Aryloxyacetic acid derivatives
C03CC01	Etacrynic acid
C03CC02	Tienilic acid
C03CD	Pyrazolone derivatives
C03CD01	Muzolimine
C03CX	Other high-ceiling diuretics
C03CX01	Etozolin
C03D	Potassium-sparing agents
C03DA	Aldosterone antagonists
C03DA01	Spironolactone
C03DA02	Potassium canrenoate
C03DA03	Canrenone
C03DA04	Eplerenone
C03DB	Other potassium-sparing agents
C03DB01	Amiloride
C03DB02	Triamterene
C03E	Diuretics and potassium-sparing agents in combination
C03EA	Low-ceiling diuretics and potassium-sparing agents
C03EA01	Hydrochlorothiazide and potassium-sparing agents
C03EA02	Trichlormethiazide and potassium-sparing agents
C03EA03	Epitizide and potassium-sparing agents
C03EA04	Altizide and potassium-sparing agents
C03EA05	Mebutizide and potassium-sparing agents
C03EA06	Chlortalidone and potassium-sparing agents
C03EA07	Cyclopenthiazide and potassium-sparing agents
C03EA12	Metolazone and potassium-sparing agents
C03EA13	Bendroflumethiazide and potassium-sparing agents
C03EA14	Butizide and potassium-sparing agents
C03EB	High-ceiling diuretics and potassium-sparing agents
C03EB01	Furosemide and potassium-sparing agents
C03EB02	Bumetanide and potassium-sparing agents
C03X	Other diuretics
C03XA	Vasopressin antagonists
C03XA01	Tolvaptan
C03XA02	Conivaptan
C04	Peripheral vasodilators
C04A	Peripheral vasodilators
C04AA	2-animo-1-phenylethanol derivatives
C04AA01	Isoxsuprine
C04AA02	Buphenine
C04AA31	Bamethan
C04AB	Imidazoline derivatives
C04AB01	Phentolamine
C04AB02	Tolazoline
C04AC	Nicotinic acid and derivatives
C04AC01	Nicotinic acid
C04AC02	Nicotinyl alcohol (pyridylcarbinol)
C04AC03	Inositol nicotinate
C04AC07	Ciclonicate
C04AD	Purine derivatives
C04AD01	Pentifylline
C04AD02	Xantinol nicotinate
C04AD03	Pentoxifylline
C04AD04	Etofylline nicotinate
C04AE	Ergot alkaloids
C04AE01	Ergoloid mesylates
C04AE02	Nicergoline
C04AE04	Dihydroergocristine
C04AE51	Ergoloid mesylates, combinations
C04AE54	Dihydroergocristine, combinations
C04AF01	Kallidinogenase
C04AX	Other peripheral vasodilators
C04AX01	Cyclandelate
C04AX02	Phenoxybenzamine
C04AX07	Vincamine
C04AX10	Moxisylyte
C04AX11	Bencyclane
C04AX17	Vinburnine
C04AX19	Sulcotidil
C04AX20	Buflomedil
C04AX21	Naftidrofuryl
C04AX23	Butalamine
C04AX24	Visnadine
C04AX26	Cetiedil
C04AX27	Cinepazide
C04AX28	Ifenprodil
C04AX30	Azapetine
C04AX32	Fasudil
C05	Vasoprotectives
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use
C05AA	Corticosteroids
C05AA01	Hydrocortisone
C05AA04	Prednisolone
C05AA05	Betamethasone
C05AA06	Fluorometholone
C05AA08	Fluocortolone
C05AA09	Dexamethasone
C05AA10	Fluocinolone acetonide
C05AA11	Fluocinonide
C05AB	Antibiotics
C05AD	Local anesthetics
C05AD01	Lidocaine
C05AD02	Tetracaine
C05AD03	Benzocaine
C05AD04	Cinchocaine
C05AD05	Procaine
C05AD06	Oxetacaine
C05AD07	Pramocaine
C05AE	Muscle relaxants
C05AE01	Glyceryl trinitrate
C05AE02	Isosorbide dinitrate
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use
C05AX01	Aluminium preparations
C05AX02	Bismuth preparations, combinations
C05AX03	Other preparations, combinations
C05AX04	Zinc preparations
C05AX05	Tribenoside
C05B	Antivaricose therapy
C05BA	Heparins or heparinoids for topical use
C05BA01	Organo-heparinoid
C05BA02	Sodium apolate
C05BA03	Heparin
C05BA04	Pentosan polysulfate sodium
C05BA51	Heparinoid, combinations
C05BA53	Heparin, combinations
C05BB	Sclerosing agents for local injection
C05BB01	Monoethanolamine oleate
C05BB02	Polidocanol
C05BB03	Invert sugar
C05BB04	Sodium tetradecyl sulfate
C05BB05	Phenol
C05BB56	Glucose, combinations
C05BX	Other sclerosing agents
C05BX01	Calcium dobesilate
C05BX51	Calcium dobesilate, combinations
C05C	Capillary stabilizing agents
C05CA	Bioflavinoids
C05CA01	Rutoside
C05CA02	Monoxerutin
C05CA03	Diosmin
C05CA04	Troxerutin
C05CA05	Hidrosmin
C05CA51	Rutoside, combinations
C05CA53	Diosmin, combinations
C05CA54	Troxerutin, combinations
C05CX	Other capillary stabilizing agents
C05CX01	Tribenoside
C07	Beta blocking agents
C07A	Beta blocking agents
C07AA	Beta blocking agents, non-selective
C07AA01	Alprenolol
C07AA02	Oxprenolol
C07AA03	Pindolol
C07AA05	Propranolol
C07AA06	Timolol
C07AA07	Sotalol
C07AA12	Nadolol
C07AA14	Mepindolol
C07AA15	Carteolol
C07AA16	Tertatolol
C07AA17	Bopindolol
C07AA19	Bupranolol
C07AA23	Penbutolol
C07AA27	Cloranolol
C07AA57	Sotalol, combination packages
C07AB	Beta blocking agents, selective
C07AB01	Practolol
C07AB02	Metoprolol
C07AB03	Atenolol
C07AB04	Acebutolol
C07AB05	Betaxolol
C07AB06	Bevantolol
C07AB07	Bisoprolol
C07AB08	Celiprolol
C07AB09	Esmolol
C07AB10	Epanolol
C07AB11	S-atenolol
C07AB12	Nebivolol
C07AB13	Talinolol
C07AB52	Metoprolol, combination packages
C07AB57	Bisoprolol, combinations
C07AG	Alpha and beta blocking agents
C07AG01	Labetalol
C07AG02	Carvedilol
C07B	Beta blocking agents and thiazides
C07BA	Beta blocking agents, non-selective, and thiazides
C07BA02	Oxprenolol and thiazides
C07BA05	Propranolol and thiazides
C07BA06	Timolol and thiazides
C07BA07	Sotalol and thiazides
C07BA12	Nadolol and thiazides
C07BA68	Metipranolol and thaizides, combinations
C07BB	Beta blocking agents, selective, and thiazides
C07BB02	Metoprolol and thiazides
C07BB03	Atenolol and thiazides
C07BB04	Acebutolol and thiazides
C07BB06	Bevantolol and thiazides
C07BB07	Bisoprolol and thiazides
C07BB52	Metoprolol and thiazides, combinations
C07BG	Alpha and beta blocking agents and thiazides
C07BG01	Labetalol and thiazides
C07C	Beta blocking agents and other diuretics
C07CA	Beta blocking agents, non-selective, and other diuretics
C07CA02	Oxprenolol and other diuretics
C07CA03	Pindolol and other diuretics
C07CA17	Bopindolol and other diuretics
C07CA23	Penbutolol and other diuretics
C07CB	Beta blocking agents, selective, and other diuretics
C07CB02	Metoprolol and other diuretics
C07CB03	Atenolol and other diuretics
C07CB53	Atenolol and other diuretics, combinations
C07CG	Alpha and beta blocking agents and other diuretics
C07CG01	Labetalol and other diuretics
C07D	Beta blocking agents, thiazides and other diuretics
C07DA	Beta blocking agents, non-selective, thiazides and other diuretics
C07DA06	Timolol, thiazides and other diuretics
C07DB	Beta blocking agents, selective, thiazides and other diuretics
C07DB01	Atenolol, thiazides and other diuretics
C07E	Beta blocking agents and vasodilators
C07EA	Beta blocking agents, non-selective, and vasodilators
C07EB	Beta blocking agents, selective, and vasodilators
C07F	Beta blocking agents and other antihypertensives
C07FA	Beta blocking agents, non-selective, and other antihypertensives
C07FA05	Propranolol and other antihypertensives
C07FB	Beta blocking agents, selective, and other antihypertensives
C07FB02	Metoprolol and other antihypertensives
C07FB03	Atenolol and other hypertensives
C08	Calcium channel blockers
C08C	Selective calcium channel blockers with mainly vascular effects
C08CA	Dihydropyridine derivatives
C08CA01	Amlodipine
C08CA02	Felodipine
C08CA03	Isradipine
C08CA04	Nicardipine
C08CA05	Nifedipine
C08CA06	Nimodipine
C08CA07	Nisoldipine
C08CA08	Nitrendipine
C08CA09	Lacidipine
C08CA10	Nilvadipine
C08CA11	Manidipine
C08CA12	Barnipidine
C08CA13	Lercanipidine
C08CA14	Cilnidipine
C08CA15	Benidipine
C08CA55	Nifedipine, combinations
C08CX	Other selective calcium channel blockers with mainly vascular effects
C08CX01	Mibefradil
C08D	Selective calcium channel blockers with direct cardiac effects
C08DA	Phenylalkylamine derivatives
C08DA01	Verapamil
C08DA02	Gallopamil
C08DA51	Verapamil, combinations
C08DB	Benzothiazepine derivatives
C08DB01	Diltiazem
C08E	Non-selective calcium channel blockers
C08EA	Phenylalkylamine derivatives
C08EA01	Fendiline
C08EA02	Bepridil
C08EX	Other non-selective calcium channel blockers
C08EX01	Lidoflazine
C08EX02	Perhexiline
C08G	Calcium channel blockers and diuretics
C08GA	Calcium channel blockers and diuretics
C08GA01	Nifedipine and diuretics
C09	Agents acting on the renin-angiotensin system
C09A	ACE inhibitors, plain
C09AA	ACE inhibitors, plain
C09AA01	Captopril
C09AA02	Enalapril
C09AA03	Lisinopril
C09AA04	Perindopril
C09AA05	Ramipril
C09AA06	Quinapril
C09AA07	Benazepril
C09AA08	Cilazapril
C09AA09	Fosinopril
C09AA10	Trandolapril
C09AA11	Spirapril
C09AA12	Delapril
C09AA13	Moexipril
C09AA14	Temocapril
C09AA15	Zofenopril
C09AA16	Imidapril
C09B	ACE inhibitors, combinations
C09BA	ACE inhibitors and diuretics
C09BA01	Captopril and diuretics
C09BA02	Enalapril and diuretics
C09BA03	Lisinopril and diuretics
C09BA04	Perindopril and diuretics
C09BA05	Ramipril and diuretics
C09BA06	Quinapril and diuretics
C09BA07	Benazepril and diuretics
C09BA08	Cilazapril and diuretics
C09BA09	Fosinopril and diuretics
C09BA12	Delapril and diuretics
C09BA13	Moexipril and diuretics
C09BA15	Zofenopril and diuretics
C09BB	ACE inhibitors and calcium channel blockers
C09BB02	Enalapril and lercanidipine
C09BB03	Lisinopril and amlodipine
C09BB04	Perindopril and amlodipine
C09BB05	Ramipril and felodipine
C09BB10	Trandolapril and verapamil
C09BB12	Delapril and manidipine
C09C	Angiotensin II antagonists, plain
C09CA	Angiotensin II antagonists, plain
C09CA01	Losartan
C09CA02	Eprosartan
C09CA03	Valsartan
C09CA04	Irbesartan
C09CA05	Tasosartan
C09CA06	Candesartan
C09CA07	Telmisartan
C09CA08	Olmesartan medoxomil
C09D	Angiotensin II antagonists, combinations
C09DA	Angiotensin II antagonists and diuretics
C09DA01	Losartan and diuretics
C09DA02	Eprosartan and diuretics
C09DA03	Valsartan and diuretics
C09DA04	Irbesartan and diuretics
C09DA06	Candesartan and diuretics
C09DA07	Telmisartan and diuretics
C09DA08	Olmesartan medoxomil and diuretics
C09DB	Angiotensin II antagonists and calcium channel blockers
C09DB01	Valsartan and amlodipine
C09DB02	Olmesartan medoxomil and amlodipine
C09DB04	Telmisartan and amlodipine
C09DX	Angiotensin II antagonists, other combinations
C09DX01	Valsartan, amlodipine and hydrochlorothiazide
C09DX02	Valsartan and aliskiren
C09X	Other agents acting on the renin-angiotensin system
C09XA	Renin-inhibitors
C09XA01	Remikiren
C09XA02	Aliskiren
C09XA52	Aliskiren and hydrochlorothiazide
C10	Lipid modifying agents
C10A	Lipid modifying agents, plain
C10AA	HMG CoA reductase inhibitors
C10AA01	Simvastatin
C10AA02	Lovastatin
C10AA03	Pravastatin
C10AA04	Fluvastatin
C10AA05	Atorvastatin
C10AA06	Cerivastatin
C10AA07	Rosuvastatin
C10AA08	Pitavastatin
C10AB01	Clofibrate
C10AB02	Bezafibrate
C10AB03	Aluminium clofibrate
C10AB04	Gemfibrozil
C10AB05	Fenofibrate
C10AB06	Simifibrate
C10AB07	Ronifibrate
C10AB08	Ciprofibrate
C10AB09	Etofibrate
C10AB10	Clofibride
C10AC	Bile acid sequestrants
C10AC01	Colestyramine
C10AC02	Colestipol
C10AC03	Colextran
C10AC04	Colesevelam
C10AD	Nicotinic acid and derivatives
C10AD01	Niceritrol
C10AD02	Nicotinic acid
C10AD03	Nicofuranose
C10AD04	Aluminium nicotinate
C10AD05	Nicotinyl alcohol (pyridylcarbinol)
C10AD06	Acipimox
C10AD52	Nicotinic acid, combinations
C10AX	Other lipid modifying agents
C10AX01	Dextrothyroxine
C10AX02	Probucol
C10AX03	Tiadenol
C10AX05	Meglutol
C10AX06	Omega-3-triglycerides incl. other esters and acids
C10AX07	Magnesium pyridoxal 5-phosphate glutamate
C10AX08	Policosanol
C10AX09	Ezetimibe
C10AX10	Alipogene tiparvovec
C10B	Lipid modifying agents, combinations
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents
C10BA01	Lovastatin and nicotinic acid
C10BA02	Simvastatin and ezetimibe
C10BA03	Pravastatin and fenofibrate
C10BX	HMG CoA reductase inhibitors, other combinations
C10BX01	Simvastatin and acetylsalicylic acid
C10BX02	Pravastatin and acetylsalicylic acid
C10BX03	Atorvastatin and amlodipine
D	Dermatologicals
D01	Antifungals for dermatological use
D01A	Antifungals for topical use
D01AA	Antibiotics
D01AA01	Nystatin
D01AA02	Natamycin
D01AA03	Hachimycin
D01AA04	Pecilocin
D01AA06	Mepartricin
D01AA07	Pyrrolnitrin
D01AA08	Griseofulvin
D01AA20	Combinations
D01AC	Imidazole and triazole derivatives
D01AC01	Clotrimazole
D01AC02	Miconazole
D01AC03	Econazole
D01AC04	Clomidazole
D01AC05	Isoconazole
D01AC06	Tiabendazole
D01AC07	Tioconazole
D01AC08	Ketoconazole
D01AC09	Sulconazole
D01AC10	Bifonazole
D01AC11	Oxiconazole
D01AC12	Fenticonazole
D01AC13	Omoconazole
D01AC14	Sertaconazole
D01AC15	Fluconazole
D01AC16	Flutrimazole
D01AC20	Combinations
D01AC52	Miconazole, combinations
D01AC60	Bifonazole, combinations
D01AE	Other antifungals for topical use
D01AE01	Bromochlorosalicylanilide
D01AE02	Methylrosaniline
D01AE03	Tribromometacresol
D01AE04	Undecylenic acid
D01AE05	Polynoxylin
D01AE06	2-(4-chlorphenoxy)-ethanol
D01AE07	Chlorphenesin
D01AE08	Ticlatone
D01AE09	Sulbentine
D01AE10	Ethyl hydroxybenzoate
D01AE11	Haloprogin
D01AE12	Salicylic acid
D01AE13	Selenium sulfide
D01AE14	Ciclopirox
D01AE15	Terbinafine
D01AE16	Amorolfine
D01AE17	Dimazole
D01AE18	Tolfnaftate
D01AE19	Tolciclate
D01AE20	Combinations
D01AE21	Flucytosine
D01AE22	Naftifine
D01AE23	Butenafine
D01AE54	Undecylenic acid, combinations
D01B	Antifungals for systemic use
D01BA	Antifungals for systemic use
D01BA01	Griseofulvin
D01BA02	Terbinafine
D02	Emollients and protectives
D02A	Emollients and protectives
D02AA	Silicone products
D02AB	Zinc products
D02AC	Soft paraffin and fat products
D02AD	Liquid plasters
D02AE	Carbamide products
D02AE01	Carbamide
D02AE51	Carbamide, combinations
D02AF	Salicylic acid preparations
D02AX	Other emollients and protectives
D02B	Protectives against UV-radiation
D02BA	Protectives against UV-radiation for topical use
D02BA01	Aminobenzoic acid
D02BA02	Octyl methoxycinnamate
D02BB	Protectives against UV-radiation for systemic use
D02BB01	Betacarotene
D03	Preparations for treatment of wounds and ulcers
D03A	Cicatrizants
D03AA	Cod-liver oil ointments
D03AX	Other cicatrizants
D03AX01	Cadexomer iodine
D03AX02	Dextranomer
D03AX03	Dexpanthenol
D03AX04	Calcium pantothenate
D03AX05	Hyaluronic acid
D03AX06	Becaplermin
D03AX09	Crilanomer
D03AX10	Enoxolone
D03B	Enzymes
D03BA	Proteolytic enzymes
D03BA01	Trypsin
D03BA02	Collagenase
D03BA52	Collagenase, combinations
D04	Antipruritics, incl. antihistamines, anesthetics, etc.
D04A	Antipruritics, incl. antihistamines, anesthetics, etc.
D04AA	Antihistamines for topical use
D04AA01	Thonzylamine
D04AA02	Mepyramine
D04AA03	Thenalidine
D04AA04	Tripelennamine
D04AA09	Chloropyramine
D04AA10	Promethazine
D04AA12	Tolpropamine
D04AA13	Dimetindene
D04AA14	Clemastine
D04AA15	Bamipine
D04AA22	Isothipendyl
D04AA32	Diphenhydramine
D04AA33	Diphenhydramine methylbromide
D04AA34	Chlorphenoxamine
D04AB	Anesthetics for topical use
D04AB01	Lidocaine
D04AB02	Cinchocaine
D04AB03	Oxybuprocaine
D04AB04	Benzocaine
D04AB05	Quinisocaine
D04AB06	Tetracaine
D04AB07	Pramocaine
D04AX	Other antipruritics
D05	Antipsoriatics
D05A	Antipsoriatics for topical use
D05AA	Tars
D05AC	Antracen derivatives
D05AC01	Dithranol
D05AC51	Dithranol, combinations
D05AD	Psoralens for topical use
D05AD01	Trioxysalen, topical
D05AD02	Methoxsalen, topical
D05AX	Other antipsoriatics for topical use
D05AX01	Fumaric acid
D05AX02	Calcipotriol
D05AX03	Calcitriol
D05AX04	Tacalcitol
D05AX05	Tazarotene
D05AX52	Calcipotriol, combinations
D05B	Antipsoriatics for systemic use
D05BA	Psoralens for systemic use
D05BA01	Trioxysalen
D05BA02	Methoxsalen
D05BA03	Bergapten
D05BB	Retinoids for treatment of psoriasis
D05BB01	Etretinate
D05BB02	Acitretin
D05BX	Other antipsoriatics for systemic use
D05BX51	Fumaric acid derivatives, combinations
D06	Antibiotics and chemotherapeutics for dermatological use
D06A	Antibiotics for topical use
D06AA	Tetracycline and derivatives
D06AA01	Demeclocycline
D06AA02	Chlortetracycline
D06AA03	Oxytetracycline
D06AA04	Tetracycline
D06AX	Other antibiotics for topical use
D06AX01	Fusidic acid
D06AX02	Chloramphenicol
D06AX04	Neomycin
D06AX05	Bacitracin
D06AX07	Gentamicin
D06AX08	Tyrothricin
D06AX09	Mupirocin
D06AX10	Virginiamycin
D06AX11	Rifaximin
D06AX12	Amikacin
D06AX13	Retapamulin
D06B	Chemotherapeutics for topical use
D06BA	Sulfonamides
D06BA01	Silver sulfadiazine
D06BA02	Sulfathiazole
D06BA03	Mafenide
D06BA04	Sulfamethizole
D06BA05	Sulfanilamide
D06BA06	Sulfamerazine
D06BA51	Silver sulfadiazine, combinations
D06BB	Antivirals
D06BB01	Idoxuridine
D06BB02	Tromantadine
D06BB03	Aciclovir
D06BB04	Podophyllotoxin
D06BB05	Inosine
D06BB06	Penciclovir
D06BB07	Lysozyme
D06BB08	Ibacitabine
D06BB09	Edoxudine
D06BB10	Imiquimod
D06BB11	Docosanol
D06BB53	Aciclovir, combinations
D06BX	Other chemotherapeutics
D06BX01	Metronidazole
D06C	Antibiotics and chemotherapeutics, combinations
D07	Corticosteroids, dermatological preparations
D07A	Corticosteroids, plain
D07AA	Corticosteroids, weak (group I)
D07AA01	Methylprednisolone
D07AA02	Hydrocortisone
D07AA03	Prednisolone
D07AB	Corticosteroids, moderately potent (group II)
D07AB01	Clobetasone
D07AB02	Hydrocortisone butyrate
D07AB03	Flumetasone
D07AB04	Fluocortin
D07AB05	Fluperolone
D07AB06	Fluorometholone
D07AB07	Fluprednidene
D07AB08	Desonide
D07AB09	Triamcinolone
D07AB10	Alclometasone
D07AB11	Hydrocortisone buteprate
D07AB19	Dexamethasone
D07AB21	Clocortolone
D07AB30	Combinations of corticosteroids
D07AC	Corticosteroids, potent (group III)
D07AC01	Betamethasone
D07AC02	Fluclorolone
D07AC03	Desoximetasone
D07AC04	Fluocinolone acetonide
D07AC05	Fluocortolone
D07AC06	Diflucortolone
D07AC07	Fludroxycortide
D07AC08	Fluocinonide
D07AC09	Budesonide
D07AC10	Diflorasone
D07AC11	Amcinonide
D07AC12	Halometasone
D07AC13	Mometasone
D07AC14	Methylprednisolone aceponate
D07AC15	Beclometasone
D07AC16	Hydrocortisone aceponate
D07AC17	Fluticasone
D07AC18	Prednicarbate
D07AC19	Difluprednate
D07AC21	Ulobetasol
D07AD	Corticosteroids, very potent (group IV)
D07AD01	Clobetasol
D07AD02	Halcinonide
D07B	Corticosteroids, combinations with antiseptics
D07BA	Corticosteroids, weak, combinations with antiseptics
D07BA01	Prednisolone and antiseptics
D07BA04	Hydrocortisone and antiseptics
D07BB	Corticosteroids, moderately potent, combinations with antiseptics
D07BB01	Flumetasone and antiseptics
D07BB02	Desonide and antiseptics
D07BB03	Triamcinolone and antiseptics
D07BB04	Hydrocortisone butyrate and antiseptics
D07BC	Corticosteroids, potent, combinations with antiseptics
D07BC01	Betamethasone and antiseptics
D07BC02	Fluocinolone acetonide and antiseptics
D07BC03	Fluocortolone and antiseptics
D07BC04	Diflucortolone and antiseptics
D07BD	Corticosteroids, very potent, combinations with antiseptics
D07C	Corticosteroids, combinations with antibiotics
D07CA	Corticosteroids, weak, combinations with antibiotics
D07CA01	Hydrocortisone and antibiotics
D07CA02	Methylprednisolone and antibiotics
D07CA03	Prednisolone and antibiotics
D07CB	Corticosteroids, moderately potent, combinations with antibiotics
D07CB01	Triamcinolone and antibiotics
D07CB02	Fluprednidene and antibiotics
D07CB03	Fluorometholone and antibiotics
D07CB04	Dexamethasone and antibiotics
D07CB05	Flumetasone and antibiotics
D07CC	Corticosteroids, potent, combinations with antibiotics
D07CC01	Betamethasone and antibiotics
D07CC02	Fluocinolone acetonide and antibiotics
D07CC03	Fludroxycortide and antibiotics
D07CC04	Beclometasone and antibiotics
D07CC05	Fluocinonide and antibiotics
D07CC06	Fluocortolone and antibiotics
D07CD	Corticosteroids, very potent, combinations with antibiotics
D07CD01	Clobetasol and antibiotics
D07X	Corticosteroids, other combinations
D07XA	Corticosteroids, weak, other combinations
D07XA01	Hydrocortisone
D07XA02	Prednisolone
D07XB	Corticosteroids, moderatley potent, other combinations
D07XB01	Flumetasone
D07XB02	Triamcinolone
D07XB03	Fluprednidene
D07XB04	Fluorometholone
D07XB05	Dexamethasone
D07XB30	Combinations of corticosteroids
D07XC	Corticosteroids, potent, other combinations
D07XC01	Betamethasone
D07XC02	Desoximetasone
D07XC03	Mometasone
D07XC04	Diflucortolone
D07XD	Corticosteroids, very potent, other combinations
D08	Antiseptics and disinfectants
D08A	Antiseptics and disinfectants
D08AA	Acridine derivatives
D08AA01	Ethacridine lactate
D08AA02	Aminoacridine
D08AA03	Euflavine
D08AB	Aluminium agents
D08AC	Biguanides and amidines
D08AC01	Dibromopropamidine
D08AC02	Chlorhexidine
D08AC03	Propamidine
D08AC04	Hexamidine
D08AC05	Polihexanide
D08AC52	Chlorhexidine, combinations
D08AD	Boric acid products
D08AE	Phenol and derivatives
D08AE01	Hexachlorophene
D08AE02	Policresulen
D08AE03	Phenol
D08AE04	Triclosan
D08AE05	Chloroxylenol
D08AE06	Biphenylol
D08AF	Nitrofuran derivatives
D08AF01	Nitrofural
D08AG	Iodine products
D08AG01	Iodine/octylphenoxypolyglycolether
D08AG02	Povidone-iodine
D08AG03	Iodine
D08AG04	Diiodohydroxypropane
D08AH	Quinoline derivatives
D08AH01	Dequalinium
D08AH02	Chlorquinaldol
D08AH03	Oxyquinoline
D08AH30	Clioquinol
D08AJ	Quaternary ammonium compounds
D08AJ01	Benzalkonium
D08AJ02	Cetrimonium
D08AJ03	Cetylpyridinium
D08AJ04	Cetrimide
D08AJ05	Benzoxonium chloride
D08AJ06	Didecyldimethylammonium chloride
D08AJ08	Benzethonium chloride
D08AJ57	Octenidine, combinations
G01AC01	Diiodohydroxyquinoline
D08AJ58	Benzethonium chloride, combinations
D08AJ59	Dodeclonium bromide, combinations
D08AK	Mercurial products
D08AK01	Mercuric amidochloride
D08AK02	Phenylmercuric borate
D08AK03	Mercuric chloride
D08AK04	Mercurochrome
D08AK05	Mercury, metallic
D08AK06	Thiomersal
D08AK30	Mercuric iodide
D08AL	Silver compounds
D08AL01	Silver nitrate
D08AX	Other antiseptics and disinfectants
D08AX01	Hydrogen peroxide
D08AX02	Eosin
D08AX03	Propanol
D08AX04	Tosylchloramide sodium
D08AX05	Isopropanol
D08AX06	Potassium permanganate
D08AX07	Sodium hypochlorite
D08AX08	Ethanol
D08AX53	Propanol, combinations
D09	Medicated dressings
D09A	Medicated dressings
D09AA	Ointment dressings with antiinfectives
D09AA01	Framycetin
D09AA02	Fusidic acid
D09AA03	Nitrofural
D09AA04	Phenylmercuric nitrate
D09AA05	Benzododecinium
D09AA06	Triclosan
D09AA07	Cetylpyridinium
D09AA08	Aluminium chlorohydrate
D09AA09	Povidone-iodine
D09AA10	Clioquinol
D09AA11	Benzalkonium
D09AA12	Chlorhexidine
D09AA13	Iodoform
D09AB	Zinc bandages
D09AB01	Zinc bandage without supplements
D09AB02	Zinc bandage with supplements
D09AX	Soft paraffin dressings
D10	Anti-acne preparations
D10A	Anti-acne preparations for topical use
D10AA	Corticosteroids, combinations for treatment of acne
D10AA01	Fluorometholone
D10AA02	Methylprednisolone
D10AA03	Dexamethasone
D10AB	Preparations containing sulfur
D10AB01	Bithionol
D10AB02	Sulfur
D10AB03	Tioxolone
D10AB05	Mesulfen
D10AD	Retinoids for topical use in acne
D10AD01	Tretinoin
D10AD02	Retinol
D10AD03	Adapalene
D10AD04	Isotretinoin
D10AD05	Motretinide
D10AD51	Tretinoin, combinations
D10AD53	Adapalene, combinations
D10AD54	Isotretinoin, combinations
D10AE	Peroxides
D10AE01	Benzoyl peroxide
D10AE51	Benzoyl peroxide, combinations
D10AF	Antiinfectives for tretament of acne
D10AF01	Clindamycin
D10AF02	Erythromycin
D10AF03	Chloramphenicol
D10AF04	Meclocycline
D10AF51	Clindamycin, combinations
D10AF52	Erythromycin, combinations
D10AX	Other anti-acne preparations for topical use
D10AX01	Aluminium chloride
D10AX02	Resorcinol
D10AX03	Azelaic acid
D10AX04	Aluminium oxide
D10AX05	Dapsone
D10AX30	Various combinations
D10B	Anti-acne preparations for systemic use
D10BA	Retinoids for treatment of acne
D10BA01	Isotretinoin
D10BX	Other anti-acne preparations for systemic use
D10BX01	Ichtasol
D11	Other dermatological preparations
D11A	Other dermatological preparations
D11AA	Antihidrotics
D11AC	Medicated shampoos
D11AC01	Cetrimide
D11AC02	Cadmium compounds
D11AC03	Selenium compounds
D11AC06	Povidone-iodine
D11AC08	Sulphur compounds
D11AC09	Xenysalate
D11AC30	Others
D11AE	Androgens for topical use
D11AE01	Metandienone
D11AF	Wart and anti-corn preparations
D11AH	Agents for atopic dermatitis, excluding corticosteroids
D11AH01	Tacrolimus
D11AH02	Pimecrolimus
D11AH03	Cromoglicic acid
D11AX	Other dermatologicals
D11AX01	Minoxidil
D11AX02	Gamolenic acid
D11AX03	Calcium gluconate
D11AX04	Lithium succinate
D11AX05	Magnesium sulfate
D11AX06	Mequinol
D11AX08	Tiratricol
D11AX09	Oxaceprol
D11AX10	Finasteride
D11AX11	Hydroquinone
D11AX12	Pyrithione zinc
D11AX13	Monobenzone
D11AX16	Eflornithine
D11AX18	Diclofenac
D11AX19	Alitretinoin
D11AX52	Gamolenic acid, combinations
D11AX57	Collagen, combinations
G	Genito urinary system and sex hormones
G01	Gynecological antiinfectives and antiseptics
G01A	Antiinfectives and antiseptics, excl. comb. with corticosteroids
G01AA	Antibiotics
G01AA01	Nystatin
G01AA02	Natamycin
G01AA03	Amphotericin
G01AA04	Candicidin
G01AA05	Chloramphenicol
G01AA06	Hachimycin
G01AA07	Oxytetracycline
G01AA08	Carfecillin
G01AA09	Mepartricin
G01AA10	Clindamycin
G01AA11	Pentamycin
G01AA51	Nystatin, combinations
G01AB	Arsenic compounds
G01AB01	Acetarsol
G01AC	Quinoline derivatives
G01AC02	Clioquinol
G01AC03	Chlorquinaldol
G01AC05	Dequalinium
G01AC06	Broxyquinoline
G01AC30	Oxyquinoline
G01AD	Organic acids
G01AD01	Lactic acid
G01AD02	Acetic acid
G01AD03	Ascorbic acid
G01AE	Sulfonamides
G01AE01	Sulfatolamide
G01AE10	Combinations of sulfonamides
G01AF	Imidazole derivatives
G01AF01	Metronidazole
G01AF02	Clotrimazole
G01AF04	Miconazole
G01AF05	Econazole
G01AF06	Ornidazole
G01AF07	Isoconazole
G01AF08	Tioconazole
G01AF11	Ketoconazole
G01AF12	Fenticonazole
G01AF13	Azanidazole
G01AF14	Propenidazole
G01AF15	Butoconazole
G01AF16	Omoconazole
G01AF17	Oxiconazole
G01AF18	Flutrimazole
G01AF20	Combinations of imidazole derivatives
G01AG	Triazole derivatives
G01AG02	Terconazole
G01AX	Other antiinfectives and antiseptics
G01AX01	Clodantoin
G01AX03	Policresulen
G01AX05	Nifuratel
G01AX06	Furazolidone
G01AX09	Methylrosaniline
G01AX11	Povidone-iodine
G01AX12	Ciclopirox
G01AX13	Protiofate
G01AX14	Lactobacillus fermentum
G01AX15	Copper usnate
G01AX16	Octenidine, combinations
G01B	Antiinfectives/antiseptics in combination with corticosteroids
G01BA	Antibiotics and corticosteroids
G01BC	Quinoline derivatives and corticosteroids
G01BD	Antiseptics and corticosteroids
G01BE	Sulfonamides and corticosteroids
G01BF	Imidazole derivatives and corticosteroids
G02	Other gynecologicals
G02A	Oxytocics
G02AB	Ergot alkaloids
G02AB01	Methylergometrine
G02AB02	Ergot alkaloids
G02AB03	Ergometrine
G02AC	Ergot alkaloids and oxytocin incl. derivatives, in combination
G02AC01	Methylergometrine and oxytocin
G02AD	Prostaglandins
G02AD01	Dinoprost
G02AD02	Dinoprostone
G02AD03	Gemeprost
G02AD04	Carboprost
G02AD05	Sulprostone
G02AD06	Misoprostol
G02AX	Other oxytocics
G02B	Contraceptives for topical use
G02BA	Intrauterine contraceptives
G02BA01	Plastic IUD
G02BA02	Plastic IUD with copper
G02BA03	Plastic IUD with progesterone
G02BB	Intravaginal contraceptives
G02BB01	Vaginal ring with pregestogen and estrogen
G02C	Other gynecologicals
G02CA	Sympathomimetics, labour repressants
G02CA01	Ritodrine
G02CA02	Buphenine
G02CA03	Fenoterol
G02CB	Prolactine inhibitors
G02CB01	Bromocriptine
G02CB02	Lisuride
G02CB03	Cabergoline
G02CB04	Quinagolide
G02CB05	Metergoline
G02CB06	Terguride
G02CC	Antiinflammatory products for vaginal administration
G02CC01	Ibuprofen
G02CC02	Naproxen
G02CC03	Benzydamine
G02CC04	Flunoxaprofen
G02CX	Other gynecologicals
G02CX01	Atosiban
G03	Sex hormones and modulators of the genital system
G03A	Hormonal contraceptives for systemic use
G03AA	Progestogens and estrogens, fixed combinations
G03AA01	Etynodiol and estrogen
G03AA02	Quingestanol and estrogen
G03AA03	Lynestrenol and estrogen
G03AA04	Megestrol and estrogen
G03AA05	Norethisterone and estrogen
G03AA06	Norgestrel and estrogen
G03AA07	Levonorgestrel and estrogen
G03AA08	Medroxyprogesterone and estrogen
G03AA09	Desogestrel and estrogen
G03AA10	Gestodene and estrogen
G03AA11	Norgestimate and estrogen
G03AA12	Drospirenone and estrogen
G03AA13	Norelgestromin and estrogen
G03AA14	Nomegestrol and estrogen
G03AB	Progestogens and estrogens, sequential preparations
G03AB01	Megestrol and estrogen
G03AB02	Lynestrenol and estrogen
G03AB03	Levonorgestrel and estrogen
G03AB04	Norethisterone and estrogen
G03AB05	Desogestrel and estrogen
G03AB06	Gestodene and estrogen
G03AB07	Chlormadinone and estrogen
G03AC	Progestogens
G03AC01	Norethisterone
G03AC02	Lynestrenol
G03AC03	Levonorgestrel
G03AC04	Quingestanol
G03AC05	Megestrol
G03AC06	Medroxyprogesterone
G03AC07	Norgestrienone
G03AC08	Etonogestrel
G03AC09	Desogestrel
G03B	Androgens
G03BA	3-oxoandrosten (4) derivatives
G03BA01	Fluoxymesterone
G03BA02	Methyltestosterone
G03BA03	Testosterone
G03BB	5-androstanon (3) derivatives
G03BB01	Mesterolone
G03BB02	Androstanolone
G03C	Estrogens
G03CA	Natural and semisynthetic estrogens, plain
G03CA01	Ethinylestradiol
G03CA03	Estradiol
G03CA04	Estriol
G03CA06	Chlorotrianisene
G03CA07	Estrone
G03CA09	Promestriene
G03CA53	Estradiol, combinations
G03CA57	Conjugated estrogens
G03CB	Synthetic estrogens, plain
G03CB01	Dienestrol
G03CB02	Diethylstilbestrol
G03CB03	Methallenestril
G03CB04	Moxestrol
G03CC	Estrogens, combinations with other drugs
G03CC02	Dienestrol
G03CC03	Methallenestril
G03CC04	Estrone
G03CC05	Diethylstilbestrol
G03CC06	Estriol
G03CX	Other estrogens
G03CX01	Tibolone
G03D	Progestogens
G03DA	Pregnen (4) derivatives
G03DA01	Gestonorone
G03DA02	Medroxyprogesterone
G03DA03	Hydroxyprogesterone
G03DA04	Progesterone
G03DB	Pregnadien derivatives
G03DB01	Dydrogesterone
G03DB02	Megestrol
G03DB03	Medrogestone
G03DB04	Nomegestrol
G03DB05	Demegestone
G03DB06	Chlormadinone
G03DB07	Promegestone
G03DC	Estren derivatives
G03DC01	Allylestrenol
G03DC02	Norethisterone
G03DC03	Lynestrenol
G03DC04	Ethisterone
G03DC06	Etynodiol
G03DC31	Methylestrenolone
G03E	Androgens and female sex hormones in combination
G03EA	Androgens and estrogens
G03EA01	Methyltestosterone and estrogen
G03EA02	Testosterone and estrogen
G03EA03	Prasterone and estrogen
G03EB	Androgen, progestogen and estrogen in combination
G03EK	Androgens and female sex hormones in combination with other drugs
G03EK01	Methyltestosterone
G03F	Progestogens and estrogens in combination
G03FA	Progestogens and estrogens, combinations
G03FA01	Norethisterone and estrogen
G03FA02	Hydroxyprogesterone and estrogen
G03FA03	Ethisterone and estrogen
G03FA04	Progesterone and estrogen
G03FA05	Methylnortestosterone and estrogen
G03FA06	Etynodiol and estrogen
G03FA07	Lynestrenol and estrogen
G03FA08	Megestrol and estrogen
G03FA09	Noretynodrel and estrogen
G03FA10	Norgestrel and estrogen
G03FA11	Levonorgestrel and estrogen
G03FA12	Medroxyprogesterone and estrogen
G03FA13	Norgestimate and estrogen
G03FA14	Dydrogesterone and estrogen
G03FA15	Dienogest and estrogen
G03FA16	Trimegestone and estrogen
G03FA17	Drospirenone and estrogen
G03FB	Progestogens and estrogens, sequential preparations
G03FB01	Norgestrel and estrogen
G03FB02	Lynestrenol and estrogen
G03FB03	Chlormadinone and estrogen
G03FB04	Megestrol and estrogen
G03FB05	Norethisterone and estrogen
G03FB06	Medroxyprogesterone and estrogen
G03FB07	Medrogestone and estrogen
G03FB08	Dydrogesterone and estrogen
G03FB09	Levonorgestrel and estrogen
G03FB10	Desogestrel and estrogen
G03FB11	Trimegestone and estrogen
G03G	Gonadotropins and other ovulation stimulants
G03GA	Gonadotropins
G03GA01	Chorionic gonadotrophin
G03GA02	Human menopausal gonadotrophin
G03GA03	Serum gonadotrophin
G03GA04	Urofollitrophin
G03GA05	Follitropin alfa
G03GA06	Follitropin beta
G03GA07	Lutropin alfa
G03GA08	Choriogonadotropin alfa
G03GA09	Corifollitropin alfa
G03GA30	Combinations
G03GB	Ovulation stimulants, synthetic
G03GB01	Cyclofenil
G03GB02	Clomifene
G03GB03	Epimestrol
G03H	Antiandrogens
G03HA	Antiandrogens, plain preparations
G03HA01	Cyproterone
G03HB	Antiandrogens and estrogens
G03HB01	Cyproterone and estrogen
G03X	Other sex hormones and modulators of the genital system
G03XA	Antigonadotropins and similar agents
G03XA01	Danazol
G03XA02	Gestrinone
G03XB	Antiprogestogens
G03XB01	Mifepristone
G03XC	Selective estrogen receptor modulators
G03XC01	Raloxifene
G03XC02	Bazedoxifene
G04	Urologicals
G04B	Other urologicals, incl. antispasmodics
G04BA	Acidifiers
G04BA01	Ammonium chloride
G04BA03	Calcium chloride
G04BC	Urinary concrement solvents
G04BD	Urinary antispasmodics
G04BD01	Emepronium
G04BD02	Flavoxate
G04BD03	Meladrazine
G04BD04	Oxybutynin
G04BD05	Terodiline
G04BD06	Propiverine
G04BD07	Tolterodine
G04BD08	Solifenacin
G04BD09	Trospium
G04BD10	Darifenacin
G04BD11	Fesoterodine
G04BE	Drugs used in erectile dysfunction
G04BE01	Alprostadil
G04BE02	Papaverine
G04BE03	Sildenafil
G04BE04	Yohimbin
G04BE05	Phentolamine
G04BE06	Moxisylyte
G04BE07	Apomorphine
G04BE08	Tadalafil
G04BE09	Vardenafil
G04BE30	Combinations
G04BE52	Papaverine, combinations
G04BX	Other urologicals
G04BX01	Magnesium hydroxide
G04BX03	Acetohydroxamic acid
G04BX06	Phenazopyridine
G04BX10	Succinimide
G04BX11	Collagen
G04BX12	Phenyl salicylate
G04BX13	Dimethyl sulfoxide
G04BX14	Dapoxetine
G04C	Drugs used in benign prostatic hypertrophy
G04CA	Alpha-adrenoreceptor antagonists
G04CA01	Alfuzosin
G04CA02	Tamsulosin
G04CA03	Terazosin
G04CA04	Silodosin
G04CA51	Alfuzosin and finasteride
G04CA52	Tamsulosin and dutasteride
G04CB	Testosterone-5-alpha reductase inhibitors
G04CB01	Finasteride
G04CB02	Dutasteride
G04CX	Other drugs used in benign prostatic hypertrophy
G04CX01	Pygeum africanum
G04CX02	Serenoa repens
G04CX03	Mepartricin
H	Systemic hormonal preparations, excl. sex hormones and insulins
H01	Pituitary and hypothalamic hormones and analogues
H01A	Anterior pituitary lobe hormones and analogues
H01AA	ACTH
H01AA01	Corticotropin
H01AA02	Tetracosactide
H01AB	Thyrotropin
H01AB01	Thyrotropin
H01AC	Somatropin and somatropin agonists
H01AC01	Somatropin
H01AC02	Somatrem
H01AC03	Mecasermin
H01AC04	Sermorelin
H01AC05	Mecasermin rinfabate
H01AX	Othr anterior pituitary lobe hormones & analogues
H01AX01	Pegvisomant
H01B	Posterior pituitary lobe hormones
H01BA	Vasopressin and analogues
H01BA01	Vasopressin
H01BA02	Desmopressin
H01BA03	Lypressin
H01BA04	Terlipressin
H01BA05	Ornipressin
H01BA06	Argipressin
H01BB	Oxytocin and analogues
H01BB01	Demoxytocin
H01BB02	Oxytocin
H01BB03	Carbetocin
H01C	Hypothalamic hormones
H01CA	Gonadotropin-releasing hormones
H01CA01	Gonadorelin
H01CA02	Nafarelin
H01CA03	Histrelin
H01CB	Antigrowth hormone
H01CB01	Somatostatin
H01CB02	Octreotide
H01CB03	Lanreotide
H01CB04	Vapreotide
H01CC	Anti-gonadotropin-releasing hormones
H01CC01	Ganirelix
H01CC02	Cetrorelix
H02	Corticosteroids for systemic use
H02A	Corticosteroids for systemic use, plain
H02AA	Mineralocorticoids
H02AA01	Aldosterone
H02AA02	Fludrocortisone
H02AA03	Desoxycortone
H02AB	Glucocorticoids
H02AB01	Betamethasone
H02AB02	Dexamethasone
H02AB03	Fluocortolone
H02AB04	Methylprednisolone
H02AB05	Paramethasone
H02AB06	Prednisolone
H02AB07	Prednisone
H02AB08	Triamcinolone
H02AB09	Hydrocortisone
H02AB10	Cortisone
H02AB11	Prednylidene
H02AB12	Rimexolone
H02AB13	Deflazacort
H02AB14	Cloprednol
H02AB15	Meprednisone
H02AB17	Cortivazol
H02B	Corticosteroids for systemic use, combinations
H02BX	Corticosteroids for systemic use, combinations
H02BX01	Methylprednisolone, combinations
H02C	Antiadrenal preparations
H02CA	Anticorticosteroids
H02CA01	Trilostane
H03	Thyroid therapy
H03A	Thyroid preparations
H03AA	Thyroid hormones
H03AA01	Levothyroxine sodium
H03AA02	Liothyronine sodium
H03AA03	Combinations of levothyroxine and liothyronine
H03AA04	Tiratricol
H03AA05	Thyroid gland preparations
H03B	Antithyroid preparations
H03BA	Thiouracils
H03BA01	Methylthiouracil
H03BA02	Propylthiouracil
H03BA03	Benzylthiouracil
H03BB	Sulfur-containing imidazole derivatives
H03BB01	Carbimazole
H03BB02	Thiamazole
H03BB52	Thiamazole, combinations
H03BC	Perchlorates
H03BC01	Potassium perchlorate
H03BX	Other antithyroid preparations
H03BX01	Diiodotyrosine
H03BX02	Dibromotyrosine
H03C	Iodine therapy
H03CA	Iodine therapy
H04	Pancreatic hormones
H04A	Glycogenolytic hormones
H04AA	Glycogenolytic hormones
H04AA01	Glucagon
H05	Calcium homeostasis
H05A	Parathyroid hormones and analogues
H05AA	Parathyroid hormones and analogues
H05AA01	Parathyroid gland extract
H05AA02	Teriparatide
H05AA03	Parathyroid hormone
H05B	Anti-parathyroid agents
H05BA	Calcitonin preparations
H05BA01	Calcitonin (salmon synthetic)
H05BA02	Calcitonin (pork natural)
H05BA03	Calcitonin (human synthetic)
H05BA04	Elcatonin
H05BX	Other anti-parathyroid agents
H05BX01	Cinacalcet
H05BX02	Paricalcitol
H05BX03	Doxercalciferol
J	Antiinfectives for systemic use
J01	Antibacterials for systemic use
J01A	Tetracyclines
J01AA	Tetracyclines
J01AA01	Demeclocycline
J01AA02	Doxycycline
J01AA03	Chlortetracycline
J01AA04	Lymecycline
J01AA05	Metacycline
J01AA06	Oxytetracycline
J01AA07	Tetracycline
J01AA08	Minocycline
J01AA09	Rolitetracycline
J01AA10	Penimepicycline
J01AA11	Clomocycline
J01AA12	Tigecycline
J01AA20	Combinations of tetracyclines
J01AA56	Oxytetracycline, combinations
J01B	Amphenicols
J01BA	Amphenicols
J01BA01	Chloramphenicol
J01BA02	Thiamphenicol
J01BA52	Thiamphenicol, combinations
J01C	Beta-lactam antibacterials, penicillins
J01CA	Penicillins with extended spectrum
J01CA01	Ampicillin
J01CA02	Pivampicillin
J01CA03	Carbenicillin
J01CA04	Amoxicillin
J01CA05	Carindacillin
J01CA06	Bacampicillin
J01CA07	Epicillin
J01CA08	Pivmecillinam
J01CA09	Azlocillin
J01CA10	Mezlocillin
J01CA11	Mecillinam
J01CA12	Piperacillin
J01CA13	Ticarcillin
J01CA14	Metampicillin
J01CA15	Talampicillin
J01CA16	Sulbenicillin
J01CA17	Temocillin
J01CA18	Hetacillin
J01CA20	Combinations
J01CA51	Ampicillin, combinations
J01CE	Beta-lactamase sensitive penicillins
J01CE01	Benzylpenicillin
J01CE02	Phenoxymethylpenicillin
J01CE03	Propicillin
J01CE04	Azidocillin
J01CE05	Pheneticillin
J01CE06	Penamecillin
J01CE07	Clometocillin
J01CE08	Benzathine benzylpenicillin
J01CE09	Procaine penicillin
J01CE10	Benzathine phenoxymethylpenicillin
J01CE30	Combinations
J01CF	Beta-lactamase resistant penicillins
J01CF01	Dicloxacillin
J01CF02	Cloxacillin
J01CF03	Methicillin
J01CF04	Oxacillin
J01CF05	Flucloxacillin
J01CG	Beta-lactamase inhibitors
J01CG01	Sulbactam
J01CG02	Tazobactam
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors
J01CR01	Ampicillin and enzyme inhibitor
J01CR02	Amoxicillin and enzyme inhibitor
J01CR03	Ticarcillin and enzyme inhibitor
J01CR04	Sultamicillin
J01CR05	Piperacillin and enzyme inhibitor
J01CR50	Combinations of penicillins
J01D	Other beta-lactam antibacterials
J01DB	First-generation cephalosporins
J01DB01	Cefalexin
J01DB02	Cefaloridine
J01DB03	Cefalotin
J01DB04	Cefazolin
J01DB05	Cefadroxil
J01DB06	Cefazedone
J01DB07	Cefatrizine
J01DB08	Cefapirin
J01DB09	Cefradine
J01DB10	Cefacetrile
J01DB11	Cefroxadine
J01DB12	Ceftezole
J01DC	Second-generation cephalosporins
J01DC01	Cefoxitin
J01DC02	Cefuroxime
J01DC03	Cefamandole
J01DC04	Cefaclor
J01DC05	Cefotetan
J01DC06	Cefonicid
J01DC07	Cefotiam
J01DC08	Loracarbef
J01DC09	Cefmetazole
J01DC10	Cefprozil
J01DC11	Ceforanide
J01DD	Third-generation cephalosporins
J01DD01	Cefotaxime
J01DD02	Ceftazidime
J01DD03	Cefsulodin
J01DD04	Ceftriaxone
J01DD05	Cefmenoxime
J01DD06	Latamoxef
J01DD07	Ceftizoxime
J01DD08	Cefixime
J01DD09	Cefodizime
J01DD10	Cefetamet
J01DD11	Cefpiramide
J01DD12	Cefoperazone
J01DD13	Cefpodoxime
J01DD14	Ceftibuten
J01DD15	Cefdinir
J01DD16	Cefditoren
J01DD17	Cefcapene
J01DD54	Ceftriaxone, combinations
J01DD62	Cefoperazone, combinations
J01DE	Fourth-generation cephalosporins
J01DE01	Cefepime
J01DE02	Cefpirome
J01DE03	Cefozopran
J01DF	Monobactams
J01DF01	Aztreonam
J01DH	Carbapenems
J01DH02	Meropenem
J01DH03	Ertapenem
J01DH04	Doripenem
J01DH05	Biapenem
J01DH51	Imipenem and enzyme inhibitor
J01DH55	Panipenem and betamipron
J01DI	Other cephalosporins
J01DI01	Ceftobiprole medocaril
J01E	Sulfonamides and trimethoprim
J01EA	Trimethoprim and derivatives
J01EA01	Trimethoprim
J01EA02	Brodimoprim
J01EA03	Iclaprim
J01EB	Short-acting sulfonamides
J01EB01	Sulfaisodimidine
J01EB02	Sulfamethizole
J01EB03	Sulfadimidine
J01EB04	Sulfapyridine
J01EB05	Sulfafurazole
J01EB06	Sulfanilamide
J01EB07	Sulfathiazole
J01EB08	Sulfathiourea
J01EB20	Combinations
J01EC	Intermediate-acting sulfonamides
J01EC01	Sulfamethoxazole
J01EC02	Sulfadiazine
J01EC03	Sulfamoxole
J01EC20	Combinations
J01ED	Long-acting sulfonamides
J01ED01	Sulfadimethoxine
J01ED02	Sulfalene
J01ED03	Sulfametomidine
J01ED04	Sulfametoxydiazine
J01ED05	Sulfamethoxypyridazine
J01ED06	Sulfaperin
J01ED07	Sulfamerazine
J01ED08	Sulfaphenazole
J01ED09	Sulfamazon
J01ED20	Combinations
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01	Sulfamethoxazole and trimethoprim
J01EE02	Sulfadiazine and trimethoprim
J01EE03	Sulfametrole and trimethoprim
J01EE04	Sulfamoxole and trimethoprim
J01EE05	Sulfadimidine and trimethoprim
J01EE06	Sulfadiazine and tetroxoprim
J01EE07	Sulfamerazine and trimethoprim
J01F	Macrolides, lincosamides and streptogramins
J01FA	Macrolides
J01FA01	Erythromycin
J01FA02	Spiramycin
J01FA03	Midecamycin
J01FA05	Oleandomycin
J01FA06	Roxithromycin
J01FA07	Josamycin
J01FA08	Troleandomycin
J01FA09	Clarithromycin
J01FA10	Azithromycin
J01FA11	Miocamycin
J01FA12	Rokitamycin
J01FA13	Dirithromycin
J01FA14	Flurithromycin
J01FA15	Telithromycin
J01FF	Lincosamides
J01FF01	Clindamycin
J01FF02	Lincomycin
J01FG	Streptogramins
J01FG01	Pristinamycin
J01FG02	Quinupristin/dalfopristin
J01G	Aminoglycoside antibacterials
J01GA	Streptomycins
J01GA01	Streptomycin
J01GA02	Streptoduocin
J01GB	Other aminoglycosides
J01GB01	Tobramycin
J01GB03	Gentamicin
J01GB04	Kanamycin
J01GB05	Neomycin
J01GB06	Amikacin
J01GB07	Netilmicin
J01GB08	Sisomicin
J01GB09	Dibekacin
J01GB10	Ribostamycin
J01GB11	Isepamicin
J01GB12	Arbekacin
J01M	Quinolone antibacterials
J01MA	Fluoroquinolones
J01MA01	Ofloxacin
J01MA02	Ciprofloxacin
J01MA03	Pefloxacin
J01MA04	Enoxacin
J01MA05	Temafloxacin
J01MA06	Norfloxacin
J01MA07	Lomefloxacin
J01MA08	Fleroxacin
J01MA09	Sparfloxacin
J01MA10	Rufloxacin
J01MA11	Grepafloxacin
J01MA12	Levofloxacin
J01MA13	Trovafloxacin
J01MA14	Moxifloxacin
J01MA15	Gemifloxacin
J01MA16	Gatifloxacin
J01MA17	Prulifloxacin
J01MA18	Pazufloxacin
J01MA19	Garenoxacin
J01MB	Other quinolones
J01MB01	Rosoxacin
J01MB02	Nalidixic acid
J01MB03	Piromidic acid
J01MB04	Pipemidic acid
J01MB05	Oxolinic acid
J01MB06	Cinoxacin
J01MB07	Flumequine
J01R	Combinations of antibacterials
J01RA	Combinations of antibacterials
J01RA01	Penicillins, comb. with other antibacterials
J01RA02	Sulfonamides, comb. with other antibacterials (excl. trimethoprim)
J01RA03	Cefuroxime, comb. with other antibacterials
J01RA04	Spiramycin, combinations with other antibacterials
J01X	Other antibacterials
J01XA	Glycopeptide antibacterials
J01XA01	Vancomycin
J01XA02	Teicoplanin
J01XA03	Telavancin
J01XA04	Dalbavancin
J01XA05	Oritavancin
J01XB	Polymyxins
J01XB01	Colistin
J01XB02	Polymyxin B
J01XC	Steroid antibacterials
J01XC01	Fusidic acid
J01XD	Imidazole derivatives
J01XD01	Metronidazole
J01XD02	Tinidazole
J01XD03	Ornidazole
J01XE	Nitrofuran derivatives
J01XE01	Nitrofurantoin
J01XE02	Nifurtoinol
J01XX	Other antibacterials
J01XX01	Fosfomycin
J01XX02	Xibornol
J01XX03	Clofoctol
J01XX04	Spectinomycin
J01XX05	Methenamine
J01XX06	Mandelic acid
J01XX07	Nitroxoline
J01XX08	Linezolid
J01XX09	Daptomycin
J01XX10	Bacitracin
J02	Antimycotics for systemic use
J02A	Antimycotics for systemic use
J02AA	Antibiotics
J02AA01	Amphotericin
J02AA02	Hachimycin
J02AB	Imidazole derivatives
J02AB01	Miconazole
J02AB02	Ketoconazole
J02AC	Triazole derivatives
J02AC01	Fluconazole
J02AC02	Itraconazole
J02AC03	Voriconazole
J02AC04	Posaconazole
J02AX	Other antimycotics for systemic use
J02AX01	Flucytosine
J02AX04	Caspofungin
J02AX05	Micafungin
J02AX06	Anidulafungin
J04	Antimycobacterials
J04A	Drugs for treatment of tuberculosis
J04AA	Aminosalicylic acid and derivatives
J04AA01	Aminosalicylic acid
J04AA02	Sodium aminosalicylate
J04AA03	Calcium aminosalicylate
J04AB	Antibiotics
J04AB01	Cycloserine
J04AB02	Rifampicin
J04AB03	Rifamycin
J04AB04	Rifabutin
J04AB05	Rifapentin
J04AB30	Capreomycin
J04AC	Hydrazides
J04AC01	Isoniazid
J04AC51	Isoniazid, combinations
J04AD	Thiocarbamide derivatives
J04AD01	Protionamide
J04AD02	Tiocarlide
J04AD03	Ethionamide
J04AK	Other drugs for treatment of tuberculosis
J04AK01	Pyrazinamide
J04AK02	Ethambutol
J04AK03	Terizidone
J04AK04	Morinamide
J04AM	Combinations of drugs for treatment of tuberculosis
J04AM01	Streptomycin and isoniazid
J04AM02	Rifampicin and isoniazid
J04AM03	Ethambutol and isoniazid
J04AM04	Thioacetazone and isoniazid
J04AM05	Rifampicin, pyrazinamide and isoniazid
J04AM06	Rifampicin, pyrazinamide, ethambutol and isoniazid
J04B	Drugs for treatment of lepra
J04BA	Drugs for treatment of lepra
J04BA01	Clofazimine
J04BA02	Dapsone
J04BA03	Aldesulfone sodium
J05	Antivirals for systemic use
J05A	Direct acting antivirals
J05AA	Thiosemicarbazones
J05AA01	Metisazone
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01	Aciclovir
J05AB02	Idoxuridine
J05AB03	Vidarabine
J05AB04	Ribavirin
J05AB06	Ganciclovir
J05AB09	Famciclovir
J05AB11	Valaciclovir
J05AB12	Cidofovir
J05AB13	Penciclovir
J05AB14	Valganciclovir
J05AB15	Brivudine
J05AC	Cyclic amines
J05AC02	Rimantadine
J05AC03	Tromantadine
J05AD	Phosphonic acid derivatives
J05AD01	Foscarnet
J05AD02	Fosfonet
J05AE	Protease inhibitors
J05AE01	Saquinavir
J05AE02	Indinavir
J05AE03	Ritonavir
J05AE04	Nelfinavir
J05AE05	Amprenavir
J05AE06	Lopinavir
J05AE07	Fosamprenavir
J05AE08	Atazanavir
J05AE09	Tipranavir
J05AE10	Darunavir
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF01	Zidovudine
J05AF02	Didanosine
J05AF03	Zalcitabine
J05AF04	Stavudine
J05AF05	Lamivudine
J05AF06	Abacavir
J05AF07	Tenofovir disoproxil
J05AF08	Adefovir dipivoxil
J05AF09	Emtricitabine
J05AF10	Entecavir
J05AF11	Telbivudine
J05AF12	Clevudine
J05AG	Non-nucleoside reverse transcriptase inhibitors
J05AG01	Nevirapine
J05AG02	Delavirdine
J05AG03	Efavirenz
J05AG04	Etravirine
J05AH	Neuraminidase inhibitors
J05AH01	Zanamivir
J05AH02	Oseltamivir
J05AR	Antivirals for treatment of HIV infections, combinations
J05AR01	Zidovudine and lamivudine
J05AR02	Lamivudine and abacavir
J05AR03	Tenofovir disoproxil and emtricitabine
J05AR04	Zidovudine, lamivudine and abacavir
J05AR05	Zidovudine, lamivudine and nevirapine
J05AR06	Emtricitabine, tenofovir disoproxil and efavirenz
J05AR07	Stavudine, lamivudine and nevirapine
J05AX	Other antivirals
J05AX01	Moroxydine
J05AX02	Lysozyme
J05AX05	Inosine pranobex
J05AX06	Pleconaril
J05AX07	Enfuvirtide
J05AX08	Raltegravir
J05AX09	Maraviroc
J05AX10	Maribavir
J06	Immune sera and immunoglobulins
J06A	Immune sera
J06AA	Immune sera
J06AA01	Diphteria antitoxin
J06AA02	Tetanus antitoxin
J06AA03	Snake venom antiserum
J06AA04	Botulinum antitoxin
J06AA05	Gas-gangrene sera
J06AA06	Rabies serum
J06B	Immunoglobulins
J06BA	Immunoglobulins, normal human
J06BA01	Immunoglobulins, normal human, for extravascular adm.
J06BA02	Immunoglobulins, normal human, for intravascular adm.
J06BB	Specific immunoglobulins
J06BB01	Anti-D (rh) immunoglobulin
J06BB02	Tetanus immunoglobulin
J06BB03	Varicella/zoster immunoglobulin
J06BB04	Hepatitis B immunoglobulin
J06BB05	Rabies immunoglobulin
J06BB06	Rubella immunoglobulin
J06BB07	Vaccinia immunoglobulin
J06BB08	Staphylococcus immunoglobulin
J06BB09	Cytomegalovirus immunoglobulin
J06BB10	Diphtheria immunoglobulin
J06BB11	Hepatitis A immunoglobulin
J06BB12	Encephalitis, tick borne immunoglobulin
J06BB13	Pertussis immunoglobulin
J06BB14	Morbilli immunoglobulin
J06BB15	Parotitis immunoglobulin
J06BB16	Palivizumab
J06BB30	Combinations
J06BC	Other immunoglobulins
J06BC01	Nebacumab (centoxin)
J07	Vaccines
J07A	Bacterial vaccines
J07AC	Anthrax vaccines
J07AC01	Anthrax antigen
J07AD	Brucellosis vaccines
J07AD01	Brucella antigen
J07AE	Cholera vaccines
J07AE01	Cholera, inactivated, whole cell
J07AE02	Cholera, live attenuated
J07AE51	Cholera, combinations with typhoid vaccine, inactivated, whole cell
J07AF	Diphtheria vaccines
J07AF01	Diphtheria toxoid
J07AG	Hemophilus influenzae B vaccines
J07AG01	Hemophilus influenzae B, purified antigen conjugated
J07AG51	Hemophilus influenzae B, combinations with toxoids
J07AG52	Hemophilus influenzae B, combinations with pertussis and toxoids
J07AG53	Hemophilus influenzae B, combinations with meningococcus C, conjugated
J07AH	Meningococcal vaccines
J07AH01	Meningococcus A, purified polysaccharides antigen
J07AH02	Other meningococcal monovalent purified polysaccharides antigen
J07AH03	Meningococcus, bivalent purified polysaccharides antigen
J07AH04	Meningococcus, tetravalent purified polysaccharides anatigen
J07AH05	Other meningococcal polyvalent purified polysaccharides antigen
J07AH06	Meningococcus B, outer membrane vesicle vaccine
J07AH07	Meningococcus C, purified polysaccharides antigen conjugated
J07AH08	Meningococcus, tetravalent purified polysaccharides antigen conjugated
J07AJ	Pertussis vaccines
J07AJ01	Pertussis, inactivated, whole cell
J07AJ02	Pertussis, purified antigen
J07AJ51	Pertussis, inactivated, whole cell, combinations with toxoids
J07AJ52	Pertussis, purified antigen, combinations with toxoids
J07AK	Plague vaccines
J07AK01	Plague, inactivated, whole cell
J07AL	Pneumococcal vaccines
J07AL01	Pneumococcus, purified polysaccharides antigen
J07AL02	Pneumococcus, purified polysaccharides antigen conjugated
J07AL52	Pneumococcus purified polysaccharides antigen and Haemophilus influenzae, conjugated
J07AM	Tetanus vaccines
J07AM01	Tetanus toxoid
J07AM51	Tetanus toxoid, combinations with diphtheria toxoid
J07AM52	Tetanus toxoid, combinations with tetanus immunoglobulin
J07AN	Tuberculosis vaccines
J07AN01	Tuberculosis, live attenuated
J07AP	Typhoid vaccines
J07AP01	Typhoid, oral, live attenuated
J07AP02	Typhoid, inactivated, whole cell
J07AP03	Typhoid, purified polysaccharide antigen
J07AP10	Typhoid, combinations with paratyphi types
J07AR	Typhus (exanthematicus) vaccines
J07AR01	Typhus exanthematicus, inactivated, whole cell
J07AX	Other bacterial vaccines
J07B	Viral vaccines
J07BA	Encephalitis vaccines
J07BA01	Encephalitis, tick borne, inactivated, whole virus
J07BA02	Encephalitis, Japanese, inactivated, whole virus
J07BB	Influenza vaccines
J07BB01	Influenza, inactivated, whole virus
J07BB02	Influenza, purified antigen
J07BB03	Influenza, live attenuated
J07BC	Hepatitis vaccines
J07BC01	Hepatitis B, purified antigen
J07BC02	Hepatitis A, inactivated, whole virus
J07BC20	Combinations
J07BD	Measles vaccines
J07BD01	Measles, live attenuated
J07BD51	Measles, combinations with mumps, live attenuated
J07BD52	Measles, combinations with mumps and rubella, live attenuated
J07BD53	Measles, combinations with rubella, live attenuated
J07BD54	Measles, combinations with mumps, rubella and varicella, live attenuated
J07BE	Mumps vaccines
J07BE01	Mumps, live attenuated
J07BF	Poliomyelitis vaccines
J07BF01	Poliomyelitis oral, monovalent, live attenuated
J07BF02	Poliomyelitis oral, trivalent, live attenuated
J07BF03	Poliomyelitis, trivalent, inactivated, whole virus
J07BG	Rabies vaccines
J07BG01	Rabies, inactivated, whole virus
J07BH	Rota virus diarrhea vaccines
J07BH01	Rota virus, live attenuated
J07BH02	Rota virus, pentavalent, live, reassorted
J07BJ	Rubella vaccines
J07BJ01	Rubella, live attenuated
J07BJ51	Rubella, combination with mumps, live attenuated
J07BK	Varicella zoster vaccines
J07BK01	Varicella, live attenuated
J07BK02	Zoster, live attenuated
J07BL	Yellow fever vaccines
J07BL01	Yellow fever, live attenuated
J07BM	Papillomavirus vaccines
J07BM01	Papillomavirus (human types 6, 11, 16, 18)
J07BM02	Papillomavirus (human types 16, 18)
J07BX	Other viral vaccines
J07C	Bacterial and viral vaccines, combined
J07CA	Bacterial and viral vaccines, combined
J07CA01	Diphtheria-poliomyelitis-tetanus
J07CA02	Diphtheria-pertussis-poliomyelitis-tetanus
J07CA03	Diphtheria-rubella-tetanus
J07CA04	Hemophilus influenzae B and poliomyelitis
J07CA05	Diphtheria-hepatitis B-pertussis-tetanus
J07CA06	Diphtheria-hemophilus influenzae B-pertussis- poliomyelitis-tetanus
J07CA07	Diphtheria-hepatitis B-tetanus
J07CA08	Hemophilus influenzae B and hepatitis B
J07CA09	Diphteria-hemophilus influenzae B-pertussis- poliomyelitis-tetanus-hepatitis B
J07CA11	Diphtheria-hemophilus influenzae B-pertussis- tetanus-hepatitus B
J07CA12	Diphtheria-pertussis-poliomyelitis-tetanus- hepatitis B
J07CA13	Diphtheria-hemophilus influenzae B-pertussis- tetanus-hepatitis B-meningococcus A + C
J07X	Other vaccines
L	Antineoplastic and immunomodulating agents
L01	Antineoplastic agents
L01A	Alkylating agents
L01AA	Nitrogen mustard analogues
L01AA01	Cyclophosphamide
L01AA02	Chlorambucil
L01AA03	Melphalan
L01AA05	Chlormethine
L01AA06	Ifosfamide
L01AA07	Trofosfamide
L01AA08	Prednimustine
L01AA09	Bendamustine
L01AB	Alkyl sulphonates
L01AB01	Busulfan
L01AB02	Treosulfan
L01AB03	Mannosulfan
L01AC	Ethylene imines
L01AC01	Thiotepa
L01AC02	Triaziquone
L01AC03	Carboquone
L01AD	Nitrosoureas
L01AD01	Carmustine
L01AD02	Lomustine
L01AD03	Semustine
L01AD04	Streptozocin
L01AD05	Fotemustine
L01AD06	Nimustine
L01AD07	Ranimustine
L01AG	Epoxides
L01AG01	Etoglucid
L01AX	Other alkylating agents
L01AX01	Mitobronitol
L01AX02	Pipobroman
L01AX03	Temozolomide
L01AX04	Dacarbazine
L01B	Antimetabolites
L01BA	Folic acid analogues
L01BA01	Methotrexate
L01BA03	Raltitrexed
L01BA04	Pemetrexed
L01BA05	Pralatrexate
L01BB	Purine analogues
L01BB02	Mercaptopurine
L01BB03	Tioguanine
L01BB04	Cladribine
L01BB05	Fludarabine
L01BB06	Clofarabine
L01BB07	Nelarabine
L01BC	Pyrimidine analogues
L01BC01	Cytarabine
L01BC02	Fluorouracil
L01BC03	Tegafur
L01BC04	Carmofur
L01BC05	Gemcitabine
L01BC06	Capecitabine
L01BC07	Azacitidine
L01BC08	Decitabine
L01BC52	Fluorouracil, combinations
L01BC53	Tegafur, combinations
L01C	Plant alkaloids and other natural products
L01CA	Vinca alkaloids and analogues
L01CA01	Vinblastine
L01CA02	Vincristine
L01CA03	Vindesine
L01CA04	Vinorelbine
L01CA05	Vinflunine
L01CB	Podophyllotoxin derivatives
L01CB01	Etoposide
L01CB02	Teniposide
L01CC	Colchicine derivatives
L01CC01	Demecolcine
L01CD	Taxanes
L01CD01	Paclitaxel
L01CD02	Docetaxel
L01CD03	Paclitaxel poliglumex
L01CX	Other plant alkaloids and natural products
L01CX01	Trabectedin
L01D	Cytotoxic antibiotics and related substances
L01DA	Actinomycines
L01DA01	Dactinomycin
L01DB	Anthracyclines and related substances
L01DB01	Doxorubicin
L01DB02	Daunorubicin
L01DB03	Epirubicin
L01DB04	Aclarubicin
L01DB05	Zorubicin
L01DB06	Idarubicin
L01DB07	Mitoxantrone
L01DB08	Pirarubicin
L01DB09	Valrubicin
L01DC	Other cytotoxic antibiotics
L01DC01	Bleomycin
L01DC02	Plicamycin
L01DC03	Mitomycin
L01DC04	Ixabepilone
L01X	Other antineoplastic agents
L01XA	Platinum compounds
L01XA01	Cisplatin
L01XA02	Carboplatin
L01XA03	Oxaliplatin
L01XA04	Satraplatin
L01XB	Methylhydrazines
L01XB01	Procarbazine
L01XC	Monoclonal antibodies
L01XC01	Edrecolomab
L01XC02	Rituximab
L01XC03	Trastuzumab
L01XC04	Alemtuzumab
L01XC05	Gemtuzumab
L01XC06	Cetuximab
L01XC07	Bevacizumab
L01XC08	Panitumumab
L01XC09	Catumaxomab
L01XC10	Ofatumumab
L01XD	Sensitizers used in photodynamic/radiation therapy
L01XD01	Porfimer sodium
L01XD03	Methyl aminolevulinate
L01XD04	Aminolevulinic acid
L01XD05	Temoporfin
L01XD06	Efaproxiral
L01XE	Protein kinase inhibitors
L01XE01	Imatinib
L01XE02	Gefitinib
L01XE03	Erlotinib
L01XE04	Sunitinib
L01XE05	Sorafenib
L01XE06	Dasatinib
L01XE07	Lapatinib
L01XE08	Nilotinib
L01XE09	Temsirolimus
L01XE10	Everolimus
L01XE11	Pazopanib
L01XX	Other antineoplastic agents
L01XX01	Amsacrine
L01XX02	Asparaginase
L01XX03	Altretamine
L01XX05	Hydroxycarbamide
L01XX07	Lonidamine
L01XX08	Pentostatin
L01XX09	Miltefosine
L01XX10	Masoprocol
L01XX11	Estramustine
L01XX14	Tretinoin
L01XX16	Mitoguazone
L01XX17	Topotecan
L01XX18	Tiazofurin
L01XX19	Irinotecan
L01XX22	Alitretinoin
L01XX23	Mitotane
L01XX24	Pegaspargase
L01XX25	Bexarotene
L01XX27	Arsenic trioxide
L01XX29	Denileukin difitox
L01XX32	Bortezomib
L01XX33	Celecoxib
L01XX35	Anagrelide
L01XX36	Oblimersen
L01XX37	Sitimagene ceradenovec
L01XX38	Vorinostat
L01XX39	Romidepsin
L01XY	Combinations of antineoplastic agents
L02	Endocrine therapy
L02A	Hormones and related agents
L02AA	Estrogens
L02AA01	Diethylstilbestrol
L02AA02	Polyestradiol phosphate
L02AA03	Ethinylestradiol
L02AA04	Fosfestrol
L02AB	Progestogens
L02AB01	Megestrol
L02AB02	Medroxyprogesterone
L02AB03	Gestonorone
L02AE	Gonadotropin releasing hormone analogues
L02AE01	Buserelin
L02AE02	Leuprorelin
L02AE03	Goserelin
L02AE04	Triptorelin
L02AX	Other hormones
L02B	Hormone antagonists and related agents
L02BA	Anti-estrogens
L02BA01	Tamoxifen
L02BA02	Toremifene
L02BA03	Fulvestrant
L02BB	Anti-androgens
L02BB01	Flutamide
L02BB02	Nilutamide
L02BB03	Bicalutamide
L02BG	Enzyme inhibitors
L02BG01	Aminogluthetimide
L02BG02	Formestane
L02BG03	Anastrozole
L02BG04	Letrozole
L02BG05	Vorozole
L02BG06	Exemestane
L02BX	Other hormone antagonists and related agents
L02BX01	Abarelix
L02BX02	Degarelix
L03	Immunostimulants
L03A	Immunostimulants
L03AA	Colony stimulating factors
L03AA02	Filgrastim
L03AA03	Molgramostim
L03AA09	Sargramostim
L03AA10	Lenograstim
L03AA12	Ancestim
L03AA13	Pegfilgrastim
L03AB	Interferons
L03AB01	Interferon alfa natural
L03AB02	Interferon beta natural
L03AB03	Interferon gamma
L03AB04	Interferon alfa-2a
L03AB05	Interferon alfa-2b
L03AB06	Interferon alfa-n1
L03AB07	Interferon beta-1a
L03AB08	Interferon beta-1b
L03AB09	Interferon alfacon-1
L03AB10	Peginterferon alfa-2b
L03AB11	Peginterferon alfa-2a
L03AB60	Peginterferon alfa-2b, combinations
L03AB61	Peginterferon alfa-2a, combinations
L03AC	Interleukins
L03AC01	Aldesleukin
L03AC02	Oprelvekin
L03AX	Other immunostimulants
L03AX01	Lentinan
L03AX02	Roquinimex
L03AX03	BCG vaccine
L03AX04	Pegademase
L03AX05	Pidotimod
L03AX07	Poly I:C
L03AX08	Poly ICLC
L03AX09	Thymopentin
L03AX10	Immunocyanin
L03AX11	Tasonermin
L03AX12	Melanoma vaccine
L03AX13	Glatiramer acetate
L03AX14	Histamine dihydrochloride
L03AX15	Mifamurtide
L03AX16	Plerixafor
L04	Immunosuppressants
L04A	Immunosuppressants
L04AA	Selective immunosuppressants
L04AA02	Muromonab-CD3
L04AA03	Antilymphocyte immunoglobulin (horse)
L04AA04	Antithymocyte immunoglobulin (rabbit)
L04AA06	Mycophenolic acid
L04AA10	Sirolimus
L04AA13	Leflunomide
L04AA15	Alefacept
L04AA18	Everolimus
L04AA19	Gusperimus
L04AA21	Efalizumab
L04AA22	Abetimus
L04AA23	Natalizumab
L04AA24	Abatacept
L04AA25	Eculizumab
L04AB	Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB01	Etanercept
L04AB02	Infliximab
L04AB03	Afelimomab
L04AB04	Adalimumab
L04AB05	Certolizumab pegol
L04AB06	Golimumab
L04AC	Interleukin inhibitors
L04AC01	Daclizumab
L04AC02	Basiliximab
L04AC03	Anakinra
L04AC04	Rilonacept
L04AC05	Ustekinumab
L04AC06	Mepolizumab
L04AC07	Tocilizumab
L04AC08	Canakinumab
L04AD	Calcineurin inhibitors
L04AD01	Ciclosporin
L04AD02	Tacrolimus
L04AX	Other immunosuppressants
L04AX01	Azathioprine
L04AX02	Thalidomide
L04AX03	Methotrexate
L04AX04	Lenalidomide
M	Musculo-skeletal system
M01	Antiinflammatory and antirheumatic products
M01A	Antiinflammatory and antirheumatic products, non-steroids
M01AA	Butylpyrazolidines
M01AA01	Phenylbutazone
M01AA02	Mofebutazone
M01AA03	Oxyphenbutazone
M01AA05	Clofezone
M01AA06	Kebuzone
M01AB	Acetic acid derivatives and related substances
M01AB01	Indometacin
M01AB02	Sulindac
M01AB03	Tolmetin
M01AB04	Zomepirac
M01AB05	Diclofenac
M01AB06	Alclofenac
M01AB07	Bumadizone
M01AB08	Etodolac
M01AB09	Lonazolac
M01AB10	Fentiazac
M01AB11	Acemetacin
M01AB12	Difenpiramide
M01AB13	Oxametacin
M01AB14	Proglumetacin
M01AB15	Ketorolac
M01AB16	Aceclofenac
M01AB17	Bufexamac
M01AB51	Indometacin, combinations
M01AB55	Diclofenac, combinations
M01AC	Oxicams
M01AC01	Piroxicam
M01AC02	Tenoxicam
M01AC04	Droxicam
M01AC05	Lornoxicam
M01AC06	Meloxicam
M01AE	Propionic acid derivatives
M01AE01	Ibuprofen
M01AE02	Naproxen
M01AE03	Ketoprofen
M01AE04	Fenoprofen
M01AE05	Fenbufen
M01AE06	Benoxaprofen
M01AE07	Suprofen
M01AE08	Pirprofen
M01AE09	Flurbiprofen
M01AE10	Indoprofen
M01AE11	Tiaprofenic acid
M01AE12	Oxaprozin
M01AE13	Ibuproxam
M01AE14	Dexibuprofen
M01AE15	Flunoxaprofen
M01AE16	Alminoprofen
M01AE17	Dexketoprofen
M01AE51	Ibuprofen, combinations
M01AE53	Ketoprofen, combinations
M01AG	Fenamates
M01AG01	Mefenamic acid
M01AG02	Tolfenamic acid
M01AG03	Flufenamic acid
M01AG04	Meclofenamic acid
M01AH	Coxibs
M01AH01	Celecoxib
M01AH02	Rofecoxib
M01AH03	Valdecoxib
M01AH04	Parecoxib
M01AH05	Etoricoxib
M01AH06	Lumiracoxib
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids
M01AX01	Nabumetone
M01AX02	Niflumic acid
M01AX04	Azapropazone
M01AX05	Glucosamine
M01AX07	Benzydamine
M01AX12	Glucosaminoglycan polysulfate
M01AX13	Proquazone
M01AX14	Orgotein
M01AX17	Nimesulide
M01AX18	Feprazone
M01AX21	Diacerein
M01AX22	Morniflumate
M01AX23	Tenidap
M01AX24	Oxaceprol
M01AX25	Chondroitin sulfate
M01AX68	Feprazone, combinations
M01B	Antiinflammatory/antirheumatic agents in combination
M01BA	Antiinflammatory/antirheumatic agents in combination with corticosteroids
M01BA01	Phenylbutazone and corticosteroids
M01BA02	Dipyrocetyl and corticosteroids
M01BA03	Acetylsalicylic acid and corticosteroids
M01BX	Other antiinflammatory/antirheumatic agents in combination with other drugs
M01C	Specific antirheumatic agents
M01CA	Quinolines
M01CA03	Oxycinchophen
M01CB	Gold preparations
M01CB01	Sodium aurothiomalate
M01CB02	Sodium aurothiosulfate
M01CB03	Auranofin
M01CB04	Aurothioglucose
M01CB05	Aurotioprol
M01CC	Penicillamine and similar agents
M01CC01	Penicillamine
M01CC02	Bucillamine
M01CX	Other specific antirheumatic agents
M02	Topical products for joint and muscular pain
M02A	Topical products for joint and muscular pain
M02AA	Antiinflammatory preparations, non-steroids for topical use
M02AA01	Phenylbutazone
M02AA02	Mofebutazone
M02AA03	Clofezone
M02AA04	Oxyphenbutazone
M02AA05	Benzydamine
M02AA06	Etofenamate
M02AA07	Piroxicam
M02AA08	Felbinac
M02AA09	Bufexamac
M02AA10	Ketoprofen
M02AA11	Bendazac
M02AA12	Naproxen
M02AA13	Ibuprofen
M02AA14	Fentiazac
M02AA15	Diclofenac
M02AA16	Feprazone
M02AA17	Niflumic acid
M02AA18	Meclofenamic acid
M02AA19	Flurbiprofen
M02AA21	Tolmetin
M02AA22	Suxibuzone
M02AA23	Indometacin
M02AA24	Nifenazone
M02AA25	Aceclofenac
M02AB	Capsaicin and similar agents
M02AB01	Capsaicin
M02AB02	Zucapsaicin
M02AC	Preparations with salicylic acid derivatives
M02AX	Other topical products for joint and muscular pain
M02AX02	Tolazoline
M02AX03	Dimethyl sulfoxide
M02AX10	Various
M03	Muscle relaxants
N01AH02	Alfentanil
M03A	Muscle relaxants, peripherally acting agents
M03AA	Curare alkaloids
M03AA01	Alcuronium
M03AA02	Tubocurarine
M03AA04	Dimethyltubocurarine
M03AB	Choline derivatives
M03AB01	Suxamethonium
M03AC	Other quaternary ammonium compounds
M03AC01	Pancuronium
M03AC02	Gallamine
M03AC03	Vecuronium
M03AC04	Atracurium
M03AC05	Hexafluronium
M03AC06	Pipecuronium bromide
M03AC07	Doxacurium chloride
M03AC08	Fazadinium bromide
M03AC09	Rocuronium bromide
M03AC10	Mivacurium chloride
M03AC11	Cisatracurium
M03AX	Other muscle relaxants, peripherally acting agents
M03AX01	Botulinum toxin
M03B	Muscle relaxants, centrally acting agents
M03BA	Carbamic acid esters
M03BA01	Phenprobamate
M03BA02	Carisoprodol
M03BA03	Methocarbamol
M03BA04	Styramate
M03BA05	Febarbamate
M03BA51	Phenprobamate, combinations excl. psycholeptics
M03BA52	Carisoprodol, combinations excl. psycholeptics
M03BA53	Methocarbamol, combinations excl. psycholeptics
M03BA71	Phenprobamate, combinations with psycholeptics
M03BA72	Carisoprodol, combinations with psycholeptics
M03BA73	Methocarbamol, combinations with psycholeptics
M03BB	Oxazol, thiazine, triazine derivatives
M03BB02	Chlormezanone
M03BB03	Chlorzoxazone
M03BB52	Chlormezanone, combinations excl. psycholeptics
M03BB53	Chlorzoxazone, combinations excl. psycholeptics
M03BB72	Chlormezanone, combinations with psycholeptics
M03BB73	Chlorzoxazone, combinations with psycholeptics
M03BC	Ethers, chemically close to antihistamines
M03BC01	Orphenadrine (citrate)
M03BC51	Orphenadrine, combinations
M03BX	Other centrally acting agents
M03BX01	Baclofen
M03BX02	Tizanidine
M03BX03	Pridinol
M03BX04	Tolperisone
M03BX05	Thiocolchicoside
M03BX06	Mephenesin
M03BX07	Tetrazepam
M03BX08	Cyclobenzaprine
M03BX09	Eperisone
M03BX30	Phenyramidol
M03C	Muscle relaxants, directly acting agents
M03CA	Dantrolene and derivatives
M03CA01	Dantrolene
M04	Antigout preparations
M04A	Antigout preparations
M04AA	Preparations inhibiting uric acid production
M04AA01	Allopurinol
M04AA02	Tisopurine
M04AA03	Febuxostat
M04AA51	Allopurinol, combinations
M04AB	Preparations increasing uric acid excretion
M04AB01	Probenecid
M04AB02	Sulfinpyrazone
M04AB03	Benzbromarone
M04AB04	Isobromindione
M04AC	Preparations with no effect on uric acid metabolism
M04AC01	Colchicine
M04AC02	Cinchophen
M04AX	Other antigout preparations
M04AX01	Urate oxidase
M04AX02	Pegloticase
M05	Drugs for treatment of bone diseases
M05B	Drugs affecting bone structure and mineralization
M05BA	Bisphosphonates
M05BA01	Etidronic acid
M05BA02	Clodronic acid
M05BA03	Pamidronic acid
M05BA04	Alendronic acid
M05BA05	Tiludronic acid
M05BA06	Ibandronic acid
M05BA07	Risedronic acid
M05BA08	Zoledronic acid
M05BB	Bisphosphonates, combinations
M05BB01	Etidronic acid and calcium, sequential
M05BB02	Risedronic acid and calcium, sequential
M05BB03	Alendronic acid and colecalciferol
M05BB04	Risedronic acid, calcium and colecalciferol, sequential
M05BC	Bone morphogenetic proteins
M05BC01	BMP-2
M05BC02	BMP-7
M05BX	Other drugs affecting bone structure and mineralization
M05BX01	Ipriflavone
M05BX02	Aluminium chlorohydrate
M05BX03	Strontium ranelate
M05BX04	Denosumab
M09	Other drugs for disorders of the musculo-skeletal system
M09A	Other drugs for disorders of the musculo-skeletal system
M09AA	Quinine and derivatives
M09AA01	Hydroquinine
M09AA72	Quinine, combinations with psycholeptics
M09AB	Enzymes
M09AB01	Chymopapain
M09AB52	Trypsin, combinations
M09AX	Other drugs for disorders of the musculo-skeletal system
M09AX01	Hyaluronic acid
N	Nervous system
N01	Anesthetics
N01A	Anesthetics, general
N01AA	Ethers
N01AA01	Anesthetic ether (diethyl ether)
N01AA02	Vinyl ether
N01AB	Halogenated hydrocarbons
N01AB01	Halothane
N01AB02	Chloroform
N01AB04	Enflurane
N01AB05	Trichloroethylene
N01AB06	Isoflurane
N01AB07	Desflurane
N01AB08	Sevoflurane
N01AF	Barbiturates, plain
N01AF01	Methohexital
N01AF02	Hexobarbital
N01AF03	Thiopental
N01AG	Barbiturates in combination with other drugs
N01AG01	Narcobarbital
N01AH	Opioid anesthetics
N01AH01	Fentanyl
N01AH03	Sufentanil
N01AH04	Phenoperidine
N01AH05	Anileridine
N01AH06	Remifentanil
N01AH51	Fentanyl, combinations
N01AX	Other general anesthetics
N01AX01	Droperidol
N01AX03	Ketamine
N01AX04	Propanidid
N01AX05	Alfaxalone
N01AX07	Etomidate
N01AX10	Propofol
N01AX11	Sodium oxybate
N01AX13	Nitrous oxide
N01AX14	Esketamine
N01AX15	Xenon
N01AX63	Nitrous oxide, combinations
N01B	Anesthetics, local
N01BA	Esters of aminobenzoic acid
N01BA01	Metabutethamine
N01BA02	Procaine
N01BA03	Tetracaine
N01BA04	Chloroprocaine
N01BA05	Benzocaine
N01BA52	Procaine, combinations
N01BB	Amides
N01BB01	Bupivacaine
N01BB02	Lidocaine
N01BB03	Mepivacaine
N01BB04	Prilocaine
N01BB05	Butanilicaine
N01BB06	Cinchocaine
N01BB07	Etidocaine
N01BB08	Articaine
N01BB09	Ropivacaine
N01BB10	Levobupivacaine
N01BB20	Combinations
N01BB51	Bupivicaine, combinations
N01BB52	Lidocaine, combinations
N01BB53	Mepivacaine, combinations
N01BB54	Prilocaine, combinations
N01BB57	Etidocaine, combinations
N01BB58	Articaine, combinations
N01BC	Esters of benzoic acid
N01BC01	Cocaine
N01BX	Other local anesthetics
N01BX01	Ethyl chloride
N01BX02	Dyclonine
N01BX03	Phenol
N01BX04	Capsaicin
N02	Analgesics
N02A	Opioids
N02AA	Natural opium alkaloids
N02AA01	Morphine
N02AA02	Opium
N02AA03	Hydromorphone
N02AA04	Nicomorphine
N02AA05	Oxycodone
N02AA08	Dihydrocodeine
N02AA09	Diamorphine
N02AA10	Papaveretum
N02AA51	Morphine, combinations
N02AA55	Oxycodone, combinations
N02AA58	Dihydrocodeine, combinations
N02AA59	Codeine, combinations excl. psycholeptics
N02AA79	Codeine, combinations with psycholeptics
N02AB	Phenylpiperidine derivatives
N02AB01	Ketobemidone
N02AB02	Pethidine
N02AB03	Fentanyl
N02AB52	Pethidine, combinations excl. psycholeptics
N02AB72	Pethidine, combinations with psycholeptics
N02AC	Diphenylpropylamine derivatives
N02AC01	Dextromoramide
N02AC03	Piritramide
N02AC04	Dextropropoxyphene
N02AC05	Bezitramide
N02AC52	Methadone, comb. excl. psycholeptics
N02AC54	Dextropropoxyphene, comb. excl. psycholeptics
N02AC74	Dextropropoxyphene, comb. with psycholeptics
N02AD	Benzomorphan derivatives
N02AD01	Pentazocine
N02AD02	Phenazocine
N02AE	Oripavine derivatives
N02AE01	Buprenorphine
N02AF	Morphinan derivatives
N02AF01	Butorphanol
N02AF02	Nalbufine
N02AG	Opioids in combination with antispasmodics
N02AG01	Morphine and antispasmodics
N02AG02	Ketobemidone and antispasmodics
N02AG03	Pethidine and antispasmodics
N02AG04	Hydromorphone and antispasmodics
N02AX	Other opioids
N02AX01	Tilidine
N02AX02	Tramadol
N02AX03	Dezocine
N02AX05	Meptazinol
N02AX06	Tapentadol
N02AX52	Tramadol, combinations
N02B	Other analgesics and antipyretics
N02BA	Salicylic acid and derivatives
N02BA01	Acetylsalicylic acid
N02BA02	Aloxiprin
N02BA03	Choline salicylate
N02BA04	Sodium salicylate
N02BA05	Salicylamide
N02BA06	Salicyloylsalicylic acid
N02BA07	Ethenzamide
N02BA08	Morpholine salicylate
N02BA09	Dipyrocetyl
N02BA10	Benorilate
N02BA11	Diflunisal
N02BA12	Potassium salicylate
N02BA14	Guacetisal
N02BA15	Carbasalate calcium
N02BA16	Imidazole salicylate
N02BA51	Acetylsalicylic acid, comb. excl. psycholeptics
N02BA55	Salicylamide, combinations excl. psycholeptics
N02BA57	Ethenzamide, combinations excl. psycholeptics
N02BA59	Dipyrocetyl, combinations excl. psycholeptics
N02BA65	Carbasalate calcium, comb. excl. psycholeptics
N02BA71	Acetylsalicylic acid, comb. with psycholeptics
N02BA75	Salicylamide, combinations with psycholeptics
N02BA77	Ethenzamide, combinations with psycholeptics
N02BA79	Dipyrocetyl, combinations with psycholeptics
N02BB	Pyrazolones
N02BB01	Phenazone
N02BB02	Metamizole sodium
N02BB03	Aminophenazone
N02BB04	Propyphenazone
N02BB05	Nifenazone
N02BB51	Phenazone, combinations excl. psycholeptics
N02BB52	Metamizole sodium, combinations excl. psycholeptics
N02BB53	Aminophenazone, combinations excl. psycholeptics
N02BB54	Propyphenazone, combinations excl. psycholeptics
N02BB71	Phenazone, combinations with psycholeptics
N02BB72	Metamizole sodium, combinations with psycholeptics
N02BB73	Aminophenazone, combinations with psycholeptics
N02BB74	Propyphenazone, combinations with psycholeptics
N02BE01	Paracetamol
N02BE03	Phenacetin
N02BE04	Bucetin
N02BE05	Propacetamol
N02BE51	Paracetamol, combinations excl. psycholeptics
N02BE53	Phenacetin, combinations excl. psycholeptics
N02BE54	Bucetin, combinations excl. psycholeptics
N02BE71	Paracetamol, combinations with psycholeptics
N02BE73	Phenacetin, combinations with psycholeptics
N02BE74	Bucetin, combinations with psycholeptics
N02BG	Other analgesics and antipyretics
N02BG02	Rimazolium
N02BG03	Glafenine
N02BG04	Floctafenine
N02BG05	Viminol
N02BG06	Nefopam
N02BG07	Flupirtine
N02BG08	Ziconotide
N02BG09	Methoxyflurane
N02BG10	Nabiximols
N02C	Antimigraine preparations
N02CA	Ergot alkaloids
N02CA01	Dihydroergotamine
N02CA02	Ergotamine
N02CA04	Methysergide
N02CA07	Lisuride
N02CA51	Dihydroergotamine, combinations
N02CA52	Ergotamine, combinations excl. psycholeptics
N02CA72	Ergotamine, comb. with psycholeptics
N02CB	Corticosteroid derivatives
N02CB01	Flumedroxone
N02CC	Selective 5HT<v>1<D>-receptor agonists
N02CC01	Sumatriptan
N02CC02	Naratriptan
N02CC03	Zolmitriptan
N02CC04	Rizatriptan
N02CC05	Almotriptan
N02CC06	Eletriptan
N02CC07	Frovatriptan
N02CX	Other antimigraine preparations
N02CX01	Pizotifen
N02CX02	Clonidine
N02CX03	Iprazochrome
N02CX05	Dimetotiazine
N02CX06	Oxetorone
N03	Antiepileptics
N03A	Antiepileptics
N03AA	Barbiturates and derivatives
N03AA01	Methylphenobarbital
N03AA02	Phenobarbital
N03AA03	Primidone
N03AA04	Barbexaclone
N03AA30	Metharbital
N03AB	Hydantoin derivatives
N03AB01	Ethotoin
N03AB02	Phenytoin
N03AB03	Amino(diphenylhydantoin) valeric acid
N03AB04	Mephenytoin
N03AB05	Fosphenytoin
N03AB52	Phenytoin, combinations
N03AB54	Mephenytoin, combinations
N03AC	Oxazolidine derivatives
N03AC01	Paramethadione
N03AC02	Trimethadione
N03AC03	Ethadione
N03AD	Succinimide derivatives
N03AD01	Ethosuximide
N03AD02	Phensuximide
N03AD03	Mesuximide
N03AD51	Ethosuximide, combinations
N03AE	Benzodiazepine derivatives
N03AE01	Clonazepam
N03AF	Carboxamide derivatives
N03AF01	Carbamazepine
N03AF02	Oxcarbazepine
N03AF03	Rufinamide
N03AF04	Eslicarbazepine
N03AG	Fatty acid derivatives
N03AG01	Valproic acid
N03AG02	Valpromide
N03AG03	Aminobutyric acid
N03AG04	Vigabatrin
N03AG05	Progabide
N03AG06	Tiagabine
N03AX	Other antiepileptics
N03AX03	Sultiame
N03AX07	Phenacemide
N03AX09	Lamotrigine
N03AX10	Felbamate
N03AX11	Topiramate
N03AX12	Gabapentin
N03AX13	Pheneturide
N03AX14	Levetiracetam
N03AX15	Zonisamide
N03AX16	Pregabalin
N03AX17	Stiripentol
N03AX18	Lacosamide
N03AX19	Carisbamate
N03AX30	Beclamide
N04	Anti-Parkinson drugs
N04A	Anticholinergic agents
N04AA	Tertiary amines
N04AA01	Trihexyphenidyl
N04AA02	Biperiden
N04AA03	Metixene
N04AA04	Procyclidine
N04AA05	Profenamine
N04AA08	Dexetimide
N04AA09	Phenglutarimide
N04AA10	Mazaticol
N04AA11	Bornaprine
N04AA12	Tropatepine
N04AB	Ethers chemically close to antihistamines
N04AB01	Etanautine
N04AB02	Orphenadrine (chloride)
N04AC	Ethers of tropine or tropine derivatives
N04AC01	Benzatropine
N04AC30	Etybenzatropine
N04B	Dopaminergic agents
N04BA	Dopa and dopa derivatives
N04BA01	Levodopa
N04BA02	Levodopa and decarboxylase inhibitor
N04BA03	Levodopa, decarboxylase inhibitor and COMT inhibitor
N04BA04	Melevodopa
N04BA05	Mevelodopa and decarboxylase inhibitor
N04BA06	Etilevodopa and decarboxylase inhibitor
N04BB	Adamantane derivatives
N04BB01	Amantadine
N04BC	Dopamine agonists
N04BC01	Bromocriptine
N04BC02	Pergolide
N04BC03	Dihydroergocryptine mesylate
N04BC04	Ropinirole
N04BC05	Pramipexole
N04BC06	Cabergoline
N04BC07	Apomorphine
N04BC08	Piribedil
N04BC09	Rotigotine
N04BD	Monoamine oxidase type B inhibitors
N04BD01	Selegiline
N04BD02	Rasagiline
N04BX	Other dopaminergic agents
N04BX01	Tolcapone
N04BX02	Entacapone
N04BX03	Budipine
N05	Psycholeptics
N05A	Antipsychotics
N05AA	Phenothiazine with aliphatic side-chain
N05AA01	Chlorpromazine
N05AA02	Levomepromazine
N05AA03	Promazine
N05AA04	Acepromazine
N05AA05	Triflupromazine
N05AA06	Cyamemazine
N05AA07	Chlorproethazine
N05AB	Phenothiazine with piperazine structure
N05AB01	Dixyrazine
N05AB02	Fluphenazine
N05AB03	Perphenazine
N05AB04	Prochlorperazine
N05AB05	Thiopropazate
N05AB06	Trifluoperazine
N05AB07	Acetophenazine
N05AB08	Thioproperazine
N05AB09	Butaperazine
N05AB10	Perazine
N05AC	Phenothiazines with piperidine structure
N05AC01	Periciazine
N05AC02	Thioridazine
N05AC03	Mesoridazine
N05AC04	Pipotiazine
N05AD	Butyrophenone derivatives
N05AD01	Haloperidol
N05AD02	Trifluperidol
N05AD03	Melperone
N05AD04	Moperone
N05AD05	Pipamperone
N05AD06	Bromperidol
N05AD07	Benperidol
N05AD08	Droperidol
N05AD09	Fluanisone
N05AE	Indole derivatives
N05AE01	Oxypertine
N05AE02	Molindone
N05AE03	Sertindole
N05AE04	Ziprasidone
N05AF	Thioxanthene derivatives
N05AF01	Flupentixol
N05AF02	Clopenthixol
N05AF03	Chlorprothixene
N05AF04	Tiotixene
N05AF05	Zuclopenthixol
N05AG	Diphenylbutylpiperidine derivatives
N05AG01	Fluspirilene
N05AG02	Pimozide
N05AG03	Penfluridol
N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05AH01	Loxapine
N05AH02	Clozapine
N05AH03	Olanzapine
N05AH04	Quetiapine
N05AH05	Asenapine
N05AH06	Clotiapine
N05AK	Neuroleptics, in tardive dyskinesia
N05AL	Benzamides
N05AL01	Sulpiride
N05AL02	Sultopride
N05AL03	Tiapride
N05AL04	Remoxipride
N05AL05	Amisulpride
N05AL06	Veraliprid
N05AL07	Levosulpiride
N05AN01	Lithium
N05AX	Other antipsychotics
N05AX07	Prothipendyl
N05AX08	Risperidone
N05AX10	Mosapramine
N05AX11	Zotepine
N05AX12	Aripiprazole
N05AX13	Paliperidone
N05B	Anxiolytics
N05BA	Benzodiazepine derivatives
N05BA01	Diazepam
N05BA02	Chlordiazepoxide
N05BA03	Medazepam
N05BA04	Oxazepam
N05BA05	Clorazepate potassium
N05BA06	Lorazepam
N05BA07	Adinazolam
N05BA08	Bromazepam
N05BA09	Clobazam
N05BA10	Ketazolam
N05BA11	Prazepam
N05BA12	Alprazolam
N05BA13	Halazepam
N05BA14	Pinazepam
N05BA15	Camazepam
N05BA16	Nordazepam
N05BA17	Fludiazepam
N05BA18	Ethyl loflazepate
N05BA19	Etizolam
N05BA21	Clotiazepam
N05BA22	Cloxazolam
N05BA23	Tofisopam
N05BA56	Lorazepam, combinations
N05BB	Diphenylmethane derivatives
N05BB01	Hydroxyzine
N05BB02	Captodiame
N05BB51	Hydroxyzine, combinations
N05BC	Carbamates
N05BC01	Meprobamate
N05BC03	Emylcamate
N05BC04	Mebutamate
N05BC51	Meprobamate, combinations
N05BD	Dibenzo-bicyclo-octadiene derivatives
N05BD01	Benzoctamine
N05BE	Azaspirodecanedione derivatives
N05BE01	Buspirone
N05BX	Other anxiolytics
N05BX01	Mefenoxalone
N05BX02	Gedocarnil
N05BX03	Etifoxine
N05C	Hypnotics and sedatives
N05CA	Barbiturates, plain
N05CA01	Pentobarbital
N05CA02	Amobarbital
N05CA03	Butobarbital
N05CA04	Barbital
N05CA05	Aprobarbital
N05CA06	Secobarbital
N05CA07	Talbutal
N05CA08	Vinylbital
N05CA09	Vinbarbital
N05CA10	Cyclobarbital
N05CA11	Heptabarbital
N05CA12	Reposal
N05CA15	Methohexital
N05CA16	Hexobarbital
N05CA19	Thiopental
N05CA20	Etallobarbital
N05CA21	Allobarbital
N05CA22	Proxibarbal
N05CB	Barbiturates, combinations
N05CB01	Combinations of barbiturates
N05CB02	Barbiturates in combination with other drugs
N05CC	Aldehydes and derivatives
N05CC01	Chloral hydrate
N05CC02	Chloralodol
N05CC03	Acetylglycinamide chloral hydrate
N05CC04	Dichloralphenazone
N05CC05	Paraldehyde
N05CD	Benzodiazepine derivatives
N05CD01	Flurazepam
N05CD02	Nitrazepam
N05CD03	Flunitrazepam
N05CD04	Estazolam
N05CD05	Triazolam
N05CD06	Lormetazepam
N05CD07	Temazepam
N05CD08	Midazolam
N05CD09	Brotizolam
N05CD10	Quazepam
N05CD11	Loprazolam
N05CD12	Doxefazepam
N05CD13	Cinolazepam
N05CE	Piperidinedione derivatives
N05CE01	Glutethimide
N05CE02	Methyprylon
N05CE03	Pyrithyldione
N05CF	Benzodiazepine related drugs
N05CF01	Zopiclone
N05CF02	Zolpidem
N05CF03	Zaleplon
N05CF04	Eszopiclone
N05CH	Melatonin receptor agonists
N05CH01	Melatonin
N05CH02	Ramelteon
N05CM	Other hypnotics and sedatives
N05CM01	Methaqualone
N05CM02	Clomethiazole
N05CM03	Bromisoval
N05CM04	Carbromal
N05CM05	Scopolamine
N05CM06	Propiomazine
N05CM07	Triclofos
N05CM08	Ethchlorvynol
N05CM09	Valerian
N05CM10	Hexapropymate
N05CM11	Bromides
N05CM12	Apronal
N05CM13	Valnoctamide
N05CM15	Methylpentynol
N05CM16	Niaprazine
N05CM18	Dexmedetomidine
N05CX	Hypnotics and sedatives in combination, excl. barbiturates
N05CX01	Meprobamate, combinations
N05CX02	Methaqualone, combinations
N05CX03	Methylpentynol, combinations
N05CX04	Clomethiazole, combinations
N05CX05	Emepronium, combinations
N05CX06	Dipiperonylaminoethanol, combinations
N06	Psychoanaleptics
N06A	Antidepressants
N06AA	Non-selective monoamine reuptake inhibitors
N06AA01	Desipramine
N06AA02	Imipramine
N06AA03	Imipramine oxide
N06AA04	Clomipramine
N06AA05	Opipramol
N06AA06	Trimipramine
N06AA07	Lofepramine
N06AA08	Dibenzepin
N06AA09	Amitriptyline
N06AA10	Nortriptyline
N06AA11	Protriptyline
N06AA12	Doxepin
N06AA13	Iprindole
N06AA14	Melitracen
N06AA15	Butriptyline
N06AA16	Dosulepin
N06AA17	Amoxapine
N06AA18	Dimetacrine
N06AA19	Amineptine
N06AA21	Maprotiline
N06AA23	Quinupramine
N06AB	Selective serotonin reuptake inhibitors
N06AB02	Zimeldine
N06AB03	Fluoxetine
N06AB04	Citalopram
N06AB05	Paroxetine
N06AB06	Sertraline
N06AB07	Alaproclate
N06AB08	Fluvoxamine
N06AB09	Etoperidone
N06AB10	Escitalopram
N06AF	Monoamine oxidase inhibitors, non-selective
N06AF01	Isocarboxazid
N06AF02	Nialamide
N06AF03	Phenelzine
N06AF04	Tranylcypromine
N06AF05	Iproniazide
N06AF06	Iproclozide
N06AG	Monoamine oxidase type A inhibitors
N06AG02	Moclobemide
N06AG03	Toloxatone
N06AX	Other antidepressants
N06AX01	Oxitriptan
N06AX02	Tryptophan
N06AX03	Mianserin
N06AX04	Nomifensine
N06AX05	Trazodone
N06AX06	Nefazodone
N06AX07	Minaprine
N06AX08	Bifemelane
N06AX09	Viloxazine
N06AX10	Oxaflozane
N06AX11	Mirtazapine
N06AX12	Bupropion
N06AX13	Medifoxamine
N06AX14	Tianeptine
N06AX15	Pivagabine
N06AX16	Venlafaxine
N06AX17	Milnacipran
N06AX18	Reboxetine
N06AX19	Gepirone
N06AX21	Duloxetine
N06AX22	Agomelatine
N06AX23	Desvenlafaxine
N06B	Psychostimulants, agents used for ADHD and nootropics
N06BA	Centrally acting sympathomimetics
N06BA01	Amfetamine
N06BA02	Dexamfetamine
N06BA03	Metamfetamine
N06BA04	Methylphenidate
N06BA05	Pemoline
N06BA06	Fencamfamin
N06BA07	Modafinil
N06BA08	Fenozolone
N06BA09	Atomoxetine
N06BA10	Fenetylline
N06BA11	Dexmethylphenidate
N06BC	Xanthine derivatives
N06BC01	Caffeine
N06BC02	Propentofylline
N06BX	Other psychostimulants and nootropics
N06BX01	Meclofenoxate
N06BX02	Pyritinol
N06BX03	Piracetam
N06BX04	Deanol
N06BX05	Fipexide
N06BX06	Citicoline
N06BX07	Oxiracetam
N06BX08	Pirisudanol
N06BX09	Linopirdine
N06BX10	Nizofenone
N06BX11	Aniracetam
N06BX12	Acetylcarnitine
N06BX13	Idebenone
N06BX14	Prolintane
N06BX15	Pipradol
N06BX16	Pramiracetam
N06BX17	Adrafinil
N06BX18	Vinpocetine
N06C	Psycholeptics and psychoanaleptics in combination
N06CA	Antidepressants in combination with psycholeptics
N06CA01	Amitriptyline and psycholeptics
N06CA02	Melitracen and psycholeptics
N06CB	Psychostimulants in combination with psycholeptics
N06D	Anti-dementia drugs
N06DA	Anticholinesterases
N06DA01	Tacrine
N06DA02	Donepezil
N06DA03	Rivastigmine
N06DA04	Galantamine
N06DX	Other anti-dementia drugs
N06DX01	Memantine
N06DX02	Ginkgo biloba
N07	Other nervous system drugs
N07A	Parasympathomimetics
N07AA	Anticholinesterases
N07AA01	Neostigmine
N07AA02	Pyridostigmine
N07AA03	Distigmine
N07AA30	Ambenonium
N07AA51	Neostigmine, combinations
N07AB	Choline esters
N07AB01	Carbachol
N07AB02	Bethanechol
N07AX	Other parasympathomimetics
N07AX01	Pilocarpine
N07AX02	Choline alfoscerate
N07AX03	Cevimeline
N07B	Drugs used in addictive disorders
N07BA	Drugs used in nicotine dependence
N07BA01	Nicotine
N07BA03	Varenicline
N07BB	Drugs used in alcohol dependence
N07BB01	Disulfiram
N07BB02	Calcium carbimide
N07BB03	Acamprosate
N07BB04	Naltrexone
N07BC	Drugs used in opioid dependence
N07BC01	Buprenorphine
N07BC02	Methadone
N07BC03	Levacetylmethadol
N07BC04	Lofexidine
N07BC51	Buprenorphine, combinations
N07C	Antivertigo preparations
N07CA	Antivertigo preparations
N07CA01	Betahistine
N07CA02	Cinnarizine
N07CA03	Flunarizine
N07CA04	Acetylleucine
N07CA52	Cinnarizine, combinations
N07X	Other nervous system drugs
N07XA	Gangliosides and ganglioside derivatives
N07XX	Other nervous system drugs
N07XX01	Tirilazad
N07XX02	Riluzole
N07XX03	Xaliproden
N07XX04	Sodium oxybate
N07XX05	Amifampridine
N07XX06	Tetrabenazine
P	Antiparasitic products, insecticides and repellents
P01	Antiprotozoals
P01A	Agents against amoebiasis and other protozoal diseases
P01AA	Hydroxyquinoline derivatives
P01AA01	Broxyquinoline
P01AA02	Clioquinol
P01AA04	Chlorquinaldol
P01AA05	Tilbroquinol
P01AA52	Clioquinol, combinations
P01AB	Nitroimidazole derivatives
P01AB01	Metronidazole
P01AB02	Tinidazole
P01AB03	Ornidazole
P01AB04	Azanidazole
P01AB05	Propenidazole
P01AB06	Nimorazole
P01AB07	Secnidazole
P01AC	Dichloroacetamide derivatives
P01AC01	Diloxanide
P01AC02	Clefamide
P01AC03	Etofamide
P01AC04	Teclozan
P01AR	Arsenic compounds
P01AR01	Arsthinol
P01AR02	Difetarsone
P01AR03	Glycobiarsol
P01AR53	Glycobiarsol, combinations
P01AX	Other agents against amoebiasis and other protozoal diseases
P01AX01	Chiniofon
P01AX02	Emetine
P01AX04	Phanquinone
P01AX05	Mepacrine
P01AX06	Atovaquone
P01AX07	Trimetrexate
P01AX08	Tenonitrozole
P01AX09	Dihydroemetine
P01AX10	Fumagillin
P01AX11	Nitazoxanide
P01AX52	Emetine, combinations
P01B	Antimalarials
P01BA	Aminoquinolines
P01BA01	Chloroquine
P01BA02	Hydroxychloroquine
P01BA03	Primaquine
P01BA06	Amodiaquine
P01BB	Biguanides
P01BB01	Proguanil
P01BB02	Cycloguanil embonate
P01BB51	Proguanil, combinations
P01BC	Methanolquinolines
P01BC01	Quinine
P01BC02	Mefloquine
P01BD	Diaminopyrimidines
P01BD01	Pyrimethamine
P01BD51	Pyrimethamine, combinations
P01BE	Artemisinin and derivatives
P01BE01	Artemisinin
P01BE02	Artemether
P01BE03	Artesunate
P01BE04	Artemotil
P01BE05	Artenimol
P01BE52	Artemether, combinations
P01BX	Other antimalarials
P01BX01	Halofantrine
P01C	Agents against leishmaniasis and trypanosomiasis
P01CA	Nitroimidazole derivatives
P01CA02	Benznidazole
P01CB	Antimony compounds
P01CB01	Meglumine antimonate
P01CB02	Sodium stibogluconate
P01CC	Nitrofuran derivatives
P01CC01	Nifurtimox
P01CC02	Nitrofural
P01CD	Arsenic compounds
P01CD01	Melarsoprol
P01CD02	Acetarsol
P01CX	Other agents against leishmaniasis and trypanosomiasis
P01CX01	Pentamidine isethionate
P01CX02	Suramin sodium
P01CX03	Eflornithine
P02	Anthelmintics
P02B	Antitrematodals
P02BA	Quinoline derivatives and related substances
P02BA01	Praziquantel
P02BA02	Oxamniquine
P02BB	Organophosphorous compounds
P02BB01	Metrifonate
P02BX	Other antitrematodal agents
P02BX01	Bithionol
P02BX02	Niridazole
P02BX03	Stibophen
P02BX04	Triclabendazole
P02C	Antinematodal agents
P02CA	Benzimidazole derivatives
P02CA01	Mebendazole
P02CA02	Tiabendazole
P02CA03	Albendazole
P02CA04	Ciclobendazole
P02CA05	Flubendazole
P02CA06	Fenbendazole
P02CA51	Mebendazole, combinations
P02CB	Piperazine and derivatives
P02CB01	Piperazine
P02CB02	Diethylcarbamazine
P02CC	Tetrahydropyrimidine derivatives
P02CC01	Pyrantel
P02CC02	Oxantel
P02CE	Imidazothiazole derivatives
P02CE01	Levamisole
P02CF	Avermectines
P02CF01	Ivermectin
P02CX	Other antinematodals
P02CX01	Pyrvinium
P02CX02	Bephenium
P02D	Anticestodals
P02DA	Salicylic acid derivatives
P02DA01	Niclosamide
P02DX	Other anticestodals
P02DX01	Desaspidin
P02DX02	Dichlorophen
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents
P03A	Ectoparasiticides, incl. scabicides
P03AA	Sulfur containing products
P03AA01	Dixanthogen
P03AA02	Potassium polysulfide
P03AA03	Mesulfen
P03AA04	Disulfiram
P03AA05	Thiram
P03AA54	Disulfiram, combinations
P03AB	Chlorine containing products
P03AB01	Clofenotane
P03AB02	Lindane
P03AB51	Clofenotane, combinations
P03AC	Pyrethrines, incl. synthetic compounds
P03AC01	Pyrethrum
P03AC02	Bioallethrin
P03AC03	Phenothrin
P03AC04	Permethrin
P03AC51	Pyrethrum, combinations
P03AC52	Bioallethrin, combinations
P03AC53	Phenothrin, combinations
P03AC54	Permethrin, combinations
P03AX	Other ectoparasiticides, incl. scabicides
P03AX01	Benzyl benzoate
P03AX02	Copper oleinate
P03AX03	Malathion
P03AX04	Quassia
P03B	Insecticides and repellents
P03BA	Pyrethrines
P03BA01	Cyfluthrin
P03BA02	Cypermethrin
P03BA03	Decamethrin
P03BA04	Tetramethrin
P03BX	Other insecticides and repellents
P03BX01	Diethyltoluamide
P03BX02	Dimethylphthalate
P03BX03	Dibutylphthalate
P03BX04	Dibutylsuccinate
P03BX05	Dimethylcarbate
P03BX06	Etohexadiol
R	Respiratory system
R01	Nasal preparations
R01A	Decongestants and other nasal preparations for topical use
R01AA	Sympathomimetics, plain
R01AA02	Cyclopentamine
R01AA03	Ephedrine
R01AA04	Phenylephrine
R01AA05	Oxymetazoline
R01AA06	Tetryzoline
R01AA07	Xylometazoline
R01AA08	Naphazoline
R01AA09	Tramazoline
R01AA10	Metizoline
R01AA11	Tuaminoheptane
R01AA12	Fenoxazoline
R01AA13	Tymazoline
R01AA14	Epinephrine
R01AB	Sympathomimetics, combinations excl. corticosteroids
R01AB01	Phenylephrine
R01AB02	Naphazoline
R01AB03	Tetryzoline
R01AB05	Ephedrine
R01AB06	Xylometazoline
R01AB07	Oxymetazoline
R01AB08	Tuaminoheptane
R01AC	Antiallergic agents, excl. corticosteroids
R01AC01	Cromoglicic acid
R01AC02	Levocabastine
R01AC03	Azelastine
R01AC04	Antazoline
R01AC05	Spaglumic acid
R01AC06	Thonzylamine
R01AC07	Nedocromil
R01AC08	Olopatadine
R01AC51	Cromoglicic acid, combinations
R01AD	Corticosteroids
R01AD01	Beclometasone
R01AD02	Prednisolone
R01AD03	Dexamethasone
R01AD04	Flunisolide
R01AD05	Budesonide
R01AD06	Betamethasone
R01AD07	Tixocortol
R01AD08	Fluticasone
R01AD09	Mometasone
R01AD11	Triamcinolone
R01AD12	Fluticasone furoate
R01AD52	Prednisolone, combinations
R01AD53	Dexamethasone, combinations
R01AD57	Tixocortol, combinations
R01AD60	Hydrocortisone, combinations
R01AX	Other nasal preparations
R01AX01	Calcium hexamine thiocyanate
R01AX02	Retinol
R01AX03	Ipratropium bromide
R01AX05	Ritiometan
R01AX06	Mupirocin
R01AX07	Hexamidine
R01AX08	Framycetin
R01AX09	Hyaluronic acid
R01AX10	Various
R01AX30	Combinations
R01B	Nasal decongestants for systemic use
R01BA	Sympathomimetics
R01BA01	Phenylpropanolamine
R01BA02	Pseudoephedrine
R01BA03	Phenylephrine
R01BA51	Phenylpropanolamine, combinations
R01BA52	Pseudoephedrine, combinations
R01BA53	Phenylephrine, combinations
R02	Throat preparations
R02A	Throat preparations
R02AA	Antiseptics
R02AA01	Ambazone
R02AA02	Dequalinium
R02AA03	Dichlorobenzyl alcohol
R02AA05	Chlorhexidine
R02AA06	Cetylpyridinium
R02AA09	Benzethonium
R02AA10	Myristyl-benzalkonium
R02AA11	Chlorquinaldol
R02AA12	Hexylresorcinol
R02AA13	Acriflavinium chloride
R02AA14	Oxyquinoline
R02AA15	Povidone-iodine
R02AA16	Benzalkonium
R02AA17	Cetrimonium
R02AA18	Hexamidine
R02AA19	Phenol
R02AA20	Various
R02AB	Antibiotics
R02AB01	Neomycin
R02AB02	Tyrothricin
R02AB03	Fusafungine
R02AB04	Bacitracin
R02AB30	Gramicidin
R02AD	Anesthetics, local
R02AD01	Benzocaine
R02AD02	Lidocaine
R02AD03	Cocaine
R02AD04	Dyclonine
R02AX	Other throat preparations
R02AX01	Flurbiprofen
R03	Drugs for obstructive airway diseases
R03A	Adrenergics, inhalants
R03AA	Alpha and beta-adrenoceptor agonists
R03AA01	Epinephrine
R03AB	Non-selective beta-adrenoceptor agonists
R03AB02	Isoprenaline
R03AB03	Orciprenaline
R03AC	Selective beta-2-adrenoceptor agonists
R03AC02	Salbutamol
R03AC03	Terbutaline
R03AC04	Fenoterol
R03AC05	Rimiterol
R03AC06	Hexoprenaline
R03AC07	Isoetarine
R03AC08	Pirbuterol
R03AC09	Tretoquinol
R03AC10	Carbuterol
R03AC11	Tulobuterol
R03AC12	Salmeterol
R03AC13	Formoterol
R03AC14	Clenbuterol
R03AC15	Reproterol
R03AC16	Procaterol
R03AC17	Bitolterol
R03AC18	Indacaterol
R03AH	Combinations of adrenergics
R03AK	Adrenergics and other drugs for obstructive airway diseases
R03AK01	Epinephrine and other drugs for obstructive airway diseases
R03AK02	Isoprenaline and other drugs for obstructive aiway diseases
R03AK03	Fenoterol and other drugs for obstructive airway diseases
R03AK04	Salbutamol and other drugs for obstructive airway diseases
R03AK05	Reproterol and other drugs for obstructive airway diseases
R03AK06	Salmeterol and other drugs for obstructive airway diseases
R03AK07	Formoterol and other drugs for obstructive airway diseases
R03B	Other drugs for obstructive airway diseases, inhalants
R03BA	Glucocorticoids
R03BA01	Beclometasone
R03BA02	Budesonide
R03BA03	Flunisolide
R03BA04	Betamethasone
R03BA05	Fluticasone
R03BA06	Triamcinolone
R03BA07	Mometasone
R03BA08	Ciclesonide
R03BB	Anticholinergics
R03BB01	Ipratropium bromide
R03BB02	Oxitropium bromide
R03BB03	Stramoni preparations
R03BB04	Tiotropium bromide
R03BC	Antiallergic agents, excl. corticosteroids
R03BC01	Cromoglicic acid
R03BC03	Nedocromil
R03BX	Other drugs for obstructive airway diseases, inhalants
R03BX01	Fenspiride
R03C	Adrenergics for systemic use
R03CA	Alpha- and beta-adrenoceptor agonists
R03CA02	Ephedrine
R03CB	Non-selective beta-adrenoceptor agonists
R03CB01	Isoprenaline
R03CB02	Methoxyphenamine
R03CB03	Orciprenaline
R03CB51	Isoprenaline, combinations
R03CB53	Orciprenaline, combinations
R03CC	Selective beta-2-adrenoceptor agonists
R03CC02	Salbutamol
R03CC03	Terbutaline
R03CC04	Fenoterol
R03CC05	Hexoprenaline
R03CC06	Isoetarine
R03CC07	Pirbuterol
R03CC08	Procaterol
R03CC09	Tretoquinol
R03CC10	Carbuterol
R03CC11	Tulobuterol
R03CC12	Bambuterol
R03CC13	Clenbuterol
R03CC14	Reproterol
R03CC53	Terbutaline, combinations
R03CK	Adrenergics and other drugs for obstructive airway diseases
R03D	Other systemic drugs for obstructive airway diseases
R03DA	Xanthines
R03DA01	Diprophylline
R03DA02	Choline theophyllinate
R03DA03	Proxyphylline
R03DA04	Theophylline
R03DA05	Aminophylline
R03DA06	Etamiphylline
R03DA07	Theobromine
R03DA08	Bamifylline
R03DA09	Acefylline piperazine
R03DA10	Bufylline
R03DA11	Doxofylline
R03DA20	Combinations of xanthines
R03DA51	Diprophylline, combinations
R03DA54	Theophylline, combinations excl. psycholeptics
R03DA55	Aminophylline, combinations
R03DA57	Theobromine, combinations
R03DA74	Theophylline, combinations with psycholeptics
R03DB	Xanthines and adrenergics
R03DB01	Diprophylline and adrenergics
R03DB02	Choline theophyllinate and adrenergics
R03DB03	Proxyphylline and adrenergics
R03DB04	Theophylline and adrenergics
R03DB05	Aminophylline and adrenergics
R03DB06	Etamiphylline and adrenergics
R03DC	Leukotriene receptor antagonists
R03DC01	Zafirlukast
R03DC02	Pranlukast
R03DC03	Montelukast
R03DC04	Ibudilast
R03DX	Other systemic drugs for obstructive airway diseases
R03DX01	Amlexanox
R03DX02	Eprozinol
R03DX03	Fenspiride
R03DX05	Omalizumab
R03DX06	Seratrodast
R03DX07	Roflumilast
R05	Cough and cold preparations
R05C	Expectorants, excl. combinations with cough suppressants
R05CA	Expectorants
R05CA01	Tyloxapol
R05CA02	Potassium iodide
R05CA03	Guaifenesin
R05CA04	Ipecacuanha
R05CA05	Althea root
R05CA06	Senega
R05CA07	Antimony pentasulphide
R05CA08	Creosote
R05CA09	Guaiacolsulfonate
R05CA10	Combinations
R05CA11	Levoverbenone
R05CB	Mucolytics
R05CB01	Acetylcysteine
R05CB02	Bromhexine
R05CB03	Carbocisteine
R05CB04	Eprazinone
R05CB05	Mesna
R05CB06	Ambroxol
R05CB07	Sobrerol
R05CB08	Domiodol
R05CB09	Letosteine
R05CB10	Combinations
R05CB11	Stepronin
R05CB12	Tiopronin
R05CB13	Dornase alfa (desoxyribonuclease)
R05CB14	Neltenexine
R05CB15	Erdosteine
R05D	Cough suppressants, excl. combinations with expectorants
R05DA	Opium alkaloids and derivatives
R05DA01	Ethylmorphine
R05DA03	Hydrocodone
R05DA04	Codeine
R05DA05	Opium alkaloids with morphine
R05DA06	Normethadone
R05DA07	Noscapine
R05DA08	Pholcodine
R05DA09	Dextromethorphan
R05DA10	Thebacon
R05DA11	Dimemorfan
R05DA12	Acetyldihydrocodeine
R05DA20	Combinations
R05DB	Other cough suppressants
R05DB01	Benzonatate
R05DB02	Benproperine
R05DB03	Clobutinol
R05DB04	Isoaminile
R05DB05	Pentoxyverine
R05DB07	Oxolamine
R05DB09	Oxeladin
R05DB10	Clofedanol
R05DB11	Pipazetate
R05DB12	Bibenzonium bromide
R05DB13	Butamirate
R05DB14	Fedrilate
R05DB15	Zipeprol
R05DB16	Dibunate
R05DB17	Droxypropine
R05DB18	Prenoxdiazine
R05DB19	Dropropizine
R05DB20	Combinations
R05DB21	Cloperastine
R05DB22	Meprotixol
R05DB23	Piperidione
R05DB24	Tipepidine
R05DB25	Morclofone
R05DB26	Nepinalone
R05DB27	Levodropropizine
R05DB28	Dimethoxanate
R05F	Cough suppressants and expectorants, combinations
R05FA	Opium derivatives and expectorants
R05FA01	Opium derivatives and mucolytics
R05FA02	Opium derivatives and expectorants
R05FB	Other cough suppressants and expectorants
R05FB01	Cough suppressants and mucolytics
R05FB02	Cough suppressants and expectorants
R05X	Other cold combination preparations
R06	Antihistamines for systemic use
R06A	Antihistamines for systemic use
R06AA	Aminoalkyl ethers
R06AA01	Bromazine
R06AA02	Diphenhydramine
R06AA04	Clemastine
R06AA06	Chlorphenoxamine
R06AA07	Diphenylpyraline
R06AA08	Carbinoxamine
R06AA09	Doxylamine
R06AA52	Diphenhydramine, combinations
R06AA54	Clemastine, combinations
R06AA56	Chlorphenoxamine, combinations
R06AA57	Diphenylpyraline, combinations
R06AB	Substituted alkylamines
R06AB01	Brompheniramine
R06AB02	Dexchlorpheniramine
R06AB03	Dimetindene
R06AB04	Chlorpheniramine
R06AB05	Pheniramine
R06AB06	Dexbrompheniramine
R06AB07	Talastine
R06AB51	Brompheniramine, combinations
R06AB52	Dexchlorpheniramine, combinations
R06AB54	Chlorpheniramine, combinations
R06AB56	Dexbrompheniramine, combinations
R06AC	Substituted ethylene diamines
R06AC01	Mepyramine
R06AC02	Histapyrrodine
R06AC03	Chloropyramine
R06AC04	Tripelennamine
R06AC05	Methapyrilene
R06AC06	Thonzylamine
R06AC52	Histapyrrodine, combinations
R06AC53	Chloropyramine, combinations
R06AD	Phenothiazine derivatives
R06AD01	Alimemazine
R06AD02	Promethazine
R06AD03	Thiethylperazine
R06AD04	Methdilazine
R06AD05	Hydroxyethylpromethazine
R06AD06	Thiazinam
R06AD07	Mequitazine
R06AD08	Oxomemazine
R06AD09	Isothipendyl
R06AD52	Promethazine, combinations
R06AD55	Hydroxyethylpromethazine, combinations
R06AE	Piperazine derivatives
R06AE01	Buclizine
R06AE03	Cyclizine
R06AE04	Chlorcyclizine
R06AE05	Meclozine
R06AE06	Oxatomide
R06AE07	Cetirizine
R06AE09	Levocetirizine
R06AE51	Buclizine, combinations
R06AE53	Cyclizine, combinations
R06AE55	Meclozine, combinations
R06AK	Combinations of antihistamines
R06AX	Other antihistamines for systemic use
R06AX01	Bamipine
R06AX02	Cyproheptadine
R06AX03	Thenalidine
R06AX04	Phenindamine
R06AX05	Antazoline
R06AX07	Triprolidine
R06AX08	Pyrrobutamine
R06AX09	Azatadine
R06AX11	Astemizole
R06AX12	Terfenadine
R06AX13	Loratadine
R06AX15	Mebhydrolin
R06AX16	Deptropine
R06AX17	Ketotifen
R06AX18	Acrivastine
R06AX19	Azelastine
R06AX21	Tritoqualine
R06AX22	Ebastine
R06AX23	Pimethixene
R06AX24	Epinastine
R06AX25	Mizolastine
R06AX26	Fexofenadine
R06AX27	Desloratidine
R06AX28	Rupatidine
R06AX53	Thenalidine, combinations
R06AX58	Pyrrobutamine, combinations
R07	Other respiratory system products
R07A	Other respiratory system products
R07AA	Lung surfactants
R07AA01	Colfosceril palmitate
R07AA02	Natural phospholipids
R07AA30	Combinations
R07AB	Respiratory stimulants
R07AB01	Doxapram
R07AB02	Nikethamide
R07AB03	Pentetrazol
R07AB04	Etamivan
R07AB05	Bemegride
R07AB06	Prethcamide
R07AB07	Almitrine
R07AB08	Dimefline
R07AB09	Mepixamox
R07AB52	Nikethamide, combinations
R07AB53	Pentetrazol, combinations
R07AX	Other respiratory system products
R07AX01	Nitric oxide
S	Sensory organs
S01	Ophthalmologicals
S01A	Antiinfectives
S01AA	Antibiotics
S01AA01	Chloramphenicol
S01AA02	Chlortetracycline
S01AA03	Neomycin
S01AA04	Oxytetracycline
S01AA05	Tyrothricin
S01AA07	Framycetin
S01AA09	Tetracycline
S01AA10	Natamycin
S01AA11	Gentamicin
S01AA12	Tobramycin
S01AA13	Fusidic acid
S01AA14	Benzylpenicillin
S01AA15	Dihydrostreptomycin
S01AA16	Rifamycine
S01AA17	Erythromycin
S01AA18	Polymyxin B
S01AA19	Ampicillin
S01AA20	Antibiotics in combination with other drugs
S01AA21	Amikacin
S01AA22	Micronomicin
S01AA23	Netilmicin
S01AA24	Kanamycin
S01AA25	Azidamfenicol
S01AA26	Azithromycin
S01AA30	Combinations of different antibiotics
S01AB	Sulfonamides
S01AB01	Sulfamethizole
S01AB02	Sulfafurazole
S01AB03	Sulfadicramide
S01AB04	Sulfacetamide
S01AB05	Sulfafenazol
S01AD	Antivirals
S01AD01	Idoxuridine
S01AD02	Trifluridine
S01AD03	Aciclovir
S01AD05	Interferon
S01AD06	Vidarabine
S01AD07	Famciclovir
S01AD08	Fomivirsen
S01AD09	Ganciclovir
S01AX	Other antiinfectives
S01AX01	Mercury compounds
S01AX02	Silver compounds
S01AX03	Zinc compounds
S01AX04	Nitrofural
S01AX05	Bibrocathol
S01AX06	Resorcinol
S01AX07	Sodium borate
S01AX08	Hexamidine
S01AX09	Chlorhexidine
S01AX10	Sodium propionate
S01AX11	Ofloxacin
S01AX12	Norfloxacin
S01AX13	Ciprofloxacin
S01AX14	Dibrompropamidine
S01AX15	Propamidine
S01AX16	Picloxydine
S01AX17	Lomefloxacin
S01AX18	Povidone-iodine
S01AX19	Levofloxacin
S01AX21	Gatifloxacin
S01AX22	Moxifloxacin
S01B	Antiinflammatory agents
S01BA	Corticosteroids, plain
S01BA01	Dexamethasone
S01BA02	Hydrocortisone
S01BA03	Cortisone
S01BA04	Prednisolone
S01BA05	Triamcinolone
S01BA06	Betamethasone
S01BA07	Fluorometholone
S01BA08	Medrysone
S01BA09	Clobetasone
S01BA10	Alclometasone
S01BA11	Desonide
S01BA12	Formocortal
S01BA13	Rimexolone
S01BA14	Loteprednol
S01BA15	Fluocinolone acetonide
S01BB	Corticosteroids and mydriatics in combination
S01BB01	Hydrocortisone and mydriatics
S01BB02	Prednisolone and mydriatics
S01BB03	Fluorometholone and mydriatics
S01BB04	Betamethasone and mydriatics
S01BC	Antiinflammatory agents, non-steroids
S01BC01	Indometacin
S01BC02	Oxyphenbutazone
S01BC03	Diclofenac
S01BC04	Flurbiprofen
S01BC05	Ketorolac
S01BC06	Piroxicam
S01BC07	Bendazac
S01BC08	Salicylic acid
S01BC09	Pranoprofen
S01BC10	Nepafenac
S01BC11	Bromfenac
S01C	Antiinflammatory agents and antiinfectives in combination
S01CA	Corticosteroids and antiinfectives in combination
S01CA01	Dexamethasone and antiinfectives
S01CA02	Prednisolone and antiinfectives
S01CA03	Hydrocortisone and antiinfectives
S01CA04	Fluocortolone and antiinfectives
S01CA05	Betamethasone and antiinfectives
S01CA06	Fludrocortisone and antiinfectives
S01CA07	Fluorometholone and antiinfectives
S01CA08	Methylprednisolone and antiinfectives
S01CA09	Chloroprednisone and antiinfectives
S01CA10	Fluocinolone acetonide and antiinfectives
S01CA11	Clobetasone and antiinfectives
S01CB	Corticosteroids/antiinfectives/mydriatics in combination
S01CB01	Dexamethasone
S01CB02	Prednisolone
S01CB03	Hydrocortisone
S01CB04	Betamethasone
S01CB05	Fluorometholone
S01CC	Antiinflammatory agents, non-steroids and antiinfectives in combination
S01CC01	Diclofenac and antiinfectives
S01E	Antiglaucoma preparations and miotics
S01EA	Sympathomimetics in glaucoma therapy
S01EA01	Epinephrine
S01EA02	Dipivefrine
S01EA03	Apraclonidine
S01EA04	Clonidine
S01EA05	Brimonidine
S01EA51	Epinephrine, combinations
S01EB	Parasympathomimetics
S01EB01	Pilocarpine
S01EB02	Carbachol
S01EB03	Ecothiopate
S01EB04	Demecarium
S01EB05	Physostigmine
S01EB06	Neostigmine
S01EB07	Fluostigmine
S01EB08	Aceclidine
S01EB09	Acetylcholine
S01EB10	Paraoxon
S01EB51	Pilocarpine, combinations
S01EB58	Aceclidine, combinations
S01EC	Carbonic anhydrase inhibitors
S01EC01	Acetazolamide
S01EC02	Diclofenamide
S01EC03	Dorzolamide
S01EC04	Brinzolamide
S01EC05	Methazolamide
S01ED	Beta blocking agents
S01ED01	Timolol
S01ED02	Betaxolol
S01ED03	Levobunolol
S01ED04	Metipranolol
S01ED05	Carteolol
S01ED06	Befunolol
S01ED51	Timolol, combinations
S01ED52	Betaxolol, combinations
S01ED54	Metipranolol, combinations
S01ED55	Carteolol, combinations
S01EE	Prostaglandin analogues
S01EE01	Latanoprost
S01EE02	Unoproston
S01EE03	Bimatoprost
S01EE04	Travoprost
S01EE05	Tafluprost
S01EX	Other antiglaucoma preparations
S01EX01	Guanethidine
S01EX02	Dapiprazole
S01EX05	Bimatoprost
S01F	Mydriatics and cycloplegics
S01FA	Anticholinergics
S01FA01	Atropine
S01FA02	Scopolamine
S01FA03	Methylscopolamine
S01FA04	Cyclopentolate
S01FA05	Homatropine
S01FA06	Tropicamide
S01FA56	Tropicamide, combinations
S01FB	Sympathomimetics excl. antiglaucoma preparations
S01FB01	Phenylephrine
S01FB02	Ephedrine
S01FB03	Ibopamine
S01G	Decongestants and antiallergics
S01GA	Sympathomimetics used as decongestants
S01GA01	Naphazoline
S01GA02	Tetryzoline
S01GA03	Xylometazoline
S01GA04	Oxymetazoline
S01GA05	Phenylephrine
S01GA06	Oxedrine
S01GA51	Naphazoline, combinations
S01GA52	Tetryzoline, combinations
S01GA53	Xylometazoline, combinations
S01GA55	Phenylephrine, combinations
S01GA56	Oxedrine, combinations
S01GX	Other antiallergics
S01GX01	Cromoglicic acid
S01GX02	Levocabastine
S01GX03	Spaglumic acid
S01GX04	Nedocromil
S01GX05	Lodoxamide
S01GX06	Emedastine
S01GX07	Azelastine
S01GX08	Ketotifen
S01GX09	Olopatidine
S01GX10	Epinastine
S01GX51	Cromoglicic acid, combinations
S01H	Local anesthetics
S01HA	Local anesthetics
S01HA01	Cocaine
S01HA02	Oxybuprocaine
S01HA03	Tetracaine
S01HA04	Proxymetacaine
S01HA05	Procaine
S01HA06	Cinchocaine
S01HA07	Lidocaine
S01HA30	Combinations
S01J	Diagnostic agents
S01JA	Colouring agents
S01JA01	Fluorescein
S01JA02	Rose bengal sodium
S01JA51	Fluorescein, combinations
S01JX	Other ophthalmological diagnostic agents
S01K	Surgical aids
S01KA	Viscoelastic substances
S01KA01	Hyaluronic acid
S01KA02	Hypromellose
S01KA51	Hyaluronic acid, combinations
S01KX	Other surgical aids
S01KX01	Chymotrypsin
S01L	Ocular vascular disorder agents
S01LA	Antineovascularisation agents
S01LA01	Verteporfin
S01LA02	Anecortave
S01LA03	Pegaptanib
S01LA04	Ranibizumab
S01X	Other ophthalmologicals
S01XA	Other ophthalmologicals
S01XA01	Guaiazulen
S01XA02	Retinol
S01XA03	Sodium chloride, hypertonic
S01XA04	Potassium iodide
S01XA05	Sodium edetate
S01XA06	Ethylmorphine
S01XA07	Alum
S01XA08	Acetylcysteine
S01XA09	Iodoheparinate
S01XA10	Inosine
S01XA11	Nandrolone
S01XA12	Dexpanthenol
S01XA13	Alteplase
S01XA14	Heparin
S01XA15	Ascorbic acid
S01XA18	Ciclosporin
S01XA20	Artificial tears and other indifferent preparations
S02	Otologicals
S02A	Antiinfectives
S02AA	Antiinfectives
S02AA01	Chloramphenicol
S02AA02	Nitrofural
S02AA03	Boric acid
S02AA04	Aluminium acetotartrate
S02AA05	Clioquinol
S02AA06	Hydrogen peroxide
S02AA07	Neomycin
S02AA08	Tetracycline
S02AA09	Chlorhexidine
S02AA10	Acetic acid
S02AA11	Polymyxin B
S02AA12	Rifamycin
S02AA13	Miconazole
S02AA14	Gentamicin
S02AA15	Ciprofloxacin
S02AA16	Ofloxacin
S02AA30	Antiinfectives, combinations
S02B	Corticosteroids
S02BA	Corticosteroids
S02BA01	Hydrocortisone
S02BA03	Prednisolone
S02BA06	Dexamethasone
S02BA07	Betamethasone
S02BA08	Fluocinolone acetonide
S02C	Corticosteroids and antiinfectives in combination
S02CA	Corticosteroids and antiinfectives in combination
S02CA01	Prednisolone and antiinfectives
S02CA02	Flumetasone and antiinfectives
S02CA03	Hydrocortisone and antiinfectives
S02CA04	Triamcinolone and antiinfectives
S02CA05	Fluocinolone acetonide and antiinfectives
S02CA06	Dexamethasone and antiinfectives
S02CA07	Fludrocortisone and antiinfectives
S02D	Other otologicals
S02DA	Analgesics and anesthetics
S02DA01	Lidocaine
S02DA02	Cocaine
S02DA03	Phenazone
S02DA30	Combinations
S02DC	Indifferent preparations
S03	Ophthalmological and otological preparations
S03A	Antiinfectives
S03AA	Antiinfectives
S03AA01	Neomycin
S03AA02	Tetracycline
S03AA03	Polymyxin B
S03AA04	Chlorhexidine
S03AA05	Hexamidine
S03AA06	Gentamicin
S03AA07	Ciprofloxacin
S03AA08	Chloramphenicol
S03AA30	Antiinfectives, combinations
S03B	Corticosteroids
S03BA	Corticosteroids
S03BA01	Dexamethasone
S03BA02	Prednisolone
S03BA03	Betamethasone
S03C	Corticosteroids and antiinfectives in combination
S03CA	Corticosteroids and antiinfectives in combination
S03CA01	Dexamethasone and antiinfectives
S03CA02	Prednisolone and antiinfectives
S03CA04	Hydrocortisone and antiinfectives
S03CA05	Fludrocortisone and antiinfectives
S03CA06	Betamethasone and antiinfectives
S03D	Other ophthalmological and otological preparations
V	Various
V01	Allergens
V01A	Allergens
V01AA	Allergen extracts
V01AA01	Feather
V01AA02	Grass pollen
V01AA03	House dust mites
V01AA04	Mould fungus and yeast fungus
V01AA05	Tree pollen
V01AA07	Insects
V01AA08	Foods
V01AA09	Textiles
V01AA10	Flowers
V01AA11	Animals
V01AA20	Various
V03	All other therapeutic products
V03A	All other therapeutic products
V03AB	Antidotes
V03AB01	Ipecacuanha
V03AB02	Nalorphine
V03AB03	Edetates
V03AB04	Pralidoxime
V03AB05	Prednisolone and promethazine
V03AB06	Thiosulfate
V03AB08	Sodium nitrite
V03AB09	Dimercaprol
V03AB13	Obidoxime
V03AB14	Protamine
V03AB15	Naloxone
V03AB16	Ethanol
V03AB17	Methylthioninium chloride
V03AB18	Potassium permanganate
V03AB19	Physostigmine
V03AB20	Copper sulphate
V03AB21	Potassium iodide
V03AB22	Amyl nitrite
V03AB23	Acetylcysteine
V03AB24	Digitalis antitoxin
V03AB25	Flumazenil
V03AB26	Methionine
V03AB27	4-dimethylaminophenol
V03AB29	Cholinesterase
V03AB31	Prussian blue
V03AB32	Glutathione
V03AB33	Hydroxocobalamin
V03AB34	Fomepizole
V03AB35	Sugammadex
V03AC	Iron chelating agents
V03AC01	Deferoxamine
V03AC02	Deferiprone
V03AC03	Deferasirox
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE01	Polystyrene sulphonate
V03AE02	Sevelamer
V03AE03	Lanthanum carbonate
V03AE04	Calcium acetate and magnesium carbonate
V03AF	Detoxifying agents for antineoplastic treatment
V03AF01	Mesna
V03AF02	Dexrazoxane
V03AF03	Calcium folinate
V03AF04	Calcium levofolinate
V03AF05	Amifostine
V03AF06	Sodium folinate
V03AF07	Rasburicase
V03AF08	Palifermin
V03AF09	Glucarpidase
V03AF10	Sodium levofolinate
V03AG	Drugs for treatment of hypercalcemia
V03AG01	Sodium cellulose phosphate
V03AH	Drugs for treatment of hypoglycemia
V03AH01	Diazoxide
V03AM	Drugs for embolisation
V03AN	Medical gases
V03AN01	Oxygen
V03AN02	Carbon dioxide
V03AN03	Helium
V03AN04	Nitrogen
V03AN05	Medical air
V03AX	Other therapeutic products
V03AX02	Nalfurafine
V03AZ	Nerve depressants
V03AZ01	Ethanol
V04	Diagnostic agents
V04B	Urine tests
V04C	Other diagnostic agents
V04CA	Tests for diabetes
V04CA01	Tolbutamide
V04CA02	Glucose
V04CB	Tests for fat absorption
V04CB01	Vitamin A concentrates
V04CC	Tests for bile duct patency
V04CC01	Sorbitol
V04CC02	Magnesium sulfate
V04CC03	Sincalide
V04CC04	Ceruletide
V04CD	Tests for pituitary function
V04CD01	Metyrapone
V04CD03	Sermorelin
V04CD04	Corticoliberin
V04CD05	Somatorelin
V04CE	Tests for liver functional capacity
V04CE01	Galactose
V04CE02	Sulphobromophtalein
V04CF	Tuberculosis diagnostics
V04CF01	Tuberculin
V04CG	Tests for gastric secretion
V04CG01	Cation exchange resins
V04CG02	Betazole
V04CG03	Histamine phosphate
V04CG04	Pentagastrin
V04CG05	Methylthioninium chloride
V04CG30	Caffeine and sodium benzoate
V04CH	Tests for renal function
V04CH01	Inulin and other polyfructosans
V04CH02	Indigo carmine
V04CH03	Phenolsulfonphthalein
V04CH04	Alsactide
V04CH30	Aminohippuric acid
V04CJ	Tests for thyreoidea function
V04CJ01	Thyrotropin
V04CJ02	Protirelin
V04CK	Tests for pancreatic function
V04CK01	Secretin
V04CK02	Pancreozymin (cholecystokinin)
V04CK03	Bentiromide
V04CL	Tests for allergic diseases
V04CM	Tests for fertility disturbances
V04CM01	Gonadorelin
V04CX	Other diagnostic agents
V06	General nutrients
V06A	Diet formulations for treatment of obesity
V06AA	Low-energy diets
V06B	Protein supplements
V06C	Infant formulas
V06CA	Nutrients without phenylalanine
V06D	Other nutrients
V06DA	Carbohydrates/proteins/minerals/vitamins, combinations
V06DB	Fat/carbohydrates/proteins/minerals/vitamins, combinations
V06DC	Carbohydrates
V06DC01	Glucose
V06DC02	Fructose
V06DD	Amino acids, incl. combinations with polypeptides
V06DE	Amino acids/carbohydrates/minerals/vitamins, combinations
V06DF	Milk substitutes
V06DX	Other combinations of nutrients
V07	All other non-therapeutic products
V07A	All other non-therapeutic products
V07AA	Plasters
V07AB	Solvents and diluting agents, incl. irrigating solutions
V07AC	Blood transfusion, auxiliary products
V07AD	Blood tests, auxiliary products
V07AN	Incontinence equipment
V07AR	Sensitivity tests, discs and tablets
V07AS	Stomi equipment
V07AT	Cosmetics
V07AV	Technical disinfectants
V07AX	Washing agents etc.
V07AY	Other non-therapeutic auxiliary products
V07AZ	Chemicals and reagents for analysis
V08	Contrast media
V08A	X-ray contrast media, iodinated
V08AA	Watersoluble, nephrotropic, high osmolar X-ray contrast media
V08AA01	Diatrizoic acid
V08AA02	Metrizoic acid
V08AA03	Iodamide
V08AA04	Iotalamic acid
V08AA05	Ioxitalamic acid
V08AA06	Ioglicic acid
V08AA07	Acetrizoic acid
V08AA08	Iocarmic acid
V08AA09	Methiodal
V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media
V08AB01	Metrizamide
V08AB02	Iohexol
V08AB03	Ioxaglic acid
V08AB04	Iopamidol
V08AB05	Iopromide
V08AB06	Iotrolan
V08AB07	Ioversol
V08AB08	Iopentol
V08AB09	Iodixanol
V08AB10	Iomeprol
V08AB11	Iobitridol
V08AB12	Ioxilan
V08AC	Watersoluble, hepatotropic X-ray contrast media
V08AC01	Iodoxamic acid
V08AC02	Iotroxic acid
V08AC03	Ioglycamic acid
V08AC04	Adipiodone
V08AC05	Iobenzamic acid
V08AC06	Iopanoic acid
V08AC07	Iocetamic acid
V08AC08	Sodium iopodate
V08AC09	Tyropanoic acid
V08AC10	Calcium iodopate
V08AD	Non-watersoluble X-ray contrast media
V08AD01	Ethyl esters of iodised fatty acids
V08AD02	Iopydol
V08AD03	Propyliodone
V08AD04	Iofendylate
V08B	X-ray contrast media, non-iodinated
V08BA	Barium sulfate containing X-ray contrast media
V08BA01	Barium sulfate with suspending agents
V08BA02	Barium sulfate without suspending agents
V08C	Magnetic resonance imaging contrast media
V08CA	Paramagnetic contrast media
V08CA01	Gadopentetic acid
V08CA02	Gadoteric acid
V08CA03	Gadodiamide
V08CA04	Gadoteridol
V08CA05	Mangafodipir
V08CA06	Gadoversetamide
V08CA07	Ferric ammonium citrate
V08CA08	Gadobenic acid
V08CA09	Gadobutrol
V08CA10	Gadoxetic acid
V08CA11	Gadofosveset
V08CB	Superparamagnetic contrast media
V08CB01	Ferumoxsil
V08CB02	Ferristene
V08CB03	Iron oxide, nanoparticles
V08CX	Other magnetic resonance imaging contrast media
V08CX01	Perflubron
V08D	Ultrasound contrast media
V08DA	Ultrasound contrast media
V08DA01	Microspheres of human albumin
V08DA02	Microparticles of galactose
V08DA03	Perflenapent
V08DA04	Microspheres of phospholipids
V08DA05	Sulfur hexafluoride
V09	Diagnostic radiopharmaceuticals
V09A	Central nervous system
V09AA	Technetium (<^>99m<D>Tc) compounds
V09AA01	Technetium (<^>99m<D>Tc) exametazime
V09AA02	Technetium (<^>99m<D>Tc) bicisate
V09AB	Iodine (<^>123<D>I) compounds
V09AB01	Iodine iofetamine (<^>123<D>I)
V09AB02	Iodine jolopride (<^>123<D>I)
V09AB03	Iodine ioflupane (<^>123<D>I)
V09AX	Other central nervous system diagnostic radiopharmaceuticals
V09AX01	Indium (<^>111<D>In) pentetic acid
V09AX03	Iodine (<>124<D>I) 2beta-carbomethoxy-3beta- (4 iodophenyl)-tropane
V09B	Skeleton
V09BA	Technetium (<^>99m<D>Tc) compounds
V09BA01	Techentium (<^>99m<D>Tc) oxidronic acid
V09BA02	Technetium (<^>99m<D>Tc) medronic acid
V09BA03	Technetium (<^>99m<D>Tc) pyrophosphate
V09BA04	Technetium (<^>99m<D>Tc) butedronic acid
V09C	Renal system
V09CA	Technetium (<^>99m<D>) compounds
V09CA01	Technetium (<^>99m<D>Tc) pentetic acid
V09CA02	Technetium (<^>99m<D>Tc) succimer
V09CA03	Technetium (<^>99m<D>Tc) mertiatide
V09CA04	Technetium (<^>99m<D>Tc) glucoheptonate
V09CA05	Technetium (<^>99m<D>Tc) gluconate
V09CX	Other renal system diagnostic radiopharmaceuticals
V09CX01	Iodine iodohippurate (<^>123<D>I)
V09CX02	Iodine iodohippurate (<^>131<D>I)
V09CX03	Sodium iothalamate (<^>125<D>I)
V09CX04	Chromium (<^>51<D>Cr) edetate
V09D	Hepatic and reticulo endothelial system
V09DA	Technetium (<^>99m<D>Tc) compounds
V09DA01	Technetium (<^>99m<D>Tc) disofenin
V09DA02	Technetium (<^>99m<D>Tc) etifenin
V09DA03	Technetium (<^>99m<D>Tc) lidofenin
V09DA04	Technetium (<^>99m<D>Tc) mebrofenin
V09DA05	Technetium (<^>99m<D>Tc) galtifenin
V09DB	Technetium (<^>99m<D>Tc), particles and colloids
V09DB01	Technetium (<^>99m<D>Tc) nanocolloid
V09DB02	Technetium (<^>99m<D>Tc0 microcolloid
V09DB03	Technetium (<^>99m<D>Tc) millimicrospheres
V09DB04	Technetium (<^>99m<D>Tc) tin colloid
V09DB05	Technetium (<^>99m<D>Tc) sulfur colloid
V09DB06	Technetium (<^>99m<D>Tc) rheniumsulfide colloid
V09DB07	Technetium (<^>99m<D>Tc) phytate
V09DX	Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals
V09DX01	Selenium (<^>75<D>Se) tauroselcholic acid
V09E	Respiratory system
V09EA	Technetium (<^>99m<D>Tc) inhalants
V09EA01	Technetium (<^>99m<D>Tc) pentetic acid
V09EA02	Technetium (<^>99m<D>Tc) technegas
V09EA03	Technetium (<^>99m<D>Tc) nanocolloid
V09EB	Technetium (<^>99m<D>Tc) particles for injection
V09EB01	Macrosalb (<^>99m<D>Tc)
V09EB02	Technetium (<^>99m<D>Tc) microspheres
V09EX	Other respiratory system diagnostic radiopharmaceuticals
V09EX01	Krypton (<^>81m<D>Kr) gas
V09EX02	Xenon (<^>127<D>Xe) gas
V09EX03	Xenon (<^>133<D>Xe) gas
V09F	Thyroid
V09FX	Various thyroid diagnostic radiopharmaceuticals
V09FX01	Technetium (<^>99m<D>Tc) pertechnetate
V09FX02	Sodium iodide (<^>123<D>I)
V09FX03	Sodium iodide (<^>131<D>I)
V09FX04	Sodium iodide (<>124<D>I)
V09G	Cardiovascular system
V09GA	Techentium (<^>99m<D>)Tc compounds
V09GA01	Technetium (<^>99m<D>Tc) sestamibi
V09GA02	Technetium (<^>99m<D>Tc) tetrofosmin
V09GA03	Technetium (<^>99m<D>Tc) teboroxime
V09GA04	Technetium (<^>99m<D>Tc) human albumin
V09GA05	Technetium (<^>99m<D>Tc) furifosmin
V09GA06	Technetium (<^>99m<D>Tc) stannous agent labelled cells
V09GA07	Technetium (<>99m<D>Tc) apcitide
V09GB	Iodine (<^>125<D>I) compounds
V09GB01	Fibrinogen (<^>125<D>I)
V09GB02	Iodine (<^>125<D>I) human albumin
V09GX	Other cardiovascular system diagnostic radiopharm
V09GX01	Thallium (<^>201<D>Tl) chloride
V09GX02	Indium (<^>111<D>In) imciromab
V09GX03	Chromium (<^>51<D>Cr) chromate lablled cells
V09H	Inflammation and infection detection
V09HA	Technetium (<^>99m<D>Tc) compounds
V09HA01	Technetium (<^>99m<D>Tc) human immunoglobulin
V09HA02	Technetium (<^>99m<D>Tc) exametazime labelled cells
V09HA03	Technetium (<^>99m<D>Tc) antigranulocyte antibody
V09HA04	Technetium (<^>99m<D>Tc) sulesomab
V09HB	Indium (<^>111<D>In) compounds
V09HB01	Indium (<^>111<D>In) oxinate labelled cells
V09HB02	Indium (<^>111<D>In) tropolonate labelled cells
V09HX	Other diagnostic radiopharmaceuticals for inflammation and infection detection
V09HX01	Gallium (<^>67<D>Ga) citrate
V09I	Tumour detection
V09IA	Technetium (<^>99m<D>Tc) compounds
V09IA01	Technetium (<^>99m<D>Tc) antiCarcinoEmbyronicAntigen antibody
V09IA02	Technetium (<^>99m<D>Tc) antimelanoma antibody
V09IA03	Technetium (<^>99m<D>Tc) pentavalent succimer
V09IA04	Technetium (<^>99m<D>Tc) votumumab
V09IA05	Technetium (<^>99m<D>Tc) depreotide
V09IA06	Technetium (Tc<^>99m<D>) arcitumomab
V09IB	Indium (<^>111<D>In) compounds
V09IB01	Indium (<^>111<D>In) pentetreotide
V09IB02	Indium (<^>111<D>In) satumomab pendetide
V09IB03	Indium (<^>111<D>In) antiovariumcarcinoma antibody
V09IB04	Indium (<^>111<D>In) capromab pendetide
V09IX	Other diagnostic radiopharmaceuticals for tumour
V09IX01	Iobenguane (<^>123<D>I)
V09IX02	Iobenguane (<^>131<D>I)
V09IX03	Iodine (<^>125<D>I) CC49-monoclonal antibody
V09IX04	Fludeoxyglucose <>18<D>F
V09IX05	Fluorodopa (<>18<D>F)
V09IX06	Sodium fluoride (<>18<D>F)
V09IX07	Fluoromethylcholine (<>18<D>F)
V09X	Other diagnostic radiopharmaceuticals
V09XA	Iodine (131I) compounds
V09XA01	Iodine (131I) norcholesterol
V09XA02	Iodocholesterol (<^>131<D>I)
V09XA03	Iodine (<^>131<D>I) human albumin
V09XX	Various diagnostic radiopharmaceuticals
V09XX01	Cobalt (<^>57<D>Co) cyanocobalamine
V09XX02	Cobalt (<^>58<D>Co) cyanocobalamine
V09XX03	Selenium (<^>75<D>Se) norcholesterol
V09XX04	Ferric (<^>59<D>Fe) citrate
V10	Therapeutic radiopharmaceuticals
V10A	Antiinflammatory agents
V10AA	Yttrium (<^>90<D>) compounds
V10AA01	Yttrium (<^>90<D>Y) citrate colloid
V10AA02	Yttrium (<^>90<D>Y) ferrihydroxide colloid
V10AA03	Yttrium (<^>90<D>Y) silicate colloid
V10AX	Other antiinflammatory therapeutic radiopharmaceuticals
V10AX01	Phosphorous (<^>32<D>P) chromicphosphate colloid
V10AX02	Samarium (<^>153<D>Sm) hydroxyapatite colloid
V10AX03	Dysprosium (<^>165<D>Dy) colloid
V10AX04	Erbium (<^>169<D>Er) citrate colloid
V10AX05	Rhenium (<^>186<D>Re) sulfide colloid
V10AX06	Gold (<^>198<D>Au) colloidal
V10B	Pain palliation (bone seeking agents)
V10BX	Various pain palliation radiopharmaceuticals
V10BX01	Strontium (<^>89<D>Sr) chloride
V10BX02	Samarium (<^>153<D>) lexidronam
V10BX03	Rhenium (<^>186<D>Re) etidronic acid
V10X	Other therapeutic radiopharmaceuticals
V10XA	Iodine (<^>131<D>I) compounds
V10XA01	Sodium iodide (<^>131<D>I)
V10XA02	Iobenguane (<^>131<D>I)
V10XA53	Tositumomab/iodine (<^>131<D>I) tositumomab
V10XX	Various therapeutic radiopharmaceuticals
V10XX01	Sodium phosphate (<^>32<D>P)
V10XX02	Ibritumomab tiuxetan (<>90<D>Y)
V20	Surgical dressings
\.


--
-- Data for Name: units; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY units (pk, unit) FROM stdin;
1	ml
2	mg
3	mg/ml
4	mg/g
5	U
6	IU
7	each
8	mcg
9	mcg/ml
10	IU/ml
11	day
12	dose
13	g
14	IU/g
15	ml/g
16	ml/ml
17	mcg/g
18	%
19	mmol
\.


--
-- Data for Name: product; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY product (pk, atccode, name, description, numeric_dose, fk_unit, packsize) FROM stdin;
1	N03AG01	SODIUM VALPROATE	Oral liquid 200 mg per 5 mL, 300 mL	1	\N	1
2	N03AX18	LACOSAMIDE	Tablet 100 mg	1	\N	56
3	V07AY	DRESSING-HYDROACTIVE (CAVITY WOUND)	Dressings 10 cm x 10 cm, 5	1	\N	1
4	C02DC01	MINOXIDIL	Tablet 10 mg	1	\N	100
5	A10BH01	SITAGLIPTIN	Tablet 50 mg (as phosphate monohydrate)	1	\N	28
6	L04AX01	AZATHIOPRINE	Tablet 50 mg	1	\N	100
7	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Oral liquid 125 mL, 36	1	\N	1
8	N02AA01	MORPHINE SULFATE	Injection 10 mg in 1 mL	1	\N	5
9	G03FB08	OESTRADIOL and OESTRADIOL with DYDROGESTERONE	Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg	1	\N	1
10	L03AB10	PEGINTERFERON ALFA-2b	Powder for injection 50 micrograms with diluent in single use injection pen	1	\N	4
11	A10AD01	INSULIN NEUTRAL-INSULIN ISOPHANE (N.P.H.), (MIXED) (Biphasic Isophane)	Injections (human) 100 units (30 units-70 units) per mL, 3 mL, 5	1	\N	1
12	L01AX03	TEMOZOLOMIDE	Capsule 140 mg	1	\N	5
13	V06DX	TRIGLYCERIDES, LONG CHAIN with GLUCOSE POLYMER	Oral liquid 250 mL, 18	1	\N	1
14	H02AB02	DEXAMETHASONE SODIUM PHOSPHATE	Injection equivalent to 4 mg dexamethasone phosphate in 1 mL	1	\N	5
15	V06D	TRIGLYCERIDES, MEDIUM CHAIN	Oil 500 mL	1	\N	1
16	S01XA20	CARMELLOSE SODIUM with GLYCERIN	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), 15 mL	1	\N	1
17	L01XE07	LAPATINIB	Tablet 250 mg (as ditosylate monohydrate)	1	\N	70
18	C07AB12	NEBIVOLOL	Tablet 10 mg (as hydrochloride)	1	\N	28
19	S01EA03	APRACLONIDINE HYDROCHLORIDE	Eye drops 5 mg (base) per mL (0.5%), 10 mL	1	\N	1
20	R06AX26	FEXOFENADINE HYDROCHLORIDE	Tablet 120 mg	1	\N	30
21	L01XC06	CETUXIMAB	Solution for I.V. infusion 100 mg in 20 mL	1	\N	1
22	C09BA04	PERINDOPRIL with INDAPAMIDE HEMIHYDRATE	Tablet containing 2.5 mg perindopril arginine-0.625 mg indapamide hemihydrate	1	\N	30
23	P01BC01	QUININE SULFATE	Tablet 300 mg	1	\N	50
24	C09AA05	RAMIPRIL	Capsule 10 mg	1	\N	30
25	C09CA06	CANDESARTAN CILEXETIL	Tablet 8 mg	1	\N	30
26	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 15 cm x 15 cm, 10	1	\N	1
27	D09A	DRESSING with CADEXOMER IODINE	Sachets 17 g (10 cm x 8 cm), 2	1	\N	1
28	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)	1	\N	1
29	C07AA03	PINDOLOL	Tablet 5 mg	1	\N	100
30	B03XA02	DARBEPOETIN ALFA	Injection 20 micrograms in 0.5 mL pre-filled injection pen	1	\N	1
31	L04AD01	CYCLOSPORIN	Capsule 100 mg	1	\N	30
32	L03AB05	INTERFERON ALFA-2b	Solution for injection 18,000,000 i.u. in 3 mL single dose vial	1	\N	1
33	J01CA04	AMOXYCILLIN	Powder for syrup 250 mg per 5 mL, 100 mL	1	\N	1
34	A03BB01	HYOSCINE BUTYLBROMIDE	Injection 20 mg in 1 mL	1	\N	5
35	V03AF03	CALCIUM FOLINATE	Injection equivalent to 300 mg folinic acid in 30 mL	1	\N	1
36	C02KX02	AMBRISENTAN	Tablet 10 mg	1	\N	30
37	J01XD01	METRONIDAZOLE	Tablet 400 mg	1	\N	5
38	N05AX08	RISPERIDONE	Tablet 2 mg (orally disintegrating)	1	\N	28
39	A02BC03	LANSOPRAZOLE	Capsule 15 mg	1	\N	30
40	S01XA20	POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), 15 mL	1	\N	1
41	G03HA01	CYPROTERONE ACETATE	Tablet 100 mg	1	\N	50
42	L01XX19	IRINOTECAN HYDROCHLORIDE TRIHYDRATE	I.V. injection 100 mg in 5 mL	1	\N	1
43	N04BA03	LEVODOPA with CARBIDOPA and ENTACAPONE	Tablet 200 mg-50 mg-200 mg	1	\N	100
44	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 100 mg (once a day extended release)	1	\N	10
45	N02AA01	MORPHINE SULFATE	Tablet 30 mg	1	\N	20
46	C08CA13	LERCANIDIPINE HYDROCHLORIDE	Tablet 20 mg	1	\N	28
47	V07AY	TAPES-PLASTER ADHESIVE ELASTIC	Roll 5 cm x 2.5 m	1	\N	1
48	L04AB02	INFLIXIMAB	Powder for I.V. infusion 100 mg	1	\N	1
49	J05AF02	DIDANOSINE	Capsule 200 mg (containing enteric coated beadlets)	1	\N	30
50	M05BA07	RISEDRONATE SODIUM	Tablet 150 mg	1	\N	1
51	L04AD01	CYCLOSPORIN	Oral liquid 100 mg per mL, 50 mL	1	\N	1
52	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Tablet 54 mg (extended release)	1	\N	30
53	A07EC02	MESALAZINE	Enemas 4 g in 60 mL, 7	1	\N	1
54	D09AB01	BANDAGE-ZINC PASTE	Bandage 7.5 cm x 6 m	1	\N	1
55	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 16 mg (modified release)	1	\N	10
56	R03DC03	MONTELUKAST SODIUM	Chewable tablet 4 mg (base)	1	\N	28
57	H03BA02	PROPYLTHIOURACIL	Tablet 50 mg	1	\N	100
58	L03AA02	FILGRASTIM	Injection 480 micrograms in 1.6 mL	1	\N	10
59	J02AC02	ITRACONAZOLE	Capsule 100 mg	1	\N	60
60	B03XA01	EPOETIN ALFA	Injection 1,000 units in 0.5 mL pre-filled syringe	1	\N	6
61	S01XA20	HYPROMELLOSE with DEXTRAN	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL	1	\N	1
62	N02BA01	ASPIRIN	Tablet 300 mg (dispersible)	1	\N	96
63	V04B	GLUCOSE and KETONE INDICATOR-URINE	Test strips, 50	1	\N	1
64	C10AA03	PRAVASTATIN	Tablet containing pravastatin sodium 10 mg	1	\N	30
65	V07AY	TAPES-PLASTER ADHESIVE HYPOALLERGENIC	Roll (dispenser) 1.9 cm x 5.4 m	1	\N	1
66	G03GA08	CHORIOGONADOTROPIN ALFA	Solution for injection 250 micrograms in 0.5 mL pre-filled syringe	1	\N	1
67	L01CA02	VINCRISTINE SULFATE	I.V. injection 1 mg in 1 mL	1	\N	5
68	N02BG	PREGABALIN	Capsule 75 mg	1	\N	56
69	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	Infant formula, powder 400 g	1	\N	1
70	L02BB	CYPROTERONE ACETATE	Tablet 100 mg	1	\N	50
71	D10BA01	ISOTRETINOIN	Capsule 20 mg	1	\N	60
72	N06AB04	CITALOPRAM HYDROBROMIDE	Tablet 10 mg (base)	1	\N	28
73	V07AY	BANDAGE-TUBULAR (LIGHTWEIGHT)	Bandage, small limb size (red), 10 m	1	\N	1
74	A06AC51	PSYLLIUM HYDROPHILIC MUCILLOID with HIGH AMYLOSE MAIZE STARCH	Oral powder 2.7 g-0.7 g per 7.5 g, 440 g	1	\N	1
75	N04BC02	PERGOLIDE MESYLATE	Tablet 250 micrograms (base)	1	\N	100
76	G03CA03	OESTRADIOL	Transdermal patches 7.6 mg (releasing approximately 100 micrograms per 24 hours), 4	1	\N	1
77	B03XA02	DARBEPOETIN ALFA	Injection 100 micrograms in 0.5 mL pre-filled syringe	1	\N	4
78	A02AD01	ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE	Oral suspension 200 mg-200 mg per 5 mL, 500 mL	1	\N	1
79	N04BX02	ENTACAPONE	Tablet 200 mg	1	\N	100
80	C09AA03	LISINOPRIL	Tablet 20 mg	1	\N	30
81	D07AC13	MOMETASONE FUROATE	Cream 1 mg per g (0.1%), 45 g	1	\N	1
82	N03AE01	CLONAZEPAM	Tablet 2 mg	1	\N	100
83	C03DA01	SPIRONOLACTONE	Tablet 25 mg	1	\N	100
84	B03XA01	EPOETIN ALFA	Injection 20,000 units in 0.5 mL pre-filled syringe	1	\N	6
85	L01XE03	ERLOTINIB	Tablet 25 mg (as hydrochloride)	1	\N	30
86	N02BG	GABAPENTIN	Capsule 400 mg	1	\N	100
87	C02KX01	BOSENTAN MONOHYDRATE	Tablet 125 mg (base)	1	\N	60
88	R03BA01	BECLOMETHASONE DIPROPIONATE	Oral pressurised inhalation 100 micrograms per dose (200 doses), CFC-free formulation	1	\N	1
89	H01CB03	LANREOTIDE ACETATE	Injection 60 mg (base) in single dose pre-filled syringe	1	\N	1
90	M01AB05	DICLOFENAC SODIUM	Tablet 50 mg (enteric coated)	1	\N	50
91	V07AY	DRESSING-ALGINATE (SUPERFICIAL WOUND)	Dressings 7.5 cm x 12 cm, 10	1	\N	1
92	N05BA01	DIAZEPAM	Tablet 5 mg	1	\N	50
93	B05BB02	SODIUM CHLORIDE with GLUCOSE	I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL (0.225%-3.75%), 500 mL	1	\N	1
94	V07AY	DRESSING-ACTIVATED CHARCOAL (MALODOROUS WOUND)	Dressings 10 cm x 10 cm, 10	1	\N	1
95	A10BD03	ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE	Tablet 2 mg (base)-1 g	1	\N	56
96	L01BB03	THIOGUANINE	Tablet 40 mg	1	\N	25
97	N06AB04	CITALOPRAM HYDROBROMIDE	Tablet 20 mg (base)	1	\N	28
98	A02BB01	MISOPROSTOL	Tablet 200 micrograms	1	\N	120
99	C01BD	SOTALOL HYDROCHLORIDE	Tablet 160 mg	1	\N	60
100	C07AA02	OXPRENOLOL HYDROCHLORIDE	Tablet 20 mg	1	\N	100
101	L04AA10	SIROLIMUS	Oral solution 1 mg per mL, 60 mL	1	\N	1
102	S01LA04	RANIBIZUMAB	Solution for intravitreal injection 2.3 mg in 0.23 mL	1	\N	1
103	A03FA01	METOCLOPRAMIDE HYDROCHLORIDE	Tablet 10 mg	1	\N	25
104	B01AC04	CLOPIDOGREL	Tablet 75 mg (as hydrogen sulfate)	1	\N	28
105	J05AB09	FAMCICLOVIR	Tablet 125 mg	1	\N	40
106	C09AA05	RAMIPRIL	Capsule 5 mg	1	\N	30
107	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 75 micrograms in 0.3 mL pre-filled syringe	1	\N	1
108	V07AY	DRESSING-GAUZE-POVIDONE-IODINE PAD	Pads 22.5 cm x 7.5 cm, 12	1	\N	1
109	V07AY	DRESSING-FILM ISLAND	Dressing 5 cm x 7 cm	1	\N	1
110	L01XC06	CETUXIMAB	Solution for I.V. infusion 500 mg in 100 mL	1	\N	1
111	C01BC04	FLECAINIDE ACETATE	Tablet 50 mg	1	\N	60
112	S01AD09	GANCICLOVIR	Intravitreal implant 4.5 mg	1	\N	1
113	M01CA	HYDROXYCHLOROQUINE SULFATE	Tablet 200 mg	1	\N	100
114	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Solution for injection 10 mg (30 i.u.) in 2 mL cartridge (with preservative)	1	\N	1
115	N03AE01	CLONAZEPAM	Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	1	\N	5
116	C10BA02	EZETIMIBE with SIMVASTATIN	Tablet 10 mg-80 mg	1	\N	30
117	N03AX18	LACOSAMIDE	Tablet 50 mg	1	\N	14
118	M01AB01	INDOMETHACIN	Capsule 25 mg	1	\N	50
119	R03BA05	FLUTICASONE PROPIONATE	Powder for oral inhalation in breath actuated device 250 micrograms per dose (60 doses)	1	\N	1
120	C09DA03	VALSARTAN with HYDROCHLOROTHIAZIDE	Tablet 320 mg-25 mg	1	\N	28
121	J05AR06	TENOFOVIR with EMTRICITABINE and EFAVIRENZ	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and efavirenz 600 mg	1	\N	30
122	V07AY	BANDAGE-COMPRESSION	Bandage, short stretch, 8 cm x 5 m	1	\N	1
123	L01XX19	IRINOTECAN HYDROCHLORIDE TRIHYDRATE	I.V. injection 300 mg in 15 mL	1	\N	1
124	N04BC01	BROMOCRIPTINE MESYLATE	Tablet 2.5 mg (base)	1	\N	60
125	R03AK07	BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE	Powder for oral inhalation in breath actuated device 100 micrograms-6 micrograms per dose (120 doses)	1	\N	1
126	V06DX	AMINO ACID FORMULA without METHIONINE, THREONINE and VALINE and low in ISOLEUCIN	Powder 200 g	1	\N	1
127	H02AB10	CORTISONE ACETATE	Tablet 25 mg	1	\N	60
128	C01BD01	AMIODARONE HYDROCHLORIDE	Tablet 100 mg	1	\N	30
129	R03AK06	FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	Powder for oral inhalation in breath actuated device 500 micrograms-50 micrograms (base) per dose (60 doses)	1	\N	1
130	M05BX	TERIPARATIDE	Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen	1	\N	1
131	L01AX03	TEMOZOLOMIDE	Capsule 5 mg	1	\N	5
132	S01XA20	POLYETHYLENE GLYCOL 400	Eye drops 2.5 mg per mL (0.25%), single dose units 0.4 mL, 20	1	\N	1
133	J01FA09	CLARITHROMYCIN	Tablet 250 mg	1	\N	100
134	L03AB60	RIBAVIRIN and PEGINTERFERON ALFA-2b	Pack containing 168 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection	1	\N	1
135	D11AC03	SELENIUM SULFIDE	Shampoo 25 mg per mL (2.5%), 125 mL	1	\N	1
136	C10AA01	SIMVASTATIN	Tablet 40 mg	1	\N	30
137	A04AD	PROCHLORPERAZINE	Tablet containing prochlorperazine maleate 5 mg	1	\N	25
138	J01CF01	DICLOXACILLIN	Capsule 250 mg	1	\N	24
139	C09DA08	OLMESARTAN MEDOXOMIL with HYDROCHLOROTHIAZIDE	Tablet 20 mg-12.5 mg	1	\N	30
140	C09BB05	RAMIPRIL with FELODIPINE	Tablet 2.5 mg-2.5 mg (modified release)	1	\N	30
141	N02AX02	TRAMADOL HYDROCHLORIDE	Capsule 50 mg	1	\N	20
142	D09AA	DRESSING with CADEXOMER IODINE	Tubes 20 g, 2	1	\N	1
143	G03DA02	MEDROXYPROGESTERONE ACETATE	Tablet 10 mg	1	\N	100
144	L01BC05	GEMCITABINE HYDROCHLORIDE	Powder for I.V. infusion 1 g (base)	1	\N	1
145	H01CB02	OCTREOTIDE	Injection (modified release) 30 mg (as acetate), vial and diluent syringe	1	\N	1
146	V07AY	DRESSING-HYDROGEL-AMORPHOUS	Tube 25 g	1	\N	1
147	M04AA01	ALLOPURINOL	Tablet 100 mg	1	\N	100
148	L01BA04	PEMETREXED DISODIUM	Powder for I.V. infusion 100 mg (base)	1	\N	1
149	L01DB03	EPIRUBICIN HYDROCHLORIDE	Solution for injection 10 mg in 5 mL	1	\N	1
150	S01XA20	CARMELLOSE SODIUM	Eye drops 10 mg per mL (1%), 15 mL	1	\N	1
151	G03CA03	OESTRADIOL	Transdermal patches 3 mg (releasing approximately 100 micrograms per 24 hours), 8	1	\N	1
152	A10BB09	GLICLAZIDE	Tablet 30 mg (modified release)	1	\N	100
153	A07EA02	HYDROCORTISONE ACETATE	Rectal foam 90 mg per applicatorful, 14 applications, aerosol 21.1 g	1	\N	1
154	J01CR02	AMOXYCILLIN with CLAVULANIC ACID	Tablet 875 mg-125 mg	1	\N	10
155	N02CX01	PIZOTIFEN MALATE	Tablet 500 micrograms (base)	1	\N	100
156	A04AD	PROCHLORPERAZINE	Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	1	\N	10
157	D11AX	DAPSONE	Tablet 25 mg	1	\N	100
158	J05AB09	FAMCICLOVIR	Tablet 500 mg	1	\N	56
159	V06DX	AMINO ACID FORMULA without PHENYLALANINE, TYROSINE and METHIONINE	Powder 500 g	1	\N	1
160	V06DX	HIGH FAT FORMULA with VITAMINS, MINERALS and TRACE ELEMENTS and low in PROTEIN a	Powder 300 g	1	\N	1
161	L01BA04	PEMETREXED DISODIUM	Powder for I.V. infusion 500 mg (base)	1	\N	1
162	B01AX06	RIVAROXABAN	Tablet 10 mg	1	\N	10
163	C07AA03	PINDOLOL	Tablet 15 mg	1	\N	50
164	P01AB01	METRONIDAZOLE	Suppositories 500 mg, 10	1	\N	1
165	D07AB09	TRIAMCINOLONE ACETONIDE	Cream 200 micrograms per g (0.02%), 100 g	1	\N	1
166	S01XA20	CARBOMER	Eye gel 2 mg per g (0.2%), 10 g	1	\N	1
167	N04BC02	PERGOLIDE MESYLATE	Tablet 1 mg (base)	1	\N	100
168	V07AY	BANDAGE-RETENTION-COTTON CREPE	Bandage 10 cm x 2.3 m	1	\N	1
169	S01AD03	ACICLOVIR	Eye ointment 30 mg per g (3%), 4.5 g	1	\N	1
170	L01CD01	PACLITAXEL	Solution concentrate for I.V. infusion 100 mg in 16.7 mL	1	\N	1
171	N05AD01	HALOPERIDOL	Oral liquid 2 mg per mL, 100 mL	1	\N	1
172	L01BA01	METHOTREXATE	Tablet 10 mg	1	\N	50
173	L01DB01	DOXORUBICIN HYDROCHLORIDE	Solution for I.V. injection or intravesical administration 10 mg in 5 mL	1	\N	1
174	C07AA07	SOTALOL HYDROCHLORIDE	Tablet 160 mg	1	\N	60
175	B05CB01	SODIUM CHLORIDE	Irrigation solution 9 mg per mL (0.9%), 500 mL	1	\N	1
176	J01CE02	PHENOXYMETHYLPENICILLIN	Capsule 500 mg	1	\N	50
177	L01XA03	OXALIPLATIN	Powder for I.V. infusion 100 mg	1	\N	1
178	B01AA03	WARFARIN SODIUM	Tablet 2 mg	1	\N	50
179	N03AX09	LAMOTRIGINE	Tablet 50 mg	1	\N	56
180	N04BB01	AMANTADINE HYDROCHLORIDE	Capsule 100 mg	1	\N	100
181	N05BA01	DIAZEPAM	Injection 10 mg in 2 mL	1	\N	5
182	N07AA02	PYRIDOSTIGMINE BROMIDE	Tablet 60 mg	1	\N	150
183	N02BE51	CODEINE PHOSPHATE with PARACETAMOL	Tablet 8 mg-500 mg	1	\N	50
184	L03AB04	INTERFERON ALFA-2a	Injection 9,000,000 i.u. in 0.5 mL single dose pre-filled syringe	1	\N	1
185	N02BG	PREGABALIN	Capsule 300 mg	1	\N	56
186	S01XA20	CARBOMER	Eye gel 2 mg per g (0.2%), single dose units 0.6 mL, 30	1	\N	1
187	J05AB14	VALGANCICLOVIR HYDROCHLORIDE	Tablet 450 mg (base)	1	\N	60
188	B01AX06	RIVAROXABAN	Tablets 10 mg, 15	1	\N	1
189	C09AA01	CAPTOPRIL	Tablet 50 mg	1	\N	90
190	L01BA01	METHOTREXATE	Solution concentrate for I.V. infusion 500 mg in 20 mL	1	\N	1
191	A10BF01	ACARBOSE	Tablet 100 mg	1	\N	90
192	V07AY	DRESSING-FOAM-MODERATE EXUDATE	Dressing, cavity, conforming, 20 g	1	\N	1
193	V07AY	TAPES-PLASTER ADHESIVE HYPOALLERGENIC	Roll 2.5 cm x 5 m	1	\N	1
194	C01DA02	GLYCERYL TRINITRATE	Transdermal patch releasing approximately 5 mg per 24 hours	1	\N	30
195	P02CA03	ALBENDAZOLE	Tablet 400 mg	1	\N	60
196	R03CA	ADRENALINE	Injection 1 mg in 1 mL (1 in 1,000)	1	\N	5
197	G03AA05	NORETHISTERONE with ETHINYLOESTRADIOL	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	1	\N	1
198	V07AY	DRESSING-ALGINATE (SUPERFICIAL WOUND)	Dressings 10 cm x 10 cm, 10	1	\N	1
199	V07AY	DRESSING-NON-ADHERENT	Dressings, non-woven, with silicone 7.5 cm x 10 cm, 10	1	\N	1
200	M05BA08	ZOLEDRONIC ACID	Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL	1	\N	1
201	N02AE01	BUPRENORPHINE	Transdermal patch 5 mg (releasing approximately 5 micrograms per hour)	1	\N	2
202	D07AC01	BETAMETHASONE VALERATE	Cream 200 micrograms (base) per g (0.02%), 100 g	1	\N	1
203	A07EC03	OLSALAZINE SODIUM	Capsule 250 mg	1	\N	100
204	C01DA02	GLYCERYL TRINITRATE	Transdermal patch releasing approximately 15 mg per 24 hours	1	\N	30
205	V07AY	DRESSING-FILM ISLAND	Dressing 9 cm x 10 cm	1	\N	1
206	G03AA07	LEVONORGESTREL with ETHINYLOESTRADIOL	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	1	\N	4
207	C09BB02	LERCANIDIPINE HYDROCHLORIDE with ENALAPRIL MALEATE	Tablet 10 mg-10 mg	1	\N	28
208	C08CA05	NIFEDIPINE	Tablet 20 mg	1	\N	60
209	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 10 cm x 10 cm, 10	1	\N	1
210	C09DA08	OLMESARTAN MEDOXOMIL with HYDROCHLOROTHIAZIDE	Tablet 40 mg-12.5 mg	1	\N	30
834	N06DX01	MEMANTINE HYDROCHLORIDE	Tablet 20 mg	1	\N	28
211	D05AX02	CALCIPOTRIOL	Cream 50 micrograms per g (0.005%), 30 g	1	\N	1
212	L03AB07	INTERFERON BETA-1a	Injection 30 micrograms (6,000,000 i.u.) in 0.5 mL single dose pre-filled syringe	1	\N	4
213	A10AC02	INSULIN ISOPHANE (N.P.H.)	Injection (bovine) 100 units per mL, 10 mL	1	\N	1
214	V06DX	ESSENTIAL AMINO ACIDS FORMULA	Powder 200 g, 2	1	\N	1
215	G03XA01	DANAZOL	Capsule 100 mg	1	\N	100
216	C09DA04	IRBESARTAN with HYDROCHLOROTHIAZIDE	Tablet 300 mg-25 mg	1	\N	30
217	A07EC02	MESALAZINE	Sachet containing granules, 1.5 g per sachet	1	\N	60
218	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Oral liquid 130 mL, 30	1	\N	1
219	S01GX01	SODIUM CROMOGLYCATE	Eye drops 20 mg per mL (2%), 10 mL	1	\N	1
220	J01MA06	NORFLOXACIN	Tablet 400 mg	1	\N	14
221	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 15 mg (controlled release)	1	\N	20
222	V07AY	BANDAGE-TUBULAR (LONG STOCKING)	Bandage, XX/large size	1	\N	1
223	D11AX	ALLANTOIN with GLYCEROL and ICHTHAMMOL	Cream 5 mg-10 mg-10 mg per g (0.5%-1%-1%), 50 g	1	\N	1
224	A07EC04	BALSALAZIDE SODIUM	Capsule 750 mg	1	\N	180
225	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 360 micrograms in 0.3 mL pre-filled syringe	1	\N	1
226	J04BA	RIFAMPICIN	Capsule 150 mg	1	\N	100
227	S01XA20	CARBOMER 974	Ocular lubricating gel 3 mg per g (0.3%), single dose units 0.5 g, 30	1	\N	1
228	J01DD04	CEFTRIAXONE	Powder for injection 500 mg	1	\N	1
229	R01AX03	IPRATROPIUM BROMIDE	Aqueous nasal spray (pump pack) 42 micrograms (anhydrous) per dose (180 doses)	1	\N	1
230	N04BA02	LEVODOPA with CARBIDOPA	Tablet 200 mg-50 mg (modified release)	1	\N	100
231	C09CA03	VALSARTAN	Tablet 160 mg	1	\N	28
232	N02BE01	PARACETAMOL	Oral liquid 240 mg per 5 mL, 200 mL	1	\N	1
233	N07BA03	VARENICLINE	Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the	1	\N	1
234	J02AC04	POSACONAZOLE	Oral suspension 40 mg per mL, 105 mL	1	\N	1
235	J01DC04	CEFACLOR	Powder for oral suspension 250 mg per 5 mL, 75 mL	1	\N	1
236	J01DD04	CEFTRIAXONE	Powder for injection 1 g	1	\N	1
237	C10AA04	FLUVASTATIN	Tablet (prolonged release) 80 mg (as sodium)	1	\N	28
238	C09DA03	VALSARTAN with HYDROCHLOROTHIAZIDE	Tablet 320 mg-12.5 mg	1	\N	28
239	G01AA01	NYSTATIN	Cream pessaries 100,000 units, 15	1	\N	1
240	M05BB02	RISEDRONATE SODIUM and CALCIUM CARBONATE	Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	1	\N	1
241	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 8 mg (modified release)	1	\N	10
242	L01XE06	DASATINIB	Tablet 100 mg	1	\N	30
243	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 200 mg (once a day extended release)	1	\N	10
244	N03AD01	ETHOSUXIMIDE	Paediatric syrup 250 mg per 5 mL, 200 mL	1	\N	1
245	L01XA01	CISPLATIN	I.V. injection 10 mg in 10 mL	1	\N	1
246	H02AB09	HYDROCORTISONE	Tablet 4 mg	1	\N	50
247	C09BB02	LERCANIDIPINE HYDROCHLORIDE with ENALAPRIL MALEATE	Tablet 10 mg-20 mg	1	\N	28
248	V07AY	DRESSING-FOAM-MODERATE EXUDATE	Dressings 10 cm x 10 cm, 10	1	\N	1
249	L01BA03	RALTITREXED	Powder for I.V. infusion 2 mg	1	\N	1
250	J05AX07	ENFUVIRTIDE	Pack containing 60 vials powder for injection 90 mg with 60 vials water for injections 1.1 mL (with syringes and swabs)	1	\N	1
251	S01EE	TRAVOPROST with TIMOLOL MALEATE	Eye drops 40 micrograms-5 mg (base) per mL (0.004%-0.5%), 2.5 mL	1	\N	1
252	N05CD07	TEMAZEPAM	Tablet 10 mg	1	\N	25
253	B01AC16	EPTIFIBATIDE ACETATE	Solution for I.V. infusion 75 mg (base) in 100 mL	1	\N	1
254	N02BG09	METHOXYFLURANE	Liquid for inhalation 999.9 mg per g, 3 mL (with inhaler)	1	\N	1
255	J01CF05	FLUCLOXACILLIN	Powder for injection 500 mg	1	\N	5
256	J01DC04	CEFACLOR	Powder for oral suspension 125 mg per 5 mL, 100 mL	1	\N	1
257	N06AG02	MOCLOBEMIDE	Tablet 150 mg	1	\N	60
258	L02AE02	LEUPRORELIN ACETATE	I.M. injection (modified release), powder for injection 7.5 mg with diluent in pre-filled dual-chamber syringe	1	\N	1
259	B03XA01	EPOETIN ALFA	Injection 2,000 units in 0.5 mL pre-filled syringe	1	\N	6
260	L01XC06	CETUXIMAB	Solution for I.V. infusion 100 mg in 50 mL	1	\N	1
261	G02CB01	BROMOCRIPTINE MESYLATE	Capsule 10 mg (base)	1	\N	100
262	J04AB02	RIFAMPICIN	Capsule 300 mg	1	\N	100
263	A10BD07	SITAGLIPTIN with METFORMIN HYDROCHLORIDE	Tablet 50 mg (as phosphate monohydrate)-850 mg	1	\N	56
264	L01BB04	CLADRIBINE	Injection 10 mg in 5 mL	1	\N	1
265	J01CF05	FLUCLOXACILLIN	Powder for injection 1 g	1	\N	5
266	J07AL01	PNEUMOCOCCAL VACCINE, POLYVALENT	Injection 0.5 mL (23 valent)	1	\N	1
267	C09CA03	VALSARTAN	Tablet 40 mg	1	\N	28
268	S01ED51	LATANOPROST with TIMOLOL MALEATE	Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL	1	\N	1
269	J01CE08	BENZATHINE BENZYLPENICILLIN	Injection 900 mg in 2.3 mL single use pre-filled syringe	1	\N	10
270	C01CA24	ADRENALINE	I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector	1	\N	1
271	J02AC01	FLUCONAZOLE	Solution for I.V. infusion 200 mg in 100 mL	1	\N	1
272	L01XX32	BORTEZOMIB	Powder for injection 3.5 mg (solvent required)	1	\N	1
273	J01GB03	GENTAMICIN SULFATE	Injection 80 mg (base) in 2 mL	1	\N	10
274	A10AB02	INSULIN NEUTRAL	Injection (bovine) 100 units per mL, 10 mL	1	\N	1
275	A10AE04	INSULIN GLARGINE	Injections (human analogue) 100 units per mL, 3 mL, 5	1	\N	1
276	J01EE01	TRIMETHOPRIM with SULFAMETHOXAZOLE	Oral suspension 40 mg-200 mg per 5 mL, 100 mL	1	\N	1
277	V06DX	MILK PROTEIN and FAT FORMULA with VITAMINS and MINERALS-CARBOHYDRATE FREE	Powder 225 g	1	\N	1
278	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 10 mg (controlled release)	1	\N	20
279	N06AX23	DESVENLAFAXINE SUCCINATE	Tablet 100 mg (base) (extended release)	1	\N	28
280	N05AL05	AMISULPRIDE	Oral solution 100 mg per mL, 60 mL	1	\N	1
281	D02AC	WOOL ALCOHOLS	Ointment 100 g	1	\N	1
282	G04CA03	TERAZOSIN HYDROCHLORIDE	Tablet 5 mg	1	\N	28
283	N07BB03	ACAMPROSATE CALCIUM	Tablet 333 mg (enteric coated)	1	\N	180
284	L04AC05	USTEKINUMAB	Injection 45 mg in 0.5 mL	1	\N	1
285	J05AF01	ZIDOVUDINE	Capsule 100 mg	1	\N	100
286	S01AX11	OFLOXACIN	Eye drops 3 mg per mL (0.3%), 5 mL	1	\N	1
287	G03BA03	TESTOSTERONE	Transdermal gel 50 mg in 5 g sachet, 30	1	\N	1
288	J01CR02	AMOXYCILLIN with CLAVULANIC ACID	Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL	1	\N	1
289	J01XC01	FUSIDIC ACID	Tablet (sodium salt) 250 mg	1	\N	36
290	V07AY	PRESSURE REDUCING PRODUCTS	Sheet 10 cm x 10 cm x 12 mm	1	\N	1
291	M01CB01	SODIUM AUROTHIOMALATE	Injection 10 mg	1	\N	10
292	A12CC	MAGNESIUM ASPARTATE	Tablet 500 mg	1	\N	50
293	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Oral liquid 1 mg per mL, 473 mL	1	\N	1
294	G03FA01	OESTRADIOL with NORETHISTERONE ACETATE	Transdermal patches 510 micrograms-4.8 mg (releasing approximately 50 micrograms- 250 micrograms per 24 hours), 8	1	\N	1
295	V07AY	DRESSING-FOAM-MODERATE EXUDATE	Dressings 7.5 cm x 7.5 cm, 10	1	\N	1
296	R03BA01	BECLOMETHASONE DIPROPIONATE	Oral pressurised inhalation in breath actuated device 100 micrograms per dose (200 doses), CFC-free formulation	1	\N	1
297	C08CA02	FELODIPINE	Tablet 10 mg (extended release)	1	\N	30
298	G04BX	SODIUM BICARBONATE	Capsule 840 mg	1	\N	100
299	L01XC02	RITUXIMAB	Solution for I.V. infusion 500 mg in 50 mL	1	\N	1
300	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	Powder 500 g	1	\N	1
301	L01CB01	ETOPOSIDE	Powder for I.V. infusion 1 g (as phosphate)	1	\N	1
302	D11AX	DAPSONE	Tablet 100 mg	1	\N	100
303	J05AE09	TIPRANAVIR	Capsule 250 mg	1	\N	120
304	R03BA05	FLUTICASONE PROPIONATE	Oral pressurised inhalation 125 micrograms per dose (120 doses), CFC-free formulation	1	\N	1
305	S01BA02	HYDROCORTISONE ACETATE	Eye ointment 10 mg per g (1%), 5 g	1	\N	1
306	S02CA04	TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE, GRAMICIDIN and NYSTATIN	Ear drops 1 mg-2.5 mg (base)- 250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 7.5 mL	1	\N	1
307	M01AC06	MELOXICAM	Capsule 7.5 mg	1	\N	30
308	L01AA03	MELPHALAN	Tablet 2 mg	1	\N	25
309	S01XA20	CARMELLOSE SODIUM	Eye drops 5 mg per mL (0.5%), 15 mL	1	\N	1
310	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Tablet 10 mg	1	\N	100
311	D05BB02	ACITRETIN	Capsule 25 mg	1	\N	100
312	C09BA06	QUINAPRIL HYDROCHLORIDE with HYDROCHLOROTHIAZIDE	Tablet 10 mg (base)-12.5 mg	1	\N	30
313	A07EC02	MESALAZINE	Enemas 1 g in 100 mL, 7	1	\N	1
314	G03DA04	PROGESTERONE	Pessary 100 mg	1	\N	15
315	V03AE03	LANTHANUM CARBONATE HYDRATE	Chewable tablet 750 mg (base)	1	\N	90
316	M01AB05	DICLOFENAC SODIUM	Tablet 25 mg (enteric coated)	1	\N	100
317	V07AY	BANDAGE-RETENTION-COHESIVE-HEAVY	Bandage 7.5 cm x 3 m	1	\N	1
318	L01AA06	IFOSFAMIDE	Powder for I.V. injection 2 g	1	\N	1
319	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	Sachets 20 g, 30	1	\N	1
320	J01FA10	AZITHROMYCIN	Tablet 500 mg	1	\N	2
321	N06AA12	DOXEPIN HYDROCHLORIDE	Tablet 50 mg (base)	1	\N	50
322	A10BH01	SITAGLIPTIN	Tablet 100 mg (as phosphate monohydrate)	1	\N	28
323	H01BA02	DESMOPRESSIN ACETATE	Tablet 200 micrograms	1	\N	30
324	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)	1	\N	1
325	D05AX02	CALCIPOTRIOL	Scalp solution 50 micrograms per mL (0.005%), 30 mL	1	\N	1
326	L01AA02	CHLORAMBUCIL	Tablet 2 mg	1	\N	25
327	L04AD01	CYCLOSPORIN	Solution concentrate for I.V. infusion 50 mg in 1 mL	1	\N	10
328	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Adhesive waterproof semi-permeable absorbent foam pads 18 cm x 18 cm, 5	1	\N	1
329	S01XA20	SOY LECITHIN	Eye spray 10 mg per mL (1%), 10 mL	1	\N	1
330	G03AB03	LEVONORGESTREL with ETHINYLOESTRADIOL	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets	1	\N	4
331	M01CX	LEFLUNOMIDE	Pack containing 3 tablets leflunomide 100 mg and 30 tablets leflunomide 20 mg	1	\N	1
332	L03AB04	INTERFERON ALFA-2a	Injection 6,000,000 i.u. in 0.5 mL single dose pre-filled syringe	1	\N	1
333	C02KX	ILOPROST TROMETAMOL	Solution for inhalation 20 micrograms (base) in 2 mL	1	\N	30
334	H02AB02	DEXAMETHASONE	Tablet 500 micrograms	1	\N	30
335	L01XA03	OXALIPLATIN	Solution concentrate for I.V. infusion 200 mg in 40 mL	1	\N	1
336	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	Sachets 25 g, 30	1	\N	1
337	N02AA01	MORPHINE SULFATE	Tablet 60 mg (controlled release)	1	\N	20
338	C08DA01	VERAPAMIL HYDROCHLORIDE	Injection 5 mg in 2 mL	1	\N	5
339	L04AA10	SIROLIMUS	Tablet 2 mg	1	\N	100
340	L01XE01	IMATINIB	Tablet 400 mg (as mesylate)	1	\N	30
341	M01AB01	INDOMETHACIN	Suppository 100 mg	1	\N	20
342	C02CA01	PRAZOSIN HYDROCHLORIDE	Tablet 5 mg (base)	1	\N	100
343	N06AB08	FLUVOXAMINE MALEATE	Tablet 50 mg	1	\N	30
344	A04AA01	ONDANSETRON	Tablet 8 mg	1	\N	4
345	C07AB02	METOPROLOL SUCCINATE	Tablet 47.5 mg (controlled release)	1	\N	30
346	N06AA16	DOTHIEPIN HYDROCHLORIDE	Tablet 75 mg	1	\N	30
347	D06BB04	PODOPHYLLOTOXIN	Cream 1.5 mg per g (0.15%), 5 g	1	\N	1
348	V06DX	AMINO ACID FORMULA with VITAMINS, MINERALS and LONG CHAIN POLYUNSATURATED FATTY	Infant formula, powder 400 g	1	\N	1
349	J02AC01	FLUCONAZOLE	Capsule 100 mg	1	\N	28
350	S01XA20	POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL	Eye drops 4 mg-3 mg per mL (0.4%-0.3%), single dose units 0.8 mL, 28	1	\N	1
351	N06AX12	BUPROPION HYDROCHLORIDE	Tablet 150 mg (sustained release)	1	\N	30
352	N06AF03	PHENELZINE SULFATE	Tablet 15 mg (base)	1	\N	100
353	A04AA01	ONDANSETRON	Wafer 8 mg	1	\N	10
354	C08DA01	VERAPAMIL HYDROCHLORIDE	Capsule 160 mg (sustained release)	1	\N	30
355	B05BB01	SODIUM CHLORIDE COMPOUND	I.V. infusion 1 L	1	\N	1
356	V07AY	BANDAGE-RETENTION-COHESIVE-LIGHT	Bandage 6 cm x 4 m	1	\N	1
357	N02CC03	ZOLMITRIPTAN	Tablet 2.5 mg	1	\N	2
358	B03BB01	FOLIC ACID	Tablet 5 mg	1	\N	100
359	V06DX	TRIGLYCERIDES, MEDIUM CHAIN and LONG CHAIN with GLUCOSE POLYMER	Compound powder 400 g	1	\N	1
360	V07AY	DRESSING-NON-ADHERENT	Dressings, non-woven, with silicone 5 cm x 7.5 cm, 10	1	\N	1
361	J05AG03	EFAVIRENZ	Oral solution 30 mg per mL, 180 mL	1	\N	1
362	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 250 mL	1	\N	18
363	N03AF02	OXCARBAZEPINE	Tablet 150 mg	1	\N	100
364	M02AC	METHYL SALICYLATE	Liniment APF, 100 mL	1	\N	1
365	N03AE	NITRAZEPAM	Tablet 5 mg	1	\N	25
366	L01AA01	CYCLOPHOSPHAMIDE	Powder for injection 2 g (solvent required)	1	\N	1
367	H02AA02	FLUDROCORTISONE ACETATE	Tablet 100 micrograms	1	\N	100
368	S01XA20	PARAFFIN	Pack containing 2 tubes compound eye ointment 3.5 g	1	\N	1
369	N05AD01	HALOPERIDOL DECANOATE	I.M. injection equivalent to 150 mg haloperidol in 3 mL	1	\N	5
370	N03AX12	GABAPENTIN	Tablet 600 mg	1	\N	100
371	C01BA03	DISOPYRAMIDE	Capsule 150 mg	1	\N	100
372	A03FA01	METOCLOPRAMIDE HYDROCHLORIDE	Injection 10 mg in 2 mL	1	\N	10
373	B03XA02	DARBEPOETIN ALFA	Injection 40 micrograms in 0.4 mL pre-filled syringe	1	\N	4
374	V03AF03	CALCIUM FOLINATE	Tablet equivalent to 15 mg folinic acid	1	\N	10
375	S01XA20	CARMELLOSE SODIUM	Eye drops 2.5 mg per mL (0.25%), single dose units 0.6 mL, 24	1	\N	1
376	N04BA02	LEVODOPA with BENSERAZIDE	Capsule 100 mg-25 mg	1	\N	100
377	C09AA10	TRANDOLAPRIL	Capsule 1 mg	1	\N	28
378	G04BE03	SILDENAFIL CITRATE	Tablet 20 mg (base)	1	\N	90
379	B03XA02	DARBEPOETIN ALFA	Injection 100 micrograms in 0.5 mL pre-filled injection pen	1	\N	1
380	G04BX	SODIUM CITRO-TARTRATE	Sachets containing oral effervescent powder 4 g, 28	1	\N	1
381	D01AC08	KETOCONAZOLE	Shampoo 10 mg per g (1%), 100 mL	1	\N	1
382	J01XD02	TINIDAZOLE	Tablet 500 mg	1	\N	4
383	V07AY	DRESSING with CADEXOMER IODINE	Sachets 3 g, 7	1	\N	1
384	S01ED51	BRIMONIDINE TARTRATE with TIMOLOL MALEATE	Eye drops 2 mg-5 mg (base) per mL (0.2%-0.5%), 5 mL	1	\N	1
385	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 5 mg (base)-10 mg (base)	1	\N	30
386	J01XD01	METRONIDAZOLE	I.V. infusion 500 mg in 100 mL	1	\N	10
387	A10AC01	INSULIN ISOPHANE (N.P.H.)	Injections (human) 100 units per mL, 3 mL, 5	1	\N	1
388	L01DB07	MITOZANTRONE HYDROCHLORIDE	Injection 25 mg (base) in 12.5 mL	1	\N	1
389	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 15 cm x 20 cm, 3	1	\N	1
390	N02BA51	CODEINE PHOSPHATE with ASPIRIN	Tablet soluble 8 mg-300 mg	1	\N	50
391	L02BG03	ANASTROZOLE	Tablet 1 mg	1	\N	30
392	S01ED01	TIMOLOL MALEATE	Eye drops (gellan gum solution) 5 mg (base) per mL (0.5%), 2.5 mL	1	\N	1
393	C10AA07	ROSUVASTATIN	Tablet 20 mg (as calcium)	1	\N	30
394	B05BB01	SODIUM CHLORIDE	I.V. infusion 154 mmol per L (0.9%), 1 L	1	\N	1
395	D01AE15	TERBINAFINE	Cream containing terbinafine hydrochloride 10 mg per g (1%), 15 g	1	\N	1
396	V06DX	AMINO ACID FORMULA with FAT, CARBOHYDRATE, VITAMINS, MINERALS and TRACE ELEMENTS	Oral liquid 125 mL, 36	1	\N	1
397	J02AB02	KETOCONAZOLE	Tablet 200 mg	1	\N	30
398	V07AY	DRESSING-NON-ADHERENT	Dressings 7.5 cm x 10 cm, 10	1	\N	1
399	N07BA03	VARENICLINE	Tablet 1 mg (as tartrate)	1	\N	56
400	S01XA20	CARMELLOSE SODIUM	Eye drops 5 mg per mL (0.5%), single dose units 0.4 mL, 30	1	\N	1
401	B03XA02	DARBEPOETIN ALFA	Injection 60 micrograms in 0.3 mL pre-filled syringe	1	\N	4
402	S01ED02	BETAXOLOL HYDROCHLORIDE	Eye drops, suspension, 2.5 mg (base) per mL (0.25%), 5 mL	1	\N	1
403	N02AA01	MORPHINE TARTRATE	Injection 120 mg in 1.5 mL	1	\N	5
404	N05AD01	HALOPERIDOL	Injection 5 mg in 1 mL	1	\N	10
405	N06AA10	NORTRIPTYLINE HYDROCHLORIDE	Tablet 10 mg (base)	1	\N	50
406	A04AD	PROCHLORPERAZINE	Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5	1	\N	1
407	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings with alginate 10 cm x 10 cm, 10	1	\N	1
408	C10AA04	FLUVASTATIN	Capsule 40 mg (as sodium)	1	\N	28
409	B01AE07	DABIGATRAN ETEXILATE	Capsule 75 mg (as mesilate)	1	\N	10
410	N02AA01	MORPHINE SULFATE	Tablet 20 mg	1	\N	20
411	C09DA04	IRBESARTAN with HYDROCHLOROTHIAZIDE	Tablet 300 mg-12.5 mg	1	\N	30
412	G03AA05	NORETHISTERONE with ETHINYLOESTRADIOL	Tablets 1 mg-35 micrograms, 21	1	\N	1
413	N03AX12	GABAPENTIN	Tablet 800 mg	1	\N	100
414	L01XE03	ERLOTINIB	Tablet 100 mg (as hydrochloride)	1	\N	30
415	L02BA01	TAMOXIFEN CITRATE	Tablet 20 mg (base)	1	\N	60
416	L01XE06	DASATINIB	Tablet 50 mg	1	\N	60
417	A14AB01	NANDROLONE DECANOATE	Injection 50 mg in 1 mL, disposable syringe	1	\N	1
1531	C07AG02	CARVEDILOL	Tablet 25 mg	1	\N	60
418	A07DA01	DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULFATE	Tablet 2.5 mg-25 micrograms	1	\N	20
419	B03AC	IRON POLYMALTOSE COMPLEX	Injection 100 mg (iron) in 2 mL	1	\N	5
420	N05AH02	CLOZAPINE	Tablet 200 mg	1	\N	100
421	J05AB09	FAMCICLOVIR	Tablet 250 mg	1	\N	56
422	L01BA01	METHOTREXATE	Solution concentrate for I.V. infusion 1000 mg in 10 mL	1	\N	1
423	N05AH02	CLOZAPINE	Oral liquid 50 mg per mL, 100 mL	1	\N	1
424	M04AA01	ALLOPURINOL	Tablet 100 mg	1	\N	200
425	V04B	COPPER SULFATE	Diagnostic compound tablets, 36	1	\N	1
426	L01DB01	DOXORUBICIN HYDROCHLORIDE	Solution for I.V. injection or intravesical administration 100 mg in 50 mL	1	\N	1
427	G04BE01	ALPROSTADIL	Intracavernosal injection 20 micrograms with diluent in single use syringe	1	\N	2
428	C01DA02	GLYCERYL TRINITRATE	Transdermal patch releasing approximately 10 mg per 24 hours	1	\N	30
429	R03DA04	THEOPHYLLINE	Syrup 133.3 mg per 25 mL, 500 mL	1	\N	1
430	L01AX03	TEMOZOLOMIDE	Capsule 20 mg	1	\N	5
431	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 200 micrograms in 0.3 mL pre-filled syringe	1	\N	1
432	L02BA02	TOREMIFENE CITRATE	Tablet 60 mg (base)	1	\N	30
433	N03AB02	PHENYTOIN SODIUM	Capsule 100 mg	1	\N	200
434	C10AA01	SIMVASTATIN	Tablet 80 mg	1	\N	30
435	P01AB01	METRONIDAZOLE	Tablet 400 mg	1	\N	5
436	C05AA01	HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDE	Ointment 5 mg-5 mg per g (0.5%-0.5%), 30 g	1	\N	1
437	C08DB01	DILTIAZEM HYDROCHLORIDE	Capsule 240 mg (controlled delivery)	1	\N	30
438	V07AY	DRESSING-GAUZE (ABSORBENT PAD)	Pads 10 cm x 10 cm, 100	1	\N	1
439	N03AB02	PHENYTOIN	Paediatric oral suspension 30 mg per 5 mL, 500 mL	1	\N	1
440	N05BA08	BROMAZEPAM	Tablet 6 mg	1	\N	30
441	R01AA05	OXYMETAZOLINE HYDROCHLORIDE	Nasal spray 500 micrograms per mL (0.05%), 18 mL	1	\N	1
442	J05AB09	FAMCICLOVIR	Tablet 500 mg	1	\N	30
443	R03BB01	IPRATROPIUM BROMIDE	Nebuliser solution single dose units 250 micrograms (anhydrous) in 1 mL, 30	1	\N	1
444	L03AA10	LENOGRASTIM	Powder for injection 33,600,000 i.u. (263 micrograms)	1	\N	10
445	A10AD04	INSULIN LISPRO-INSULIN LISPRO PROTAMINE SUSPENSION	Injections (human analogue) 100 units (50 units-50 units) per mL, 3 mL, 5	1	\N	1
446	D01AE14	CICLOPIROX OLAMINE	Shampoo 15 mg per g (1.5%), 60 mL	1	\N	1
447	C02CA01	PRAZOSIN HYDROCHLORIDE	Tablet 1 mg (base)	1	\N	100
448	D01BA01	GRISEOFULVIN	Tablet 125 mg	1	\N	100
449	S01BB	PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE	Eye drops 10 mg-1.2 mg per mL (1%-0.12%), 10 mL	1	\N	1
450	J01DE01	CEFEPIME	Powder for injection 2 g (solvent required)	1	\N	1
451	J05AF07	TENOFOVIR	Tablet containing tenofovir disoproxil fumarate 300 mg	1	\N	30
452	J01DC04	CEFACLOR	Tablet 375 mg (sustained release)	1	\N	10
453	C03BA11	INDAPAMIDE HEMIHYDRATE	Tablet 1.5 mg (sustained release)	1	\N	90
454	H02AB06	PREDNISOLONE	Tablet 5 mg	1	\N	60
455	C09AA05	RAMIPRIL	Capsule 1.25 mg	1	\N	30
456	A02AC10	CALCIUM CARBONATE with GLYCINE	Tablet 420 mg-180 mg	1	\N	100
457	J05AD01	FOSCARNET SODIUM	I.V. infusion 24 mg per mL, 250 mL	1	\N	6
458	C09DB01	AMLODIPINE with VALSARTAN	Tablet 5 mg (as besylate)-160 mg	1	\N	28
459	N02BE01	PARACETAMOL	Oral liquid 120 mg per 5 mL, 100 mL	1	\N	1
460	S01XA20	POLYVINYL ALCOHOL	Eye drops 30 mg per mL (3%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	1	\N	1
461	R03BA05	FLUTICASONE PROPIONATE	Oral pressurised inhalation 50 micrograms per dose (120 doses), CFC-free formulation	1	\N	1
462	C03AA03	HYDROCHLOROTHIAZIDE	Tablet 25 mg	1	\N	100
463	A02AD01	ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and SIMETHICONE	Tablet 400 mg-400 mg-40 mg	1	\N	100
464	V07AY	DRESSING-FILM	Dressing 15 cm x 20 cm	1	\N	1
465	N02CA01	DIHYDROERGOTAMINE MESYLATE	Injection 1 mg in 1 mL	1	\N	5
466	G04CA03	TERAZOSIN HYDROCHLORIDE	Tablet 10 mg	1	\N	28
467	J01FF02	LINCOMYCIN	Injection 600 mg in 2 mL	1	\N	5
468	N05AH03	OLANZAPINE	Wafer 5 mg	1	\N	28
469	V07AY	TAPES-PLASTER ADHESIVE HYPOALLERGENIC	Stretch roll 5 cm x 5 m	1	\N	1
470	L01CB01	ETOPOSIDE	Solution for I.V. infusion 100 mg in 5 mL	1	\N	1
471	R03BA01	BECLOMETHASONE DIPROPIONATE	Oral pressurised inhalation in breath actuated device 50 micrograms per dose (200 doses), CFC-free formulation	1	\N	1
472	D10BA01	ISOTRETINOIN	Capsule 10 mg	1	\N	60
473	V03AF01	MESNA	Solution for I.V. injection 400 mg in 4 mL	1	\N	15
474	A09AA02	PANCREATIC EXTRACT	Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity	1	\N	100
475	G03DC02	NORETHISTERONE	Tablet 5 mg	1	\N	30
476	S01AA12	TOBRAMYCIN	Eye drops 3 mg per mL (0.3%), 5 mL	1	\N	1
477	N03AF01	CARBAMAZEPINE	Tablet 200 mg	1	\N	200
478	N02AA01	MORPHINE SULFATE	Tablet 15 mg (controlled release)	1	\N	20
479	N05AN01	LITHIUM CARBONATE	Tablet 250 mg	1	\N	200
480	H01CB02	OCTREOTIDE	Injection 100 micrograms (as acetate) in 1 mL	1	\N	5
481	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Butterfly shape 7 cm	1	\N	1
482	J01FA01	ERYTHROMYCIN ETHYL SUCCINATE	Powder for oral liquid 400 mg (base) per 5 mL, 100 mL	1	\N	1
483	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 4 mg	1	\N	20
484	J05AB09	FAMCICLOVIR	Tablet 250 mg	1	\N	21
485	G03CA03	OESTRADIOL	Transdermal patches 1.17 mg (releasing approximately 75 micrograms per 24 hours), 8	1	\N	1
486	N06AX11	MIRTAZAPINE	Tablet 30 mg (orally disintegrating)	1	\N	30
487	V07AB	SODIUM CHLORIDE	Injection 9 mg per mL (0.9%), 10 mL	1	\N	5
488	N05AH02	CLOZAPINE	Tablet 100 mg	1	\N	100
489	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 50 mg (twice daily sustained release)	1	\N	20
490	B03AA07	FERROUS SULFATE	Oral liquid 30 mg per mL, 250 mL	1	\N	1
491	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 1.6 mg (4.8 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
492	G03BA03	TESTOSTERONE UNDECANOATE	Capsule 40 mg	1	\N	60
493	V07AY	BANDAGE-TUBULAR	Bandage 7.5 cm x 1 m	1	\N	1
494	R03BA02	BUDESONIDE	Powder for oral inhalation in breath actuated device 100 micrograms per dose (200 doses)	1	\N	1
495	C10AA03	PRAVASTATIN	Tablet containing pravastatin sodium 80 mg	1	\N	30
496	R01BA02	PSEUDOEPHEDRINE HYDROCHLORIDE	Tablet 60 mg	1	\N	12
497	N06AA12	DOXEPIN HYDROCHLORIDE	Capsule 25 mg (base)	1	\N	50
498	C02KX03	SITAXENTAN SODIUM	Tablet 100 mg	1	\N	30
499	C09AA05	RAMIPRIL	Tablet 2.5 mg	1	\N	30
500	C08DA01	VERAPAMIL HYDROCHLORIDE	Tablet 240 mg (sustained release)	1	\N	30
501	L01XX17	TOPOTECAN HYDROCHLORIDE	Powder for I.V. infusion 4 mg (base)	1	\N	5
502	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Powder 500 g	1	\N	1
503	C09AA05	RAMIPRIL	Pack containing 7 tablets 2.5 mg, 21 tablets 5 mg and 10 capsules 10 mg	1	\N	1
504	N03AX11	TOPIRAMATE	Tablet 25 mg	1	\N	60
505	A10BD02	METFORMIN HYDROCHLORIDE with GLIBENCLAMIDE	Tablet 500 mg-5 mg	1	\N	90
506	M05BA06	IBANDRONIC ACID	Tablet 50 mg (as ibandronate sodium monohydrate)	1	\N	28
507	D01AC01	CLOTRIMAZOLE	Lotion 10 mg per mL (1%), 20 mL	1	\N	1
508	N03AF02	OXCARBAZEPINE	Tablet 600 mg	1	\N	100
509	H05BA01	SALCATONIN	Injection 100 i.u. in 1 mL	1	\N	5
510	S01XA20	POLYVINYL ALCOHOL	Eye drops 30 mg per mL (3%), 15 mL	1	\N	1
511	B03XA02	DARBEPOETIN ALFA	Injection 30 micrograms in 0.3 mL pre-filled syringe	1	\N	4
512	B01AX06	RIVAROXABAN	Tablets 10 mg, 30	1	\N	1
513	M05BA03	DISODIUM PAMIDRONATE	Concentrated injection 90 mg in 10 mL	1	\N	1
514	L04AA13	LEFLUNOMIDE	Pack containing 3 tablets leflunomide 100 mg and 30 tablets leflunomide 20 mg	1	\N	1
515	L02AE	GOSERELIN ACETATE and BICALUTAMIDE	Pack containing 1 subcutaneous implant goserelin 3.6 mg in pre-filled injection syringe and 28 tablets bicalutamide 50 mg	1	\N	1
516	N06AB10	ESCITALOPRAM OXALATE	Tablet 20 mg (base)	1	\N	28
517	J01AA02	DOXYCYCLINE	Tablet 50 mg (as monohydrate)	1	\N	25
518	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 40 mg (controlled release)	1	\N	20
519	G02C	RICINOLEIC ACID with ACETIC ACID and HYDROXYQUINOLINE SULFATE	Vaginal jelly 7 mg-9.4 mg-250 micrograms per g (0.7%-0.94%-0.025%), 100 g	1	\N	1
520	L04AD02	TACROLIMUS	Capsule 1 mg	1	\N	100
521	G03GA05	FOLLITROPIN ALFA	Injection set containing 1 vial powder for injection 450 i.u. and 1 pre-filled syringe solvent 1 mL	1	\N	1
522	L01XX27	ARSENIC TRIOXIDE	Injection concentrate 10 mg in 10 mL	1	\N	10
523	S01AA26	AZITHROMYCIN	Tablet 500 mg	1	\N	2
524	L03AB07	INTERFERON BETA-1a	Injection set comprising 1 vial powder for injection 30 micrograms (6,000,000 i.u.) with diluent	1	\N	4
525	L03AB10	PEGINTERFERON ALFA-2b	Powder for injection 120 micrograms with diluent in single use injection pen	1	\N	4
526	A10AC01	INSULIN ISOPHANE (N.P.H.)	Injection (human) 100 units per mL, 10 mL	1	\N	1
527	N06AB06	SERTRALINE HYDROCHLORIDE	Tablet 50 mg (base)	1	\N	30
528	A10AD01	INSULIN NEUTRAL-INSULIN ISOPHANE (N.P.H.), (MIXED) (Biphasic Isophane)	Injections (human) 100 units (50 units-50 units) per mL, 3 mL, 5	1	\N	1
529	M05BA02	SODIUM CLODRONATE TETRAHYDRATE	Tablet equivalent to 800 mg sodium clodronate	1	\N	60
530	J01CA04	AMOXYCILLIN	Powder for paediatric oral drops 100 mg per mL, 20 mL	1	\N	1
531	C08CA01	AMLODIPINE	Tablet 10 mg (as maleate)	1	\N	30
532	J01FA01	ERYTHROMYCIN	Capsule 250 mg	1	\N	25
533	A06AH01	METHYLNALTREXONE	Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL	1	\N	1
534	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Sachets 20 g, 30	1	\N	1
535	J05AG03	EFAVIRENZ	Tablet 600 mg	1	\N	30
536	N07BC51	BUPRENORPHINE HYDROCHLORIDE with NALOXONE HYDROCHLORIDE	Sublingual tablet 8 mg (base)-2 mg (base)	1	\N	28
537	A07EC02	MESALAZINE	Sachet containing prolonged release granules, 1 g per sachet	1	\N	100
538	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Sachets 25 g, 30	1	\N	1
539	D11AA	DIPHEMANIL METHYLSULFATE	Dusting powder 20 mg per g (2%), 50 g	1	\N	1
540	H02AB02	DEXAMETHASONE	Tablet 4 mg	1	\N	30
541	C01BD	SOTALOL HYDROCHLORIDE	Tablet 80 mg	1	\N	60
542	R05CB13	DORNASE ALFA	Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL	1	\N	30
543	J05AF11	TELBIVUDINE	Tablet 600 mg	1	\N	28
544	G04BD	PROPANTHELINE BROMIDE	Tablet 15 mg	1	\N	100
545	L03AB10	PEGINTERFERON ALFA-2b	Powder for injection 150 micrograms with diluent in single use injection pen	1	\N	4
546	N07BB04	NALTREXONE HYDROCHLORIDE	Tablet 50 mg	1	\N	30
547	P02CF01	IVERMECTIN	Tablet 3 mg	1	\N	4
548	G03CA03	OESTRADIOL	Transdermal gel 1 mg in 1 g sachet, 28	1	\N	1
549	G03CA03	OESTRADIOL	Transdermal patches 1.5 mg (releasing approximately 50 micrograms per 24 hours), 8	1	\N	1
550	N05AE04	ZIPRASIDONE HYDROCHLORIDE	Capsule 80 mg (base)	1	\N	60
551	J01DD01	CEFOTAXIME	Powder for injection 1 g	1	\N	1
552	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-LIGHT EXUDATE)	Dressings 10 cm x 10 cm, 10	1	\N	1
553	N03AF01	CARBAMAZEPINE	Tablet 100 mg	1	\N	200
554	L01XA01	CISPLATIN	I.V. injection 100 mg in 100 mL	1	\N	1
555	L02AE03	GOSERELIN ACETATE	Subcutaneous implant 3.6 mg (base) in pre-filled injection syringe	1	\N	1
556	R03CA	ADRENALINE	I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector	1	\N	1
557	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Sachets 18.2 g, 60	1	\N	1
558	N06AA16	DOTHIEPIN HYDROCHLORIDE	Capsule 25 mg	1	\N	50
559	N03AX11	TOPIRAMATE	Tablet 200 mg	1	\N	60
560	N03AX16	PREGABALIN	Capsule 300 mg	1	\N	56
561	R03AC03	TERBUTALINE SULFATE	Powder for oral inhalation in breath actuated device 500 micrograms per dose (200 doses)	1	\N	1
562	B05AA06	GELATIN - SUCCINYLATED	I.V. infusion 20 g per 500 mL, 500 mL	1	\N	1
563	N05AX13	PALIPERIDONE	Tablet 6 mg (prolonged release)	1	\N	28
564	P01BE52	ARTEMETHER with LUMEFANTRINE	Tablet 20 mg-120 mg	1	\N	24
565	G02CB03	CABERGOLINE	Tablet 500 micrograms	1	\N	8
566	G03CA03	OESTRADIOL	Tablet 2 mg	1	\N	56
567	N04BC06	CABERGOLINE	Tablet 1 mg	1	\N	30
568	H01CB02	OCTREOTIDE	Injection (modified release) 20 mg (as acetate), vial and diluent syringe	1	\N	1
569	C07AB12	NEBIVOLOL	Tablet 1.25 mg (as hydrochloride)	1	\N	28
570	V07AY	BANDAGE-ABSORBENT WOOL	Bandage 10 cm x 3 m	1	\N	6
571	L04AA06	MYCOPHENOLATE SODIUM	Tablet (enteric coated) 360 mg (mycophenolic acid)	1	\N	120
572	L01BC05	GEMCITABINE HYDROCHLORIDE	Solution concentrate for I.V. infusion 500 mg (base) in 50 mL	1	\N	1
573	J05AB01	ACICLOVIR	Tablet 800 mg	1	\N	120
574	H02AB10	CORTISONE ACETATE	Tablet 5 mg	1	\N	50
575	J01AA02	DOXYCYCLINE	Tablet 100 mg (as monohydrate)	1	\N	21
576	V01AA07	INSECT ALLERGEN EXTRACT-YELLOW JACKET VENOM	Injection set containing 550 micrograms	1	\N	1
577	H02AB09	HYDROCORTISONE SODIUM SUCCINATE	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	1	\N	1
578	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	Oral liquid 130 mL, 30	1	\N	1
579	R03AC02	SALBUTAMOL SULFATE	Capsule containing powder for oral inhalation 200 micrograms (base) (for use in Ventolin Rotahaler)	1	\N	100
580	D11AC30	PINE TAR with CADE OIL, COAL TAR SOLUTION, ARACHIS OIL EXTRACT OF CRUDE COAL TAR	Scalp cleanser 3 mg-3 mg-1 mg-3 mg-10 mg per mL (0.3%-0.3%-0.1%-0.3%-1%), 300 mL	1	\N	1
581	A02BA01	CIMETIDINE	Tablet 400 mg	1	\N	60
582	M01AE01	IBUPROFEN	Tablet 400 mg	1	\N	30
583	A07DA03	LOPERAMIDE HYDROCHLORIDE	Capsule 2 mg	1	\N	12
584	N04BC07	APOMORPHINE HYDROCHLORIDE	Injection 50 mg in 5 mL	1	\N	5
585	S01GA51	ANTAZOLINE with NAPHAZOLINE	Eye drops 5 mg (phosphate)-500 micrograms (hydrochloride) per mL (0.5%-0.05%), 15 mL	1	\N	1
586	D11AX	CATIONIC CONDITIONER with PANTHENOL	Cream 200 g	1	\N	1
587	L01DC01	BLEOMYCIN SULFATE	Powder for injection 15,000 i.u. (solvent required)	1	\N	1
588	J01XD01	METRONIDAZOLE BENZOATE	Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL	1	\N	1
589	N05AH03	OLANZAPINE	Powder for injection 405 mg (as pamoate monohydrate) with diluent	1	\N	1
590	V07AY	BANDAGE-TUBULAR (FINGER)	Complete pack including applicator	1	\N	1
591	R05DA04	CODEINE PHOSPHATE	Tablet 30 mg	1	\N	20
592	L03AB04	INTERFERON ALFA-2a	Injection 3,000,000 i.u. in 0.5 mL single dose pre-filled syringe	1	\N	1
593	L04AD01	CYCLOSPORIN	Capsule 25 mg	1	\N	30
594	V03AF01	MESNA	Solution for I.V. injection 1 g in 10 mL	1	\N	15
595	V06DX	ESSENTIAL AMINO ACIDS FORMULA with VITAMINS and MINERALS	Sachets 12.5 g, 50	1	\N	1
596	C10AA07	ROSUVASTATIN	Tablet 10 mg (as calcium)	1	\N	30
597	L01XE03	ERLOTINIB	Tablet 150 mg (as hydrochloride)	1	\N	30
598	G03AA05	NORETHISTERONE with MESTRANOL	Tablets 1 mg-50 micrograms, 21	1	\N	1
599	M01AC01	PIROXICAM	Capsule 20 mg	1	\N	25
600	J05AB11	VALACICLOVIR HYDROCHLORIDE	Tablet 500 mg (base)	1	\N	30
601	G03AA07	LEVONORGESTREL with ETHINYLOESTRADIOL	Pack containing 21 tablets 125 micrograms-50 micrograms and 7 inert tablets	1	\N	4
602	S01AA01	CHLORAMPHENICOL	Eye drops 5 mg per mL (0.5%), 10 mL	1	\N	1
603	A02BA01	CIMETIDINE	Tablet 200 mg	1	\N	120
604	J05AF10	ENTECAVIR MONOHYDRATE	Tablet 0.5 mg	1	\N	30
605	N06AX21	DULOXETINE HYDROCHLORIDE	Capsule 30 mg (base)	1	\N	28
606	V07AY	BANDAGE-ZINC PASTE	Bandage 7.5 cm x 6 m	1	\N	1
607	J01FA09	CLARITHROMYCIN	Tablet 250 mg	1	\N	14
608	N02AA01	MORPHINE SULFATE	Sachet containing controlled release granules for oral suspension, 20 mg per sachet	1	\N	20
609	R03DA04	THEOPHYLLINE	Tablet 200 mg (sustained release)	1	\N	100
610	C09DA07	TELMISARTAN with HYDROCHLOROTHIAZIDE	Tablet 40 mg-12.5 mg	1	\N	28
611	V07AY	DRESSING-FILM	Dressings 6 cm x 7 cm, 8	1	\N	1
612	N06AB05	PAROXETINE	Tablet 20 mg (as mesilate)	1	\N	30
613	R03BA05	FLUTICASONE PROPIONATE	Powder for oral inhalation in breath actuated device 100 micrograms per dose (60 doses)	1	\N	1
614	C02AC05	MOXONIDINE	Tablet 200 micrograms	1	\N	30
615	L03AB10	PEGINTERFERON ALFA-2b	Powder for injection 100 micrograms with diluent in single use injection pen	1	\N	4
616	L03AA13	PEGFILGRASTIM	Injection 6 mg in 0.6 mL single use pre-filled syringe	1	\N	1
617	H02AB07	PREDNISONE	Tablet 1 mg	1	\N	100
618	N02AC	METHADONE HYDROCHLORIDE	Injection 10 mg in 1 mL	1	\N	5
619	A02BA03	FAMOTIDINE	Tablet 20 mg	1	\N	60
620	A07EA01	PREDNISOLONE SODIUM PHOSPHATE	Suppositories equivalent to 5 mg prednisolone, 10	1	\N	1
621	R03BA02	BUDESONIDE	Powder for oral inhalation in breath actuated device 200 micrograms per dose (200 doses)	1	\N	1
622	N07BA01	NICOTINE	Transdermal patches releasing approximately 14 mg per 24 hours, 7	1	\N	1
623	J05AE03	RITONAVIR	Capsule 100 mg	1	\N	84
624	N06AB10	ESCITALOPRAM OXALATE	Tablet 10 mg (base)	1	\N	28
625	N02AA01	MORPHINE SULFATE	Sachet containing controlled release granules for oral suspension, 30 mg per sachet	1	\N	20
626	N02AA01	MORPHINE SULFATE	Capsule 30 mg (controlled release)	1	\N	10
627	A10BG03	PIOGLITAZONE HYDROCHLORIDE	Tablet 45 mg (base)	1	\N	28
628	A02BA04	NIZATIDINE	Capsule 300 mg	1	\N	30
629	N02AC	METHADONE HYDROCHLORIDE	Oral liquid 25 mg per 5 mL, 200 mL	1	\N	1
630	L04AB01	ETANERCEPT	Injections 50 mg in 1 mL single use pre-filled syringes, 4	1	\N	1
631	M05BA03	DISODIUM PAMIDRONATE	Injection set containing 1 vial powder for I.V. infusion 90 mg and 1 ampoule solvent 10 mL	1	\N	1
632	S01EE	BIMATOPROST with TIMOLOL MALEATE	Eye drops 300 micrograms-5 mg (base) per mL (0.03%-0.5%), 3 mL	1	\N	1
633	N03AX11	TOPIRAMATE	Tablet 100 mg	1	\N	60
634	V07AY	DRESSING-FILM ISLAND	Dressings 8 cm x 10 cm, 5	1	\N	1
635	A01AB04	AMPHOTERICIN	Lozenge 10 mg	1	\N	20
636	A07EC02	MESALAZINE	Sachet containing granules, 500 mg per sachet	1	\N	100
637	V06DB	PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES	Compound powder 400 g	1	\N	1
638	C01CA24	ADRENALINE	Injection 1 mg in 1 mL (1 in 1,000)	1	\N	5
639	J01FA10	AZITHROMYCIN	Tablet 500 mg	1	\N	3
640	A09AA02	PANCRELIPASE	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity	1	\N	100
641	L04AA24	ABATACEPT	Powder for I.V. infusion 250 mg	1	\N	1
642	V07AY	BANDAGE-TUBULAR	Bandage, straight, size C	1	\N	1
643	G04CB01	FINASTERIDE	Tablet 5 mg	1	\N	30
644	R06AD02	PROMETHAZINE HYDROCHLORIDE	Tablet 10 mg	1	\N	50
645	N05AH02	CLOZAPINE	Tablet 25 mg	1	\N	100
646	L04AA06	MYCOPHENOLATE MOFETIL	Powder for oral suspension 1 g per 5 mL, 165 mL	1	\N	1
647	G03GB02	CLOMIPHENE CITRATE	Tablet 50 mg	1	\N	10
648	V03AE01	SODIUM POLYSTYRENE SULFONATE	Oral powder 454 g	1	\N	1
649	M03AX01	CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX	Lyophilised powder for I.M. injection 500 units	1	\N	1
650	A10BB12	GLIMEPIRIDE	Tablet 1 mg	1	\N	30
651	A07EC02	MESALAZINE	Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g	1	\N	1
652	N03AX12	GABAPENTIN	Capsule 300 mg	1	\N	100
653	C09DA07	TELMISARTAN with HYDROCHLOROTHIAZIDE	Tablet 80 mg-25 mg	1	\N	28
654	N02AA01	MORPHINE SULFATE	Tablet 100 mg (controlled release)	1	\N	20
655	M01AB55	DICLOFENAC SODIUM with MISOPROSTOL	Tablet 50 mg-200 micrograms	1	\N	60
656	N06DA03	RIVASTIGMINE	Transdermal patch 18 mg (releasing approximately 9.5 mg per 24 hours)	1	\N	30
657	A10BB09	GLICLAZIDE	Tablet 80 mg	1	\N	100
658	R03AK06	FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	Oral pressurised inhalation 250 micrograms-25 micrograms (base) per dose (120 doses), CFC-free formulation	1	\N	1
659	M01AB05	DICLOFENAC SODIUM	Tablet 25 mg (enteric coated)	1	\N	50
660	G04BX	PHENOXYBENZAMINE HYDROCHLORIDE	Capsules 10 mg, 100	1	\N	1
661	N04BA03	LEVODOPA with CARBIDOPA and ENTACAPONE	Tablet 100 mg-25 mg-200 mg	1	\N	100
662	N04AA02	BIPERIDEN HYDROCHLORIDE	Tablet 2 mg	1	\N	100
663	S01EB01	PILOCARPINE HYDROCHLORIDE	Eye drops 40 mg per mL (4%), 15 mL	1	\N	1
664	S01EC03	DORZOLAMIDE HYDROCHLORIDE	Eye drops 20 mg (base) per mL (2%), 5 mL	1	\N	1
665	N03AX14	LEVETIRACETAM	Oral solution 100 mg per mL, 300 mL	1	\N	1
666	A11CC04	CALCITRIOL	Capsule 0.25 microgram	1	\N	100
667	M01CC01	PENICILLAMINE	Tablet 250 mg	1	\N	100
668	L04AD01	CYCLOSPORIN	Capsule 50 mg	1	\N	30
669	J05AF02	DIDANOSINE	Capsule 400 mg (containing enteric coated beadlets)	1	\N	30
670	R06AE07	CETIRIZINE HYDROCHLORIDE	Tablet 10 mg	1	\N	30
671	J01CE09	PROCAINE PENICILLIN	Injection 1.5 g	1	\N	5
672	V07AY	DRESSING-HYDROACTIVE (DEBRIDEMENT)	Dressings 4 cm, 8	1	\N	1
673	J01FA01	ERYTHROMYCIN ETHYL SUCCINATE	Tablet 400 mg (base)	1	\N	25
674	N07BC51	BUPRENORPHINE HYDROCHLORIDE with NALOXONE HYDROCHLORIDE	Sublingual tablet 2 mg (base)-0.5 mg (base)	1	\N	28
675	L02BA01	TAMOXIFEN CITRATE	Tablet 10 mg (base)	1	\N	60
676	J05AF08	ADEFOVIR DIPIVOXIL	Tablet 10 mg	1	\N	30
677	M05BB03	ALENDRONATE SODIUM with COLECALCIFEROL	Tablet equivalent to 70 mg alendronic acid with 70 micrograms colecalciferol	1	\N	4
678	J01CA04	AMOXYCILLIN	Tablet 1 g	1	\N	14
679	D07AC01	BETAMETHASONE VALERATE	Ointment 500 micrograms (base) per g (0.05%), 15 g	1	\N	1
680	V07AY	DRESSING with CADEXOMER IODINE	Sachets 5 g (6 cm x 4 cm), 5	1	\N	1
681	L03AA02	FILGRASTIM	Injection 300 micrograms in 1 mL	1	\N	10
682	N06DA03	RIVASTIGMINE HYDROGEN TARTRATE	Oral solution 2 mg (base) per mL, 120 mL	1	\N	1
683	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 100 mg (base)	1	\N	28
684	V07AY	BANDAGE-TUBULAR (SHORT STOCKING)	Bandage, medium C/D size	1	\N	1
685	S01XA20	CARMELLOSE SODIUM	Eye drops 10 mg per mL (1%), single dose units 0.4 mL, 30	1	\N	1
686	H02AB09	HYDROCORTISONE SODIUM SUCCINATE	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	1	\N	1
687	S01XA20	HYPROMELLOSE	Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative)	1	\N	1
688	J01XA01	VANCOMYCIN	Powder for injection 500 mg (500,000 i.u.) vancomycin activity	1	\N	1
689	J01CA01	AMPICILLIN	Powder for injection 1 g	1	\N	5
690	M03AX01	BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX	Lyophilised powder for I.M. injection 100 units	1	\N	1
691	S01XA20	POLYVINYL ALCOHOL	Eye drops 14 mg per mL (1.4%), 15 mL	1	\N	1
692	G03BA03	TESTOSTERONE UNDECANOATE	I.M. injection 1,000 mg in 4 mL	1	\N	1
693	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Capsule 40 mg (modified release)	1	\N	30
694	B01AC06	ASPIRIN	Tablet 100 mg (enteric coated)	1	\N	84
695	C08CA05	NIFEDIPINE	Tablet 30 mg (controlled release)	1	\N	30
696	V07AY	DRESSING-HYDROGEL-SHEET	Dressings 9.5 cm x 10.2 cm, 5	1	\N	1
697	L03AB07	INTERFERON BETA-1a	Solution for injection 132 micrograms in 1.5 mL multidose cartridge	1	\N	4
698	N05AX12	ARIPIPRAZOLE	Tablet 30 mg	1	\N	30
699	N02AA01	MORPHINE SULFATE	Tablet 10 mg (controlled release)	1	\N	20
700	L03AB61	RIBAVIRIN and PEGINTERFERON ALFA-2a	Pack containing 140 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	1	\N	1
701	A12AA	CALCIUM	Tablet 250 mg (as citrate)	1	\N	120
702	M01AH01	CELECOXIB	Capsule 100 mg	1	\N	60
703	V07AY	DRESSING-TULLE NON-GAUZE-PARAFFIN	Dressing 7.6 cm x 7.6 cm	1	\N	1
704	A03BA01	ATROPINE SULFATE	Injection 600 micrograms in 1 mL	1	\N	10
705	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Capsule 30 mg (modified release)	1	\N	30
706	M04AB01	PROBENECID	Tablet 500 mg	1	\N	100
707	D07AC14	METHYLPREDNISOLONE ACEPONATE	Fatty ointment 1 mg per g (0.1%), 15 g	1	\N	1
708	R06AD02	PROMETHAZINE HYDROCHLORIDE	Tablet 25 mg	1	\N	50
709	N05AE04	ZIPRASIDONE HYDROCHLORIDE	Capsule 60 mg (base)	1	\N	60
710	J01CA01	AMPICILLIN	Powder for injection 500 mg	1	\N	5
711	J01CE02	PHENOXYMETHYLPENICILLIN	Capsule 250 mg	1	\N	50
712	L02AE02	LEUPRORELIN ACETATE	Suspension for subcutaneous injection (modified release), 30 mg injection set	1	\N	1
713	J05AF06	ABACAVIR SULFATE	Oral solution 20 mg (base) per mL, 240 mL	1	\N	1
714	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Tablet 36 mg (extended release)	1	\N	30
715	L01CA01	VINBLASTINE SULFATE	Solution for I.V. injection 10 mg in 10 mL	1	\N	5
716	L01AX03	TEMOZOLOMIDE	Capsule 250 mg	1	\N	5
717	L03AA02	FILGRASTIM	Injection 480 micrograms in 0.5 mL single use pre-filled syringe	1	\N	10
718	L01CD02	DOCETAXEL	Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL	1	\N	1
719	A10BB12	GLIMEPIRIDE	Tablet 4 mg	1	\N	30
720	A07EC01	SULFASALAZINE	Tablet 500 mg (enteric coated)	1	\N	100
721	A06AB56	DOCUSATE SODIUM with SENNA	Tablet 50 mg-8 mg	1	\N	90
722	J01CF01	DICLOXACILLIN	Capsule 500 mg	1	\N	24
723	S02DC	DICHLOROBENZENE with CHLORBUTOL and TURPENTINE OIL	Ear drops 20 mg-50 mg-0.1 mL per mL (2%-5%-10%), 11 mL	1	\N	1
724	A06AC01	PSYLLIUM HYDROPHILIC MUCILLOID	Oral powder (orange-flavoured, sugar-free) 283 g	1	\N	1
725	C09CA02	EPROSARTAN MESYLATE	Tablet 400 mg (base)	1	\N	28
726	B01AC22	PRASUGREL	Tablet 5 mg (as hydrochloride)	1	\N	28
727	N04BC07	APOMORPHINE HYDROCHLORIDE	Injection 20 mg in 2 mL	1	\N	5
728	C03BA04	CHLORTHALIDONE	Tablet 25 mg	1	\N	50
729	N06AX18	REBOXETINE MESILATE	Tablet 4 mg (base)	1	\N	60
730	N04BA02	LEVODOPA with BENSERAZIDE	Dispersible tablet 50 mg-12.5 mg	1	\N	100
731	C09CA08	OLMESARTAN MEDOXOMIL	Tablet 40 mg	1	\N	30
732	C09DB01	AMLODIPINE with VALSARTAN	Tablet 10 mg (as besylate)-160 mg	1	\N	28
733	B03BB01	FOLIC ACID	Tablet 500 micrograms	1	\N	100
734	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 72 i.u. (24 mg) cartridge with 3.15 mL diluent (with preservative)	1	\N	1
735	R03BA02	BUDESONIDE	Nebuliser suspension single dose units 500 micrograms in 2 mL, 30	1	\N	1
736	A02BX02	SUCRALFATE	Tablet equivalent to 1 g anhydrous sucralfate	1	\N	120
737	C08DA01	VERAPAMIL HYDROCHLORIDE	Tablet 180 mg (sustained release)	1	\N	30
738	V07AY	BANDAGE-RETENTION-COTTON CREPE	Bandage 5 cm x 2.3 m	1	\N	1
739	B01AD11	TENECTEPLASE	Powder for injection 50 mg with solvent	1	\N	1
740	L01DB06	IDARUBICIN HYDROCHLORIDE	Capsule 10 mg	1	\N	1
741	N04AA01	BENZHEXOL HYDROCHLORIDE	Tablet 2 mg	1	\N	200
742	S01BC04	FLURBIPROFEN SODIUM	Eye drops 300 micrograms per mL (0.03%), single dose units 0.4 mL, 5	1	\N	1
743	L04AA13	LEFLUNOMIDE	Tablet 10 mg	1	\N	30
744	V06DX	MINERAL MIXTURE	Powder 250 g	1	\N	1
745	N05AX08	RISPERIDONE	Tablet 0.5 mg (orally disintegrating)	1	\N	28
746	B03XA01	EPOETIN ALFA	Injection 5,000 units in 0.5 mL pre-filled syringe	1	\N	6
747	N05AX08	RISPERIDONE	Tablet 2 mg	1	\N	60
748	G03GA05	FOLLITROPIN ALFA	Injection 300 i.u. in 0.5 mL multi-dose cartridge	1	\N	1
749	P01BB51	ATOVAQUONE with PROGUANIL HYDROCHLORIDE	Tablet 250 mg-100 mg	1	\N	12
750	V07AY	BANDAGE-CALICO	Bandage, triangular, large	1	\N	1
751	J02AB02	KETOCONAZOLE	Tablet 200 mg	1	\N	10
752	L01DC01	BLEOMYCIN SULFATE	Powder for injection 15,000 i.u.	1	\N	10
753	J02AC01	FLUCONAZOLE	Capsule 50 mg	1	\N	28
754	N02BE01	PARACETAMOL	Tablet 665 mg (modified release)	1	\N	96
755	J05AE07	FOSAMPRENAVIR CALCIUM	Oral liquid 50 mg (base) per mL, 225 mL	1	\N	1
756	C01BB01	LIGNOCAINE HYDROCHLORIDE	Infusion 500 mg in 5 mL	1	\N	10
757	C07AB02	METOPROLOL SUCCINATE	Tablet 95 mg (controlled release)	1	\N	30
758	N03AF01	CARBAMAZEPINE	Oral suspension 100 mg per 5 mL, 300 mL	1	\N	1
759	V07AY	DRESSING-ALGINATE (CAVITY WOUND)	Ropes 2 g (30 cm), 5	1	\N	1
760	R03BA08	CICLESONIDE	Oral pressurised inhalation 160 micrograms per dose (120 doses), CFC-free formulation	1	\N	1
761	B01AB01	HEPARIN SODIUM	Injection 5,000 units in 0.2 mL	1	\N	5
762	V07AY	BANDAGE-TUBULAR	Bandage 10 cm x 1 m	1	\N	1
763	N03AB02	PHENYTOIN	Tablet 50 mg	1	\N	200
764	N07XX06	TETRABENAZINE	Tablet 25 mg	1	\N	112
765	V07AY	TAPES-PLASTER ADHESIVE HYPOALLERGENIC	Roll (dispenser) 1.9 cm x 7.3 m	1	\N	1
766	V06DX	TRIGLYCERIDES, LONG CHAIN with GLUCOSE POLYMER	Oral liquid 1 L, 6	1	\N	1
767	V07AY	DRESSING-ALGINATE (SUPERFICIAL WOUND)	Dressing 10 cm x 10 cm	1	\N	1
768	H05BA01	SALCATONIN	Injection 50 i.u. in 1 mL	1	\N	5
769	V07AY	DRESSING-GAUZE-EYE PAD	Pads, 12	1	\N	1
770	J01DB01	CEPHALEXIN	Granules for syrup 125 mg per 5 mL, 100 mL	1	\N	1
771	D04AX	PINE TAR with TRIETHANOLAMINE LAURYL SULFATE	Solution 23 mg-60 mg per mL (2.3%-6%), 500 mL	1	\N	1
772	N05AX13	PALIPERIDONE	Tablet 3 mg (prolonged release)	1	\N	28
773	A02BX	SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE	Oral liquid 1 g-320 mg-534 mg in 20 mL, 500 mL	1	\N	1
774	C09CA04	IRBESARTAN	Tablet 300 mg	1	\N	30
775	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPH	Powder 500 g	1	\N	1
776	N02AA01	MORPHINE SULFATE	Injection 15 mg in 1 mL	1	\N	5
777	C10AA05	ATORVASTATIN	Tablet 10 mg (as calcium)	1	\N	30
778	J05AR04	ABACAVIR SULFATE with LAMIVUDINE and ZIDOVUDINE	Tablet 300 mg (base)-150 mg-300 mg	1	\N	60
779	V07AY	TAPES-PLASTER ADHESIVE (WITH SILICONE)	Roll 2 cm x 3 m	1	\N	1
780	M01AH01	CELECOXIB	Capsule 200 mg	1	\N	30
781	G03GA05	FOLLITROPIN ALFA	Injection set containing 1 vial powder for injection 1,050 i.u. and 1 pre-filled syringe solvent 2 mL	1	\N	1
782	N03AF01	CARBAMAZEPINE	Tablet 200 mg (controlled release)	1	\N	200
783	V07AY	GAUZE and COTTON TISSUE (COMBINE ROLL)	Wrapped pack 10 cm x 10 m	1	\N	1
784	G03CA03	OESTRADIOL	Transdermal patches 750 micrograms (releasing approximately 25 micrograms per 24 hours), 8	1	\N	1
785	J04BA02	DAPSONE	Tablet 25 mg	1	\N	100
786	J01CF05	FLUCLOXACILLIN	Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL	1	\N	1
787	N05BA04	OXAZEPAM	Tablet 30 mg	1	\N	25
788	V07AY	DRESSING-FOAM-HEAVY EXUDATE	Dressings 10 cm x 10 cm, 10	1	\N	1
789	L01CA04	VINORELBINE TARTRATE	Capsule 30 mg (base)	1	\N	1
790	V06DX	ARGININE with CARBOHYDRATE	Sachets 4 g containing 500 mg arginine, 30	1	\N	1
791	G03CA03	OESTRADIOL VALERATE	Tablet 2 mg	1	\N	56
792	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 10 cm x 10 cm, 5	1	\N	1
793	N02AB03	FENTANYL	Transdermal patch 12.6 mg (releasing approximately 75 micrograms per hour)	1	\N	5
794	V06DX	WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, LONG CHAIN POLYUNSATURATED F	Sachets 100 g, 10	1	\N	1
795	L02AE02	LEUPRORELIN ACETATE	Suspension for subcutaneous injection (modified release), 22.5 mg injection set	1	\N	1
796	C09AA04	PERINDOPRIL	Tablet containing 4 mg perindopril erbumine	1	\N	30
797	V03AF03	CALCIUM FOLINATE	Injection equivalent to 50 mg folinic acid in 5 mL	1	\N	10
798	L01CD01	NAB PACLITAXEL	Powder for I.V. injection 100 mg (base)	1	\N	1
799	S02AA15	CIPROFLOXACIN	Ear drops 3 mg per mL (0.3%), 5 mL	1	\N	1
800	J05AF05	LAMIVUDINE	Oral solution 10 mg per mL, 240 mL	1	\N	1
801	B01AD07	RETEPLASE (Recombinant plasminogen activator)	Pack containing 2 vials powder for injection 10 units, 2 single use pre-filled syringes with solvent, 2 reconstitution spikes and 2 needles	1	\N	1
802	L02AB02	MEDROXYPROGESTERONE ACETATE	Tablet 500 mg	1	\N	30
803	N06AX03	MIANSERIN HYDROCHLORIDE	Tablet 10 mg	1	\N	50
804	C02CA01	PRAZOSIN HYDROCHLORIDE	Tablet 2 mg (base)	1	\N	100
805	A02BA04	NIZATIDINE	Capsule 150 mg	1	\N	60
806	N04BA03	LEVODOPA with CARBIDOPA and ENTACAPONE	Tablet 50 mg-12.5 mg-200 mg	1	\N	100
807	N05AE04	ZIPRASIDONE HYDROCHLORIDE	Capsule 20 mg (base)	1	\N	60
808	V03AF03	CALCIUM FOLINATE	Injection equivalent to 100 mg folinic acid in 10 mL	1	\N	10
809	G03FB05	OESTRADIOL and OESTRADIOL with NORETHISTERONE ACETATE	Pack containing 4 transdermal patches oestradiol 780 micrograms (releasing approximately 50 micrograms per 24 hours) and 4 transdermal	1	\N	1
810	L03AB07	INTERFERON BETA-1a	Injection 44 micrograms (12,000,000 i.u.) in 0.5 mL single dose pre-filled syringe	1	\N	12
811	N03AG01	SODIUM VALPROATE	Tablet 500 mg (enteric coated)	1	\N	100
812	A04AA01	ONDANSETRON	Tablet 4 mg	1	\N	10
813	L01XA03	OXALIPLATIN	Solution concentrate for I.V. infusion 50 mg in 10 mL	1	\N	1
814	S01EA	BRIMONIDINE TARTRATE with TIMOLOL MALEATE	Eye drops 2 mg-5 mg (base) per mL (0.2%-0.5%), 5 mL	1	\N	1
815	M05BA03	DISODIUM PAMIDRONATE	Injection set containing 2 vials powder for I.V. infusion 30 mg and 2 ampoules solvent 10 mL	1	\N	1
816	G04BE03	SILDENAFIL CITRATE	Tablet 50 mg (base)	1	\N	4
817	N05AX12	ARIPIPRAZOLE	Tablet 20 mg	1	\N	30
818	B01AE07	DABIGATRAN ETEXILATE	Capsules 75 mg (as mesilate), 60	1	\N	1
819	C09BB10	TRANDOLAPRIL with VERAPAMIL HYDROCHLORIDE	Tablet 2 mg-180 mg (sustained release)	1	\N	28
820	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Sachets 29 g, 30	1	\N	1
821	J05AF02	DIDANOSINE	Capsule 125 mg (containing enteric coated beadlets)	1	\N	30
822	D06AX09	MUPIROCIN	Ointment 20 mg per g (2%), 15 g	1	\N	1
823	L01XE06	DASATINIB	Tablet 20 mg	1	\N	60
824	L03AB03	INTERFERON GAMMA-1b	Injection 2,000,000 i.u. in 0.5 mL	1	\N	6
825	J01XD01	METRONIDAZOLE	Suppositories 500 mg, 10	1	\N	1
826	N03AX03	SULTHIAME	Tablet 50 mg	1	\N	200
827	R05DA08	PHOLCODINE	Linctus 1 mg per mL (0.1%), 100 mL	1	\N	1
828	B01AX05	FONDAPARINUX SODIUM	Injection 2.5 mg in 0.5 mL single dose pre-filled syringe	1	\N	7
829	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 25 mg (base)	1	\N	28
830	J01DD04	CEFTRIAXONE	Powder for injection 1 g	1	\N	5
831	J01EA01	TRIMETHOPRIM	Tablet 300 mg	1	\N	7
832	S01GX02	LEVOCABASTINE HYDROCHLORIDE	Eye drops 500 micrograms per mL (0.05%), 4 mL (120 doses)	1	\N	1
833	J01DD01	CEFOTAXIME	Powder for injection 2 g	1	\N	10
835	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 80 mg (base)	1	\N	28
836	D01AC01	CLOTRIMAZOLE	Cream 10 mg per g (1%), 20 g	1	\N	1
837	J02AC01	FLUCONAZOLE	Solution for I.V. infusion 100 mg in 50 mL	1	\N	1
838	J04AB04	RIFABUTIN	Capsule 150 mg	1	\N	30
839	M05BX	CALCITRIOL	Capsule 0.25 microgram	1	\N	100
840	C09AA09	FOSINOPRIL SODIUM	Tablet 20 mg	1	\N	30
841	B03XA01	EPOETIN BETA	Injection 5,000 units in 0.3 mL pre-filled syringe	1	\N	6
842	D01AC02	MICONAZOLE NITRATE	Powder 20 mg per g (2%), 30 g	1	\N	1
843	B01AB04	DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium-porcine mucous)	Injection 2,500 units (anti-Xa) in 0.2 mL single dose pre-filled syringe	1	\N	10
844	N05AL05	AMISULPRIDE	Tablet 200 mg	1	\N	60
845	J01EE01	TRIMETHOPRIM with SULFAMETHOXAZOLE	Tablet 80 mg-400 mg	1	\N	10
846	D07CB01	TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE, GRAMICIDIN and NYSTATIN	Ointment 1 mg-2.5 mg (base)-250 micrograms- 100,000 units per g (0.1%-0.25% (base)-0.025%- 100,000 units in 1 g), 15 g	1	\N	1
847	N06DA02	DONEPEZIL HYDROCHLORIDE	Tablet 5 mg	1	\N	28
848	J04AC01	ISONIAZID	Tablet 100 mg	1	\N	100
849	V07AY	BANDAGE-RETENTION-COHESIVE-HEAVY	Bandage 15 cm x 1.3 m	1	\N	1
850	A09AA02	PANCREATIC EXTRACT	Capsule (containing enteric coated minimicrospheres) providing not less than 5,000 BP units of lipase activity	1	\N	100
851	G03XA02	GESTRINONE	Capsule 2.5 mg	1	\N	8
852	S02CA06	DEXAMETHASONE with FRAMYCETIN SULFATE and GRAMICIDIN	Ear drops 500 micrograms-5 mg-50 micrograms per mL, 8 mL	1	\N	1
853	J05AE07	FOSAMPRENAVIR CALCIUM	Tablet 700 mg (base)	1	\N	60
854	S01XA20	HYPROMELLOSE with CARBOMER 980	Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g	1	\N	1
855	N07BA01	NICOTINE	Transdermal patches releasing approximately 10 mg per 16 hours, 7	1	\N	1
856	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 36 i.u. (12 mg) cartridge with 3.15 mL diluent (with preservative)	1	\N	1
857	V07AY	PRESSURE REDUCING PRODUCTS	Sheet 10 cm x 10 cm x 3 mm	1	\N	1
858	B01AC16	EPTIFIBATIDE ACETATE	Solution for I.V. injection 20 mg (base) in 10 mL	1	\N	1
859	A06AX01	GLYCEROL	Suppositories 1.4 g (for children), 12	1	\N	1
860	G03BA03	TESTOSTERONE	Transdermal patches 12.2 mg (releasing approximately 2.5 mg per 24 hours), 60	1	\N	1
861	L01XA03	OXALIPLATIN	Solution concentrate for I.V. infusion 100 mg in 20 mL	1	\N	1
862	V07AY	DRESSING-NON-ADHERENT	Dressings 10 cm x 10 cm, 10	1	\N	1
863	B05BB01	SODIUM LACTATE COMPOUND	I.V. infusion 1 L	1	\N	1
864	V07AY	DRESSING-HYDROCOLLOID (CAVITY WOUND)	Paste 30 g	1	\N	1
865	N02AB03	FENTANYL	Lozenges 400 micrograms (as citrate), 3	1	\N	1
866	L02AE	GOSERELIN ACETATE and BICALUTAMIDE	Pack containing 1 subcutaneous implant goserelin 10.8 mg in pre-filled injection syringe and 84 tablets bicalutamide 50 mg	1	\N	1
867	C03CA01	FRUSEMIDE	Tablet 500 mg	1	\N	50
868	C10AA01	SIMVASTATIN	Tablet 20 mg	1	\N	30
869	V07AY	DRESSING-HYDROCOLLOID (CAVITY WOUND)	Paste 50 g	1	\N	1
870	N02BE01	PARACETAMOL	Tablet 500 mg	1	\N	100
871	M03BX01	BACLOFEN	Intrathecal injection 10 mg in 5 mL	1	\N	1
872	G03BA03	TESTOSTERONE	Transdermal patches 24.3 mg (releasing approximately 5 mg per 24 hours), 30	1	\N	1
873	J05AX08	RALTEGRAVIR POTASSIUM	Tablet 400 mg (base)	1	\N	60
874	J04BA	RIFAMPICIN	Syrup 100 mg per 5 mL, 60 mL	1	\N	1
875	N05BE01	BUSPIRONE HYDROCHLORIDE	Tablet 10 mg	1	\N	50
876	D01AC02	MICONAZOLE NITRATE	Cream 20 mg per g (2%), 15 g	1	\N	1
877	N06AA02	IMIPRAMINE HYDROCHLORIDE	Tablet 10 mg	1	\N	50
878	P02CC01	PYRANTEL EMBONATE	Tablet 125 mg (base)	1	\N	6
879	M05BX	RALOXIFENE HYDROCHLORIDE	Tablet 60 mg	1	\N	28
880	V06DF	MILK POWDER-SYNTHETIC	Low calcium compound powder 400 g	1	\N	1
881	N06DA04	GALANTAMINE HYDROBROMIDE	Capsule 8 mg (base) (prolonged release)	1	\N	28
882	N06AA09	AMITRIPTYLINE HYDROCHLORIDE	Tablet 50 mg	1	\N	50
883	N02BG	GABAPENTIN	Capsule 100 mg	1	\N	100
884	N03AX14	LEVETIRACETAM	Tablet 1 g	1	\N	60
885	V06DB	PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES	Compound powder 450 g	1	\N	1
886	J05AF09	EMTRICITABINE	Capsule 200 mg	1	\N	30
887	N02AA01	MORPHINE SULFATE	Capsule 120 mg (controlled release)	1	\N	10
888	V06DC	AMYLOPECTIN, MODIFIED LONG CHAIN	Sachets 60 g, 30	1	\N	1
889	A10BA02	METFORMIN HYDROCHLORIDE	Tablet 500 mg	1	\N	100
890	A11DA01	THIAMINE HYDROCHLORIDE	Tablet 100 mg	1	\N	100
891	C09AA05	RAMIPRIL	Capsule 2.5 mg	1	\N	30
892	B01AC17	TIROFIBAN HYDROCHLORIDE	Solution concentrate for I.V. infusion 12.5 mg (base) in 50 mL	1	\N	1
893	L01DB03	EPIRUBICIN HYDROCHLORIDE	Solution for injection 200 mg in 100 mL	1	\N	1
894	S01XA20	CARMELLOSE SODIUM	Ocular lubricating gel 10 mg per mL (1%), single dose units 0.6 mL, 28	1	\N	1
895	A10BB12	GLIMEPIRIDE	Tablet 3 mg	1	\N	30
896	L01DB06	IDARUBICIN HYDROCHLORIDE	Capsule 5 mg	1	\N	1
897	C09AA01	CAPTOPRIL	Oral solution 5 mg per mL, 95 mL	1	\N	1
898	N04BA02	LEVODOPA with CARBIDOPA	Tablet 100 mg-25 mg	1	\N	100
899	L04AD01	CYCLOSPORIN	Capsule 10 mg	1	\N	60
900	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 5 cm x 6 cm, 10	1	\N	1
901	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 0.6 mg (1.8 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
902	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 100 mg (twice daily sustained release)	1	\N	20
903	V07AY	BANDAGE-COMPRESSION	Bandage, high stretch, 10 cm x 3 m	1	\N	1
1605	N02AC04	DEXTROPROPOXYPHENE NAPSYLATE	Capsule 100 mg	1	\N	10
904	V06DF	MILK POWDER-LACTOSE FREE FORMULA	Infant formula powder 900 g	1	\N	1
905	N06DA03	RIVASTIGMINE HYDROGEN TARTRATE	Capsule 3 mg (base)	1	\N	56
906	C10AB05	FENOFIBRATE	Tablet 48 mg	1	\N	60
907	A02BC01	OMEPRAZOLE	Tablet 20 mg (as magnesium)	1	\N	30
908	D11AC30	SALICYLIC ACID with COAL TAR SOLUTION	Scalp cleanser 20 mg-50 mg per mL (2%-5%), 200 mL	1	\N	1
909	N06AA02	IMIPRAMINE HYDROCHLORIDE	Tablet 25 mg	1	\N	50
910	V07AY	GLOVES PLASTIC (DISPOSABLE)	Gloves, small, 100	1	\N	1
911	C09AA06	QUINAPRIL	Tablet 20 mg (as hydrochloride)	1	\N	30
912	G02CB01	BROMOCRIPTINE MESYLATE	Capsule 5 mg (base)	1	\N	60
913	J04BA02	DAPSONE	Tablet 100 mg	1	\N	100
914	A02AD01	ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and SIMETHICONE	Oral suspension 400 mg-400 mg-30 mg per 5 mL, 500 mL	1	\N	1
915	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE, THREONINE and	Infant formula, powder 400 g	1	\N	1
916	G01AF02	CLOTRIMAZOLE	Vaginal cream 50 mg per 5 g (1%), 35 g	1	\N	1
917	H01AA02	TETRACOSACTRIN	Injection 1 mg in 1 mL	1	\N	1
918	A03AB05	PROPANTHELINE BROMIDE	Tablet 15 mg	1	\N	100
919	C07AG02	CARVEDILOL	Tablet 6.25 mg	1	\N	60
920	S01BA01	DEXAMETHASONE	Eye drops 1 mg per mL (0.1%), 5 mL	1	\N	1
921	R03CC03	TERBUTALINE SULFATE	Injection 500 micrograms in 1 mL	1	\N	5
922	C01BB02	MEXILETINE HYDROCHLORIDE	Capsule 200 mg	1	\N	100
923	H01BA02	DESMOPRESSIN ACETATE	Intranasal solution 100 micrograms per mL, 2.5 mL	1	\N	1
924	R01AX03	IPRATROPIUM BROMIDE	Aqueous nasal spray (pump pack) 21 micrograms (anhydrous) per dose (180 doses)	1	\N	1
925	D10BA01	ISOTRETINOIN	Capsule 40 mg	1	\N	30
926	A10BG03	PIOGLITAZONE HYDROCHLORIDE	Tablet 30 mg (base)	1	\N	28
927	C09CA03	VALSARTAN	Tablet 80 mg	1	\N	28
928	N06AB03	FLUOXETINE HYDROCHLORIDE	Tablet 20 mg (base) (dispersible)	1	\N	28
929	N02CC02	NARATRIPTAN	Tablet 2.5 mg (as hydrochloride)	1	\N	2
930	N05AH04	QUETIAPINE	Tablet 200 mg (as fumarate)	1	\N	60
931	A02BA02	RANITIDINE HYDROCHLORIDE	Syrup 150 mg (base) per 10 mL, 300 mL	1	\N	1
932	C09AA05	RAMIPRIL	Tablet 5 mg	1	\N	30
933	V06DB	AMINO ACIDS-SYNTHETIC, FORMULA	Compound powder 400 g	1	\N	1
934	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Infant formula, powder 400 g	1	\N	1
935	N07BA01	NICOTINE	Transdermal patches releasing approximately 7 mg per 24 hours, 7	1	\N	1
936	B01AC13	ABCIXIMAB	I.V. injection 10 mg in 5 mL	1	\N	1
937	V07AY	DRESSING-FOAM with SILICONE-LIGHT EXUDATE	Dressings 10 cm x 10 cm, 5	1	\N	1
938	J05AG04	ETRAVIRINE	Tablet 100 mg	1	\N	120
939	S01GA01	NAPHAZOLINE HYDROCHLORIDE	Eye drops 1 mg per mL (0.1%), 15 mL	1	\N	1
940	M05BA06	IBANDRONIC ACID	Concentrated injection for I.V. infusion 6 mg (as ibandronate sodium monohydrate) in 6 mL	1	\N	1
941	C08DB01	DILTIAZEM HYDROCHLORIDE	Capsule 180 mg (controlled delivery)	1	\N	30
942	C07AA02	OXPRENOLOL HYDROCHLORIDE	Tablet 40 mg	1	\N	100
943	H03BB01	CARBIMAZOLE	Tablet 5 mg	1	\N	100
944	V07AY	DRESSING-GAUZE-PARAFFIN	Dressings 10 cm x 10 cm, 10	1	\N	1
945	N06AX11	MIRTAZAPINE	Tablet 30 mg	1	\N	30
946	S01EE	LATANOPROST with TIMOLOL MALEATE	Eye drops 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL	1	\N	1
947	C07AB12	NEBIVOLOL	Tablet 1.25 mg (as hydrochloride), 28	1	\N	1
948	G03CA03	OESTRADIOL	Transdermal patches 3.8 mg (releasing approximately 50 micrograms per 24 hours), 4	1	\N	1
949	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-LIGHT EXUDATE)	Dressings 5 cm x 7 cm, 10	1	\N	1
950	A10BG02	ROSIGLITAZONE MALEATE	Tablet 4 mg (base)	1	\N	28
951	A04AD	PROMETHAZINE HYDROCHLORIDE	Tablet 10 mg	1	\N	50
952	C08CA01	AMLODIPINE	Tablet 5 mg (as maleate)	1	\N	30
953	C01AA05	DIGOXIN	Oral solution for children 50 micrograms per mL, 60 mL	1	\N	1
954	P01AX	PYRIMETHAMINE	Tablet 25 mg	1	\N	50
955	M01CB01	SODIUM AUROTHIOMALATE	Injection 20 mg	1	\N	10
956	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 1.2 mg (3.6 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
957	A04AA04	DOLASETRON MESYLATE	I.V. injection 100 mg in 5 mL	1	\N	1
958	L03AB04	INTERFERON ALFA-2a	Injection 4,500,000 i.u. in 0.5 mL single dose pre-filled syringe	1	\N	1
959	N05BX	CLOMIPRAMINE HYDROCHLORIDE	Tablet 25 mg	1	\N	50
960	V07AY	DRESSING-ALGINATE (SUPERFICIAL WOUND)	Dressings 15 cm x 20 cm, 10	1	\N	1
961	A07EC02	MESALAZINE	Tablet 500 mg (enteric coated)	1	\N	100
962	C02AB01	METHYLDOPA	Tablet 250 mg	1	\N	100
963	C07AG02	CARVEDILOL	Tablet 3.125 mg	1	\N	30
964	A02BC03	LANSOPRAZOLE	Tablet 15 mg (orally disintegrating)	1	\N	28
965	D07AA02	HYDROCORTISONE ACETATE	Cream 10 mg per g (1%), 30 g	1	\N	1
966	M05BA07	RISEDRONATE SODIUM	Tablet 30 mg	1	\N	28
967	A06AX01	GLYCEROL	Suppositories 700 mg (for infants), 12	1	\N	1
968	L01BA01	METHOTREXATE	Injection 5 mg in 2 mL	1	\N	5
969	A07EC03	OLSALAZINE SODIUM	Tablet 500 mg	1	\N	100
970	J01FA09	CLARITHROMYCIN	Tablet 500 mg	1	\N	100
971	A02BC01	OMEPRAZOLE	Capsule 20 mg	1	\N	30
972	S01XA20	PARAFFIN	Compound eye ointment 3.5 g	1	\N	1
973	S01ED51	TRAVOPROST with TIMOLOL MALEATE	Eye drops 40 micrograms-5 mg (base) per mL (0.004%-0.5%), 2.5 mL	1	\N	1
974	G03BA03	TESTOSTERONE	Subcutaneous implant 200 mg	1	\N	1
975	N03AX16	PREGABALIN	Capsule 75 mg	1	\N	56
976	J02AC03	VORICONAZOLE	Tablet 50 mg	1	\N	56
977	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 12 mg (36 i.u.) in 1 mL cartridge (with preservative)	1	\N	1
978	N06DA04	GALANTAMINE HYDROBROMIDE	Capsule 16 mg (base) (prolonged release)	1	\N	28
979	A04AD	PROMETHAZINE HYDROCHLORIDE	Tablet 25 mg	1	\N	50
980	N05BA12	ALPRAZOLAM	Tablet 2 mg	1	\N	50
981	C01BA03	DISOPYRAMIDE	Capsule 100 mg	1	\N	100
982	A04AA01	ONDANSETRON	Syrup 4 mg per 5 mL, 50 mL	1	\N	1
983	B03XA02	DARBEPOETIN ALFA	Injection 20 micrograms in 0.5 mL pre-filled syringe	1	\N	4
984	H05BX01	CINACALCET HYDROCHLORIDE	Tablet 60 mg (base)	1	\N	28
985	V03AC02	DEFERIPRONE	Oral solution 100 mg per mL, 250 mL	1	\N	1
986	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 60 mg (base)	1	\N	28
987	N06AX11	MIRTAZAPINE	Tablet 45 mg (orally disintegrating)	1	\N	30
988	V03AC03	DEFERASIROX	Tablet 500 mg (dispersible)	1	\N	28
989	C03BA11	INDAPAMIDE HEMIHYDRATE	Tablet 2.5 mg	1	\N	90
990	C02KX02	AMBRISENTAN	Tablet 5 mg	1	\N	30
991	L01DB03	EPIRUBICIN HYDROCHLORIDE	Solution for injection 100 mg in 50 mL	1	\N	1
992	V01AA07	INSECT ALLERGEN EXTRACT-PAPER WASP VENOM	Injection set containing 550 micrograms	1	\N	1
993	G03AA05	NORETHISTERONE with MESTRANOL	Pack containing 21 tablets 1 mg-50 micrograms and 7 inert tablets	1	\N	1
994	B01AB05	ENOXAPARIN SODIUM	Solution for injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL	1	\N	10
995	C07AB12	NEBIVOLOL	Tablet 5 mg (as hydrochloride)	1	\N	28
996	L01XA01	CISPLATIN	I.V. injection 50 mg in 50 mL	1	\N	1
997	N07BC02	METHADONE HYDROCHLORIDE	Tablet 10 mg	1	\N	20
998	J02AC01	FLUCONAZOLE	Solution for I.V. infusion 400 mg in 200 mL	1	\N	1
999	L01DB06	IDARUBICIN HYDROCHLORIDE	Solution for I.V. injection 10 mg in 10 mL	1	\N	6
1000	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Powder 325 g	1	\N	1
1001	L01AA01	CYCLOPHOSPHAMIDE	Powder for injection 500 mg (solvent required)	1	\N	1
1002	V06DX	TRIGLYCERIDES-MEDIUM CHAIN, FORMULA	Sachets 16 g, 25	1	\N	1
1003	G02CB01	BROMOCRIPTINE MESYLATE	Tablet 2.5 mg (base)	1	\N	30
1004	C08DB01	DILTIAZEM HYDROCHLORIDE	Capsule 360 mg (controlled delivery)	1	\N	30
1005	B05BA03	GLUCOSE	I.V. infusion 69.5 mmol (anhydrous) per 250 mL (5%), 250 mL	1	\N	1
1006	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)	1	\N	1
1007	L04AA18	EVEROLIMUS	Tablet 0.25 mg	1	\N	60
1008	L04AX04	LENALIDOMIDE	Capsule 25 mg	1	\N	21
1009	C07AA07	SOTALOL HYDROCHLORIDE	Tablet 80 mg	1	\N	60
1010	N02AB03	FENTANYL	Lozenges 200 micrograms (as citrate), 3	1	\N	1
1011	A06AC01	PSYLLIUM HYDROPHILIC MUCILLOID	Oral powder (non-flavoured) 336 g	1	\N	1
1012	M01AE02	NAPROXEN	Tablet 750 mg (sustained release)	1	\N	28
1013	C01DX16	NICORANDIL	Tablets 20 mg, 60	1	\N	1
1014	V07AY	DRESSING-FILM ISLAND	Dressings 5 cm x 7.2 cm, 5	1	\N	1
1015	N02CC01	SUMATRIPTAN	Tablet (fast disintegrating) 50 mg (as succinate)	1	\N	2
1016	V04CA02	GLUCOSE INDICATOR-BLOOD	Test strips, 100	1	\N	1
1017	L03AB05	INTERFERON ALFA-2b	Solution for injection 25,000,000 i.u. in 2.5 mL single dose vial	1	\N	1
1018	V07AY	DRESSING-ALGINATE (CAVITY WOUND)	Rope 2 g	1	\N	1
1019	C09DA08	OLMESARTAN MEDOXOMIL with HYDROCHLOROTHIAZIDE	Tablet 40 mg-25 mg	1	\N	30
1020	H02AB06	PREDNISOLONE SODIUM PHOSPHATE	Oral solution equivalent to 5 mg prednisolone per mL, 30 mL	1	\N	1
1021	J01DE01	CEFEPIME	Powder for injection 1 g (solvent required)	1	\N	1
1022	C10AA07	ROSUVASTATIN	Tablet 5 mg (as calcium)	1	\N	30
1023	R03BA08	CICLESONIDE	Oral pressurised inhalation 80 micrograms per dose (120 doses), CFC-free formulation	1	\N	1
1024	A12AA04	CALCIUM	Tablet 600 mg (as carbonate)	1	\N	240
1025	G03AA07	LEVONORGESTREL with ETHINYLOESTRADIOL	Tablets 150 micrograms-30 micrograms, 21	1	\N	4
1026	V07AY	BANDAGE-TUBULAR (LONG STOCKING)	Bandage, large size	1	\N	1
1027	N03AG06	TIAGABINE HYDROCHLORIDE	Tablet 10 mg (base)	1	\N	50
1028	L01DB01	DOXORUBICIN HYDROCHLORIDE, PEGYLATED LIPOSOMAL	Suspension for I.V. infusion 20 mg in 10 mL	1	\N	1
1029	A04AA01	ONDANSETRON	I.V. injection 8 mg in 4 mL	1	\N	1
1030	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Round 10 cm	1	\N	1
1031	C09AA02	ENALAPRIL MALEATE	Tablet 5 mg	1	\N	30
1032	A10AB05	INSULIN ASPART	Injections (human analogue) 100 units per mL, 3 mL, 5	1	\N	1
1033	C07AB07	BISOPROLOL FUMARATE	Tablet 10 mg	1	\N	28
1034	B03XA02	DARBEPOETIN ALFA	Injection 60 micrograms in 0.3 mL pre-filled injection pen	1	\N	1
1035	J01CA04	AMOXYCILLIN	Capsule 500 mg	1	\N	20
1036	G04CA02	TAMSULOSIN HYDROCHLORIDE	Tablet 400 micrograms (prolonged release)	1	\N	30
1037	A06AX01	GLYCEROL	Suppositories 2.8 g (for adults), 12	1	\N	1
1038	C08CA01	AMLODIPINE	Tablet 10 mg (as besylate)	1	\N	30
1039	V07AY	DRESSING-FOAM-MODERATE EXUDATE	Dressings 20 cm x 15 cm, 10	1	\N	1
1040	L01BC02	FLUOROURACIL	Injection 500 mg in 10 mL	1	\N	1
1041	N03AX09	LAMOTRIGINE	Tablet 5 mg	1	\N	56
1042	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 18 mg (base)	1	\N	28
1043	N05BA08	BROMAZEPAM	Tablet 3 mg	1	\N	30
1044	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Sachets 29 g, 30	1	\N	1
1045	M01AE03	KETOPROFEN	Suppository 100 mg	1	\N	20
1046	L03AB61	RIBAVIRIN and PEGINTERFERON ALFA-2a	Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	1	\N	1
1047	J01AA02	DOXYCYCLINE	Capsule 50 mg (as hydrochloride)	1	\N	25
1048	N06DA03	RIVASTIGMINE HYDROGEN TARTRATE	Capsule 6 mg (base)	1	\N	56
1049	M05BA03	DISODIUM PAMIDRONATE	Concentrated injection 30 mg in 10 mL	1	\N	1
1050	C10BA02	EZETIMIBE with SIMVASTATIN	Tablet 10 mg-20 mg	1	\N	30
1051	C04AX02	PHENOXYBENZAMINE HYDROCHLORIDE	Capsules 10 mg, 30	1	\N	1
1052	N05AB06	TRIFLUOPERAZINE HYDROCHLORIDE	Tablet 5 mg (base)	1	\N	100
1053	V07AY	BANDAGE-TUBULAR (SHORT STOCKING)	Bandage, small B/C size	1	\N	1
1054	J05AG01	NEVIRAPINE	Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL	1	\N	1
1055	N03AX12	GABAPENTIN	Capsule 100 mg	1	\N	100
1056	B05BB02	SODIUM CHLORIDE with GLUCOSE	I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL (0.45%-2.5%), 500 mL	1	\N	1
1057	B05BB01	SODIUM LACTATE COMPOUND	I.V. infusion 500 mL	1	\N	1
1058	G03AC01	NORETHISTERONE	Tablets 350 micrograms, 28	1	\N	1
1059	V04CA02	GLUCOSE INDICATOR-BLOOD	Test strips, 50	1	\N	1
1060	M03CA01	DANTROLENE SODIUM	Capsule 25 mg	1	\N	100
1061	N05AH03	OLANZAPINE	Tablet 10 mg	1	\N	28
1062	A01AD11	CARMELLOSE SODIUM	Mouth spray 10 mg per mL, 25 mL	1	\N	1
1063	L02BB03	BICALUTAMIDE	Tablet 50 mg	1	\N	28
1064	A02BC02	PANTOPRAZOLE SODIUM SESQUIHYDRATE	Tablet (enteric coated), equivalent to 20 mg pantoprazole	1	\N	30
1065	N05BA12	ALPRAZOLAM	Tablet 500 micrograms	1	\N	50
1066	N05AX08	RISPERIDONE	Tablet 0.5 mg	1	\N	60
1067	V06DX	WHEY PROTEIN FORMULA supplemented with AMINO ACIDS, VITAMINS and MINERALS, and l	Powder 400 g	1	\N	1
1068	V07AY	DRESSING-NON-ADHERENT	Dressings 7.5 cm x 10 cm, 6	1	\N	1
1069	N05AX08	RISPERIDONE	Tablet 4 mg (orally disintegrating)	1	\N	28
1070	V07AY	BANDAGE-TUBULAR (LIGHTWEIGHT)	Bandage, large limb size (blue), 10 m	1	\N	1
1071	D02BA	SUNSCREENS	Solid stick 4.5 g	1	\N	1
1072	P01BC01	QUININE BISULFATE	Tablet 300 mg	1	\N	50
1073	S01XA20	HYPROMELLOSE	Eye drops 5 mg per mL (0.5%), 15 mL	1	\N	1
1074	J01FA09	CLARITHROMYCIN	Powder for oral liquid 250 mg per 5 mL, 50 mL	1	\N	1
1075	N02AB03	FENTANYL	Lozenges 1600 micrograms (as citrate), 3	1	\N	1
1076	D02AX	SKIN EMOLLIENT	Lotion 500 mL	1	\N	1
1077	V07AY	DRESSING-FOAM with SILICONE-HEAVY EXUDATE	Dressings 7.5 cm x 7.5 cm, 5	1	\N	1
1078	B01AA03	WARFARIN SODIUM	Tablet 5 mg	1	\N	50
1079	J05AE01	SAQUINAVIR MESYLATE	Tablet 500 mg (base)	1	\N	120
1080	L04AA23	NATALIZUMAB	Solution concentrate for I.V. infusion 300 mg in 15 mL	1	\N	1
1081	L01DB01	DOXORUBICIN HYDROCHLORIDE	Solution for I.V. injection or intravesical administration 20 mg in 10 mL	1	\N	1
1082	V07AY	DRESSING-FILM	Dressings 10 cm x 12 cm, 4	1	\N	1
1083	N05AB04	PROCHLORPERAZINE	Tablet containing prochlorperazine maleate 5 mg	1	\N	25
1084	D09A	DRESSING with CADEXOMER IODINE	Sachets 3 g, 7	1	\N	1
1085	S02DC	CARBAMIDE PEROXIDE	Ear drops 65 mg per mL (6.5%), 12 mL	1	\N	1
1086	J01GB03	GENTAMICIN SULFATE	Injection 80 mg (base) in 2 mL	1	\N	5
1087	N06AX11	MIRTAZAPINE	Tablet 15 mg (orally disintegrating)	1	\N	30
1088	N02AA01	MORPHINE SULFATE	Capsule 90 mg (controlled release)	1	\N	10
1089	R03AC02	SALBUTAMOL SULFATE	Oral pressurised inhalation in breath actuated device 100 micrograms (base) per dose (200 doses), CFC-free formulation	1	\N	1
1090	A07EC01	SULFASALAZINE	Tablet 500 mg	1	\N	100
1091	C08CA02	FELODIPINE	Tablet 2.5 mg (extended release)	1	\N	30
1092	J04BA	RIFAMPICIN	Capsule 150 mg	1	\N	10
1093	C10AA01	SIMVASTATIN	Tablet 10 mg	1	\N	30
1094	H01CB02	OCTREOTIDE	Injection 500 micrograms (as acetate) in 1 mL	1	\N	5
1095	S01ED02	BETAXOLOL HYDROCHLORIDE	Eye drops, solution, 5 mg (base) per mL (0.5%), 5 mL	1	\N	1
1096	C08CA05	NIFEDIPINE	Tablet 60 mg (controlled release)	1	\N	30
1097	C07AA05	PROPRANOLOL HYDROCHLORIDE	Tablet 40 mg	1	\N	100
1098	C09AA04	PERINDOPRIL	Tablet containing 5 mg perindopril arginine	1	\N	30
1099	V04CA02	GLUCOSE INDICATOR-BLOOD	Test strips, 51	1	\N	1
1100	C10BA02	EZETIMIBE with SIMVASTATIN	Tablet 10 mg-10 mg	1	\N	30
1101	N05AE04	ZIPRASIDONE HYDROCHLORIDE	Capsule 40 mg (base)	1	\N	60
1102	A10BA02	METFORMIN HYDROCHLORIDE	Tablet 500 mg (extended release)	1	\N	90
1103	D05AX52	CALCIPOTRIOL with BETAMETHASONE DIPROPIONATE	Ointment 50 micrograms-500 micrograms (base) per g (0.005%-0.05%), 30 g	1	\N	1
1104	A12AA04	CALCIUM	Tablet (chewable) 500 mg (as carbonate)	1	\N	60
1105	N06AX11	MIRTAZAPINE	Tablet 15 mg	1	\N	30
1106	H01CB03	LANREOTIDE ACETATE	Injection 90 mg (base) in single dose pre-filled syringe	1	\N	1
1107	L01BC05	GEMCITABINE HYDROCHLORIDE	Powder for I.V. infusion 2 g (base)	1	\N	1
1108	B03XA01	EPOETIN ALFA	Injection 10,000 units in 1 mL pre-filled syringe	1	\N	6
1109	R03AC13	EFORMOTEROL FUMARATE DIHYDRATE	Powder for oral inhalation in breath actuated device 6 micrograms per dose (60 doses)	1	\N	1
1110	M03BX01	BACLOFEN	Tablet 25 mg	1	\N	100
1111	N02AA59	CODEINE PHOSPHATE with PARACETAMOL	Tablet 30 mg-500 mg	1	\N	20
1112	L01CB01	ETOPOSIDE	Powder for I.V. infusion 100 mg (as phosphate)	1	\N	1
1113	J01XD01	METRONIDAZOLE	Tablet 400 mg	1	\N	21
1114	B05AA06	POLYGELINE	I.V. infusion 17.5 g per 500 mL (3.5%) with electrolytes, 500 mL	1	\N	1
1115	M01AE11	TIAPROFENIC ACID	Tablet 300 mg	1	\N	60
1116	D11AX	ZINC OXIDE with STARCH and CHLORPHENESIN	Dusting powder 100 g	1	\N	1
1117	L04AB01	ETANERCEPT	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	1	\N	1
1118	N05AX08	RISPERIDONE	Powder for I.M. injection 37.5 mg (modified release) with 2 mL diluent in pre-filled syringe	1	\N	1
1816	V07AY	DRESSING with CADEXOMER IODINE	Tubes 10 g, 4	1	\N	1
1119	V06DX	VALINE with CARBOHYDRATE	Sachets 4 g containing 50 mg valine, 30	1	\N	1
1120	L01BC02	FLUOROURACIL	Injection 1000 mg in 20 mL	1	\N	1
1121	J05AE08	ATAZANAVIR	Capsule 300 mg (as sulfate)	1	\N	30
1122	J01CF05	FLUCLOXACILLIN	Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL	1	\N	1
1123	B01AB01	HEPARIN SODIUM	Injection (preservative-free) 5,000 units in 5 mL	1	\N	50
1124	N04BA02	LEVODOPA with BENSERAZIDE	Tablet 200 mg-50 mg	1	\N	100
1125	A12BA01	POTASSIUM CHLORIDE	Tablet 600 mg (sustained release)	1	\N	100
1126	V03AG	SODIUM ACID PHOSPHATE	Compound effervescent tablet containing elemental phosphorus 500 mg, sodium 469 mg (20.4 mmol), potassium 123 mg (3.1 mmol)	1	\N	100
1127	N02AB03	FENTANYL	Transdermal patch 4.2 mg (releasing approximately 25 micrograms per hour)	1	\N	5
1128	N04BC05	PRAMIPEXOLE HYDROCHLORIDE	Tablet 125 micrograms	1	\N	30
1129	L04AA06	MYCOPHENOLATE MOFETIL	Tablet 500 mg	1	\N	50
1130	M03CA01	DANTROLENE SODIUM	Capsule 50 mg	1	\N	100
1131	A01AD02	BENZYDAMINE HYDROCHLORIDE	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	1	\N	1
1132	L04AX02	THALIDOMIDE	Capsule 50 mg	1	\N	28
1133	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPH	Sachets 20 g, 30	1	\N	1
1134	D11AX18	DICLOFENAC SODIUM	Gel 30 mg per g (3%), 25 g	1	\N	1
1135	J01CA04	AMOXYCILLIN	Powder for syrup 125 mg per 5 mL, 100 mL	1	\N	1
1136	N05AH02	CLOZAPINE	Tablet 50 mg	1	\N	100
1137	A06AB02	BISACODYL	Tablets 5 mg, 200	1	\N	1
1138	R03AK06	FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	Oral pressurised inhalation 50 micrograms-25 micrograms (base) per dose (120 doses), CFC-free formulation	1	\N	1
1139	M03BX01	BACLOFEN	Tablet 10 mg	1	\N	100
1140	J04AB02	RIFAMPICIN	Capsule 300 mg	1	\N	10
1141	L04AA10	SIROLIMUS	Tablet 1 mg	1	\N	100
1142	N02AA01	MORPHINE HYDROCHLORIDE	Oral solution 2 mg per mL, 200 mL	1	\N	1
1143	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Dressings (foam alternative) 10 cm x 10 cm, 10	1	\N	1
1144	A06AB02	BISACODYL	Suppositories 10 mg, 10	1	\N	1
1145	A10AB04	INSULIN LISPRO	Injections (human analogue) 100 units per mL, 3 mL, 5	1	\N	1
1146	A07EC02	MESALAZINE	Enemas 2 g in 60 mL, 7	1	\N	1
1147	L02AB01	MEGESTROL ACETATE	Tablet 160 mg	1	\N	30
1148	N07AB02	BETHANECHOL CHLORIDE	Tablet 10 mg	1	\N	100
1149	C01DA02	GLYCERYL TRINITRATE	Tablets 600 micrograms, 100	1	\N	1
1150	D01AE16	AMOROLFINE HYDROCHLORIDE	Nail treatment kit containing nail lacquer 50 mg (base) per mL (5%), 5 mL, 60 isopropyl alcohol cleaning pads, 10 spatulas and 30 nail files	1	\N	1
1151	V07AY	DRESSING with SILVER	Hydroactive dressings adhesive 12.5 cm x 12.5 cm, 5	1	\N	1
1152	V07AY	DRESSING-HYDROFIBRE (ALTERNATE TO ALGINATES)	Dressings 15 cm x 15 cm, 5	1	\N	1
1153	L01BB05	FLUDARABINE PHOSPHATE	Tablet 10 mg	1	\N	20
1154	C03CA01	FRUSEMIDE	Oral solution 10 mg per mL, 30 mL	1	\N	1
1155	V07AY	BANDAGE-COMPRESSION	Bandage, high stretch, 10 cm x 3.5 m	1	\N	1
1156	G02CB03	CABERGOLINE	Tablet 500 micrograms	1	\N	2
1157	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 30 mg (controlled release)	1	\N	20
1158	L04AD02	TACROLIMUS	Capsule 500 micrograms	1	\N	100
1159	B01AE07	DABIGATRAN ETEXILATE	Capsules 110 mg (as mesilate), 60	1	\N	1
1160	D11AX	IMIQUIMOD	Cream 50 mg per g (5%), 250 mg single use sachets, 12	1	\N	1
1161	M01CC01	PENICILLAMINE	Tablet 125 mg	1	\N	100
1162	D07AC13	MOMETASONE FUROATE	Ointment 1 mg per g (0.1%), 15 g	1	\N	1
1163	D05AA	ALLANTOIN with SULFUR, PHENOL, COAL TAR SOLUTION and MENTHOL	Gel 25 mg-5 mg-5 mg-0.05 mL-7.5 mg per g (2.5%-0.5%-0.5%-5%-0.75%), 30 g	1	\N	1
1164	C09AA06	QUINAPRIL	Tablet 5 mg (as hydrochloride)	1	\N	30
1165	J01AA08	MINOCYCLINE	Capsule 100 mg	1	\N	11
1166	D02AX	CARMELLOSE SODIUM with PECTIN and GELATIN	Paste 167 mg-167 mg-167 mg per g (16.7%-16.7%- 16.7%), 5 g	1	\N	1
1167	H01CB02	OCTREOTIDE	Injection (modified release) 10 mg (as acetate), vial and diluent syringe	1	\N	1
1168	C02KX	EPOPROSTENOL SODIUM	Powder for I.V. infusion 1.5 mg (base) with diluent	1	\N	1
1169	A10BG03	PIOGLITAZONE HYDROCHLORIDE	Tablet 15 mg (base)	1	\N	28
1170	R03AC02	SALBUTAMOL SULFATE	Nebuliser solution 5 mg (base) per mL (0.5%), 30 mL	1	\N	1
1171	G03GA05	FOLLITROPIN ALFA	Injection set containing 1 vial powder for injection 75 i.u. and 1 pre-filled syringe solvent 1 mL	1	\N	1
1172	D07AC01	BETAMETHASONE DIPROPIONATE	Cream 500 micrograms (base) per g (0.05%), 15 g	1	\N	1
1173	N06AX03	MIANSERIN HYDROCHLORIDE	Tablet 20 mg	1	\N	50
1174	R03BC03	NEDOCROMIL SODIUM	Oral pressurised inhalation 2 mg per dose (112 doses), CFC-free formulation	1	\N	1
1175	M05BB04	RISEDRONATE SODIUM and CALCIUM CARBONATE with COLECALCIFEROL	Pack containing 4 tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium	1	\N	1
1176	D07AC13	MOMETASONE FUROATE	Cream 1 mg per g (0.1%), 15 g	1	\N	1
1177	N06AX16	VENLAFAXINE HYDROCHLORIDE	Capsule 150 mg (base) (modified release)	1	\N	28
1178	L04AX	RITUXIMAB	Solution for I.V. infusion 500 mg in 50 mL	1	\N	1
1179	M01AC06	MELOXICAM	Tablet 7.5 mg	1	\N	30
1180	C10AB04	GEMFIBROZIL	Tablet 600 mg	1	\N	60
1181	C08DA01	VERAPAMIL HYDROCHLORIDE	Tablet 40 mg	1	\N	100
1182	J05AR	LOPINAVIR with RITONAVIR	Tablet 100 mg-25 mg	1	\N	60
1183	M01AB05	DICLOFENAC SODIUM	Suppository 100 mg	1	\N	20
1184	C10AA07	ROSUVASTATIN	Tablet 40 mg (as calcium)	1	\N	30
1185	D01AC08	KETOCONAZOLE	Shampoo 20 mg per g (2%), 60 mL	1	\N	1
1186	G04CA03	TERAZOSIN HYDROCHLORIDE	Tablet 2 mg	1	\N	28
1187	A11EA	VITAMIN B GROUP COMPLEX	Oral liquid 200 mL	1	\N	1
1188	L01DC01	BLEOMYCIN SULFATE	Powder for injection 15,000 i.u.	1	\N	1
1189	A09AA02	PANCREATIC EXTRACT	Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity	1	\N	100
1190	J01FA06	ROXITHROMYCIN	Tablet 300 mg	1	\N	5
1191	N02AC	METHADONE HYDROCHLORIDE	Tablet 10 mg	1	\N	20
1192	A02BA01	CIMETIDINE	Tablet 800 mg	1	\N	30
1193	M05BA08	ZOLEDRONIC ACID	Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL	1	\N	1
1194	N05AX12	ARIPIPRAZOLE	Tablet 10 mg	1	\N	30
1195	D07AB09	TRIAMCINOLONE ACETONIDE	Ointment 200 micrograms per g (0.02%), 100 g	1	\N	1
1196	G04BD04	OXYBUTYNIN	Transdermal patches 36 mg (releasing approximately 3.9 mg per 24 hours), 8	1	\N	1
1197	A02BA03	FAMOTIDINE	Tablet 40 mg	1	\N	30
1198	L01CD01	PACLITAXEL	Solution concentrate for I.V. infusion 150 mg in 25 mL	1	\N	1
1199	J05AR01	LAMIVUDINE with ZIDOVUDINE	Tablet 150 mg-300 mg	1	\N	60
1200	J05AE10	DARUNAVIR	Tablet 300 mg (as ethanolate)	1	\N	120
1201	N02AA01	MORPHINE SULFATE	Capsule 10 mg (containing sustained release pellets)	1	\N	20
1202	J01DB04	CEPHAZOLIN	Powder for injection 2 g	1	\N	1
1203	R03BB01	IPRATROPIUM BROMIDE	Nebuliser solution single dose units 500 micrograms (anhydrous) in 1 mL, 30	1	\N	1
1204	L03AB60	RIBAVIRIN and PEGINTERFERON ALFA-2b	Pack containing 196 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection	1	\N	1
1205	N06DX01	MEMANTINE HYDROCHLORIDE	Oral drops 10 mg per g, 50 g	1	\N	1
1206	L01XE04	SUNITINIB	Capsule 25 mg (as malate)	1	\N	28
1207	C09AA09	FOSINOPRIL SODIUM	Tablet 10 mg	1	\N	30
1208	N07BA	BUPROPION HYDROCHLORIDE	Tablet 150 mg (sustained release)	1	\N	90
1209	N02CC04	RIZATRIPTAN	Wafer 10 mg (as benzoate)	1	\N	2
1210	A10BG02	ROSIGLITAZONE MALEATE	Tablet 8 mg (base)	1	\N	28
1211	N02AB03	FENTANYL	Lozenges 800 micrograms (as citrate), 3	1	\N	1
1212	C09DA06	CANDESARTAN CILEXETIL with HYDROCHLOROTHIAZIDE	Tablet 16 mg-12.5 mg	1	\N	30
1213	J05AR	LOPINAVIR with RITONAVIR	Oral liquid 400 mg-100 mg per 5 mL, 60 mL	1	\N	1
1214	N05AD01	HALOPERIDOL	Tablet 5 mg	1	\N	50
1215	D07AC13	MOMETASONE FUROATE	Lotion 1 mg per g (0.1% w/w), 30 mL	1	\N	1
1216	V04B	GLUCOSE INDICATOR-URINE	Test strips, 50	1	\N	1
1217	N05BA04	OXAZEPAM	Tablet 15 mg	1	\N	25
1218	H02AB02	DEXAMETHASONE SODIUM PHOSPHATE	Injection equivalent to 8 mg dexamethasone phosphate in 2 mL	1	\N	5
1219	C09DA02	EPROSARTAN MESYLATE with HYDROCHLOROTHIAZIDE	Tablet 600 mg (base)-12.5 mg	1	\N	28
1220	A07AA01	NEOMYCIN SULFATE	Tablet 500 mg	1	\N	25
1221	N02AA05	OXYCODONE	Suppository 30 mg	1	\N	12
1222	R03BA05	FLUTICASONE PROPIONATE	Oral pressurised inhalation 250 micrograms per dose (120 doses), CFC-free formulation	1	\N	1
1223	A04AA01	ONDANSETRON	Tablet 4 mg	1	\N	4
1224	L01BC01	CYTARABINE	Injection 100 mg in 5 mL	1	\N	5
1225	V07AY	TAPES-PLASTER ADHESIVE ELASTIC	Roll 2.5 cm x 2.5 m	1	\N	1
1226	C09CA06	CANDESARTAN CILEXETIL	Tablet 32 mg	1	\N	30
1227	M01AE02	NAPROXEN SODIUM	Tablet 550 mg	1	\N	50
1228	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 20 cm x 20 cm, 3	1	\N	1
1229	V03AF03	CALCIUM FOLINATE	Injection equivalent to 50 mg folinic acid in 5 mL	1	\N	1
1230	G04BE01	ALPROSTADIL	Intracavernosal injection 10 micrograms with diluent in single use syringe	1	\N	2
1231	N05AF01	FLUPENTHIXOL DECANOATE	Oily I.M. injection 40 mg in 2 mL	1	\N	5
1232	C09CA04	IRBESARTAN	Tablet 150 mg	1	\N	30
1233	L01XE02	GEFITINIB	Tablet 250 mg	1	\N	30
1234	S02CA04	TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE, GRAMICIDIN and NYSTATIN	Ear ointment 1 mg-2.5 mg (base)- 250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 5 g	1	\N	1
1235	J01AA02	DOXYCYCLINE	Capsule 100 mg (as hydrochloride)	1	\N	7
1236	G03AB04	NORETHISTERONE with ETHINYLOESTRADIOL	Pack containing 12 tablets 500 micrograms-35 micrograms, 9 tablets 1 mg-35 micrograms and 7 inert tablets	1	\N	1
1237	N03AG01	SODIUM VALPROATE	Syrup 200 mg per 5 mL, 300 mL	1	\N	1
1238	V07AY	DRESSING-NON-ADHERENT	Dressings, self-adhesive, 7.5 cm x 10 cm, 6	1	\N	1
1239	M05BX03	STRONTIUM RANELATE	Sachet containing granules for oral suspension 2 g	1	\N	28
1240	C01CA24	ADRENALINE	I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector	1	\N	1
1241	V03AF03	CALCIUM FOLINATE	Injection equivalent to 100 mg folinic acid in 10 mL	1	\N	1
1242	D02AA	DIMETHICONE with GLYCEROL	Cream 150 mg-20 mg per g (15%-2%), 75 g	1	\N	1
1243	A10AD	INSULIN ASPART-INSULIN ASPART PROTAMINE SUSPENSION	Injections (human analogue) 100 units (30 units-70 units) per mL, 3 mL, 5	1	\N	1
1244	M01AC01	PIROXICAM	Dispersible tablet 10 mg	1	\N	50
1245	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Dressings (foam alternative) 15 cm x 18 cm, 5	1	\N	1
1246	R03DC03	MONTELUKAST SODIUM	Chewable tablet 5 mg (base)	1	\N	28
1247	C02AC01	CLONIDINE	Tablet 150 micrograms	1	\N	100
1248	J01CR02	AMOXYCILLIN with CLAVULANIC ACID	Tablet 500 mg-125 mg	1	\N	10
1249	C09DA04	IRBESARTAN with HYDROCHLOROTHIAZIDE	Tablet 150 mg-12.5 mg	1	\N	30
1250	L04AA13	LEFLUNOMIDE	Tablet 20 mg	1	\N	30
1251	A02BC05	ESOMEPRAZOLE MAGNESIUM TRIHYDRATE	Tablet (enteric coated), equivalent to 40 mg esomeprazole	1	\N	30
1252	B01AC06	ASPIRIN	Capsule 100 mg (containing enteric coated pellets)	1	\N	84
1253	R03AK06	FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	Powder for oral inhalation in breath actuated device 250 micrograms-50 micrograms (base) per dose (60 doses)	1	\N	1
1254	S01AX13	CIPROFLOXACIN	Eye drops 3 mg per mL (0.3%), 5 mL	1	\N	1
1255	L01DB07	MITOZANTRONE HYDROCHLORIDE	Injection 20 mg (base) in 10 mL	1	\N	1
1256	R03AK07	BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE	Powder for oral inhalation in breath actuated device 200 micrograms-6 micrograms per dose (120 doses)	1	\N	1
1257	V06DX	PHENYLALANINE with CARBOHYDRATE	Sachets 4 g containing 50 mg phenylalanine, 30	1	\N	1
1258	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Dressings, island, 11 cm x 11 cm, 10	1	\N	1
1259	L01CA04	VINORELBINE TARTRATE	Solution for I.V. infusion 50 mg (base) in 5 mL	1	\N	1
1260	B05BB01	ELECTROLYTE REPLACEMENT SOLUTION	I.V. infusion 1 L	1	\N	1
1261	J01DD01	CEFOTAXIME	Powder for injection 2 g	1	\N	1
1262	L01DB01	DOXORUBICIN HYDROCHLORIDE	Solution for I.V. injection or intravesical administration 50 mg in 25 mL	1	\N	1
1263	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 174 mL, 30	1	\N	1
1264	H02AB06	PREDNISOLONE	Tablet 25 mg	1	\N	30
1265	A10BA02	METFORMIN HYDROCHLORIDE	Tablet 1 g	1	\N	90
1266	C09AA05	RAMIPRIL	Tablet 1.25 mg	1	\N	30
1267	N03AX11	TOPIRAMATE	Tablet 50 mg	1	\N	60
1268	C09DA07	TELMISARTAN with HYDROCHLOROTHIAZIDE	Tablet 80 mg-12.5 mg	1	\N	28
1269	V07AY	DRESSING-HYDROACTIVE (DEBRIDEMENT)	Dressings 5.5 cm, 8	1	\N	1
1270	B05BB01	SODIUM CHLORIDE	I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL	1	\N	1
1271	A10AB06	INSULIN GLULISINE	Injection (human analogue) 100 units per mL, 10 mL	1	\N	1
1272	C01BB01	LIGNOCAINE HYDROCHLORIDE	Injection 100 mg in 5 mL	1	\N	5
1273	L01DB07	MITOZANTRONE HYDROCHLORIDE	Injection 10 mg (base) in 5 mL	1	\N	1
1274	C09AA03	LISINOPRIL	Tablet 5 mg	1	\N	30
1275	V03AC01	DESFERRIOXAMINE MESYLATE	Powder for injection 500 mg	1	\N	10
1276	L01CD01	PACLITAXEL	Solution concentrate for I.V. infusion 30 mg in 5 mL	1	\N	1
1277	S01ED51	DORZOLAMIDE HYDROCHLORIDE with TIMOLOL MALEATE	Eye drops 20 mg (base)-5 mg (base) per mL (2%-0.5%), 5 mL	1	\N	1
1278	C03EA01	HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDE	Tablet 50 mg-5 mg	1	\N	50
1279	L01BB05	FLUDARABINE PHOSPHATE	Powder for I.V. injection 50 mg	1	\N	5
1280	D01AA01	NYSTATIN	Cream 100,000 units per g, 15 g	1	\N	1
1281	N03AG04	VIGABATRIN	Oral powder, sachet 500 mg	1	\N	60
1282	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 5 mg (15 i.u.) in 1 mL cartridge (with preservative)	1	\N	1
1283	J01CR02	AMOXYCILLIN with CLAVULANIC ACID	Powder for syrup 400 mg-57 mg per 5 mL, 60 mL	1	\N	1
1284	G03CA03	OESTRADIOL	Transdermal patches 585 micrograms (releasing approximately 37.5 micrograms per 24 hours), 8	1	\N	1
1285	B03XA02	DARBEPOETIN ALFA	Injection 150 micrograms in 0.3 mL pre-filled injection pen	1	\N	1
1286	A06AG20	SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE	Enemas 3.125 g-450 mg-45 mg in 5 mL, 4	1	\N	1
1287	V07AY	COTTON WOOL ROLL	Roll 100 g	1	\N	1
1288	N06DA03	RIVASTIGMINE	Transdermal patch 9 mg (releasing approximately 4.6 mg per 24 hours)	1	\N	30
1289	N05AH04	QUETIAPINE	Tablet 25 mg (as fumarate)	1	\N	60
1290	P01BD01	PYRIMETHAMINE	Tablet 25 mg	1	\N	50
1291	B01AA03	WARFARIN SODIUM	Tablet 1 mg	1	\N	50
1292	J05AG02	DELAVIRDINE MESYLATE	Tablet 100 mg	1	\N	360
1293	G04BE03	SILDENAFIL CITRATE	Tablet 100 mg (base)	1	\N	4
1294	G03HA01	CYPROTERONE ACETATE	Tablet 50 mg	1	\N	20
1295	B03XA01	EPOETIN ALFA	Injection 30,000 units in 0.75 mL pre-filled syringe	1	\N	6
1296	N05AH04	QUETIAPINE	Tablet 300 mg (as fumarate)	1	\N	60
1297	H03AA01	THYROXINE SODIUM	Tablet equivalent to 75 micrograms anhydrous thyroxine sodium	1	\N	200
1298	D01AC02	MICONAZOLE	Tincture 20 mg per mL (2%), 30 mL	1	\N	1
1299	R03DA04	THEOPHYLLINE	Tablet 300 mg (sustained release)	1	\N	100
1300	D09AA09	DRESSING-GAUZE-POVIDONE-IODINE PAD	Pads 22.5 cm x 7.5 cm, 12	1	\N	1
1301	N03AX14	LEVETIRACETAM	Tablet 250 mg	1	\N	60
1302	A10BB01	GLIBENCLAMIDE	Tablet 5 mg	1	\N	100
1303	L01BA01	METHOTREXATE	Injection 50 mg in 2 mL	1	\N	5
1304	N05AH03	OLANZAPINE	Powder for injection 210 mg (as pamoate monohydrate) with diluent	1	\N	1
1305	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 10 cm x 10 cm, 5	1	\N	1
1306	B03XA02	DARBEPOETIN ALFA	Injection 50 micrograms in 0.5 mL pre-filled syringe	1	\N	4
1307	L02AB02	MEDROXYPROGESTERONE ACETATE	Tablet 250 mg	1	\N	60
1308	N02AX02	TRAMADOL HYDROCHLORIDE	Injection 100 mg in 2 mL	1	\N	5
1309	N05AC01	PERICYAZINE	Tablet 10 mg	1	\N	100
1310	B05BB02	SODIUM CHLORIDE with GLUCOSE	I.V. infusion 31 mmol-222 mmol (anhydrous) per L (0.18%-4%), 1 L	1	\N	1
1311	D06AX09	MUPIROCIN	Cream 20 mg (as calcium) per g (2%), 15 g	1	\N	1
1312	S01ED01	TIMOLOL MALEATE	Eye drops 2.5 mg (base) per mL (0.25%), 5 mL	1	\N	1
1313	L02AE04	TRIPTORELIN	Powder for I.M. injection (prolonged release) 11.25 mg (as embonate) with solvent, syringe and needles	1	\N	1
1314	N06AA09	AMITRIPTYLINE HYDROCHLORIDE	Tablet 10 mg	1	\N	50
1315	N05AF05	ZUCLOPENTHIXOL DECANOATE	Oily I.M. injection 200 mg in 1 mL	1	\N	5
1316	N04BA02	LEVODOPA with BENSERAZIDE	Capsule 200 mg-50 mg	1	\N	100
1317	L01BC05	GEMCITABINE HYDROCHLORIDE	Powder for I.V. infusion 200 mg (base)	1	\N	1
1318	L04AB04	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled pen	1	\N	2
1319	R03BC01	SODIUM CROMOGLYCATE	Capsule containing powder for oral inhalation 20 mg (for use in Intal Spinhaler or Intal Halermatic)	1	\N	100
1320	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE, THREONINE and	Powder 500 g	1	\N	1
1321	V07AY	DRESSING-FOAM with SILICONE-LIGHT EXUDATE	Dressings 6 cm x 8.5 cm, 5	1	\N	1
1322	N03AD01	ETHOSUXIMIDE	Capsule 250 mg	1	\N	200
1323	N02AA01	MORPHINE HYDROCHLORIDE	Oral solution 10 mg per mL, 200 mL	1	\N	1
1324	B01AD10	DROTRECOGIN ALFA (ACTIVATED)	Powder for I.V. infusion 5 mg	1	\N	1
1325	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 5 mg (base)-40 mg (base)	1	\N	30
1326	V06DB	AMINO ACID SYNTHETIC FORMULA supplemented with LONG CHAIN POLYUNSATURATED FATTY	Compound powder 400 g	1	\N	1
1327	N05AD01	HALOPERIDOL	Tablet 500 micrograms	1	\N	100
1328	B01AC09	EPOPROSTENOL SODIUM	Powder for I.V. infusion 500 micrograms (base) with diluent	1	\N	1
1329	A02BA02	RANITIDINE HYDROCHLORIDE	Effervescent tablet 150 mg (base)	1	\N	30
1330	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Injection 2 mg in 1 mL	1	\N	5
1331	C01AA05	DIGOXIN	Tablet 62.5 micrograms	1	\N	200
1332	L01DC01	BLEOMYCIN SULFATE	Powder for injection 15,000 i.u. (solvent required)	1	\N	10
1333	B03XA01	EPOETIN ALFA	Injection 40,000 units in 1 mL pre-filled syringe	1	\N	1
1334	J05AE03	RITONAVIR	Oral solution 600 mg per 7.5 mL (80 mg per mL), 90 mL	1	\N	1
1335	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEU	Powder 500 g	1	\N	1
1336	L03AA10	LENOGRASTIM	Powder for injection 13,400,000 i.u. (105 micrograms)	1	\N	10
1337	D07AC14	METHYLPREDNISOLONE ACEPONATE	Cream 1 mg per g (0.1%), 15 g	1	\N	1
1338	C10AA05	ATORVASTATIN	Tablet 40 mg (as calcium)	1	\N	30
1339	L01XA02	CARBOPLATIN	Solution for I.V. injection 150 mg in 15 mL	1	\N	1
1340	N04BC07	APOMORPHINE HYDROCHLORIDE	Solution for subcutaneous infusion 50 mg in 10 mL pre-filled syringe	1	\N	5
1341	L03AB10	PEGINTERFERON ALFA-2b	Powder for injection 80 micrograms with diluent in single use injection pen	1	\N	4
1342	N05AF01	FLUPENTHIXOL DECANOATE	Oily I.M. injection 100 mg in 1 mL	1	\N	5
1343	V03AX	POLY-L-LACTIC ACID	Powder for injection 150 mg	1	\N	1
1344	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Sachets 20 g, 30	1	\N	1
1345	N06AA09	AMITRIPTYLINE HYDROCHLORIDE	Tablet 25 mg	1	\N	50
1346	L02AE04	TRIPTORELIN	Powder for I.M. injection (prolonged release) 3.75 mg (as embonate) with solvent, syringe and needles	1	\N	1
1347	V04CA02	GLUCOSE INDICATOR-BLOOD	Test strips, 25	1	\N	1
1348	S01XA20	POLYVINYL ALCOHOL	Eye drops 14 mg per mL (1.4%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	1	\N	1
1349	J01XX05	HEXAMINE HIPPURATE	Tablet 1 g	1	\N	100
1350	V07AY	BANDAGE-RETENTION-COHESIVE-HEAVY	Bandage 10 cm x 1.3 m	1	\N	1
1351	N06AX12	BUPROPION HYDROCHLORIDE	Tablet 150 mg (sustained release)	1	\N	90
1352	N05AB04	PROCHLORPERAZINE	Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5	1	\N	1
1353	H01CB03	LANREOTIDE ACETATE	Powder for suspension for injection 30 mg (base) with diluent ampoule	1	\N	1
1354	J05AF05	LAMIVUDINE	Tablet 150 mg	1	\N	60
1355	C07AG02	CARVEDILOL	Tablet 12.5 mg	1	\N	60
1356	G03FB05	OESTRADIOL and OESTRADIOL with NORETHISTERONE ACETATE	Pack containing 4 transdermal patches oestradiol 4 mg (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol	1	\N	1
1357	S01ED01	TIMOLOL MALEATE	Eye drops (gellan gum solution) 2.5 mg (base) per mL (0.25%), 2.5 mL	1	\N	1
1358	L03AB05	INTERFERON ALFA-2b	Solution for injection 30,000,000 i.u. in 1.2 mL multi-dose injection pen	1	\N	1
1359	J05AB01	ACICLOVIR	Tablet 800 mg	1	\N	35
1360	A10AB01	INSULIN NEUTRAL	Injections (human) 100 units per mL, 3 mL, 5	1	\N	1
1361	J01EE01	TRIMETHOPRIM with SULFAMETHOXAZOLE	Tablet 160 mg-800 mg	1	\N	10
1362	V07AY	BANDAGE-COMPRESSION	Bandage, high stretch, 7.5 cm x 3 m	1	\N	1
1363	J05AE08	ATAZANAVIR	Capsule 100 mg (as sulfate)	1	\N	60
1364	A06AG02	BISACODYL	Enemas 10 mg in 5 mL, 25	1	\N	1
1365	N02CC01	SUMATRIPTAN	Tablet 50 mg (as succinate)	1	\N	4
1366	C09CA06	CANDESARTAN CILEXETIL	Tablet 4 mg	1	\N	30
1367	V06DX	SOY PROTEIN and FAT FORMULA with VITAMINS and MINERALS-CARBOHYDRATE FREE	Liquid 384 mL	1	\N	1
1368	D02AA	DIMETHICONE with GLYCEROL	Cream 150 mg-20 mg per g (15%-2%), 500 g	1	\N	1
1369	G03CA03	OESTRADIOL	Transdermal patches 2 mg (releasing approximately 25 micrograms per 24 hours), 8	1	\N	1
1370	N05AH03	OLANZAPINE	Wafer 10 mg	1	\N	28
1371	N03AX18	LACOSAMIDE	Tablets 150 mg, 14	1	\N	1
1372	N03AX03	SULTHIAME	Tablet 200 mg	1	\N	200
1373	D07AC13	MOMETASONE FUROATE	Ointment 1 mg per g (0.1%), 45 g	1	\N	1
1374	N02AB03	FENTANYL	Transdermal patch 16.8 mg (releasing approximately 100 micrograms per hour)	1	\N	5
1375	V06DX	ISOLEUCINE with CARBOHYDRATE	Sachets 4 g containing 50 mg isoleucine, 30	1	\N	1
1376	M01AE02	NAPROXEN	Tablet 250 mg	1	\N	50
1377	C05AA01	HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDE	Suppositories 5 mg-5 mg, 12	1	\N	1
1378	M05BA03	DISODIUM PAMIDRONATE	Injection set containing 4 vials powder for I.V. infusion 15 mg and 4 ampoules solvent 5 mL	1	\N	1
1379	V07AY	BANDAGE-TUBULAR (LONG STOCKING)	Bandage, medium size	1	\N	1
1380	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Sachets 25 g, 30	1	\N	1
1381	B01AB05	ENOXAPARIN SODIUM	Injection 60 mg (6,000 i.u. anti-Xa) in 0.6 mL pre-filled syringe	1	\N	10
1382	L04AA18	EVEROLIMUS	Tablet 0.5 mg	1	\N	60
1383	B03XA02	DARBEPOETIN ALFA	Injection 10 micrograms in 0.4 mL pre-filled syringe	1	\N	4
1384	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 10 mg (base)-10 mg (base)	1	\N	30
1385	N02BG	PREGABALIN	Capsule 25 mg	1	\N	56
1386	N04BA02	LEVODOPA with BENSERAZIDE	Tablet 100 mg-25 mg	1	\N	100
1387	V07AY	DRESSING-ACTIVATED CHARCOAL (MALODOROUS WOUND)	Dressings 15 cm x 20 cm, 5	1	\N	1
1388	D01AC08	KETOCONAZOLE	Shampoo 20 mg per g (2%), 100 mL	1	\N	1
1389	L04AB01	ETANERCEPT	Injection 50 mg in 1 mL single use auto-injector, 4	1	\N	1
1390	S01LA01	VERTEPORFIN	Powder for I.V. infusion 15 mg	1	\N	1
1391	V07AY	BANDAGE-COMPRESSION	Bandage, four layer	1	\N	1
1392	N02AB03	FENTANYL	Transdermal patch 2.1 mg (releasing approximately 12 micrograms per hour)	1	\N	5
1393	R03AC02	SALBUTAMOL SULFATE	Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation	1	\N	1
1394	G03CA03	OESTRADIOL	Transdermal patches 780 micrograms (releasing approximately 50 micrograms per 24 hours), 8	1	\N	1
1395	A07EC02	MESALAZINE	Sachet containing granules, 1 g per sachet	1	\N	100
1396	J02AC01	FLUCONAZOLE	Capsule 200 mg	1	\N	28
1397	H03AA02	LIOTHYRONINE SODIUM	Tablet 20 micrograms	1	\N	100
1398	P01AB01	METRONIDAZOLE	Tablet 200 mg	1	\N	21
1399	J05AF05	LAMIVUDINE	Oral solution 5 mg per mL, 240 mL	1	\N	1
1400	S01XA20	POLYETHYLENE GLYCOL 400	Eye drops 2.5 mg per mL (0.25%), 15 mL	1	\N	1
1401	A07EA01	PREDNISOLONE SODIUM PHOSPHATE	Retention enema equivalent to 20 mg prednisolone in 100 mL	1	\N	7
1402	V07AY	BANDAGE-TUBULAR (LONG STOCKING)	Bandage, small size	1	\N	1
1403	A01AB03	CHLORHEXIDINE GLUCONATE	Mouth wash 2 mg per mL (0.2%), 300 mL	1	\N	1
1404	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 5 mg (controlled release)	1	\N	20
1405	V07AY	BANDAGE-RETENTION-COHESIVE-HEAVY	Bandage 5 cm x 1.3 m	1	\N	1
1406	N06AX21	DULOXETINE HYDROCHLORIDE	Capsule 60 mg (base)	1	\N	28
1407	D01AC02	MICONAZOLE NITRATE	Cream 20 mg per g (2%), 30 g	1	\N	1
1408	J05AB11	VALACICLOVIR HYDROCHLORIDE	Tablet 500 mg (base)	1	\N	100
1409	D07AA02	HYDROCORTISONE ACETATE	Topical ointment 10 mg per g (1%), 30 g	1	\N	1
1410	N02BG	GABAPENTIN	Capsule 300 mg	1	\N	100
1411	D02BA	SUNSCREENS	Lotion (non-alcoholic) 125 mL	1	\N	1
1412	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings 20 cm x 20 cm, 5	1	\N	1
1413	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 40 mg (base)	1	\N	28
1414	D09AB01	BANDAGE-ZINC PASTE	Bandage 10 cm x 9.1 m	1	\N	1
1415	A01AD11	CARMELLOSE SODIUM	Mouth spray 10 mg per mL, 100 mL	1	\N	1
1416	V07AY	BANDAGE-COMPRESSION	Bandage, two layer, 18 cm-22 cm (red)	1	\N	1
1417	A12BA01	POTASSIUM CHLORIDE with POTASSIUM BICARBONATE	Effervescent tablet 14 mmol potassium and 8 mmol chloride	1	\N	60
1418	V07AY	BANDAGE-TUBULAR	Bandage 6.25 cm x 1 m	1	\N	1
1419	C05AX04	ZINC OXIDE	Compound ointment 50 g	1	\N	1
1420	P01AX06	ATOVAQUONE	Oral suspension 750 mg per 5 mL, 210 mL	1	\N	1
1421	N02CC01	SUMATRIPTAN	Nasal spray 20 mg in 0.1 mL single dose unit	1	\N	2
1422	N02BE51	CODEINE PHOSPHATE with PARACETAMOL	Tablet 15 mg-500 mg	1	\N	20
1423	B05BA03	GLUCOSE	I.V. infusion 278 mmol (anhydrous) per 500 mL (10%), 500 mL	1	\N	1
1424	V07AY	BANDAGE-ZINC PASTE	Bandages 80 cm (stockings), 4	1	\N	1
1425	V07AY	BANDAGE-TUBULAR	Bandage, straight, size D	1	\N	1
1426	L01BC05	GEMCITABINE HYDROCHLORIDE	Solution concentrate for I.V. infusion 200 mg (base) in 20 mL	1	\N	1
1427	J01CE01	BENZYLPENICILLIN	Powder for injection 600 mg	1	\N	1
1428	R03AC02	SALBUTAMOL SULFATE	Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30	1	\N	1
1429	N02AA05	OXYCODONE HYDROCHLORIDE	Capsule 10 mg	1	\N	20
1430	L03AB05	INTERFERON ALFA-2b	Solution for injection 10,000,000 i.u. in 1 mL single dose vial	1	\N	5
1431	C09BA06	QUINAPRIL HYDROCHLORIDE with HYDROCHLOROTHIAZIDE	Tablet 20 mg (base)-12.5 mg	1	\N	30
1432	N04BA02	LEVODOPA with BENSERAZIDE	Dispersible tablet 100 mg-25 mg	1	\N	100
1433	N03AG06	TIAGABINE HYDROCHLORIDE	Tablet 5 mg (base)	1	\N	50
1434	L04AA06	MYCOPHENOLATE SODIUM	Tablet (enteric coated) 180 mg (mycophenolic acid)	1	\N	120
1435	C04AX02	PHENOXYBENZAMINE HYDROCHLORIDE	Capsule 10 mg	1	\N	100
1436	H02AB04	METHYLPREDNISOLONE SODIUM SUCCINATE	Powder for injection equivalent to 1 g methylprednisolone with diluent	1	\N	1
1437	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 1 mg (3 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
1438	R03DA04	THEOPHYLLINE	Tablet 250 mg (sustained release)	1	\N	100
1439	S01BA02	HYDROCORTISONE ACETATE	Eye ointment 5 mg per g (0.5%), 5 g	1	\N	1
1440	A07EC02	MESALAZINE	Sachet containing prolonged release granules, 2 g per sachet	1	\N	60
1441	J05AG03	EFAVIRENZ	Tablet 200 mg	1	\N	90
1442	A01AB11	NYSTATIN	Oral suspension 100,000 units per mL, 24 mL	1	\N	1
1443	G03FA01	OESTRADIOL with NORETHISTERONE ACETATE	Transdermal patches 620 micrograms-2.7 mg (releasing approximately 50 micrograms- 140 micrograms per 24 hours), 8	1	\N	1
1444	N07XX02	RILUZOLE	Tablet 50 mg	1	\N	56
1445	L01CA04	VINORELBINE TARTRATE	Capsule 20 mg (base)	1	\N	1
1446	L01BC06	CAPECITABINE	Tablet 500 mg	1	\N	120
1447	A04AA02	GRANISETRON HYDROCHLORIDE	Tablet 2 mg (base)	1	\N	1
1448	L04AB04	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled pen, 6	1	\N	1
1449	A02BC02	PANTOPRAZOLE SODIUM SESQUIHYDRATE	Sachet containing granules 40 mg	1	\N	30
1450	N05AX12	ARIPIPRAZOLE	Tablet 15 mg	1	\N	30
1451	N03AF02	OXCARBAZEPINE	Oral suspension 60 mg per mL, 250 mL	1	\N	1
1452	S01FA01	ATROPINE SULFATE	Eye drops 10 mg per mL (1%), 15 mL	1	\N	1
1453	C01AA05	DIGOXIN	Tablet 250 micrograms	1	\N	100
1454	V03AB15	NALOXONE HYDROCHLORIDE	Injection 2 mg in 5 mL	1	\N	1
1455	L02AB02	MEDROXYPROGESTERONE ACETATE	Tablet 100 mg	1	\N	100
1456	A04AA04	DOLASETRON MESYLATE	Tablet 200 mg	1	\N	2
1457	S01BA07	FLUOROMETHOLONE	Eye drops 1 mg per mL (0.1%), 5 mL	1	\N	1
1458	J01GB01	TOBRAMYCIN SULFATE	Injection 80 mg (base) in 2 mL	1	\N	5
1459	D04AB01	LIGNOCAINE HYDROCHLORIDE with CARBOXYMETHYLCELLULOSE	Mucilage 20 mg-25 mg per mL (2%-2.5%), 200 mL	1	\N	1
1460	G03GA05	FOLLITROPIN ALFA	Injection 450 i.u. in 0.75 mL multi-dose cartridge	1	\N	1
1461	B01AE07	DABIGATRAN ETEXILATE	Capsule 110 mg (as mesilate)	1	\N	10
1462	H01CB03	LANREOTIDE ACETATE	Injection 120 mg (base) in single dose pre-filled syringe	1	\N	1
1463	S01EE04	TRAVOPROST	Eye drops 40 micrograms per mL (0.004%), 2.5 mL	1	\N	1
1464	V06DX	VALINE with CARBOHYDRATE	Sachets 4 g containing 1 g valine, 30	1	\N	1
1465	N02AA01	MORPHINE SULFATE	Sachet containing controlled release granules for oral suspension, 200 mg per sachet	1	\N	20
1466	N05BA01	DIAZEPAM	Tablet 2 mg	1	\N	50
1467	N03AA03	PRIMIDONE	Tablet 250 mg	1	\N	200
1468	L01XE06	DASATINIB	Tablet 70 mg	1	\N	60
1469	H02AB04	METHYLPREDNISOLONE ACETATE	Injection 40 mg in 1 mL	1	\N	5
1470	D01AC02	MICONAZOLE NITRATE	Cream 20 mg per g (2%), 70 g	1	\N	1
1471	A08AB01	ORLISTAT	Capsule 120 mg	1	\N	84
1472	D07AC14	METHYLPREDNISOLONE ACEPONATE	Lotion 1 mg per g (0.1%), 20 g	1	\N	1
1473	V07AY	DRESSING-HYDROGEL-AMORPHOUS	Tubes 15 g, 10	1	\N	1
1474	L01XE04	SUNITINIB	Capsule 50 mg (as malate)	1	\N	28
1475	D11AF	SALICYLIC ACID with LACTIC ACID	Liquid 167 mg-167 mg per g (16.7%-16.7%), 15 mL	1	\N	1
1476	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without LYSINE and low in TRYPTOPH	Infant formula, powder 400 g	1	\N	1
1477	N05AX08	RISPERIDONE	Oral solution 1 mg per mL, 100 mL	1	\N	1
1478	G03CA03	OESTRADIOL	Implant 100 mg	1	\N	1
1479	N02BG	GABAPENTIN	Tablet 800 mg	1	\N	100
1480	L01DB01	DOXORUBICIN HYDROCHLORIDE	Solution for I.V. injection or intravesical administration 200 mg in 100 mL	1	\N	1
1481	M04AA01	ALLOPURINOL	Tablet 300 mg	1	\N	60
1482	C07AB02	METOPROLOL TARTRATE	Tablet 50 mg	1	\N	100
1483	C10AC01	CHOLESTYRAMINE	Sachets 4.7 g (equivalent to 4 g cholestyramine), 50	1	\N	1
1484	B01AB01	HEPARIN SODIUM	Injection 35,000 units in 35 mL	1	\N	1
1485	C09CA03	VALSARTAN	Tablet 320 mg	1	\N	28
1486	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 4 mg (modified release)	1	\N	10
1487	J04BA	RIFAMPICIN	Capsule 300 mg	1	\N	100
1488	D01AC10	BIFONAZOLE	Cream 10 mg per g (1%), 15 g	1	\N	1
1489	H04AA01	GLUCAGON HYDROCHLORIDE	Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe	1	\N	1
1490	B01AC05	TICLOPIDINE HYDROCHLORIDE	Tablet 250 mg	1	\N	60
1491	D07AC01	BETAMETHASONE VALERATE	Ointment 1 mg (base) per g (0.1%), 30 g	1	\N	1
1492	B02AA02	TRANEXAMIC ACID	Tablet 500 mg	1	\N	100
1493	L04AX04	LENALIDOMIDE	Capsule 15 mg	1	\N	21
1494	N04AC01	BENZTROPINE MESYLATE	Tablet 2 mg	1	\N	60
1495	M01AC06	MELOXICAM	Capsule 15 mg	1	\N	30
1496	V06DF	MILK POWDER-LACTOSE MODIFIED	Lactose-predigested powder 900 g	1	\N	1
1497	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 8 mg (24 i.u.) vial with 1.37 mL diluent cartridge (with preservative) (for use with one.click auto-injector)	1	\N	1
1498	L01BC05	GEMCITABINE HYDROCHLORIDE	Solution concentrate for I.V. infusion 1000 mg (base) in 100 mL	1	\N	1
1499	C09DA06	CANDESARTAN CILEXETIL with HYDROCHLOROTHIAZIDE	Tablet 32 mg-25 mg	1	\N	30
1500	A10BA02	METFORMIN HYDROCHLORIDE	Tablets 500 mg (extended release), 120	1	\N	1
1501	M02AC	METHYL SALICYLATE	Compound cream APF, 100 g	1	\N	1
1502	R03CC02	SALBUTAMOL SULFATE	Syrup 2 mg (base) per 5 mL, 150 mL	1	\N	1
1503	J01CA04	AMOXYCILLIN	Sachet containing oral powder 3 g	1	\N	1
1504	N02AE01	BUPRENORPHINE	Transdermal patch 10 mg (releasing approximately 10 micrograms per hour)	1	\N	2
1505	A02BC03	LANSOPRAZOLE	Tablet 30 mg (orally disintegrating)	1	\N	28
1506	N07BC02	METHADONE HYDROCHLORIDE	Oral liquid 25 mg per 5 mL, 200 mL	1	\N	1
1507	C08DA01	VERAPAMIL HYDROCHLORIDE	Tablet 120 mg	1	\N	100
1508	B01AA03	WARFARIN SODIUM	Tablet 3 mg	1	\N	50
1509	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-LIGHT EXUDATE)	Dressings 9 cm x 14 cm, 10	1	\N	1
1510	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 30 micrograms in 0.3 mL pre-filled syringe	1	\N	1
1511	L01AA01	CYCLOPHOSPHAMIDE	Tablet 50 mg	1	\N	50
1512	S01AB04	SULFACETAMIDE SODIUM	Eye drops 100 mg per mL (10%), 15 mL	1	\N	1
1513	J01FA10	AZITHROMYCIN	Powder for oral suspension 200 mg per 5 mL, 15 mL	1	\N	1
1514	J01XE01	NITROFURANTOIN	Capsule 50 mg	1	\N	30
1515	A04AD12	APREPITANT	Pack containing 1 capsule 125 mg and 2 capsules 80 mg	1	\N	1
1516	S01AA12	TOBRAMYCIN	Eye ointment 3 mg per g (0.3%), 3.5 g	1	\N	1
1517	J01DB01	CEPHALEXIN	Capsule 500 mg	1	\N	20
1518	J01DB04	CEPHAZOLIN	Powder for injection 1 g	1	\N	10
1519	J02AC03	VORICONAZOLE	Tablet 200 mg	1	\N	56
1520	N06AB10	ESCITALOPRAM OXALATE	Oral solution 10 mg (base) per mL, 28 mL	1	\N	1
1521	V07AY	GLOVES PLASTIC (DISPOSABLE)	Gloves, medium, 100	1	\N	1
1522	J04AB02	RIFAMPICIN	Capsule 150 mg	1	\N	100
1523	G03DB01	DYDROGESTERONE	Tablet 10 mg	1	\N	28
1524	G03GA05	FOLLITROPIN ALFA	Injection 900 i.u. in 1.5 mL multi-dose cartridge	1	\N	1
1525	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	Oral liquid 130 mL, 30	1	\N	1
1526	R05CA10	SENEGA and AMMONIA	Mixture 200 mL	1	\N	1
1527	C03CA01	FRUSEMIDE	Tablet 20 mg	1	\N	50
1528	V06DF	MILK POWDER-LACTOSE FREE FORMULA	Lactose-predigested powder infant formula 900 g	1	\N	1
1529	C09CA07	TELMISARTAN	Tablet 80 mg	1	\N	28
1530	H03AA01	THYROXINE SODIUM	Tablet equivalent to 100 micrograms anhydrous thyroxine sodium	1	\N	200
1532	S01EA05	BRIMONIDINE TARTRATE	Eye drops 2 mg per mL (0.2%), 5 mL	1	\N	1
1533	B03BA03	HYDROXOCOBALAMIN	Injection 1 mg in 1 mL	1	\N	3
1534	A04AA03	TROPISETRON HYDROCHLORIDE	Capsule 5 mg (base)	1	\N	2
1535	N06AB06	SERTRALINE HYDROCHLORIDE	Tablet 100 mg (base)	1	\N	30
1536	P03AC04	PERMETHRIN	Cream 50 mg per g (5%), 30 g	1	\N	1
1537	L04AA06	MYCOPHENOLATE MOFETIL	Capsule 250 mg	1	\N	100
1538	J01MA02	CIPROFLOXACIN	Tablet 250 mg	1	\N	14
1539	M05BA04	ALENDRONATE SODIUM	Tablet equivalent to 70 mg alendronic acid	1	\N	4
1540	G03XA01	DANAZOL	Capsule 200 mg	1	\N	100
1541	A07AA09	VANCOMYCIN	Capsule 125 mg (125,000 i.u.) vancomycin activity	1	\N	20
1542	P02BA01	PRAZIQUANTEL	Tablet 600 mg	1	\N	8
1543	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Powder 400 g	1	\N	1
1544	D01AC02	MICONAZOLE NITRATE	Lotion 20 mg per mL (2%), 30 g	1	\N	1
1545	V03AE02	SEVELAMER HYDROCHLORIDE	Tablet 800 mg	1	\N	180
1546	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 5 mg (base)-80 mg (base)	1	\N	30
1547	N07BC02	METHADONE HYDROCHLORIDE	Injection 10 mg in 1 mL	1	\N	5
1548	R03BA05	FLUTICASONE PROPIONATE	Powder for oral inhalation in breath actuated device 500 micrograms per dose (60 doses)	1	\N	1
1549	V07AY	DRESSING-HYDROFIBRE (ALTERNATE TO ALGINATES)	Dressings 10 cm x 10 cm, 10	1	\N	1
1550	D09AX	DRESSING-GAUZE-PARAFFIN with CHLORHEXIDINE ACETATE	Dressings 10 cm x 10 cm, 10	1	\N	1
1551	L01DB03	EPIRUBICIN HYDROCHLORIDE	Solution for injection 50 mg in 25 mL	1	\N	1
1552	V07AY	GAUZE and COTTON TISSUE (COMBINE ROLL)	Wrapped pack 9 cm x 10 m	1	\N	1
1553	S01ED01	TIMOLOL MALEATE	Eye gel 1 mg (base) per g (0.1%), 5 g	1	\N	1
1554	H02AB09	HYDROCORTISONE	Tablet 20 mg	1	\N	60
1555	N05AB04	PROCHLORPERAZINE	Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	1	\N	10
1556	A06AC53	STERCULIA with FRANGULA BARK	Granules 620 mg-80 mg per g (62%-8%), 500 g	1	\N	1
1557	D01AE15	TERBINAFINE	Gel 10 mg per g (1%), 15 g	1	\N	1
1558	A10BB07	GLIPIZIDE	Tablet 5 mg	1	\N	100
1559	J01FA10	AZITHROMYCIN	Tablet 600 mg	1	\N	8
1560	S01AA01	CHLORAMPHENICOL	Eye ointment 10 mg per g (1%), 4 g	1	\N	1
1561	D05BB02	ACITRETIN	Capsule 10 mg	1	\N	100
1562	A04AA01	ONDANSETRON	I.V. injection 4 mg in 2 mL	1	\N	1
1563	N04BC01	BROMOCRIPTINE MESYLATE	Capsule 5 mg (base)	1	\N	60
1564	C01DA08	ISOSORBIDE DINITRATE	Tablet 10 mg	1	\N	100
1565	N05AA01	CHLORPROMAZINE HYDROCHLORIDE	Mixture 25 mg per 5 mL, 100 mL	1	\N	1
1566	C03CA01	FRUSEMIDE	Tablet 40 mg	1	\N	100
1567	N02BG	PREGABALIN	Capsule 150 mg	1	\N	56
1568	C02KX01	BOSENTAN MONOHYDRATE	Tablet 62.5 mg (base)	1	\N	60
1569	N04AC01	BENZTROPINE MESYLATE	Injection 2 mg in 2 mL	1	\N	5
1570	N06AA04	CLOMIPRAMINE HYDROCHLORIDE	Tablet 25 mg	1	\N	50
1571	A02BA02	RANITIDINE HYDROCHLORIDE	Tablet 300 mg (base)	1	\N	30
1572	C05AX04	ZINC OXIDE	Compound suppositories, 12	1	\N	1
1573	C09AA10	TRANDOLAPRIL	Capsule 4 mg	1	\N	28
1574	V07AY	DRESSING with CADEXOMER IODINE	Sachets 17 g (10 cm x 8 cm), 2	1	\N	1
1575	C01BB02	MEXILETINE HYDROCHLORIDE	Capsule 50 mg	1	\N	100
1576	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Non-adhesive waterproof semi-permeable absorbent foam pads 15 cm x 15 cm, 5	1	\N	1
1577	L04AA18	EVEROLIMUS	Tablet 0.75 mg	1	\N	60
1578	A07AA02	NYSTATIN	Capsule 500,000 units	1	\N	50
1579	N06DA04	GALANTAMINE HYDROBROMIDE	Capsule 24 mg (base) (prolonged release)	1	\N	28
1580	N06AX	LITHIUM CARBONATE	Tablet 450 mg (slow release)	1	\N	100
1581	N03AG01	SODIUM VALPROATE	Crushable tablet 100 mg	1	\N	100
1582	B01AB04	DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium-porcine mucous)	Injection 5,000 units (anti-Xa) in 0.2 mL single dose pre-filled syringe	1	\N	10
1583	D07AC14	METHYLPREDNISOLONE ACEPONATE	Ointment 1 mg per g (0.1%), 15 g	1	\N	1
1584	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 120 micrograms in 0.3 mL pre-filled syringe	1	\N	1
1585	V07AY	DRESSING-FILM	Dressings 10 cm x 12 cm, 10	1	\N	1
1586	J01CE02	PHENOXYMETHYLPENICILLIN	Tablet 250 mg	1	\N	25
1587	N03AX18	LACOSAMIDE	Tablets 100 mg, 14	1	\N	1
1588	N05AA01	CHLORPROMAZINE HYDROCHLORIDE	Injection 50 mg in 2 mL	1	\N	10
1589	M01CB03	AURANOFIN	Tablet 3 mg	1	\N	60
1590	V07AY	DRESSING with CADEXOMER IODINE	Sachets 10 g (8 cm x 6 cm), 3	1	\N	1
1591	N02AA05	OXYCODONE HYDROCHLORIDE	Capsule 5 mg	1	\N	20
1592	V03AC01	DESFERRIOXAMINE MESYLATE	Powder for injection 2 g	1	\N	1
1593	N05AX08	RISPERIDONE	Powder for I.M. injection 25 mg (modified release) with 2 mL diluent in pre-filled syringe	1	\N	1
1594	C09BA02	ENALAPRIL MALEATE with HYDROCHLOROTHIAZIDE	Tablet 20 mg-6 mg	1	\N	30
1595	J01DD01	CEFOTAXIME	Powder for injection 1 g	1	\N	10
1596	S01EC04	BRINZOLAMIDE	Eye drops 10 mg per mL (1%), 5 mL	1	\N	1
1597	J01CE01	BENZYLPENICILLIN	Powder for injection 3 g	1	\N	1
1598	N04AA01	BENZHEXOL HYDROCHLORIDE	Tablet 5 mg	1	\N	200
1599	R03BB01	IPRATROPIUM BROMIDE	Oral pressurised inhalation 21 micrograms per dose (200 doses), CFC-free formulation	1	\N	1
1600	M01AC01	PIROXICAM	Capsule 10 mg	1	\N	50
1601	N05BA12	ALPRAZOLAM	Tablet 250 micrograms	1	\N	50
1602	B05BB01	SODIUM CHLORIDE	I.V. infusion 513 mmol per L (3%), 1 L	1	\N	1
1603	C09BA09	FOSINOPRIL SODIUM with HYDROCHLOROTHIAZIDE	Tablet 10 mg-12.5 mg	1	\N	30
1604	A06AB02	BISACODYL	Suppositories 10 mg, 12	1	\N	1
1606	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 130 mL, 30	1	\N	1
1607	H02AB07	PREDNISONE	Tablet 25 mg	1	\N	30
1608	D07AA02	HYDROCORTISONE ACETATE	Topical ointment 10 mg per g (1%), 50 g	1	\N	1
1609	C08DA01	VERAPAMIL HYDROCHLORIDE	Tablet 160 mg	1	\N	60
1610	J01FF01	CLINDAMYCIN	Capsule 150 mg	1	\N	24
1611	G03GA06	FOLLITROPIN BETA	Solution for injection 900 i.u. in 1.08 mL multi-dose cartridge	1	\N	1
1612	V06DX	TYROSINE with CARBOHYDRATE	Sachets 4 g containing 1 g tyrosine, 30	1	\N	1
1613	H05BX01	CINACALCET HYDROCHLORIDE	Tablet 30 mg (base)	1	\N	28
1614	M05BA07	RISEDRONATE SODIUM	Tablet 5 mg	1	\N	28
1615	C03CA01	FRUSEMIDE	Injection 20 mg in 2 mL	1	\N	5
1616	D02AE01	UREA	Cream 100 mg per g (10%), 100 g	1	\N	1
1617	B01AB04	DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium-porcine mucous)	Injection 10,000 units (anti-Xa) in 1 mL single dose pre-filled syringe	1	\N	10
1618	B03XA02	DARBEPOETIN ALFA	Injection 80 micrograms in 0.4 mL pre-filled injection pen	1	\N	1
1619	C07AG01	LABETALOL HYDROCHLORIDE	Tablet 100 mg	1	\N	100
1620	P01AB01	METRONIDAZOLE	Tablet 400 mg	1	\N	21
1621	N02AA01	MORPHINE SULFATE	Tablet 5 mg (controlled release)	1	\N	20
1622	C01DA14	ISOSORBIDE MONONITRATE	Tablet 120 mg (sustained release)	1	\N	30
1623	N03AX11	TOPIRAMATE	Capsule 25 mg	1	\N	60
1624	A02BC03	LANSOPRAZOLE	Capsule 30 mg	1	\N	28
1625	A04AD	PROMETHAZINE HYDROCHLORIDE	Injection 50 mg in 2 mL	1	\N	5
1626	A04AA01	ONDANSETRON	Wafer 8 mg	1	\N	4
1627	V07AY	DRESSING-ACTIVATED CHARCOAL (MALODOROUS WOUND)	Dressing 10.5 cm x 10.5 cm	1	\N	1
1628	G03GA06	FOLLITROPIN BETA	Solution for injection 600 i.u. in 0.72 mL multi-dose cartridge	1	\N	1
1629	L01BC02	FLUOROURACIL	Injection 500 mg in 10 mL	1	\N	5
1630	V07AY	BANDAGE-RETENTION-COHESIVE-HEAVY	Bandage 7.5 cm x 1.3 m	1	\N	1
1631	N06AX11	MIRTAZAPINE	Tablet 45 mg	1	\N	30
1632	H05AA02	TERIPARATIDE	Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen	1	\N	1
1633	P01BA02	HYDROXYCHLOROQUINE SULFATE	Tablet 200 mg	1	\N	100
1634	R06AX13	LORATADINE	Tablet 10 mg	1	\N	30
1635	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 2 mg	1	\N	20
1636	R03BA01	BECLOMETHASONE DIPROPIONATE	Oral pressurised inhalation 50 micrograms per dose (200 doses), CFC-free formulation	1	\N	1
1637	L02AE02	LEUPRORELIN ACETATE	Suspension for subcutaneous injection (modified release), 45 mg injection set	1	\N	1
1638	L01CB01	ETOPOSIDE	Capsule 50 mg	1	\N	20
1639	C01DX16	NICORANDIL	Tablets 10 mg, 60	1	\N	1
1640	N03AF02	OXCARBAZEPINE	Tablet 300 mg	1	\N	100
1641	A10BD03	ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE	Tablet 2 mg (base)-500 mg	1	\N	56
1642	C09AA10	TRANDOLAPRIL	Capsule 2 mg	1	\N	28
1643	A10AD01	INSULIN NEUTRAL-INSULIN ISOPHANE (N.P.H.), (MIXED) (Biphasic Isophane)	Injection (human) 100 units (30 units-70 units) per mL, 10 mL	1	\N	1
1644	D01AC08	KETOCONAZOLE	Cream 20 mg per g (2%), 30 g	1	\N	1
1645	L04AX03	METHOTREXATE	Tablet 2.5 mg	1	\N	30
1646	R01AD05	BUDESONIDE	Aqueous nasal spray (pump pack) 64 micrograms per dose (120 doses)	1	\N	1
1647	V07AY	DRESSING-ALGINATE (CAVITY WOUND)	Rope 2 g	1	\N	5
1648	A10BD07	SITAGLIPTIN with METFORMIN HYDROCHLORIDE	Tablet 50 mg (as phosphate monohydrate)-500 mg	1	\N	56
1649	N02AA01	MORPHINE SULFATE	Tablet 10 mg	1	\N	20
1650	C02KX	EPOPROSTENOL SODIUM	Powder for I.V. infusion 500 micrograms (base) with diluent	1	\N	1
1651	M01AE02	NAPROXEN	Tablet 500 mg	1	\N	50
1652	N05BA12	ALPRAZOLAM	Tablet 1 mg	1	\N	50
1653	G04BD04	OXYBUTYNIN HYDROCHLORIDE	Tablet 5 mg	1	\N	100
1654	R03AC13	EFORMOTEROL FUMARATE DIHYDRATE	Powder for oral inhalation in breath actuated device 12 micrograms per dose (60 doses)	1	\N	1
1655	A10AE05	INSULIN DETEMIR	Injections (human analogue) 100 units per mL, 3 mL, 5	1	\N	1
1656	L01AB01	BUSULFAN	Tablet 2 mg	1	\N	100
1657	V07AY	TAPES-PLASTER ADHESIVE HYPOALLERGENIC	Roll 5 cm x 5 m	1	\N	1
1658	J05AG01	NEVIRAPINE	Tablet 200 mg	1	\N	60
1659	N06AA10	NORTRIPTYLINE HYDROCHLORIDE	Tablet 25 mg (base)	1	\N	50
1660	J05AB11	VALACICLOVIR HYDROCHLORIDE	Tablet 500 mg (base)	1	\N	42
1661	V06DX	CARBOHYDRATE, FAT, VITAMINS, MINERALS and TRACE ELEMENTS	Powder 400 g	1	\N	1
1662	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 10 mg (base)-80 mg (base)	1	\N	30
1663	M01AC06	MELOXICAM	Tablet 15 mg	1	\N	30
1664	H02AB04	METHYLPREDNISOLONE SODIUM SUCCINATE	Powder for injection equivalent to 40 mg methylprednisolone with diluent	1	\N	5
1665	N03AX16	PREGABALIN	Capsule 150 mg	1	\N	56
1666	V07AY	DRESSING-FOAM-HEAVY EXUDATE	Dressings 20 cm x 15 cm, 10	1	\N	1
1667	A03FA03	DOMPERIDONE	Tablet 10 mg	1	\N	25
1668	J01AA02	DOXYCYCLINE	Capsule 100 mg (as hydrochloride)	1	\N	21
1669	L01BB04	CLADRIBINE	Solution for I.V. infusion 10 mg in 10 mL	1	\N	7
1670	A04AA01	ONDANSETRON	Tablet 8 mg	1	\N	10
1671	C07AB07	BISOPROLOL FUMARATE	Tablet 2.5 mg	1	\N	28
1672	B05BA03	GLUCOSE	I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL	1	\N	1
1673	L02BB	CYPROTERONE ACETATE	Tablet 50 mg	1	\N	50
1674	C07AG01	LABETALOL HYDROCHLORIDE	Tablet 200 mg	1	\N	100
1675	C08DA01	VERAPAMIL HYDROCHLORIDE	Tablet 80 mg	1	\N	100
1676	A02BD05	OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLIN	Pack containing 14 capsules omeprazole 20 mg, 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg	1	\N	1
1677	J01DB01	CEPHALEXIN	Capsule 250 mg	1	\N	20
1678	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 20 mg (controlled release)	1	\N	20
1679	H02AB08	TRIAMCINOLONE ACETONIDE	Injection 10 mg in 1 mL	1	\N	5
1680	N03AX11	TOPIRAMATE	Capsule 50 mg	1	\N	60
1681	N05CD03	FLUNITRAZEPAM	Tablet 1 mg	1	\N	30
1682	J05AE08	ATAZANAVIR	Capsule 200 mg (as sulfate)	1	\N	60
1683	A07EC02	MESALAZINE	Tablet 500 mg (prolonged release)	1	\N	100
1684	S01EB01	PILOCARPINE HYDROCHLORIDE	Eye drops 10 mg per mL (1%), 15 mL	1	\N	1
1685	S01EC	DORZOLAMIDE HYDROCHLORIDE with TIMOLOL MALEATE	Eye drops 20 mg (base)-5 mg (base) per mL (2%-0.5%), 5 mL	1	\N	1
1686	G03CA03	OESTRADIOL	Transdermal patches 2 mg (releasing approximately 25 micrograms per 24 hours), 4	1	\N	1
1687	N05AA01	CHLORPROMAZINE HYDROCHLORIDE	Tablet 100 mg	1	\N	100
1688	G04BX	PHENOXYBENZAMINE HYDROCHLORIDE	Capsules 10 mg, 30	1	\N	1
1689	B03XA02	DARBEPOETIN ALFA	Injection 40 micrograms in 0.4 mL pre-filled injection pen	1	\N	1
1690	D07AC01	BETAMETHASONE VALERATE	Ointment 200 micrograms (base) per g (0.02%), 100 g	1	\N	1
1691	M01AE03	KETOPROFEN	Capsule 200 mg (sustained release)	1	\N	28
1692	G03AC03	LEVONORGESTREL	Tablets 30 micrograms, 28	1	\N	4
1693	N05AL05	AMISULPRIDE	Tablet 100 mg	1	\N	30
1694	A04AD	PROMETHAZINE HYDROCHLORIDE	Oral liquid 5 mg per 5 mL, 100 mL	1	\N	1
1695	N05AF01	FLUPENTHIXOL DECANOATE	Oily I.M. injection 20 mg in 1 mL	1	\N	5
1696	L03AB61	RIBAVIRIN and PEGINTERFERON ALFA-2a	Pack containing 112 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 180 micrograms	1	\N	1
1697	J01XD01	METRONIDAZOLE	I.V. infusion 500 mg in 100 mL	1	\N	1
1698	N02BG	GABAPENTIN	Tablet 600 mg	1	\N	100
1699	L04AB04	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled syringe	1	\N	2
1700	C09CA02	EPROSARTAN MESYLATE	Tablet 600 mg (base)	1	\N	28
1701	B01AD11	TENECTEPLASE	Powder for injection 40 mg with solvent	1	\N	1
1702	G03HA01	CYPROTERONE ACETATE	Tablet 50 mg	1	\N	50
1703	C02DB02	HYDRALAZINE HYDROCHLORIDE	Tablet 50 mg	1	\N	100
1704	V07AY	BANDAGE-RETENTION-COHESIVE-LIGHT	Bandages 2.5 cm x 4 m, 2	1	\N	1
1705	V06DX	ISOLEUCINE with CARBOHYDRATE	Sachets 4 g containing 1 g isoleucine, 30	1	\N	1
1706	N02AA01	MORPHINE SULFATE	Sachet containing controlled release granules for oral suspension, 100 mg per sachet	1	\N	20
1707	A02BC01	OMEPRAZOLE	Tablet 20 mg	1	\N	30
1708	N06BA09	ATOMOXETINE HYDROCHLORIDE	Capsule 10 mg (base)	1	\N	28
1709	V07AY	BANDAGE-TUBULAR (LIGHTWEIGHT)	Bandage, medium limb size (green), 10 m	1	\N	1
1710	N05AX08	RISPERIDONE	Powder for I.M. injection 50 mg (modified release) with 2 mL diluent in pre-filled syringe	1	\N	1
1711	D07AC01	BETAMETHASONE DIPROPIONATE	Ointment 500 micrograms (base) per g (0.05%), 15 g	1	\N	1
1712	N06DA03	RIVASTIGMINE HYDROGEN TARTRATE	Capsule 4.5 mg (base)	1	\N	56
1713	V06DX	ESSENTIAL AMINO ACIDS FORMULA with MINERALS and VITAMIN C	Powder 400 g	1	\N	1
1714	D07AA02	HYDROCORTISONE ACETATE	Cream 10 mg per g (1%), 50 g	1	\N	1
1715	A07EC02	MESALAZINE	Tablet 250 mg (enteric coated)	1	\N	100
1716	S02AA30	NEOMYCIN UNDECENOATE with BACITRACIN ZINC	Ear ointment 12 mg (3.5 mg base)-400 units per g, 10 g	1	\N	1
1717	L01AC01	THIOTEPA	Powder for injection 15 mg	1	\N	1
1718	G02CB04	QUINAGOLIDE HYDROCHLORIDE	Tablet 75 micrograms (base)	1	\N	30
1719	S01AA26	AZITHROMYCIN	Powder for oral suspension 200 mg per 5 mL, 15 mL	1	\N	1
1720	C10AC02	COLESTIPOL HYDROCHLORIDE	Sachets 5 g, 120	1	\N	1
1721	N05AH03	OLANZAPINE	Tablet 2.5 mg	1	\N	28
1722	L01XE01	IMATINIB	Tablet 100 mg (as mesylate)	1	\N	60
1723	D09AA	DRESSING with CADEXOMER IODINE	Tubes 10 g, 4	1	\N	1
1724	N06BA07	MODAFINIL	Tablet 100 mg	1	\N	60
1725	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 80 mg (controlled release)	1	\N	20
1726	V07AY	BANDAGE-TUBULAR	Bandage 8.75 cm x 1 m	1	\N	1
1727	J05AE08	ATAZANAVIR	Capsule 150 mg (as sulfate)	1	\N	60
1728	L01DB01	DOXORUBICIN HYDROCHLORIDE, PEGYLATED LIPOSOMAL	Suspension for I.V. infusion 50 mg in 25 mL	1	\N	1
1729	L01XA02	CARBOPLATIN	Solution for I.V. injection 450 mg in 45 mL	1	\N	1
1730	N07AA02	PYRIDOSTIGMINE BROMIDE	Tablet 180 mg (modified release)	1	\N	100
1731	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 10 mg (base)-40 mg (base)	1	\N	30
1732	C08CA05	NIFEDIPINE	Tablet 10 mg	1	\N	60
1733	J01CE10	PHENOXYMETHYLPENICILLIN	Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL	1	\N	1
1734	L01CA04	VINORELBINE TARTRATE	Solution for I.V. infusion 10 mg (base) in 1 mL	1	\N	1
1735	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-LIGHT EXUDATE)	Dressings 5 cm x 6 cm, 10	1	\N	1
1736	D07AC01	BETAMETHASONE VALERATE	Cream 1 mg (base) per g (0.1%), 30 g	1	\N	1
1737	D09AX	DRESSING-GAUZE-PARAFFIN	Dressings 10 cm x 10 cm, 10	1	\N	1
1738	B05CB01	SODIUM CHLORIDE	Irrigation solution 9 mg per mL (0.9%), 1 L	1	\N	1
1739	C09DB01	AMLODIPINE with VALSARTAN	Tablet 5 mg (as besylate)-80 mg	1	\N	28
1740	M05BB04	RISEDRONATE SODIUM and CALCIUM CARBONATE with COLECALCIFEROL	Pack containing 4 tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g	1	\N	1
1741	G03BA03	TESTOSTERONE ESTERS	Injection 100 mg	1	\N	1
1742	C01BC04	FLECAINIDE ACETATE	Tablet 100 mg	1	\N	60
1743	C02AC01	CLONIDINE	Tablet 100 micrograms	1	\N	100
1744	S01AA11	GENTAMICIN SULFATE	Eye drops 3 mg (base) per mL (0.3%), 5 mL	1	\N	1
1745	A04AA02	GRANISETRON HYDROCHLORIDE	Concentrated injection 3 mg (base) in 3 mL	1	\N	1
1746	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 10 mg (base)-20 mg (base)	1	\N	30
1747	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 32 mg (modified release)	1	\N	10
1748	M05BA01	DISODIUM ETIDRONATE	Tablet 200 mg	1	\N	60
1749	G03CA03	OESTRADIOL	Transdermal patches 5.7 mg (releasing approximately 75 micrograms per 24 hours), 4	1	\N	1
1750	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 200 mg (twice daily sustained release)	1	\N	20
1751	S02DC	DOCUSATE SODIUM	Ear drops 5 mg per mL (0.5%), 10 mL	1	\N	1
1752	M02AC	METHYL SALICYLATE	Ointment BP, 100 g	1	\N	1
1753	S01EB01	PILOCARPINE HYDROCHLORIDE	Eye drops 20 mg per mL (2%), 15 mL	1	\N	1
1754	N06AG02	MOCLOBEMIDE	Tablet 300 mg	1	\N	60
1755	C09DA06	CANDESARTAN CILEXETIL with HYDROCHLOROTHIAZIDE	Tablet 32 mg-12.5 mg	1	\N	30
1756	L01AX03	TEMOZOLOMIDE	Capsule 100 mg	1	\N	5
1757	L01BA01	METHOTREXATE	Tablet 10 mg	1	\N	15
1758	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Sachets 27.8 g, 30	1	\N	1
1759	B01AB05	ENOXAPARIN SODIUM	Injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL pre-filled syringe	1	\N	10
1760	L04AX01	AZATHIOPRINE	Tablet 25 mg	1	\N	100
1761	N06AB04	CITALOPRAM HYDROBROMIDE	Tablet 40 mg (base)	1	\N	28
1762	J05AR03	TENOFOVIR with EMTRICITABINE	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	1	\N	30
1763	S02AA01	CHLORAMPHENICOL	Ear drops (aqueous) 5 mg per mL (0.5%), 5 mL	1	\N	1
1764	A12BA01	POTASSIUM CHLORIDE	Tablet 600 mg (sustained release)	1	\N	200
1765	V07AY	DRESSING-ALGINATE (SUPERFICIAL WOUND)	Dressing 5 cm x 5 cm	1	\N	1
1766	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 1.4 mg (4.2 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
1767	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Dressings, island, 18 cm x 18 cm, 5	1	\N	1
1768	G03XC01	RALOXIFENE HYDROCHLORIDE	Tablet 60 mg	1	\N	28
1769	C09AA04	PERINDOPRIL	Tablet containing 2 mg perindopril erbumine	1	\N	30
1770	B01AC06	ASPIRIN	Tablet 100 mg	1	\N	112
1771	G03CA04	OESTRIOL	Vaginal cream 1 mg per g (0.1%), 15 g	1	\N	1
1772	G03BA03	TESTOSTERONE ESTERS	Injection 250 mg	1	\N	1
1773	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Injection 10 mg in 1 mL	1	\N	5
1774	N04BA03	LEVODOPA with CARBIDOPA and ENTACAPONE	Tablet 125 mg-31.25 mg-200 mg	1	\N	100
1775	B01AC06	ASPIRIN	Tablet 100 mg (with glycine)	1	\N	90
1776	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)	1	\N	1
1777	B05BB01	SODIUM CHLORIDE	I.V. infusion 38.5 mmol per 250 mL (0.9%), 250 mL	1	\N	1
1778	V07AY	DRESSING-FOAM with SILICONE-MODERATE EXUDATE	Dressings 10 cm x 10 cm, 5	1	\N	1
1779	J05AF01	ZIDOVUDINE	Capsule 250 mg	1	\N	60
1780	H01AB01	THYROTROPIN ALFA	Powder for injection 0.9 mg, 2	1	\N	1
1781	A07EC02	MESALAZINE	Suppositories 1 g, 28	1	\N	1
1782	B05BA03	GLUCOSE	I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L	1	\N	1
1783	V07AY	DRESSING-HYDROACTIVE (CAVITY WOUND)	Dressings 5 cm x 6 cm, 10	1	\N	1
1784	N07BC01	BUPRENORPHINE HYDROCHLORIDE	Sublingual tablet 400 micrograms (base)	1	\N	7
1785	N07BC01	BUPRENORPHINE HYDROCHLORIDE	Sublingual tablet 8 mg (base)	1	\N	7
1786	G02CB01	BROMOCRIPTINE MESYLATE	Tablet 2.5 mg (base)	1	\N	60
1787	V07AY	DRESSING-HYDROFIBRE (ALTERNATE TO ALGINATES)	Ropes 2 g (30 cm), 5	1	\N	1
1788	L01BA01	METHOTREXATE	Solution concentrate for I.V. infusion 5000 mg in 50 mL	1	\N	1
1789	N04BA03	LEVODOPA with CARBIDOPA and ENTACAPONE	Tablet 75 mg-18.75 mg-200 mg	1	\N	100
1790	D06BB10	IMIQUIMOD	Cream 50 mg per g (5%), 250 mg single use sachets, 12	1	\N	1
1791	G03DA04	PROGESTERONE	Vaginal gel (prolonged release) 90 mg in single dose pre-filled applicator	1	\N	15
1792	D01AE18	TOLNAFTATE	Spray aerosol 10 mg per g (1%), 100 g	1	\N	1
1793	C10AA03	PRAVASTATIN	Tablet containing pravastatin sodium 20 mg	1	\N	30
1794	C03CA01	FRUSEMIDE	Tablet 20 mg	1	\N	100
1795	A10AB01	INSULIN NEUTRAL	Injection (human) 100 units per mL, 10 mL	1	\N	1
1796	L01CD01	PACLITAXEL	Solution concentrate for I.V. infusion 300 mg in 50 mL	1	\N	1
1797	L03AB60	RIBAVIRIN and PEGINTERFERON ALFA-2b	Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection	1	\N	1
1798	L01DB06	IDARUBICIN HYDROCHLORIDE	Solution for I.V. injection 5 mg in 5 mL	1	\N	3
1799	N05AB02	FLUPHENAZINE DECANOATE	Injection 12.5 mg in 0.5 mL	1	\N	5
1800	V07AY	BANDAGE-COMPRESSION	Bandage, two layer, 22 cm-28 cm (yellow)	1	\N	1
1801	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 125 mL, 30	1	\N	1
1802	J01MA02	CIPROFLOXACIN	Tablet 750 mg	1	\N	14
1803	V07AY	DRESSING-FOAM-MODERATE EXUDATE	Dressings 12.5 cm x 12.5 cm, 10	1	\N	1
1804	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Injection 500 mg in 50 mL	1	\N	1
1805	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 62.5 mL, 60	1	\N	1
1806	D11AH02	PIMECROLIMUS	Cream 10 mg per g (1%), 15 g	1	\N	1
1807	L01BC02	FLUOROURACIL	Cream 50 mg per g (5%), 20 g	1	\N	1
1808	J02AC03	VORICONAZOLE	Powder for oral suspension 40 mg per mL, 70 mL	1	\N	1
1809	L01XE05	SORAFENIB	Tablet 200 mg (as tosylate)	1	\N	60
1810	L02BG04	LETROZOLE	Tablet 2.5 mg	1	\N	30
1811	C09AA04	PERINDOPRIL	Tablet containing 8 mg perindopril erbumine	1	\N	30
1812	B05AA07	HYDROXYETHYL STARCH 130/0.4	I.V. infusion 30 g per 500 mL, 500 mL	1	\N	1
1813	J01MA02	CIPROFLOXACIN	Tablet 500 mg	1	\N	14
1814	J01FA06	ROXITHROMYCIN	Tablet 150 mg	1	\N	10
1815	R03AC02	SALBUTAMOL SULFATE	Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30	1	\N	1
1817	R03BC01	SODIUM CROMOGLYCATE	Oral pressurised inhalation 5 mg per dose (112 doses), CFC-free formulation	1	\N	1
1818	N07BA01	NICOTINE	Transdermal patches releasing approximately 15 mg per 16 hours, 7	1	\N	1
1819	N05AX08	RISPERIDONE	Tablet 1 mg	1	\N	60
1820	L01CD01	PACLITAXEL	Solution concentrate for I.V. infusion 30 mg in 5 mL	1	\N	5
1821	G04CA03	TERAZOSIN HYDROCHLORIDE	Starter pack containing 7 tablets 1 mg and 7 tablets 2 mg	1	\N	1
1822	C02KX	SILDENAFIL CITRATE	Tablet 20 mg (base)	1	\N	90
1823	G03AC08	ETONOGESTREL	Subcutaneous implant 68 mg	1	\N	1
1824	V01AA07	INSECT ALLERGEN EXTRACT-HONEY BEE VENOM	Injection set containing 550 micrograms	1	\N	1
1825	J01DC02	CEFUROXIME AXETIL	Tablet 250 mg (base)	1	\N	14
1826	N03AA02	PHENOBARBITONE SODIUM	Injection 200 mg in 1 mL	1	\N	5
1827	N07BA01	NICOTINE	Transdermal patch releasing approximately 15 mg per 16 hours	1	\N	28
1828	A10BD02	METFORMIN HYDROCHLORIDE with GLIBENCLAMIDE	Tablet 250 mg-1.25 mg	1	\N	90
1829	L01BB05	FLUDARABINE PHOSPHATE	Powder for I.V. injection 50 mg	1	\N	1
1830	J05AB01	ACICLOVIR	Tablet 200 mg	1	\N	25
1831	B03XA01	EPOETIN BETA	Injection 10,000 units in 0.6 mL pre-filled syringe	1	\N	6
1832	A06AH01	METHYLNALTREXONE	Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL	1	\N	7
1833	R03BA02	BUDESONIDE	Powder for oral inhalation in breath actuated device 400 micrograms per dose (200 doses)	1	\N	1
1834	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	Powder 500 g	1	\N	1
1835	L02AE02	LEUPRORELIN ACETATE	I.M. injection (modified release), powder for injection 22.5 mg with diluent in pre-filled dual-chamber syringe	1	\N	1
1836	N05AA01	CHLORPROMAZINE HYDROCHLORIDE	Tablet 10 mg	1	\N	100
1837	A06AG20	SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	1	\N	1
1838	C03DB01	AMILORIDE HYDROCHLORIDE	Tablet 5 mg	1	\N	50
1839	N02AA	CODEINE PHOSPHATE	Tablet 30 mg	1	\N	20
1840	V06D	TRIGLYCERIDES, MEDIUM CHAIN	Emulsion 250 mL	1	\N	1
1841	J05AB06	GANCICLOVIR SODIUM	Powder for I.V. infusion equivalent to 500 mg ganciclovir	1	\N	5
1842	C09BB10	TRANDOLAPRIL with VERAPAMIL HYDROCHLORIDE	Tablet 4 mg-240 mg (sustained release)	1	\N	28
1843	L01XC07	BEVACIZUMAB	Solution for I.V. infusion 400 mg in 16 mL	1	\N	1
1844	H03AA01	THYROXINE SODIUM	Tablet equivalent to 50 micrograms anhydrous thyroxine sodium	1	\N	200
1845	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 0.8 mg (2.4 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
1846	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	Sachets 20 g, 30	1	\N	1
1847	J07AM51	DIPHTHERIA and TETANUS VACCINE, ADSORBED, DILUTED FOR ADULT USE	Injection 0.5 mL in pre-filled syringe	1	\N	5
1848	G03CA03	OESTRADIOL VALERATE	Tablet 1 mg	1	\N	56
1849	N02AA05	OXYCODONE HYDROCHLORIDE	Tablet 5 mg	1	\N	20
1850	R03BC01	SODIUM CROMOGLYCATE	Oral pressurised inhalation 1 mg per dose (200 doses)	1	\N	1
1851	J05AR	LOPINAVIR with RITONAVIR	Tablet 200 mg-50 mg	1	\N	120
1852	G03CA03	OESTRADIOL	Transdermal patches 1.56 mg (releasing approximately 100 micrograms per 24 hours), 8	1	\N	1
1853	N03AX16	PREGABALIN	Capsule 25 mg	1	\N	56
1854	V07AY	BANDAGE-COMPRESSION	Bandage, high stretch, 7.5 cm x 3.5 m	1	\N	1
1855	N02CC01	SUMATRIPTAN	Tablet 50 mg (as succinate)	1	\N	2
1856	A01AD11	HYPROMELLOSE	Oral gel 20 mg per g, 100 g	1	\N	1
1857	N05AB06	TRIFLUOPERAZINE HYDROCHLORIDE	Tablet 2 mg (base)	1	\N	100
1858	L02BB01	FLUTAMIDE	Tablet 250 mg	1	\N	100
1859	A09AA02	PANCREATIC EXTRACT	Capsule (containing enteric coated minimicrospheres) providing not less than 40,000 BP units of lipase activity	1	\N	100
1860	C03DA04	EPLERENONE	Tablet 50 mg	1	\N	30
1861	V07AY	DRESSING-NON-ADHERENT	Dressings 5 cm x 7.5 cm, 10	1	\N	1
1862	L03AB08	INTERFERON BETA-1b	Injection set including 1 vial powder for injection 8,000,000 i.u. (250 micrograms) and solvent	1	\N	15
1863	C10AX09	EZETIMIBE	Tablet 10 mg	1	\N	30
1864	D06BA01	SILVER SULFADIAZINE	Cream 10 mg per g (1%), 50 g	1	\N	1
1865	J01CE02	PHENOXYMETHYLPENICILLIN	Tablet 500 mg	1	\N	25
1866	L01AA01	CYCLOPHOSPHAMIDE	Powder for injection 2 g	1	\N	1
1867	A06AD15	MACROGOL 3350	Sachets containing powder for solution 6.563 g with electrolytes, 30	1	\N	1
1868	L03AB11	PEGINTERFERON ALFA-2a	Injection 180 micrograms in 0.5 mL single use pre-filled syringe	1	\N	4
1869	N05AA01	CHLORPROMAZINE HYDROCHLORIDE	Tablet 25 mg	1	\N	100
1870	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	Sachets 25 g, 30	1	\N	1
1871	V03AF03	CALCIUM FOLINATE	Injection equivalent to 50 mg folinic acid in 5 mL	1	\N	5
1872	N06DA03	RIVASTIGMINE HYDROGEN TARTRATE	Capsule 1.5 mg (base)	1	\N	56
1873	L02AE	GOSERELIN ACETATE and BICALUTAMIDE	Pack containing 1 subcutaneous implant goserelin 10.8 mg in pre-filled injection syringe and 28 tablets bicalutamide 50 mg	1	\N	1
1874	V07AY	BANDAGE-RETENTION-COTTON CREPE	Bandage 7.5 cm x 2.3 m	1	\N	1
1875	M01CB01	SODIUM AUROTHIOMALATE	Injection 50 mg	1	\N	10
1876	N06AB05	PAROXETINE	Tablet 20 mg (as hydrochloride)	1	\N	30
1877	L04AB04	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled syringe, 6	1	\N	1
1878	D08AG02	POVIDONE-IODINE	Solution 100 mg per mL (10%), 100 mL	1	\N	1
1879	L03AA02	FILGRASTIM	Injection 300 micrograms in 0.5 mL single use pre-filled syringe	1	\N	10
1880	N05AX08	RISPERIDONE	Tablet 1 mg (orally disintegrating)	1	\N	28
1881	N05AH03	OLANZAPINE	Tablet 7.5 mg	1	\N	28
1882	C09BA04	PERINDOPRIL with INDAPAMIDE HEMIHYDRATE	Tablet containing 5 mg perindopril arginine-1.25 mg indapamide hemihydrate	1	\N	30
1883	V03AC03	DEFERASIROX	Tablet 250 mg (dispersible)	1	\N	28
1884	R03BA02	BUDESONIDE	Nebuliser suspension single dose units 1 mg in 2 mL, 30	1	\N	1
1885	D11AC30	SALICYLIC ACID with COAL TAR SOLUTION and PINE TAR	Scalp cleanser 20 mg-10 mg-10 mg per mL (2%-1%-1%), 250 mL	1	\N	1
1886	J01AA08	MINOCYCLINE	Tablet 50 mg	1	\N	60
1887	N04BC01	BROMOCRIPTINE MESYLATE	Capsule 10 mg (base)	1	\N	100
1888	N03AX12	GABAPENTIN	Capsule 400 mg	1	\N	100
1889	V07AY	TAPES-PLASTER ADHESIVE (WITH SILICONE)	Roll 4 cm x 1.5 m	1	\N	1
1890	N03AX09	LAMOTRIGINE	Tablet 100 mg	1	\N	56
1891	L01DB03	EPIRUBICIN HYDROCHLORIDE	Solution for injection 20 mg in 10 mL	1	\N	1
1892	L03AX03	BCG IMMUNOTHERAPEUTIC (Bacillus Calmette-Gue rin/ Connaught strain)	Single dose set comprising 1 vial powder for intravesical administration containing 6.6 to 19.2 x 10 8 CFU and 1 vial diluent 3 mL	1	\N	1
1893	M05BB01	DISODIUM ETIDRONATE and CALCIUM CARBONATE	Pack containing 28 tablets disodium etidronate 200 mg and 76 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium)	1	\N	1
1894	L01BB05	FLUDARABINE PHOSPHATE	Solution for I.V. injection 50 mg in 2 mL	1	\N	5
1895	C09CA07	TELMISARTAN	Tablet 40 mg	1	\N	28
1896	C07AB02	METOPROLOL SUCCINATE	Tablet 23.75 mg (controlled release)	1	\N	15
1897	D11AX	SKIN CLEANSER	Lotion 500 mL	1	\N	1
1898	A10BB12	GLIMEPIRIDE	Tablet 2 mg	1	\N	30
1899	J01CF05	FLUCLOXACILLIN	Capsule 250 mg (as sodium)	1	\N	24
1900	D06BB04	PODOPHYLLOTOXIN	Paint 5 mg per mL (0.5%), 3.5 mL (with 30 swabs)	1	\N	1
1901	M05BA03	DISODIUM PAMIDRONATE	Concentrated injection 60 mg in 10 mL	1	\N	1
1902	N02AA01	MORPHINE SULFATE	Tablet 30 mg (controlled release)	1	\N	20
1903	J05AB09	FAMCICLOVIR	Tablet 250 mg	1	\N	20
1904	G04BX	PHENOXYBENZAMINE HYDROCHLORIDE	Capsule 10 mg	1	\N	100
1905	L01BC06	CAPECITABINE	Tablet 150 mg	1	\N	60
1906	A10BF01	ACARBOSE	Tablet 50 mg	1	\N	90
1907	S01EC01	ACETAZOLAMIDE	Tablet 250 mg	1	\N	100
1908	A02AD01	ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE	Oral suspension 250 mg-120 mg-120 mg per 5 mL, 500 mL	1	\N	1
1909	G03DA02	MEDROXYPROGESTERONE ACETATE	Tablet 10 mg	1	\N	30
1910	L03AB60	RIBAVIRIN and PEGINTERFERON ALFA-2b	Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection	1	\N	1
1911	N06AX23	DESVENLAFAXINE SUCCINATE	Tablet 50 mg (base) (extended release)	1	\N	28
1912	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 100 micrograms in 0.3 mL pre-filled syringe	1	\N	1
1913	N05AD01	HALOPERIDOL DECANOATE	I.M. injection equivalent to 50 mg haloperidol in 1 mL	1	\N	5
1914	C03EA01	HYDROCHLOROTHIAZIDE with TRIAMTERENE	Tablet 25 mg-50 mg	1	\N	100
1915	N02AA01	MORPHINE HYDROCHLORIDE	Oral solution 5 mg per mL, 200 mL	1	\N	1
1916	G04BE08	TADALAFIL	Tablet 20 mg	1	\N	4
1917	J01XD01	METRONIDAZOLE	Tablet 200 mg	1	\N	21
1918	N04BC02	PERGOLIDE MESYLATE	Tablet 50 micrograms (base)	1	\N	100
1919	J05AF04	STAVUDINE	Capsule 30 mg	1	\N	60
1920	C07AA05	PROPRANOLOL HYDROCHLORIDE	Tablet 160 mg	1	\N	50
1921	N05AX08	RISPERIDONE	Tablet 4 mg	1	\N	60
1922	L04AX04	LENALIDOMIDE	Capsule 5 mg	1	\N	21
1923	L04AD02	TACROLIMUS	Capsule 5 mg	1	\N	50
1924	N05AH04	QUETIAPINE	Tablet (modified release) 300 mg (as fumarate)	1	\N	60
1925	B01AE06	BIVALIRUDIN TRIFLUOROACETATE	Powder for I.V. injection 250 mg (base)	1	\N	1
1926	N02AA05	OXYCODONE HYDROCHLORIDE	Capsule 20 mg	1	\N	20
1927	A02BC04	RABEPRAZOLE SODIUM	Tablet 10 mg (enteric coated)	1	\N	28
1928	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE)	Dressings, sacral, 5	1	\N	1
1929	J01AA02	DOXYCYCLINE	Tablet 50 mg (as hydrochloride)	1	\N	25
1930	L01XX05	HYDROXYUREA	Capsule 500 mg	1	\N	100
1931	L01XE08	NILOTINIB	Capsule 200 mg (as hydrochloride monohydrate)	1	\N	28
1932	A03AA04	MEBEVERINE HYDROCHLORIDE	Tablet 135 mg	1	\N	90
1933	B03XA01	EPOETIN BETA	Injection 3,000 units in 0.3 mL pre-filled syringe	1	\N	6
1934	B03XA01	EPOETIN ALFA	Injection 4,000 units in 0.4 mL pre-filled syringe	1	\N	6
1935	L02AE02	LEUPRORELIN ACETATE	I.M. injection (modified release), powder for injection 30 mg with diluent in pre-filled dual-chamber syringe	1	\N	1
1936	R03CA	ADRENALINE	I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector	1	\N	1
1937	A06AA02	DOCUSATE SODIUM	Tablet 50 mg	1	\N	100
1938	A04AA03	TROPISETRON HYDROCHLORIDE	I.V. injection 5 mg (base) in 5 mL	1	\N	1
1939	N06AX16	VENLAFAXINE HYDROCHLORIDE	Capsule 75 mg (base) (modified release)	1	\N	28
1940	L01XC07	BEVACIZUMAB	Solution for I.V. infusion 100 mg in 4 mL	1	\N	1
1941	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE	Infant formula, powder 400 g	1	\N	1
1942	A02BC02	PANTOPRAZOLE SODIUM SESQUIHYDRATE	Tablet (enteric coated), equivalent to 40 mg pantoprazole	1	\N	30
1943	M01CX	LEFLUNOMIDE	Tablet 20 mg	1	\N	30
1944	R06AD02	PROMETHAZINE HYDROCHLORIDE	Injection 50 mg in 2 mL	1	\N	5
1945	D09A	DRESSING with CADEXOMER IODINE	Sachets 5 g (6 cm x 4 cm), 5	1	\N	1
1946	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Sachets 50 g, 30	1	\N	1
1947	A10AB05	INSULIN ASPART	Injection (human analogue) 100 units per mL, 10 mL	1	\N	1
1948	N07AA02	PYRIDOSTIGMINE BROMIDE	Tablet 10 mg	1	\N	100
1949	L01CD02	DOCETAXEL	Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL	1	\N	1
1950	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 8 mg	1	\N	20
1951	G03CA03	OESTRADIOL	Vaginal tablets 25 micrograms, 15	1	\N	1
1952	C09AA03	LISINOPRIL	Tablet 10 mg	1	\N	30
1953	N03AX09	LAMOTRIGINE	Tablet 200 mg	1	\N	56
1954	L02BA01	TAMOXIFEN CITRATE	Tablet 20 mg (base)	1	\N	30
1955	J01GB01	TOBRAMYCIN SULFATE	Injection 500 mg (base) in 5 mL (without preservative)	1	\N	10
1956	B03XA01	EPOETIN ALFA	Injection 8,000 units in 0.8 mL pre-filled syringe	1	\N	6
1957	N03AE01	CLONAZEPAM	Tablet 500 micrograms	1	\N	100
1958	M01AC01	PIROXICAM	Dispersible tablet 20 mg	1	\N	25
1959	R03AK07	BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE	Powder for oral inhalation in breath actuated devices 400 micrograms-12 micrograms per dose (60 doses), 2	1	\N	1
1960	V07AY	DRESSING-HYDROACTIVE (DEBRIDEMENT)	Dressings 7.5 cm x 7.5 cm, 8	1	\N	1
1961	V07AY	DRESSING with SILVER	Hydroactive dressings non-adhesive 10 cm x 10 cm, 5	1	\N	1
1962	C09AA06	QUINAPRIL	Tablet 10 mg (as hydrochloride)	1	\N	30
1963	N02AX02	TRAMADOL HYDROCHLORIDE	Oral drops 100 mg per mL, 10 mL	1	\N	1
1964	N05AH04	QUETIAPINE	Tablet 100 mg (as fumarate)	1	\N	90
1965	L01XA03	OXALIPLATIN	Powder for I.V. infusion 50 mg	1	\N	1
1966	V07AY	TAPES-NON-WOVEN RETENTION (POLYACRYLATE)	Roll 2.5 cm x 9.1 m	1	\N	1
1967	B03XA02	DARBEPOETIN ALFA	Injection 150 micrograms in 0.3 mL pre-filled syringe	1	\N	4
1968	A04AA02	GRANISETRON HYDROCHLORIDE	Tablet 2 mg (base)	1	\N	5
1969	G03DA04	PROGESTERONE	Pessary 200 mg	1	\N	15
1970	N02BE01	PARACETAMOL	Suppositories 500 mg, 24	1	\N	1
1971	B03XA01	EPOETIN BETA	Injection 4,000 units in 0.3 mL pre-filled syringe	1	\N	6
1972	G03CA03	OESTRADIOL	Transdermal patches 390 micrograms (releasing approximately 25 micrograms per 24 hours), 8	1	\N	1
1973	J01AA02	DOXYCYCLINE	Tablet 100 mg (as hydrochloride)	1	\N	7
1974	G03AA05	NORETHISTERONE with ETHINYLOESTRADIOL	Tablets 500 micrograms-35 micrograms, 21	1	\N	1
1975	G03GA05	FOLLITROPIN ALFA	Injection set containing 10 vials powder for injection 75 i.u. and 10 pre-filled syringes solvent 1 mL	1	\N	1
1976	G04BE03	SILDENAFIL CITRATE	Tablet 25 mg (base)	1	\N	4
1977	N04BC06	CABERGOLINE	Tablet 2 mg	1	\N	30
1978	L03AB60	RIBAVIRIN and PEGINTERFERON ALFA-2b	Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection	1	\N	1
1979	A10AB04	INSULIN LISPRO	Injection (human analogue) 100 units per mL, 10 mL	1	\N	1
1980	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Tablet 27 mg (extended release)	1	\N	30
1981	V03AC03	DEFERASIROX	Tablet 125 mg (dispersible)	1	\N	28
1982	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 125 mL, 36	1	\N	1
1983	N05AC01	PERICYAZINE	Tablet 2.5 mg	1	\N	100
1984	C10AA05	ATORVASTATIN	Tablet 80 mg (as calcium)	1	\N	30
1985	A02BC01	OMEPRAZOLE	Tablet 10 mg (as magnesium)	1	\N	30
1986	B01AB05	ENOXAPARIN SODIUM	Injection 20 mg (2,000 i.u. anti-Xa) in 0.2 mL pre-filled syringe	1	\N	10
1987	N06AA12	DOXEPIN HYDROCHLORIDE	Capsule 10 mg (base)	1	\N	50
1988	R03AC13	EFORMOTEROL FUMARATE DIHYDRATE	Capsule containing powder for oral inhalation 12 micrograms (for use in Foradile Aerolizer)	1	\N	60
1989	J04AB02	RIFAMPICIN	Syrup 100 mg per 5 mL, 60 mL	1	\N	1
1990	L01XE04	SUNITINIB	Capsule 12.5 mg (as malate)	1	\N	28
1991	N05AX13	PALIPERIDONE	Tablet 9 mg (prolonged release)	1	\N	28
1992	J01FA01	ERYTHROMYCIN LACTOBIONATE	Powder for I.V. infusion 1 g (base)	1	\N	1
1993	L04AX03	METHOTREXATE	Tablet 10 mg	1	\N	15
1994	J01XE01	NITROFURANTOIN	Capsule 100 mg	1	\N	30
1995	R01AC02	LEVOCABASTINE HYDROCHLORIDE	Nasal spray 500 micrograms per mL (0.05%), 10 mL (100 doses)	1	\N	1
1996	A10BA02	METFORMIN HYDROCHLORIDE	Tablet 850 mg	1	\N	60
1997	C09AA01	CAPTOPRIL	Tablet 12.5 mg	1	\N	90
1998	A10BH01	SITAGLIPTIN	Tablet 25 mg (as phosphate monohydrate)	1	\N	28
1999	C09DA03	VALSARTAN with HYDROCHLOROTHIAZIDE	Tablet 80 mg-12.5 mg	1	\N	28
2000	M04AC01	COLCHICINE	Tablet 500 micrograms	1	\N	100
2001	R06AD02	PROMETHAZINE HYDROCHLORIDE	Oral liquid 5 mg per 5 mL, 100 mL	1	\N	1
2002	G03CA03	OESTRADIOL	Transdermal patches 8 mg (releasing approximately 100 micrograms per 24 hours), 8	1	\N	1
2003	B03XA02	DARBEPOETIN ALFA	Injection 80 micrograms in 0.4 mL pre-filled syringe	1	\N	4
2004	V06DX	AMINO ACID FORMULA without PHENYLALANINE	Sachets containing powder 20 g, 30	1	\N	1
2005	A07AA09	VANCOMYCIN	Capsule 250 mg (250,000 i.u.) vancomycin activity	1	\N	20
2006	V07AY	TAPES-NON-WOVEN RETENTION (POLYACRYLATE)	Roll 2.5 cm x 10 m	1	\N	1
2007	C08CA01	AMLODIPINE	Tablet 5 mg (as besylate)	1	\N	30
2008	A02BC04	RABEPRAZOLE SODIUM	Tablet 20 mg (enteric coated)	1	\N	30
2009	R06AX02	CYPROHEPTADINE HYDROCHLORIDE	Tablet 4 mg	1	\N	50
2010	N03AF01	CARBAMAZEPINE	Tablet 400 mg (controlled release)	1	\N	200
2011	N05AX08	RISPERIDONE	Tablet 0.5 mg	1	\N	20
2012	N05AB02	FLUPHENAZINE DECANOATE	Injection 25 mg in 1 mL	1	\N	5
2013	V07AY	DRESSING-HYDROGEL-AMORPHOUS	Tubes 30 g, 3	1	\N	1
2014	L02AB02	MEDROXYPROGESTERONE ACETATE	Tablet 200 mg	1	\N	60
2015	P02CC01	PYRANTEL EMBONATE	Tablet 250 mg (base)	1	\N	6
2016	B01AC11	ILOPROST TROMETAMOL	Solution for inhalation 20 micrograms (base) in 2 mL	1	\N	30
2017	C09AA01	CAPTOPRIL	Tablet 25 mg	1	\N	90
2018	N06BA02	DEXAMPHETAMINE SULFATE	Tablet 5 mg	1	\N	100
2019	G03GA01	HUMAN CHORIONIC GONADOTROPHIN	Powder for injection 5,000 units with solvent	1	\N	1
2020	N05AB06	TRIFLUOPERAZINE HYDROCHLORIDE	Tablet 1 mg (base)	1	\N	100
2021	C09CA06	CANDESARTAN CILEXETIL	Tablet 16 mg	1	\N	30
2022	R01AX06	MUPIROCIN	Nasal ointment 20 mg (as calcium) per g (2%), 3 g	1	\N	1
2023	C10BA02	EZETIMIBE with SIMVASTATIN	Tablet 10 mg-40 mg	1	\N	30
2024	C09AA04	PERINDOPRIL	Tablet containing 2.5 mg perindopril arginine	1	\N	30
2025	B03XA01	EPOETIN ALFA	Injection 3,000 units in 0.3 mL pre-filled syringe	1	\N	6
2026	N05AX08	RISPERIDONE	Tablet 3 mg	1	\N	60
2027	J05AF02	DIDANOSINE	Capsule 250 mg (containing enteric coated beadlets)	1	\N	30
2028	J05AF05	LAMIVUDINE	Tablet 300 mg	1	\N	30
2029	N05AH03	OLANZAPINE	Tablet 5 mg	1	\N	28
2030	A02BA02	RANITIDINE HYDROCHLORIDE	Tablet 150 mg (base)	1	\N	60
2031	C09BB05	RAMIPRIL with FELODIPINE	Tablet 5 mg-5 mg (modified release)	1	\N	30
2032	L04AX04	LENALIDOMIDE	Capsule 10 mg	1	\N	21
2033	B03XA01	EPOETIN BETA	Injection 2,000 units in 0.3 mL pre-filled syringe	1	\N	6
2034	V07AY	BANDAGE-ZINC PASTE	Bandage 10 cm x 9.1 m	1	\N	1
2035	L01XA02	CARBOPLATIN	Solution for I.V. injection 50 mg in 5 mL	1	\N	1
2036	J05AF04	STAVUDINE	Capsule 40 mg	1	\N	60
2037	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 4 mg (12 i.u.) vial with 3.5 mL diluent (with preservative)	1	\N	1
2038	N03AX09	LAMOTRIGINE	Tablet 25 mg	1	\N	56
2039	C08CA13	LERCANIDIPINE HYDROCHLORIDE	Tablet 10 mg	1	\N	28
2040	D02BA	SUNSCREENS	Cream 100 g	1	\N	1
2041	V07AY	GLOVES PLASTIC (DISPOSABLE)	Gloves, large, 100	1	\N	1
2042	R06AX26	FEXOFENADINE HYDROCHLORIDE	Tablet 60 mg	1	\N	20
2043	V03AC02	DEFERIPRONE	Tablet 500 mg	1	\N	100
2044	C09DA03	VALSARTAN with HYDROCHLOROTHIAZIDE	Tablet 160 mg-12.5 mg	1	\N	28
2045	A10BD02	METFORMIN HYDROCHLORIDE with GLIBENCLAMIDE	Tablet 500 mg-2.5 mg	1	\N	90
2046	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Injection 50 mg in 5 mL	1	\N	5
2047	A10BD07	SITAGLIPTIN with METFORMIN HYDROCHLORIDE	Tablet 50 mg (as phosphate monohydrate)-1000 mg	1	\N	56
2048	N06AB08	FLUVOXAMINE MALEATE	Tablet 100 mg	1	\N	30
2049	N02CA04	METHYSERGIDE	Tablet 1 mg	1	\N	50
2050	V03AE03	LANTHANUM CARBONATE HYDRATE	Chewable tablet 1000 mg (base)	1	\N	90
2051	G02BA03	LEVONORGESTREL	Intrauterine drug delivery system 52 mg (releasing approximately 20 micrograms per 24 hours)	1	\N	1
2052	N06AX	LITHIUM CARBONATE	Tablet 250 mg	1	\N	200
2053	N05AH04	QUETIAPINE	Tablet (modified release) 50 mg (as fumarate)	1	\N	60
2054	N07BC01	BUPRENORPHINE HYDROCHLORIDE	Sublingual tablet 2 mg (base)	1	\N	7
2055	B01AX06	RIVAROXABAN	Tablets 10 mg, 10	1	\N	1
2056	M01AB02	SULINDAC	Tablet 100 mg	1	\N	50
2057	C07AB03	ATENOLOL	Tablet 50 mg	1	\N	30
2058	G03DA02	MEDROXYPROGESTERONE ACETATE	Tablet 5 mg	1	\N	56
2059	S01GA51	ANTAZOLINE with NAPHAZOLINE	Eye drops 5 mg (sulfate)-250 micrograms (nitrate) per mL (0.5%-0.025%), 10 mL	1	\N	1
2060	C09AA02	ENALAPRIL MALEATE	Tablet 10 mg	1	\N	30
2061	C07AB07	BISOPROLOL FUMARATE	Tablet 5 mg	1	\N	28
2062	A04AA01	ONDANSETRON	Wafer 4 mg	1	\N	10
2063	G03CA04	OESTRIOL	Pessaries 500 micrograms, 15	1	\N	1
2064	C09CA04	IRBESARTAN	Tablet 75 mg	1	\N	30
2065	J05AF06	ABACAVIR SULFATE	Tablet 300 mg (base)	1	\N	60
2066	V07AY	BANDAGE-TUBULAR	Bandage 6.75 cm x 1 m	1	\N	1
2067	B01AC09	EPOPROSTENOL SODIUM	Powder for I.V. infusion 1.5 mg (base) with diluent	1	\N	1
2068	D09AB01	BANDAGE-ZINC PASTE	Bandages 80 cm (stockings), 4	1	\N	1
2069	V07AY	BANDAGE-TUBULAR	Bandage, straight, size E	1	\N	1
2070	C01DX	PERHEXILINE MALEATE	Tablet 100 mg	1	\N	100
2071	V07AY	BANDAGE-RETENTION-COHESIVE-LIGHT	Bandage 10 cm x 4 m	1	\N	1
2072	N05CF01	ZOPICLONE	Tablet 7.5 mg	1	\N	30
2073	J05AX09	MARAVIROC	Tablet 150 mg	1	\N	60
2074	H01BA02	DESMOPRESSIN ACETATE	Nasal spray (pump pack) 10 micrograms per actuation, 60 actuations, 6 mL	1	\N	1
2075	L03AB05	INTERFERON ALFA-2b	Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen	1	\N	1
2076	N06DX01	MEMANTINE HYDROCHLORIDE	Tablet 10 mg	1	\N	56
2077	J05AF01	ZIDOVUDINE	Syrup 10 mg per mL, 200 mL	1	\N	1
2078	N07BA01	NICOTINE	Transdermal patches releasing approximately 5 mg per 16 hours, 7	1	\N	1
2079	A06AB06	SENNA STANDARDISED	Tablet 7.5 mg	1	\N	100
2080	B03AD02	FERROUS FUMARATE with FOLIC ACID	Tablet 310 mg (equivalent to 100 mg iron)-350 micrograms	1	\N	60
2081	G03BA03	TESTOSTERONE	Subcutaneous implant 100 mg	1	\N	1
2082	M05BA07	RISEDRONATE SODIUM	Tablet 35 mg	1	\N	4
2083	N02AA01	MORPHINE SULFATE	Capsule 100 mg (containing sustained release pellets)	1	\N	20
2084	G03CA03	OESTRADIOL	Implant 50 mg	1	\N	1
2085	G03GA06	FOLLITROPIN BETA	Solution for injection 300 i.u. in 0.36 mL multi-dose cartridge	1	\N	1
2086	N02CX	CYPROHEPTADINE HYDROCHLORIDE	Tablet 4 mg	1	\N	50
2087	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 1.8 mg (5.4 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
2088	A06AD11	LACTULOSE	Mixture 3.34 g per 5 mL, 500 mL	1	\N	1
2089	V07AY	DRESSING-HYDROGEL-AMORPHOUS	Tube 50 g	1	\N	1
2090	C02AC05	MOXONIDINE	Tablet 400 micrograms	1	\N	30
2091	J01DD04	CEFTRIAXONE	Powder for injection 2 g	1	\N	1
2092	V06DX	CYSTINE with CARBOHYDRATE	Sachets 4 g containing 500 mg cystine, 30	1	\N	1
2093	J01FA01	ERYTHROMYCIN ETHYL SUCCINATE	Powder for oral liquid 200 mg (base) per 5 mL, 100 mL	1	\N	1
2094	J05AF04	STAVUDINE	Powder for oral solution 1 mg per mL, 200 mL	1	\N	1
2095	N05AH04	QUETIAPINE	Tablet (modified release) 200 mg (as fumarate)	1	\N	60
2096	S01XA20	HYPROMELLOSE with DEXTRAN	Eye drops 3 mg-1 mg per mL (0.3%-0.1%), single dose units 0.4 mL, 28	1	\N	1
2097	N02AA01	MORPHINE SULFATE	Tablet 200 mg (controlled release)	1	\N	20
2098	G03BA03	TESTOSTERONE ENANTHATE	Injection 250 mg in 1 mL	1	\N	3
2099	J01XA01	VANCOMYCIN	Powder for injection 1 g (1,000,000 i.u.) vancomycin activity	1	\N	1
2100	M05BA04	ALENDRONATE SODIUM	Tablet equivalent to 40 mg alendronic acid	1	\N	30
2101	A10BB09	GLICLAZIDE	Tablet 60 mg (modified release)	1	\N	60
2102	S03AA	FRAMYCETIN SULFATE	Eye and ear drops 5 mg per mL (0.5%), 8 mL	1	\N	1
2103	L01BA01	METHOTREXATE	Tablet 2.5 mg	1	\N	30
2104	A10AB06	INSULIN GLULISINE	Injections (human analogue) 100 units per mL, 3 mL, 5	1	\N	1
2105	J02AA01	AMPHOTERICIN	Powder for injection 50 mg	1	\N	1
2106	J05AR02	ABACAVIR SULFATE with LAMIVUDINE	Tablet 600 mg (base)-300 mg	1	\N	30
2107	V07AY	TAPES-PLASTER ADHESIVE ELASTIC	Roll 7.5 cm x 2.5 m	1	\N	1
2108	C10AA04	FLUVASTATIN	Capsule 20 mg (as sodium)	1	\N	28
2109	L02BB02	NILUTAMIDE	Tablet 150 mg	1	\N	30
2110	L03AX13	GLATIRAMER ACETATE	Injection 20 mg in 1 mL single dose pre-filled syringe	1	\N	28
2111	S01XA20	CARMELLOSE SODIUM with GLYCERIN	Eye drops 5 mg-9 mg per mL (0.5%-0.9%), single dose units 0.4 mL, 30	1	\N	1
2112	A07CA	ELECTROLYTE REPLACEMENT (ORAL)	Sachets containing powder for oral solution 4.9 g, 10	1	\N	1
2113	L03AB05	INTERFERON ALFA-2b	Solution for injection 60,000,000 i.u. in 1.2 mL multi-dose injection pen	1	\N	1
2114	C09AA04	PERINDOPRIL	Tablet containing 10 mg perindopril arginine	1	\N	30
2115	M01AB02	SULINDAC	Tablet 200 mg	1	\N	50
2116	R03BB04	TIOTROPIUM BROMIDE MONOHYDRATE	Capsule containing powder for oral inhalation 18 micrograms (base) (for use in HandiHaler)	1	\N	30
2117	L01AD05	FOTEMUSTINE	Powder for injection 208 mg with solvent	1	\N	1
2118	A07AA02	NYSTATIN	Tablet 500,000 units	1	\N	50
2119	D02AX	SKIN EMOLLIENT	Bath oil 500 mL	1	\N	1
2120	C10AA01	SIMVASTATIN	Tablet 5 mg	1	\N	30
2121	R03AK06	FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	Powder for oral inhalation in breath actuated device 100 micrograms-50 micrograms (base) per dose (60 doses)	1	\N	1
2122	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Tablet 18 mg (extended release)	1	\N	30
2123	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE	Oral liquid 87 mL, 30	1	\N	1
2124	A05AA02	URSODEOXYCHOLIC ACID	Capsule 250 mg	1	\N	100
2125	A12AA04	CALCIUM	Tablet 600 mg (as carbonate)	1	\N	120
2126	M01AE02	NAPROXEN	Tablet 1 g (sustained release)	1	\N	28
2127	C03CC01	ETHACRYNIC ACID	Tablet 25 mg	1	\N	100
2128	S01EE01	LATANOPROST	Eye drops 50 micrograms per mL (0.005%), 2.5 mL	1	\N	1
2129	J01CA04	AMOXYCILLIN	Capsule 250 mg	1	\N	20
2130	L01XC03	TRASTUZUMAB	Powder for I.V. infusion 150 mg	1	\N	1
2131	N06AB03	FLUOXETINE HYDROCHLORIDE	Capsule 20 mg (base)	1	\N	28
2132	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Non-adhesive waterproof semi-permeable absorbent foam pads 10 cm x 10 cm, 10	1	\N	1
2133	N03AG01	SODIUM VALPROATE	Tablet 200 mg (enteric coated)	1	\N	100
2134	N02AA01	MORPHINE SULFATE	Capsule 20 mg (containing sustained release pellets)	1	\N	20
2135	L01AA01	CYCLOPHOSPHAMIDE	Powder for injection 1 g (solvent required)	1	\N	1
2136	P01AB02	TINIDAZOLE	Tablet 500 mg	1	\N	4
2137	N02AA01	MORPHINE SULFATE	Capsule 60 mg (controlled release)	1	\N	10
2138	G01AA01	NYSTATIN	Vaginal cream 100,000 units per dose, 15 doses, 75 g	1	\N	1
2139	B03XA01	EPOETIN BETA	Injection 20,000 units in 0.6 mL pre-filled syringe	1	\N	6
2140	C09AA10	TRANDOLAPRIL	Capsule 500 micrograms	1	\N	28
2141	J05AE02	INDINAVIR SULFATE	Capsule 400 mg (base)	1	\N	180
2142	N03AE01	CLONAZEPAM	Oral liquid 2.5 mg per mL, 10 mL	1	\N	1
2143	M01AG01	MEFENAMIC ACID	Capsule 250 mg	1	\N	50
2144	N04BA02	LEVODOPA with BENSERAZIDE	Capsule 100 mg-25 mg (sustained release)	1	\N	100
2145	R03AC12	SALMETEROL XINAFOATE	Powder for oral inhalation in breath actuated device 50 micrograms (base) per dose (60 doses)	1	\N	1
2146	N03AX14	LEVETIRACETAM	Tablet 500 mg	1	\N	60
2147	P02CA03	ALBENDAZOLE	Tablet 200 mg	1	\N	6
2148	V06DX	AMINO ACID FORMULA without PHENYLALANINE	Tablets 1 g, 75	1	\N	1
2149	V07AY	DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-LIGHT EXUDATE)	Dressings 10 cm x 10 cm, 5	1	\N	1
2150	B01AC06	ASPIRIN	Tablet 300 mg (dispersible)	1	\N	96
2151	J01DB04	CEPHAZOLIN	Powder for injection 1 g	1	\N	5
2152	L02AE03	GOSERELIN ACETATE	Subcutaneous implant (long acting) 10.8 mg (base) in pre-filled injection syringe	1	\N	1
2153	J01AA02	DOXYCYCLINE	Tablet 100 mg (as monohydrate)	1	\N	7
2154	R01AA05	OXYMETAZOLINE HYDROCHLORIDE	Nasal spray 500 micrograms per mL (0.05%), 15 mL	1	\N	1
2155	R03BC01	SODIUM CROMOGLYCATE	Oral pressurised inhalation 1 mg per dose (200 doses), CFC-free formulation	1	\N	1
2156	L01CB01	ETOPOSIDE	Solution for I.V. infusion 100 mg in 5 mL	1	\N	5
2157	L01XX19	IRINOTECAN HYDROCHLORIDE TRIHYDRATE	I.V. injection 500 mg in 25 mL	1	\N	1
2158	J01DB04	CEPHAZOLIN	Powder for injection 500 mg	1	\N	5
2159	C09AA05	RAMIPRIL	Tablet 10 mg	1	\N	30
2160	L01CB01	ETOPOSIDE	Capsule 100 mg	1	\N	10
2161	C03DA01	SPIRONOLACTONE	Tablet 100 mg	1	\N	100
2162	B01AC30	DIPYRIDAMOLE with ASPIRIN	Capsule 200 mg (sustained release)-25 mg	1	\N	60
2163	A06AB56	DOCUSATE SODIUM with SENNA	Tablet 50 mg-8 mg	1	\N	100
2164	N04BC05	PRAMIPEXOLE HYDROCHLORIDE	Tablet 250 micrograms	1	\N	100
2165	D07AC01	BETAMETHASONE VALERATE	Cream 500 micrograms (base) per g (0.05%), 15 g	1	\N	1
2166	N05BE01	BUSPIRONE HYDROCHLORIDE	Tablet 5 mg	1	\N	50
2167	N04BC05	PRAMIPEXOLE HYDROCHLORIDE	Tablet 1 mg	1	\N	100
2168	G03CA03	OESTRADIOL	Transdermal patches 4 mg (releasing approximately 50 micrograms per 24 hours), 8	1	\N	1
2169	N07BA01	NICOTINE	Transdermal patches releasing approximately 21 mg per 24 hours, 7	1	\N	1
2170	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-LIGHT EXUDATE)	Dressings 10 cm x 10 cm, 5	1	\N	1
2171	N05AH03	OLANZAPINE	Powder for injection 300 mg (as pamoate monohydrate) with diluent	1	\N	1
2172	H01CA02	NAFARELIN ACETATE	Nasal spray (pump pack) 200 micrograms (base) per dose (60 doses)	1	\N	1
2173	D09A	DRESSING with CADEXOMER IODINE	Sachets 10 g (8 cm x 6 cm), 3	1	\N	1
2174	J01CA04	AMOXYCILLIN	Powder for oral suspension 500 mg per 5 mL, 100 mL	1	\N	1
2175	C10BX03	AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM	Tablet 5 mg (base)-20 mg (base)	1	\N	30
2176	L01BB02	MERCAPTOPURINE	Tablet 50 mg	1	\N	25
2177	J01FA06	ROXITHROMYCIN	Tablet for oral suspension 50 mg	1	\N	10
2178	H01AC01	SOMATROPIN (Recombinant human growth hormone)	Injection 2 mg (6 i.u.) with diluent in single use syringe (without preservative)	1	\N	7
2179	N02AB03	FENTANYL	Lozenges 1200 micrograms (as citrate), 3	1	\N	1
2180	S01BA07	FLUOROMETHOLONE ACETATE	Eye drops 1 mg per mL (0.1%), 5 mL	1	\N	1
2181	S01FA05	HOMATROPINE HYDROBROMIDE	Eye drops 20 mg per mL (2%), 15 mL	1	\N	1
2182	N02AA05	OXYCODONE HYDROCHLORIDE	Oral solution 5 mg per 5 mL, 250 mL	1	\N	1
2183	N03AG06	TIAGABINE HYDROCHLORIDE	Tablet 15 mg (base)	1	\N	50
2184	N03AX18	LACOSAMIDE	Tablet 150 mg	1	\N	56
2185	J05AB01	ACICLOVIR	Tablet 200 mg	1	\N	50
2186	V07AY	DRESSING-HYDROGEL-SHEET	Dressings 10 cm x 10 cm, 5	1	\N	1
2187	C09DA03	VALSARTAN with HYDROCHLOROTHIAZIDE	Tablet 160 mg-25 mg	1	\N	28
2188	N05AL05	AMISULPRIDE	Tablet 400 mg	1	\N	60
2189	D11AX	ALLANTOIN with GLYCEROL and ICHTHAMMOL	Ointment 5 mg-10 mg-10 mg per g (0.5%-1%-1%), 50 g	1	\N	1
2190	S01EE03	BIMATOPROST	Eye drops 300 micrograms per mL (0.03%), 3 mL	1	\N	1
2191	N03AX18	LACOSAMIDE	Tablet 200 mg	1	\N	56
2192	A04AA01	ONDANSETRON	Wafer 4 mg	1	\N	4
2193	J05AX09	MARAVIROC	Tablet 300 mg	1	\N	60
2194	M05BA05	TILUDRONATE DISODIUM	Tablet equivalent to 200 mg tiludronic acid	1	\N	56
2195	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 150 mg (twice daily sustained release)	1	\N	20
2196	J05AB11	VALACICLOVIR HYDROCHLORIDE	Tablet 500 mg (base)	1	\N	10
2197	J05AF10	ENTECAVIR MONOHYDRATE	Tablet 1 mg	1	\N	30
2198	B03XA01	EPOETIN BETA	Injection 6,000 units in 0.3 mL pre-filled syringe	1	\N	6
2199	J01GB01	TOBRAMYCIN SULFATE	Injection 80 mg (base) in 2 mL (without preservative)	1	\N	5
2200	L03AX03	BCG-TICE (Bacillus Calmette-Gue rin/ Tice strain)	Vial containing powder for intravesical administration approximately 5 x 10 8 CFU	1	\N	3
2201	C09CA08	OLMESARTAN MEDOXOMIL	Tablet 20 mg	1	\N	30
2202	A10AD04	INSULIN LISPRO-INSULIN LISPRO PROTAMINE SUSPENSION	Injections (human analogue) 100 units (25 units-75 units) per mL, 3 mL, 5	1	\N	1
2203	N07BA	BUPROPION HYDROCHLORIDE	Tablet 150 mg (sustained release)	1	\N	30
2204	H02AB06	PREDNISOLONE	Tablet 1 mg	1	\N	100
2205	J05AF05	LAMIVUDINE	Tablet 100 mg	1	\N	28
2206	B01AC07	DIPYRIDAMOLE	Capsule 200 mg (sustained release)	1	\N	60
2207	N05AH04	QUETIAPINE	Tablet (modified release) 400 mg (as fumarate)	1	\N	60
2208	L01XC02	RITUXIMAB	Solution for I.V. infusion 100 mg in 10 mL	1	\N	2
2209	N06AX16	VENLAFAXINE HYDROCHLORIDE	Capsule 37.5 mg (base) (modified release)	1	\N	28
2210	N06BA04	METHYLPHENIDATE HYDROCHLORIDE	Capsule 20 mg (modified release)	1	\N	30
2211	J05AB01	ACICLOVIR	Tablet 200 mg	1	\N	90
2212	C03DA04	EPLERENONE	Tablet 25 mg	1	\N	30
2213	C09AA02	ENALAPRIL MALEATE	Tablet 20 mg	1	\N	30
2214	L01AA01	CYCLOPHOSPHAMIDE	Powder for injection 500 mg	1	\N	1
2215	C08DA01	VERAPAMIL HYDROCHLORIDE	Capsule 240 mg (sustained release)	1	\N	30
2216	L03AB11	PEGINTERFERON ALFA-2a	Injection 135 micrograms in 0.5 mL single use pre-filled syringe	1	\N	4
2217	N02AB03	FENTANYL	Lozenges 600 micrograms (as citrate), 3	1	\N	1
2218	G03GA01	HUMAN CHORIONIC GONADOTROPHIN	Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL	1	\N	1
2219	N05AB02	FLUPHENAZINE DECANOATE	Injection 50 mg in 2 mL	1	\N	5
2220	C01DA14	ISOSORBIDE MONONITRATE	Tablet 60 mg (sustained release)	1	\N	30
2221	L01AA01	CYCLOPHOSPHAMIDE	Powder for injection 1 g	1	\N	1
2222	C01DA02	GLYCERYL TRINITRATE	Sublingual spray (pump pack) 400 micrograms per dose (200 doses)	1	\N	1
2223	V07AY	BANDAGE-TUBULAR (SHORT STOCKING)	Bandage, large D/E size	1	\N	1
2224	N04BA03	LEVODOPA with CARBIDOPA and ENTACAPONE	Tablet 150 mg-37.5 mg-200 mg	1	\N	100
2225	V07AY	DRESSING-FOAM with SILICONE-HEAVY EXUDATE	Dressings 10 cm x 10 cm, 5	1	\N	1
2226	S01ED51	BIMATOPROST with TIMOLOL MALEATE	Eye drops 300 micrograms-5 mg (base) per mL (0.03%-0.5%), 3 mL	1	\N	1
2227	J01DB03	CEFALOTIN	Powder for injection 1 g	1	\N	10
2228	G03DA02	MEDROXYPROGESTERONE ACETATE	Injection 50 mg in 1 mL	1	\N	1
2229	N05AN01	LITHIUM CARBONATE	Tablet 450 mg (slow release)	1	\N	100
2230	V07AY	DRESSING-FOAM with CHARCOAL (MALODOROUS WOUND)	Dressings 10 cm x 10 cm, 10	1	\N	1
2231	D01BA01	GRISEOFULVIN	Tablet 500 mg	1	\N	28
2232	N03AX11	TOPIRAMATE	Capsule 15 mg	1	\N	60
2233	N02AE01	BUPRENORPHINE	Transdermal patch 20 mg (releasing approximately 20 micrograms per hour)	1	\N	2
2234	N02AA01	MORPHINE SULFATE	Capsule 50 mg (containing sustained release pellets)	1	\N	20
2235	C10AA05	ATORVASTATIN	Tablet 20 mg (as calcium)	1	\N	30
2236	D11AF	SALICYLIC ACID	Gel 270 mg per g (27%), 15 g	1	\N	1
2305	B01AX06	RIVAROXABAN	Tablet 10 mg	1	\N	15
2237	C10AA03	PRAVASTATIN	Tablet containing pravastatin sodium 40 mg	1	\N	30
2238	J01DB01	CEPHALEXIN	Granules for syrup 250 mg per 5 mL, 100 mL	1	\N	1
2239	J04BA	RIFAMPICIN	Capsule 300 mg	1	\N	10
2240	V07AY	DRESSING-NON-ADHERENT	Dressings 5 cm x 5 cm, 5	1	\N	1
2241	C08CA02	FELODIPINE	Tablet 5 mg (extended release)	1	\N	30
2242	C01BD01	AMIODARONE HYDROCHLORIDE	Tablet 200 mg	1	\N	30
2243	N02AB03	FENTANYL	Transdermal patch 8.4 mg (releasing approximately 50 micrograms per hour)	1	\N	5
2244	V07AY	DRESSING with SILVER	Tulle dressings 10 cm x 10 cm, 3	1	\N	1
2245	M01AE02	NAPROXEN	Oral suspension 125 mg per 5 mL, 474 mL	1	\N	1
2246	D01BA02	TERBINAFINE	Tablet 250 mg (as hydrochloride)	1	\N	42
2247	V07AY	BANDAGE-RETENTION-COHESIVE-HEAVY	Bandage 10 cm x 2 m	1	\N	1
2248	V07AY	DRESSING-GAUZE-PARAFFIN with CHLORHEXIDINE ACETATE	Dressings 10 cm x 10 cm, 10	1	\N	1
2249	H03AA01	THYROXINE SODIUM	Tablet equivalent to 200 micrograms anhydrous thyroxine sodium	1	\N	200
2250	L01AA06	IFOSFAMIDE	Powder for I.V. injection 1 g	1	\N	1
2251	G01AF02	CLOTRIMAZOLE	Vaginal cream 100 mg per 5 g (2%), 20 g	1	\N	1
2252	R03AK06	FLUTICASONE PROPIONATE with SALMETEROL XINAFOATE	Oral pressurised inhalation 125 micrograms-25 micrograms (base) per dose (120 doses), CFC-free formulation	1	\N	1
2253	N03AB02	PHENYTOIN SODIUM	Capsule 30 mg	1	\N	200
2254	V06DX	AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE	Sachets 29 g, 30	1	\N	1
2255	C04AX02	PHENOXYBENZAMINE HYDROCHLORIDE	Capsules 10 mg, 100	1	\N	1
2256	N06AF04	TRANYLCYPROMINE SULFATE	Tablet 10 mg (base)	1	\N	50
2257	H02AB01	BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE	Injection 3 mg-3.9 mg (equivalent to 5.7 mg betamethasone) in 1 mL	1	\N	5
2258	V07AY	DRESSING with CADEXOMER IODINE	Tubes 20 g, 2	1	\N	1
2259	V06DB	TRIGLYCERIDES-MEDIUM CHAIN, FORMULA	Compound powder 400 g	1	\N	1
2260	A06AC01	ISPAGHULA HUSK	Sachets 3.5 g, 30	1	\N	1
2261	C08DB01	DILTIAZEM HYDROCHLORIDE	Tablet 60 mg	1	\N	90
2262	C10AB05	FENOFIBRATE	Tablet 145 mg	1	\N	30
2263	P02CA01	MEBENDAZOLE	Tablet 100 mg	1	\N	6
2264	V03AE03	LANTHANUM CARBONATE HYDRATE	Chewable tablet 500 mg (base)	1	\N	90
2265	J04AB02	RIFAMPICIN	Capsule 150 mg	1	\N	10
2266	M05BB03	ALENDRONATE SODIUM with COLECALCIFEROL	Tablet equivalent to 70 mg alendronic acid with 140 micrograms colecalciferol	1	\N	4
2267	V07AY	DRESSING-ALGINATE (CAVITY WOUND)	Ropes 2 g (40 cm), 6	1	\N	1
2268	N04BA02	LEVODOPA with CARBIDOPA	Tablet 250 mg-25 mg	1	\N	100
2269	R01AC01	SODIUM CROMOGLYCATE	Nasal spray metered dose pump 20 mg per mL (2%), 26 mL	1	\N	1
2270	V07AY	DRESSING-HYDROACTIVE (SUPERFICIAL WOUND-HIGH EXUDATE)	Adhesive waterproof semi-permeable absorbent foam pads 12 cm x 12 cm, 10	1	\N	1
2271	B01AC22	PRASUGREL	Tablet 10 mg (as hydrochloride)	1	\N	28
2272	N03AA02	PHENOBARBITONE	Tablet 30 mg	1	\N	200
2273	N06DA02	DONEPEZIL HYDROCHLORIDE	Tablet 10 mg	1	\N	28
2274	V07AY	DRESSING-GAUZE (ABSORBENT PAD)	Pads 5 cm x 5 cm, 100	1	\N	1
2275	A06AB02	BISACODYL	Tablet 5 mg	1	\N	200
2276	P01AB01	METRONIDAZOLE BENZOATE	Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL	1	\N	1
2277	N02AA01	MORPHINE SULFATE	Sachet containing controlled release granules for oral suspension, 60 mg per sachet	1	\N	20
2278	V07AY	BANDAGE-TUBULAR (FINGER)	Refill	1	\N	1
2279	H02AB07	PREDNISONE	Tablet 5 mg	1	\N	60
2280	B01AC30	CLOPIDOGREL with ASPIRIN	Tablet 75 mg (as hydrogen sulfate)-100 mg	1	\N	30
2281	N05CD02	NITRAZEPAM	Tablet 5 mg	1	\N	25
2282	C07AB02	METOPROLOL SUCCINATE	Tablet 190 mg (controlled release)	1	\N	30
2283	J01CF05	FLUCLOXACILLIN	Capsule 500 mg (as sodium)	1	\N	24
2284	C08CA05	NIFEDIPINE	Tablet 20 mg (controlled release)	1	\N	30
2285	A02BD06	ESOMEPRAZOLE MAGNESIUM TRIHYDRATE and CLARITHROMYCIN and AMOXYCILLIN	Pack containing 14 tablets (enteric coated) equivalent to 20 mg esomeprazole, 14 tablets clarithromycin 500 mg and 28 capsules amox	1	\N	1
2286	C01DA08	ISOSORBIDE DINITRATE	Sublingual tablet 5 mg	1	\N	100
2287	M05BA02	SODIUM CLODRONATE TETRAHYDRATE	Capsule equivalent to 400 mg sodium clodronate	1	\N	100
2288	D05AA	COAL TAR - PREPARED	Gel 10 mg per g (1%), 100 mL	1	\N	1
2289	N04BA02	LEVODOPA with BENSERAZIDE	Capsule 50 mg-12.5 mg	1	\N	100
2290	C08EX02	PERHEXILINE MALEATE	Tablet 100 mg	1	\N	100
2291	S01ED01	TIMOLOL MALEATE	Eye drops 5 mg (base) per mL (0.5%), 5 mL	1	\N	1
2292	J01CR03	TICARCILLIN with CLAVULANIC ACID	Powder for injection 3 g-100 mg (solvent required)	1	\N	10
2293	N02AA03	HYDROMORPHONE HYDROCHLORIDE	Tablet 64 mg (modified release)	1	\N	10
2294	G04BE08	TADALAFIL	Tablet 10 mg	1	\N	4
2295	C02DB02	HYDRALAZINE HYDROCHLORIDE	Tablet 25 mg	1	\N	100
2296	C07AA05	PROPRANOLOL HYDROCHLORIDE	Tablet 10 mg	1	\N	100
2297	N02AX02	TRAMADOL HYDROCHLORIDE	Tablet 300 mg (once a day extended release)	1	\N	10
2298	A01AB03	CHLORHEXIDINE GLUCONATE	Mouth wash 2 mg per mL (0.2%), 250 mL	1	\N	1
2299	N07BC02	METHADONE HYDROCHLORIDE	Oral liquid 25 mg per 5 mL, 1 L	1	\N	1
2300	B03AC02	IRON SUCROSE	Concentrate for solution for infusion 2.7 g (equivalent to 100 mg iron (III)) in 5 mL	1	\N	5
2301	A02BC05	ESOMEPRAZOLE MAGNESIUM TRIHYDRATE	Tablet (enteric coated), equivalent to 20 mg esomeprazole	1	\N	30
2302	B03XA01	EPOETIN ALFA	Injection 6,000 units in 0.6 mL pre-filled syringe	1	\N	6
2303	B01AB05	ENOXAPARIN SODIUM	Injection 80 mg (8,000 i.u. anti-Xa) in 0.8 mL pre-filled syringe	1	\N	10
2304	L02AE02	LEUPRORELIN ACETATE	Suspension for subcutaneous injection (modified release), 7.5 mg injection set	1	\N	1
2306	L01XX19	IRINOTECAN HYDROCHLORIDE TRIHYDRATE	I.V. injection 40 mg in 2 mL	1	\N	1
2307	B01AB04	DALTEPARIN SODIUM (Low Molecular Weight Heparin Sodium-porcine mucous)	Injection 7,500 units (anti-Xa) in 0.75 mL single dose pre-filled syringe	1	\N	10
2308	A10BD03	ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE	Tablet 4 mg (base)-1 g	1	\N	56
2309	V06DX	VITAMINS, MINERALS and TRACE ELEMENTS with CARBOHYDRATE	Powder 200 g	1	\N	1
2310	L04AX03	METHOTREXATE	Tablet 10 mg	1	\N	50
2311	L01AD01	CARMUSTINE	Implants 7.7 mg, 8	1	\N	1
2312	V07AY	BANDAGE-COMPRESSION	Bandage, two layer, 28 cm-32 cm (green)	1	\N	1
2313	V07AY	DRESSING-ALGINATE (SUPERFICIAL WOUND)	Dressings 5 cm x 5 cm, 10	1	\N	1
2314	M01CX	LEFLUNOMIDE	Tablet 10 mg	1	\N	30
2315	V06DB	TRIGLYCERIDES-MEDIUM CHAIN, FORMULA	Compound powder 420 g	1	\N	1
2316	L03AB61	RIBAVIRIN and PEGINTERFERON ALFA-2a	Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes peginterferon alfa-2a injection 135 micrograms	1	\N	1
2317	V07AY	DRESSING-NON-ADHERENT	Dressings 10 cm x 10 cm, 5	1	\N	1
2318	N03AG04	VIGABATRIN	Tablet 500 mg	1	\N	100
2319	G02CB04	QUINAGOLIDE HYDROCHLORIDE	Pack containing 3 tablets 25 micrograms (base) and 3 tablets 50 micrograms (base)	1	\N	1
2320	N05AX08	RISPERIDONE	Tablet 3 mg (orally disintegrating)	1	\N	28
2321	M05BA03	DISODIUM PAMIDRONATE	Concentrated injection 15 mg in 5 mL	1	\N	1
2322	G03AC06	MEDROXYPROGESTERONE ACETATE	Injection 150 mg in 1 mL	1	\N	1
2323	C09BA09	FOSINOPRIL SODIUM with HYDROCHLOROTHIAZIDE	Tablet 20 mg-12.5 mg	1	\N	30
2324	N02AA01	MORPHINE SULFATE	Injection 30 mg in 1 mL	1	\N	5
2325	A06AD15	MACROGOL 3350	Sachets containing powder for solution 13.125 g with electrolytes, 30	1	\N	1
2326	C07AB02	METOPROLOL TARTRATE	Tablet 100 mg	1	\N	60
2327	B01AB05	ENOXAPARIN SODIUM	Injection 100 mg (10,000 i.u. anti-Xa) in 1 mL pre-filled syringe	1	\N	10
2328	G03AA05	NORETHISTERONE with ETHINYLOESTRADIOL	Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets	1	\N	1
2329	N04BD01	SELEGILINE HYDROCHLORIDE	Tablet 5 mg	1	\N	100
2330	L02BG06	EXEMESTANE	Tablet 25 mg	1	\N	30
2331	H01CB02	OCTREOTIDE	Injection 50 micrograms (as acetate) in 1 mL	1	\N	5
2332	J05AB12	CIDOFOVIR	Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial	1	\N	1
2333	C09BA04	PERINDOPRIL with INDAPAMIDE HEMIHYDRATE	Tablet containing 4 mg perindopril erbumine-1.25 mg indapamide hemihydrate	1	\N	30
2334	A10BD03	ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE	Tablet 4 mg (base)-500 mg	1	\N	56
2335	L04AC03	ANAKINRA	Injection 100 mg in 0.67 mL single use pre-filled syringe	1	\N	28
2336	B03XA03	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Injection 50 micrograms in 0.3 mL pre-filled syringe	1	\N	1
2337	J05AF04	STAVUDINE	Capsule 20 mg	1	\N	60
2338	N05AD01	HALOPERIDOL	Tablet 1.5 mg	1	\N	100
2339	V07AY	TAPES-PLASTER ADHESIVE HYPOALLERGENIC	Roll 1.25 cm x 5 m	1	\N	1
2340	H05BX01	CINACALCET HYDROCHLORIDE	Tablet 90 mg (base)	1	\N	28
2341	V06DX	AMINO ACID FORMULA without PHENYLALANINE	Capsules 500 mg, 200	1	\N	1
2342	H01BA02	DESMOPRESSIN ACETATE	Wafer 120 micrograms (base)	1	\N	30
\.


--
-- Data for Name: brand; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY brand (fk_product, fk_manufacturer, brand, price, from_pbs) FROM stdin;
1	162	Epilim Liquid	$34.92	t
2	171	Vimpat	$188.45	t
3	159	Allevyn Plus Cavity 66047573	$178.36	t
4	135	Loniten	$52.83	t
5	99	Januvia	$91.19	t
6	4	Thioprine	$56.50	t
6	11	Imuran	$56.50	t
6	60	Azamun	$56.50	t
6	64	GenRx Azathioprine	$56.50	t
6	156	Azapin	$56.50	t
6	165	Azathioprine Sandoz	$56.50	t
7	151	MSUD Anamix Junior LQ	$2,507.98	t
8	69	Hospira Pty Limited	$14.20	t
9	158	Femoston 2/10	$18.76	t
10	155	PEG-Intron Redipen	$920.00	t
11	94	Humulin 30/70	$224.32	t
11	112	Mixtard 30/70 InnoLet	$224.32	t
11	116	Mixtard 30/70 Penfill 3 mL	$224.32	t
12	155	Temodal	$1,112.18	t
12	155	Temodal	$3,266.10	t
13	172	ProZero	$339.78	t
14	69	Hospira Pty Limited	$18.08	t
15	151	MCT Oil	$52.38	t
16	5	Optive	$10.59	t
17	59	Tykerb	$3,387.46	t
18	36	Nebilet	$68.02	t
19	10	Iopidine 0.5%	$41.77	t
20	4	Xergic	$29.42	t
20	162	Telfast 120	$41.52	t
20	165	Fexal	$34.71	t
21	154	Erbitux	$341.00	t
21	154	Erbitux	$391.06	t
22	153	Coversyl Plus LD 2.5mg/0.625mg	$16.53	t
23	11	Quinate	$14.46	t
24	4	Tryzan Caps 10	$23.23	t
24	13	Ramace 10 mg	$23.23	t
24	35	Pharmacor Ramipril 10	$23.23	t
24	61	Ramipril-DP	$23.23	t
24	63	Ramipril generichealth	$23.23	t
24	64	GenRx Ramipril	$23.23	t
24	156	Prilace 10	$23.23	t
24	162	Tritace 10 mg	$23.23	t
24	165	Ramipril Sandoz	$23.23	t
24	174	Ramipril Winthrop	$23.23	t
25	9	Atacand	$22.75	t
26	72	Hydrocoll 900939/1	$89.91	t
27	159	Iodosorb 66051360	$144.84	t
28	94	Humatrope	$297.00	t
29	4	Barbloc 5	$11.48	t
29	120	Visken 5	$11.48	t
30	7	Aranesp SureClick	$88.24	t
31	120	Neoral 100	$169.46	t
31	120	Neoral 100	$388.86	t
31	165	Cicloral	$169.46	t
31	165	Cicloral	$388.86	t
32	155	Intron A	$178.74	t
33	4	Alphamox 250	$11.68	t
33	31	Chem mart Amoxycillin	$11.68	t
33	59	Amoxil Forte	$11.68	t
33	60	Bgramin	$11.68	t
33	64	GenRx Amoxycillin	$11.68	t
33	145	Ranmoxy	$11.68	t
33	156	Cilamox	$11.68	t
33	165	Amoxycillin Sandoz	$11.68	t
33	169	Terry White Chemists Amoxycillin	$11.68	t
34	29	Buscopan	$24.21	t
35	69	Leucovorin Calcium	$265.44	t
35	69	Leucovorin Calcium	$309.82	t
36	59	Volibris	$4,035.00	t
37	4	Metrogyl 400	$7.88	t
38	80	Risperdal Quicklet	$113.60	t
39	4	Zopral	$20.27	t
39	179	Zoton	$20.27	t
40	10	Systane	$10.59	t
41	60	Procur 100	$169.76	t
41	64	GenRx Cyproterone Acetate	$169.76	t
41	152	Androcur-100	$169.76	t
41	164	Cyprostat-100	$169.76	t
41	165	Cyprohexal	$169.76	t
42	4	Irinotecan Alphapharm	$567.24	t
42	4	Irinotecan Alphapharm	$640.72	t
42	63	Irinotecan Actavis	$567.24	t
42	63	Irinotecan Actavis	$640.72	t
42	69	Hospira Pty Limited	$567.22	t
42	69	Hospira Pty Limited	$640.72	t
42	78	Irinotecan Ebewe	$567.24	t
42	78	Irinotecan Ebewe	$640.72	t
42	124	Omegapharm Irinotecan	$567.24	t
42	124	Omegapharm Irinotecan	$640.72	t
42	141	Camptosar	$567.24	t
42	141	Camptosar	$640.72	t
42	165	Irinotecan Sandoz	$567.24	t
42	165	Irinotecan Sandoz	$640.72	t
42	177	Tecan	$567.24	t
42	177	Tecan	$640.72	t
43	120	Stalevo 200/50/200mg	$399.62	t
44	74	Durotram XR	$13.37	t
45	51	Anamorph	$14.24	t
46	158	Zanidip	$27.32	t
46	158	Zanidip	$31.67	t
47	27	Leukoplast 1072	$18.56	t
48	155	Remicade	$751.70	t
48	155	Remicade	$846.98	t
49	24	Videx EC	$163.40	t
50	162	Actonel Once-a-Month	$56.98	t
51	120	Neoral	$315.79	t
51	120	Neoral	$712.66	t
52	80	Concerta	$72.95	t
53	122	Salofalk	$445.90	t
54	159	Viscopaste 4948	$70.64	t
54	161	Zincaband 3604	$29.20	t
54	182	Steripaste 3610	$29.66	t
55	80	Jurnista	$41.32	t
56	99	Singulair	$47.93	t
57	137	PTU	$49.64	t
58	7	Neupogen	$2,407.00	t
59	80	Sporanox	$246.79	t
60	80	Eprex 1000	$147.00	t
61	10	Tears Naturale	$10.65	t
61	76	Poly-Tears	$10.65	t
62	147	Solprin	$8.59	t
63	23	Keto-Diastix	$17.42	t
63	148	Keto-Diabur- Test 5000	$17.30	t
64	4	Cholstat 10	$21.59	t
64	31	Chem mart Pravastatin	$21.59	t
64	35	Pravastatin 10	$21.59	t
64	51	Pravachol	$21.59	t
64	60	Pravastatin-GA 10	$21.59	t
64	63	Pravastatin generichealth	$21.59	t
64	64	GenRx Pravastatin	$21.59	t
64	156	Lipostat 10	$21.59	t
64	165	Liprachol	$21.59	t
64	169	Terry White Chemists Pravastatin	$21.59	t
64	170	APO-Pravastatin	$21.59	t
64	174	Pravastatin Winthrop	$21.59	t
65	100	Nexcare Durable Cloth First Aid Tape 799	$11.05	t
66	154	Ovidrel	$54.80	t
67	69	Hospira Pty Limited	$128.36	t
67	69	Hospira Pty Limited	$158.24	t
67	141	Pfizer Australia Pty Ltd	$128.36	t
67	141	Pfizer Australia Pty Ltd	$158.24	t
68	134	Lyrica	$84.96	t
69	151	TYR Anamix infant	$769.30	t
70	60	Procur 100	$169.76	t
70	64	GenRx Cyproterone Acetate	$169.76	t
70	152	Androcur-100	$169.76	t
70	164	Cyprostat-100	$169.76	t
70	165	Cyprohexal	$169.76	t
71	60	Oratane	$141.04	t
71	64	GenRx Isotretinoin	$141.04	t
71	150	Roaccutane	$141.04	t
72	4	Celapram	$17.31	t
73	161	Tubifast 2434	$28.36	t
74	156	Nucolox	$21.27	t
75	11	Permax	$66.18	t
76	152	Climara 100	$19.66	t
77	7	Aranesp	$1,379.21	t
78	82	Mylanta P	$15.90	t
79	120	Comtan	$281.82	t
80	4	Lisodur	$20.99	t
80	9	Zestril	$20.99	t
80	18	Lisinobell	$20.99	t
80	31	Chem mart Lisinopril	$20.99	t
80	35	Lisinopril 20	$20.99	t
80	60	Liprace	$20.99	t
80	61	Lisinopril-GA	$20.99	t
80	63	Lisinopril generichealth	$20.99	t
80	64	GenRx Lisinopril	$20.99	t
80	73	Lisinopril Hexal	$20.99	t
80	99	Prinivil 20	$20.99	t
80	145	Lisinopril Ranbaxy	$20.99	t
80	156	Fibsol 20	$20.99	t
80	165	Lisinopril Sandoz	$20.99	t
80	169	Terry White Chemists Lisinopril	$20.99	t
80	170	APO-Lisinopril	$20.99	t
80	174	Lisinopril Winthrop	$20.99	t
81	155	Elocon	$26.81	t
82	4	Paxam 2	$19.38	t
82	4	Paxam 2	$32.34	t
82	150	Rivotril	$19.38	t
82	150	Rivotril	$32.34	t
83	4	Spiractin 25	$12.49	t
83	135	Aldactone	$12.49	t
84	80	Eprex 20,000	$2,040.00	t
85	150	Tarceva	$794.19	t
86	4	Nupentin 400	$82.24	t
86	6	Pendine 400	$82.24	t
86	14	Gantin	$82.24	t
86	35	Gabapentin 400	$82.24	t
86	61	Douglas Gabapentin 400mg	$82.24	t
86	64	GenRx Gabapentin	$82.24	t
86	69	DBL Gabapentin	$82.24	t
86	134	Neurontin	$82.24	t
86	134	Neurontin	$83.24	t
86	156	Gabatine 400	$82.24	t
86	165	Gabahexal 400mg	$82.24	t
87	12	Tracleer	$4,035.00	t
88	74	Qvar 100	$33.46	t
89	77	Somatuline Autogel	$1,345.00	t
90	4	Fenac	$11.05	t
90	31	Chem mart Diclofenac	$11.05	t
90	60	Diclofenac-GA	$11.05	t
90	64	GenRx Diclofenac	$11.05	t
90	120	Voltaren 50	$11.05	t
90	156	Clonac 50	$11.05	t
90	165	Diclofenac Sandoz	$11.05	t
90	169	Terry White Chemists Diclofenac	$11.05	t
90	170	APO-Diclofenac	$11.05	t
91	30	Kaltostat 168212	$91.08	t
92	4	Antenex 5	$7.93	t
92	60	Diazepam-GA	$7.93	t
92	145	Ranzepam	$7.93	t
92	150	Valium	$7.93	t
92	156	Valpam 5	$7.93	t
93	28	Baxter Healthcare Pty Ltd	$28.77	t
94	30	CarboFLEX 403202	$78.98	t
95	59	Avandamet	$68.43	t
96	59	Lanvis	$198.66	t
97	4	Celapram	$22.95	t
97	18	Citalobell	$22.95	t
97	31	Chem mart Citalopram	$22.95	t
97	35	Citalopram 20	$22.95	t
97	60	Ciazil	$22.95	t
97	63	Citalopram generichealth	$22.95	t
97	64	GenRx Citalopram	$22.95	t
97	93	Cipramil	$22.95	t
97	145	Celica	$22.95	t
97	156	Talam	$22.95	t
97	165	Citalopram Sandoz	$22.95	t
97	169	Terry White Chemists Citalopram	$22.95	t
97	170	APO-Citalopram	$22.95	t
98	135	Cytotec	$52.12	t
99	4	Cardol	$26.50	t
99	31	Chem mart Sotalol	$26.50	t
99	51	Sotacor	$26.50	t
99	64	GenRx Sotalol	$26.50	t
99	156	Solavert	$26.50	t
99	165	Sotalol Sandoz	$26.50	t
99	169	Terry White Chemists Sotalol	$26.50	t
100	4	Corbeton 20	$10.00	t
101	179	Rapamune	$468.00	t
101	179	Rapamune	$529.74	t
102	120	Lucentis	$1,976.36	t
103	4	Pramin	$8.20	t
103	173	Maxolon	$8.20	t
104	24	Iscover	$71.61	t
104	31	Chem mart Clopidogrel	$71.61	t
104	162	Plavix	$71.61	t
104	165	Clopidogrel Sandoz	$71.61	t
104	169	Terry White Chemists Clopidogrel	$71.61	t
104	170	APO-Clopidogrel	$71.61	t
105	120	Famvir	$137.06	t
106	4	Tryzan Caps 5	$15.93	t
106	35	Pharmacor Ramipril 5	$15.93	t
106	61	Ramipril-DP	$15.93	t
106	63	Ramipril generichealth	$15.93	t
107	150	Mircera	$471.59	t
108	49	Betadine	$33.54	t
109	100	Tegaderm Transparent Island 3582	$16.22	t
110	154	Erbitux	$1,705.00	t
110	154	Erbitux	$1,851.36	t
111	74	Tambocor	$39.05	t
112	26	Vitrasert	$6,000.00	t
113	162	Plaquenil	$37.59	t
114	77	NutropinAq	$495.00	t
115	150	Rivotril	$18.58	t
116	99	Vytorin	$123.97	t
117	171	Vimpat	$30.21	t
118	4	Arthrexin	$12.08	t
118	11	Indocid	$12.08	t
119	59	Flixotide Accuhaler	$30.66	t
120	120	Co-Diovan 320/25	$32.80	t
121	58	Atripla	$1,217.74	t
122	27	Comprilan 1027	$72.42	t
123	78	Irinotecan Ebewe	$850.12	t
123	78	Irinotecan Ebewe	$957.03	t
123	134	Camptosar	$850.12	t
123	134	Camptosar	$957.03	t
124	4	Kripton 2.5	$32.73	t
124	120	Parlodel	$32.73	t
125	9	Symbicort Turbuhaler 100/6	$54.47	t
126	151	XMTVI Asadon	$1,392.47	t
127	11	Cortate	$17.74	t
128	4	Aratac 100	$15.02	t
128	156	Rithmik 100	$15.02	t
128	162	Cordarone X 100	$15.02	t
128	165	Cardinorm	$15.02	t
129	59	Seretide Accuhaler 500/50	$78.67	t
130	94	Forteo	$438.37	t
131	155	Temodal	$73.75	t
131	155	Temodal	$208.05	t
132	8	Blink Intensive Tears	$39.37	t
133	1	Klacid	$36.12	t
134	155	Pegatron	$1,353.83	t
134	155	Pegatron	$2,039.76	t
135	1	Selsun	$14.14	t
136	4	Zimstat	$44.45	t
136	18	Simvabell	$44.45	t
136	31	Chem mart Simvastatin	$44.45	t
136	35	Simvasyn	$44.45	t
136	53	Lipex 40	$44.45	t
136	60	Simvastatin-DP	$44.45	t
136	61	Simvastatin-GA 40	$44.45	t
136	63	Simvastatin generichealth	$44.45	t
136	64	GenRx Simvastatin	$44.45	t
136	98	Pharmacor Simvastatin 40	$44.45	t
136	99	Zocor	$44.45	t
136	145	Ransim	$44.45	t
136	156	Simvar 40	$44.45	t
136	165	Simvahexal	$44.45	t
136	169	Terry White Chemists Simvastatin	$44.45	t
136	170	APO-Simvastatin	$44.45	t
136	174	Simvastatin Winthrop	$44.45	t
136	187	Simvastatin-Spirit 40	$44.45	t
137	13	Stemzine	$9.95	t
137	162	Stemetil	$9.95	t
138	4	Distaph 250	$11.45	t
138	156	Dicloxsig	$11.45	t
139	155	Olmetec Plus	$27.36	t
140	162	Triasyn 2.5/2.5	$21.00	t
141	4	Tramedo	$9.16	t
141	31	Chem mart Tramadol	$9.16	t
141	36	Tramal	$9.16	t
141	64	GenRx Tramadol	$9.16	t
141	156	Zydol	$9.16	t
141	169	Terry White Chemists Tramadol	$9.16	t
141	187	Lodam 50	$9.16	t
142	159	Iodosorb Ointment 66051230	$99.79	t
143	87	Ralovera	$31.70	t
143	135	Provera	$31.70	t
144	63	Gemcitabine Actavis	$425.00	t
144	63	Gemcitabine Actavis	$481.66	t
144	69	DBL Gemcitabine for Injection	$425.00	t
144	69	DBL Gemcitabine for Injection	$481.66	t
144	78	Gemcitabine Ebewe	$425.00	t
144	78	Gemcitabine Ebewe	$481.66	t
144	94	Gemzar	$425.00	t
144	94	Gemzar	$481.66	t
144	187	Gemcite	$425.00	t
144	187	Gemcite	$481.66	t
145	120	Sandostatin LAR	$2,223.33	t
146	159	Intrasite Gel 7313	$59.54	t
147	4	Progout 100	$13.20	t
148	94	Alimta	$311.97	t
148	94	Alimta	$359.85	t
149	78	Epirubicin Ebewe	$178.04	t
149	78	Epirubicin Ebewe	$215.86	t
149	135	Pharmorubicin Solution	$178.04	t
149	135	Pharmorubicin Solution	$215.86	t
150	5	Refresh Liquigel	$10.59	t
151	120	Estraderm MX 100	$19.66	t
152	4	Glyade MR	$13.72	t
152	31	Chem mart Gliclazide MR	$13.72	t
152	145	Oziclide MR	$13.72	t
152	153	Diamicron MR	$13.72	t
152	169	Terry White Chemists Gliclazide MR	$13.72	t
152	170	APO-Gliclazide MR	$13.72	t
153	11	Colifoam	$38.34	t
154	6	Clamoxyl Duo forte	$14.60	t
154	31	Chem mart Amoxycillin and Clavulanic Acid	$14.60	t
154	35	Clavycillin 875/125	$14.60	t
154	59	Augmentin Duo forte	$14.60	t
154	60	GA-Amclav Forte 875/125	$14.60	t
154	64	GenRx Amoxycillin and Clavulanic Acid	$14.60	t
154	156	Moxiclav Duo Forte 875/125	$14.60	t
154	165	Curam Duo Forte 875/125	$14.60	t
154	169	Terry White Chemists Amoxycillin and Clavulan	$14.60	t
155	120	Sandomigran 0.5	$21.75	t
156	162	Stemetil	$16.82	t
157	91	Link Medical Products Pty Ltd	$100.58	t
158	120	Famvir	$356.93	t
159	151	XPTM Tyrosidon	$2,671.98	t
160	151	KetoCal	$988.26	t
161	94	Alimta	$1,559.86	t
161	94	Alimta	$1,701.41	t
162	23	Xarelto	$101.14	t
163	4	Barbloc 15	$13.71	t
163	120	Visken 15	$13.71	t
164	162	Flagyl	$23.16	t
165	51	Tricortone	$14.72	t
165	156	Aristocort 0.02%	$14.72	t
166	26	GelTears	$10.43	t
166	115	PAA	$10.43	t
166	120	Viscotears	$10.43	t
167	11	Permax	$241.69	t
168	27	Elastocrepe 36102320	$27.82	t
168	84	Telfa 8254F	$25.38	t
169	59	Zovirax	$35.06	t
170	24	Taxol	$1,134.88	t
170	24	Taxol	$1,259.44	t
170	63	Paclitaxel Actavis	$1,134.88	t
170	63	Paclitaxel Actavis	$1,259.44	t
170	69	Anzatax	$1,134.88	t
170	69	Anzatax	$1,259.44	t
170	78	Paclitaxel Ebewe	$1,134.88	t
170	78	Paclitaxel Ebewe	$1,259.44	t
171	156	Serenace	$17.47	t
172	135	Methoblastin	$46.70	t
173	69	Hospira Pty Limited	$42.08	t
173	69	Hospira Pty Limited	$56.18	t
173	78	Doxorubicin Ebewe	$42.08	t
173	78	Doxorubicin Ebewe	$56.18	t
173	135	Adriamycin Solution	$42.08	t
173	135	Adriamycin Solution	$56.18	t
174	4	Cardol	$26.50	t
174	31	Chem mart Sotalol	$26.50	t
174	51	Sotacor	$26.50	t
174	64	GenRx Sotalol	$26.50	t
174	156	Solavert	$26.50	t
174	165	Sotalol Sandoz	$26.50	t
174	169	Terry White Chemists Sotalol	$26.50	t
175	28	Baxter Healthcare Pty Ltd	$10.33	t
176	11	LPV	$13.84	t
176	51	Cilicaine VK	$13.84	t
176	60	Cilopen VK	$13.84	t
177	4	Oxaliplatin Alphapharm	$609.63	t
177	4	Oxaliplatin Alphapharm	$688.11	t
177	63	Oxaliplatin Actavis	$609.63	t
177	63	Oxaliplatin Actavis	$688.11	t
177	69	Hospira Pty Limited	$609.63	t
177	69	Hospira Pty Limited	$688.11	t
177	78	Oxaliplatin Ebewe	$609.63	t
177	78	Oxaliplatin Ebewe	$688.11	t
177	136	Oxaliplatin Link	$609.63	t
177	136	Oxaliplatin Link	$688.11	t
177	174	Winthrop Oxaliplatin	$609.63	t
177	174	Winthrop Oxaliplatin	$688.11	t
177	187	Oxalatin	$609.63	t
177	187	Oxalatin	$688.11	t
178	156	Coumadin	$12.77	t
179	4	Lamogine	$44.24	t
179	59	Lamictal	$44.24	t
179	60	Lamotrigine-DP	$44.24	t
179	61	Lamotrigine-GA	$44.24	t
179	63	Lamotrigine generichealth	$44.24	t
179	64	GenRx Lamotrigine	$44.24	t
179	98	Lamotrust 50	$44.24	t
179	145	Lamidus	$44.24	t
179	156	Seaze 50	$44.24	t
179	165	Lamotrigine Sandoz	$44.24	t
180	120	Symmetrel 100	$44.30	t
181	69	Hospira Pty Limited	$12.29	t
182	173	Mestinon	$56.00	t
183	51	Codalgin	$12.86	t
183	162	Panamax Co.	$11.74	t
184	150	Roferon-A	$89.38	t
184	150	Roferon-A	$446.90	t
184	150	Roferon-A	$506.12	t
185	134	Lyrica	$183.14	t
186	120	Viscotears	$37.32	t
187	150	Valcyte	$2,245.80	t
188	23	Xarelto	$148.66	t
189	4	Zedace	$35.70	t
189	60	Genepharm Pty Ltd	$35.70	t
189	64	GenRx Captopril	$35.70	t
189	156	Capoten	$35.70	t
189	165	Captohexal	$35.70	t
190	69	Hospira Pty Limited	$49.04	t
190	69	Hospira Pty Limited	$64.42	t
191	23	Glucobay 100	$40.92	t
192	159	Cavicare 4563	$84.82	t
193	27	Leukopor 2472	$12.73	t
193	27	Leukosilk 1022	$13.24	t
194	74	Minitran 5	$28.18	t
194	120	Transiderm-Nitro 25	$28.18	t
194	155	Nitro-Dur 5	$28.18	t
195	59	Eskazole	$185.25	t
196	9	AstraZeneca Pty Ltd	$20.34	t
197	87	Norimin-1 28 Day	$16.86	t
197	135	Brevinor-1	$16.86	t
198	71	Restore CalciCare 9937	$71.64	t
198	159	Algisite M 66000520	$94.05	t
199	97	Mepitel 290710	$107.62	t
200	120	Aclasta	$589.17	t
201	96	Norspan	$26.70	t
202	47	Antroquoril	$24.96	t
202	51	Cortival 1/5	$24.96	t
202	155	Celestone-M	$24.96	t
202	156	Betnovate 1/5	$24.96	t
203	171	Dipentum	$61.41	t
204	74	Minitran 15	$34.95	t
204	155	Nitro-Dur 15	$34.95	t
205	100	Tegaderm Transparent Island 3586	$27.72	t
206	152	Microgynon 30 ED	$17.43	t
206	164	Levlen ED	$17.43	t
206	179	Monofeme 28	$17.43	t
206	180	Nordette 28	$17.43	t
207	158	Zan-Extra 10/10	$29.21	t
208	4	Adefin 20	$18.17	t
208	23	Adalat 20	$18.17	t
208	64	GenRx Nifedipine	$18.17	t
208	165	Nifehexal	$18.17	t
209	72	Hydrocoll 900938/1	$48.15	t
209	159	Replicare Ultra 66000434	$76.78	t
210	155	Olmetec Plus	$32.44	t
211	36	Daivonex	$28.06	t
212	16	Avonex	$1,056.77	t
213	11	Hypurin Isophane	$172.02	t
214	151	Essential Amino Acid Mix	$1,200.57	t
215	4	Azol 100	$58.58	t
216	24	Avapro HCT 300/25	$34.69	t
216	162	Karvezide 300/25	$34.69	t
217	122	Salofalk	$244.92	t
218	172	MSUD Cooler	$3,098.38	t
219	3	Cromolux	$14.53	t
219	162	Opticrom	$14.53	t
220	4	Nufloxib	$17.72	t
220	31	Chem mart Norfloxacin	$17.72	t
220	61	Genepharm Pty Ltd	$17.72	t
220	64	GenRx Norfloxacin	$17.72	t
220	99	Noroxin	$17.72	t
220	156	Roxin	$17.72	t
220	165	Norflohexal	$17.72	t
220	169	Terry White Chemists Norfloxacin	$17.72	t
221	96	OxyContin	$27.93	t
222	161	Tubigrip 1486	$40.18	t
223	46	Egoderm Cream	$18.10	t
224	136	Colazide	$124.85	t
225	150	Mircera	$1,750.80	t
226	4	Rimycin 150	$37.01	t
227	10	Poly Gel	$36.06	t
228	79	Ceftriaxone ICP	$10.41	t
228	79	Ceftriaxone ICP	$26.37	t
229	29	Atrovent Nasal Forte	$30.47	t
230	99	Sinemet CR	$67.87	t
231	120	Diovan	$23.90	t
232	162	Panamax 240 Elixir	$10.68	t
233	134	Champix	$103.76	t
234	155	Noxafil	$4,269.72	t
235	4	Keflor	$13.82	t
235	11	Ceclor	$13.82	t
235	31	Chem mart Cefaclor	$13.82	t
235	64	GenRx Cefaclor	$13.82	t
235	145	Ozcef	$13.82	t
235	156	Aclor 250	$13.82	t
235	165	Cefaclor Sandoz	$13.82	t
235	169	Terry White Chemists Cefaclor	$13.82	t
236	69	DBL Ceftriaxone	$37.57	t
236	79	Ceftriaxone ICP	$37.57	t
236	150	Rocephin	$37.57	t
236	165	Ceftriaxone Sandoz	$37.57	t
237	120	Lescol XL	$46.84	t
238	120	Co-Diovan 320/12.5	$30.73	t
239	156	Nilstat	$13.79	t
240	162	Actonel Combi	$53.34	t
241	80	Jurnista	$28.61	t
242	24	Sprycel	$10,424.94	t
243	74	Durotram XR	$16.34	t
244	134	Zarontin	$25.29	t
245	141	Pfizer Australia Pty Ltd	$6.68	t
245	141	Pfizer Australia Pty Ltd	$14.68	t
246	4	Hysone 4	$11.10	t
247	158	Zan-Extra 10/20	$32.02	t
248	182	Lyofoam Flat 603093	$49.48	t
249	69	Tomudex	$760.02	t
249	69	Tomudex	$856.29	t
250	150	Fuzeon	$2,213.00	t
251	10	Duotrav	$46.82	t
252	4	Temaze	$7.71	t
252	4	Temaze	$9.00	t
252	51	Temtabs	$7.71	t
252	51	Temtabs	$9.00	t
252	156	Normison	$7.71	t
252	156	Normison	$9.00	t
252	170	APO-Temazepam	$7.71	t
252	170	APO-Temazepam	$9.00	t
253	155	Integrilin	$1,020.36	t
254	41	Penthrox	$44.78	t
255	11	Flucil	$15.49	t
255	168	Flubiclox	$15.49	t
256	4	Keflor	$13.49	t
256	11	Ceclor	$13.49	t
256	31	Chem mart Cefaclor	$13.49	t
256	64	GenRx Cefaclor	$13.49	t
256	145	Ozcef	$13.49	t
256	156	Aclor 125	$13.49	t
256	165	Cefaclor Sandoz	$13.49	t
256	169	Terry White Chemists Cefaclor	$13.49	t
257	4	Amira 150	$18.76	t
257	31	Chem mart Moclobemide	$18.76	t
257	60	Clobemix	$18.76	t
257	64	GenRx Moclobemide	$18.76	t
257	150	Aurorix	$18.76	t
257	165	Mohexal	$18.76	t
257	169	Terry White Chemists Moclobemide	$18.76	t
258	1	Lucrin Depot 7.5mg PDS	$420.20	t
259	80	Eprex 2000	$272.00	t
260	154	Erbitux	$341.00	t
260	154	Erbitux	$391.06	t
261	4	Kripton 10	$155.94	t
261	120	Parlodel	$155.94	t
262	4	Rimycin 300	$64.94	t
263	99	Janumet	$97.28	t
264	122	Litak	$4,483.22	t
264	122	Litak	$4,629.57	t
265	11	Flucil	$20.66	t
265	69	Hospira Pty Limited	$20.66	t
265	168	Flubiclox	$20.66	t
266	36	Pneumovax 23	$46.13	t
267	120	Diovan	$16.01	t
268	134	Xalacom	$46.82	t
269	11	Bicillin L-A	$293.11	t
270	6	EpiPen Jr.	$106.00	t
271	28	Baxter Healthcare Pty Ltd	$291.25	t
271	134	Diflucan	$291.25	t
271	165	Fluconazole Hexal	$291.25	t
272	80	Velcade	$7,002.38	t
273	141	Pfizer Australia Pty Ltd	$20.22	t
274	11	Hypurin Neutral	$172.02	t
275	13	Lantus SoloStar	$432.72	t
275	162	Lantus	$432.72	t
276	150	Bactrim	$9.05	t
276	156	Septrin	$9.05	t
277	151	Carbohydrate Free Mixture	$648.42	t
278	96	OxyContin	$21.95	t
279	179	Pristiq	$50.42	t
280	162	Solian Solution	$148.74	t
281	17	Eucerin	$12.80	t
282	1	Hytrin	$58.19	t
283	4	Campral	$166.58	t
284	80	Stelara	$4,601.42	t
285	59	Retrovir	$205.46	t
286	5	Ocuflox	$32.14	t
287	152	Testogel	$95.12	t
288	6	Clamoxyl	$12.47	t
288	59	Augmentin	$12.47	t
288	165	Curam	$12.47	t
289	36	Fucidin	$90.89	t
290	83	Spenco Dermal Pad 10-561	$49.32	t
291	162	Myocrisin	$67.03	t
292	15	Magmin	$14.39	t
292	139	Mag-Sup	$14.39	t
293	96	Dilaudid	$63.70	t
294	120	Estalis continuous 50/250	$19.66	t
295	182	Lyofoam Flat 603092	$42.84	t
296	74	Qvar 100 Autohaler	$39.13	t
297	6	Felodur ER 10 mg	$23.67	t
297	9	Plendil ER	$23.67	t
297	156	Felodil XR 10	$23.67	t
298	11	Sodibic	$14.00	t
299	150	Mabthera	$2,263.57	t
299	150	Mabthera	$2,339.99	t
300	151	XMET Maxamaid	$1,784.74	t
300	151	XMET Maxamum	$2,704.74	t
301	24	Etopophos	$276.50	t
301	24	Etopophos	$321.71	t
302	91	Link Medical Products Pty Ltd	$113.84	t
303	29	Aptivus	$1,071.00	t
304	59	Flixotide	$30.66	t
305	156	Hycor	$12.94	t
306	51	Otocomb Otic	$11.27	t
306	156	Kenacomb Otic	$11.27	t
307	29	Mobic	$21.80	t
307	156	Movalis 7.5	$21.80	t
308	59	Alkeran	$50.88	t
309	5	Refresh Tears Plus	$10.59	t
310	120	Ritalin 10	$17.30	t
311	166	Neotigason	$393.21	t
312	134	Accuretic 10/12.5mg	$19.39	t
313	52	Pentasa	$336.22	t
314	129	Orion Laboratories Pty Ltd	$50.40	t
315	186	Fosrenol	$395.28	t
315	186	Fosrenol	$449.42	t
316	4	Fenac 25	$13.06	t
317	27	Coplus 3629	$20.06	t
318	28	Holoxan	$592.00	t
318	28	Holoxan	$668.37	t
319	172	TYR gel	$1,798.42	t
320	134	Zithromax	$21.70	t
320	165	Azithromycin Sandoz	$21.70	t
321	4	Deptran 50	$9.71	t
322	99	Januvia	$91.19	t
323	52	Minirin	$64.25	t
323	52	Minirin	$179.91	t
324	116	Norditropin NordiFlex	$946.50	t
324	116	Norditropin SimpleXx	$742.50	t
325	36	Daivonex	$28.06	t
326	59	Leukeran	$137.98	t
327	120	Sandimmun	$54.10	t
328	37	Biatain Adhesive 3423	$93.82	t
329	146	tearsagain	$36.06	t
330	152	Triquilar ED	$17.43	t
330	164	Logynon ED	$17.43	t
330	179	Trifeme 28	$17.43	t
330	180	Triphasil 28	$17.43	t
331	162	Arava	$215.12	t
332	150	Roferon-A	$59.58	t
332	150	Roferon-A	$297.90	t
332	150	Roferon-A	$344.72	t
333	152	Ventavis	$1,076.00	t
334	11	Dexmethsone	$8.84	t
335	162	Eloxatin	$1,216.50	t
335	162	Eloxatin	$1,344.32	t
336	172	TYR Express	$3,098.38	t
337	96	MS Contin	$44.01	t
337	156	Momex SR 60	$44.01	t
338	1	Isoptin	$12.38	t
339	179	Rapamune	$1,446.67	t
339	179	Rapamune	$1,583.69	t
340	120	Glivec	$3,918.69	t
341	11	Indocid	$22.50	t
342	4	Pressin 5	$20.85	t
342	31	Chem mart Prazosin	$20.85	t
342	64	GenRx Prazosin	$20.85	t
342	134	Minipress	$20.85	t
342	169	Terry White Chemists Prazosin	$20.85	t
343	6	Movox 50	$20.37	t
343	156	Faverin 50	$20.37	t
343	158	Luvox	$20.37	t
343	165	Voxam	$20.37	t
343	170	APO-Fluvoxamine	$20.37	t
344	59	Zofran	$42.68	t
344	59	Zofran	$56.90	t
344	149	Ondansetron-RL	$42.68	t
344	149	Ondansetron-RL	$56.90	t
344	156	Onsetron 8	$42.68	t
344	156	Onsetron 8	$56.90	t
344	165	Ondaz	$42.68	t
344	165	Ondaz	$56.90	t
344	170	APO-Ondansetron	$42.68	t
344	170	APO-Ondansetron	$56.90	t
345	9	Toprol-XL 47.5	$72.46	t
346	1	Prothiaden	$8.96	t
346	4	Dothep 75	$8.96	t
347	163	Wartec Cream	$52.66	t
348	151	PKU Anamix infant	$703.62	t
349	4	Dizole 100	$131.36	t
349	69	DBL Fluconazole	$131.36	t
349	134	Diflucan	$131.36	t
349	145	Ozole	$131.36	t
349	165	Fluconazole Sandoz	$131.36	t
349	174	Fluconazole Winthrop	$131.36	t
350	10	Systane	$34.08	t
351	4	Prexaton	$75.84	t
351	59	Zyban	$75.84	t
351	73	Clorprax	$75.84	t
352	91	Nardil	$100.10	t
353	59	Zofran Zydis	$132.63	t
353	149	Ondansetron-RL Zydis	$132.63	t
353	165	Ondaz Zydis	$132.63	t
354	156	Veracaps SR	$12.45	t
355	28	Baxter Healthcare Pty Ltd	$30.02	t
356	27	Handygauze Cohesive 8633	$14.70	t
357	9	Zomig	$25.84	t
357	9	Zomig	$28.60	t
358	4	Megafol 5	$14.02	t
359	151	Duocal	$295.54	t
360	97	Mepitel 290510	$63.62	t
361	99	Stocrin	$135.79	t
362	151	Easiphen	$1,313.27	t
363	120	Trileptal	$72.27	t
364	20	Gold Cross	$9.94	t
365	4	Alodorm	$7.89	t
365	4	Alodorm	$9.36	t
365	173	Mogadon	$7.89	t
365	173	Mogadon	$9.36	t
366	28	Endoxan	$56.60	t
367	156	Florinef	$24.30	t
368	5	Lacri-Lube	$21.19	t
368	76	Poly Visc	$21.19	t
368	133	Ircal	$21.19	t
369	80	Haldol decanoate	$46.23	t
370	64	GenRx Gabapentin	$126.77	t
370	134	Neurontin	$126.77	t
370	134	Neurontin	$127.77	t
370	145	Gabaran	$126.77	t
370	165	Gabahexal 600mg	$126.77	t
371	162	Rythmodan	$36.18	t
372	173	Maxolon	$12.99	t
373	7	Aranesp	$586.10	t
374	69	Leucovorin Calcium	$79.14	t
374	69	Leucovorin Calcium	$100.02	t
375	38	TheraTears	$40.42	t
376	150	Madopar 125	$38.92	t
377	1	Gopten	$14.30	t
377	4	Tranalpha	$14.30	t
377	61	Trandolapril-DP	$14.30	t
377	63	Trandolapril generichealth	$14.30	t
377	156	Dolapril 1	$14.30	t
377	170	APO-Trandolapril	$14.30	t
378	134	Revatio	$898.43	t
379	7	Aranesp SureClick	$344.80	t
380	60	Uracol	$13.55	t
380	156	Ural Sachets	$13.55	t
381	82	Nizoral 1%	$17.60	t
382	62	Simplotan	$9.30	t
382	134	Fasigyn	$9.30	t
383	159	Iodosorb Powder 66051070	$62.69	t
384	5	Combigan	$26.90	t
385	134	Caduet 5/10	$51.62	t
386	69	DBL Metronidazole Intravenous Infusion	$32.00	t
386	165	Metronidazole Sandoz	$32.00	t
387	94	Humulin NPH	$224.32	t
387	112	Protaphane InnoLet	$224.32	t
387	113	Protaphane NovoLet 3 mL	$224.32	t
387	116	Protaphane Penfill 3 mL	$224.32	t
388	28	Onkotrone	$210.45	t
388	28	Onkotrone	$250.70	t
388	141	Pfizer Australia Pty Ltd	$210.45	t
388	141	Pfizer Australia Pty Ltd	$250.70	t
389	71	Restore Plus 9957	$133.26	t
390	51	Aspalgin	$13.57	t
391	9	Arimidex	$180.18	t
392	99	Timoptol XE	$12.62	t
393	9	Crestor	$86.21	t
394	25	B. Braun Australia Pty Ltd	$23.52	t
394	28	Baxter Healthcare Pty Ltd	$23.52	t
394	136	Pharmatel Fresenius Kabi Pty Limited	$23.52	t
395	108	Lamisil	$21.89	t
395	108	Lamisil	$37.36	t
396	151	TYR Anamix junior LQ	$2,507.98	t
397	80	Nizoral	$42.17	t
398	72	Atrauman 499513	$15.24	t
399	134	Champix	$233.06	t
400	5	Cellufresh	$36.06	t
401	7	Aranesp	$850.87	t
402	10	Betoptic S	$15.11	t
403	69	Hospira Pty Limited	$31.56	t
404	156	Serenace	$22.28	t
405	11	Allegron	$13.32	t
406	162	Stemetil	$19.93	t
407	37	Comfeel Plus Ulcer Dressing 3110	$81.99	t
408	115	Vastin	$30.72	t
408	120	Lescol	$30.72	t
409	29	Pradaxa	$81.16	t
410	96	Sevredol	$15.51	t
411	24	Avapro HCT 300/12.5	$32.46	t
411	162	Karvezide 300/12.5	$32.46	t
412	135	Brevinor-1	$16.86	t
413	4	Pendine 800	$166.86	t
413	14	Gantin	$166.86	t
413	64	GenRx Gabapentin	$166.86	t
413	134	Neurontin	$166.86	t
413	134	Neurontin	$167.86	t
413	145	Gabaran	$166.86	t
414	150	Tarceva	$2,703.34	t
415	4	Genox 20	$60.24	t
415	31	Chem mart Tamoxifen	$60.24	t
415	60	Tamoxen 20 mg	$60.24	t
415	64	GenRx Tamoxifen	$60.24	t
415	156	Tamosin	$60.24	t
415	165	Tamoxifen Sandoz	$60.24	t
415	169	Terry White Chemists Tamoxifen	$60.24	t
416	24	Sprycel	$5,250.68	t
417	155	Deca-Durabolin	$21.20	t
418	20	Lomotil	$8.57	t
418	67	Lofenoxal	$8.57	t
419	11	Ferrum H	$51.16	t
419	156	Ferrosig	$51.16	t
420	69	Clopine 200	$518.62	t
421	120	Famvir	$356.93	t
422	69	Hospira Pty Limited	$98.09	t
422	69	Hospira Pty Limited	$122.44	t
422	78	Methotrexate Ebewe	$98.09	t
422	78	Methotrexate Ebewe	$122.44	t
423	69	Clopine Suspension	$135.00	t
424	31	Chem mart Allopurinol	$13.19	t
424	51	Allosig	$13.19	t
424	64	GenRx Allopurinol	$13.19	t
424	156	Zyloprim	$13.19	t
424	165	Allopurinol Sandoz	$13.19	t
424	169	Terry White Chemists Allopurinol	$13.19	t
425	23	Clinitest	$71.48	t
426	78	Doxorubicin Ebewe	$88.92	t
426	78	Doxorubicin Ebewe	$111.59	t
427	135	Caverject Impulse	$103.62	t
428	74	Minitran 10	$34.95	t
428	120	Transiderm-Nitro 50	$34.95	t
428	155	Nitro-Dur 10	$34.95	t
429	74	Nuelin	$10.82	t
430	155	Temodal	$204.39	t
430	155	Temodal	$567.93	t
431	150	Mircera	$1,012.79	t
432	155	Fareston	$69.11	t
433	134	Dilantin Sodium	$30.12	t
434	4	Zimstat	$59.42	t
434	18	Simvabell	$59.42	t
434	31	Chem mart Simvastatin	$59.42	t
434	35	Simvasyn	$59.42	t
434	53	Lipex 80	$59.42	t
434	60	Simvastatin-DP	$59.42	t
434	61	Simvastatin-GA 80	$59.42	t
434	63	Simvastatin generichealth	$59.42	t
434	64	GenRx Simvastatin	$59.42	t
434	98	Pharmacor Simvastatin 80	$59.42	t
434	99	Zocor	$59.42	t
434	145	Ransim	$59.42	t
434	156	Simvar 80	$59.42	t
434	165	Simvahexal	$59.42	t
434	169	Terry White Chemists Simvastatin	$59.42	t
434	170	APO-Simvastatin	$59.42	t
434	174	Simvastatin Winthrop	$59.42	t
434	187	Simvastatin-Spirit 80	$59.42	t
435	4	Metrogyl 400	$7.88	t
436	162	Proctosedyl	$20.04	t
437	13	Vasocardol CD	$21.07	t
437	31	Chem mart Diltiazem CD	$21.07	t
437	60	Dilzem CD	$21.07	t
437	64	GenRx Diltiazem CD	$21.07	t
437	162	Cardizem CD	$21.07	t
437	165	Diltahexal CD	$21.07	t
437	169	Terry White Chemists Diltiazem CD	$21.07	t
438	27	Handy 5674	$27.40	t
439	134	Dilantin	$21.61	t
440	150	Lexotan	$33.40	t
441	156	Logicin Rapid Relief	$16.76	t
442	120	Famvir	$202.35	t
443	4	Ipratrin	$37.28	t
443	29	Atrovent	$37.28	t
443	141	Ipravent	$37.28	t
443	156	Aeron 250	$37.28	t
443	170	APO-Ipratropium	$37.28	t
444	69	Granocyte 34	$1,283.60	t
445	86	Humalog Mix50 KwikPen	$264.22	t
445	94	Humalog Mix50	$264.22	t
446	163	Stieprox Liquid	$16.56	t
447	4	Pressin 1	$12.62	t
447	31	Chem mart Prazosin	$12.62	t
447	64	GenRx Prazosin	$12.62	t
447	134	Minipress	$12.62	t
447	169	Terry White Chemists Prazosin	$12.62	t
448	156	Grisovin	$25.87	t
449	5	Prednefrin Forte	$24.16	t
450	24	Maxipime	$331.62	t
451	58	Viread	$483.10	t
452	4	Keflor CD	$12.89	t
452	11	Ceclor CD	$12.89	t
452	31	Chem mart Cefaclor CD	$12.89	t
452	60	Douglas Cefaclor-CD	$12.89	t
452	61	Cefaclor-GA	$12.89	t
452	64	GenRx Cefaclor CD	$12.89	t
452	92	Karlor CD	$12.89	t
452	145	Ozcef	$12.89	t
452	169	Terry White Chemists Cefaclor CD	$12.89	t
453	153	Natrilix SR	$19.31	t
454	11	Panafcortelone	$8.58	t
454	51	Solone	$8.58	t
455	4	Tryzan Caps 1.25	$11.60	t
455	35	Pharmacor Ramipril 1.25	$11.60	t
455	61	Ramipril-DP	$11.60	t
455	63	Ramipril generichealth	$11.60	t
456	100	Titralac	$23.18	t
457	9	Foscavir	$395.00	t
458	120	Exforge 5/160	$33.48	t
459	162	Panamax	$9.38	t
460	3	Vistil Forte	$10.43	t
461	59	Flixotide Junior	$17.09	t
462	137	Dithiazide	$21.24	t
463	82	Mylanta Double Strength	$46.12	t
464	100	Tegaderm Transparent 1628	$30.66	t
465	120	Dihydergot	$17.06	t
466	1	Hytrin	$86.06	t
467	135	Lincocin	$33.74	t
468	94	Zyprexa Zydis	$99.27	t
469	27	Leukoflex 1124	$17.21	t
470	69	Hospira Pty Limited	$138.25	t
470	69	Hospira Pty Limited	$169.92	t
471	74	Qvar 50 Autohaler	$27.87	t
472	60	Oratane	$92.79	t
472	150	Roaccutane	$92.79	t
473	28	Uromitexan	$81.89	t
473	28	Uromitexan	$103.28	t
474	158	Creon 25,000	$137.90	t
475	152	Primolut N	$33.01	t
476	10	Tobrex	$19.28	t
477	4	Teril	$30.20	t
477	120	Tegretol 200	$30.20	t
477	165	Carbamazepine Sandoz	$30.20	t
478	96	MS Contin	$20.35	t
479	11	Lithicarb	$16.89	t
480	69	Hospira Pty Limited	$70.17	t
480	120	Sandostatin 0.1	$70.17	t
480	181	Octreotide MaxRx	$70.17	t
481	37	Comfeel Plus Pressure Relieving 3350	$55.17	t
482	4	E-Mycin 400	$13.39	t
482	91	E.E.S. Granules	$13.39	t
483	96	Dilaudid	$19.85	t
484	120	Famvir	$143.58	t
485	120	Estradot 75	$19.66	t
486	155	Avanza SolTab	$27.34	t
487	134	Pfizer Australia Pty Ltd	$16.69	t
488	69	Clopine 100	$259.31	t
488	120	Clozaril 100	$259.31	t
489	36	Tramal SR 50	$11.63	t
490	3	Ferro-Liquid	$19.35	t
491	135	Genotropin MiniQuick	$554.40	t
492	155	Andriol Testocaps	$37.53	t
493	161	Tubigrip D 1546	$18.17	t
494	9	Pulmicort Turbuhaler	$23.34	t
495	31	Chem mart Pravastatin	$61.51	t
495	51	Pravachol	$61.51	t
495	60	Pravastatin-GA 80	$61.51	t
495	63	Pravastatin generichealth	$61.51	t
495	156	Lipostat 80	$61.51	t
495	165	Pravastatin Sandoz	$61.51	t
495	169	Terry White Chemists Pravastatin	$61.51	t
495	170	APO-Pravastatin	$61.51	t
496	156	Logicin Sinus	$11.02	t
497	4	Deptran 25	$9.40	t
497	134	Sinequan	$9.40	t
498	134	Thelin	$2,743.80	t
499	4	Tryzan Tabs 2.5	$14.00	t
499	13	Ramace 2.5 mg	$14.00	t
499	31	Chem mart Ramipril	$14.00	t
499	156	Prilace 2.5	$14.00	t
499	162	Tritace 2.5 mg	$14.00	t
499	165	Ramipril Sandoz	$14.00	t
499	169	Terry White Chemists Ramipril	$14.00	t
499	170	APO-Ramipril	$14.00	t
499	174	Ramipril Winthrop	$14.00	t
500	1	Isoptin SR	$16.15	t
500	4	Anpec SR	$16.15	t
500	85	Cordilox SR	$16.15	t
501	59	Hycamtin	$1,980.00	t
501	59	Hycamtin	$2,126.36	t
502	151	XP Maxamaid	$884.02	t
502	151	XP Maxamum	$1,352.42	t
503	162	Tritace Titration Pack	$22.03	t
504	4	Tamate	$41.70	t
504	80	Topamax	$41.70	t
504	156	Epiramax 25	$41.70	t
504	165	Topiramate Sandoz	$41.70	t
504	170	APO-Topiramate	$41.70	t
505	6	Glucovance 500mg/5mg	$17.08	t
506	69	Bondronat	$342.34	t
507	23	Canesten	$13.06	t
507	23	Canesten	$19.70	t
508	120	Trileptal	$187.98	t
509	120	Miacalcic 100	$161.13	t
510	5	Liquifilm Forte	$10.43	t
510	133	PVA Forte	$10.43	t
511	7	Aranesp	$482.87	t
512	23	Xarelto	$279.89	t
513	69	Pamisol	$327.84	t
514	162	Arava	$215.12	t
515	9	ZolaCos CP 3.6/50	$483.55	t
516	4	LoxaLate	$29.09	t
516	31	Chem mart Escitalopram	$29.09	t
516	60	Esipram	$29.09	t
516	93	Lexapro	$29.09	t
516	156	Lexam 20	$29.09	t
516	165	Esitalo	$29.09	t
516	169	Terry White Chemists Escitalopram	$29.09	t
516	170	APO-Escitalopram	$29.09	t
517	31	Chem mart Doxycycline	$10.07	t
517	64	GenRx Doxycycline	$10.07	t
517	156	Frakas	$10.07	t
517	165	Doxyhexal	$10.07	t
517	169	Terry White Chemists Doxycycline	$10.07	t
518	96	OxyContin	$48.35	t
519	80	Aci-Jel	$32.90	t
520	80	Prograf	$374.67	t
520	80	Prograf	$427.27	t
521	154	Gonal-f	$216.00	t
521	154	Gonal-f	$841.89	t
522	137	Phenasen	$24,049.62	t
522	137	Phenasen	$24,196.08	t
523	134	Zithromax	$21.70	t
523	165	Azithromycin Sandoz	$21.70	t
524	16	Avonex	$1,056.77	t
525	155	PEG-Intron Redipen	$2,208.00	t
526	94	Humulin NPH	$133.82	t
526	116	Protaphane	$133.82	t
527	4	Eleva 50	$24.66	t
527	31	Chem mart Sertraline	$24.66	t
527	35	Sertraline 50	$24.66	t
527	60	Sertraline-GA	$24.66	t
527	63	Sertraline generichealth	$24.66	t
527	64	GenRx Sertraline	$24.66	t
527	134	Zoloft	$24.66	t
527	141	Xydep 50	$24.66	t
527	145	Setrona	$24.66	t
527	156	Sertra 50	$24.66	t
527	165	Concorz	$24.66	t
527	169	Terry White Chemists Sertraline	$24.66	t
527	174	Sertraline Winthrop	$24.66	t
528	116	Mixtard 50/50 Penfill 3 mL	$224.32	t
529	152	Bonefos 800 mg	$391.44	t
530	59	Amoxil	$13.17	t
530	59	Amoxil	$13.78	t
531	187	Amlo 10	$24.39	t
532	184	Eryc	$9.43	t
532	185	DBL Erythromycin	$9.43	t
533	179	Relistor	$130.59	t
534	172	MSUD-gel	$1,798.42	t
535	99	Stocrin	$452.64	t
536	147	Suboxone	$120.40	t
537	52	Pentasa	$279.63	t
538	172	MSUD Express	$3,098.38	t
539	155	Prantal	$17.36	t
540	11	Dexmethsone	$12.40	t
541	51	Sotacor	$15.78	t
541	64	GenRx Sotalol	$15.78	t
541	156	Solavert	$15.78	t
541	165	Sotalol Sandoz	$15.78	t
542	150	Pulmozyme	$1,180.00	t
543	120	Sebivo	$250.88	t
544	156	Pro-Banthine	$26.46	t
545	155	PEG-Intron Redipen	$2,760.00	t
546	24	ReVia	$141.01	t
546	63	Naltrexone generichealth	$141.01	t
546	181	Naltrexone QP	$141.01	t
547	99	Stromectol	$31.31	t
548	155	Sandrena	$17.53	t
549	120	Estraderm MX 50	$17.53	t
550	134	Zeldox	$330.43	t
551	165	Cefotaxime Sandoz	$27.22	t
552	30	DuoDERM Extra Thin H7955	$71.72	t
552	37	Comfeel Plus Transparent 3533	$69.78	t
552	72	Hydrocoll Thin 900942/1	$48.15	t
553	120	Tegretol 100	$19.14	t
553	165	Carbamazepine Sandoz	$19.14	t
554	69	Hospira Pty Limited	$45.15	t
554	69	Hospira Pty Limited	$59.83	t
554	78	Cisplatin Ebewe	$45.15	t
554	78	Cisplatin Ebewe	$59.83	t
554	141	Pfizer Australia Pty Ltd	$45.15	t
554	141	Pfizer Australia Pty Ltd	$59.83	t
555	9	Zoladex Implant	$333.00	t
556	6	EpiPen Jr.	$106.00	t
557	151	add-ins	$1,640.07	t
558	1	Prothiaden	$8.96	t
558	4	Dothep 25	$8.96	t
559	4	Tamate	$153.30	t
559	80	Topamax	$153.30	t
559	156	Epiramax 200	$153.30	t
559	165	Topiramate Sandoz	$153.30	t
559	170	APO-Topiramate	$153.30	t
560	134	Lyrica	$183.14	t
561	9	Bricanyl Turbuhaler	$17.83	t
562	25	Gelofusine	$45.75	t
563	80	Invega	$169.68	t
564	120	Riamet	$96.90	t
565	135	Dostinex	$67.49	t
565	156	Tinexa	$67.49	t
566	158	Zumenon	$13.85	t
567	141	Cabaser	$61.98	t
567	156	Bergoline 1	$61.98	t
568	120	Sandostatin LAR	$1,776.74	t
569	36	Nebilet	$50.62	t
570	30	Surepress 650948	$20.32	t
571	120	Myfortic	$444.56	t
571	120	Myfortic	$503.53	t
572	78	Gemcitabine Ebewe	$425.00	t
572	78	Gemcitabine Ebewe	$481.66	t
573	4	Acyclo-V 800	$446.33	t
573	59	Zovirax 800 mg	$446.33	t
573	60	Lovir	$446.33	t
573	165	Acihexal	$446.33	t
574	11	Cortate	$15.30	t
575	64	GenRx Doxycycline	$12.56	t
576	70	Albey Yellow Jacket Venom	$238.38	t
577	135	Solu-Cortef	$16.94	t
577	135	Solu-Cortef	$37.98	t
578	172	TYR Cooler	$3,098.38	t
579	59	Ventolin Rotacaps	$18.50	t
580	163	Polytar	$21.03	t
581	4	Magicul 400	$19.97	t
581	64	GenRx Cimetidine	$19.97	t
582	1	Brufen	$9.19	t
582	1	Brufen	$14.73	t
583	11	Gastro-Stop Loperamide	$8.55	t
583	82	Imodium	$8.55	t
584	69	APO-go	$194.65	t
585	5	Albalon-A	$14.80	t
586	46	SebiRinse	$14.25	t
587	69	Hospira Pty Limited	$482.52	t
588	162	Flagyl S	$17.17	t
589	94	Zyprexa Relprevv	$499.78	t
590	161	Tubegauz 0501633	$17.77	t
591	51	Fawns and McAllan Proprietary Limited	$16.87	t
592	150	Roferon-A	$29.80	t
592	150	Roferon-A	$447.00	t
592	150	Roferon-A	$506.22	t
593	120	Neoral 25	$39.98	t
593	120	Neoral 25	$100.98	t
593	165	Cicloral	$39.98	t
593	165	Cicloral	$100.98	t
594	28	Uromitexan	$185.44	t
594	28	Uromitexan	$223.81	t
595	172	EAA Supplement	$1,516.50	t
596	9	Crestor	$62.50	t
597	150	Tarceva	$3,309.66	t
598	135	Norinyl-1	$16.86	t
599	4	Mobilis 20	$12.20	t
599	31	Chem mart Piroxicam	$12.20	t
599	64	GenRx Piroxicam	$12.20	t
599	134	Feldene	$12.20	t
599	169	Terry White Chemists Piroxicam	$12.20	t
600	59	Valtrex	$155.43	t
601	152	Microgynon 50 ED	$17.43	t
602	134	Chloromycetin	$11.00	t
602	156	Chlorsig	$11.00	t
603	4	Magicul 200	$19.97	t
604	24	Baraclude	$384.30	t
605	94	Cymbalta	$38.22	t
606	159	Viscopaste 4948	$70.64	t
606	161	Zincaband 3604	$29.20	t
606	182	Steripaste 3610	$29.66	t
607	1	Klacid	$12.68	t
607	4	Kalixocin	$12.68	t
607	31	Chem mart Clarithromycin	$12.68	t
607	60	Clarac	$12.68	t
607	64	GenRx Clarithromycin	$12.68	t
607	156	Clarithro 250	$12.68	t
607	165	Clarihexal	$12.68	t
607	169	Terry White Chemists Clarithromycin	$12.68	t
607	170	APO-Clarithromycin	$12.68	t
608	96	MS Contin Suspension 20 mg	$48.22	t
609	74	Nuelin-SR 200	$12.16	t
610	29	Micardis Plus 40/12.5 mg	$23.73	t
611	100	Nexcare Tegaderm Transparent H1624	$15.64	t
612	35	Pharmacor Paroxo 20	$25.48	t
612	63	Paroxetine generichealth	$25.48	t
613	59	Flixotide Junior Accuhaler	$17.09	t
614	158	Physiotens	$19.53	t
615	155	PEG-Intron Redipen	$1,840.00	t
616	7	Neulasta	$1,925.00	t
617	11	Panafcort	$8.95	t
617	92	Predsone	$8.95	t
618	156	Physeptone	$30.82	t
619	4	Pamacid 20	$17.41	t
619	31	Chem mart Famotidine	$17.41	t
619	60	Pepzan	$17.41	t
619	64	GenRx Famotidine	$17.41	t
619	99	Pepcidine M	$17.41	t
619	156	Ausfam 20	$17.41	t
619	165	Famohexal	$17.41	t
619	169	Terry White Chemists Famotidine	$17.41	t
620	156	Predsol	$43.32	t
621	9	Pulmicort Turbuhaler	$31.08	t
622	4	QuitX	$54.56	t
622	56	Nicabate CQ 14	$68.74	t
623	1	Norvir	$106.17	t
624	4	LoxaLate	$28.95	t
624	31	Chem mart Escitalopram	$28.95	t
624	60	Esipram	$28.95	t
624	93	Lexapro	$28.95	t
624	156	Lexam 10	$28.95	t
624	165	Esitalo	$28.95	t
624	169	Terry White Chemists Escitalopram	$28.95	t
624	170	APO-Escitalopram	$28.95	t
625	96	MS Contin Suspension 30 mg	$49.43	t
626	96	MS Mono	$20.35	t
627	94	Actos	$116.64	t
628	4	Tacidine	$19.06	t
628	11	Tazac	$19.06	t
628	92	Nizac	$19.06	t
629	106	Biodone Forte	$7.40	t
629	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$7.40	t
629	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$18.28	t
630	179	Enbrel	$1,630.01	t
630	179	Enbrel	$1,774.37	t
631	120	Aredia 90 mg	$327.84	t
632	5	Ganfort 0.3/5	$46.82	t
633	4	Tamate	$93.86	t
633	80	Topamax	$93.86	t
633	156	Epiramax 100	$93.86	t
633	165	Topiramate Sandoz	$93.86	t
633	170	APO-Topiramate	$93.86	t
634	159	Cutifilm Plus 76308	$40.00	t
635	156	Fungilin	$12.03	t
636	122	Salofalk	$297.44	t
637	118	Alfare	$171.94	t
638	9	AstraZeneca Pty Ltd	$20.34	t
639	134	Zithromax	$31.51	t
640	167	Panzytrat 25000	$137.90	t
641	24	Orencia	$504.43	t
642	17	Elastoplast 2225	$15.11	t
643	99	Proscar	$111.69	t
643	165	Finasta	$102.12	t
644	162	Phenergan	$14.67	t
645	69	Clopine 25	$69.15	t
645	120	Clozaril 25	$69.15	t
646	150	CellCept	$244.51	t
646	150	CellCept	$289.84	t
647	154	Serophene	$36.00	t
647	162	Clomid	$36.00	t
648	162	Resonium-A	$65.56	t
649	77	Dysport	$650.00	t
650	4	Aylide 1	$9.10	t
650	13	Dimirel	$9.10	t
650	156	Diapride 1	$9.10	t
650	162	Amaryl	$9.10	t
650	165	Glimepiride Sandoz	$9.10	t
650	170	APO-Glimepiride	$9.10	t
651	122	Salofalk	$336.22	t
652	4	Nupentin 300	$62.01	t
652	14	Gantin	$62.01	t
652	35	Gabapentin 300	$62.01	t
652	60	Gabapentin-GA	$62.01	t
652	61	Douglas Gabapentin 300mg	$62.01	t
652	64	GenRx Gabapentin	$62.01	t
652	69	DBL Gabapentin	$62.01	t
652	134	Neurontin	$62.01	t
652	134	Neurontin	$63.00	t
652	156	Gabatine 300	$62.01	t
652	165	Gabahexal 300mg	$62.01	t
653	29	Micardis Plus 80/25 mg	$33.07	t
654	96	MS Contin	$56.49	t
654	156	Momex SR 100	$56.49	t
655	135	Arthrotec 50	$37.78	t
656	120	Exelon Patch 10	$166.09	t
657	4	Glyade	$13.52	t
657	31	Chem mart Gliclazide	$13.52	t
657	64	GenRx Gliclazide	$13.52	t
657	156	Nidem	$13.52	t
657	165	Mellihexal	$13.52	t
657	169	Terry White Chemists Gliclazide	$13.52	t
658	59	Seretide MDI 250/25	$78.67	t
659	31	Chem mart Diclofenac	$13.06	t
659	60	Diclofenac-GA	$13.06	t
659	120	Voltaren 25	$13.06	t
659	156	Clonac 25	$13.06	t
659	165	Diclofenac Sandoz	$13.06	t
659	169	Terry White Chemists Diclofenac	$13.06	t
659	170	APO-Diclofenac	$13.06	t
660	57	Dibenzyline	$1,164.47	t
661	120	Stalevo 100/25/200mg	$341.92	t
662	91	Akineton	$20.88	t
663	10	Isopto Carpine	$17.05	t
664	99	Trusopt	$21.29	t
665	171	Keppra	$111.42	t
666	4	Sical	$43.25	t
666	60	Calcitriol-GA	$43.25	t
666	61	Calcitriol-DP	$43.25	t
666	64	GenRx Calcitriol	$43.25	t
666	150	Rocaltrol	$43.25	t
666	156	Kosteo	$43.25	t
666	165	Citrihexal	$43.25	t
667	6	D-Penamine	$43.51	t
668	120	Neoral 50	$83.17	t
668	120	Neoral 50	$203.16	t
668	165	Cicloral	$83.17	t
668	165	Cicloral	$203.16	t
669	24	Videx EC	$326.79	t
670	4	Alzene	$29.65	t
670	82	Zyrtec	$39.45	t
670	165	Zilarex	$32.87	t
671	156	Cilicaine	$92.22	t
672	72	TenderWet 24 Active	$67.90	t
673	4	E-Mycin	$10.92	t
673	91	E.E.S. 400 Filmtab	$10.92	t
674	147	Suboxone	$42.00	t
675	4	Genox 10	$38.88	t
676	58	Hepsera	$625.00	t
677	99	Fosamax Plus	$46.57	t
678	19	Amoxycillin Sandoz	$10.79	t
678	165	Maxamox	$10.79	t
679	51	Cortival 1/2	$8.50	t
679	156	Betnovate 1/2	$8.50	t
680	159	Iodosorb 66051330	$95.22	t
681	7	Neupogen	$1,504.00	t
682	120	Exelon	$155.45	t
683	94	Strattera	$147.11	t
684	161	Tubigrip 1480	$30.44	t
685	5	Celluvisc	$36.06	t
686	135	Solu-Cortef	$15.92	t
686	135	Solu-Cortef	$60.96	t
687	115	In a Wink Moisturising	$10.43	t
687	120	Genteal	$10.43	t
688	11	Vancocin CP	$17.96	t
688	11	Vancocin CP	$35.27	t
688	69	Hospira Pty Limited	$17.96	t
688	69	Hospira Pty Limited	$35.27	t
688	165	Vancomycin Sandoz	$17.96	t
688	165	Vancomycin Sandoz	$35.27	t
689	11	Aspen Ampicyn	$14.07	t
689	92	Austrapen	$14.07	t
689	168	Ibimicyn	$14.07	t
690	5	Botox	$415.50	t
691	5	Liquifilm Tears	$10.43	t
691	133	PVA Tears	$10.43	t
692	152	Reandron 1000	$147.41	t
693	120	Ritalin LA	$56.71	t
694	56	Cartia	$13.71	t
695	4	Adefin XL 30	$19.07	t
695	23	Adalat Oros 30	$19.07	t
695	156	Addos XR 30	$19.07	t
695	170	APO-Nifedipine XR	$19.07	t
696	81	Nu-Gel 2497	$83.20	t
697	154	Rebif 44	$1,056.77	t
698	24	Abilify	$303.49	t
699	96	MS Contin	$17.24	t
699	156	Momex SR 10	$17.24	t
700	150	Pegasys RBV	$1,622.91	t
701	23	Citracal	$14.31	t
701	23	Citracal	$22.20	t
702	135	Celebrex	$32.31	t
703	81	Adaptic 2012	$15.72	t
704	9	AstraZeneca Pty Ltd	$20.54	t
705	120	Ritalin LA	$54.05	t
706	137	Pro-Cid	$75.69	t
707	36	Advantan	$14.29	t
708	162	Phenergan	$16.76	t
709	134	Zeldox	$253.63	t
710	92	Austrapen	$11.08	t
710	168	Ibimicyn	$11.08	t
711	11	LPV	$11.41	t
711	51	Cilicaine VK	$11.41	t
711	60	Cilopen VK	$11.41	t
712	69	Eligard 4 month	$1,451.33	t
713	59	Ziagen	$82.14	t
714	80	Concerta	$62.36	t
715	69	Hospira Pty Limited	$84.06	t
715	69	Hospira Pty Limited	$105.84	t
716	155	Temodal	$1,863.31	t
717	7	Neupogen	$2,407.00	t
718	162	Taxotere	$288.29	t
718	162	Taxotere	$334.39	t
718	162	Taxotere	$576.58	t
718	162	Taxotere	$651.16	t
719	4	Aylide 4	$14.46	t
719	13	Dimirel	$14.46	t
719	156	Diapride 4	$14.46	t
719	162	Amaryl	$14.46	t
719	165	Glimepiride Sandoz	$14.46	t
719	170	APO-Glimepiride	$14.46	t
720	87	Pyralin EN	$56.04	t
720	135	Salazopyrin-EN	$56.04	t
721	51	Coloxyl with Senna	$16.70	t
722	4	Distaph 500	$16.94	t
722	24	Diclocil	$16.94	t
722	156	Dicloxsig	$16.94	t
723	2	Cerumol	$14.08	t
724	143	Metamucil Smooth Texture Orange	$21.67	t
725	158	Teveten	$29.08	t
725	158	Teveten	$31.08	t
726	94	Effient	$96.43	t
727	69	Apomine	$77.86	t
728	91	Hygroton 25	$13.64	t
729	135	Edronax	$38.76	t
730	150	Madopar Rapid 62.5	$23.00	t
731	155	Olmetec	$30.24	t
732	120	Exforge 10/160	$40.69	t
733	4	Megafol 0.5	$13.78	t
734	94	Humatrope	$1,188.00	t
735	9	Pulmicort Respules	$37.86	t
736	4	Ulcyte	$24.05	t
736	11	Carafate	$24.05	t
737	1	Isoptin 180 SR	$13.72	t
737	85	Cordilox 180 SR	$13.72	t
738	27	Elastocrepe 36102520	$18.28	t
738	84	Telfa 8252F	$17.44	t
739	29	Metalyse	$2,057.06	t
740	135	Zavedos	$451.62	t
741	156	Artane	$15.32	t
742	5	Ocufen	$15.37	t
743	13	Arabloc	$93.66	t
743	162	Arava	$93.66	t
744	151	Metabolic Mineral Mixture	$58.54	t
745	80	Risperdal Quicklet	$34.30	t
746	80	Eprex 5000	$556.50	t
747	4	Rixadone	$111.58	t
747	35	Resdone 2	$111.58	t
747	60	Risperidone-GA	$111.58	t
747	63	Risperidone generichealth	$111.58	t
747	80	Risperdal	$111.58	t
747	145	Ozidal	$111.58	t
747	156	Rispa	$111.58	t
747	170	APO-Risperidone	$111.58	t
748	154	Gonal-f Pen	$144.00	t
748	154	Gonal-f Pen	$563.43	t
749	59	Malarone	$67.00	t
750	27	Handy 5608	$13.49	t
751	80	Nizoral	$19.79	t
752	24	Blenoxane	$425.74	t
752	156	Blenamax	$425.74	t
753	4	Dizole 50	$70.56	t
753	69	DBL Fluconazole	$70.56	t
753	134	Diflucan	$70.56	t
753	145	Ozole	$70.56	t
753	156	Fluzole 50	$70.56	t
753	165	Fluconazole Sandoz	$70.56	t
754	56	Panadol Osteo	$16.64	t
755	59	Telzir	$101.56	t
756	9	Xylocard 500	$29.59	t
757	9	Toprol-XL 95	$88.96	t
758	120	Tegretol Liquid	$21.35	t
759	71	Restore CalciCare 9940	$82.12	t
760	117	Alvesco 160	$42.25	t
761	69	Hospira Pty Limited	$15.48	t
762	161	Tubigrip F 1548	$18.17	t
763	134	Dilantin Infatabs	$30.12	t
764	122	Orphan Australia Pty Ltd	$337.55	t
765	100	Nexcare Gentle Paper First Aid Tape 789	$11.05	t
766	172	ProZero	$304.02	t
767	37	Comfeel SeaSorb Dressing 3710	$90.12	t
767	114	Sorbsan 1410	$84.42	t
768	120	Miacalcic 50	$207.66	t
769	84	Curity 4112	$12.83	t
770	4	Ibilex 125	$11.83	t
770	11	Keflex	$11.83	t
770	31	Chem mart Cephalexin	$11.83	t
770	60	Cilex	$11.83	t
770	64	GenRx Cephalexin	$11.83	t
770	92	Ialex	$11.83	t
770	165	Cefalexin Sandoz	$11.83	t
770	169	Terry White Chemists Cephalexin	$11.83	t
771	46	Pinetarsol	$22.52	t
771	66	Hamilton Pine Tar Solution	$20.73	t
772	80	Invega	$161.07	t
773	147	Gaviscon P	$14.68	t
774	24	Avapro	$30.24	t
774	162	Karvea	$30.24	t
775	151	XLYS, LOW TRY Maxamaid	$1,784.74	t
776	69	Hospira Pty Limited	$14.56	t
777	134	Lipitor	$42.70	t
778	59	Trizivir	$852.00	t
779	97	Mepitac 298300	$21.37	t
780	135	Celebrex	$32.31	t
781	154	Gonal-f	$504.00	t
781	154	Gonal-f	$656.19	t
782	120	Tegretol CR 200	$30.69	t
783	81	JJ 12010	$17.21	t
784	120	Estraderm MX 25	$17.53	t
785	91	Link Medical Products Pty Ltd	$100.58	t
786	92	Aspen Pharmacare Australia Pty Limited	$20.07	t
787	4	Alepam 30	$7.86	t
787	4	Alepam 30	$9.30	t
787	51	Murelax	$7.86	t
787	51	Murelax	$9.30	t
787	156	Serepax	$7.86	t
787	156	Serepax	$9.30	t
788	159	Allevyn 66007637	$117.44	t
788	182	Lyofoam Extra 603088	$75.06	t
789	48	Navelbine	$2,433.46	t
790	172	Arginine Amino Acid Supplement	$516.02	t
791	152	Progynova	$14.21	t
792	30	DuoDERM CGF H7660	$81.40	t
792	71	Restore Plus 9956	$58.82	t
793	80	Durogesic 75	$127.28	t
794	172	RenaStart	$1,329.30	t
795	69	Eligard 3 month	$1,108.76	t
796	4	Perindo	$18.14	t
796	31	Chem mart Perindopril	$18.14	t
796	35	Perindopril 4	$18.14	t
796	60	Perindopril-GA	$18.14	t
796	61	Perindopril-DP	$18.14	t
796	64	GenRx Perindopril	$18.14	t
796	145	Ozapace	$18.14	t
796	156	Indopril 4	$18.14	t
796	169	Terry White Chemists Perindopril	$18.14	t
797	134	Leucovorin Calcium	$122.95	t
797	134	Leucovorin Calcium	$151.84	t
798	168	Abraxane	$401.48	t
798	168	Abraxane	$456.09	t
799	10	Ciloxan	$19.28	t
800	59	3TC	$86.48	t
801	166	Rapilysin 10 U	$2,066.96	t
802	135	Provera	$130.80	t
803	4	Lumin 10	$15.75	t
803	155	Tolvon	$15.75	t
804	4	Pressin 2	$14.93	t
804	31	Chem mart Prazosin	$14.93	t
804	64	GenRx Prazosin	$14.93	t
804	134	Minipress	$14.93	t
804	169	Terry White Chemists Prazosin	$14.93	t
805	4	Tacidine	$19.06	t
805	11	Tazac	$19.06	t
805	92	Nizac	$19.06	t
806	120	Stalevo 50/12.5/200mg	$311.88	t
807	134	Zeldox	$90.61	t
808	134	Leucovorin Calcium	$226.90	t
808	134	Leucovorin Calcium	$268.44	t
809	120	Estalis sequi 50/140	$19.66	t
809	120	Estalis sequi 50/250	$19.66	t
810	154	Rebif 44	$1,056.77	t
811	4	Valpro 500	$57.36	t
811	156	Valprease 500	$57.36	t
811	162	Epilim EC	$57.36	t
811	165	Sodium Valproate Sandoz	$57.36	t
811	174	Valproate Winthrop EC 500	$57.36	t
812	59	Zofran	$86.98	t
812	149	Ondansetron-RL	$86.98	t
812	156	Onsetron 4	$86.98	t
812	165	Ondaz	$86.98	t
812	170	APO-Ondansetron	$86.98	t
813	162	Eloxatin	$315.60	t
813	162	Eloxatin	$363.75	t
814	5	Combigan	$26.90	t
815	120	Aredia 30 mg	$218.56	t
815	120	Aredia 30 mg	$259.41	t
816	134	Viagra	$75.49	t
817	24	Abilify	$253.43	t
818	29	Pradaxa	$228.21	t
819	1	Tarka 2/180	$22.72	t
820	151	MSUD Anamix Junior	$1,800.46	t
821	24	Videx EC	$140.43	t
822	59	Bactroban	$16.28	t
823	24	Sprycel	$3,246.36	t
824	29	Imukin	$1,360.90	t
825	162	Flagyl	$23.16	t
826	137	Ospolot	$46.12	t
827	20	Gold Cross	$9.02	t
827	74	Duro-Tuss	$14.61	t
828	59	Arixtra	$140.54	t
829	94	Strattera	$221.18	t
830	181	Max Pharma Pty Ltd	$37.59	t
831	4	Alprim	$8.48	t
831	156	Triprim	$8.48	t
832	82	Livostin	$18.24	t
833	69	Hospira Pty Limited	$44.35	t
834	93	Ebixa	$109.00	t
835	94	Strattera	$147.11	t
836	4	Clonea	$8.84	t
836	4	Clonea	$11.26	t
837	134	Diflucan	$162.52	t
837	165	Fluconazole Hexal	$162.52	t
838	135	Mycobutin	$147.00	t
839	4	Sical	$43.25	t
839	60	Calcitriol-GA	$43.25	t
839	61	Calcitriol-DP	$43.25	t
839	64	GenRx Calcitriol	$43.25	t
839	150	Rocaltrol	$43.25	t
839	156	Kosteo	$43.25	t
839	165	Citrihexal	$43.25	t
840	4	Monace 20	$20.25	t
840	24	Monopril	$20.25	t
840	64	GenRx Fosinopril	$20.25	t
840	156	Fosipril 20	$20.25	t
840	165	Fosinopril Sandoz	$20.25	t
841	150	NeoRecormon	$556.50	t
842	82	Daktarin	$15.56	t
843	135	Fragmin	$55.61	t
843	135	Fragmin	$104.74	t
844	4	Sulprix	$118.88	t
844	162	Solian 200	$118.88	t
844	165	Amisulpride Sandoz	$118.88	t
844	174	Amisulpride 200 Winthrop	$118.88	t
845	4	Resprim	$8.67	t
846	156	Kenacomb	$19.09	t
847	134	Aricept	$155.45	t
848	51	Fawns and McAllan Proprietary Limited	$11.86	t
849	22	Peg 7425	$28.18	t
850	158	Creon 5000	$119.22	t
851	162	Dimetriose	$81.81	t
852	13	Otodex	$9.50	t
852	162	Sofradex	$9.50	t
853	59	Telzir	$568.74	t
854	115	HPMC PAA	$10.43	t
854	120	Genteal gel	$10.43	t
855	82	Nicorette Patch	$54.78	t
856	94	Humatrope	$594.00	t
857	83	Spenco Dermal Pad 10-553	$28.50	t
858	155	Integrilin	$262.54	t
859	139	Petrus Pharmaceuticals Pty Ltd	$19.26	t
859	139	Petrus Pharmaceuticals Pty Ltd	$29.76	t
860	69	Androderm	$95.84	t
861	162	Eloxatin	$609.63	t
861	162	Eloxatin	$688.11	t
862	159	Melolin 66974933	$32.40	t
863	25	B. Braun Australia Pty Ltd	$23.52	t
863	28	Baxter Healthcare Pty Ltd	$23.52	t
863	136	Pharmatel Fresenius Kabi Pty Limited	$23.52	t
864	30	DuoDERM Paste H7930	$145.12	t
865	122	Actiq	$115.60	t
865	122	Actiq	$680.13	t
866	9	ZolaCos CP 10.8/50(84)	$1,544.59	t
867	51	Urex-Forte	$18.74	t
868	4	Zimstat	$33.20	t
868	18	Simvabell	$33.20	t
868	31	Chem mart Simvastatin	$33.20	t
868	35	Simvasyn	$33.20	t
868	53	Lipex 20	$33.20	t
868	60	Simvastatin-DP	$33.20	t
868	61	Simvastatin-GA 20	$33.20	t
868	63	Simvastatin generichealth	$33.20	t
868	64	GenRx Simvastatin	$33.20	t
868	98	Pharmacor Simvastatin 20	$33.20	t
868	99	Zocor	$33.20	t
868	145	Ransim	$33.20	t
868	156	Simvar 20	$33.20	t
868	165	Simvahexal	$33.20	t
868	169	Terry White Chemists Simvastatin	$33.20	t
868	170	APO-Simvastatin	$33.20	t
868	174	Simvastatin Winthrop	$33.20	t
868	187	Simvastatin-Spirit 20	$33.20	t
869	37	Comfeel Paste 4701	$43.22	t
870	31	Chem mart Paracetamol	$8.42	t
870	31	Chem mart Paracetamol	$12.42	t
870	51	Paralgin	$8.42	t
870	51	Paralgin	$12.42	t
870	60	Febridol	$8.42	t
870	60	Febridol	$12.42	t
870	63	Generic Health Pty Ltd	$8.42	t
870	63	Generic Health Pty Ltd	$12.42	t
870	131	Dymadon P	$8.42	t
870	131	Dymadon P	$12.42	t
870	162	Panamax	$8.42	t
870	162	Panamax	$12.42	t
870	165	Paracetamol Sandoz	$8.42	t
870	165	Paracetamol Sandoz	$12.42	t
870	169	Terry White Chemists Paracetamol	$8.42	t
870	169	Terry White Chemists Paracetamol	$12.42	t
870	170	APO-Paracetamol	$8.42	t
870	170	APO-Paracetamol	$12.42	t
870	183	Pharmacy Choice Paracetamol	$8.42	t
870	183	Pharmacy Choice Paracetamol	$12.42	t
871	120	Lioresal Intrathecal	$148.37	t
872	69	Androderm	$95.84	t
873	99	Isentress	$1,146.90	t
874	162	Rifadin	$28.57	t
875	156	Buspar	$54.84	t
876	82	Daktarin	$15.90	t
877	91	Tofranil 10	$8.63	t
877	140	Tolerade 10	$8.63	t
878	4	Anthel 125	$8.41	t
879	94	Evista	$57.87	t
880	119	Locasol	$381.38	t
881	80	Reminyl	$130.82	t
882	4	Endep 50	$8.89	t
883	4	Nupentin 100	$23.81	t
883	14	Gantin	$23.81	t
883	69	DBL Gabapentin	$23.81	t
883	134	Neurontin	$23.81	t
883	134	Neurontin	$24.81	t
883	156	Gabatine 100	$23.81	t
883	170	APO-Gabapentin	$23.81	t
884	171	Keppra	$145.33	t
885	119	Pepti-Junior Gold	$109.86	t
886	58	Emtriva	$282.00	t
887	96	MS Mono	$44.01	t
888	172	Glycosade	$752.30	t
889	4	Diaformin	$13.09	t
889	6	Diabex	$13.09	t
889	18	Metforbell	$13.09	t
889	31	Chem mart Metformin	$13.09	t
889	35	Metformin 500	$13.09	t
889	60	Metformin-GA	$13.09	t
889	61	Genepharm (Australia) Limited	$13.09	t
889	63	Metformin generichealth	$13.09	t
889	64	GenRx Metformin	$13.09	t
889	102	Glucophage	$13.09	t
889	145	Metformin Ranbaxy	$13.09	t
889	156	Formet 500	$13.09	t
889	165	Glucohexal	$13.09	t
889	169	Terry White Chemists Metformin	$13.09	t
890	162	Betamin	$10.82	t
891	4	Tryzan Caps 2.5	$14.00	t
891	35	Pharmacor Ramipril 2.5	$14.00	t
891	61	Ramipril-DP	$14.00	t
891	63	Ramipril generichealth	$14.00	t
892	11	Aggrastat	$363.11	t
893	78	Epirubicin Ebewe	$825.86	t
893	78	Epirubicin Ebewe	$929.91	t
894	38	TheraTears	$34.08	t
895	4	Aylide 3	$13.00	t
895	13	Dimirel	$13.00	t
895	156	Diapride 3	$13.00	t
895	162	Amaryl	$13.00	t
895	165	Glimepiride Sandoz	$13.00	t
895	170	APO-Glimepiride	$13.00	t
896	135	Zavedos	$247.11	t
897	156	Capoten	$111.82	t
898	4	Kinson	$39.61	t
898	99	Sinemet 100/25	$39.61	t
899	120	Neoral 10	$37.20	t
899	120	Neoral 10	$94.42	t
900	159	Cutinova Hydro 66047441	$46.13	t
901	135	Genotropin MiniQuick	$207.90	t
902	4	Tramedo SR 100	$13.86	t
902	31	Chem mart Tramadol SR	$13.86	t
902	36	Tramal SR 100	$13.86	t
902	156	Zydol SR 100	$13.86	t
902	165	Tramahexal SR	$13.86	t
902	169	Terry White Chemists Tramadol SR	$13.86	t
902	170	APO-Tramadol SR	$13.86	t
902	187	Lodam SR 100	$13.86	t
903	27	Tensopress 66004348	$116.82	t
903	30	Surepress 650947	$72.92	t
904	179	S-26 LF	$112.87	t
905	120	Exelon	$155.45	t
906	158	Lipidil	$30.05	t
907	6	Acimax Tablets	$29.34	t
907	9	Losec Tablets	$29.34	t
907	138	Omepral	$29.34	t
908	55	Ionil-T	$20.38	t
909	91	Tofranil 25	$8.63	t
909	140	Tolerade 25	$8.63	t
910	27	Handy 4207	$12.20	t
911	4	Qpril 20	$19.73	t
911	6	Filpril	$19.73	t
911	35	Pharmacor Quinapril 20	$19.73	t
911	60	Quinapril-GA	$19.73	t
911	63	Quinapril generichealth	$19.73	t
911	134	Accupril	$19.73	t
911	156	Acquin 20	$19.73	t
911	165	Quinapril Sandoz	$19.73	t
911	170	APO-Quinapril	$19.73	t
912	4	Kripton 5	$50.25	t
912	120	Parlodel	$50.25	t
913	91	Link Medical Products Pty Ltd	$113.84	t
914	82	Mylanta Double Strength	$22.64	t
915	151	MMA/PA Anamix infant	$769.30	t
916	170	APO-Clotrimazole 6 Day Cream	$15.08	t
917	120	Synacthen Depot 1 mg/1 mL	$71.27	t
918	156	Pro-Banthine	$26.46	t
919	4	Dicarz	$48.40	t
919	31	Chem mart Carvedilol 6.25 mg	$48.40	t
919	51	Dilasig 6.25	$48.40	t
919	60	GN-Carvedilol	$48.40	t
919	63	Carvedilol generichealth	$48.40	t
919	64	GenRx Carvedilol	$48.40	t
919	95	Kredex	$48.40	t
919	150	Dilatrend 6.25	$48.40	t
919	156	Vedilol 6.25	$48.40	t
919	165	Carvedilol Sandoz	$48.40	t
919	169	Terry White Chemists Carvedilol 6.25 mg	$48.40	t
920	10	Maxidex	$10.61	t
921	9	Bricanyl	$30.59	t
922	29	Mexitil	$63.79	t
923	52	Minirin	$161.17	t
924	29	Atrovent Nasal Aqueous	$23.59	t
925	60	Oratane	$127.92	t
926	94	Actos	$91.19	t
927	120	Diovan	$20.13	t
928	6	Lovan 20 Tab	$20.81	t
928	94	Prozac Tab	$20.81	t
929	59	Naramig	$25.90	t
929	59	Naramig	$28.68	t
930	9	Seroquel	$187.70	t
931	59	Zantac Syrup	$21.72	t
931	59	Zantac Syrup	$23.92	t
932	4	Tryzan Tabs 5	$15.93	t
932	13	Ramace 5 mg	$15.93	t
932	31	Chem mart Ramipril	$15.93	t
932	156	Prilace 5	$15.93	t
932	162	Tritace 5 mg	$15.93	t
932	165	Ramipril Sandoz	$15.93	t
932	169	Terry White Chemists Ramipril	$15.93	t
932	170	APO-Ramipril	$15.93	t
932	174	Ramipril Winthrop	$15.93	t
933	1	EleCare	$361.14	t
933	1	EleCare	$531.66	t
933	151	Neocate	$361.14	t
933	151	Neocate Advance	$361.14	t
933	151	Neocate Advance Tropical Flavour	$361.14	t
934	151	MSUD Anamix infant	$769.30	t
935	4	QuitX	$51.38	t
936	94	ReoPro	$1,453.11	t
937	97	Mepilex Lite 284100	$38.21	t
938	80	Intelence	$616.50	t
939	5	Albalon Liquifilm	$15.09	t
940	69	Bondronat	$341.36	t
941	13	Vasocardol CD	$17.26	t
941	31	Chem mart Diltiazem CD	$17.26	t
941	60	Dilzem CD	$17.26	t
941	64	GenRx Diltiazem CD	$17.26	t
941	162	Cardizem CD	$17.26	t
941	165	Diltahexal CD	$17.26	t
941	169	Terry White Chemists Diltiazem CD	$17.26	t
942	4	Corbeton 40	$11.78	t
943	91	Neo-Mercazole	$31.04	t
944	159	Jelonet 7404	$19.29	t
945	4	Axit 30	$27.34	t
945	31	Chem mart Mirtazapine	$27.34	t
945	60	Mirtazapine-DP	$27.34	t
945	64	GenRx Mirtazapine	$27.34	t
945	155	Avanza	$27.34	t
945	156	Mirtazon	$27.34	t
945	165	Mirtazapine Sandoz	$27.34	t
945	169	Terry White Chemists Mirtazapine	$27.34	t
946	134	Xalacom	$46.82	t
947	36	Nebilet	$29.25	t
948	152	Climara 50	$17.53	t
949	37	Comfeel Plus Transparent 3530	$41.72	t
950	59	Avandia	$61.52	t
951	162	Phenergan	$14.67	t
952	187	Amlo 5	$16.68	t
953	156	Lanoxin	$28.68	t
954	59	Daraprim	$16.37	t
955	162	Myocrisin	$102.67	t
956	135	Genotropin MiniQuick	$415.80	t
957	162	Anzemet	$18.50	t
957	162	Anzemet	$29.29	t
958	150	Roferon-A	$44.70	t
958	150	Roferon-A	$223.50	t
958	150	Roferon-A	$264.72	t
959	4	Placil	$16.83	t
959	31	Chem mart Clomipramine	$16.83	t
959	64	GenRx Clomipramine	$16.83	t
959	120	Anafranil 25	$16.83	t
959	169	Terry White Chemists Clomipramine	$16.83	t
960	159	Algisite M 66000521	$225.99	t
961	122	Salofalk	$297.44	t
962	4	Hydopa	$13.65	t
962	11	Aldomet	$13.65	t
963	31	Chem mart Carvedilol 3.125 mg	$15.53	t
963	51	Dilasig 3.125	$15.53	t
963	60	GN-Carvedilol	$15.53	t
963	64	GenRx Carvedilol	$15.53	t
963	95	Kredex	$15.53	t
963	150	Dilatrend 3.125	$15.53	t
963	156	Vedilol 3.125	$15.53	t
963	169	Terry White Chemists Carvedilol 3.125 mg	$15.53	t
964	179	Zoton FasTabs	$19.33	t
965	51	Cortic-DS 1%	$8.98	t
965	156	Sigmacort	$8.98	t
966	162	Actonel	$304.62	t
967	139	Petrus Pharmaceuticals Pty Ltd	$18.84	t
967	139	Petrus Pharmaceuticals Pty Ltd	$28.80	t
968	69	Hospira Pty Limited	$25.08	t
968	69	Hospira Pty Limited	$37.44	t
969	171	Dipentum	$103.29	t
970	1	Klacid	$72.24	t
971	165	Probitor	$29.34	t
972	10	Duratears	$21.84	t
972	76	Poly Visc	$21.84	t
973	10	Duotrav	$46.82	t
974	155	Schering-Plough Pty Limited	$209.55	t
975	134	Lyrica	$84.96	t
976	134	Vfend	$700.87	t
977	135	Genotropin	$594.00	t
978	80	Reminyl	$158.59	t
979	162	Phenergan	$16.76	t
980	4	Kalma 2	$20.06	t
980	31	Chem mart Alprazolam	$20.06	t
980	60	Alprazolam-GA	$20.06	t
980	64	GenRx Alprazolam	$20.06	t
980	135	Xanax Tri-Score	$20.06	t
980	156	Alprax 2	$20.06	t
980	165	Alprazolam Sandoz	$20.06	t
980	169	Terry White Chemists Alprazolam	$20.06	t
981	162	Rythmodan	$27.15	t
982	59	Zofran syrup 50 mL	$68.12	t
982	59	Zofran syrup 50 mL	$86.98	t
983	7	Aranesp	$352.96	t
984	7	Sensipar	$593.72	t
984	7	Sensipar	$670.32	t
985	122	Ferriprox	$225.28	t
986	94	Strattera	$221.18	t
987	155	Avanza SolTab	$41.24	t
988	120	Exjade	$934.30	t
989	4	Dapa-Tabs	$17.48	t
989	31	Chem mart Indapamide	$17.48	t
989	60	Indapamide-GA	$17.48	t
989	61	Napamide 2.5 mg	$17.48	t
989	64	GenRx Indapamide	$17.48	t
989	153	Natrilix	$17.48	t
989	156	Insig	$17.48	t
989	165	Indahexal	$17.48	t
989	169	Terry White Chemists Indapamide	$17.48	t
990	59	Volibris	$4,035.00	t
991	69	Hospira Pty Limited	$838.42	t
991	69	Hospira Pty Limited	$943.94	t
991	78	Epirubicin Ebewe	$838.42	t
991	78	Epirubicin Ebewe	$943.94	t
992	70	Albey Paper Wasp Venom	$238.38	t
993	135	Norinyl-1/28	$16.86	t
994	162	Clexane	$108.88	t
995	36	Nebilet	$60.94	t
996	69	Hospira Pty Limited	$17.92	t
996	69	Hospira Pty Limited	$28.58	t
996	141	Pfizer Australia Pty Ltd	$17.92	t
996	141	Pfizer Australia Pty Ltd	$28.58	t
997	156	Physeptone	$15.48	t
998	28	Baxter Healthcare Pty Ltd	$72.41	t
999	135	Zavedos Solution	$1,958.44	t
999	135	Zavedos Solution	$2,104.80	t
1000	1	Phenex-2	$861.82	t
1001	28	Endoxan	$40.70	t
1002	172	MCT Pro-Cal	$215.62	t
1003	4	Kripton 2.5	$19.58	t
1003	120	Parlodel	$19.58	t
1004	13	Vasocardol CD	$25.64	t
1004	162	Cardizem CD	$25.64	t
1004	165	Diltahexal CD	$25.64	t
1005	25	B. Braun Australia Pty Ltd	$24.37	t
1005	136	Glucose 5% Freeflex	$24.37	t
1006	116	Norditropin NordiFlex	$631.00	t
1006	116	Norditropin SimpleXx	$495.00	t
1007	120	Certican	$240.30	t
1007	120	Certican	$282.79	t
1008	32	Revlimid	$6,934.20	t
1009	51	Sotacor	$15.78	t
1009	64	GenRx Sotalol	$15.78	t
1009	156	Solavert	$15.78	t
1009	165	Sotalol Sandoz	$15.78	t
1010	122	Actiq	$115.60	t
1010	122	Actiq	$680.13	t
1011	143	Metamucil Regular	$21.67	t
1012	95	Proxen SR 750	$12.38	t
1012	150	Naprosyn SR750	$12.38	t
1013	162	Ikorel	$31.26	t
1014	159	Cutifilm Plus 76309	$25.42	t
1015	59	Imigran FDT	$25.12	t
1016	103	FreeStyle Lite	$53.16	t
1016	103	Optium glucose	$53.16	t
1016	103	Precision Plus	$54.66	t
1016	103	SofTact	$53.16	t
1016	148	Accu-Chek Performa	$53.16	t
1017	155	Intron A	$248.25	t
1018	114	Sorbsan 1411	$109.12	t
1019	155	Olmetec Plus	$34.69	t
1020	11	Redipred	$15.14	t
1020	92	PredMix	$15.14	t
1021	24	Maxipime	$183.82	t
1022	9	Crestor	$45.75	t
1023	117	Alvesco 80	$26.15	t
1024	3	Calci-Tab 600	$22.20	t
1025	152	Microgynon 30	$17.43	t
1026	161	Tubigrip 1484	$40.18	t
1027	122	Gabitril	$138.84	t
1028	155	Caelyx	$622.99	t
1028	155	Caelyx	$703.05	t
1029	59	Zofran	$21.08	t
1029	59	Zofran	$32.49	t
1029	134	Pfizer Australia Pty Ltd	$21.08	t
1029	134	Pfizer Australia Pty Ltd	$32.49	t
1029	149	Ondansetron-RL	$21.08	t
1029	149	Ondansetron-RL	$32.49	t
1029	156	Onsetron	$21.08	t
1029	156	Onsetron	$32.49	t
1029	165	Ondaz	$21.08	t
1029	165	Ondaz	$32.49	t
1030	37	Comfeel Plus Pressure Relieving 3353	$59.62	t
1031	4	Alphapril	$13.14	t
1031	18	Enalabell	$13.14	t
1031	31	Chem mart Enalapril	$13.14	t
1031	61	Enalapril-DP 5mg	$13.14	t
1031	63	Enalapril generichealth	$13.14	t
1031	64	GenRx Enalapril	$13.14	t
1031	99	Renitec M	$13.14	t
1031	156	Auspril	$13.14	t
1031	165	Enahexal	$13.14	t
1031	169	Terry White Chemists Enalapril	$13.14	t
1031	174	Enalapril Winthrop	$13.14	t
1032	110	NovoRapid FlexPen	$264.22	t
1032	116	NovoRapid Penfill 3 mL	$264.22	t
1033	4	Bispro 10	$73.48	t
1033	6	Bicor	$73.48	t
1033	165	Bisoprolol Sandoz	$73.48	t
1034	7	Aranesp SureClick	$212.72	t
1035	4	Alphamox 500	$10.65	t
1035	31	Chem mart Amoxycillin	$10.65	t
1035	59	Amoxil	$10.65	t
1035	61	Amoxycillin-DP	$10.65	t
1035	64	GenRx Amoxycillin	$10.65	t
1035	145	Amoxycillin Ranbaxy	$10.65	t
1035	156	Cilamox	$10.65	t
1035	165	Amoxycillin Sandoz	$10.65	t
1035	169	Terry White Chemists Amoxycillin	$10.65	t
1035	170	APO-Amoxycillin	$10.65	t
1036	36	Flomaxtra	$63.36	t
1037	139	Petrus Pharmaceuticals Pty Ltd	$19.74	t
1037	139	Petrus Pharmaceuticals Pty Ltd	$30.88	t
1038	4	Nordip	$24.39	t
1038	6	Perivasc	$24.39	t
1038	31	Chem mart Amlodipine	$24.39	t
1038	35	Pharmacor Amlodipine 10	$24.39	t
1038	60	Amlodipine-GA	$24.39	t
1038	61	Norvapine	$24.39	t
1038	63	Amlodipine generichealth	$24.39	t
1038	134	Norvasc	$24.39	t
1038	145	Ozlodip	$24.39	t
1038	165	Amlodipine Sandoz	$24.39	t
1038	169	Terry White Chemists Amlodipine	$24.39	t
1038	170	APO-Amlodipine	$24.39	t
1039	182	Lyofoam Flat 603095	$101.86	t
1040	69	Hospira Pty Limited	$42.50	t
1040	69	Hospira Pty Limited	$56.72	t
1041	4	Lamogine	$16.75	t
1041	59	Lamictal	$16.75	t
1041	156	Seaze 5	$16.75	t
1042	94	Strattera	$221.18	t
1043	150	Lexotan	$27.38	t
1044	151	PKU Anamix Junior	$892.10	t
1045	162	Orudis	$25.30	t
1046	150	Pegasys RBV	$1,703.18	t
1047	184	Doryx	$10.07	t
1047	185	DBL Doxycycline	$10.07	t
1048	120	Exelon	$155.45	t
1049	69	Pamisol	$109.28	t
1049	69	Pamisol	$259.42	t
1050	99	Vytorin	$96.59	t
1051	57	Dibenyline	$204.90	t
1052	57	Stelazine	$13.86	t
1053	161	Tubigrip 1479	$30.44	t
1054	29	Viramune	$135.00	t
1055	4	Nupentin 100	$23.81	t
1055	14	Gantin	$23.81	t
1055	69	DBL Gabapentin	$23.81	t
1055	134	Neurontin	$23.81	t
1055	134	Neurontin	$24.81	t
1055	156	Gabatine 100	$23.81	t
1055	170	APO-Gabapentin	$23.81	t
1056	28	Baxter Healthcare Pty Ltd	$28.77	t
1057	25	B. Braun Australia Pty Ltd	$18.32	t
1057	136	Pharmatel Fresenius Kabi Pty Limited	$18.32	t
1058	80	Micronor	$16.86	t
1058	87	Locilan 28 Day	$16.86	t
1058	135	Noriday 28 Day	$16.86	t
1059	23	Glucostix	$45.90	t
1059	25	Omnitest EZ	$53.18	t
1059	25	Omnitest Plus	$53.18	t
1059	34	Bionime Rightest	$53.18	t
1059	40	TrueTrack	$53.18	t
1059	44	MyGlucoHealth	$53.18	t
1059	68	WaveSense Jazz	$53.18	t
1059	90	CareSens	$53.18	t
1059	103	FreeStyle	$53.18	t
1059	103	Freestyle Papillon	$53.18	t
1059	103	Optium Omega	$53.18	t
1059	107	Betachek	$53.18	t
1059	107	Betachek G5	$53.18	t
1059	107	Glucoflex-R	$45.90	t
1059	126	Lifeline Attest	$53.18	t
1059	130	Glucocard 01 Sensor	$53.18	t
1059	130	GlucoOz	$53.18	t
1059	142	SensoCard	$53.18	t
1059	148	Accu-Chek Active	$53.18	t
1059	148	Accu-Chek Go	$53.18	t
1059	148	Accu-Chek Mobile	$53.18	t
1059	148	Advantage II	$53.18	t
1059	175	MWD Pen Sensor Strips	$53.18	t
1060	141	Dantrium	$59.48	t
1061	94	Zyprexa	$194.00	t
1062	66	Aquae	$10.79	t
1063	4	Cosamide	$171.64	t
1063	9	Cosudex	$171.64	t
1063	60	Bicalutamide-GA	$171.64	t
1063	145	Bicalutamide Ranbaxy	$171.64	t
1063	156	Calutex	$171.64	t
1063	170	APO-Bicalutamide	$171.64	t
1064	4	Salpraz	$18.89	t
1064	31	Chem mart Pantoprazole	$18.89	t
1064	60	Pantoprazole-GA	$18.89	t
1064	111	Pantoloc	$18.89	t
1064	117	Somac	$18.89	t
1064	121	Panto	$18.89	t
1064	145	Ozpan	$18.89	t
1064	165	Pantoprazole Sandoz	$18.89	t
1064	169	Terry White Chemists Pantoprazole	$18.89	t
1064	170	APO-Pantoprazole	$18.89	t
1065	4	Kalma 0.5	$11.48	t
1065	135	Xanax	$11.48	t
1065	156	Alprax 0.5	$11.48	t
1065	165	Alprazolam Sandoz	$11.48	t
1066	4	Rixadone	$31.32	t
1066	35	Resdone 0.5	$31.32	t
1066	60	Risperidone-GA	$31.32	t
1066	145	Ozidal	$31.32	t
1066	156	Rispa	$31.32	t
1067	151	Kindergen	$1,065.94	t
1068	84	Telfa 2140C	$11.23	t
1069	80	Risperdal Quicklet	$217.42	t
1070	161	Tubifast 2438	$35.58	t
1071	66	Hamilton Solastick 30+	$12.30	t
1072	11	Quinbisul	$14.46	t
1073	156	Methopt	$10.43	t
1074	1	Klacid	$37.22	t
1075	122	Actiq	$115.60	t
1075	122	Actiq	$680.13	t
1076	104	Alpha Keri Lotion	$17.35	t
1077	97	Mepilex Border 295200	$30.77	t
1078	51	Marevan	$14.03	t
1078	156	Coumadin	$14.03	t
1079	150	Invirase	$505.56	t
1080	16	Tysabri	$2,038.46	t
1081	135	Adriamycin Solution	$75.24	t
1081	135	Adriamycin Solution	$95.38	t
1082	100	Nexcare Tegaderm Transparent H1626	$19.65	t
1083	13	Stemzine	$9.95	t
1083	162	Stemetil	$9.95	t
1084	159	Iodosorb Powder 66051070	$62.69	t
1085	88	Ear Clear for Ear Wax Removal	$14.40	t
1086	69	Hospira Pty Limited	$20.22	t
1087	155	Avanza SolTab	$20.37	t
1088	96	MS Mono	$33.15	t
1089	74	Airomir Autohaler	$38.60	t
1090	135	Salazopyrin	$51.90	t
1091	6	Felodur ER 2.5 mg	$13.42	t
1091	9	Plendil ER	$13.42	t
1092	4	Rimycin 150	$11.96	t
1093	4	Zimstat	$25.04	t
1093	18	Simvabell	$25.04	t
1093	31	Chem mart Simvastatin	$25.04	t
1093	35	Simvasyn	$25.04	t
1093	53	Lipex 10	$25.04	t
1093	60	Simvastatin-DP	$25.04	t
1093	61	Simvastatin-GA 10	$25.04	t
1093	63	Simvastatin generichealth	$25.04	t
1093	64	GenRx Simvastatin	$25.04	t
1093	98	Pharmacor Simvastatin 10	$25.04	t
1093	99	Zocor	$25.04	t
1093	145	Ransim	$25.04	t
1093	156	Simvar 10	$25.04	t
1093	165	Simvahexal	$25.04	t
1093	169	Terry White Chemists Simvastatin	$25.04	t
1093	170	APO-Simvastatin	$25.04	t
1093	174	Simvastatin Winthrop	$25.04	t
1093	187	Simvastatin-Spirit 10	$25.04	t
1094	69	Hospira Pty Limited	$351.24	t
1094	120	Sandostatin 0.5	$351.24	t
1094	181	Octreotide MaxRx	$351.24	t
1095	10	Betoptic	$15.11	t
1095	76	BetoQuin	$15.11	t
1096	4	Adefin XL 60	$22.31	t
1096	23	Adalat Oros 60	$22.31	t
1096	156	Addos XR 60	$22.31	t
1096	170	APO-Nifedipine XR	$22.31	t
1097	4	Deralin 40	$10.56	t
1097	9	Inderal	$10.56	t
1098	153	Coversyl 5mg	$18.14	t
1099	148	Accu-Chek Integra	$53.18	t
1100	99	Vytorin	$88.79	t
1101	134	Zeldox	$175.11	t
1102	4	Diaformin XR	$14.42	t
1102	6	Diabex XR	$14.42	t
1102	156	Metex XR	$14.42	t
1103	36	Daivobet	$42.14	t
1104	74	Cal-Sup	$18.44	t
1104	74	Cal-Sup	$30.46	t
1105	4	Axit 15	$20.37	t
1106	77	Somatuline Autogel	$1,790.00	t
1107	69	DBL Gemcitabine for Injection	$425.97	t
1107	69	DBL Gemcitabine for Injection	$482.74	t
1108	80	Eprex 10000	$1,037.00	t
1109	9	Oxis Turbuhaler	$26.38	t
1110	4	Clofen 25	$60.09	t
1110	31	Chem mart Baclofen	$60.09	t
1110	64	GenRx Baclofen	$60.09	t
1110	120	Lioresal 25	$60.09	t
1110	156	Stelax 25	$60.09	t
1110	169	Terry White Chemists Baclofen	$60.09	t
1111	6	Codapane Forte	$8.08	t
1111	6	Codapane Forte	$11.40	t
1111	13	Prodeine Forte	$8.08	t
1111	13	Prodeine Forte	$11.40	t
1111	33	Dolaforte	$8.08	t
1111	33	Dolaforte	$11.40	t
1111	51	Codalgin Forte	$8.08	t
1111	51	Codalgin Forte	$11.40	t
1111	162	Panadeine Forte	$8.08	t
1111	162	Panadeine Forte	$11.40	t
1111	165	Comfarol Forte	$8.08	t
1111	165	Comfarol Forte	$11.40	t
1111	170	APO- Paracetamol/Codeine 500/30	$8.08	t
1111	170	APO- Paracetamol/Codeine 500/30	$11.40	t
1112	24	Etopophos	$138.25	t
1112	24	Etopophos	$169.92	t
1113	4	Metrogyl 400	$10.03	t
1113	13	Metronide 400	$10.03	t
1113	162	Flagyl	$10.03	t
1114	3	Haemaccel	$45.75	t
1115	162	Surgam	$17.58	t
1116	156	Z.S.C.	$12.26	t
1117	179	Enbrel	$815.00	t
1117	179	Enbrel	$1,829.00	t
1118	80	Risperdal Consta	$402.68	t
1119	172	Valine Amino Acid Supplement	$516.02	t
1120	78	Fluorouracil Ebewe	$36.15	t
1120	78	Fluorouracil Ebewe	$49.77	t
1121	24	Reyataz	$521.91	t
1122	92	Aspen Pharmacare Australia Pty Limited	$16.36	t
1123	141	Pfizer Australia Pty Ltd	$52.93	t
1124	150	Madopar	$50.01	t
1125	115	Duro-K	$13.16	t
1125	120	Slow-K	$13.16	t
1126	120	Phosphate Sandoz	$81.63	t
1127	80	Durogesic 25	$56.28	t
1128	29	Sifrol	$11.74	t
1129	150	CellCept	$185.23	t
1129	150	CellCept	$627.81	t
1130	141	Dantrium	$67.42	t
1131	74	Difflam	$22.26	t
1132	32	Thalomid	$420.00	t
1133	172	GA gel	$1,797.30	t
1134	36	Solaraze 3% Gel	$58.19	t
1135	4	Alphamox 125	$10.84	t
1135	31	Chem mart Amoxycillin	$10.84	t
1135	59	Amoxil	$10.84	t
1135	60	Bgramin	$10.84	t
1135	64	GenRx Amoxycillin	$10.84	t
1135	145	Ranmoxy	$10.84	t
1135	165	Amoxycillin Sandoz	$10.84	t
1135	169	Terry White Chemists Amoxycillin	$10.84	t
1136	69	Clopine 50	$138.30	t
1137	3	Lax-Tab	$13.94	t
1137	11	Bisalax	$13.94	t
1138	59	Seretide MDI 50/25	$47.20	t
1139	4	Clofen 10	$32.08	t
1139	31	Chem mart Baclofen	$32.08	t
1139	64	GenRx Baclofen	$32.08	t
1139	120	Lioresal 10	$32.08	t
1139	156	Stelax 10	$32.08	t
1139	169	Terry White Chemists Baclofen	$32.08	t
1140	4	Rimycin 300	$13.55	t
1141	179	Rapamune	$723.33	t
1141	179	Rapamune	$815.25	t
1142	96	Ordine 2	$18.34	t
1143	30	CombiDERM 651031	$54.90	t
1144	29	Dulcolax	$21.57	t
1144	29	Dulcolax	$42.39	t
1144	139	Petrus Bisacodyl Suppositories	$21.57	t
1144	139	Petrus Bisacodyl Suppositories	$42.39	t
1145	86	Humalog KwikPen	$264.22	t
1145	94	Humalog	$264.22	t
1146	122	Salofalk	$336.22	t
1147	156	Megace	$72.95	t
1148	66	Uro-Carb	$21.03	t
1149	51	Lycinate	$12.27	t
1149	156	Anginine Stabilised	$12.27	t
1150	55	Loceryl	$96.14	t
1151	37	Biatain Ag 9632	$191.29	t
1152	30	Aquacel 177903	$208.70	t
1153	65	Fludara	$975.07	t
1154	162	Lasix	$17.06	t
1155	27	Eloflex 2480	$55.67	t
1155	161	Setopress 3505	$78.57	t
1156	135	Dostinex	$24.43	t
1157	96	OxyContin	$41.22	t
1158	80	Prograf	$187.34	t
1158	80	Prograf	$225.85	t
1159	29	Pradaxa	$228.21	t
1160	74	Aldara	$159.95	t
1161	6	D-Penamine	$31.63	t
1162	47	Novasone	$14.23	t
1162	155	Elocon	$14.23	t
1163	46	Egopsoryl-TA	$16.02	t
1164	4	Qpril 5	$13.96	t
1164	6	Filpril	$13.96	t
1164	35	Pharmacor Quinapril 5	$13.96	t
1164	61	Quinapril-DP	$13.96	t
1164	63	Quinapril generichealth	$13.96	t
1164	134	Accupril	$13.96	t
1164	156	Acquin 5	$13.96	t
1164	165	Quinapril Sandoz	$13.96	t
1164	170	APO-Quinapril	$13.96	t
1165	4	Akamin 100	$9.65	t
1166	156	Orabase	$11.85	t
1167	120	Sandostatin LAR	$1,334.96	t
1168	59	Flolan	$83.37	t
1169	94	Actos	$61.52	t
1170	141	Pfizer Australia Pty Ltd	$11.02	t
1171	154	Gonal-f 75	$36.00	t
1171	154	Gonal-f 75	$247.57	t
1172	47	Eleuphrat	$13.41	t
1172	155	Diprosone	$13.41	t
1173	4	Lumin 20	$26.12	t
1173	155	Tolvon	$26.12	t
1174	162	Tilade CFC-Free	$37.69	t
1175	162	Actonel Combi D	$53.34	t
1176	47	Novasone	$14.23	t
1176	155	Elocon	$14.23	t
1177	179	Efexor-XR	$50.42	t
1178	150	Mabthera	$2,263.57	t
1178	150	Mabthera	$2,339.99	t
1179	4	Moxicam 7.5	$21.80	t
1179	18	Meloxibell	$21.80	t
1179	29	Mobic	$21.80	t
1179	31	Chem mart Meloxicam 7.5 mg	$21.80	t
1179	35	Pharmacor Meloxicam 7.5	$21.80	t
1179	60	Meloxicam-GA	$21.80	t
1179	64	GenRx Meloxicam	$21.80	t
1179	145	Meloxicam Ranbaxy	$21.80	t
1179	156	Movalis 7.5	$21.80	t
1179	165	Meloxicam Sandoz	$21.80	t
1179	169	Terry White Chemists Meloxicam 7.5 mg	$21.80	t
1179	174	Meloxicam Winthrop	$21.80	t
1180	4	Lipigem	$29.70	t
1180	6	Jezil	$29.70	t
1180	31	Chem mart Gemfibrozil	$29.70	t
1180	35	Pharmacor Gemfibrozil 600	$29.70	t
1180	60	Lipazil 600 mg	$29.70	t
1180	64	GenRx Gemfibrozil	$29.70	t
1180	134	Lopid	$29.70	t
1180	156	Ausgem	$29.70	t
1180	165	Gemhexal	$29.70	t
1180	169	Terry White Chemists Gemfibrozil	$29.70	t
1181	1	Isoptin	$11.51	t
1181	4	Anpec 40	$11.51	t
1182	1	Kaletra	$171.25	t
1183	120	Voltaren 100	$24.92	t
1184	9	Crestor	$120.19	t
1185	82	Nizoral 2%	$18.31	t
1186	1	Hytrin	$41.69	t
1187	178	Accomin Adult Tonic	$13.34	t
1188	69	Hospira Pty Limited	$425.80	t
1189	158	Creon 10,000	$170.77	t
1190	4	Roximycin	$11.76	t
1190	13	Biaxsig	$11.76	t
1190	31	Chem mart Roxithromycin	$11.76	t
1190	60	Roxithromycin-GA	$11.76	t
1190	156	Roxar 300	$11.76	t
1190	162	Rulide	$11.76	t
1190	165	Roxide	$11.76	t
1190	169	Terry White Chemists Roxithromycin	$11.76	t
1190	170	APO-Roxithromycin	$11.76	t
1191	156	Physeptone	$15.48	t
1192	4	Magicul 800	$19.97	t
1192	64	GenRx Cimetidine	$19.97	t
1193	120	Zometa	$450.00	t
1194	24	Abilify	$152.25	t
1195	51	Tricortone	$14.72	t
1195	156	Aristocort 0.02%	$14.72	t
1196	69	Oxytrol	$36.41	t
1197	4	Pamacid 40	$17.41	t
1197	31	Chem mart Famotidine	$17.41	t
1197	60	Pepzan	$17.41	t
1197	64	GenRx Famotidine	$17.41	t
1197	99	Pepcidine	$17.41	t
1197	156	Ausfam 40	$17.41	t
1197	165	Famohexal	$17.41	t
1197	169	Terry White Chemists Famotidine	$17.41	t
1198	63	Paclitaxel Actavis	$1,686.24	t
1198	63	Paclitaxel Actavis	$1,832.60	t
1198	69	Anzatax	$1,686.24	t
1198	69	Anzatax	$1,832.60	t
1198	78	Paclitaxel Ebewe	$1,686.24	t
1198	78	Paclitaxel Ebewe	$1,832.60	t
1199	59	Combivir	$578.60	t
1200	80	Prezista	$1,048.71	t
1201	59	Kapanol	$17.24	t
1202	165	Cefazolin Sandoz	$120.52	t
1203	4	Ipratrin Adult	$42.64	t
1203	29	Atrovent Adult	$42.64	t
1203	141	Ipravent	$42.64	t
1203	156	Aeron 500	$42.64	t
1203	170	APO-Ipratropium	$42.64	t
1204	155	Pegatron	$2,182.24	t
1205	93	Ebixa	$98.02	t
1206	134	Sutent	$3,521.76	t
1207	4	Monace 10	$15.65	t
1207	24	Monopril	$15.65	t
1207	64	GenRx Fosinopril	$15.65	t
1207	156	Fosipril 10	$15.65	t
1207	165	Fosinopril Sandoz	$15.65	t
1208	4	Prexaton	$165.28	t
1208	59	Zyban	$165.28	t
1208	73	Clorprax	$165.28	t
1209	99	Maxalt	$25.12	t
1210	59	Avandia	$91.19	t
1211	122	Actiq	$115.60	t
1211	122	Actiq	$680.13	t
1212	9	Atacand Plus 16/12.5	$31.13	t
1213	1	Kaletra	$129.00	t
1214	156	Serenace	$10.54	t
1215	47	Novasone	$18.71	t
1215	155	Elocon	$18.71	t
1216	23	Clinistix	$19.82	t
1216	23	Diastix	$18.84	t
1217	4	Alepam 15	$7.67	t
1217	4	Alepam 15	$8.92	t
1217	156	Serepax	$7.67	t
1217	156	Serepax	$8.92	t
1218	69	Hospira Pty Limited	$27.58	t
1219	158	Teveten Plus 600/12.5	$32.11	t
1220	4	Neosulf	$15.05	t
1221	137	Proladone	$43.66	t
1222	59	Flixotide	$49.72	t
1223	59	Zofran	$27.25	t
1223	59	Zofran	$40.12	t
1223	149	Ondansetron-RL	$27.25	t
1223	149	Ondansetron-RL	$40.12	t
1223	156	Onsetron 4	$27.25	t
1223	156	Onsetron 4	$40.12	t
1223	165	Ondaz	$27.25	t
1223	165	Ondaz	$40.12	t
1223	170	APO-Ondansetron	$27.25	t
1223	170	APO-Ondansetron	$40.12	t
1224	141	Pfizer Australia Pty Ltd	$75.34	t
1224	141	Pfizer Australia Pty Ltd	$95.52	t
1225	27	Leukoplast 1071	$12.76	t
1226	9	Atacand	$46.62	t
1227	95	Crysanal	$13.10	t
1227	150	Anaprox 550	$13.10	t
1228	71	Restore Plus 9958	$158.43	t
1229	69	Leucovorin Calcium	$122.95	t
1229	69	Leucovorin Calcium	$151.82	t
1230	135	Caverject Impulse	$82.62	t
1231	93	Fluanxol Depot	$26.38	t
1232	24	Avapro	$25.15	t
1232	162	Karvea	$25.15	t
1233	9	Iressa	$3,851.36	t
1234	51	Otocomb Otic	$8.25	t
1234	156	Kenacomb Otic	$8.25	t
1235	184	Doryx	$8.47	t
1235	184	Doryx	$14.62	t
1235	185	DBL Doxycycline	$8.47	t
1235	185	DBL Doxycycline	$14.62	t
1236	87	Improvil 28 Day	$16.86	t
1236	135	Synphasic	$16.86	t
1237	162	Epilim Syrup	$34.92	t
1238	84	Telfa 7650C	$12.02	t
1239	153	Protos 2 g	$53.34	t
1240	6	EpiPen	$106.00	t
1241	78	Calcium Folinate Ebewe	$226.90	t
1241	78	Calcium Folinate Ebewe	$268.42	t
1242	46	Silic 15	$12.53	t
1243	110	NovoMix 30 FlexPen	$264.22	t
1243	116	NovoMix 30 Penfill 3 mL	$264.22	t
1244	4	Mobilis D-10	$12.50	t
1245	30	CombiDERM 651027	$71.72	t
1246	99	Singulair	$45.71	t
1247	29	Catapres	$37.44	t
1248	6	Clamoxyl Duo	$12.16	t
1248	59	Augmentin Duo	$12.16	t
1248	60	GA-Amclav 500/125	$12.16	t
1248	156	Moxiclav Duo 500/125	$12.16	t
1248	165	Curam Duo 500/125	$12.16	t
1248	170	APO-Amoxycillin/ Clavulanic Acid 500/125	$12.16	t
1249	24	Avapro HCT 150/12.5	$27.37	t
1249	162	Karvezide 150/12.5	$27.37	t
1250	13	Arabloc	$139.26	t
1250	162	Arava	$139.26	t
1251	9	Nexium	$50.81	t
1252	184	Astrix	$14.62	t
1253	59	Seretide Accuhaler 250/50	$59.31	t
1254	10	Ciloxan	$29.62	t
1254	76	CiloQuin	$29.62	t
1255	28	Onkotrone	$168.46	t
1255	28	Onkotrone	$205.55	t
1255	69	Hospira Pty Limited	$168.46	t
1255	69	Hospira Pty Limited	$205.55	t
1255	78	Mitozantrone Ebewe	$168.46	t
1255	78	Mitozantrone Ebewe	$205.55	t
1255	141	Pfizer Australia Pty Ltd	$168.46	t
1255	141	Pfizer Australia Pty Ltd	$205.55	t
1256	9	Symbicort Turbuhaler 200/6	$58.77	t
1257	172	Phenylalanine Amino Acid Supplement	$516.02	t
1258	81	Tielle MTL101E	$111.24	t
1259	48	Navelbine	$1,087.44	t
1259	48	Navelbine	$1,210.10	t
1259	69	Hospira Pty Limited	$1,087.44	t
1259	69	Hospira Pty Limited	$1,210.10	t
1259	78	Vinorelbine Ebewe	$1,087.44	t
1259	78	Vinorelbine Ebewe	$1,210.10	t
1259	91	Vinorelbine Link	$1,087.44	t
1259	91	Vinorelbine Link	$1,210.10	t
1260	28	Plasma-Lyte 148	$21.96	t
1261	165	Cefotaxime Sandoz	$44.32	t
1262	69	Hospira Pty Limited	$133.38	t
1262	69	Hospira Pty Limited	$164.16	t
1262	78	Doxorubicin Ebewe	$133.38	t
1262	78	Doxorubicin Ebewe	$164.16	t
1262	135	Adriamycin Solution	$133.38	t
1262	135	Adriamycin Solution	$164.16	t
1263	172	PKU Cooler 20	$2,054.02	t
1264	11	Panafcortelone	$10.33	t
1264	51	Solone	$10.33	t
1265	4	Diaformin 1000	$18.04	t
1265	6	Diabex 1000	$18.04	t
1265	60	Metformin-GA	$18.04	t
1265	156	Formet 1000	$18.04	t
1265	165	Glucohexal	$18.04	t
1266	4	Tryzan Tabs 1.25	$11.60	t
1266	13	Ramace 1.25 mg	$11.60	t
1266	31	Chem mart Ramipril	$11.60	t
1266	156	Prilace 1.25	$11.60	t
1266	162	Tritace 1.25 mg	$11.60	t
1266	165	Ramipril Sandoz	$11.60	t
1266	169	Terry White Chemists Ramipril	$11.60	t
1266	170	APO-Ramipril	$11.60	t
1266	174	Ramipril Winthrop	$11.60	t
1267	4	Tamate	$61.99	t
1267	80	Topamax	$61.99	t
1267	156	Epiramax 50	$61.99	t
1267	165	Topiramate Sandoz	$61.99	t
1267	170	APO-Topiramate	$61.99	t
1268	29	Micardis Plus 80/12.5 mg	$30.98	t
1269	72	TenderWet Active Cavity	$68.66	t
1270	25	B. Braun Australia Pty Ltd	$18.32	t
1270	136	Pharmatel Fresenius Kabi Pty Limited	$18.32	t
1271	162	Apidra	$159.27	t
1272	134	Pfizer Australia Pty Ltd	$37.33	t
1273	141	Pfizer Australia Pty Ltd	$84.23	t
1273	141	Pfizer Australia Pty Ltd	$106.04	t
1274	4	Lisodur	$14.13	t
1274	9	Zestril	$14.13	t
1274	18	Lisinobell	$14.13	t
1274	31	Chem mart Lisinopril	$14.13	t
1274	35	Lisinopril 5	$14.13	t
1274	60	Liprace	$14.13	t
1274	61	Lisinopril-GA	$14.13	t
1274	63	Lisinopril generichealth	$14.13	t
1274	64	GenRx Lisinopril	$14.13	t
1274	73	Lisinopril Hexal	$14.13	t
1274	99	Prinivil 5	$14.13	t
1274	145	Lisinopril Ranbaxy	$14.13	t
1274	156	Fibsol 5	$14.13	t
1274	169	Terry White Chemists Lisinopril	$14.13	t
1274	170	APO-Lisinopril	$14.13	t
1274	174	Lisinopril Winthrop	$14.13	t
1275	69	Hospira Pty Limited	$95.08	t
1275	120	Desferal 500 mg	$95.08	t
1276	24	Taxol	$844.55	t
1276	24	Taxol	$950.77	t
1276	63	Paclitaxel Actavis	$844.55	t
1276	63	Paclitaxel Actavis	$950.77	t
1276	69	Anzatax	$844.55	t
1276	69	Anzatax	$950.77	t
1277	99	Cosopt	$27.49	t
1278	11	Moduretic	$13.88	t
1279	65	Fludara	$1,430.64	t
1279	65	Fludara	$1,567.02	t
1280	51	Mycostatin	$12.49	t
1280	51	Mycostatin	$18.56	t
1281	162	Sabril	$67.70	t
1282	135	Genotropin	$247.50	t
1283	6	Clamoxyl Duo 400	$13.98	t
1283	59	Augmentin Duo 400	$13.98	t
1283	165	Curam Duo	$13.98	t
1284	120	Estradot 37.5	$17.53	t
1285	7	Aranesp SureClick	$513.75	t
1286	82	Microlax	$12.10	t
1287	81	JJ 02013	$10.51	t
1288	120	Exelon Patch 5	$166.09	t
1289	9	Seroquel	$53.66	t
1290	59	Daraprim	$16.37	t
1291	51	Marevan	$12.42	t
1291	156	Coumadin	$12.42	t
1292	134	Rescriptor	$271.58	t
1293	134	Viagra	$81.12	t
1294	4	Cyprone	$52.74	t
1294	60	Procur	$52.74	t
1294	64	GenRx Cyproterone Acetate	$52.74	t
1294	152	Androcur	$52.74	t
1294	164	Cyprostat	$52.74	t
1294	165	Cyprohexal	$52.74	t
1295	80	Eprex 30,000	$3,015.00	t
1296	9	Seroquel	$266.23	t
1297	51	Eutroxsig	$24.74	t
1297	156	Oroxine	$24.74	t
1298	82	Daktarin	$19.47	t
1299	74	Nuelin-SR 300	$14.70	t
1300	49	Betadine	$33.54	t
1301	171	Keppra	$56.42	t
1302	4	Glimel	$11.60	t
1302	162	Daonil	$11.60	t
1303	69	Hospira Pty Limited	$24.52	t
1303	69	Hospira Pty Limited	$36.73	t
1303	141	Pfizer Australia Pty Ltd	$24.52	t
1303	141	Pfizer Australia Pty Ltd	$36.73	t
1304	94	Zyprexa Relprevv	$499.78	t
1305	159	Cutinova Hydro 66047443	$75.98	t
1306	7	Aranesp	$724.62	t
1307	135	Provera	$130.57	t
1308	36	Tramal 100	$14.30	t
1308	165	Tramahexal	$14.30	t
1309	162	Neulactil	$14.46	t
1310	28	Baxter Healthcare Pty Ltd	$23.52	t
1311	59	Bactroban	$16.28	t
1312	53	Timoptol	$11.80	t
1312	156	Tenopt	$11.80	t
1313	77	Diphereline	$1,108.76	t
1314	4	Endep 10	$8.44	t
1315	93	Clopixol Depot	$25.34	t
1316	150	Madopar	$50.01	t
1317	63	Gemcitabine Actavis	$172.12	t
1317	63	Gemcitabine Actavis	$209.50	t
1317	69	DBL Gemcitabine for Injection	$172.12	t
1317	69	DBL Gemcitabine for Injection	$209.50	t
1317	78	Gemcitabine Ebewe	$172.12	t
1317	78	Gemcitabine Ebewe	$209.50	t
1317	94	Gemzar	$172.12	t
1317	94	Gemzar	$209.50	t
1317	187	Gemcite	$172.12	t
1317	187	Gemcite	$209.50	t
1318	1	Humira	$1,774.36	t
1319	60	Intal Spincaps	$32.43	t
1320	151	XMTVI Maxamaid	$1,784.74	t
1320	151	XMTVI Maxamum	$2,704.74	t
1321	97	Mepilex Lite 284000	$28.06	t
1322	134	Zarontin	$54.10	t
1323	96	Ordine 10	$25.24	t
1324	94	Xigris	$467.14	t
1325	134	Caduet 5/40	$88.87	t
1326	1	EleCare LCP	$367.86	t
1326	151	Neocate LCP	$367.86	t
1327	156	Serenace	$10.05	t
1328	59	Flolan	$41.69	t
1329	59	Zantac	$17.90	t
1329	59	Zantac	$21.16	t
1330	96	Dilaudid	$22.84	t
1331	51	Sigmaxin-PG	$10.58	t
1331	156	Lanoxin-PG	$10.58	t
1332	24	Blenoxane	$482.49	t
1332	156	Blenamax	$482.49	t
1333	80	Eprex 40,000	$660.00	t
1334	1	Norvir	$91.00	t
1335	151	MSUD AID III	$2,671.98	t
1335	151	MSUD Maxamaid	$1,784.74	t
1335	151	MSUD Maxamum	$2,704.74	t
1336	69	Granocyte 13	$512.50	t
1337	36	Advantan	$14.29	t
1338	134	Lipitor	$79.05	t
1339	69	Hospira Pty Limited	$371.40	t
1339	69	Hospira Pty Limited	$423.78	t
1339	78	Carboplatin Ebewe	$371.40	t
1339	78	Carboplatin Ebewe	$423.78	t
1339	141	Pfizer Australia Pty Ltd	$371.40	t
1339	141	Pfizer Australia Pty Ltd	$423.78	t
1340	69	Apomine PFS	$194.65	t
1341	155	PEG-Intron Redipen	$1,472.00	t
1342	93	Fluanxol Concentrated Depot	$44.87	t
1343	162	Sculptra	$446.46	t
1344	172	PKU-gel	$891.02	t
1345	4	Endep 25	$8.56	t
1346	77	Diphereline	$420.20	t
1347	144	On-Call Plus	$53.18	t
1348	3	Vistil	$10.43	t
1349	74	Hiprex	$42.38	t
1350	22	Peg 7423	$21.04	t
1351	4	Prexaton	$165.28	t
1351	59	Zyban	$165.28	t
1351	73	Clorprax	$165.28	t
1352	162	Stemetil	$19.93	t
1353	77	Somatuline LA	$750.00	t
1354	59	3TC	$282.00	t
1355	4	Dicarz	$57.97	t
1355	31	Chem mart Carvedilol 12.5 mg	$57.97	t
1355	51	Dilasig 12.5	$57.97	t
1355	60	GN-Carvedilol	$57.97	t
1355	63	Carvedilol generichealth	$57.97	t
1355	64	GenRx Carvedilol	$57.97	t
1355	95	Kredex	$57.97	t
1355	150	Dilatrend 12.5	$57.97	t
1355	156	Vedilol 12.5	$57.97	t
1355	165	Carvedilol Sandoz	$57.97	t
1355	169	Terry White Chemists Carvedilol 12.5 mg	$57.97	t
1356	120	Estracombi	$19.66	t
1357	99	Timoptol XE	$11.80	t
1358	155	Intron A Redipen	$297.90	t
1358	155	Intron A Redipen	$893.70	t
1358	155	Intron A Redipen	$1,005.75	t
1359	4	Acyclo-V 800	$146.32	t
1359	35	Aciclovir 800	$146.32	t
1359	59	Zovirax 800 mg	$146.32	t
1359	60	Lovir	$146.32	t
1359	64	GenRx Aciclovir	$146.32	t
1359	165	Acihexal	$146.32	t
1360	94	Humulin R	$224.32	t
1360	116	Actrapid Penfill 3 mL	$224.32	t
1361	4	Resprim Forte	$9.39	t
1361	150	Bactrim DS	$9.39	t
1361	156	Septrin Forte	$9.39	t
1362	27	Tensopress 66004347	$89.37	t
1363	24	Reyataz	$347.94	t
1364	11	Bisalax	$39.24	t
1364	11	Bisalax	$57.08	t
1365	156	Sumagran 50	$25.13	t
1366	9	Atacand	$19.25	t
1367	1	RCF	$670.02	t
1368	46	Silic 15	$26.41	t
1369	120	Estraderm 25	$17.53	t
1370	94	Zyprexa Zydis	$194.00	t
1371	171	Vimpat	$74.69	t
1372	137	Ospolot	$98.57	t
1373	155	Elocon	$26.81	t
1374	80	Durogesic 100	$155.76	t
1375	172	Isoleucine Amino Acid Supplement	$516.02	t
1376	4	Inza 250	$13.72	t
1376	150	Naprosyn	$13.72	t
1377	162	Proctosedyl	$18.94	t
1378	120	Aredia 15 mg	$218.56	t
1378	120	Aredia 15 mg	$259.41	t
1379	161	Tubigrip 1483	$40.18	t
1380	172	PKU-Express	$1,549.14	t
1381	162	Clexane	$79.68	t
1381	162	Clexane	$152.94	t
1382	120	Certican	$480.60	t
1382	120	Certican	$543.83	t
1383	7	Aranesp	$187.41	t
1384	134	Caduet 10/10	$58.57	t
1385	134	Lyrica	$42.65	t
1386	150	Madopar 125	$38.92	t
1387	30	CarboFLEX 403204	$89.87	t
1388	60	Sebizole	$19.37	t
1389	179	Enbrel	$1,630.01	t
1389	179	Enbrel	$1,774.37	t
1390	120	Visudyne	$2,246.36	t
1391	159	Profore 66050016	$209.07	t
1391	159	Profore Lite 66050415	$141.37	t
1392	80	Durogesic 12	$47.16	t
1393	6	Asmol CFC-free	$10.82	t
1393	6	Asmol CFC-free	$15.22	t
1393	59	Ventolin CFC-free	$11.41	t
1393	59	Ventolin CFC-free	$15.22	t
1393	74	Airomir	$10.82	t
1393	74	Airomir	$15.22	t
1394	120	Estradot 50	$17.53	t
1395	122	Salofalk	$279.63	t
1396	4	Dizole 200	$245.69	t
1396	69	DBL Fluconazole	$245.69	t
1396	134	Diflucan	$245.69	t
1396	145	Ozole	$245.69	t
1396	156	Fluzole 200	$245.69	t
1396	165	Fluconazole Sandoz	$245.69	t
1396	170	APO-Fluconazole	$245.69	t
1396	174	Fluconazole Winthrop	$245.69	t
1397	156	Tertroxin	$83.53	t
1398	4	Metrogyl 200	$7.96	t
1398	13	Metronide 200	$7.96	t
1398	162	Flagyl	$7.96	t
1399	59	Zeffix	$69.91	t
1400	8	Blink Intensive Tears	$10.59	t
1401	156	Predsol	$221.18	t
1402	161	Tubigrip 1482	$40.18	t
1403	128	Savacol Mouth and Throat Rinse	$15.28	t
1404	96	OxyContin	$21.18	t
1405	22	Peg 7420	$14.02	t
1406	94	Cymbalta	$50.42	t
1407	82	Daktarin	$14.79	t
1408	59	Valtrex	$423.18	t
1409	51	Cortic-DS 1%	$8.98	t
1409	156	Sigmacort	$8.98	t
1410	4	Nupentin 300	$62.01	t
1410	14	Gantin	$62.01	t
1410	35	Gabapentin 300	$62.01	t
1410	60	Gabapentin-GA	$62.01	t
1410	61	Douglas Gabapentin 300mg	$62.01	t
1410	64	GenRx Gabapentin	$62.01	t
1410	69	DBL Gabapentin	$62.01	t
1410	134	Neurontin	$62.01	t
1410	134	Neurontin	$63.00	t
1410	156	Gabatine 300	$62.01	t
1410	165	Gabahexal 300mg	$62.01	t
1411	46	SunSense Ultra SPF 30+	$16.99	t
1411	66	Hamilton Sunscreen Family Sunscreen Milk SPF	$16.07	t
1411	134	Aquasun Lotion SPF 18	$15.98	t
1412	30	DuoDERM CGF H7662	$222.32	t
1413	94	Strattera	$221.18	t
1414	30	Flexidress 650941	$28.78	t
1415	66	Aquae	$12.46	t
1416	159	ProGuide 66000780	$47.86	t
1416	159	ProGuide 66000780	$168.94	t
1417	11	Chlorvescent	$15.49	t
1418	161	Tubigrip B 1520	$18.17	t
1419	82	Anusol	$14.44	t
1420	59	Wellvone	$1,034.57	t
1421	59	Imigran	$19.78	t
1422	162	Prodeine 15	$9.23	t
1423	136	Pharmatel Fresenius Kabi Pty Limited	$18.32	t
1424	159	ZipZoc 66051550	$81.42	t
1425	17	Elastoplast 2226	$15.11	t
1426	78	Gemcitabine Ebewe	$172.12	t
1426	78	Gemcitabine Ebewe	$209.50	t
1427	36	BenPen	$42.92	t
1428	4	Asmol 5 uni-dose	$13.03	t
1428	4	Asmol 5 uni-dose	$19.64	t
1428	35	Pharmacor Salbutamol 5	$13.03	t
1428	35	Pharmacor Salbutamol 5	$19.64	t
1428	59	Ventolin Nebules	$13.76	t
1428	59	Ventolin Nebules	$19.64	t
1428	60	Salbutamol-GA	$13.03	t
1428	60	Salbutamol-GA	$19.64	t
1428	64	GenRx Salbutamol	$13.03	t
1428	64	GenRx Salbutamol	$19.64	t
1428	156	Butamol 5	$13.03	t
1428	156	Butamol 5	$19.64	t
1428	165	Salbutamol Sandoz	$13.03	t
1428	165	Salbutamol Sandoz	$19.64	t
1429	96	OxyNorm	$15.42	t
1430	155	Intron A	$496.50	t
1431	134	Accuretic 20/12.5mg	$21.96	t
1432	150	Madopar Rapid 125	$38.92	t
1433	122	Gabitril	$72.64	t
1434	120	Myfortic	$222.28	t
1434	120	Myfortic	$263.42	t
1435	57	Dibenyline	$67.36	t
1436	134	Solu-Medrol	$97.25	t
1437	135	Genotropin MiniQuick	$346.50	t
1438	74	Nuelin-SR 250	$13.32	t
1439	156	Hycor	$11.68	t
1440	52	Pentasa	$312.30	t
1441	99	Stocrin	$452.64	t
1442	51	Mycostatin	$10.85	t
1442	156	Nilstat	$10.85	t
1443	120	Estalis continuous 50/140	$19.66	t
1444	162	Rilutek	$662.00	t
1445	48	Navelbine	$2,051.22	t
1446	150	Xeloda	$695.17	t
1447	69	Kytril	$44.44	t
1447	69	Kytril	$58.98	t
1448	1	Humira	$5,036.36	t
1449	117	Somac	$31.98	t
1450	24	Abilify	$212.56	t
1451	120	Trileptal	$138.12	t
1452	156	Atropt	$21.77	t
1453	51	Sigmaxin	$10.89	t
1453	156	Lanoxin	$10.89	t
1454	36	Naloxone Min-I-Jet	$43.49	t
1454	36	Naloxone Min-I-Jet	$78.08	t
1455	135	Provera	$93.85	t
1456	162	Anzemet	$37.02	t
1456	162	Anzemet	$50.72	t
1457	5	FML Liquifilm	$10.61	t
1457	10	Flucon	$10.61	t
1458	69	Hospira Pty Limited	$65.02	t
1459	9	Xylocaine Viscous	$79.35	t
1460	154	Gonal-f Pen	$216.00	t
1460	154	Gonal-f Pen	$841.92	t
1461	29	Pradaxa	$81.16	t
1462	77	Somatuline Autogel	$2,240.00	t
1463	10	Travatan	$42.14	t
1464	172	Valine 1000 Amino Acid Supplement	$566.98	t
1465	96	MS Contin Suspension 200 mg	$124.11	t
1466	4	Antenex 2	$7.79	t
1466	150	Valium	$7.79	t
1466	156	Valpam 2	$7.79	t
1467	91	Mysoline	$83.49	t
1468	24	Sprycel	$6,465.01	t
1469	87	Depo-Nisolone	$24.97	t
1469	135	Depo-Medrol	$24.97	t
1470	82	Daktarin	$16.79	t
1471	150	Xenical	$128.64	t
1472	36	Advantan	$15.00	t
1473	30	DuoDERM Gel H7990	$64.48	t
1473	37	Comfeel Purilon Gel 3900	$72.09	t
1474	134	Sutent	$6,897.44	t
1475	163	Duofilm Solution	$18.15	t
1476	151	GA1 Anamix infant	$769.30	t
1477	80	Risperdal	$118.03	t
1478	155	Schering-Plough Pty Limited	$116.09	t
1479	4	Pendine 800	$166.86	t
1479	14	Gantin	$166.86	t
1479	64	GenRx Gabapentin	$166.86	t
1479	134	Neurontin	$166.86	t
1479	134	Neurontin	$167.86	t
1479	145	Gabaran	$166.86	t
1480	78	Doxorubicin Ebewe	$177.83	t
1480	78	Doxorubicin Ebewe	$215.62	t
1480	134	Adriamycin	$177.83	t
1480	134	Adriamycin	$215.62	t
1481	4	Progout 300	$10.42	t
1481	31	Chem mart Allopurinol	$10.42	t
1481	51	Allosig	$10.42	t
1481	64	GenRx Allopurinol	$10.42	t
1481	156	Zyloprim	$10.42	t
1481	165	Allopurinol Sandoz	$10.42	t
1481	169	Terry White Chemists Allopurinol	$10.42	t
1482	4	Minax 50	$10.84	t
1482	9	Betaloc	$10.84	t
1482	31	Chem mart Metoprolol	$10.84	t
1601	135	Xanax	$9.55	t
1482	64	GenRx Metoprolol	$10.84	t
1482	120	Lopresor 50	$10.84	t
1482	156	Metrol 50	$10.84	t
1482	165	Metohexal	$10.84	t
1482	169	Terry White Chemists Metoprolol	$10.84	t
1483	156	Questran Lite	$57.46	t
1484	69	Hospira Pty Limited	$278.58	t
1485	120	Diovan	$28.65	t
1486	80	Jurnista	$24.71	t
1487	4	Rimycin 300	$64.94	t
1488	23	Mycospor	$18.77	t
1489	116	GlucaGen Hypokit	$45.63	t
1490	4	Tilodene	$143.68	t
1491	156	Betnovate	$22.43	t
1492	135	Cyklokapron	$51.68	t
1493	32	Revlimid	$6,581.61	t
1494	137	Benztrop	$12.76	t
1495	29	Mobic	$28.83	t
1495	156	Movalis 15	$28.83	t
1496	157	Digestelact	$72.81	t
1497	154	Saizen 8 mg click.easy	$396.00	t
1498	78	Gemcitabine Ebewe	$425.00	t
1498	78	Gemcitabine Ebewe	$481.66	t
1499	9	Atacand Plus 32/25	$50.49	t
1500	4	Diaformin XR	$17.09	t
1500	6	Diabex XR	$17.09	t
1500	156	Metex XR	$17.09	t
1501	20	Gold Cross	$14.02	t
1502	59	Ventolin	$22.20	t
1503	59	Amoxil	$9.11	t
1504	96	Norspan	$40.77	t
1505	179	Zoton FasTabs	$29.54	t
1506	106	Biodone Forte	$7.40	t
1506	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$7.40	t
1506	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$18.28	t
1507	1	Isoptin	$19.52	t
1508	51	Marevan	$12.69	t
1509	37	Comfeel Plus Transparent 3536	$84.52	t
1510	150	Mircera	$194.30	t
1511	135	Cycloblastin	$31.29	t
1512	5	Bleph 10	$14.96	t
1513	134	Zithromax	$21.59	t
1514	141	Macrodantin	$20.38	t
1515	99	Emend	$120.00	t
1515	99	Emend	$148.34	t
1516	10	Tobrex	$22.38	t
1517	4	Ibilex 500	$10.77	t
1517	11	Keflex	$10.77	t
1517	18	Cephabell	$10.77	t
1517	31	Chem mart Cephalexin	$10.77	t
1517	60	Cilex	$10.77	t
1517	63	Cephalexin generichealth	$10.77	t
1517	64	GenRx Cephalexin	$10.77	t
1517	92	Ialex	$10.77	t
1517	98	Cephatrust 500	$10.77	t
1517	145	Rancef	$10.77	t
1517	165	Cefalexin Sandoz	$10.77	t
1517	169	Terry White Chemists Cephalexin	$10.77	t
1518	11	Kefzol	$65.33	t
1518	165	Cefazolin Sandoz	$65.33	t
1519	134	Vfend	$2,631.08	t
1520	93	Lexapro	$34.30	t
1521	27	Handy 4208	$12.20	t
1522	4	Rimycin 150	$37.01	t
1523	158	Duphaston	$16.62	t
1524	154	Gonal-f Pen	$432.00	t
1524	154	Gonal-f Pen	$1,115.24	t
1525	172	HCU Cooler	$3,098.38	t
1526	20	Gold Cross	$9.18	t
1527	51	Urex-M	$9.02	t
1527	162	Lasix-M	$9.02	t
1528	119	Karicare De-Lact	$88.92	t
1529	29	Micardis	$28.91	t
1530	51	Eutroxsig	$24.71	t
1530	156	Oroxine	$24.71	t
1531	4	Dicarz	$70.85	t
1531	31	Chem mart Carvedilol 25 mg	$70.85	t
1531	51	Dilasig 25	$70.85	t
1531	60	GN-Carvedilol	$70.85	t
1531	63	Carvedilol generichealth	$70.85	t
1531	64	GenRx Carvedilol	$70.85	t
1531	95	Kredex	$70.85	t
1531	150	Dilatrend 25	$70.85	t
1531	156	Vedilol 25	$70.85	t
1531	165	Carvedilol Sandoz	$70.85	t
1531	169	Terry White Chemists Carvedilol 25 mg	$70.85	t
1532	5	Alphagan	$20.70	t
1532	133	Enidin	$20.70	t
1533	69	Neo-B12	$17.22	t
1534	120	Navoban	$37.02	t
1534	120	Navoban	$50.72	t
1535	4	Eleva 100	$24.66	t
1535	31	Chem mart Sertraline	$24.66	t
1535	35	Sertraline 100	$24.66	t
1535	60	Sertraline-GA	$24.66	t
1535	63	Sertraline generichealth	$24.66	t
1535	64	GenRx Sertraline	$24.66	t
1535	134	Zoloft	$24.66	t
1535	141	Xydep 100	$24.66	t
1535	145	Setrona	$24.66	t
1535	156	Sertra 100	$24.66	t
1535	165	Concorz	$24.66	t
1535	169	Terry White Chemists Sertraline	$24.66	t
1536	82	Lyclear	$16.77	t
1537	150	CellCept	$185.23	t
1537	150	CellCept	$627.81	t
1538	6	C-Flox 250	$26.33	t
1538	23	Ciproxin 250	$26.33	t
1538	64	GenRx Ciprofloxacin	$26.33	t
1538	145	Cifran	$26.33	t
1538	156	Ciprol 250	$26.33	t
1538	165	Profloxin	$26.33	t
1539	4	Adronat	$46.57	t
1539	18	Alendrobell 70mg	$46.57	t
1539	31	Chem mart Alendronate 70mg	$46.57	t
1539	60	Alendronate-GA	$46.57	t
1539	99	Fosamax Once Weekly	$46.57	t
1539	145	Ossmax 70mg	$46.57	t
1539	156	Alendro Once Weekly	$46.57	t
1539	165	Alendronate Sandoz	$46.57	t
1539	169	Terry White Chemists Alendronate 70mg	$46.57	t
1539	170	APO-Alendronate	$46.57	t
1540	4	Azol 200	$86.97	t
1541	11	Vancocin	$240.82	t
1542	23	Biltricide	$40.85	t
1543	1	Phenex-2	$848.58	t
1544	82	Daktarin	$16.72	t
1545	65	Renagel	$310.00	t
1545	65	Renagel	$357.73	t
1546	134	Caduet 5/80	$120.06	t
1547	156	Physeptone	$30.82	t
1548	59	Flixotide Accuhaler	$49.72	t
1549	30	Aquacel 177902	$100.98	t
1550	159	Bactigras 7457	$25.44	t
1551	69	Hospira Pty Limited	$849.84	t
1551	69	Hospira Pty Limited	$956.74	t
1551	78	Epirubicin Ebewe	$849.84	t
1551	78	Epirubicin Ebewe	$956.74	t
1551	135	Pharmorubicin Solution	$849.84	t
1551	135	Pharmorubicin Solution	$956.74	t
1552	27	BSN 2902165	$15.39	t
1553	120	Nyogel	$13.22	t
1554	4	Hysone 20	$14.65	t
1555	162	Stemetil	$16.82	t
1556	109	Normacol Plus	$24.95	t
1556	109	Normacol Plus	$32.22	t
1557	108	Lamisil DermGel	$23.35	t
1558	4	Melizide	$11.69	t
1558	135	Minidiab	$11.69	t
1559	134	Zithromax	$59.34	t
1560	134	Chloromycetin	$9.76	t
1560	156	Chlorsig	$9.76	t
1561	166	Neotigason	$205.77	t
1562	59	Zofran	$13.27	t
1562	59	Zofran	$22.83	t
1562	134	Pfizer Australia Pty Ltd	$13.27	t
1562	134	Pfizer Australia Pty Ltd	$22.83	t
1562	149	Ondansetron-RL	$13.27	t
1562	149	Ondansetron-RL	$22.83	t
1562	156	Onsetron	$13.27	t
1562	156	Onsetron	$22.83	t
1562	165	Ondaz	$13.27	t
1562	165	Ondaz	$22.83	t
1563	4	Kripton 5	$50.25	t
1563	120	Parlodel	$50.25	t
1564	4	Sorbidin	$13.98	t
1565	162	Largactil	$11.70	t
1566	4	Uremide	$8.79	t
1566	31	Chem mart Frusemide	$8.79	t
1566	51	Urex	$8.79	t
1566	60	Frusid	$8.79	t
1566	64	GenRx Frusemide	$8.79	t
1566	162	Lasix	$8.79	t
1566	165	Frusehexal 40 mg	$8.79	t
1566	169	Terry White Chemists Frusemide	$8.79	t
1567	134	Lyrica	$124.24	t
1568	12	Tracleer	$4,035.00	t
1569	50	Cogentin	$103.59	t
1570	4	Placil	$16.83	t
1570	31	Chem mart Clomipramine	$16.83	t
1570	64	GenRx Clomipramine	$16.83	t
1570	120	Anafranil 25	$16.83	t
1570	169	Terry White Chemists Clomipramine	$16.83	t
1571	4	Rani 2	$17.87	t
1571	31	Chem mart Ranitidine	$17.87	t
1571	59	Zantac	$17.87	t
1571	64	GenRx Ranitidine	$17.87	t
1571	145	Ulcaid	$17.87	t
1571	156	Ausran	$17.87	t
1571	165	Ranihexal	$17.87	t
1571	169	Terry White Chemists Ranitidine	$17.87	t
1572	82	Anusol	$13.35	t
1573	1	Gopten	$24.10	t
1573	4	Tranalpha	$24.10	t
1573	61	Trandolapril-DP	$24.10	t
1573	63	Trandolapril generichealth	$24.10	t
1573	156	Dolapril 4	$24.10	t
1573	170	APO-Trandolapril	$24.10	t
1574	159	Iodosorb 66051360	$144.84	t
1575	29	Mexitil	$33.22	t
1576	37	Biatain Non-adhesive 3413	$86.45	t
1577	120	Certican	$720.90	t
1577	120	Certican	$1,578.62	t
1578	156	Nilstat	$17.98	t
1579	80	Reminyl	$187.77	t
1580	59	Quilonum SR	$34.30	t
1581	162	Epilim	$32.00	t
1582	135	Fragmin	$57.65	t
1582	135	Fragmin	$108.88	t
1583	36	Advantan	$14.29	t
1584	150	Mircera	$706.13	t
1585	159	Op-Site Flexigrid 4629	$30.49	t
1586	156	Abbocillin-VK Filmtab	$11.58	t
1587	171	Vimpat	$52.29	t
1588	162	Largactil	$16.82	t
1589	57	Ridaura	$63.55	t
1590	159	Iodosorb 66051340	$137.45	t
1591	96	OxyNorm	$12.30	t
1592	69	Hospira Pty Limited	$38.03	t
1592	120	Desferal 2 g	$38.03	t
1593	80	Risperdal Consta	$315.20	t
1594	99	Renitec Plus 20/6	$28.48	t
1594	165	Enalapril/HCT Sandoz	$28.48	t
1595	69	Hospira Pty Limited	$27.27	t
1596	10	Azopt	$23.45	t
1596	76	BrinzoQuin	$23.45	t
1597	36	BenPen	$12.75	t
1597	36	BenPen	$66.92	t
1598	156	Artane	$22.01	t
1599	29	Atrovent	$35.28	t
1600	4	Mobilis 10	$12.50	t
1600	31	Chem mart Piroxicam	$12.50	t
1600	64	GenRx Piroxicam	$12.50	t
1600	134	Feldene	$12.50	t
1600	169	Terry White Chemists Piroxicam	$12.50	t
1601	4	Kalma 0.25	$9.55	t
1601	156	Alprax 0.25	$9.55	t
1601	165	Alprazolam Sandoz	$9.55	t
1602	28	Baxter Healthcare Pty Ltd	$16.74	t
1603	24	Monoplus 10/12.5	$21.93	t
1603	145	Hyforil	$21.93	t
1603	165	Fosinopril/HCT Sandoz 10mg/12.5mg	$21.93	t
1603	170	APO-Fosinopril HCTZ 10/12.5	$21.93	t
1604	139	Petrus Bisacodyl Suppositories	$18.81	t
1604	139	Petrus Bisacodyl Suppositories	$28.72	t
1605	11	Doloxene	$22.27	t
1606	172	PKU Cooler 15	$1,548.34	t
1607	11	Panafcort	$11.62	t
1607	51	Sone	$11.62	t
1608	51	Cortic-DS 1%	$8.65	t
1608	156	Sigmacort	$8.65	t
1609	1	Isoptin	$18.44	t
1610	87	Cleocin	$20.30	t
1610	135	Dalacin C	$20.30	t
1611	155	Puregon 900 IU/1.08 mL	$432.11	t
1611	155	Puregon 900 IU/1.08 mL	$1,115.22	t
1612	172	Tyrosine Amino Acid Supplement	$516.02	t
1613	7	Sensipar	$296.86	t
1613	7	Sensipar	$343.60	t
1614	162	Actonel	$53.34	t
1615	3	Frusemide-Claris	$10.48	t
1615	162	Lasix	$10.48	t
1615	165	Frusehexal	$10.48	t
1616	5	Aquacare H.P.	$12.19	t
1616	66	Urederm	$12.45	t
1616	127	Calmurid	$12.77	t
1617	135	Fragmin	$109.38	t
1618	7	Aranesp SureClick	$280.00	t
1619	4	Presolol 100	$15.64	t
1619	156	Trandate	$15.64	t
1620	4	Metrogyl 400	$10.03	t
1620	13	Metronide 400	$10.03	t
1620	162	Flagyl	$10.03	t
1621	96	MS Contin	$15.42	t
1622	9	Imdur 120 mg	$21.74	t
1622	138	Monodur 120 mg	$21.74	t
1623	80	Topamax Sprinkle	$41.19	t
1624	4	Zopral	$29.54	t
1624	145	Lanzopran	$29.54	t
1624	170	APO-Lansoprazole	$29.54	t
1625	69	Hospira Pty Limited	$22.32	t
1626	59	Zofran Zydis	$42.68	t
1626	59	Zofran Zydis	$56.90	t
1626	149	Ondansetron-RL Zydis	$42.68	t
1626	149	Ondansetron-RL Zydis	$56.90	t
1626	165	Ondaz Zydis	$42.68	t
1626	165	Ondaz Zydis	$56.90	t
1627	81	Actisorb Plus MAC031	$100.92	t
1628	155	Puregon 600 IU/0.72 mL	$288.09	t
1628	155	Puregon 600 IU/0.72 mL	$749.08	t
1629	78	Fluorouracil Ebewe	$42.50	t
1629	78	Fluorouracil Ebewe	$56.70	t
1630	22	Peg 7422	$17.30	t
1631	31	Chem mart Mirtazapine	$41.24	t
1631	155	Avanza	$41.24	t
1631	156	Mirtazon	$41.24	t
1631	165	Mirtazapine Sandoz	$41.24	t
1631	169	Terry White Chemists Mirtazapine	$41.24	t
1631	170	APO-Mirtazapine	$41.24	t
1632	94	Forteo	$438.37	t
1633	162	Plaquenil	$37.59	t
1634	4	Allereze	$32.99	t
1634	155	Claratyne	$44.74	t
1634	165	Lorano	$43.65	t
1635	96	Dilaudid	$17.10	t
1636	74	Qvar 50	$19.29	t
1637	69	Eligard 6 month	$2,123.98	t
1638	24	Vepesid	$462.28	t
1639	162	Ikorel	$24.14	t
1640	120	Trileptal	$115.08	t
1641	59	Avandamet	$65.09	t
1642	1	Gopten	$15.90	t
1642	4	Tranalpha	$15.90	t
1642	61	Trandolapril-DP	$15.90	t
1642	63	Trandolapril generichealth	$15.90	t
1642	156	Dolapril 2	$15.90	t
1642	170	APO-Trandolapril	$15.90	t
1643	94	Humulin 30/70	$133.82	t
1644	82	Nizoral 2% Cream	$23.12	t
1645	69	Hospira Pty Limited	$13.40	t
1645	135	Methoblastin	$13.40	t
1646	138	Budamax Aqueous	$31.73	t
1647	30	Kaltostat 168117	$115.26	t
1648	99	Janumet	$94.82	t
1649	96	Sevredol	$14.51	t
1650	59	Flolan	$41.69	t
1651	4	Inza 500	$12.91	t
1651	150	Naprosyn	$12.91	t
1652	4	Kalma 1	$15.23	t
1652	31	Chem mart Alprazolam	$15.23	t
1652	60	Alprazolam-GA	$15.23	t
1652	64	GenRx Alprazolam	$15.23	t
1652	135	Xanax	$15.23	t
1652	156	Alprax 1	$15.23	t
1652	165	Alprazolam Sandoz	$15.23	t
1652	169	Terry White Chemists Alprazolam	$15.23	t
1653	162	Ditropan	$15.77	t
1653	165	Oxybutynin Sandoz	$15.77	t
1653	174	Oxybutynin Winthrop	$15.77	t
1654	9	Oxis Turbuhaler	$36.44	t
1655	110	Levemir FlexPen	$432.72	t
1655	116	Levemir Penfill	$432.72	t
1656	59	Myleran	$86.26	t
1657	27	Leukopor 2474	$16.21	t
1657	27	Leukosilk 1024	$17.05	t
1658	29	Viramune	$271.58	t
1659	11	Allegron	$15.10	t
1660	59	Valtrex	$214.06	t
1661	151	Energivit	$291.46	t
1662	134	Caduet 10/80	$127.44	t
1663	4	Moxicam 15	$28.83	t
1663	18	Meloxibell	$28.83	t
1663	29	Mobic	$28.83	t
1663	31	Chem mart Meloxicam 15 mg	$28.83	t
1663	35	Pharmacor Meloxicam 15	$28.83	t
1663	60	Meloxicam-GA	$28.83	t
1663	64	GenRx Meloxicam	$28.83	t
1663	145	Meloxicam Ranbaxy	$28.83	t
1663	156	Movalis 15	$28.83	t
1663	165	Meloxicam Sandoz	$28.83	t
1663	169	Terry White Chemists Meloxicam 15 mg	$28.83	t
1663	174	Meloxicam Winthrop	$28.83	t
1664	134	Solu-Medrol	$36.23	t
1665	134	Lyrica	$124.24	t
1666	182	Lyofoam Extra 603090	$189.11	t
1667	80	Motilium	$8.89	t
1668	184	Doryx	$12.52	t
1668	185	DBL Doxycycline	$12.52	t
1669	80	Leustatin	$4,483.23	t
1669	80	Leustatin	$4,629.59	t
1670	59	Zofran	$132.63	t
1670	149	Ondansetron-RL	$132.63	t
1670	156	Onsetron 8	$132.63	t
1670	165	Ondaz	$132.63	t
1670	170	APO-Ondansetron	$132.63	t
1671	4	Bispro 2.5	$49.94	t
1671	6	Bicor	$49.94	t
1671	165	Bisoprolol Sandoz	$49.94	t
1672	25	B. Braun Australia Pty Ltd	$18.32	t
1672	136	Pharmatel Fresenius Kabi Pty Limited	$18.32	t
1673	4	Cyprone	$207.72	t
1673	60	Procur	$207.72	t
1673	64	GenRx Cyproterone Acetate	$207.72	t
1673	152	Androcur	$207.72	t
1673	164	Cyprostat	$207.72	t
1673	165	Cyprohexal	$207.72	t
1674	4	Presolol 200	$21.60	t
1674	156	Trandate	$21.60	t
1675	1	Isoptin	$15.46	t
1675	4	Anpec 80	$15.46	t
1676	1	Klacid Hp 7	$74.18	t
1677	4	Ibilex 250	$8.85	t
1677	11	Keflex	$8.85	t
1677	18	Cephabell	$8.85	t
1677	31	Chem mart Cephalexin	$8.85	t
1677	60	Cilex	$8.85	t
1677	63	Cephalexin generichealth	$8.85	t
1677	64	GenRx Cephalexin	$8.85	t
1677	92	Ialex	$8.85	t
1677	98	Cephatrust 250	$8.85	t
1677	145	Rancef	$8.85	t
1677	165	Cefalexin Sandoz	$8.85	t
1677	169	Terry White Chemists Cephalexin	$8.85	t
1678	96	OxyContin	$31.87	t
1679	156	Kenacort-A10	$25.77	t
1680	80	Topamax Sprinkle	$61.94	t
1681	4	Hypnodorm	$13.27	t
1682	24	Reyataz	$695.88	t
1683	52	Pentasa	$297.44	t
1684	10	Isopto Carpine	$12.78	t
1685	99	Cosopt	$27.49	t
1686	152	Climara 25	$17.53	t
1687	162	Largactil	$17.44	t
1688	57	Dibenyline	$204.90	t
1689	7	Aranesp SureClick	$146.53	t
1690	47	Antroquoril	$24.96	t
1690	155	Celestone-M	$24.96	t
1691	13	Oruvail SR	$19.63	t
1691	162	Orudis SR 200	$19.63	t
1692	152	Microlut 28	$17.32	t
1693	4	Sulprix	$33.71	t
1693	162	Solian 100	$33.71	t
1693	165	Amisulpride Sandoz	$33.71	t
1693	174	Amisulpride 100 Winthrop	$33.71	t
1694	162	Phenergan	$15.34	t
1695	93	Fluanxol Depot	$19.22	t
1696	150	Pegasys RBV	$1,542.64	t
1697	28	Baxter Healthcare Pty Ltd	$31.97	t
1698	64	GenRx Gabapentin	$126.77	t
1698	134	Neurontin	$126.77	t
1698	134	Neurontin	$127.77	t
1698	145	Gabaran	$126.77	t
1698	165	Gabahexal 600mg	$126.77	t
1699	1	Humira	$1,774.36	t
1700	158	Teveten	$30.03	t
1701	29	Metalyse	$1,960.76	t
1702	4	Cyprone	$207.72	t
1702	60	Procur	$207.72	t
1702	64	GenRx Cyproterone Acetate	$207.72	t
1702	152	Androcur	$207.72	t
1702	164	Cyprostat	$207.72	t
1702	165	Cyprohexal	$207.72	t
1703	4	Alphapress 50	$17.42	t
1704	27	Handygauze Cohesive 8631	$12.52	t
1705	172	Isoleucine 1000 Amino Acid Supplement	$566.98	t
1706	96	MS Contin Suspension 100 mg	$66.56	t
1707	31	Chem mart Omeprazole	$29.34	t
1707	60	Omeprazole-GA	$29.34	t
1707	64	GenRx Omeprazole	$29.34	t
1707	145	Omeprazole Ranbaxy	$29.34	t
1707	165	Meprazol	$29.34	t
1707	169	Terry White Chemists Omeprazole	$29.34	t
1707	170	APO-Omeprazole	$29.34	t
1707	174	Omeprazole Winthrop	$29.34	t
1707	187	Ozmep	$29.34	t
1708	94	Strattera	$221.18	t
1709	161	Tubifast 2436	$32.02	t
1710	80	Risperdal Consta	$489.90	t
1711	47	Eleuphrat	$13.41	t
1711	155	Diprosone	$13.41	t
1712	120	Exelon	$155.45	t
1713	151	Dialamine	$634.17	t
1714	51	Cortic-DS 1%	$8.65	t
1714	156	Sigmacort	$8.65	t
1714	173	Cortef	$8.65	t
1715	59	Mesasal	$93.43	t
1716	66	Nemdyn	$8.66	t
1717	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$126.20	t
1717	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$155.66	t
1718	52	Norprolac	$54.79	t
1719	134	Zithromax	$21.59	t
1720	135	Colestid	$67.69	t
1721	94	Zyprexa	$53.55	t
1722	120	Glivec	$2,032.53	t
1723	159	Iodosorb Ointment 66051240	$100.72	t
1724	36	Modavigil	$346.98	t
1725	96	OxyContin	$71.70	t
1726	161	Tubigrip E 1547	$18.17	t
1727	24	Reyataz	$521.91	t
1728	155	Caelyx	$1,483.30	t
1728	155	Caelyx	$1,621.79	t
1729	69	Hospira Pty Limited	$233.30	t
1729	69	Hospira Pty Limited	$275.26	t
1729	78	Carboplatin Ebewe	$233.30	t
1729	78	Carboplatin Ebewe	$275.26	t
1729	141	Pfizer Australia Pty Ltd	$233.30	t
1729	141	Pfizer Australia Pty Ltd	$275.26	t
1730	173	Mestinon Timespan	$114.47	t
1731	134	Caduet 10/40	$96.25	t
1732	4	Adefin 10	$15.86	t
1732	23	Adalat 10	$15.86	t
1733	51	Cilicaine V	$22.40	t
1733	156	Abbocillin-V	$22.40	t
1734	48	Navelbine	$1,039.52	t
1734	48	Navelbine	$1,160.18	t
1734	69	Hospira Pty Limited	$1,039.52	t
1734	69	Hospira Pty Limited	$1,160.18	t
1734	78	Vinorelbine Ebewe	$1,039.52	t
1734	78	Vinorelbine Ebewe	$1,160.18	t
1734	91	Vinorelbine Link	$1,039.52	t
1734	91	Vinorelbine Link	$1,160.18	t
1735	159	Allevyn Thin 66047576	$55.20	t
1736	156	Betnovate	$22.43	t
1737	159	Jelonet 7404	$19.29	t
1738	28	Baxter Healthcare Pty Ltd	$10.65	t
1739	120	Exforge 5/80	$29.71	t
1740	162	Actonel Combi D	$53.34	t
1741	155	Sustanon 100	$20.67	t
1742	4	Flecatab	$46.08	t
1742	74	Tambocor	$46.08	t
1743	29	Catapres 100	$28.88	t
1744	5	Genoptic	$18.77	t
1745	69	Kytril	$25.42	t
1745	69	Kytril	$37.85	t
1746	134	Caduet 10/20	$75.19	t
1747	80	Jurnista	$65.97	t
1748	141	Didronel	$115.17	t
1749	152	Climara 75	$19.66	t
1750	4	Tramedo SR 200	$18.63	t
1750	31	Chem mart Tramadol SR	$18.63	t
1750	36	Tramal SR 200	$18.63	t
1750	156	Zydol SR 200	$18.63	t
1750	165	Tramahexal SR	$18.63	t
1750	169	Terry White Chemists Tramadol SR	$18.63	t
1750	170	APO-Tramadol SR	$18.63	t
1750	187	Lodam SR 200	$18.63	t
1751	109	Waxsol	$14.47	t
1752	20	Gold Cross	$12.17	t
1753	10	Isopto Carpine	$14.08	t
1754	4	Amira 300	$30.18	t
1754	31	Chem mart Moclobemide	$30.18	t
1754	60	Clobemix	$30.18	t
1754	64	GenRx Moclobemide	$30.18	t
1754	150	Aurorix 300 mg	$30.18	t
1754	156	Maosig	$30.18	t
1754	165	Mohexal	$30.18	t
1754	169	Terry White Chemists Moclobemide	$30.18	t
1755	9	Atacand Plus 32/12.5	$48.55	t
1756	155	Temodal	$808.22	t
1756	155	Temodal	$2,389.29	t
1757	135	Methoblastin	$22.47	t
1758	151	Lophlex	$1,549.44	t
1759	162	Clexane	$108.88	t
1760	11	Imuran	$37.18	t
1760	165	Azahexal	$37.18	t
1761	4	Celapram	$34.39	t
1761	64	GenRx Citalopram	$34.39	t
1761	165	Citalopram Sandoz	$34.39	t
1761	170	APO-Citalopram	$34.39	t
1762	58	Truvada	$765.10	t
1763	134	Chloromycetin	$11.05	t
1764	11	Span-K	$13.16	t
1765	37	Comfeel SeaSorb Dressing 3705	$46.92	t
1766	135	Genotropin MiniQuick	$485.10	t
1767	81	Tielle MT2442	$135.84	t
1768	94	Evista	$57.87	t
1769	4	Perindo	$12.73	t
1769	31	Chem mart Perindopril	$12.73	t
1769	35	Perindopril 2	$12.73	t
1769	60	Perindopril-GA	$12.73	t
1769	61	Perindopril-DP	$12.73	t
1769	64	GenRx Perindopril	$12.73	t
1769	145	Ozapace	$12.73	t
1769	156	Indopril 2	$12.73	t
1769	169	Terry White Chemists Perindopril	$12.73	t
1770	184	Astrix	$8.10	t
1770	185	DBL Aspirin 100 mg	$8.10	t
1771	155	Ovestin	$19.09	t
1772	155	Sustanon 250	$33.48	t
1773	96	Dilaudid-HP	$28.97	t
1774	120	Stalevo 125/31.25/200mg	$353.96	t
1775	147	Cardiprin 100	$15.67	t
1776	116	Norditropin NordiFlex	$315.50	t
1776	116	Norditropin SimpleXx	$247.50	t
1776	165	Omnitrope	$247.50	t
1777	25	B. Braun Australia Pty Ltd	$24.37	t
1777	136	Sodium Chloride 0.9% Freeflex	$24.37	t
1778	97	Mepilex 294100	$42.68	t
1779	59	Retrovir	$308.19	t
1780	65	Thyrogen	$1,901.42	t
1781	52	Pentasa	$127.72	t
1782	25	B. Braun Australia Pty Ltd	$23.52	t
1782	28	Baxter Healthcare Pty Ltd	$23.52	t
1782	136	Pharmatel Fresenius Kabi Pty Limited	$23.52	t
1783	159	Allevyn Plus Cavity 66047571	$84.60	t
1784	147	Subutex	$6.16	t
1785	147	Subutex	$30.10	t
1786	4	Kripton 2.5	$32.73	t
1786	120	Parlodel	$32.73	t
1787	30	Aquacel 177904	$83.71	t
1788	78	Methotrexate Ebewe	$490.48	t
1788	78	Methotrexate Ebewe	$554.87	t
1789	120	Stalevo 75/18.75/200mg	$325.12	t
1790	74	Aldara	$159.95	t
1791	154	Crinone 8%	$148.50	t
1792	155	Tinaderm	$14.68	t
1793	4	Cholstat 20	$30.54	t
1793	31	Chem mart Pravastatin	$30.54	t
1793	35	Pravastatin 20	$30.54	t
1793	51	Pravachol	$30.54	t
1793	60	Pravastatin-GA 20	$30.54	t
1793	63	Pravastatin generichealth	$30.54	t
1793	64	GenRx Pravastatin	$30.54	t
1793	145	Vastoran	$30.54	t
1793	156	Lipostat 20	$30.54	t
1793	165	Liprachol	$30.54	t
1793	169	Terry White Chemists Pravastatin	$30.54	t
1793	170	APO-Pravastatin	$30.54	t
1793	174	Pravastatin Winthrop	$30.54	t
1794	31	Chem mart Frusemide	$9.03	t
1794	60	Frusid	$9.03	t
1794	64	GenRx Frusemide	$9.03	t
1794	169	Terry White Chemists Frusemide	$9.03	t
1795	94	Humulin R	$133.82	t
1795	116	Actrapid	$133.82	t
1796	24	Taxol	$1,703.29	t
1796	24	Taxol	$1,849.65	t
1796	63	Paclitaxel Actavis	$1,703.29	t
1796	63	Paclitaxel Actavis	$1,849.65	t
1796	69	Anzatax	$1,703.29	t
1796	69	Anzatax	$1,849.65	t
1796	78	Paclitaxel Ebewe	$1,703.29	t
1796	78	Paclitaxel Ebewe	$1,849.65	t
1797	155	Pegatron	$917.38	t
1797	155	Pegatron	$1,211.36	t
1797	155	Pegatron	$1,407.33	t
1797	155	Pegatron	$1,603.31	t
1797	155	Pegatron	$1,897.28	t
1798	135	Zavedos Solution	$503.00	t
1798	135	Zavedos Solution	$568.88	t
1799	24	Modecate	$19.22	t
1800	159	ProGuide 66000781	$47.86	t
1800	159	ProGuide 66000781	$168.94	t
1801	151	PKU Lophlex LQ 20	$1,549.44	t
1802	6	C-Flox 750	$62.50	t
1802	18	Ciprofloxacin-BW	$62.50	t
1802	23	Ciproxin 750	$62.50	t
1802	35	Ciprofloxacin 750	$62.50	t
1802	61	Genepharm (Australia) Limited	$62.50	t
1802	64	GenRx Ciprofloxacin	$62.50	t
1802	145	Cifran	$62.50	t
1802	156	Ciprol 750	$62.50	t
1802	165	Ciprofloxacin Sandoz	$62.50	t
1803	159	Allevyn Adhesive 66000044	$117.66	t
1804	96	Dilaudid-HP	$75.41	t
1805	119	PKU Lophlex LQ 10	$1,059.36	t
1806	120	Elidel	$33.79	t
1807	173	Efudix	$50.88	t
1808	134	Vfend	$2,749.90	t
1809	23	Nexavar	$6,457.08	t
1810	120	Femara 2.5 mg	$180.18	t
1811	4	Perindo	$24.34	t
1811	31	Chem mart Perindopril	$24.34	t
1811	35	Perindopril 8	$24.34	t
1811	60	Perindopril-GA	$24.34	t
1811	61	Perindopril-DP	$24.34	t
1811	64	GenRx Perindopril	$24.34	t
1811	145	Ozapace	$24.34	t
1811	156	Indopril 8	$24.34	t
1811	169	Terry White Chemists Perindopril	$24.34	t
1812	136	Voluven 6%	$45.75	t
1813	6	C-Flox 500	$44.75	t
1813	18	Ciprofloxacin-BW	$44.75	t
1813	23	Ciproxin 500	$44.75	t
1813	35	Ciprofloxacin 500	$44.75	t
1813	60	Ciprofloxacin-GA	$44.75	t
1813	61	Genepharm (Australia) Limited	$44.75	t
1813	64	GenRx Ciprofloxacin	$44.75	t
1813	145	Cifran	$44.75	t
1813	156	Ciprol 500	$44.75	t
1813	165	Profloxin	$44.75	t
1814	4	Roximycin	$11.76	t
1814	13	Biaxsig	$11.76	t
1814	31	Chem mart Roxithromycin	$11.76	t
1814	60	Roxithromycin-GA	$11.76	t
1814	156	Roxar 150	$11.76	t
1814	162	Rulide	$11.76	t
1814	165	Roxide	$11.76	t
1814	169	Terry White Chemists Roxithromycin	$11.76	t
1814	170	APO-Roxithromycin	$11.76	t
1815	4	Asmol 2.5 uni-dose	$12.68	t
1815	4	Asmol 2.5 uni-dose	$18.94	t
1815	35	Pharmacor Salbutamol 2.5	$12.68	t
1815	35	Pharmacor Salbutamol 2.5	$18.94	t
1815	59	Ventolin Nebules	$13.41	t
1815	59	Ventolin Nebules	$18.94	t
1815	60	Salbutamol-GA	$12.68	t
1815	60	Salbutamol-GA	$18.94	t
1815	64	GenRx Salbutamol	$12.68	t
1815	64	GenRx Salbutamol	$18.94	t
1815	141	Pfizer Australia Pty Ltd	$12.68	t
1815	141	Pfizer Australia Pty Ltd	$18.94	t
1815	156	Butamol 2.5	$12.68	t
1815	156	Butamol 2.5	$18.94	t
1815	165	Salbutamol Sandoz	$12.68	t
1815	165	Salbutamol Sandoz	$18.94	t
1816	159	Iodosorb Ointment 66051240	$100.72	t
1817	162	Intal Forte CFC-Free	$37.04	t
1818	82	Nicorette Patch	$59.96	t
1819	4	Rixadone	$52.73	t
1819	35	Resdone 1	$52.73	t
1819	60	Risperidone-GA	$52.73	t
1819	63	Risperidone generichealth	$52.73	t
1819	80	Risperdal	$52.73	t
1819	145	Ozidal	$52.73	t
1819	156	Rispa	$52.73	t
1819	170	APO-Risperidone	$52.73	t
1820	78	Paclitaxel Ebewe	$844.56	t
1820	78	Paclitaxel Ebewe	$950.81	t
1821	1	Hytrin	$20.05	t
1822	134	Revatio	$898.43	t
1823	155	Implanon	$215.92	t
1824	70	Albey Bee Venom	$238.38	t
1825	59	Zinnat	$18.62	t
1826	51	Fawns and McAllan Proprietary Limited	$39.02	t
1827	82	Nicorette Patch	$55.22	t
1828	6	Glucovance 250mg/1.25mg	$13.55	t
1829	63	Fludarabine Actavis	$1,430.65	t
1829	63	Fludarabine Actavis	$1,567.02	t
1829	177	Farine	$1,430.65	t
1829	177	Farine	$1,567.02	t
1830	4	Acyclo-V 200	$69.54	t
1830	59	Zovirax 200 mg	$69.54	t
1830	60	Lovir	$69.54	t
1830	165	Acihexal	$69.54	t
1831	150	NeoRecormon	$1,037.00	t
1832	179	Relistor	$287.84	t
1833	9	Pulmicort Turbuhaler	$45.84	t
1834	151	XPhen, Tyr Maxamaid	$1,784.74	t
1834	151	XPhen, Tyr Maxamum	$2,704.74	t
1835	1	Lucrin Depot 3 Month PDS	$1,108.76	t
1836	162	Largactil	$10.49	t
1837	82	Microlax	$36.58	t
1837	82	Microlax	$52.44	t
1838	4	Kaluril	$10.98	t
1839	51	Fawns and McAllan Proprietary Limited	$16.87	t
1840	151	Liquigen	$214.42	t
1841	150	Cymevene	$280.00	t
1842	1	Tarka 4/240	$33.18	t
1843	150	Avastin	$1,720.00	t
1843	150	Avastin	$1,866.36	t
1844	51	Eutroxsig	$24.07	t
1844	156	Oroxine	$24.07	t
1845	135	Genotropin MiniQuick	$277.20	t
1846	172	HCU gel	$1,798.42	t
1847	36	ADT Booster	$75.34	t
1847	36	ADT Booster	$275.02	t
1848	152	Progynova	$11.88	t
1849	156	Endone	$12.30	t
1850	162	Intal	$31.27	t
1851	1	Kaletra	$685.00	t
1852	120	Estradot 100	$19.66	t
1853	134	Lyrica	$42.65	t
1854	161	Setopress 3504	$68.37	t
1855	4	Sumatab	$25.12	t
1855	59	Imigran	$25.12	t
1856	66	Aquae Gel	$12.91	t
1857	57	Stelazine	$13.48	t
1858	4	Flutamin	$209.26	t
1858	155	Eulexin	$209.26	t
1859	158	Creon 40,000	$215.62	t
1860	134	Inspra	$112.77	t
1861	84	Telfa 1970C	$11.02	t
1862	152	Betaferon	$1,180.16	t
1863	99	Ezetrol	$70.97	t
1864	159	Flamazine	$19.15	t
1865	156	Abbocillin-VK Filmtab	$14.06	t
1866	28	Endoxan	$42.43	t
1867	109	Movicol-Half	$18.53	t
1868	150	Pegasys	$1,350.23	t
1869	162	Largactil	$11.09	t
1870	172	HCU express	$3,098.38	t
1871	78	Calcium Folinate Ebewe	$122.96	t
1871	78	Calcium Folinate Ebewe	$151.85	t
1872	120	Exelon	$155.45	t
1873	9	ZolaCos CP 10.8/50(28)	$1,254.04	t
1874	27	Elastocrepe 36102420	$22.40	t
1874	84	Telfa 8253F	$22.22	t
1875	162	Myocrisin	$124.79	t
1876	4	Paxtine	$25.48	t
1876	31	Chem mart Paroxetine	$25.48	t
1876	35	Paroxetine 20	$25.48	t
1876	59	Aropax	$25.48	t
1876	60	Paroxetine-DP	$25.48	t
1876	61	Paroxetine-GA	$25.48	t
1876	64	GenRx Paroxetine	$25.48	t
1876	156	Extine 20	$25.48	t
1876	165	Paroxetine Sandoz	$25.48	t
1876	169	Terry White Chemists Paroxetine	$25.48	t
1877	1	Humira	$5,036.36	t
1878	49	Betadine Antiseptic Liquid	$20.82	t
1879	7	Neupogen	$1,504.00	t
1880	80	Risperdal Quicklet	$59.78	t
1881	94	Zyprexa	$147.11	t
1882	153	Coversyl Plus 5mg/1.25mg	$29.12	t
1883	120	Exjade	$467.15	t
1884	9	Pulmicort Respules	$49.00	t
1885	46	Sebitar	$18.84	t
1886	4	Akamin 50	$15.49	t
1886	156	Minomycin-50	$15.49	t
1887	4	Kripton 10	$155.94	t
1887	120	Parlodel	$155.94	t
1888	4	Nupentin 400	$82.24	t
1888	6	Pendine 400	$82.24	t
1888	14	Gantin	$82.24	t
1888	35	Gabapentin 400	$82.24	t
1888	61	Douglas Gabapentin 400mg	$82.24	t
1888	64	GenRx Gabapentin	$82.24	t
1888	69	DBL Gabapentin	$82.24	t
1888	134	Neurontin	$82.24	t
1888	134	Neurontin	$83.24	t
1888	156	Gabatine 400	$82.24	t
1888	165	Gabahexal 400mg	$82.24	t
1889	97	Mepitac 298400	$21.37	t
1890	4	Lamogine	$67.49	t
1890	59	Lamictal	$67.49	t
1890	60	Lamotrigine-DP	$67.49	t
1890	61	Lamotrigine-GA	$67.49	t
1890	63	Lamotrigine generichealth	$67.49	t
1890	64	GenRx Lamotrigine	$67.49	t
1890	98	Lamotrust 100	$67.49	t
1890	145	Lamidus	$67.49	t
1890	156	Seaze 100	$67.49	t
1890	165	Lamotrigine Sandoz	$67.49	t
1891	135	Pharmorubicin Solution	$343.68	t
1891	135	Pharmorubicin Solution	$393.94	t
1892	162	ImmuCyst	$405.00	t
1892	162	ImmuCyst	$459.87	t
1893	141	Didrocal	$70.69	t
1894	78	Fludarabine Ebewe	$1,430.64	t
1894	78	Fludarabine Ebewe	$1,567.02	t
1895	29	Micardis	$21.66	t
1896	9	Toprol-XL 23.75	$21.04	t
1897	66	Hamilton Skin Therapy Wash	$20.74	t
1898	4	Aylide 2	$11.55	t
1898	13	Dimirel	$11.55	t
1898	156	Diapride 2	$11.55	t
1898	162	Amaryl	$11.55	t
1898	165	Glimepiride Sandoz	$11.55	t
1898	170	APO-Glimepiride	$11.55	t
1899	4	Staphylex 250	$11.45	t
1899	11	Flopen	$11.45	t
1900	66	Condyline Paint	$39.75	t
1901	69	Pamisol	$218.56	t
1901	69	Pamisol	$259.41	t
1902	96	MS Contin	$29.03	t
1902	156	Momex SR 30	$29.03	t
1903	120	Famvir	$137.06	t
1904	57	Dibenyline	$67.36	t
1905	150	Xeloda	$123.93	t
1906	23	Glucobay 50	$30.90	t
1907	156	Diamox	$23.79	t
1908	51	Gastrogel	$17.70	t
1909	87	Ralovera	$15.67	t
1909	135	Provera	$15.67	t
1909	165	Medroxyhexal	$15.67	t
1910	155	Pegatron	$1,353.83	t
1910	155	Pegatron	$1,745.79	t
1910	155	Pegatron	$2,039.76	t
1911	179	Pristiq	$43.31	t
1912	150	Mircera	$609.90	t
1913	80	Haldol decanoate	$26.67	t
1914	4	Hydrene 25/50	$12.89	t
1915	96	Ordine 5	$21.02	t
1916	94	Cialis	$83.02	t
1917	4	Metrogyl 200	$7.96	t
1917	13	Metronide 200	$7.96	t
1917	162	Flagyl	$7.96	t
1918	11	Permax	$52.93	t
1919	24	Zerit	$333.68	t
1920	4	Deralin 160	$11.01	t
1921	4	Rixadone	$223.43	t
1921	35	Resdone 4	$223.43	t
1921	60	Risperidone-GA	$223.43	t
1921	63	Risperidone generichealth	$223.43	t
1921	80	Risperdal	$223.43	t
1921	145	Ozidal	$223.43	t
1921	156	Rispa	$223.43	t
1921	170	APO-Risperidone	$223.43	t
1922	32	Revlimid	$5,392.38	t
1923	80	Prograf	$936.68	t
1923	80	Prograf	$1,053.30	t
1924	9	Seroquel XR	$266.23	t
1925	36	Angiomax	$671.75	t
1926	96	OxyNorm	$20.15	t
1927	80	Pariet	$37.78	t
1928	71	Restore Plus Sacral 9959	$99.60	t
1929	4	Doxylin 50	$10.07	t
1929	60	Doxy-50	$10.07	t
1929	134	Vibra-Tabs	$10.07	t
1930	24	Hydrea	$76.46	t
1931	120	Tasigna	$5,490.42	t
1932	4	Colese	$26.91	t
1932	158	Colofac	$31.41	t
1933	150	NeoRecormon	$351.00	t
1934	80	Eprex 4000	$447.00	t
1935	1	Lucrin Depot 4 Month PDS	$1,451.33	t
1936	6	EpiPen	$106.00	t
1937	51	Coloxyl 50	$14.31	t
1938	120	Navoban	$18.50	t
1938	120	Navoban	$29.29	t
1939	179	Efexor-XR	$43.31	t
1940	150	Avastin	$472.50	t
1940	150	Avastin	$534.77	t
1941	151	HCU Anamix infant	$769.30	t
1942	4	Salpraz	$31.98	t
1942	31	Chem mart Pantoprazole	$31.98	t
1942	60	Pantoprazole-GA	$31.98	t
1942	111	Pantoloc	$31.98	t
1942	117	Somac	$31.98	t
1942	121	Panto	$31.98	t
1942	145	Ozpan	$31.98	t
1942	156	Sozol	$31.98	t
1942	165	Pantoprazole Sandoz	$31.98	t
1942	169	Terry White Chemists Pantoprazole	$31.98	t
1942	170	APO-Pantoprazole	$31.98	t
1943	13	Arabloc	$139.26	t
1943	162	Arava	$139.26	t
1944	69	Hospira Pty Limited	$22.32	t
1945	159	Iodosorb 66051330	$95.22	t
1946	151	XP Maxamum	$1,512.06	t
1947	116	NovoRapid	$159.27	t
1948	173	Mestinon	$19.67	t
1949	162	Taxotere	$1,155.45	t
1949	162	Taxotere	$1,280.83	t
1950	96	Dilaudid	$30.03	t
1951	116	Vagifem	$23.24	t
1952	4	Lisodur	$17.99	t
1952	9	Zestril	$17.99	t
1952	18	Lisinobell	$17.99	t
1952	31	Chem mart Lisinopril	$17.99	t
1952	35	Lisinopril 10	$17.99	t
1952	60	Liprace	$17.99	t
1952	63	Lisinopril generichealth	$17.99	t
1952	64	GenRx Lisinopril	$17.99	t
1952	73	Lisinopril Hexal	$17.99	t
1952	99	Prinivil 10	$17.99	t
1952	145	Lisinopril Ranbaxy	$17.99	t
1952	156	Fibsol 10	$17.99	t
1952	169	Terry White Chemists Lisinopril	$17.99	t
1952	170	APO-Lisinopril	$17.99	t
1952	174	Lisinopril Winthrop	$17.99	t
1953	4	Lamogine	$109.01	t
1953	59	Lamictal	$109.01	t
1953	60	Lamotrigine-DP	$109.01	t
1953	61	Lamotrigine-GA	$109.01	t
1953	63	Lamotrigine generichealth	$109.01	t
1953	64	GenRx Lamotrigine	$109.01	t
1953	98	Lamotrust 200	$109.01	t
1953	145	Lamidus	$109.01	t
1953	156	Seaze 200	$109.01	t
1953	165	Lamotrigine Sandoz	$109.01	t
1954	9	Nolvadex-D	$60.26	t
1955	137	Tobra-Day	$357.37	t
1956	80	Eprex 8000	$856.80	t
1957	4	Paxam 0.5	$13.31	t
1957	4	Paxam 0.5	$20.20	t
1957	150	Rivotril	$13.31	t
1957	150	Rivotril	$20.20	t
1958	4	Mobilis D-20	$12.20	t
1958	134	Feldene-D	$12.20	t
1959	9	Symbicort Turbuhaler 400/12	$86.89	t
1960	72	TenderWet 24 Active	$92.19	t
1961	37	Biatain Ag 9622	$175.89	t
1962	4	Qpril 10	$17.16	t
1962	6	Filpril	$17.16	t
1962	35	Pharmacor Quinapril 10	$17.16	t
1962	61	Quinapril-DP	$17.16	t
1962	63	Quinapril generichealth	$17.16	t
1962	134	Accupril	$17.16	t
1962	156	Acquin 10	$17.16	t
1962	170	APO-Quinapril	$17.16	t
1963	36	Tramal	$13.71	t
1964	9	Seroquel	$139.47	t
1965	4	Oxaliplatin Alphapharm	$315.60	t
1965	4	Oxaliplatin Alphapharm	$363.75	t
1965	63	Oxaliplatin Actavis	$315.60	t
1965	63	Oxaliplatin Actavis	$363.75	t
1965	69	Hospira Pty Limited	$315.60	t
1965	69	Hospira Pty Limited	$363.75	t
1965	78	Oxaliplatin Ebewe	$315.60	t
1965	78	Oxaliplatin Ebewe	$363.75	t
1965	187	Oxalatin	$315.60	t
1965	187	Oxalatin	$363.75	t
1966	100	Medipore 2961	$12.87	t
1967	7	Aranesp	$2,055.00	t
1968	69	Kytril	$137.84	t
1969	129	Orion Laboratories Pty Ltd	$55.60	t
1970	56	Panadol	$26.82	t
1971	150	NeoRecormon	$447.00	t
1972	120	Estradot 25	$17.53	t
1973	4	Doxylin 100	$8.47	t
1973	4	Doxylin 100	$12.57	t
1973	4	Doxylin 100	$14.62	t
1973	60	Doxy-100	$8.47	t
1973	60	Doxy-100	$12.57	t
1973	60	Doxy-100	$14.62	t
1973	134	Vibramycin	$8.47	t
1973	134	Vibramycin	$12.57	t
1973	134	Vibramycin	$14.62	t
1973	156	Doxsig	$8.47	t
1973	156	Doxsig	$12.57	t
1973	156	Doxsig	$14.62	t
1974	135	Brevinor	$16.86	t
1975	154	Gonal-f 75	$360.00	t
1975	154	Gonal-f 75	$470.68	t
1976	134	Viagra	$60.68	t
1977	141	Cabaser	$80.89	t
1977	156	Bergoline 2	$80.89	t
1978	155	Pegatron	$1,059.87	t
1978	155	Pegatron	$1,549.81	t
1979	94	Humalog	$159.27	t
1980	80	Concerta	$57.66	t
1981	120	Exjade	$233.58	t
1982	119	PKU Anamix Junior LQ	$1,269.86	t
1983	162	Neulactil	$10.41	t
1984	134	Lipitor	$110.25	t
1985	9	Losec Tablets	$22.58	t
1986	162	Clexane	$104.74	t
1987	4	Deptran 10	$8.97	t
1987	134	Sinequan	$8.97	t
1988	120	Foradile	$37.33	t
1989	162	Rifadin	$28.57	t
1990	134	Sutent	$1,834.20	t
1991	80	Invega	$226.01	t
1992	91	Erythrocin-I.V.	$88.92	t
1993	135	Methoblastin	$22.47	t
1994	141	Macrodantin	$26.26	t
1995	82	Livostin	$18.24	t
1996	4	Diaformin 850	$13.09	t
1996	6	Diabex 850	$13.09	t
1996	18	Metforbell	$13.09	t
1996	31	Chem mart Metformin	$13.09	t
1996	35	Metformin 850	$13.09	t
1996	60	Metformin-GA	$13.09	t
1996	61	Genepharm (Australia) Limited	$13.09	t
1996	63	Metformin generichealth	$13.09	t
1996	64	GenRx Metformin	$13.09	t
1996	102	Glucophage	$13.09	t
1996	145	Metformin Ranbaxy	$13.09	t
1996	156	Formet 850	$13.09	t
1996	165	Glucohexal	$13.09	t
1996	169	Terry White Chemists Metformin	$13.09	t
1997	4	Zedace	$16.68	t
1997	64	GenRx Captopril	$16.68	t
1997	165	Captohexal	$16.68	t
1998	99	Januvia	$91.19	t
1999	120	Co-Diovan 80/12.5	$22.21	t
2000	11	Colgout	$11.24	t
2000	92	Lengout	$11.24	t
2001	162	Phenergan	$15.34	t
2002	120	Estraderm 100	$19.66	t
2003	7	Aranesp	$1,120.00	t
2004	151	Phlexy-10 Drink Mix	$1,462.91	t
2005	11	Vancocin	$457.20	t
2006	97	Mefix 310250	$11.04	t
2007	4	Nordip	$16.68	t
2007	6	Perivasc	$16.68	t
2007	31	Chem mart Amlodipine	$16.68	t
2007	35	Pharmacor Amlodipine 5	$16.68	t
2007	60	Amlodipine-GA	$16.68	t
2007	61	Norvapine	$16.68	t
2007	63	Amlodipine generichealth	$16.68	t
2007	134	Norvasc	$16.68	t
2007	145	Ozlodip	$16.68	t
2007	165	Amlodipine Sandoz	$16.68	t
2007	169	Terry White Chemists Amlodipine	$16.68	t
2007	170	APO-Amlodipine	$16.68	t
2008	80	Pariet	$37.78	t
2009	11	Periactin	$14.20	t
2010	120	Tegretol CR 400	$51.02	t
2011	80	Risperdal	$31.32	t
2011	170	APO-Risperidone	$31.32	t
2012	24	Modecate	$26.38	t
2013	30	DuoDERM Gel H7987	$97.11	t
2014	135	Provera	$105.73	t
2015	4	Anthel 250	$9.48	t
2016	152	Ventavis	$1,076.00	t
2017	4	Zedace	$21.27	t
2017	60	Genepharm Pty Ltd	$21.27	t
2017	64	GenRx Captopril	$21.27	t
2017	156	Capoten	$21.27	t
2017	165	Captopril Sandoz	$21.27	t
2018	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$18.19	t
2019	155	Pregnyl	$11.49	t
2020	57	Stelazine	$13.31	t
2021	9	Atacand	$28.91	t
2022	59	Bactroban	$20.63	t
2023	99	Vytorin	$107.85	t
2024	153	Coversyl 2.5mg	$12.73	t
2025	80	Eprex 3000	$351.00	t
2026	4	Rixadone	$168.58	t
2026	35	Resdone 3	$168.58	t
2026	60	Risperidone-GA	$168.58	t
2026	63	Risperidone generichealth	$168.58	t
2026	80	Risperdal	$168.58	t
2026	145	Ozidal	$168.58	t
2026	156	Rispa	$168.58	t
2026	170	APO-Risperidone	$168.58	t
2027	24	Videx EC	$204.24	t
2028	59	3TC	$282.00	t
2029	94	Zyprexa	$99.27	t
2030	4	Rani 2	$17.87	t
2030	31	Chem mart Ranitidine	$17.87	t
2030	59	Zantac	$17.87	t
2030	60	Ranoxyl	$17.87	t
2030	64	GenRx Ranitidine	$17.87	t
2030	145	Ulcaid	$17.87	t
2030	156	Ausran	$17.87	t
2030	165	Ranihexal	$17.87	t
2030	169	Terry White Chemists Ranitidine	$17.87	t
2031	162	Triasyn 5.0/5.0	$25.56	t
2032	32	Revlimid	$5,643.33	t
2033	150	NeoRecormon	$272.00	t
2034	30	Flexidress 650941	$28.78	t
2035	69	Hospira Pty Limited	$51.28	t
2035	69	Hospira Pty Limited	$67.08	t
2035	78	Carboplatin Ebewe	$51.28	t
2035	78	Carboplatin Ebewe	$67.08	t
2035	141	Pfizer Australia Pty Ltd	$51.28	t
2035	141	Pfizer Australia Pty Ltd	$67.08	t
2036	24	Zerit	$444.90	t
2037	52	Zomacton	$198.00	t
2038	4	Lamogine	$29.40	t
2038	59	Lamictal	$29.40	t
2038	60	Lamotrigine-DP	$29.40	t
2038	61	Lamotrigine-GA	$29.40	t
2038	63	Lamotrigine generichealth	$29.40	t
2038	64	GenRx Lamotrigine	$29.40	t
2038	98	Lamotrust 25	$29.40	t
2038	145	Lamidus	$29.40	t
2038	156	Seaze 25	$29.40	t
2038	165	Lamotrigine Sandoz	$29.40	t
2039	158	Zanidip	$18.91	t
2039	158	Zanidip	$21.39	t
2040	66	Hamilton Sunscreen Family Sunscreen Cream SPF	$16.07	t
2041	27	Handy 4209	$12.20	t
2042	4	Xergic	$35.76	t
2042	162	Telfast	$48.18	t
2042	165	Fexal	$41.13	t
2043	122	Ferriprox	$450.56	t
2044	120	Co-Diovan 160/12.5	$25.98	t
2045	6	Glucovance 500mg/2.5mg	$15.92	t
2046	96	Dilaudid-HP	$52.00	t
2047	99	Janumet	$97.90	t
2048	4	Movox 100	$27.55	t
2048	156	Faverin 100	$27.55	t
2048	158	Luvox	$27.55	t
2048	165	Voxam	$27.55	t
2048	170	APO-Fluvoxamine	$27.55	t
2049	91	Deseril	$44.96	t
2050	186	Fosrenol	$445.01	t
2050	186	Fosrenol	$504.03	t
2051	152	Mirena	$246.41	t
2052	11	Lithicarb	$16.89	t
2053	9	Seroquel XR	$100.45	t
2054	147	Subutex	$10.50	t
2055	23	Xarelto	$101.14	t
2056	4	Aclin	$16.34	t
2057	4	Noten	$10.27	t
2057	9	Tenormin	$10.27	t
2057	31	Chem mart Atenolol	$10.27	t
2057	61	Atenolol-GA	$10.27	t
2057	64	GenRx Atenolol	$10.27	t
2057	156	Tensig	$10.27	t
2057	165	Atehexal	$10.27	t
2057	169	Terry White Chemists Atenolol	$10.27	t
2057	170	APO-Atenolol	$10.27	t
2058	87	Ralovera	$15.03	t
2058	135	Provera	$15.03	t
2059	120	Antistine-Privine	$13.86	t
2060	4	Alphapril	$17.45	t
2060	18	Enalabell	$17.45	t
2060	31	Chem mart Enalapril	$17.45	t
2060	61	Enalapril-DP 10mg	$17.45	t
2060	63	Enalapril generichealth	$17.45	t
2060	64	GenRx Enalapril	$17.45	t
2060	99	Renitec	$17.45	t
2060	156	Auspril	$17.45	t
2060	165	Enahexal	$17.45	t
2060	169	Terry White Chemists Enalapril	$17.45	t
2060	174	Enalapril Winthrop	$17.45	t
2061	4	Bispro 5	$60.08	t
2061	6	Bicor	$60.08	t
2061	165	Bisoprolol Sandoz	$60.08	t
2062	59	Zofran Zydis	$86.98	t
2062	149	Ondansetron-RL Zydis	$86.98	t
2062	165	Ondaz Zydis	$86.98	t
2063	155	Ovestin Ovula	$21.26	t
2064	24	Avapro	$21.11	t
2064	162	Karvea	$21.11	t
2065	59	Ziagen	$423.00	t
2066	161	Tubigrip C 1545	$18.17	t
2067	59	Flolan	$83.37	t
2068	159	ZipZoc 66051550	$81.42	t
2069	17	Elastoplast 2227	$15.11	t
2070	156	Pexsig	$62.62	t
2071	27	Handygauze Cohesive 8635	$17.14	t
2072	4	Imrest	$21.76	t
2072	162	Imovane	$23.34	t
2073	134	Celsentri	$917.70	t
2074	52	Minirin Nasal Spray	$83.73	t
2074	52	Minirin Nasal Spray	$161.04	t
2075	155	Intron A Redipen	$178.74	t
2075	155	Intron A Redipen	$536.22	t
2075	155	Intron A Redipen	$606.03	t
2076	93	Ebixa	$109.00	t
2076	156	Memanxa	$109.00	t
2077	59	Retrovir	$44.88	t
2078	82	Nicorette Patch	$50.82	t
2079	147	Senokot	$13.86	t
2080	3	Ferro-f-tab	$12.79	t
2081	155	Schering-Plough Pty Limited	$209.58	t
2082	162	Actonel Once-a-Week	$53.34	t
2083	59	Kapanol	$55.10	t
2084	155	Schering-Plough Pty Limited	$76.36	t
2085	155	Puregon 300 IU/0.36 mL	$144.04	t
2085	155	Puregon 300 IU/0.36 mL	$563.43	t
2086	11	Periactin	$14.20	t
2087	135	Genotropin MiniQuick	$623.70	t
2088	4	Actilax	$14.23	t
2088	60	Lac-Dol	$14.23	t
2088	64	GenRx Lactulose	$14.23	t
2088	156	Genlac	$14.23	t
2088	158	Duphalac	$14.23	t
2088	165	Lactocur	$14.23	t
2089	81	Solugel 10336	$33.12	t
2089	159	SoloSite Gel 36361338	$27.75	t
2090	158	Physiotens	$28.78	t
2091	69	DBL Ceftriaxone	$61.72	t
2091	79	Ceftriaxone ICP	$61.72	t
2091	150	Rocephin	$61.72	t
2091	165	Ceftriaxone Sandoz	$61.72	t
2092	172	Cystine Amino Acid Supplement	$516.02	t
2093	4	E-Mycin 200	$12.31	t
2093	91	E.E.S. 200	$12.31	t
2094	24	Zerit	$116.68	t
2095	9	Seroquel XR	$187.70	t
2096	10	Bion Tears	$36.24	t
2097	96	MS Contin	$92.95	t
2098	152	Primoteston Depot	$33.48	t
2099	69	Hospira Pty Limited	$17.95	t
2099	69	Hospira Pty Limited	$41.01	t
2099	165	Vancomycin Sandoz	$17.95	t
2099	165	Vancomycin Sandoz	$41.01	t
2100	99	Fosamax 40 mg	$135.93	t
2101	153	Diamicron 60mg MR	$15.18	t
2102	162	Soframycin	$10.11	t
2103	69	Hospira Pty Limited	$13.40	t
2103	135	Methoblastin	$13.40	t
2104	162	Apidra SoloStar	$264.22	t
2105	24	Fungizone	$34.65	t
2106	59	Kivexa	$564.00	t
2107	27	Leukoplast 1073	$22.13	t
2108	115	Vastin	$26.25	t
2108	120	Lescol	$26.25	t
2109	162	Anandron	$236.56	t
2110	162	Copaxone	$1,092.65	t
2111	5	Optive	$36.06	t
2112	11	O.R.S.	$13.19	t
2112	60	restore O.R.S.	$13.19	t
2112	162	Repalyte New Formulation	$13.19	t
2113	155	Intron A Redipen	$595.80	t
2114	153	Coversyl 10mg	$24.34	t
2115	4	Aclin 200	$15.28	t
2116	29	Spiriva	$76.89	t
2117	153	Muphoran	$982.14	t
2117	153	Muphoran	$1,100.58	t
2118	156	Nilstat	$17.98	t
2119	46	QV Bath Oil	$19.76	t
2119	66	Hamilton Skin Therapy Oil	$19.85	t
2119	104	Alpha Keri Bath Oil	$17.35	t
2120	4	Zimstat	$19.89	t
2120	18	Simvabell	$19.89	t
2120	35	Simvasyn	$19.89	t
2120	99	Zocor	$19.89	t
2120	165	Simvahexal	$19.89	t
2121	59	Seretide Accuhaler 100/50	$47.20	t
2122	80	Concerta	$53.30	t
2123	172	PKU Cooler 10	$1,034.78	t
2124	122	Ursofalk	$372.60	t
2125	139	CAL-600	$14.31	t
2125	139	CAL-600	$22.20	t
2126	95	Proxen SR 1000	$14.37	t
2126	150	Naprosyn SR1000	$14.37	t
2127	50	Edecrin	$197.30	t
2128	141	Xalatan	$42.14	t
2129	4	Alphamox 250	$8.55	t
2129	31	Chem mart Amoxycillin	$8.55	t
2129	59	Amoxil	$8.55	t
2129	60	Amoxycillin-GA	$8.55	t
2129	61	Amoxycillin-DP	$8.55	t
2129	64	GenRx Amoxycillin	$8.55	t
2129	145	Amoxycillin Ranbaxy	$8.55	t
2129	156	Cilamox	$8.55	t
2129	165	Amoxycillin Sandoz	$8.55	t
2129	169	Terry White Chemists Amoxycillin	$8.55	t
2129	170	APO-Amoxycillin	$8.55	t
2130	150	Herceptin	$1,030.21	t
2131	4	Zactin	$20.81	t
2131	6	Lovan	$20.81	t
2131	18	Fluoxebell	$20.81	t
2131	31	Chem mart Fluoxetine	$20.81	t
2131	35	Fluoxetine 20	$20.81	t
2131	60	Fluoxetine-GA	$20.81	t
2131	63	Fluoxetine generichealth	$20.81	t
2131	64	GenRx Fluoxetine	$20.81	t
2131	94	Prozac 20	$20.81	t
2131	156	Auscap	$20.81	t
2131	165	Fluohexal	$20.81	t
2131	169	Terry White Chemists Fluoxetine	$20.81	t
2132	37	Biatain Non-adhesive 3410	$87.93	t
2133	4	Valpro 200	$33.30	t
2133	156	Valprease 200	$33.30	t
2133	162	Epilim EC	$33.30	t
2133	165	Sodium Valproate Sandoz	$33.30	t
2133	174	Valproate Winthrop EC 200	$33.30	t
2134	59	Kapanol	$20.94	t
2135	28	Endoxan	$32.65	t
2136	62	Simplotan	$9.30	t
2136	134	Fasigyn	$9.30	t
2137	96	MS Mono	$29.03	t
2138	156	Nilstat	$13.79	t
2139	150	NeoRecormon	$2,040.00	t
2140	1	Gopten	$9.50	t
2140	4	Tranalpha	$9.50	t
2140	61	Trandolapril-DP	$9.50	t
2140	63	Trandolapril generichealth	$9.50	t
2140	156	Dolapril 0.5	$9.50	t
2140	170	APO-Trandolapril	$9.50	t
2141	99	Crixivan 400 mg	$455.00	t
2142	150	Rivotril	$10.73	t
2142	150	Rivotril	$15.04	t
2143	132	Ponstan	$18.16	t
2144	150	Madopar HBS	$42.00	t
2145	59	Serevent Accuhaler	$37.33	t
2146	171	Keppra	$89.80	t
2147	59	Zentel	$33.10	t
2148	151	Phlexy-10	$1,426.98	t
2149	71	Restore Extra Thin 9921	$53.28	t
2150	147	Solprin	$8.59	t
2151	69	Hospira Pty Limited	$65.32	t
2152	9	Zoladex 10.8 Implant	$1,108.76	t
2153	31	Chem mart Doxycycline	$8.47	t
2153	31	Chem mart Doxycycline	$12.57	t
2153	31	Chem mart Doxycycline	$14.62	t
2153	64	GenRx Doxycycline	$8.47	t
2153	64	GenRx Doxycycline	$14.62	t
2153	165	Doxyhexal	$8.47	t
2153	165	Doxyhexal	$12.57	t
2153	165	Doxyhexal	$14.62	t
2153	169	Terry White Chemists Doxycycline	$8.47	t
2153	169	Terry White Chemists Doxycycline	$12.57	t
2153	169	Terry White Chemists Doxycycline	$14.62	t
2154	155	Drixine	$16.63	t
2155	162	Intal CFC-Free	$31.27	t
2156	78	Etoposide Ebewe	$138.27	t
2156	78	Etoposide Ebewe	$169.96	t
2157	69	Hospira Pty Limited	$1,454.70	t
2157	69	Hospira Pty Limited	$1,592.05	t
2157	78	Irinotecan Ebewe	$1,454.70	t
2157	78	Irinotecan Ebewe	$1,592.05	t
2158	69	Hospira Pty Limited	$44.86	t
2159	4	Tryzan Tabs 10	$23.23	t
2159	31	Chem mart Ramipril	$23.23	t
2159	162	Tritace	$23.23	t
2159	165	Ramipril Sandoz	$23.23	t
2159	169	Terry White Chemists Ramipril	$23.23	t
2159	170	APO-Ramipril	$23.23	t
2160	24	Vepesid	$405.84	t
2161	4	Spiractin 100	$30.32	t
2161	135	Aldactone	$30.32	t
2162	29	Asasantin SR	$37.19	t
2163	60	Soflax	$14.41	t
2164	29	Sifrol	$41.27	t
2165	51	Cortival 1/2	$8.50	t
2165	156	Betnovate 1/2	$8.50	t
2166	156	Buspar	$37.99	t
2167	29	Sifrol	$152.14	t
2168	120	Estraderm 50	$17.53	t
2169	4	QuitX	$57.68	t
2169	56	Nicabate CQ 21	$68.74	t
2170	159	Allevyn Thin 66047578	$100.52	t
2171	94	Zyprexa Relprevv	$809.26	t
2172	135	Synarel	$95.51	t
2173	159	Iodosorb 66051340	$137.45	t
2174	165	Maxamox	$14.69	t
2175	134	Caduet 5/20	$67.81	t
2176	59	Purinethol	$251.94	t
2177	162	Rulide D	$12.89	t
2178	135	Genotropin MiniQuick	$693.00	t
2179	122	Actiq	$115.60	t
2179	122	Actiq	$680.13	t
2180	10	Flarex	$10.61	t
2181	10	Isopto Homatropine	$17.97	t
2182	96	OxyNorm Liquid 5mg/5mL	$20.72	t
2183	122	Gabitril	$196.88	t
2184	171	Vimpat	$272.64	t
2185	64	GenRx Aciclovir	$69.54	t
2186	72	Aquaclear 900796	$53.28	t
2187	120	Co-Diovan 160/25	$28.06	t
2188	4	Sulprix	$209.82	t
2188	156	Amipride 400	$209.82	t
2188	162	Solian 400	$209.82	t
2188	165	Amisulpride Sandoz	$209.82	t
2188	174	Amisulpride 400 Winthrop	$209.82	t
2189	46	Egoderm Ointment	$18.10	t
2190	5	Lumigan	$42.14	t
2191	171	Vimpat	$355.38	t
2192	59	Zofran Zydis	$27.25	t
2192	59	Zofran Zydis	$40.12	t
2192	149	Ondansetron-RL Zydis	$27.25	t
2192	149	Ondansetron-RL Zydis	$40.12	t
2192	165	Ondaz Zydis	$27.25	t
2192	165	Ondaz Zydis	$40.12	t
2193	134	Celsentri	$917.70	t
2194	69	Skelid	$304.62	t
2195	4	Tramedo SR 150	$16.45	t
2195	31	Chem mart Tramadol SR	$16.45	t
2195	36	Tramal SR 150	$16.45	t
2195	156	Zydol SR 150	$16.45	t
2195	165	Tramahexal SR	$16.45	t
2195	169	Terry White Chemists Tramadol SR	$16.45	t
2195	170	APO-Tramadol SR	$16.45	t
2195	187	Lodam SR 150	$16.45	t
2196	59	Valtrex	$105.78	t
2197	24	Baraclude	$625.00	t
2198	150	NeoRecormon	$660.60	t
2199	141	Pfizer Australia Pty Ltd	$65.02	t
2200	155	OncoTICE	$491.83	t
2200	155	OncoTICE	$556.39	t
2201	155	Olmetec	$25.15	t
2202	86	Humalog Mix25 KwikPen	$264.22	t
2202	94	Humalog Mix25	$264.22	t
2203	4	Prexaton	$75.84	t
2203	59	Zyban	$75.84	t
2203	73	Clorprax	$75.84	t
2204	11	Panafcortelone	$8.43	t
2204	92	Predsolone	$8.43	t
2205	59	Zeffix	$149.36	t
2206	29	Persantin SR	$36.96	t
2207	9	Seroquel XR	$354.02	t
2208	150	Mabthera	$905.43	t
2208	150	Mabthera	$948.07	t
2209	179	Efexor-XR	$27.53	t
2210	120	Ritalin LA	$46.20	t
2211	4	Acyclo-V 200	$121.90	t
2211	31	Chem mart Aciclovir	$121.90	t
2211	35	Aciclovir 200	$121.90	t
2211	59	Zovirax 200 mg	$121.90	t
2211	60	Lovir	$121.90	t
2211	64	GenRx Aciclovir	$121.90	t
2211	145	Ozvir	$121.90	t
2211	165	Acihexal	$121.90	t
2211	169	Terry White Chemists Aciclovir	$121.90	t
2212	134	Inspra	$112.77	t
2213	4	Alphapril	$20.46	t
2213	18	Enalabell	$20.46	t
2213	31	Chem mart Enalapril	$20.46	t
2213	61	Enalapril-DP 20mg	$20.46	t
2213	63	Enalapril generichealth	$20.46	t
2213	64	GenRx Enalapril	$20.46	t
2213	99	Renitec 20	$20.46	t
2213	156	Auspril	$20.46	t
2213	165	Enahexal	$20.46	t
2213	169	Terry White Chemists Enalapril	$20.46	t
2214	28	Endoxan	$27.72	t
2215	156	Veracaps SR	$16.24	t
2216	150	Pegasys	$1,165.90	t
2217	122	Actiq	$115.60	t
2217	122	Actiq	$680.13	t
2218	155	Pregnyl	$39.57	t
2218	155	Pregnyl	$53.47	t
2219	24	Modecate	$37.65	t
2220	4	Duride	$12.88	t
2220	9	Imdur Durule	$12.88	t
2220	31	Chem mart Isosorbide Mononitrate	$12.88	t
2220	60	Imtrate 60 mg	$12.88	t
2220	64	GenRx Isosorbide Mononitrate	$12.88	t
2220	138	Monodur 60 mg	$12.88	t
2220	165	Isomonit	$12.88	t
2220	169	Terry White Chemists Isosorbide Mononitrate	$12.88	t
2221	28	Endoxan	$21.21	t
2222	162	Nitrolingual Pumpspray	$20.13	t
2223	161	Tubigrip 1481	$30.44	t
2224	120	Stalevo 150/37.5/200mg	$371.96	t
2225	97	Mepilex Border 295300	$42.68	t
2226	5	Ganfort 0.3/5	$46.82	t
2227	11	Keflin Neutral	$40.09	t
2227	69	Hospira Pty Limited	$40.09	t
2227	165	Cefalotin Sandoz	$40.09	t
2228	135	Depo-Provera	$11.79	t
2229	59	Quilonum SR	$34.30	t
2230	161	Lyofoam C 603025	$174.06	t
2231	156	Grisovin 500	$26.99	t
2232	80	Topamax Sprinkle	$32.18	t
2233	96	Norspan	$56.08	t
2234	59	Kapanol	$34.55	t
2235	134	Lipitor	$58.00	t
2236	163	Duofilm Gel	$19.54	t
2237	4	Cholstat 40	$43.55	t
2237	31	Chem mart Pravastatin	$43.55	t
2237	35	Pravastatin 40	$43.55	t
2237	51	Pravachol	$43.55	t
2237	60	Pravastatin-GA 40	$43.55	t
2237	63	Pravastatin generichealth	$43.55	t
2237	64	GenRx Pravastatin	$43.55	t
2237	145	Vastoran	$43.55	t
2237	156	Lipostat 40	$43.55	t
2237	165	Pravastatin Sandoz	$43.55	t
2237	169	Terry White Chemists Pravastatin	$43.55	t
2237	170	APO-Pravastatin	$43.55	t
2237	174	Pravastatin Winthrop	$43.55	t
2238	4	Ibilex 250	$13.23	t
2238	11	Keflex	$13.23	t
2238	31	Chem mart Cephalexin	$13.23	t
2238	60	Cilex	$13.23	t
2238	64	GenRx Cephalexin	$13.23	t
2238	92	Ialex	$13.23	t
2238	165	Cefalexin Sandoz	$13.23	t
2238	169	Terry White Chemists Cephalexin	$13.23	t
2239	4	Rimycin 300	$13.55	t
2240	159	Cutilin Non-Stick Wound Pad 76301	$14.36	t
2240	159	Melolin 36361357	$15.06	t
2241	6	Felodur ER 5 mg	$16.05	t
2241	9	Plendil ER	$16.05	t
2241	156	Felodil XR 5	$16.05	t
2242	4	Aratac 200	$21.72	t
2242	31	Chem mart Amiodarone	$21.72	t
2242	64	GenRx Amiodarone	$21.72	t
2242	156	Rithmik 200	$21.72	t
2242	162	Cordarone X 200	$21.72	t
2242	165	Cardinorm	$21.72	t
2242	169	Terry White Chemists Amiodarone	$21.72	t
2243	80	Durogesic 50	$95.38	t
2244	72	Atrauman Ag 499572	$43.78	t
2245	150	Naprosyn	$78.17	t
2246	4	Zabel	$102.82	t
2246	35	Terbinafine 250	$102.82	t
2246	61	Terbinafine-DP	$102.82	t
2246	64	GenRx Terbinafine	$102.82	t
2246	98	Terbix 250	$102.82	t
2246	120	Lamisil	$102.82	t
2246	120	Lamisil	$104.28	t
2246	145	Sebifin 250	$102.82	t
2246	156	Tamsil	$102.82	t
2246	165	Terbihexal	$102.82	t
2247	100	Coban 1584	$19.36	t
2248	159	Bactigras 7457	$25.44	t
2249	51	Eutroxsig	$27.86	t
2249	156	Oroxine	$27.86	t
2250	28	Holoxan	$295.75	t
2250	28	Holoxan	$342.42	t
2251	170	APO-Clotrimazole 3 Day Cream	$15.08	t
2252	59	Seretide MDI 125/25	$59.31	t
2253	134	Dilantin Sodium	$29.18	t
2254	119	TYR Anamix Junior	$1,800.46	t
2255	57	Dibenzyline	$1,164.47	t
2256	57	Parnate	$33.55	t
2257	155	Celestone Chronodose	$25.77	t
2258	159	Iodosorb Ointment 66051230	$99.79	t
2259	151	Monogen	$421.30	t
2260	147	Fybogel	$17.64	t
2261	4	Coras	$16.20	t
2261	13	Vasocardol	$16.20	t
2261	31	Chem mart Diltiazem	$16.20	t
2261	60	Dilzem 60 mg	$16.20	t
2261	64	GenRx Diltiazem	$16.20	t
2261	162	Cardizem	$16.20	t
2261	165	Diltahexal	$16.20	t
2261	169	Terry White Chemists Diltiazem	$16.20	t
2262	158	Lipidil	$41.75	t
2263	20	Vermox	$20.05	t
2264	186	Fosrenol	$261.77	t
2264	186	Fosrenol	$305.87	t
2265	4	Rimycin 150	$11.96	t
2266	60	Dronalen Plus	$46.57	t
2266	99	Fosamax Plus 70 mg/140 mcg	$46.57	t
2267	37	Comfeel SeaSorb Filler 3740	$137.72	t
2268	99	Sinemet	$46.50	t
2268	165	Levohexal	$46.50	t
2269	162	Rynacrom	$20.36	t
2270	37	Biatain Adhesive 3420	$96.95	t
2271	94	Effient	$106.43	t
2272	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$15.28	t
2273	134	Aricept	$155.45	t
2274	27	Handy 5672	$13.88	t
2275	3	Lax-Tab	$14.44	t
2275	11	Bisalax	$14.44	t
2276	162	Flagyl S	$17.17	t
2277	96	MS Contin Suspension 60 mg	$54.69	t
2278	161	Tubegauz 0501658	$13.73	t
2279	11	Panafcort	$9.30	t
2279	51	Sone	$9.30	t
2280	24	DuoCover	$76.27	t
2280	162	CoPlavix	$76.27	t
2281	4	Alodorm	$7.89	t
2281	4	Alodorm	$9.36	t
2281	173	Mogadon	$7.89	t
2281	173	Mogadon	$9.36	t
2282	9	Toprol-XL 190	$109.60	t
2283	4	Staphylex 500	$16.94	t
2283	11	Flopen	$16.94	t
2284	23	Adalat Oros 20mg	$18.14	t
2284	23	Adalat Oros 20mg	$20.40	t
2285	9	Nexium Hp7	$81.36	t
2286	156	Isordil Sublingual	$14.88	t
2287	152	Bonefos	$334.08	t
2288	60	Exorex	$33.08	t
2289	150	Madopar 62.5	$23.00	t
2290	156	Pexsig	$62.62	t
2291	53	Timoptol	$12.62	t
2291	156	Tenopt	$12.62	t
2292	59	Timentin	$163.32	t
2293	80	Jurnista	$109.31	t
2294	94	Cialis	$77.25	t
2295	4	Alphapress 25	$15.50	t
2296	4	Deralin 10	$10.19	t
2296	9	Inderal	$10.19	t
2297	74	Durotram XR	$19.79	t
2298	123	Plaqacide	$11.89	t
2299	106	Biodone Forte	$34.57	t
2299	156	Sigma Pharmaceuticals (Australia) Pty Ltd	$34.57	t
2300	11	Venofer	$139.48	t
2301	9	Nexium	$33.36	t
2302	80	Eprex 6000	$660.60	t
2303	162	Clexane	$90.70	t
2304	69	Eligard 1 month	$420.20	t
2305	23	Xarelto	$148.66	t
2306	4	Irinotecan Alphapharm	$113.45	t
2306	4	Irinotecan Alphapharm	$140.60	t
2306	63	Irinotecan Actavis	$113.45	t
2306	63	Irinotecan Actavis	$140.60	t
2306	69	Hospira Pty Limited	$113.45	t
2306	69	Hospira Pty Limited	$140.60	t
2306	78	Irinotecan Ebewe	$113.45	t
2306	78	Irinotecan Ebewe	$140.60	t
2306	124	Omegapharm Irinotecan	$113.45	t
2306	124	Omegapharm Irinotecan	$140.60	t
2306	141	Camptosar	$113.45	t
2306	141	Camptosar	$140.60	t
2306	165	Irinotecan Sandoz	$113.45	t
2306	165	Irinotecan Sandoz	$140.60	t
2306	177	Tecan	$113.45	t
2306	177	Tecan	$140.60	t
2307	135	Fragmin	$83.65	t
2307	135	Fragmin	$160.88	t
2308	59	Avandamet	$98.09	t
2309	151	Paediatric Seravit	$390.42	t
2310	135	Methoblastin	$46.70	t
2311	122	Gliadel	$16,044.86	t
2312	159	ProGuide 66000782	$47.86	t
2312	159	ProGuide 66000782	$168.94	t
2313	30	Kaltostat 168210	$49.40	t
2313	71	Restore CalciCare 9938	$40.52	t
2313	159	Algisite M 66000519	$49.36	t
2314	13	Arabloc	$93.66	t
2314	162	Arava	$93.66	t
2315	151	Caprilon	$467.46	t
2316	150	Pegasys RBV	$1,536.42	t
2317	159	Cutilin Non-Stick Wound Pad 76300	$22.46	t
2318	162	Sabril	$100.93	t
2319	52	Norprolac	$11.47	t
2320	80	Risperdal Quicklet	$165.72	t
2321	69	Pamisol	$54.64	t
2321	69	Pamisol	$259.42	t
2322	87	Depo-Ralovera	$14.48	t
2322	135	Depo-Provera	$14.48	t
2323	24	Monoplus 20/12.5	$29.21	t
2323	145	Hyforil	$29.21	t
2323	165	Fosinopril/HCT Sandoz 20mg/12.5mg	$29.21	t
2323	170	APO-Fosinopril HCTZ 20/12.5	$29.21	t
2323	187	Fosetic 20/12.5	$29.21	t
2324	69	Hospira Pty Limited	$16.04	t
2325	109	Movicol	$24.79	t
2325	109	Movicol	$31.94	t
2326	4	Minax 100	$12.03	t
2326	9	Betaloc	$12.03	t
2326	31	Chem mart Metoprolol	$12.03	t
2326	64	GenRx Metoprolol	$12.03	t
2326	120	Lopresor 100	$12.03	t
2326	156	Metrol 100	$12.03	t
2326	165	Metohexal	$12.03	t
2326	169	Terry White Chemists Metoprolol	$12.03	t
2327	162	Clexane	$109.08	t
2328	87	Norimin 28 Day	$16.86	t
2328	135	Brevinor	$16.86	t
2329	4	Selgene	$54.70	t
2329	11	Eldepryl	$54.70	t
2330	135	Aromasin	$180.18	t
2331	69	Hospira Pty Limited	$35.09	t
2331	120	Sandostatin 0.05	$35.09	t
2331	181	Octreotide MaxRx	$35.09	t
2332	58	Vistide	$900.00	t
2333	4	Perindo Combi 4/1.25	$29.12	t
2333	31	Chem mart Perindopril/ Indapamide 4/1.25	$29.12	t
2333	64	GenRx Perindopril/ Indapamide 4/1.25	$29.12	t
2333	169	Terry White Chemists Perindopril/ Indapamide	$29.12	t
2334	59	Avandamet	$94.76	t
2335	50	Kineret	$1,364.88	t
2336	150	Mircera	$323.84	t
2337	24	Zerit	$280.00	t
2338	156	Serenace	$10.53	t
2339	27	Leukopor 2471	$10.34	t
2339	27	Leukosilk 1021	$10.62	t
2340	7	Sensipar	$890.58	t
2340	7	Sensipar	$1,002.27	t
2341	151	Phlexy-10	$1,276.34	t
2342	52	Minirin Melt	$70.85	t
\.


--
-- Data for Name: severity_level; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY severity_level (pk, description, comment) FROM stdin;
1	irrelevant	largely academic point. No warning given
2	reference	For reference only. No warning given
3	significant	noticeable, but often does not affect clinical decision, warning in sidebar
4	major	usually affects clinical decision, but sometimes is overridden, warning highlighted in sidebar, plus auditory warning. Note: no more than 10% of prescriptions should trigger\na warning of this level, otherwise it will become useless.
5	critical	Warning in dialogue box, prescriber must click to override, entry made in notes. Use very rarely. Example: Roaccutane in a known to be pregnant woman
\.


--
-- Data for Name: clinical_effects; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY clinical_effects (pk, description, fk_severity) FROM stdin;
1	pruritis	2
2	nausea	2
3	diarrhoea	2
4	constipation	2
5	postural hypotension	3
6	hepatitis	3
7	renal failure	3
8	ototoxicity	4
9	drowsiness	3
10	tremor	3
11	confusion	4
12	psychosis	4
13	fatal ventricular arrthymias, including <i>torsades de pointes</i>	5
14	severe foetal abnormalities	5
15	loss of contraceptive effect	4
16	seizures	4
\.


--
-- Data for Name: disease_code; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY disease_code (pk, code, description) FROM stdin;
\.


--
-- Data for Name: evidence_levels; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY evidence_levels (pk, description) FROM stdin;
1	proven by trial or many case reports
2	presumed and not tested
3	isolated case reports
4	suspected
5	possible
6	unlikely
7	unknown
\.


--
-- Data for Name: flags; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY flags (pk, description) FROM stdin;
1	paediatric
2	gluten-free
3	slow-release
4	enteric-coated
5	flavoured
\.


--
-- Data for Name: patient_categories; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY patient_categories (pk, description, comment) FROM stdin;
1	pregnancy	\N
2	lactation	\N
3	child	\N
4	elderly	\N
5	renal failure	\N
6	hepatic failure	\N
7	high abuse potential	\N
8	history of poor adherence	\N
9	falls risk	\N
\.


--
-- Data for Name: pharmacologic_mechanisms; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY pharmacologic_mechanisms (pk, description) FROM stdin;
1	competition for hepatic metabolism
2	competition for renal excretion
3	competition for plasma protein binding-site
4	antagonism at target receptor
5	induction of hepatic metabolism
6	additive effect at target receptor
7	idiosyncratic
8	literature unclear/conflicting
\.


--
-- Data for Name: sources; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY sources (pk, source_category, description) FROM stdin;
1	i	Rang, Dale, and Ritter <i>Pharmacology</i>, 1999
2	i	Health Insurance Commission (Australia)
3	i	World Health Organisation
4	i	Bundesamt fuer Sozialversicherung (die Schweiz)
5	i	CRISNET (Belgium)
\.


--
-- Data for Name: topic; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY topic (pk, title, target) FROM stdin;
1	name	p
2	general	h
3	pharmaco-kinetics	h
4	indications	h
5	action	h
6	chemical structure	h
7	side-effects	p
8	general	p
9	dosage hints	h
\.


--
-- Data for Name: info; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY info (pk, comment, fk_topic, created_at, fk_clinical_effect, fk_pharmacologic_mechanism, fk_evidence_level, fk_source, fk_patient_category) FROM stdin;
\.


--
-- Data for Name: link_atc_info; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY link_atc_info (atccode, fk_info) FROM stdin;
\.


--
-- Data for Name: link_flag_product; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY link_flag_product (fk_product, fk_flag) FROM stdin;
\.


--
-- Data for Name: manufacturer; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY manufacturer (pk, name, address, telephone, facsimile, code) FROM stdin;
1	Abbott Australasia Pty Ltd	Sir Joseph Banks Corporate Park 32-34 Lord Street Botany NSW 2019	(02) 9384 9700	(02) 9384 9800	AB
2	Alberto Culver Company	14 Loyalty Road North Rocks NSW 2151	(02) 9630 5099	(02) 9683 5026	AC
3	AFT Pharmaceuticals Pty Limited	Unit 2, Level 5 255 George Street NSW 2000	1800 097 639	1800 097 810	AE
4	Alphapharm Pty Limited	Chase Building 2 Wentworth Park Road Glebe NSW 2037	(02) 9298 3999	(02) 9566 4686	AF
5	Allergan Australia Pty Ltd	Level 4, 810 Pacific Highway Gordon NSW 2072	1800 252 224	(02) 9498 0290	AG
6	Alphapharm Medical A Division of Alphapharm Pty Limited	Chase Building 2 Wentworth Park Road Glebe NSW 2037	(02) 9298 3999	(02) 9566 4686	AL
7	Amgen Australia Pty Ltd	Level 7, 123 Epping Road North Ryde NSW 2113	(02) 9870 1333	(02) 9870 1344	AN
8	Advanced Medical Optics Australia Pty Ltd	Level 3, Building 2 20 Bridge Street Pymble NSW 2073	1800 266 111	1800 266 222	AO
9	AstraZeneca Pty Ltd	Alma Road North Ryde NSW 2113	(02) 9978 3500	(02) 9978 3700	AP
10	Alcon Laboratories (Australia) Pty Ltd	Allambie Grove Park 25 Frenchs Forest Road East Frenchs Forest NSW 2086	1800 025 004	(02) 9452 5209	AQ
11	Aspen Pharmacare Australia Pty Ltd	First Floor 34-36 Chandos Street St Leonards NSW 2065	(02) 8436 8300	(02) 9901 3540	AS
12	Actelion Pharmaceuticals Australia Pty Ltd	Level 2 West, Suites 48-50 7 Narabang Way Belrose NSW 2085	(02) 9486 4600	(02) 9986 1344	AT
13	Aventis Pharma Division of Sanofi-Aventis Australia Pty Limited	Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113	(02) 8666 2000	(02) 8666 3000	AV
14	Arrow Pharmaceuticals Pty Ltd A member of Sigma Group of Companies	96 Merrindale Drive Croydon Vic 3136	(03) 9839 2800	(03) 9839 2753	AW
15	Blackmores Ltd	23 Roseberry Street Balgowlah NSW 2093	(02) 9951 0111	(02) 9949 1954	BB
16	Biogen Idec Australia Pty Ltd	Suite 2, Level 4 123 Epping Road North Ryde NSW 2113	(02) 8875 3900	(02) 9889 1162	BD
17	Beiersdorf Australia Limited	4 Khartoum Road North Ryde NSW 2113	(02) 9888 0977	(02) 9887 3487	BE
18	Bellwether Pharma Limited	Suite 2, Level 2 71 Epping Road North Ryde NSW 2113	(02) 8875 5700	(02) 9889 2250	BF
19	Biochemie Australia A Division of Sandoz Pty Ltd	Level 4, Suite 7-19 100 Harris Street Pyrmont NSW 2009	(02) 9566 1500	(02) 9566 1458	BG
20	Biotech Pharmaceuticals Pty Ltd	83 Cherry Lane Laverton North Vic 3026	(03) 9278 7555	(03) 9369 6730	BI
21	Barrere Surgical Co.	PO Box 84 Sydney South NSW 2000			BJ
22	Becton Dickinson Pty Ltd	80 Rushdale Street Knoxfield Vic 3180	(03) 9764 2444	(03) 9764 2550	BK
23	Bayer Australia Limited	875 Pacific Highway Pymble NSW 2073	(02) 9391 6000	(02) 9988 3311	BN
24	Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd	556 Princes Highway Noble Park Vic 3174	(03) 9213 4000	(03) 9701 1518	BQ
25	B. Braun Australia Pty Ltd	Norwest Business Park 17 Lexington Drive Bella Vista NSW 2153	(02) 9629 0200	(02) 9629 0299	BR
26	Bausch & Lomb Surgical A Division of Bausch & Lomb (Australia) Pty Ltd	Level 4, 113 Wicks Road North Ryde NSW 2113	(02) 9887 1444	(02) 9888 9642	BU
27	B.S.N.	315 Ferntree Gully Road Mount Waverley Vic 3149	(03) 8540 6777	1800 671 000	BV
28	Baxter Healthcare Pty Limited	1 Baxter Drive Old Toongabbie NSW 2146	(02) 9848 1111	(02) 9848 1123	BX
29	Boehringer Ingelheim Pty Limited	78 Waterloo Road North Ryde NSW 2113	(02) 8875 8800	(02) 8875 8801	BY
30	ConvaTec A Division of Bristol-Myers Squibb Australia Pty Ltd	606 Hawthorn Road East Brighton Vic 3187	1800 335 276	(03) 9525 0920	CC
31	Chem mart Pty Limited	Level 7, 5 Queens Road Melbourne Vic 3004	(03) 9918 2500	(03) 9918 2006	CH
32	Celgene Pty Ltd	Level 7, 607 St Kilda Road Melbourne Vic 3004	(03) 9539 5500	(03) 9539 5566	CJ
33	Chemists' Own Pty Ltd A member of Sigma Group of Companies	96 Merrindale Drive Croydon Vic 3136	(03) 9839 2800	(03) 9839 2753	CO
34	CS Pharma Australia Pty Ltd	6 Ulundri Drive Castle Hill NSW 2154	(02) 9899 3975	(02) 9899 3975	CQ
35	Pharmacor Limited	5/36 Campbell Avenue Cromer NSW 2099	(02) 9981 4470	(02) 9981 4475	CR
36	CSL Limited	45 Poplar Road Parkville Vic 3052	(03) 9389 1911	(03) 9388 2351	CS
37	Coloplast Pty Ltd	33 Gilby Road Mount Waverley Vic 3149	1800 673 317	(03) 9541 1199	CT
38	Contact Lens Centre Australia Pty Ltd	Unit D6, Hallmark Business Park Cnr Westall and Centre Roads Clayton Vic 3168	(03) 9543 1811	(03) 9543 8066	CX
39	Colostomy Association of South Australia	PO Box 96 Rundle Street SA 5000			CY
40	Diabetes Association of Australia	26 Arundel Street Glebe NSW 2037	1800 451 737	(02) 9566 4235	DB
41	Medical Developments International Limited	7/56 Smith Road Springvale Vic 3171	(03) 9547 1888	(03) 9547 0262	DV
42	Denyer Bros Pty Ltd	118-120 Adderley Street Auburn NSW 2144	(02) 748 6776	(02) 748 6754	DY
43	Eagle Pharmaceuticals Pty Ltd	4/40 Carrington Road Castle Hill NSW 2154	(02) 9899 9099	(02) 9899 6564	EG
44	Entra Health Systems Pty Ltd	12/60 Castlereagh Street Sydney NSW 2000	(02) 8005 4745	(02) 8088 7105	EH
45	T.G. Eakin Ltd	PO Box 164 Rozelle NSW 2039			EK
46	Ego Pharmaceuticals Pty Ltd	21-31 Malcolm Road Braeside Vic 3195	(03) 9587 1088	(03) 9580 7647	EO
47	Essex Laboratories	Level 4, 66 Waterloo Road North Ryde NSW 2113	(02) 8988 8000	(02) 9852 7500	EX
48	Pierre Fabre Medicament Australia Pty Limited	Unit 26B, Parkview Business Centre 1 Maitland Place Baulkham Hills NSW 2153	(02) 8858 2800	(02) 8858 2888	FB
49	Faulding Healthcare Pty Ltd	87 Yarraman Place Virginia Qld 4014	(07) 3212 8777	(07) 3212 8790	FH
50	PharmaLink Pty Ltd	Level 8, 67 Albert Avenue Chatswood NSW 2067	(02) 9080 7200	(02) 9080 7201	FK
51	Fawns and McAllan Pty Ltd A member of Sigma Group of Companies	96 Merrindale Drive Croydon Vic 3136	(03) 9839 2800	(03) 9839 2753	FM
52	Ferring Pharmaceuticals Pty Ltd	Suite 2B, Level 2 802 Pacific Highway Gordon NSW 2072	(02) 9497 2300	(02) 9497 2399	FP
53	Charles E. Frosst Division of Merck Sharp & Dohme (Australia) Pty Ltd	54-68 Ferndell Street South Granville NSW 2142	(02) 9795 9500	(02) 9795 9595	FR
54	Future Environmental Services Pty Ltd	P.O. Box 163 Gardenvale Vic 3185	(03) 9596 8809		FS
55	Galderma Australia Pty Ltd	Suite 4, 13B Narabang Way Belrose NSW 2085	(02) 9479 0600	(02) 9986 1699	GA
56	GlaxoSmithKline Consumer Healthcare	82 Hughes Avenue Ermington NSW 2115	(02) 9684 0888	(02) 9684 6958	GC
57	Goldshield Healthcare (Australia) Pty Ltd	Suite 3, Level 1 118-124 Willoughby Road Crows Nest NSW 2059	(02) 9431 6333	(02) 9906 7147	GH
58	Gilead Sciences Pty Ltd	Level 1, 128 Jolimont Road East Melbourne Vic 3002	(03) 9272 4400	(03) 9272 4435	GI
59	GlaxoSmithKline Australia Pty Ltd	1061 Mountain Highway Boronia Vic 3155	(03) 9721 6000	(03) 9729 5319	GK
60	Genepharm Pty Ltd	151-153 Clarendon Street South Melbourne Vic 3205	1800 678 302	(03) 8677 6666	GM
61	Genepharm (Australia) Limited	151-153 Clarendon Street South Melbourne Vic 3205	1800 678 302	(03) 8677 6666	GN
62	GP Laboratories A Division of Pfizer Pty Limited	38-42 Wharf Road West Ryde NSW 2114	(02) 9850 3333	(02) 9858 1347	GP
63	Generic Health Pty Ltd	Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124	(03) 9809 7900	(03) 9809 7999	GQ
64	GenRx A Division of Apotex Pty Ltd	66 Waterloo Road North Ryde NSW 2113	(02) 8877 8333	(02) 8877 8377	GX
65	Genzyme Australasia Pty Ltd	Level 1, Building C 12-24 Talavera Road North Ryde NSW 2113	(02) 9978 3900	(02) 9889 3900	GZ
66	Hamilton Laboratories Pty Ltd	217 Flinders Street Adelaide SA 5000	(08) 8223 2957	(08) 8232 1480	HA
67	Biotech Healthcare A division of Biotech Pharmaceuticals Pty Ltd	83 Cherry Lane Laverton North Vic 3026	(03) 9278 7555	(03) 9369 6730	HC
68	HealthSense Products Pty Ltd	87 Pitfield Crescent Rowville Vic 3178	1300 462 188		HE
69	Hospira Pty Ltd	(David Bull Laboratories, Faulding Pharmaceuticals) Level 6, 390 St Kilda Road Melbourne Vic 3004	(03) 9868 0700	(03) 9868 0111	HH
70	Helex-A Pty Ltd	9/7 Anella Avenue Castle Hill NSW 2154	(02) 9846 1911	(02) 9846 1930	HL
71	Hollister (Distributed in Australia by Liberty Medical Pty Ltd)	Unit 6, 345 Ingles Street Port Melbourne Vic 3207	(03) 9673 4300	(03) 9646 4018	HO
72	Paul Hartmann Pty Ltd	27-28/11-21 Underwood Road Homebush NSW 2140	1800 805 839	(02) 8762 7100	HR
73	Hexal Australia A division of Sandoz Pty Ltd	Level 4, Suite 7-19 100 Harris Street Pyrmont NSW 2009	(02) 9566 1500	(02) 9566 1458	HX
74	iNova Pharmaceuticals (Australia) Pty Limited	9-15 Chilvers Road Thornleigh NSW 2120	(02) 9875 6333	(02) 9875 6416	IA
75	Indoplas Pty Ltd	PO Box 405 Mona Vale NSW 2103	(02) 9997 8033	(02) 9997 3760	IP
76	Ioquin A Division of Alcon Laboratories (Australia) Pty Ltd	Allambie Grove Park 25 Frenchs Forest Road East Frenchs Forest NSW 2086	1800 025 004	(02) 9452 5209	IQ
77	Ipsen Pty Ltd	Suite 6, 40 Montclair Avenue Glen Waverley Vic 3150	(03) 8544 8100	(03) 9562 5152	IS
78	InterPharma Pty Ltd	Suite 3, 14 Sydney Road Manly NSW 2095	(02) 9976 6876	(02) 9976 6859	IT
79	Intensive Care Products Pty Ltd	Level 1, APP House 14 Rodborough Road Frenchs Forest NSW 2086	(02) 9984 2280	(02) 9984 2222	IZ
80	Janssen-Cilag Pty Ltd	1-5 Khartoum Road North Ryde NSW 2113	(02) 8875 3333	(02) 8875 3300	JC
81	Johnson & Johnson Medical	1-5 Khartoum Road North Ryde NSW 2113	(02) 9878 9111	1800 808 233	JJ
82	Johnson & Johnson Pacific Pty Limited	45 Jones Street Ultimo NSW 2007	13 1565	(02) 8260 8102	JT
83	Kimberly-Clark Australia Pty Ltd	52 Alfred Street South Milsons Point NSW 2061	(02) 9963 8888	(02) 9957 5687	KC
84	Kendall Australasia Pty Ltd	22 Giffnock Avenue North Ryde NSW 2113	1800 252 467	(02) 9888 7378	KE
85	Knoll A Division of Abbott Australasia Pty Ltd	Captain Cook Drive Kurnell NSW 2231	(02) 9668 9711	(02) 9668 8459	KN
86	KwikPen Products of Eli Lilly Australia Pty Limited	112 Wharf Road West Ryde NSW 2114	(02) 9325 4444	(02) 9325 4410	KP
87	Kenral Division of Pharmacia Australia Pty Limited	59 Kirby Street Rydalmere NSW 2116	(02) 9848 3000	(02) 9848 3333	KR
88	Key Pharmaceuticals Pty Ltd	12 Lyonpark Road Macquarie Park NSW 2113	(02) 8113 6200	(02) 8113 6222	KY
89	L.A. Chemicals Pty Ltd	213 Angas Street Adelaide SA 5000	(08) 414 1711	(08) 231 3916	LA
90	Life Bioscience Pty Ltd	10 Atherton Road Oakleigh Vic 3166	1800 114 610	(03) 8660 2785	LB
91	Link Medical Products Pty Ltd	Level 1, Bridgepoint Centre 3 Brady Street Mosman NSW 2088	(02) 9960 0150	(02) 9960 0149	LM
92	Lennon Healthcare A Division of Aspen Pharmacare Australia Pty Ltd	First Floor 34-36 Chandos Street St Leonards NSW 2065	(02) 8436 8300	(02) 9901 3540	LN
93	Lundbeck Australia Pty Ltd	Unit 1, 10 Inglewood Place Norwest Business Park Baulkham Hills NSW 2153	(02) 9836 1655	(02) 9836 1755	LU
94	Eli Lilly Australia Pty Limited	112 Wharf Road West Ryde NSW 2114	(02) 9325 4444	(02) 9325 4410	LY
95	Macarthur Research Division of Roche Products Pty Ltd	4-10 Inman Road Dee Why NSW 2099	(02) 9454 9000	(02) 9981 3229	MD
96	Mundipharma Pty Ltd	Level 33, 50 Bridge Street Sydney NSW 2000	(02) 9231 7200	(02) 9223 0011	MF
97	Molnlycke Health Care Pty Ltd	Building 1, Ground Floor 14 Aquatic Drive Frenchs Forest NSW 2086	(02) 9453 1144	(02) 9453 1155	MH
98	Meditech Int. Pty Ltd	Unit 5, 36 Campbell Avenue Cromer NSW 2099	(02) 9981 4470	(02) 9981 4475	MI
99	Merck Sharp & Dohme (Australia) Pty Ltd	54-68 Ferndell Street South Granville NSW 2142	(02) 9795 9500	(02) 9795 9595	MK
100	3M Pharmaceuticals Australia Pty Ltd	9-15 Chilvers Road Thornleigh NSW 2120	(02) 9875 6333	(02) 9875 6416	MM
101	Medical Products Distribution Pty Ltd	61 Danks Street Port Melbourne Vic 3207	(03) 9646 4144		MP
102	Alphapharm Pharmaceuticals	Chase Building 2 Wentworth Park Road Glebe NSW 2037	(02) 9298 3999	(02) 9566 4686	MQ
103	Abbott Diabetes Care (A Division of Abbott Australasia Pty Ltd)	666 Doncaster Road Doncaster Vic 3108	(03) 9843 7100	(03) 9855 8020	MS
104	Mentholatum Australasia Pty Ltd	12-16 Janine Street Scoresby Vic 3179	(03) 9763 0322	(03) 9763 2699	MT
105	Melbourne Ostomy Supplies	PO Box 76 Mentone Vic 3194			MU
106	Biomed Aust Pty Ltd	c/- Robinson Legal Level 4, 350 Kent Street Sydney NSW 2000	(02) 9299 2100	(02) 9299 2201	MW
107	National Diagnostic Products	22/39 Herbert Street St Leonards NSW 2065	(02) 9432 8100	(02) 9432 1151	NA
108	Novartis Consumer Health Australasia Pty Ltd	327-333 Police Road Mulgrave Vic 3170	(03) 9701 2711	(03) 9701 2911	NC
109	Norgine Pty Limited	3/14 Rodborough Road Frenchs Forest NSW 2086	(02) 9972 7500	(02) 9972 7522	NE
110	FlexPen Products of Novo Nordisk Pharmaceuticals Pty Ltd	Level 3, 21 Solent Circuit Baulkham Hills NSW 2153	(02) 8858 3600	(02) 8858 3799	NF
111	Nycomed Healthcare Pty Limited	2 Lyon Park Road Macquarie Park North Ryde NSW 2113	(02) 9859 6900	(02) 9859 6950	NH
112	InnoLet Products of Novo Nordisk Pharmaceuticals Pty Ltd	Level 3, 21 Solent Circuit Baulkham Hills NSW 2153	(02) 8858 3600	(02) 8858 3799	NI
113	NovoLet Products of Novo Nordisk Pharmaceuticals Pty Ltd	Level 3, 21 Solent Circuit Baulkham Hills NSW 2153	(02) 8858 3600	(02) 8858 3799	NL
114	Unomedical Pty Ltd	11-17 Wilmette Place Mona Vale NSW 2103	(02) 9997 8033	(02) 9997 3760	UM
115	Novartis Medicines A Division of Novartis Pharmaceuticals Australia Pty Ltd	54 Waterloo Road North Ryde NSW 2113	(02) 9805 3555	(02) 9887 4551	NM
116	Novo Nordisk Pharmaceuticals Pty Ltd	Level 3, 21 Solent Circuit Baulkham Hills NSW 2153	(02) 8858 3600	(02) 8858 3799	NO
117	Nycomed Pty Ltd	2 Lyon Park Road Macquarie Park North Ryde NSW 2113	(02) 9859 6900	(02) 9859 6950	NQ
118	Nestle Australia Ltd	60 Bathurst Street Sydney NSW 2000	(02) 9931 2345	(02) 9931 2610	NT
119	Nutricia Australia Pty Limited	Talavera Corporate Centre Level 4, Building D 12-24 Talavera Road North Ryde NSW 2113	(02) 8875 0300	(02) 8978 4841	NU
120	Novartis Pharmaceuticals Australia Pty Ltd	54 Waterloo Road North Ryde NSW 2113	(02) 9805 3555	(02) 9887 4551	NV
121	Nycomed Services Pty Limited	2 Lyon Park Road Macquarie Park North Ryde NSW 2113	(02) 9859 6900	(02) 9859 6950	NZ
122	Orphan Australia Pty Ltd	300 Frankston-Dandenong Road Dandenong Vic 3175	(03) 9709 2200	(03) 9709 2299	OA
123	Oral B Laboratories Pty Ltd	Level 3, 90 Mount Street North Sydney NSW 2060	(02) 9957 6499	(02) 9957 5383	OB
124	Omegapharm Pty Ltd	15a Leinster Street Ormond Vic 3204	(03) 9578 0806	(03) 9578 0806	OE
125	Omnigon Pty Ltd	22 Wellington Street St Kilda Vic 3182	(03) 9526 6954	(03) 9529 2663	OG
126	Boian Surgical Pty Ltd	486 King Georges Road Beverly Hills NSW 2209	(02) 9580 7447	(02) 9580 7450	OI
127	Owen Laboratories Division of Galderma Australia Pty Ltd	9 Rodborough Road Frenchs Forest NSW 2086	1800 800 765	(02) 9975 5374	OL
128	Colgate Oral Care	345 George Street Sydney NSW 2000	(02) 9229 5600	(02) 9232 8448	OM
129	Orion Laboratories Pty Ltd	25-29 Delawney Street Balcatta WA 6021	(08) 9441 7800	(08) 9441 7888	ON
130	Medical Specialties Australia Pty Ltd	54 Gibbes Street Chatswood NSW 2067	(02) 9417 7955	(02) 9417 5779	OZ
131	Pfizer Consumer Healthcare Pty Ltd	32 Cawarra Road Caringbah NSW 2229	(02) 9710 6500	(02) 9710 6644	PC
132	Parke Davis Pty Ltd	32 Cawarra Road Caringbah NSW 2229	(02) 9710 6500	(02) 9710 6400	PD
133	Pacific EyeCare A Division of Allergan Australia Pty Ltd	Level 4, 810 Pacific Highway Gordon NSW 2072	1800 252 224	(02) 9498 0290	PE
134	Pfizer Pty Limited	38-42 Wharf Road West Ryde NSW 2114	(02) 9850 3333	(02) 9858 1347	PF
135	Pharmacia Australia Pty Limited	38-42 Wharf Road West Ryde NSW 2114	(02) 9850 3333	(02) 9858 1347	PH
136	Pharmatel Fresenius Kabi Pty Ltd	Unit 6, 6-18 Bridge Road Hornsby NSW 2077	(02) 9472 2222	(02) 9472 2255	PK
137	Phebra	332 Burns Bay Road Lane Cove NSW 2066	(02) 9420 9199	(02) 9420 9177	PL
138	PMC Pharma A Division of AstraZeneca Pty Ltd	Alma Road North Ryde NSW 2113	(02) 9978 3500	(02) 9978 3700	PM
139	Petrus Pharmaceuticals Pty Ltd	Level 3, IBM Building 1060 Hay Street West Perth WA 6005	(08) 9368 5954	(08) 9368 6692	PP
140	PMIP Pty Ltd	Unit 18 6a Prosperity Parade Warriewood NSW 2102	(02) 9997 7176	(02) 9960 1049	PQ
141	Pharmacia & Upjohn Pty Limited	38-42 Wharf Road West Ryde NSW 2114	(02) 9850 3333	(02) 9858 1347	PU
142	Point of Care Diagnostics Australia Pty Ltd	Unit 14, 76 Reserve Road Artarmon NSW 2064	(02) 9437 1355	(02) 9437 1399	PX
143	Procter & Gamble Pharmaceuticals Australia Pty Ltd	99 Phillip Street Parramatta NSW 2150	(02) 9685 4500	(02) 9685 4777	PY
144	Prohealth Asia Pacific Pty Ltd	Suite 108A, 20 Lexington Drive Bella Vista NSW 2153	1300 024 784	1300 008 463	PZ
145	Ranbaxy Australia Pty Limited	Suite 4.02, Level 4 Building D 12-24 Talavera Road North Ryde NSW 2113	(02) 9647 1172	(02) 9647 1172	RA
146	BioRevive Pty Ltd	Level 1, 263 Mary Street Richmond Vic 3121	(03) 8416 0399	(03) 8416 0345	RB
147	Reckitt Benckiser (Australia) Pty Limited	44 Wharf Road West Ryde NSW 2114	(02) 9857 2000	(02) 9857 2004	RC
148	Roche Diagnostics Australia Pty Ltd	31 Victoria Avenue Castle Hill NSW 2154	(02) 9899 7999	(02) 9634 4696	RD
149	Real-RL Division of GlaxoSmithKline Australia Pty Ltd	1061 Mountain Highway Boronia Vic 3155	(03) 9721 6000	(03) 9721 5319	RE
150	Roche Products Pty Ltd	4-10 Inman Road Dee Why NSW 2099	(02) 9454 9000	(02) 9971 7401	RO
151	Nutricia Australia - Clinical	A division of Nutricia Australia Pty Limited Talavera Corporate Centre Level 4, Building D 12-24 Talavera Road North Ryde NSW 2113	(02) 8875 0300	(02) 8978 4841	SB
152	Schering Pty Ltd Australian Subsidiary of Schering AG, Berlin	875 Pacific Highway Pymble NSW 2073	(02) 9391 6000	(02) 9988 3311	SC
153	Servier Laboratories (Aust.) Pty Ltd	8 Cato Street Hawthorn Vic 3122	(03) 8823 7333	(03) 9822 9790	SE
154	Merck Serono Australia Pty Ltd	Unit 3-4, 25 Frenchs Forest Road East Frenchs Forest NSW 2086	(02) 8977 4100	(02) 9975 1516	SG
155	Schering-Plough Pty Ltd	Level 4, 66 Waterloo Road North Ryde NSW 2113	(02) 8988 8000	(02) 9852 7500	SH
156	Sigma Pharmaceuticals (Australia ) Pty Ltd A member of Sigma Group of Companies	96 Merrindale Drive Croydon Vic 3136	(03) 9839 2800	(03) 9839 2753	SI
157	Sharpe Laboratories Pty Ltd	12 Hope Street Ermington NSW 2115	(02) 9858 5622	(02) 9858 5957	SJ
158	Solvay Pharmaceuticals Division of Solvay Biosciences Pty Ltd	Level 1, Building 2 Pymble Corporate Centre 20 Bridge Street Pymble NSW 2073	(02) 9440 0977	(02) 9440 0910	SM
159	Smith & Nephew Healthcare	315 Ferntree Gully Road Mount Waverley Vic 3149	(03) 8540 6777	1800 671 000	SN
160	Simpla Plastics Australia Pty Ltd	9 Milverton Avenue Karrinyup WA 6018			SP
161	SSL Australia Pty Ltd	225 Beach Road Mordialloc Vic 3195	1800 999 155	(03) 9587 6870	SS
162	Sanofi-Aventis Australia Pty Ltd	Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113	(02) 8666 2000	(02) 8666 3000	SW
163	Stiefel Laboratories Pty Limited	Unit 14, 5 Salisbury Road Castle Hill NSW 2154	(02) 9894 5088	(02) 9894 5016	SX
164	Schering AG	875 Pacific Highway Pymble NSW 2073	(02) 9391 6000	(02) 9988 3311	SY
165	Sandoz Pty Ltd	Level 4, Suite 7-19 100 Harris Street Pyrmont NSW 2009	(02) 9566 1500	(02) 9566 1458	SZ
166	Actavis Australia Pty Ltd	Deacons 225 George Street Sydney NSW 2000	(08) 8267 6121	(08) 8267 6121	TA
167	Technipro Marketing Pty Ltd	Unit 10, 13 Berry Street Clyde NSW 2142	(02) 9897 5899	(02) 9897 5799	TM
168	Specialised Therapeutics Australia Pty Ltd	Suite 3-4, 6 Westbrook Street East Kew Vic 3102	(03) 9859 1493	(03) 9859 6950	TS
169	Terry White Chemists	Level 7, 5 Queens Road Melbourne Vic 3004	(03) 9918 2500	(03) 9918 2006	TW
170	Apotex Pty Ltd	66 Waterloo Road North Ryde NSW 2113	(02) 8877 8333	(02) 8877 8377	TX
171	UCB Pharma A Division of UCB Australia Pty Ltd	Level 1, 1155 Malvern Road Malvern Vic 3144	(03) 9828 1800	(03) 9828 1860	UC
172	Vitaflo Australia Pty Ltd	110 Fyans Street South Geelong Vic 3220	(03) 5229 8222	(03) 5229 8225	VF
173	Valeant Pharmaceuticals Australasia Pty Ltd	Level 7, Suite 7.02 3 Rider Boulevard Rhodes NSW 2138	1800 630 056	(02) 9743 4053	VT
174	Winthrop Pharmaceuticals Division of Sanofi-Aventis Australia Pty Limited	Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113	(02) 8666 2000	(02) 8666 3000	WA
175	MedWatchDoc	27 Goodwin Street West Ryde NSW 2114	(02) 9809 0665	(02) 9989 8469	WF
176	Wooltec Australia	80C Charles Street Putney NSW 2112	(02) 809 2322	(02) 807 3235	WO
177	Willow Pharmaceuticals Pty Limited	Level 31, ABN Amro Tower 88 Phillip Street Sydney NSW 2000	(02) 9518 1735	(02) 9518 1835	WQ
178	Wyeth Consumer Healthcare Pty Ltd	17-19 Solent Circuit Norwest Business Park Baulkham Hills NSW 2153	1800 555 057	(02) 9023 0016	WT
179	Wyeth Australia Pty Limited	17-19 Solent Circuit Norwest Business Park Baulkham Hills NSW 2153	(02) 9761 8200	(02) 9023 0000	WX
180	Wyeth Pharmaceuticals Division of Wyeth Australia Pty Limited	17-19 Solent Circuit Norwest Business Park Baulkham Hills NSW 2153	(02) 9761 8200	(02) 9023 0000	WY
181	Max Pharma Pty Ltd	Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124	(03) 9809 7900	(03) 9809 7999	XF
182	Aaxis Pacific Pty Ltd	24-32 Forge Street Blacktown NSW 2148	(02) 9881 3333	(02) 9881 3322	XP
183	Symbion Pharmacy Services Pty Ltd	Level 7, 5 Queens Road Melbourne Vic 3004	(03) 9918 2000	(03) 9918 2006	YM
184	Mayne Pharma International Pty Ltd	1538 Main North Road Salisbury SA 5106	(08) 8209 2666	(08) 8281 6998	YN
185	Mayne Products Pty Ltd	1538 Main North Road Salisbury SA 5106	(08) 8209 2666	(08) 8281 6998	YT
186	Shire Australia Pty Limited	Level 9, Avaya House 123 Epping Road North Ryde NSW 2113	1800 012 612	(02) 8875 7977	ZI
187	Spirit Pharmaceuticals Pty Ltd	117 Harrington Street The Rocks Sydney NSW 2000	(02) 9251 1088	(02) 9251 1099	ZP
\.


--
-- Data for Name: pbs; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY pbs (fk_product, quantity, max_rpt, pbscode, chapter, restrictionflag) FROM stdin;
190	1	0	8863L	GE	U
18	28	5	9312D	GE	A
1588	10	0	3455W	DB	U
196	5	0	5004J	DT	U
1952	30	5	2457H	GE	U
1402	2	0	4674B	R1	U
2293	10	0	9409F	GE	R
2073	60	0	9572T	HS	A
594	15	5	5961R	CT	R
2151	10	0	1257E	GE	R
1241	10	1	5886T	CT	U
2339	1	0	4783R	R1	U
1259	4	2	5993K	CT	A
1656	100	0	1128J	GE	U
2149	2	1	4908H	R1	U
1141	100	0	6436R	HS	A
914	2	5	4118R	R1	U
1401	28	3	1920C	GE	U
288	1	0	5009P	DT	R
1078	50	2	2211J	GE	U
215	100	5	1285P	GE	A
284	1	2	9304Q	GE	A
1989	1	0	8025J	GE	R
1788	1	0	5876G	CT	U
2190	1	5	8620Q	GE	U
1157	20	0	9400R	GE	R
608	20	0	8490W	GE	R
1339	6	0	1161D	GE	U
2055	1	0	9468H	GE	A
831	7	1	2922T	GE	U
1707	30	5	8333N	GE	R
900	1	1	4885D	R1	U
340	30	2	9177B	GE	A
1343	2	4	9475Q	GE	A
1066	60	2	8787L	GE	A
110	1	0	9137X	GE	A
718	1	0	5842L	CT	A
545	4	0	6415P	HS	A
2287	100	2	8132B	GE	R
811	200	2	2290M	GE	U
1214	50	5	2770T	GE	U
284	1	1	9305R	GE	A
1178	1	7	8666D	GE	A
120	28	5	9482C	GE	R
1183	40	0	5079H	DT	U
1016	1	11	9257F	GE	R
1848	56	2	1663M	GE	U
1857	100	5	2386N	GE	U
733	200	0	2958Q	GE	U
126	5	5	3079C	GE	R
694	84	1	4077N	R1	U
798	1	0	5847R	CT	A
784	1	5	8311K	GE	U
2245	1	3	5397C	PL	A
1251	30	1	8601Q	GE	R
181	5	0	3458B	DB	U
595	4	5	9385Y	GE	R
939	1	1	4035J	R1	U
1027	100	5	8222R	GE	A
1101	60	5	9071K	GE	A
1345	50	2	2418G	GE	U
1059	2	11	9265P	GE	R
55	10	0	9407D	GE	R
870	300	4	8784H	GE	R
389	3	1	4853K	R1	U
2230	2	0	4892L	R1	U
323	30	5	8663Y	GE	A
1019	30	5	2170F	GE	R
979	50	2	4073J	R1	U
738	2	0	4727T	R1	U
392	1	5	1926J	GE	U
2208	2	3	5978P	CT	A
1183	40	3	1302M	GE	U
1908	2	5	2159P	GE	U
75	100	5	2809W	GE	R
924	1	5	4089F	R1	R
2178	7	0	6319N	GH	R
945	30	5	8513C	GE	R
452	10	0	5045M	DT	U
2281	50	3	5359C	PL	A
2057	30	5	1081X	GE	U
725	56	5	8951D	GE	A
895	30	5	8533D	GE	U
745	56	5	8870W	GE	A
2246	42	1	2804N	GE	A
219	1	5	5529B	OT	R
355	4	1	2266G	GE	U
2202	5	1	8390N	GE	U
772	28	5	9140C	GE	A
552	1	1	4924E	R1	U
711	50	5	1705R	GE	R
688	2	0	3130R	GE	R
1439	1	0	1497T	GE	U
1758	3	5	8804J	GE	R
1893	1	1	8056B	GE	A
5	28	5	9181F	GE	A
1775	90	1	4076M	R1	U
175	1	2	4460R	R1	U
1699	2	5	9034L	GE	A
836	1	1	4004R	R1	U
2332	1	0	6247T	HS	A
404	10	0	3456X	DB	U
1364	1	0	5306G	PL	A
1308	5	0	3484J	DB	U
1983	100	5	3052P	GE	U
309	1	11	9211T	GE	R
1086	10	1	2824P	GE	U
1059	2	11	9276F	GE	R
461	1	5	8516F	GE	U
348	8	5	8479G	GE	R
346	30	2	1358L	GE	U
1564	200	2	2587E	GE	U
2078	2	0	4576W	R1	A
1734	16	2	5992J	CT	A
226	100	0	1982H	GE	A
898	100	5	1242J	GE	U
283	180	1	8357W	GE	A
1073	1	11	9214Y	GE	R
915	8	5	8058D	GE	R
1636	1	5	8406K	GE	U
90	50	0	5365J	PL	A
552	1	1	4907G	R1	U
294	1	5	8428N	GE	U
209	1	1	4945G	R1	U
2038	56	5	2848X	GE	A
507	2	3	1027C	GE	A
1112	5	0	8120J	GE	U
1460	1	0	6432M	IF	R
688	5	0	3131T	GE	R
49	30	0	6299M	HS	A
483	20	0	5116G	DT	R
1335	8	5	8260R	GE	R
516	28	5	8701Y	GE	R
630	1	5	9088H	GE	A
592	15	5	5946Y	CT	A
516	28	5	9433L	GE	R
1722	60	5	9113P	GE	A
1454	1	0	1753G	GE	U
523	2	2	8336R	GE	R
1793	30	5	2834E	GE	R
933	8	5	8575H	GE	A
156	10	0	3477B	DB	U
1512	1	2	2063N	GE	U
1223	4	0	5967C	CT	R
1566	100	1	2412Y	GE	U
771	1	2	4408B	R1	U
2044	28	5	9373H	GE	R
1029	1	0	5972H	CT	R
1548	1	1	8149X	GE	U
463	200	5	4453J	R1	U
2268	100	5	1245M	GE	U
411	30	5	8405J	GE	R
66	1	0	9631X	IF	R
25	30	5	8296P	GE	U
1014	2	0	4898T	R1	U
577	6	0	1510L	GE	R
1246	28	5	8628D	GE	A
108	1	2	4779M	R1	U
2032	21	0	9643M	HS	A
1832	7	3	5424L	PL	A
447	100	5	1479W	GE	U
1780	1	0	2700D	GE	A
857	2	0	4676D	R1	U
421	56	5	8217L	GE	A
657	100	5	2449X	GE	U
1389	1	3	9455P	GE	A
368	1	5	5522P	OT	U
891	30	5	9121C	GE	U
1851	120	0	6495W	HS	A
2300	5	0	8807M	GE	A
200	1	0	9350D	GE	A
2251	1	0	4017K	R1	U
1211	3	0	5404K	PL	A
798	1	0	9415M	GE	A
2059	1	1	4031E	R1	U
48	1	0	6397Q	HS	A
716	5	5	8381D	GE	A
2128	1	5	5552F	OT	U
822	1	0	4350Y	R1	R
728	100	1	1585K	GE	U
1081	4	0	1340M	GE	U
1040	10	0	2528C	GE	U
690	1	0	6103F	MF	R
293	1	0	8424J	GE	R
487	5	0	5211G	DT	U
770	1	1	3094W	GE	U
1016	1	11	9269W	GE	R
1224	10	1	5918L	CT	U
1560	1	0	5511C	OT	U
1759	20	3	8639Q	GE	R
1255	1	0	5965Y	CT	U
1984	30	5	8521L	GE	R
869	2	3	4895P	R1	U
765	1	0	4849F	R1	U
1272	5	0	5142P	DT	U
1455	100	2	2725K	GE	R
379	1	0	6492Q	HS	A
1778	1	0	4626L	R1	U
2237	30	11	9239G	GE	R
533	3	0	5423K	PL	A
1278	100	1	1486F	GE	U
367	200	1	1433K	GE	U
528	5	1	2062M	GE	U
1597	10	0	3399X	DT	U
1624	28	1	2240X	GE	R
1006	1	0	6296J	GH	R
2056	100	3	2047R	GE	R
67	10	0	2374Y	GE	U
1625	10	0	1948M	GE	U
2066	1	0	4856N	R1	U
1356	1	5	8029N	GE	U
1320	8	5	8061G	GE	R
2097	20	2	5391R	PL	A
1155	5	0	4657D	R1	U
1837	2	3	5331N	PL	A
1917	21	1	1636D	GE	U
212	4	5	8805K	GE	A
2179	3	0	5405L	PL	A
994	20	0	9195Y	GE	U
1059	2	5	8795X	GE	U
1645	30	5	1622J	GE	U
21	1	6	9138Y	GE	A
1369	1	5	1743R	GE	U
2013	3	1	4913N	R1	U
1520	1	5	8849R	GE	R
192	1	1	4694C	R1	U
1191	20	0	1609Q	GE	R
8	5	0	1644M	GE	U
19	1	2	8083K	GE	R
2035	2	0	5906W	CT	U
2208	2	7	5896H	CT	A
1924	60	5	9204K	GE	A
1010	3	0	5401G	PL	A
630	1	5	9090K	GE	A
567	30	5	8393R	GE	R
1950	20	0	8543P	GE	R
2060	30	5	1368B	GE	U
153	2	3	1502C	GE	R
10	4	0	6411K	HS	A
109	10	0	4689T	R1	U
1059	2	11	9472M	GE	R
1482	100	5	1324Q	GE	U
394	5	1	2264E	GE	U
829	56	5	9094P	GE	A
1608	1	0	5114E	DT	R
1796	1	0	8360B	GE	A
1231	5	0	2256R	GE	U
21	1	0	5836E	CT	A
410	20	0	8670H	GE	R
1882	30	5	2845R	GE	R
659	100	3	1299J	GE	R
1471	84	2	4570M	R1	A
1496	3	10	2357C	GE	A
1734	16	2	8280T	GE	A
1467	200	2	1939C	GE	U
1376	100	3	5345H	PL	A
2117	1	4	5900M	CT	A
1357	1	5	5549C	OT	U
2303	10	1	8263X	GE	U
1006	1	0	6466H	GH	R
351	30	0	8465M	GE	A
1120	5	0	9005Y	GE	U
1913	5	0	2765M	GE	U
1083	25	0	5205Y	DT	U
2235	30	5	8214H	GE	R
2340	28	0	9627Q	HS	A
1374	5	0	8894D	GE	R
340	30	2	9179D	GE	A
428	30	5	8011P	GE	U
2182	1	0	5190E	DT	R
1427	10	1	1775K	GE	U
2238	1	1	3095X	GE	U
1249	30	5	8404H	GE	R
1755	30	5	9314F	GE	R
969	100	5	8086N	GE	A
2180	1	0	5533F	OT	U
828	7	0	8775W	GE	A
1898	30	5	8451T	GE	U
1674	100	5	1567L	GE	U
310	100	5	8839F	GE	A
274	5	2	1713E	GE	U
475	30	2	2993M	GE	U
2136	4	0	1465D	GE	U
554	1	0	2580T	GE	U
1217	50	5	3134Y	GE	A
874	1	0	8025J	GE	R
825	1	0	1642K	GE	U
2164	100	5	9152Q	GE	R
542	30	0	6120D	HS	A
1543	8	5	8545R	GE	R
2058	56	2	2323G	GE	U
557	3	5	1411G	GE	R
64	30	11	9237E	GE	R
380	1	4	4049D	R1	R
687	1	5	5518K	OT	R
2157	1	3	9119Y	GE	A
2289	100	5	2227F	GE	U
1468	60	2	9284P	GE	A
1235	7	1	2708M	GE	U
2282	30	5	8735R	GE	A
861	1	2	8848Q	GE	A
93	5	1	2279Y	GE	U
2191	56	5	9338L	GE	A
2064	30	5	8246B	GE	U
2257	5	0	2694T	GE	R
1685	1	5	8567X	GE	R
711	50	0	1789E	GE	U
1641	56	5	9059T	GE	A
1395	100	5	8599N	GE	A
1960	1	0	4950M	R1	U
1477	1	2	9293D	GE	A
280	2	5	8736T	GE	A
1075	3	0	5406M	PL	A
1257	4	5	9384X	GE	R
1217	50	0	5373T	PL	A
404	10	0	2768Q	GE	U
1702	100	5	1270W	GE	A
961	200	5	8731M	GE	A
1058	4	2	1967M	GE	U
1986	20	3	8716R	GE	R
803	50	5	1627P	GE	R
50	1	5	9391G	GE	A
1648	56	5	9449H	GE	A
767	10	1	4831G	R1	U
1792	1	0	4481W	R1	U
593	60	3	8658Q	GE	A
993	4	2	3179H	GE	U
1217	25	0	3132W	GE	U
638	5	0	5004J	DT	U
1430	5	0	6246R	HS	A
1065	50	0	2131E	GE	A
1511	50	2	1266P	GE	U
547	4	0	8359Y	GE	A
1634	30	0	4313B	R1	U
1358	3	5	5956L	CT	A
1394	1	5	8763F	GE	U
2261	90	5	1335G	GE	U
846	1	0	4482X	R1	U
833	10	0	5049R	DT	R
4	100	5	2313R	GE	A
1066	60	5	8869T	GE	A
1894	5	3	5841K	CT	A
1267	60	5	8164Q	GE	A
42	2	3	5959P	CT	A
406	1	0	5208D	DT	U
2118	50	0	3342X	DT	U
197	4	2	2775C	GE	U
977	1	0	6312F	GH	R
1224	10	1	2884T	GE	U
1644	1	2	9024Y	GE	A
232	1	0	3349G	DT	U
1868	4	0	6449K	HS	A
1435	100	5	1862B	GE	R
854	1	5	8564R	GE	R
1059	2	5	9298J	GE	U
498	30	0	9622K	HS	A
425	2	3	1228P	GE	U
202	2	0	2812B	GE	R
2081	6	0	8098F	GE	A
633	60	5	8165R	GE	A
1322	200	2	1413J	GE	U
1018	10	0	4832H	R1	U
998	1	0	1757L	GE	A
330	4	2	1392G	GE	U
510	1	11	9222J	GE	R
1530	200	1	2175L	GE	U
1382	60	0	6460B	HS	A
1079	120	0	6498B	HS	A
144	2	2	8050Q	GE	A
2020	100	5	2185B	GE	U
102	1	2	1382R	GE	A
2174	1	0	5225B	DT	U
1113	21	0	5155H	DT	R
695	30	5	1906H	GE	U
1334	1	0	6494T	HS	A
625	20	0	8146R	GE	R
546	30	1	8370M	GE	A
804	100	5	1480X	GE	U
1205	1	5	2059J	GE	A
1083	25	0	2893G	GE	U
319	4	5	8631G	GE	R
973	1	5	5555J	OT	R
555	1	5	1454M	GE	A
1495	30	3	8888T	GE	R
754	192	3	5343F	PL	A
350	2	5	5532E	OT	A
1697	5	0	5154G	DT	R
951	50	0	5328K	PL	A
2217	20	2	5409Q	PL	A
781	1	5	8674M	GE	R
1107	1	2	5845P	CT	A
240	1	5	4059P	R1	A
166	1	5	5503P	OT	R
1137	2	0	3261P	PQ	U
529	60	2	8265B	GE	R
1978	1	0	6400W	HS	A
1895	28	5	8355R	GE	U
574	50	4	1246N	GE	U
181	5	0	2558P	GE	U
138	24	0	8121K	GE	R
2051	1	0	8633J	GE	R
838	30	0	6195C	HS	A
1059	2	11	9486G	GE	R
1059	2	5	8825L	GE	U
682	1	5	8563Q	GE	A
1510	1	0	9574X	HS	A
2104	5	1	1921D	GE	U
862	1	0	4861W	R1	U
344	4	0	8225X	GE	R
1573	28	5	8758Y	GE	U
1651	50	3	1659H	GE	R
1685	1	5	5542Q	OT	R
1990	28	3	9420T	GE	A
1059	2	5	2891E	GE	U
821	30	0	6298L	HS	A
618	5	0	1606M	GE	R
1474	28	1	9490L	GE	A
967	3	5	2555L	GE	R
177	1	2	5995M	CT	A
959	50	2	1561E	GE	R
1011	1	1	4422R	R1	U
2056	100	0	5383H	PL	A
1134	1	3	4046Y	R1	A
1815	2	5	2000G	GE	R
1562	1	0	1596B	GE	A
1448	1	0	9187M	GE	A
2169	2	2	4573Q	R1	A
446	1	0	4106D	R1	R
984	28	5	9158B	GE	A
40	1	11	9219F	GE	R
90	50	3	1300K	GE	R
169	1	0	1002R	GE	R
1433	100	5	8221Q	GE	A
955	10	1	2017E	GE	U
893	1	0	8858F	GE	U
2007	30	5	2751T	GE	U
1870	4	5	8744F	GE	R
423	1	0	9632Y	HS	A
305	1	0	2441L	GE	U
1837	2	0	5332P	PL	A
1416	4	0	4941C	R1	R
1357	1	5	1925H	GE	U
91	1	1	4683L	R1	U
1398	21	1	1636D	GE	U
1958	25	0	5202T	DT	R
177	1	2	8540L	GE	A
1834	8	5	3078B	GE	R
1153	20	5	9184J	GE	A
2071	2	0	4662J	R1	U
1095	1	5	2825Q	GE	U
1852	1	5	8765H	GE	U
792	2	1	4897R	R1	U
315	90	0	9636E	HS	A
817	30	5	8719X	GE	A
1914	100	1	1280J	GE	U
1158	100	0	6328C	HS	A
303	120	0	9610T	HS	A
2258	1	2	4933P	R1	U
756	10	0	2876J	GE	U
949	1	1	4888G	R1	U
1450	30	5	8718W	GE	A
204	30	5	8119H	GE	U
1386	100	5	2229H	GE	U
170	2	0	8018B	GE	A
1752	1	1	4023R	R1	U
1291	50	2	2843P	GE	U
443	2	5	1542E	GE	R
311	100	2	2020H	GE	A
1689	1	0	6489M	HS	A
388	1	0	5966B	CT	U
2262	30	11	9247Q	GE	R
2037	1	0	6266T	GH	R
1419	1	1	4039N	R1	U
1729	2	0	5908Y	CT	U
97	28	5	8220P	GE	R
198	1	1	4700J	R1	U
1902	20	0	1654C	GE	R
255	5	0	5094D	DT	U
1785	7	0	6309C	MD	R
400	3	5	5506T	OT	A
967	3	3	5311M	PL	A
564	24	0	9498X	GE	A
1699	2	2	9188N	GE	A
252	50	5	2088X	GE	A
2153	28	0	9107H	GE	R
1075	20	2	5412W	PL	A
207	28	5	9144G	GE	R
1846	4	5	8677Q	GE	R
460	1	5	8832W	GE	R
1555	10	0	2369Q	GE	U
434	30	11	9245N	GE	R
2123	4	5	2382J	GE	R
861	1	2	5878J	CT	A
2229	200	2	8290H	GE	U
2083	20	0	5242X	DT	R
591	20	0	1214X	GE	U
398	1	0	4944F	R1	U
1059	2	11	9268T	GE	R
468	28	5	8433W	GE	A
976	56	2	9363T	GE	A
2195	20	0	5235M	DT	R
1131	1	3	5385K	PL	A
1934	6	0	6206P	HS	A
1832	7	0	5425M	PL	A
2275	200	3	5301B	PL	A
328	1	2	4930L	R1	U
1506	1	0	5400F	PL	A
1650	1	0	6477X	HS	A
787	50	5	3135B	GE	A
1501	1	1	4022Q	R1	U
1620	21	0	5155H	DT	R
666	100	3	2502Q	GE	A
1931	112	2	9285Q	GE	A
1561	100	2	2019G	GE	A
136	30	11	9244M	GE	R
989	90	1	2436F	GE	U
329	2	5	5545W	OT	A
488	100	0	6102E	HS	A
1262	3	0	1342P	GE	U
591	20	0	5063L	DT	U
239	1	1	4012E	R1	U
755	1	0	6454Q	HS	A
732	28	5	9377M	GE	R
1651	50	0	5177L	DT	R
2088	1	0	5388N	PL	A
1172	1	1	1115Q	GE	R
983	4	0	6321Q	HS	A
1919	60	0	6189R	HS	A
2036	60	0	6190T	HS	A
2093	1	0	3334L	DT	U
1494	60	2	2362H	GE	U
1347	4	5	9193W	GE	U
1533	3	0	9048F	GE	R
2216	4	0	6439X	HS	A
741	200	2	1109J	GE	U
67	10	0	5991H	CT	U
748	1	0	6431L	IF	R
707	1	0	8128T	GE	R
1362	5	0	4736G	R1	U
621	1	5	2071B	GE	U
1864	1	0	9479X	GE	R
602	1	0	5055C	DT	U
1880	56	2	8790P	GE	A
950	28	5	8689H	GE	A
1527	100	1	2414C	GE	U
887	10	0	5067Q	DT	R
1059	2	5	2890D	GE	U
194	30	5	1515R	GE	U
1862	15	5	8101J	GE	A
929	4	5	9734H	SB	A
358	200	1	1437P	GE	U
1180	60	5	1453L	GE	R
958	5	4	5996N	CT	A
2299	1	0	6172W	MD	R
1063	28	5	8094B	GE	A
987	30	5	8857E	GE	R
1442	1	0	3343Y	DT	U
495	30	5	8829Q	GE	R
543	28	0	9630W	HS	A
635	20	0	3306B	DT	U
929	4	5	8298R	SB	A
335	1	2	5999R	CT	A
1957	100	0	5340C	PL	A
1489	1	0	3467L	DB	U
1722	60	2	9178C	GE	A
1217	25	0	5192G	DT	U
1770	112	1	8202Q	GE	U
1475	1	0	4386W	R1	U
553	200	0	5039F	DT	U
136	30	5	8173E	GE	R
199	1	0	4244J	R1	U
1059	2	5	9471L	GE	U
2085	1	0	6335K	IF	R
1586	50	0	3360W	DT	U
1248	10	1	1891M	GE	R
1180	60	11	9248R	GE	R
1073	1	5	5517J	OT	R
1146	4	1	8616L	GE	A
416	60	5	2482P	GE	A
1132	28	0	6469L	HS	A
702	60	3	8439E	GE	R
1556	1	1	4558X	R1	U
2063	1	2	1771F	GE	U
2199	10	1	8872Y	GE	R
548	1	5	8286D	GE	U
1713	5	5	2027Q	GE	R
1404	20	0	8681X	GE	R
1503	1	0	3309E	DT	U
1491	1	2	4132L	R1	U
472	60	3	2591J	GE	A
264	7	0	5889Y	CT	A
211	1	1	2080L	GE	R
1971	6	0	6482E	HS	A
426	1	0	8827N	GE	U
582	90	3	5368M	PL	A
1449	30	2	9423Y	GE	R
1235	7	0	3322W	DT	U
834	28	5	9306T	GE	A
396	4	5	9330C	GE	R
365	50	3	5359C	PL	A
1312	1	5	1278G	GE	U
1314	50	2	2417F	GE	U
1684	1	5	2595N	GE	U
845	10	0	3389J	DT	U
854	1	5	5519L	OT	R
2250	5	5	8076C	GE	R
725	56	5	8397Y	GE	U
2003	4	0	6438W	HS	A
300	8	5	8328H	GE	R
750	1	0	4717G	R1	U
1502	2	5	1103C	GE	U
1783	1	1	4918W	R1	U
2280	30	5	9296G	GE	A
1326	8	5	2246F	GE	A
1295	6	0	9623L	HS	A
582	30	0	3192B	GE	U
629	1	2	5399E	PL	A
2256	50	2	2444P	GE	U
1458	10	1	1356J	GE	R
370	100	5	8559L	GE	A
1317	4	2	8049P	GE	A
646	1	0	6364Y	HS	A
1553	1	5	8803H	GE	U
1604	3	3	5304E	PL	A
2325	1	3	5389P	PL	A
766	4	5	9309Y	GE	R
904	5	0	8282X	GE	A
1297	200	1	9287T	GE	U
1216	2	2	3104J	GE	U
1481	60	2	2604C	GE	U
2240	2	0	4819P	R1	U
1973	28	0	2702F	GE	R
1074	1	0	9192T	GE	R
2236	1	0	4389B	R1	U
1569	5	0	3038X	GE	U
2187	28	5	9374J	GE	R
1777	5	1	9473N	GE	U
193	1	0	4787Y	R1	U
577	2	0	1501B	GE	U
1320	8	5	8059E	GE	R
1166	1	0	4518T	R1	U
2082	4	5	8621R	GE	A
2183	100	5	8223T	GE	A
697	4	5	9332E	GE	A
2017	90	5	1148K	GE	U
2231	28	2	2982Y	GE	U
387	5	1	1761Q	GE	U
1980	30	5	2172H	GE	A
2161	100	5	2340E	GE	U
374	10	0	5904R	CT	R
260	1	0	9097T	GE	A
872	1	5	8619P	GE	A
800	1	0	6194B	HS	A
474	200	21	9227P	GE	R
1963	1	0	5150C	DT	R
844	60	5	8595J	GE	A
300	8	5	8416Y	GE	R
1121	30	0	9614B	HS	A
711	50	0	3363B	DT	U
985	1	0	9638G	HS	A
1829	5	3	5840J	CT	A
1730	100	5	2608G	GE	U
1221	12	0	5194J	DT	R
448	100	2	1460W	GE	U
1092	10	0	1981G	GE	R
2075	1	0	6253D	HS	A
1526	1	4	4074K	R1	U
641	1	0	9621J	HS	A
1655	5	1	9040T	GE	R
632	1	5	9464D	GE	R
2192	4	0	8410P	GE	R
480	5	0	6228T	HS	A
1642	28	5	2793B	GE	U
173	4	0	1336H	GE	U
2270	1	1	4929K	R1	U
1030	5	0	4679G	R1	U
185	56	5	4324N	R1	A
1875	10	1	2018F	GE	U
482	1	1	2428T	GE	U
1323	1	0	5239R	DT	R
549	1	5	8140K	GE	U
1059	2	5	2917M	GE	U
1159	1	0	9321N	GE	A
594	15	5	8079F	GE	R
2026	60	5	3171X	GE	A
2330	30	5	8506Q	GE	R
2246	42	1	4011D	R1	A
1187	1	2	4493L	R1	U
1319	100	5	2878L	GE	U
704	10	0	5022H	DT	U
554	1	0	5911D	CT	U
1376	100	3	1674D	GE	R
2338	100	5	2767P	GE	U
2218	1	0	6178E	IF	R
1012	28	3	5347K	PL	A
1235	28	0	2703G	GE	R
183	50	2	4171M	R1	U
151	1	5	8312L	GE	U
34	5	0	4279F	R1	U
11	5	1	1763T	GE	U
1661	8	5	8369L	GE	R
2132	1	1	4927H	R1	U
1714	1	1	2881P	GE	R
454	60	4	1917X	GE	U
1861	1	0	4755G	R1	U
1766	7	0	6316K	GH	R
1632	1	5	9411H	GE	A
1208	90	0	8710K	GE	A
1720	1	11	9250W	GE	R
134	1	0	6410J	HS	A
877	50	2	2420J	GE	U
84	6	0	6434P	HS	A
778	60	0	6327B	HS	A
245	1	0	5909B	CT	U
2170	2	1	4906F	R1	U
883	100	5	8505P	GE	A
1939	28	5	8301X	GE	R
1413	56	5	9095Q	GE	A
344	4	0	5968D	CT	R
1736	1	2	4131K	R1	U
499	30	5	1945J	GE	U
1090	200	5	2093E	GE	U
341	40	3	5378C	PL	A
1400	1	5	9491M	GE	R
2056	100	0	5217N	DT	R
1968	5	1	8873B	GE	A
164	1	0	5157K	DT	U
2292	10	0	2179Q	GE	R
871	1	0	6284R	HS	A
1637	1	0	8859G	GE	A
12	5	5	9362R	GE	A
579	200	5	1099W	GE	U
2080	60	1	9011G	GE	U
1772	3	3	2101N	GE	A
590	1	0	4798M	R1	U
1111	20	0	3316M	DT	U
718	2	0	5921P	CT	A
2322	1	1	3118D	GE	U
664	1	5	5541P	OT	U
1615	5	0	2413B	GE	U
320	2	2	8336R	GE	R
296	1	5	8409N	GE	R
1592	1	0	6270B	HS	A
238	28	5	9481B	GE	R
663	1	5	5538L	OT	U
1037	3	0	4246L	R1	R
1038	30	5	2752W	GE	U
1646	1	0	4092J	R1	R
156	10	0	5206B	DT	U
2306	1	3	8414W	GE	A
813	1	2	8847P	GE	A
1466	50	0	3161J	GE	U
1378	1	0	8208B	GE	A
1577	60	0	6461C	HS	A
1376	100	0	5176K	DT	R
93	5	0	5215L	DT	U
619	60	5	2487X	GE	U
2075	3	5	5953H	CT	A
1338	30	11	9232X	GE	R
1300	1	2	4779M	R1	U
584	5	0	9640J	HS	A
552	1	1	4947J	R1	U
2244	1	0	4648P	R1	A
927	28	5	9369D	GE	U
1389	1	5	9458T	GE	A
1890	56	5	2850B	GE	A
1712	56	5	8499H	GE	A
1120	5	0	5872C	CT	U
322	28	5	9182G	GE	A
752	10	0	5903Q	CS	R
1651	50	3	5346J	PL	A
1623	60	5	8372P	GE	A
1364	1	2	1263L	GE	R
416	60	2	9283N	GE	A
195	60	2	8459F	GE	A
318	5	5	5944W	CT	R
560	56	5	4324N	R1	A
1169	28	5	8694N	GE	A
2099	1	0	2269K	GE	R
1627	10	0	4681J	R1	U
1143	1	0	4692Y	R1	U
121	30	0	9650X	HS	A
1028	1	0	6249X	HS	A
632	1	5	5558M	OT	R
1218	5	1	1291Y	GE	U
938	120	0	9639H	HS	A
119	1	5	8148W	GE	U
2010	200	0	5037D	DT	U
1088	10	0	5066P	DT	R
127	60	4	1247P	GE	U
1679	5	0	2990J	GE	R
285	100	0	6153W	HS	A
1396	28	5	1475P	GE	A
237	28	11	9236D	GE	R
459	1	2	1747Y	GE	U
936	3	0	8048N	GE	A
350	2	5	9170P	GE	A
2321	4	0	8461H	GE	A
1917	21	0	3339R	DT	U
1984	30	11	9233Y	GE	R
1059	2	5	8749L	GE	U
1409	1	1	2888B	GE	R
2220	30	5	1558B	GE	U
1056	5	1	2278X	GE	U
1591	20	0	5191F	DT	R
1376	100	0	5349M	PL	A
244	1	5	1414K	GE	U
640	200	10	8366H	GE	U
116	30	5	8882L	GE	A
911	30	5	1970Q	GE	U
1364	2	0	3263R	PQ	U
63	2	4	9255D	GE	R
341	40	3	2757D	GE	U
2333	30	5	8449Q	GE	R
735	1	5	2065Q	GE	A
2115	50	0	5384J	PL	A
54	2	3	4750B	R1	U
1219	28	5	8624X	GE	R
434	30	5	8313M	GE	R
1062	1	1	4568K	R1	U
2307	20	3	8643X	GE	R
2334	56	5	9061X	GE	A
1156	2	0	8115D	GE	R
233	1	0	9128K	GE	A
37	5	2	1626N	GE	U
347	1	0	4390C	R1	A
692	1	1	9004X	GE	A
260	1	6	9098W	GE	A
1787	1	1	4698G	R1	U
797	5	5	5890B	CT	U
476	1	2	2328M	GE	R
2214	2	0	5914G	CT	U
1975	1	0	6374L	IF	R
45	20	0	1646P	GE	R
31	30	0	6354K	HS	A
510	1	5	2681D	GE	R
842	1	2	9029F	GE	A
2172	1	5	2962X	GE	A
1686	1	5	8485N	GE	U
1046	1	0	6396P	HS	A
1062	1	0	5335T	PL	A
1677	20	1	3058Y	GE	U
691	1	11	9220G	GE	R
1255	1	0	1929M	GE	U
1059	2	5	8759B	GE	U
1367	120	5	8577K	GE	R
2042	60	0	4237B	R1	U
630	1	5	9431J	GE	A
48	1	0	9617E	HS	A
101	1	0	6437T	HS	A
624	28	5	9432K	GE	R
2279	60	4	1935W	GE	U
1144	9	0	3250C	PQ	U
259	6	0	6204M	HS	A
1856	1	0	5422J	PL	A
907	30	5	9110L	GE	R
242	60	2	9343R	GE	A
1624	28	5	2241Y	GE	R
2284	30	5	8938K	GE	A
2138	1	1	4013F	R1	U
970	100	0	6152T	HS	A
1903	20	1	2274Q	GE	A
365	50	0	5360D	PL	A
1665	56	5	4323M	R1	A
967	3	0	5314Q	PL	A
2208	2	3	8293L	GE	A
1454	1	0	5175J	DT	U
424	200	2	2600W	GE	U
1483	2	11	9249T	GE	R
252	50	0	5376Y	PL	A
996	1	0	5910C	CT	U
414	30	3	9167L	GE	A
2008	30	2	8509W	GE	R
1638	20	0	1396L	GE	U
500	30	5	1241H	GE	U
1825	14	1	8292K	GE	U
2085	3	5	8565T	GE	R
2301	30	1	8886Q	GE	R
492	60	5	2115H	GE	A
2106	30	0	6458X	HS	A
478	20	0	8489T	GE	R
1534	2	0	5986C	CT	R
1099	2	11	9275E	GE	R
888	4	5	9386B	GE	R
709	60	5	9072L	GE	A
1912	1	0	9577C	HS	A
2099	1	0	5083M	DT	R
409	20	1	9318K	GE	A
1348	1	11	9221H	GE	R
1750	20	0	5236N	DT	R
1177	28	5	8302Y	GE	R
1426	4	2	9401T	GE	A
252	25	0	2089Y	GE	U
1315	5	0	8097E	GE	U
1949	1	0	5922Q	CT	A
2246	42	0	2285G	GE	A
1318	2	3	9103D	GE	A
1277	1	5	5542Q	OT	R
2259	8	5	8478F	GE	R
166	1	5	8384G	GE	R
1737	1	0	4759L	R1	U
522	60	2	9453M	GE	A
843	20	3	8641T	GE	R
1887	100	5	1445C	GE	R
1349	100	5	3124K	GE	U
400	3	5	2338C	GE	A
1270	5	0	5021G	DT	U
1537	100	0	6208R	HS	A
2181	1	2	2541R	GE	U
2285	1	0	8738X	GE	R
859	3	5	2556M	GE	R
734	1	0	6345Y	GH	R
223	1	2	4281H	R1	U
299	1	7	8666D	GE	A
218	4	5	2375B	GE	R
59	60	5	8196J	GE	A
1781	1	1	8752P	GE	R
1067	16	5	8587Y	GE	A
762	1	0	4859R	R1	U
956	7	0	6315J	GH	R
1457	1	0	5513E	OT	U
266	1	0	1903E	GE	R
979	50	3	5326H	PL	A
1874	2	0	4728W	R1	U
797	5	5	8740B	GE	U
1718	30	5	8822H	GE	A
1610	24	0	3138E	GE	R
2309	6	5	9328Y	GE	A
1276	5	0	3026G	GE	A
2050	90	0	9637F	HS	A
966	28	1	8482K	GE	A
2294	4	5	4596X	R1	A
1950	20	0	5117H	DT	R
1051	3	5	1166J	GE	R
1691	28	3	1590Q	GE	R
890	100	2	4043T	R1	U
2082	4	5	4444X	R1	A
1059	2	11	9264N	GE	R
342	100	5	1478T	GE	U
301	1	0	5933G	CT	U
1654	1	5	8240Q	GE	R
1216	2	4	9252Y	GE	R
2130	1	0	6497Y	SY	A
1722	60	2	9176Y	GE	A
879	28	5	8363E	GE	A
1545	180	5	2142R	GE	A
1538	14	0	1208N	GE	A
664	1	5	8488R	GE	U
582	90	0	5123P	DT	R
1195	2	0	2118L	GE	R
1469	5	0	1928L	GE	R
2215	30	5	2207E	GE	U
1227	50	3	1795L	GE	R
412	4	2	2773Y	GE	U
1323	1	0	2124T	GE	R
1559	8	0	6221K	HS	A
1710	2	5	8782F	GE	A
118	100	0	5379D	PL	A
1227	50	0	5354T	PL	A
101	1	3	8725F	GE	A
2142	2	3	5339B	PL	A
2160	10	0	1389D	GE	U
978	28	5	8771P	GE	A
219	1	5	1127H	GE	R
1192	30	5	1159B	GE	U
1788	1	0	8852X	GE	U
1332	10	0	2315W	SB	R
2221	1	0	5915H	CT	U
940	1	0	9619G	HS	A
1974	4	2	2772X	GE	U
886	30	0	6137B	HS	A
1040	10	0	5935J	CT	U
1696	1	0	6394M	HS	A
105	40	1	8092X	GE	A
1519	56	2	9364W	GE	A
148	1	3	9131N	GE	A
1586	50	5	1703P	GE	R
610	28	5	8622T	GE	R
1978	1	0	6405D	HS	A
1503	1	0	1878W	GE	U
1699	2	3	8737W	GE	A
696	2	0	4911L	R1	U
176	50	0	3364C	DT	U
912	60	5	1446D	GE	R
2086	100	2	1798P	GE	R
2324	5	0	1647Q	GE	U
1059	2	11	9278H	GE	R
1016	1	5	9154T	GE	U
1073	1	5	2956N	GE	R
1094	5	0	6229W	HS	A
1420	1	0	8300W	GE	A
2321	1	0	6286W	HS	A
6	100	2	2687K	GE	U
1859	200	21	9413K	GE	R
359	8	5	3136C	GE	R
1059	2	5	8890X	GE	U
2264	90	0	9635D	HS	A
851	8	5	8015W	GE	A
670	30	0	4175R	R1	U
1889	1	0	4240E	R1	U
1716	1	0	2296W	GE	U
1411	1	2	4546G	R1	U
345	30	5	8733P	GE	A
2284	30	5	8610E	GE	U
663	1	5	2598R	GE	U
375	4	5	5509Y	OT	A
2336	1	0	9575Y	HS	A
360	1	0	4243H	R1	U
1724	120	5	8816B	GE	A
1793	30	11	9238F	GE	R
167	100	5	2810X	GE	R
847	28	5	8495D	GE	A
1821	1	0	4396J	R1	A
630	1	5	9086F	GE	A
1996	60	5	1801T	GE	U
1682	60	0	6452N	HS	A
2111	3	5	9307W	GE	A
357	4	5	8266C	SB	A
606	2	3	4750B	R1	U
1684	1	5	5536J	OT	U
1339	6	0	5907X	CT	U
92	50	3	5356X	PL	A
601	4	2	1456P	GE	U
727	5	0	9607P	HS	A
495	30	11	9240H	GE	R
1489	1	1	1449G	GE	U
2276	1	0	1630T	GE	U
1516	1	0	2329N	GE	R
1765	10	1	4684M	R1	U
537	100	5	2234N	GE	A
1330	5	0	5129Y	DT	U
1657	1	0	4789C	R1	U
659	100	3	5361E	PL	A
1652	50	2	2132F	GE	A
1537	300	3	8649F	GE	A
1944	10	0	3488N	DB	U
260	1	0	5831X	CT	A
988	28	0	9600G	HS	A
749	12	0	9439T	GE	A
1799	5	0	1046C	GE	U
1953	56	5	2851C	GE	A
1337	1	0	8054X	GE	R
1756	5	5	8380C	GE	A
301	1	0	8515E	GE	U
1699	2	5	9189P	GE	A
318	5	5	8077D	GE	R
1353	1	0	6332G	HS	A
40	1	5	8676P	GE	R
1567	56	5	4323M	R1	A
332	1	0	6212Y	HS	A
73	1	0	4671W	R1	U
672	1	0	4949L	R1	U
1431	30	5	8590D	GE	R
1144	3	5	1260H	GE	R
2070	100	5	1822X	GE	A
700	1	0	6395N	HS	A
1070	1	0	4673Y	R1	U
1288	30	5	9161E	GE	A
1910	1	0	6407F	HS	A
933	8	5	2244D	GE	A
2325	1	5	8612G	GE	R
637	8	5	2676W	GE	A
99	60	5	2043M	GE	R
2065	60	0	6264Q	HS	A
2148	24	5	8678R	GE	R
1207	30	5	1182F	GE	U
165	2	0	2117K	GE	R
598	4	2	3176E	GE	U
942	100	5	2961W	GE	U
249	3	2	5977N	CT	A
789	16	2	9010F	GE	A
494	1	5	2070Y	GE	U
2153	7	1	9105F	GE	U
1126	100	5	2946C	GE	A
1062	1	3	5333Q	PL	A
2273	28	5	8496E	GE	A
159	4	5	2379F	GE	R
1707	30	1	8331L	GE	R
2000	100	2	1227N	GE	U
865	3	0	5402H	PL	A
909	50	2	2421K	GE	U
614	30	5	9019Q	GE	R
221	20	0	9399Q	GE	R
937	1	0	4645L	R1	U
1045	40	3	1588N	GE	U
972	2	11	9217D	GE	R
2240	2	0	4860T	R1	U
2139	6	0	6486J	HS	A
780	30	3	8440F	GE	R
703	10	1	4909J	R1	U
1858	100	5	1417N	GE	A
2159	30	5	1316G	GE	U
1776	1	0	6476W	GH	R
2122	30	5	2387P	GE	A
2286	200	2	2588F	GE	U
1562	1	0	5971G	CT	R
1853	56	5	4320J	R1	A
2110	28	5	8726G	GE	A
460	1	5	5528Y	OT	R
334	30	4	1292B	GE	U
1389	1	5	9456Q	GE	A
1154	1	3	2411X	GE	U
1489	1	0	5105Q	DT	U
1059	2	5	9300L	GE	U
353	10	1	8413T	GE	A
140	30	5	2626F	GE	R
790	4	5	9437Q	GE	R
1355	60	5	8257N	GE	A
1879	10	0	6291D	HS	A
654	20	0	5167Y	DT	R
378	90	0	9605M	HS	A
1761	28	5	8703C	GE	R
815	1	0	8209C	GE	A
1400	1	5	5559N	OT	R
2155	1	5	8767K	GE	U
1262	3	0	5927Y	CT	U
581	60	5	1158Y	GE	U
1726	1	0	4858Q	R1	U
2153	21	0	9108J	GE	R
321	50	2	1012G	GE	U
1732	60	5	1694E	GE	U
2250	5	5	5943T	CT	R
999	6	0	8531B	GE	R
1229	5	5	5890B	CT	U
1562	1	0	8226Y	GE	R
1072	50	2	1972T	GE	A
1824	1	0	2886X	GE	U
1907	100	3	1004W	GE	U
2219	5	0	1001Q	GE	U
809	1	5	8425K	GE	U
1131	1	1	1121B	GE	R
967	8	0	3265W	PQ	U
196	5	0	3451P	DB	U
1672	5	0	5005K	DT	U
150	1	5	8593G	GE	R
1050	30	5	9484E	GE	A
2311	1	0	8898H	GE	R
836	2	3	1017M	GE	A
1080	1	0	9624M	HS	A
1611	1	0	6464F	IF	R
2264	90	5	9403X	GE	A
1	2	2	2293Q	GE	U
146	4	3	4894N	R1	U
1542	8	0	9447F	GE	A
161	1	3	9130M	GE	A
602	1	2	5512D	OT	U
589	1	5	9303P	GE	A
1590	1	2	4936T	R1	U
592	15	4	5945X	CT	A
1860	30	5	8880J	GE	A
1916	4	5	4597Y	R1	A
609	100	5	8230E	GE	U
2283	24	0	5091Y	DT	R
2152	1	1	8093Y	GE	A
391	30	5	8179L	GE	R
420	100	0	6418T	HS	A
2190	1	5	5551E	OT	U
2050	90	5	9405B	GE	A
486	30	5	8856D	GE	R
1464	4	5	9434M	GE	R
1183	40	3	5363G	PL	A
1649	20	2	5393W	PL	A
1036	30	5	4070F	R1	A
2319	1	0	8860H	GE	A
777	30	5	8213G	GE	R
482	1	0	3337P	DT	U
1171	5	5	8672K	GE	R
2324	5	0	5170D	DT	U
184	5	4	5998Q	CT	A
523	2	0	8200N	GE	R
659	100	0	5364H	PL	A
2281	25	0	2723H	GE	U
2237	30	5	8197K	GE	R
1525	4	5	9133Q	GE	R
1823	1	0	8487Q	GE	U
305	1	0	5516H	OT	U
1522	100	0	1982H	GE	A
1873	1	0	9065D	GE	A
1103	1	1	9494Q	GE	R
464	6	0	4688R	R1	U
341	40	0	5128X	DT	U
100	100	5	2942W	GE	U
905	56	5	8498G	GE	A
1135	1	0	3302T	DT	U
1415	1	3	5334R	PL	A
1318	2	5	9100Y	GE	A
1593	2	5	8780D	GE	A
747	60	5	3170W	GE	A
1397	100	2	2318B	GE	A
36	30	0	9649W	HS	A
2072	30	0	4522B	R1	R
459	1	0	3348F	DT	U
2116	30	5	8626B	GE	R
630	1	3	9091L	GE	A
1117	2	3	9037P	GE	A
1679	5	0	5233K	DT	R
2188	60	5	8596K	GE	A
1790	1	1	4134N	R1	A
1012	28	0	5351P	PL	A
1254	2	0	1217C	GE	A
157	100	1	8801F	GE	U
2249	200	1	2173J	GE	U
1865	50	0	3028J	GE	U
647	10	5	1211R	GE	R
1555	10	0	5206B	DT	U
432	30	5	8216K	GE	R
178	50	2	2209G	GE	U
649	1	0	6293F	MF	R
1947	5	2	8571D	GE	U
1660	42	0	8064K	GE	A
843	10	1	8603T	GE	U
2137	10	0	8492Y	GE	R
1434	120	0	6369F	HS	A
1044	4	5	8613H	GE	R
704	10	0	3453R	DB	U
1923	50	3	8648E	GE	A
1185	1	1	1574W	GE	A
172	50	2	1623K	GE	R
1926	20	0	8502L	GE	R
2204	100	4	3152X	GE	U
787	50	3	5372R	PL	A
1237	2	2	2295T	GE	U
267	28	0	9368C	GE	U
176	50	0	2965C	GE	U
631	1	0	6223M	HS	A
490	1	2	8815Y	GE	U
859	8	0	3266X	PQ	U
1407	1	2	9027D	GE	A
1118	2	5	8781E	GE	A
1124	100	5	2228G	GE	U
1881	28	5	8186W	GE	A
1834	8	5	8446M	GE	R
1906	90	5	8188Y	GE	U
996	1	0	2579R	GE	U
722	24	0	8122L	GE	R
349	28	5	1472L	GE	A
1227	50	0	5186Y	DT	R
2296	100	5	2565B	GE	U
825	1	0	5157K	DT	U
873	60	0	9629T	HS	A
123	1	3	9410G	GE	A
388	1	0	1930N	GE	U
1497	1	0	6329D	GH	R
974	3	0	8099G	GE	A
2255	1	5	9286R	GE	R
1814	10	1	1760P	GE	U
1181	100	5	1248Q	GE	U
1117	2	3	8637N	GE	A
1371	1	1	9336J	GE	A
1816	1	2	4932N	R1	U
689	5	0	3314K	DT	U
535	30	0	6356M	HS	A
837	7	0	1473M	GE	A
263	56	5	9450J	GE	A
1318	2	5	9104E	GE	A
1403	1	0	4204G	R1	U
2295	200	2	1640H	GE	U
23	50	2	1975Y	GE	A
298	100	2	9470K	GE	U
1883	28	0	6500D	HS	A
527	30	5	8836C	GE	R
1393	2	5	8288F	GE	U
1260	2	1	3199J	GE	U
782	200	2	2426Q	GE	U
731	30	5	2148C	GE	U
1990	28	1	9417P	GE	A
131	5	5	8378Y	GE	A
570	6	0	4653X	R1	U
1077	1	0	4642H	R1	U
2019	1	0	6181H	IF	R
2097	20	0	4349X	R1	R
680	1	2	4935R	R1	U
786	1	0	5258R	DT	R
2156	5	0	5931E	CT	U
57	200	2	1955X	GE	U
1897	1	2	4549K	R1	U
1909	30	2	2321E	GE	U
12	15	2	9361Q	GE	A
1550	1	2	4845B	R1	U
747	60	2	9079W	GE	A
1318	2	2	9190Q	GE	A
1499	30	5	9315G	GE	R
1276	5	0	5973J	CT	A
2339	1	0	4785W	R1	U
2147	6	1	8503M	GE	A
103	25	0	5151D	DT	U
1801	3	5	9021T	GE	R
1053	2	0	4661H	R1	U
679	1	1	2815E	GE	R
1602	2	1	2260Y	GE	U
1150	1	1	4010C	R1	R
1703	200	2	1639G	GE	U
973	1	5	9057Q	GE	R
1037	8	0	3267Y	PQ	U
449	1	2	3112T	GE	R
1534	2	0	2745L	GE	R
814	1	5	8826M	GE	R
2302	6	0	6303R	HS	A
1443	1	5	8427M	GE	U
1007	60	0	6459Y	HS	A
901	7	0	9628R	GH	R
174	60	5	2043M	GE	R
2254	4	5	9395L	GE	R
1261	10	0	1086E	GE	R
1582	20	3	8642W	GE	R
841	6	0	6483F	HS	A
2048	30	5	8174F	GE	R
1776	1	0	6465G	GH	R
578	4	5	9132P	GE	R
894	3	5	8824K	GE	A
605	28	0	9155W	GE	R
2107	1	0	4782Q	R1	U
550	60	5	9073M	GE	A
2156	5	0	1390E	GE	U
435	5	0	5159M	DT	U
1944	10	0	1948M	GE	U
1059	2	11	9325T	GE	R
38	56	2	9080X	GE	A
656	30	5	9162F	GE	A
469	1	0	4788B	R1	U
1869	100	5	1197B	GE	U
630	1	0	9615C	HS	A
227	3	5	5502N	OT	A
68	56	5	4322L	R1	A
166	1	11	9210R	GE	R
1745	1	0	8729K	GE	R
1751	1	0	4199B	R1	U
2305	15	0	9469J	GE	A
1653	100	5	8039D	GE	R
254	1	0	3489P	DB	U
908	1	2	4560B	R1	U
2056	100	3	5381F	PL	A
1059	2	5	8723D	GE	U
1095	1	5	5544T	OT	U
1477	1	5	8100H	GE	A
1275	10	0	6113R	HS	A
1900	1	0	4566H	R1	A
88	1	5	8407L	GE	U
331	1	0	8373Q	GE	A
203	100	5	1728Y	GE	A
1296	60	5	8580N	GE	A
539	1	1	4191N	R1	U
2084	1	0	4365R	R1	R
1833	1	5	2072C	GE	U
1813	14	0	1209P	GE	A
1059	2	11	9274D	GE	R
406	1	2	2895J	GE	U
94	1	0	4742N	R1	U
1001	2	0	1079T	GE	U
186	3	5	8578L	GE	A
111	60	5	1088G	GE	R
1202	10	0	9326W	GE	R
103	25	0	1207M	GE	U
1532	1	5	8351M	GE	U
90	50	0	5077F	DT	R
813	1	2	5877H	CT	A
691	1	5	5526W	OT	R
1675	100	5	1250T	GE	U
1229	5	5	8740B	GE	U
262	100	0	1983J	GE	A
1614	28	5	8481J	GE	A
1612	4	5	9165J	GE	R
2315	8	5	8629E	GE	R
1326	8	5	9340N	GE	A
2075	3	4	5893E	CT	A
1993	15	1	2272N	GE	U
2318	100	5	2667J	GE	A
1937	100	2	4200C	R1	U
561	1	5	1252X	GE	U
1884	1	5	2066R	GE	A
720	200	5	2096H	GE	U
1088	10	0	8493B	GE	R
640	200	21	9229R	GE	R
2167	100	5	9153R	GE	R
1486	10	0	5023J	DT	R
193	1	0	4794H	R1	U
1347	4	11	9256E	GE	R
1273	1	0	5964X	CT	U
2021	30	5	8297Q	GE	U
1016	1	5	2979T	GE	U
1119	4	5	9135T	GE	R
685	3	5	2324H	GE	A
32	1	0	6218G	HS	A
1059	2	5	8190C	GE	U
1384	30	5	9053L	GE	R
1309	100	5	3053Q	GE	U
1209	4	5	9313E	GE	A
1336	10	0	6337M	HS	A
372	10	0	1206L	GE	U
1560	1	0	1171P	GE	U
1099	2	5	8806L	GE	U
1810	30	5	8245Y	GE	R
1700	28	5	8447N	GE	U
1847	20	0	3463G	DB	U
96	25	1	1233X	GE	U
2128	1	5	8243W	GE	U
1837	4	0	3274H	PQ	U
1808	4	2	9452L	GE	A
1380	4	5	8591E	GE	R
2217	20	0	5415B	PL	A
832	1	1	4310W	R1	U
1303	5	0	2395C	GE	U
2153	7	0	5082L	DT	U
673	25	1	2750R	GE	U
2088	1	3	5387M	PL	A
1461	20	1	9319L	GE	A
645	100	0	6101D	HS	A
1961	1	0	4646M	R1	A
2115	50	3	2048T	GE	R
2099	3	0	2270L	GE	R
1283	1	1	8319W	GE	R
671	5	0	1794K	GE	U
1360	5	1	1762R	GE	U
1298	1	2	9031H	GE	A
1528	5	0	2350Q	GE	A
2277	20	0	8305D	GE	R
616	1	0	6363X	HS	A
1910	1	0	6409H	HS	A
760	1	5	8854B	GE	U
1479	100	5	8389M	GE	A
117	14	1	9333F	GE	A
1093	30	11	9242K	GE	R
1610	24	0	5057E	DT	R
2054	7	0	6308B	MD	R
948	1	5	8125P	GE	U
1838	100	1	3109P	GE	U
751	10	0	1573T	GE	A
629	1	0	6171T	MD	R
2094	1	0	6250Y	HS	A
556	1	0	8697R	GE	A
1756	15	2	8821G	GE	A
2242	30	5	2343H	GE	R
241	10	0	3357Q	DT	R
1587	1	1	9334G	GE	A
112	1	0	6256G	HS	A
1162	1	0	1915T	GE	R
652	100	5	4592Q	R1	A
1463	1	5	5554H	OT	U
1804	1	0	8423H	GE	U
1921	60	5	3172Y	GE	A
1037	3	5	2557N	GE	R
1505	28	5	9478W	GE	R
365	25	0	2723H	GE	U
2120	30	11	9241J	GE	R
1776	1	0	6295H	GH	R
1122	1	0	9149M	GE	R
1790	1	1	2546B	GE	A
2208	2	7	8665C	GE	A
1855	4	5	8144P	GE	A
2314	30	5	8374R	GE	A
1316	100	5	2226E	GE	U
1016	1	11	9271Y	GE	R
1626	4	0	5970F	CT	R
1485	28	5	9371F	GE	U
720	200	11	9209Q	GE	R
785	100	1	8801F	GE	U
2096	3	5	8299T	GE	A
2011	60	2	8787L	GE	A
1956	6	0	6305W	HS	A
340	30	2	9124F	GE	A
2269	1	5	4468E	R1	U
1438	100	5	2634P	GE	U
990	30	0	9648T	HS	A
1427	10	0	3486L	DB	U
1493	21	0	9644N	HS	A
33	1	1	1887H	GE	U
1871	5	5	8740B	GE	U
597	30	3	9168M	GE	A
2163	100	2	4028B	R1	U
1782	5	1	2245E	GE	U
1965	1	2	5994L	CT	A
1139	100	5	2729P	GE	U
265	5	0	5095E	DT	U
793	5	0	8893C	GE	R
1250	30	5	8375T	GE	A
155	100	2	3074T	GE	U
1389	1	5	9462B	GE	A
1943	30	5	8375T	GE	A
1507	100	5	1254B	GE	U
635	20	1	2931G	GE	U
1609	60	5	1253Y	GE	U
2004	7	5	2347M	GE	R
308	25	1	2547C	GE	U
145	1	0	6428H	HS	A
1108	6	0	6207Q	HS	A
1472	1	0	8618N	GE	R
1512	1	2	5530C	OT	U
1211	20	0	5416C	PL	A
86	100	5	4593R	R1	A
982	1	1	8233H	GE	A
48	1	0	6448J	HS	A
742	1	0	5514F	OT	U
848	100	2	1554T	GE	U
1170	2	2	2003K	GE	R
2098	3	3	2114G	GE	A
509	15	5	2997R	GE	A
1613	28	5	9157Y	GE	A
1318	2	5	9191R	GE	A
401	4	0	6325X	HS	A
787	25	0	3133X	GE	U
191	90	5	8189B	GE	U
823	60	2	9125G	GE	A
419	5	0	2593L	GE	U
1518	10	0	1257E	GE	R
1697	5	1	1638F	GE	R
718	1	0	9291B	GE	A
2297	10	0	5003H	DT	R
1611	2	5	8871X	GE	R
2079	100	1	4455L	R1	U
1059	2	11	9281L	GE	R
143	100	2	2722G	GE	R
253	3	0	8684C	GE	A
408	28	5	8024H	GE	R
144	2	2	5937L	CT	A
1955	10	1	9480Y	GE	R
1059	2	5	2860M	GE	U
1149	1	5	1459T	GE	U
2047	56	5	9451K	GE	A
1576	1	2	4928J	R1	U
1859	200	10	9412J	GE	U
368	1	11	9218E	GE	R
1335	4	5	8310J	GE	R
2275	200	0	5305F	PL	A
190	1	0	5873D	CT	U
1517	20	1	3119E	GE	U
1025	4	2	1393H	GE	U
2024	30	5	9006B	GE	U
1206	28	3	9421W	GE	A
1959	1	5	8750M	GE	R
1081	4	0	5926X	CT	U
624	28	5	8700X	GE	R
1579	28	5	8772Q	GE	A
2271	28	5	9496T	GE	A
141	20	0	5232J	DT	R
1468	60	5	2485T	GE	A
1942	30	2	8007K	GE	R
325	1	1	9163G	GE	R
864	10	0	4896Q	R1	U
1203	2	5	8238N	GE	R
323	90	5	8662X	GE	A
1719	1	0	8201P	GE	R
1678	20	0	8386J	GE	R
1878	1	0	4411E	R1	U
515	1	5	9064C	GE	A
2335	28	3	8773R	GE	A
110	1	6	5839H	CT	A
416	60	2	9126H	GE	A
436	1	0	4036K	R1	U
1410	100	5	4592Q	R1	A
2207	60	5	9205L	GE	A
1717	2	1	5984Y	CT	U
243	10	0	5002G	DT	R
1615	5	0	3466K	DB	U
992	1	0	2918N	GE	U
724	1	1	4419N	R1	U
1688	3	5	1166J	GE	R
384	1	5	5535H	OT	R
407	1	1	4923D	R1	U
1381	20	3	8640R	GE	R
339	100	3	8833X	GE	A
2074	1	5	8712M	GE	A
1552	1	0	4767X	R1	U
801	1	0	8253J	GE	R
1140	10	0	1984K	GE	R
1649	20	0	8669G	GE	R
1580	200	2	8290H	GE	U
1426	4	2	5843M	CT	A
994	20	3	9196B	GE	R
213	5	2	1711C	GE	U
1649	20	0	5395Y	PL	A
1739	28	5	9375K	GE	R
887	10	0	8494C	GE	R
1539	4	5	8511Y	GE	A
269	10	0	5027N	DT	U
208	60	5	1695F	GE	U
745	56	2	8788M	GE	A
1746	30	5	9054M	GE	R
1414	2	3	4670T	R1	U
1348	1	5	8831T	GE	R
128	30	5	2344J	GE	R
2166	50	0	4144D	R1	A
2274	1	0	4707R	R1	U
2025	6	0	6205N	HS	A
1071	1	2	4543D	R1	U
1333	1	0	6339P	HS	A
1279	5	3	5840J	CT	A
320	2	0	8200N	GE	R
2074	2	5	8711L	GE	A
941	30	5	1312C	GE	U
228	1	0	9058R	GE	R
1446	120	2	8362D	GE	A
899	60	0	6232B	HS	A
965	1	0	5111B	DT	R
884	60	5	8656N	GE	A
1354	60	0	6193Y	HS	A
1850	1	5	2872E	GE	U
1256	1	5	8625Y	GE	R
1409	1	0	5112C	DT	R
2075	3	4	8572E	GE	A
278	20	0	5247E	DT	R
787	50	0	5374W	PL	A
1359	35	0	1052J	GE	A
808	10	1	8812T	GE	U
1059	2	5	8739Y	GE	U
1915	1	0	5238Q	DT	R
1616	1	2	4042R	R1	U
1456	2	0	5923R	CT	R
566	56	2	8274L	GE	U
2147	6	0	9047E	GE	A
1289	60	5	8456C	GE	A
1692	4	2	2913H	GE	U
485	1	5	8764G	GE	U
1540	100	5	1287R	GE	A
181	5	0	5073B	DT	U
1010	20	2	5407N	PL	A
221	20	0	5015Y	DT	R
706	100	5	1940D	GE	U
1577	120	3	8842J	GE	A
571	120	0	6370G	HS	A
2126	28	0	5352Q	PL	A
2227	10	0	3376Q	DT	U
371	100	5	2924X	GE	U
1829	5	3	9185K	GE	A
386	5	0	5154G	DT	R
820	4	5	8745G	GE	R
1110	100	5	2730Q	GE	U
958	5	4	8551C	GE	A
1029	1	0	1597C	GE	A
1204	1	0	9634C	HS	A
1871	5	5	5890B	CT	U
1825	14	0	5052X	DT	U
1555	10	0	3477B	DB	U
2142	2	0	5342E	PL	A
583	12	0	1571Q	GE	U
858	2	0	8683B	GE	A
339	100	0	6457W	HS	A
1389	1	3	9461Y	GE	A
1407	1	1	4454K	R1	U
638	5	1	1016L	GE	U
2177	10	1	8129W	GE	U
2278	1	0	4726R	R1	U
2320	56	5	9075P	GE	A
169	1	0	5501M	OT	R
2252	1	5	8518H	GE	R
1954	60	5	2110C	GE	R
450	10	0	8316Q	GE	A
2238	1	0	3320R	DT	U
917	5	5	2832C	GE	U
1928	2	1	4842W	R1	U
639	3	0	4115N	R1	R
441	1	0	4379L	R1	U
2257	5	0	5034Y	DT	R
309	1	5	5507W	OT	R
577	2	0	3470P	DB	U
636	200	5	8598M	GE	A
1298	1	1	4341L	R1	U
1348	1	5	5527X	OT	R
1136	100	0	6417R	HS	A
204	30	5	8026K	GE	U
1578	50	0	1699K	GE	U
28	1	0	6169Q	GH	R
2185	50	0	1003T	GE	A
2125	240	1	4142B	R1	R
410	20	2	5394X	PL	A
1621	20	0	8035X	GE	R
1910	1	0	6402Y	HS	A
1892	3	1	5901N	CT	R
2267	2	0	4682K	R1	U
48	1	0	9612X	HS	A
958	1	0	6211X	HS	A
654	20	0	1656E	GE	R
585	1	1	4032F	R1	U
82	100	0	5341D	PL	A
652	100	5	1834M	GE	A
2145	1	5	8141L	GE	R
1326	8	5	9339M	GE	A
1117	1	0	6367D	HS	A
651	4	1	8768L	GE	A
1743	100	5	3145M	GE	U
417	1	7	1671Y	GE	A
242	60	5	9342Q	GE	A
2126	28	0	5179N	DT	R
2001	1	3	5327J	PL	A
1920	50	5	2899N	GE	U
1474	28	3	9422X	GE	A
1929	25	5	2711Q	GE	R
489	20	0	3338Q	DT	R
2077	1	0	6155Y	HS	A
613	1	5	8147T	GE	U
118	100	0	5126T	DT	R
1273	1	0	1932Q	GE	U
435	5	2	1626N	GE	U
1100	30	5	9483D	GE	A
1160	1	1	4559Y	R1	A
958	5	5	5947B	CT	A
519	1	0	4434J	R1	U
2213	30	5	1369C	GE	U
1293	4	5	4586J	R1	A
1168	1	0	6478Y	HS	A
110	1	6	9139B	GE	A
575	21	0	9108J	GE	R
2023	30	5	8881K	GE	A
1032	5	1	8435Y	GE	U
1811	30	5	8704D	GE	U
2014	60	2	2316X	GE	R
1310	5	0	5214K	DT	U
626	10	0	5064M	DT	R
51	2	3	8661W	GE	A
1992	5	0	1397M	GE	U
1735	1	1	4905E	R1	U
1145	5	1	8212F	GE	U
1213	1	0	6341R	HS	A
2266	4	5	9183H	GE	A
1466	50	0	5071X	DT	U
1643	5	2	1426C	GE	U
699	20	0	5164T	DT	R
104	28	5	8358X	GE	A
479	200	2	3059B	GE	U
2129	20	1	1884E	GE	U
1286	1	0	4462W	R1	U
1601	50	0	2130D	GE	A
823	60	5	2478K	GE	A
1694	1	0	5330M	PL	A
2146	60	5	8655M	GE	A
397	30	5	1572R	GE	A
2012	5	0	3098C	GE	U
1147	30	2	2734X	GE	R
1199	60	0	6234D	HS	A
39	30	5	8198L	GE	R
809	1	5	8426L	GE	U
1225	1	0	4780N	R1	U
1524	1	0	6433N	IF	R
730	100	5	8218M	GE	U
51	1	0	6125J	HS	A
2176	100	2	1598D	GE	U
158	56	5	8896F	GE	A
1432	100	5	8219N	GE	U
530	1	1	9714G	SB	A
1466	50	0	5357Y	PL	A
1988	60	5	8136F	GE	R
295	1	1	4890J	R1	U
1800	4	0	4942D	R1	R
1175	1	5	9147K	GE	A
1709	1	0	4672X	R1	U
87	60	0	6430K	HS	A
536	28	0	6471N	MD	R
1096	30	5	1907J	GE	U
893	1	0	5884Q	CT	U
220	14	1	3010K	GE	A
933	8	5	8443J	GE	A
1189	500	10	8020D	GE	U
1358	3	5	8476D	GE	A
1604	8	0	3276K	PQ	U
1797	1	0	6404C	HS	A
1390	1	0	1349B	GE	A
953	2	3	3164M	GE	U
453	90	1	8532C	GE	U
278	20	0	8385H	GE	R
525	4	0	6414N	HS	A
1253	1	5	8431R	GE	R
1711	1	1	1119X	GE	R
1130	100	2	1780Q	GE	R
316	100	3	1299J	GE	R
289	36	1	2312Q	GE	R
1005	5	1	9474P	GE	U
1729	2	0	1162E	GE	U
1098	30	5	9007C	GE	U
719	30	5	8452W	GE	U
1979	5	2	8084L	GE	U
2245	1	0	5398D	PL	A
1425	1	0	4664L	R1	U
1628	2	5	8566W	GE	R
1344	4	5	8555G	GE	R
2027	30	0	6300N	HS	A
2283	24	0	1527J	GE	R
1059	2	11	9301M	GE	R
352	100	1	2856H	GE	R
1271	5	2	9224L	GE	U
1599	2	5	8671J	GE	U
1683	200	5	2214M	GE	A
1965	1	2	8539K	GE	A
1695	5	0	2255Q	GE	U
1034	1	0	6490N	HS	A
14	5	0	3472R	DB	U
2039	28	5	8939L	GE	A
1421	2	5	8341B	GE	A
1410	100	5	1834M	GE	A
688	2	0	3323X	DT	R
1658	60	0	6215D	HS	A
1281	60	5	2668K	GE	A
1138	1	5	8517G	GE	R
1284	1	5	8762E	GE	U
1428	1	0	3497C	DB	U
830	5	0	1784X	GE	R
1672	5	1	9444C	GE	U
217	60	5	9206M	GE	A
2137	10	0	5065N	DT	R
805	60	5	1505F	GE	U
64	30	5	2833D	GE	R
1221	12	0	2481N	GE	R
1676	1	0	8272J	GE	R
1626	4	0	8411Q	GE	R
1819	60	2	8789N	GE	A
1059	2	5	9485F	GE	U
457	6	0	6134W	HS	A
1506	1	0	6171T	MD	R
1733	2	0	5012T	DT	U
1877	1	0	9186L	GE	A
55	10	0	3358R	DT	R
1794	100	1	2414C	GE	U
933	8	5	8755T	GE	A
796	30	5	3051N	GE	U
1605	50	0	4081T	R1	U
2198	6	0	6484G	HS	A
1556	1	1	1104D	GE	R
684	2	0	4815K	R1	U
2224	200	4	8799D	GE	A
904	5	5	8283Y	GE	A
1466	50	3	5355W	PL	A
45	20	0	5163R	DT	R
968	5	0	5962T	CT	U
1055	100	5	4591P	R1	A
1125	200	1	2642C	GE	U
1149	1	0	5108W	DT	U
1054	1	0	9571R	HS	A
1998	28	5	9180E	GE	A
1294	20	5	1269T	GE	A
2157	1	3	5833B	CT	A
520	100	0	6216E	HS	A
678	14	1	8581P	GE	R
1045	40	0	5139L	DT	U
222	2	0	4675C	R1	U
142	1	2	4933P	R1	U
118	100	3	5377B	PL	A
154	10	0	5006L	DT	R
209	1	1	4921B	R1	U
1608	1	1	2882Q	GE	R
1022	30	5	9042X	GE	R
1290	50	0	1966L	GE	U
356	2	0	4719J	R1	U
1116	1	1	4497Q	R1	U
1704	1	0	4718H	R1	U
1206	28	1	9489K	GE	A
653	28	5	9381R	GE	R
1595	10	0	5048Q	DT	R
1635	20	0	8541M	GE	R
40	1	5	5524R	OT	R
246	50	4	1499X	GE	U
1160	1	1	2546B	GE	A
1142	1	0	5237P	DT	R
1308	5	0	5231H	DT	R
2248	1	2	4845B	R1	U
1059	2	5	9063B	GE	U
899	120	3	8657P	GE	A
63	2	4	9254C	GE	R
1835	1	1	8876E	GE	A
1571	30	5	1977C	GE	U
860	1	5	8460G	GE	A
600	30	5	8134D	GE	A
551	10	0	5048Q	DT	R
1277	1	5	8567X	GE	R
1189	500	21	9226N	GE	R
141	20	2	8611F	GE	R
1171	1	0	6373K	IF	R
496	12	0	4029C	R1	U
1557	1	0	4463X	R1	R
1911	28	5	9366Y	GE	R
615	4	0	6413M	HS	A
1547	5	0	1606M	GE	R
470	5	0	5931E	CT	U
906	60	11	9246P	GE	R
1233	30	1	8769M	GE	A
1082	1	0	4687Q	R1	U
52	30	5	2432B	GE	A
972	2	5	5523Q	OT	U
132	5	5	5560P	OT	A
148	1	3	5835D	CT	A
1185	1	0	4008Y	R1	R
1779	60	0	6154X	HS	A
22	30	5	2190G	GE	U
807	60	5	9070J	GE	A
980	50	2	8118G	GE	A
1164	30	5	1968N	GE	U
1183	40	0	5366K	PL	A
1473	1	1	4912M	R1	U
2040	1	2	4544E	R1	U
62	96	0	5018D	DT	U
2016	30	0	6456T	HS	A
667	100	1	2838J	GE	U
671	5	0	3371K	DT	U
1198	2	0	3017T	GE	A
474	200	10	8021E	GE	U
427	6	3	4580C	R1	A
1459	1	0	4308R	R1	U
2083	20	0	2841M	GE	R
3	2	1	4919X	R1	U
2281	50	0	5360D	PL	A
2179	20	0	5417D	PL	A
1318	2	4	9426D	GE	A
1706	20	0	5245C	DT	R
1757	15	1	2272N	GE	U
779	1	0	4239D	R1	U
2312	1	0	4940B	R1	R
1049	1	0	6287X	HS	A
60	6	0	6251B	HS	A
881	28	5	8770N	GE	A
34	5	3	5317W	PL	A
1442	1	1	3033P	GE	U
1492	100	2	2180R	GE	U
85	30	3	9166K	GE	A
196	5	1	1016L	GE	U
1940	1	0	9442Y	GE	A
1325	30	5	9051J	GE	R
269	10	0	2267H	GE	U
364	1	1	4026X	R1	U
478	20	0	5161P	DT	R
2209	28	0	8868R	GE	R
662	200	2	2544X	GE	U
1807	1	0	4222F	R1	U
894	3	5	5510B	OT	A
582	30	0	5124Q	DT	U
787	25	0	5193H	DT	U
135	1	0	4452H	R1	U
1039	1	1	4878R	R1	U
410	20	0	5396B	PL	A
502	8	5	2738D	GE	R
104	28	3	4179Y	R1	A
773	2	5	2014B	GE	U
1335	8	5	8057C	GE	R
1551	4	0	5930D	CT	U
1773	5	0	5130B	DT	U
1669	7	0	5912E	CT	A
1393	1	0	3495Y	DB	U
1326	8	5	2560R	GE	A
2143	50	2	1824B	GE	R
1157	20	0	5016B	DT	R
1318	2	3	9101B	GE	A
1197	30	5	2488Y	GE	U
1128	30	0	9151P	GE	R
1797	1	0	6399T	HS	A
1117	2	5	9429G	GE	A
1329	60	5	1937Y	GE	U
125	1	5	8796Y	GE	R
972	2	5	1754H	GE	U
975	56	5	4322L	R1	A
896	3	0	2446R	GE	R
37	5	0	5159M	DT	U
971	30	5	1327W	GE	R
870	300	0	5224Y	DT	R
1010	20	0	5413X	PL	A
83	100	5	2339D	GE	U
232	1	2	1770E	GE	U
1148	100	2	1062X	GE	U
1619	100	5	1566K	GE	U
982	1	0	5848T	CT	R
433	200	2	1874P	GE	U
644	50	0	5328K	PL	A
1210	28	5	8690J	GE	A
7	4	5	9499Y	GE	R
1705	4	5	9436P	GE	R
1352	1	0	5208D	DT	U
1117	2	5	8779C	GE	A
403	5	0	1607N	GE	U
1158	100	3	8646C	GE	A
1324	1	0	8614J	GE	A
2179	20	2	5411T	PL	A
275	5	1	9039R	GE	U
150	1	11	9212W	GE	R
1899	24	0	1526H	GE	R
1272	5	0	3474W	DB	U
473	15	5	5960Q	CT	R
708	50	3	5326H	PL	A
2203	30	0	8465M	GE	A
1247	100	5	3141H	GE	U
2306	1	3	5958N	CT	A
281	1	1	4041Q	R1	U
1423	5	1	9445D	GE	U
1161	100	1	2721F	GE	U
2120	30	5	2013Y	GE	R
2340	28	5	9159C	GE	A
299	1	3	5979Q	CT	A
1817	1	5	8334P	GE	U
897	1	5	8760C	GE	R
255	5	0	1524F	GE	U
2206	60	5	8335Q	GE	R
276	1	0	3391L	DT	U
1727	60	0	6451M	HS	A
173	4	0	5925W	CT	U
748	3	5	8713N	GE	R
1976	4	5	4584G	R1	A
2291	1	5	1279H	GE	U
2239	10	0	1984K	GE	R
15	2	5	3128P	GE	A
1406	28	5	9156X	GE	R
439	1	3	2692Q	GE	U
497	50	2	1013H	GE	U
968	5	0	2396D	GE	U
299	1	3	8294M	GE	A
1863	30	5	8757X	GE	A
1866	1	0	5916J	CT	U
63	2	2	3106L	GE	U
588	1	0	3341W	DT	U
1163	1	2	4505D	R1	U
1742	60	5	1090J	GE	R
1398	21	0	3339R	DT	U
1113	21	1	1621H	GE	R
1389	1	3	9457R	GE	A
429	1	5	2614N	GE	U
1940	1	0	5849W	CT	A
1786	60	5	1443Y	GE	R
1453	100	1	1322N	GE	U
2127	200	1	8748K	GE	R
98	120	2	1648R	GE	A
1035	20	0	3300Q	DT	U
154	10	1	8254K	GE	R
1840	8	5	9327X	GE	A
1361	10	1	2951H	GE	U
422	1	0	8851W	GE	U
623	84	0	6203L	HS	A
2247	2	0	4660G	R1	U
456	200	5	4055K	R1	U
722	24	0	5097G	DT	R
1918	100	0	2808T	GE	R
1694	1	3	5327J	PL	A
1429	20	0	5197M	DT	R
1760	100	2	2688L	GE	U
276	1	1	3103H	GE	U
1699	2	3	9077R	GE	A
788	1	1	4795J	R1	U
206	4	2	1394J	GE	U
1280	2	3	1698J	GE	A
2189	1	2	4280G	R1	U
1318	2	5	9102C	GE	A
26	1	1	4946H	R1	U
1217	50	3	5371Q	PL	A
1849	20	0	5195K	DT	R
1964	90	5	8457D	GE	A
324	1	0	6297K	GH	R
2211	90	5	1007B	GE	A
502	8	5	2739E	GE	R
354	30	5	2206D	GE	U
470	5	0	1390E	GE	U
1657	1	0	4790D	R1	U
913	100	1	1272Y	GE	U
951	50	2	4072H	R1	U
1803	1	0	4590N	R1	U
1327	100	5	2761H	GE	U
1304	2	5	9294E	GE	A
1424	1	3	4760M	R1	U
1338	30	5	8215J	GE	R
2009	100	2	1798P	GE	R
763	200	2	1249R	GE	U
604	30	0	9602J	HS	A
1239	28	5	3036T	GE	A
2175	30	5	9050H	GE	R
686	1	0	3096Y	GE	U
599	25	3	1898X	GE	R
2001	1	0	5330M	PL	A
363	100	5	8584T	GE	A
1630	2	0	4812G	R1	U
1784	7	0	6307Y	MD	R
247	28	5	9145H	GE	R
332	5	5	8183Q	GE	A
1721	28	5	8170B	GE	A
1841	5	0	6136Y	HS	A
2088	1	5	3064G	GE	R
754	192	5	8814X	GE	R
455	30	5	9120B	GE	U
409	20	0	9322P	GE	A
1994	30	1	1693D	GE	U
538	4	5	8632H	GE	R
850	500	21	9225M	GE	R
1797	1	0	6408G	HS	A
875	50	0	4145E	R1	A
1012	28	0	5178M	DT	R
818	1	0	9320M	GE	A
1123	50	5	1463B	GE	U
1508	50	2	2844Q	GE	U
534	4	5	8592F	GE	R
1059	2	11	9261K	GE	R
2184	56	5	9337K	GE	A
1826	5	0	1853M	GE	R
240	1	5	8899J	GE	A
919	60	5	8256M	GE	A
1176	1	0	1913Q	GE	R
357	4	5	9736K	SB	A
1973	21	0	2714W	GE	R
1995	1	2	4311X	R1	U
341	40	0	5380E	PL	A
9	1	5	8244X	GE	U
1966	1	0	4915Q	R1	U
1531	60	5	8258P	GE	A
1061	28	5	8187X	GE	A
510	1	5	5525T	OT	R
1216	2	2	2352T	GE	U
1427	10	0	3398W	DT	U
2114	30	5	9008D	GE	U
115	5	0	1807D	GE	R
1867	1	0	5420G	PL	A
1244	50	0	5201R	DT	R
249	3	2	8284B	GE	A
947	1	5	9310B	GE	A
14	5	0	2509C	GE	U
2341	16	5	8554F	GE	R
2125	120	1	4082W	R1	R
445	5	1	8874C	GE	U
80	30	5	2458J	GE	U
139	30	5	2161R	GE	R
1361	10	0	3390K	DT	U
810	12	5	8403G	GE	A
163	50	5	3065H	GE	U
462	100	1	1484D	GE	U
1797	1	0	6401X	HS	A
332	5	4	8552D	GE	A
1771	1	1	1781R	GE	U
1523	28	2	1350C	GE	U
1346	1	5	9378N	GE	A
2068	1	3	4760M	R1	U
676	30	0	6450L	HS	A
513	1	0	6289B	HS	A
2210	30	5	2276T	GE	A
1625	10	0	3374N	DT	U
1244	50	3	1895R	GE	R
1131	1	0	5032W	DT	R
385	30	5	9049G	GE	R
1476	8	5	2650L	GE	R
1585	1	0	4893M	R1	U
840	30	5	1183G	GE	U
1370	28	5	8434X	GE	A
1722	60	2	9115R	GE	A
1270	5	1	9392H	GE	U
1303	5	0	5963W	CT	U
1128	30	2	9393J	GE	R
399	112	0	9129L	GE	A
2011	60	5	8869T	GE	A
1606	4	5	8846N	GE	R
90	50	3	5362F	PL	A
2186	2	0	4806Y	R1	U
1600	50	3	1897W	GE	R
819	28	5	9387C	GE	R
573	120	5	8234J	GE	A
1598	200	1	1110K	GE	U
1211	20	2	5410R	PL	A
2129	20	0	3301R	DT	U
1043	60	0	4150K	R1	A
1500	1	5	9435N	GE	U
2075	3	5	8348J	GE	A
1806	1	1	8802G	GE	A
2262	30	5	9023X	GE	R
1553	1	5	5546X	OT	U
413	100	5	4595W	R1	A
332	5	4	5997P	CT	A
743	30	5	8374R	GE	A
2165	1	1	2813C	GE	R
138	24	0	5096F	DT	R
418	20	0	2501P	GE	U
1975	1	5	8673L	GE	R
2097	20	0	8453X	GE	A
2091	5	0	1785Y	GE	R
1607	30	4	1936X	GE	U
1865	50	0	3361X	DT	U
1596	1	5	8483L	GE	U
859	3	0	5315R	PL	A
562	3	0	8444K	GE	U
1016	1	5	8522M	GE	U
1790	1	1	4559Y	R1	A
2	56	5	9335H	GE	A
565	8	5	8114C	GE	A
521	1	0	6376N	IF	R
107	1	0	9576B	HS	A
46	28	5	8940M	GE	A
164	1	0	1642K	GE	U
2100	30	5	8090T	GE	A
1391	5	0	4598B	R1	U
758	1	5	2427R	GE	U
92	50	0	3162K	GE	U
1241	10	1	8812T	GE	U
558	50	2	1357K	GE	U
1728	1	0	8570C	GE	A
1457	1	5	1204J	GE	U
1747	10	0	3367F	DT	R
685	3	5	5505R	OT	A
1259	4	2	8281W	GE	A
41	50	5	8019C	GE	A
2142	2	0	1808E	GE	A
2089	3	3	4914P	R1	U
1449	30	5	9424B	GE	R
1970	1	0	5320B	PL	A
878	6	0	3047J	GE	U
1265	90	5	8607B	GE	U
1389	1	3	9459W	GE	A
1012	28	3	1614Y	GE	R
1178	1	7	5897J	CT	A
1117	2	3	9035M	GE	A
1505	28	1	9477T	GE	R
1515	1	0	5888X	CT	A
1212	30	5	8504N	GE	R
79	200	4	8367J	GE	A
1313	1	1	9379P	GE	A
1470	1	1	9028E	GE	A
1769	30	5	3050M	GE	U
1056	5	0	5216M	DT	U
245	1	0	2578Q	GE	U
708	50	0	5329L	PL	A
1415	1	0	5336W	PL	A
110	1	0	5837F	CT	A
161	1	3	5834C	CT	A
1417	60	1	3012M	GE	U
1589	60	5	1095P	GE	U
1720	1	5	1224K	GE	U
1340	5	0	9647R	HS	A
1329	60	5	8903N	GE	A
62	96	1	1010E	GE	U
876	2	3	9026C	GE	A
1819	60	5	3169T	GE	A
1946	3	5	8727H	GE	R
327	10	0	6109M	HS	A
182	150	5	1959D	GE	U
1982	4	5	9396M	GE	R
2227	10	1	2964B	GE	U
1876	30	5	2242B	GE	R
823	60	2	9282M	GE	A
742	1	0	8699W	GE	U
184	1	0	6213B	HS	A
286	2	0	8383F	GE	A
1248	10	0	5008N	DT	R
1569	5	0	5031T	DT	U
524	4	5	8289G	GE	A
1059	2	11	9279J	GE	R
1048	56	5	8500J	GE	A
1698	100	5	4594T	R1	A
241	10	0	9406C	GE	R
405	50	2	2522R	GE	R
2201	30	5	2147B	GE	U
1440	60	5	2287J	GE	A
465	5	0	3460D	DB	U
1986	20	0	8558K	GE	U
883	100	5	4591P	R1	A
2265	10	0	1981G	GE	R
1028	1	0	5891C	CT	A
717	10	0	6292E	HS	A
1957	200	2	1805B	GE	A
1938	1	0	2746M	GE	R
1445	20	2	9009E	GE	A
508	100	5	8586X	GE	A
194	30	5	8027L	GE	U
2297	10	0	9201G	GE	R
1541	40	0	3113W	GE	A
184	5	5	8184R	GE	A
256	1	0	5046N	DT	U
465	5	0	1323P	GE	U
991	2	0	8817C	GE	U
340	30	2	9116T	GE	A
744	1	5	1451J	GE	R
892	1	2	8350L	GE	A
2101	60	5	9302N	GE	U
1059	2	11	9267R	GE	R
612	30	5	9197C	GE	R
1797	1	0	6406E	HS	A
2328	4	2	2774B	GE	U
1514	30	1	1692C	GE	U
1404	20	0	5227D	DT	R
870	100	0	5196L	DT	U
361	1	0	6372J	HS	A
430	5	5	8379B	GE	A
282	28	5	4398L	R1	A
1200	120	0	9616D	HS	A
686	6	0	1511M	GE	R
1377	1	0	4038M	R1	U
1330	5	0	8420E	GE	U
506	28	2	9357L	GE	R
2028	30	0	6435Q	HS	A
1223	4	0	8224W	GE	R
1264	30	4	1916W	GE	U
13	6	5	9308X	GE	R
1389	1	5	9460X	GE	A
316	100	0	5076E	DT	R
2109	30	5	8131Y	GE	A
852	1	2	2781J	GE	U
481	5	0	4678F	R1	U
46	28	5	8679T	GE	U
1740	1	5	4380M	R1	A
2292	10	0	5230G	DT	R
251	1	5	5555J	OT	R
1837	2	2	2091C	GE	R
1484	12	5	1076P	GE	U
1663	30	3	8562P	GE	R
1699	2	4	9425C	GE	A
934	8	5	2380G	GE	R
2317	2	0	4862X	R1	U
1633	100	1	1512N	GE	U
1117	2	5	9036N	GE	A
658	1	5	8519J	GE	R
1671	28	5	8604W	GE	A
1767	1	0	4696E	R1	U
1007	60	3	8840G	GE	A
1144	3	3	5303D	PL	A
2263	6	0	4325P	R1	U
184	5	4	8553E	GE	A
572	4	2	5852B	CT	A
1383	4	0	6320P	HS	A
2022	1	0	9440W	GE	A
168	2	0	4729X	R1	U
576	1	0	2883R	GE	U
665	1	5	9169N	GE	A
422	1	0	5875F	CT	U
1763	1	2	1172Q	GE	U
2046	5	0	8422G	GE	U
365	50	5	2732T	GE	A
74	1	1	4416K	R1	U
61	1	5	5520M	OT	R
714	30	5	2388Q	GE	A
1618	1	0	6491P	HS	A
669	30	0	6301P	HS	A
61	1	11	9216C	GE	R
1997	90	5	1147J	GE	U
673	25	0	3336N	DT	U
553	200	2	2422L	GE	U
1059	2	5	9358M	GE	U
235	1	1	2461M	GE	U
1318	2	3	9099X	GE	A
69	8	5	8445L	GE	R
1122	1	0	5257Q	DT	R
2218	1	5	1581F	GE	R
681	10	0	6126K	HS	A
1090	200	11	9208P	GE	R
530	1	0	3310F	DS	U
582	90	3	3190X	GE	R
337	20	0	1655D	GE	R
1015	4	5	8885P	GE	A
1226	30	5	8889W	GE	U
1753	1	5	2596P	GE	U
1498	2	2	5844N	CT	A
571	120	3	8653K	GE	A
903	5	0	4748X	R1	U
225	1	0	9580F	HS	A
518	20	0	5249G	DT	R
1105	30	5	9365X	GE	R
1948	100	5	2724J	GE	U
952	30	5	1343Q	GE	U
1382	60	3	8841H	GE	A
200	1	0	9288W	GE	A
375	4	5	8823J	GE	A
1938	1	0	5987D	CT	R
493	1	0	4857P	R1	U
617	100	4	1934T	GE	U
859	3	3	5312N	PL	A
1173	50	5	1628Q	GE	R
1967	4	0	6365B	HS	A
608	20	0	5171E	DT	R
701	120	1	4332B	R1	R
2182	1	0	8644Y	GE	R
231	28	5	9370E	GE	U
774	30	5	8248D	GE	U
114	1	0	9604L	GH	R
42	2	3	8415X	GE	A
264	7	0	8800E	GE	A
48	1	0	6496X	HS	A
655	60	2	4190M	R1	A
1097	100	5	2566C	GE	U
248	1	1	4891K	R1	U
839	100	3	2502Q	GE	A
372	10	0	3476Y	DB	U
2111	3	5	5561Q	OT	A
965	1	1	2887Y	GE	R
1415	1	0	4569L	R1	U
921	5	0	1034K	GE	U
1151	1	0	4647N	R1	A
520	100	3	8647D	GE	A
160	24	5	9446E	GE	R
522	60	2	5851Y	CT	A
1429	20	0	8501K	GE	R
113	100	1	1512N	GE	U
377	28	5	2792Y	GE	U
1651	50	0	5350N	PL	A
34	5	0	3473T	DB	U
257	60	5	1900B	GE	R
721	90	2	4198Y	R1	U
2324	5	0	3480E	DB	U
1631	30	5	8883M	GE	R
1282	1	0	6330E	GH	R
2226	1	5	9464D	GE	R
309	1	5	8548X	GE	R
659	100	0	5076E	DT	R
1311	1	0	4348W	R1	R
626	10	0	8491X	GE	R
1582	10	1	2816F	GE	U
335	1	2	2310N	GE	A
845	10	1	2949F	GE	U
1215	1	0	8043H	GE	R
2089	3	3	4599C	R1	U
370	100	5	4594T	R1	A
2217	3	0	5403J	PL	A
1747	10	0	9408E	GE	R
1381	10	1	8262W	GE	U
1524	2	5	8715Q	GE	R
514	1	0	8373Q	GE	A
1845	7	0	6313G	GH	R
1896	15	0	8732N	GE	A
2168	1	5	1744T	GE	U
2313	1	1	4699H	R1	U
1031	30	5	1370D	GE	U
1059	2	11	9259H	GE	R
56	28	5	8627C	GE	A
61	1	5	1509K	GE	R
1026	2	0	4799N	R1	U
54	2	3	4669R	R1	U
1629	10	0	2528C	GE	U
1591	20	0	8464L	GE	R
933	8	5	8754R	GE	A
333	30	0	6456T	HS	A
2113	1	0	6255F	HS	A
1690	2	0	2820K	GE	R
384	1	5	8826M	GE	R
413	100	5	8389M	GE	A
129	1	5	8432T	GE	R
926	28	5	8695P	GE	A
1408	100	0	6280M	HS	A
1699	2	3	9033K	GE	A
272	4	2	9118X	GE	A
1867	1	5	9146J	GE	R
134	1	0	6403B	HS	A
507	1	1	4005T	R1	U
1935	1	1	8877F	GE	A
302	100	1	1272Y	GE	U
687	1	11	9213X	GE	R
795	1	1	8708H	GE	A
2046	5	0	5131C	DT	U
1931	112	5	9171Q	GE	A
484	21	0	8002E	GE	A
1059	2	5	2263D	GE	U
34	5	0	5318X	PL	A
630	1	3	9089J	GE	A
1701	1	0	8526R	GE	R
1292	360	0	6243N	HS	A
1951	1	2	1742Q	GE	U
2015	6	0	3048K	GE	U
1565	1	5	1201F	GE	U
1603	30	5	8400D	GE	R
907	30	1	9109K	GE	R
2095	60	5	9203J	GE	A
2260	1	1	4285M	R1	U
290	2	0	4677E	R1	U
1574	1	0	4937W	R1	U
944	1	0	4759L	R1	U
505	90	5	8811R	GE	U
487	5	1	2026P	GE	U
1486	10	0	9299K	GE	R
1754	60	5	8003F	GE	R
390	50	2	4061R	R1	U
2253	200	2	1873N	GE	U
1178	1	0	9611W	HS	A
1057	5	1	9416N	GE	U
660	1	5	9286R	GE	R
293	1	0	5132D	DT	R
806	200	4	8797B	GE	A
2193	60	0	9573W	HS	A
1059	2	11	9258G	GE	R
1888	100	5	4593R	R1	A
527	30	5	2236Q	GE	R
1261	10	0	5049R	DT	R
2316	1	0	6392K	HS	A
668	60	3	8659R	GE	A
1622	30	5	8273K	GE	U
1536	1	1	3054R	GE	U
27	1	0	4937W	R1	U
930	60	5	8458E	GE	A
382	4	0	1465D	GE	U
889	100	5	2430X	GE	U
2276	1	0	3341W	DT	U
737	30	5	2208F	GE	U
1301	60	5	8654L	GE	A
1059	2	5	9324R	GE	U
2226	1	5	5558M	OT	R
1272	5	0	2875H	GE	U
402	1	5	2811Y	GE	U
587	10	0	2315W	SB	R
491	7	0	6317L	GH	R
1680	60	5	8520K	GE	A
646	1	3	8651H	GE	A
2134	20	0	5240T	DT	R
777	30	11	9230T	GE	R
593	30	0	6352H	HS	A
1880	56	5	8792R	GE	A
856	1	0	6170R	GH	R
1418	1	0	4855M	R1	U
306	1	2	2971J	GE	U
622	2	0	4572P	R1	A
1041	56	5	8063J	GE	A
2192	4	0	5969E	CT	R
44	10	0	5001F	DT	R
2323	30	5	8401E	GE	R
1687	100	5	1199D	GE	U
718	2	0	8071T	GE	A
291	10	0	2016D	GE	U
2126	28	3	1615B	GE	R
726	28	5	9495R	GE	A
230	100	5	1255C	GE	A
304	1	5	8345F	GE	U
1551	4	0	1377L	GE	U
81	1	0	4342M	R1	U
1621	20	0	5162Q	DT	R
686	1	0	3471Q	DB	U
29	100	5	3062E	GE	U
933	8	5	8574G	GE	A
1021	10	0	8315P	GE	A
1392	5	0	8878G	GE	R
270	1	0	8697R	GE	A
1228	3	1	4854L	R1	U
1985	30	5	8332M	GE	R
1490	60	5	2095G	GE	A
35	4	1	9041W	GE	U
2108	28	11	9234B	GE	R
902	20	0	5234L	DT	R
532	25	0	3325B	DT	U
1569	5	0	3457Y	DB	U
962	100	5	1629R	GE	U
628	30	5	1504E	GE	U
1196	1	5	9454N	GE	R
2307	10	1	8271H	GE	U
1107	1	2	9414L	GE	A
511	4	0	6322R	HS	A
957	1	0	8192E	GE	R
473	15	5	8078E	GE	R
1744	1	2	1441W	GE	R
922	100	5	1683N	GE	U
2222	1	5	8171C	GE	U
1017	1	0	6219H	HS	A
442	30	0	8897G	GE	A
1479	100	5	4595W	R1	A
1725	20	0	5250H	DT	R
1498	2	2	9402W	GE	A
1104	240	1	3116B	GE	A
2243	5	0	8892B	GE	R
1243	5	1	8609D	GE	U
2067	1	0	6478Y	HS	A
58	10	0	6127L	HS	A
1230	6	3	4579B	R1	A
1456	2	0	8191D	GE	R
460	1	11	9223K	GE	R
256	1	1	2460L	GE	U
2281	25	0	5189D	DT	U
1422	20	2	4170L	R1	U
1350	2	0	4813H	R1	U
1462	1	0	6425E	HS	A
736	120	2	2055E	GE	U
118	100	3	2454E	GE	R
2222	1	0	3475X	DB	U
386	5	1	1638F	GE	R
1405	2	0	4811F	R1	U
186	3	5	5504Q	OT	A
288	1	1	1892N	GE	R
21	1	6	5838G	CT	A
265	5	1	1525G	GE	U
229	1	5	4090G	R1	R
2290	100	5	1822X	GE	A
1328	1	0	6477X	HS	A
1583	1	0	8055Y	GE	R
1201	20	0	8349K	GE	R
48	1	0	9613Y	HS	A
1554	60	4	1500Y	GE	U
2002	1	5	1745W	GE	U
986	56	5	9096R	GE	A
1613	28	0	9625N	HS	A
82	200	2	1806C	GE	A
437	30	5	1313D	GE	U
292	50	0	4321K	R1	R
131	15	2	8819E	GE	A
1167	1	0	6426F	HS	A
781	1	0	6375M	IF	R
273	10	1	2824P	GE	U
693	30	5	2283E	GE	A
77	4	0	6326Y	HS	A
1535	30	5	8837D	GE	R
438	1	0	4708T	R1	U
1117	2	5	8638P	GE	A
260	1	6	5832Y	CT	A
1987	50	2	1011F	GE	U
577	6	0	5118J	DT	R
216	30	5	2136K	GE	R
1741	3	3	2670M	GE	A
33	1	0	3393N	DT	U
467	5	0	5144R	DT	U
82	100	3	5338Y	PL	A
235	1	0	5047P	DT	U
1681	30	0	4216X	R1	A
1867	1	3	5419F	PL	A
958	5	5	8182P	GE	A
2115	50	3	5382G	PL	A
2301	30	5	8600P	GE	R
1949	1	0	8074Y	GE	A
1400	1	11	9492N	GE	R
2043	100	0	6416Q	HS	A
1428	2	5	2001H	GE	R
1844	200	1	2174K	GE	U
606	2	3	4669R	R1	U
932	30	5	1946K	GE	U
1798	3	0	8530Y	GE	R
2052	200	2	3059B	GE	U
368	1	5	1750D	GE	U
794	8	5	9382T	GE	A
532	25	1	1404X	GE	U
1216	2	4	9253B	GE	R
1037	3	3	5313P	PL	A
630	1	3	9085E	GE	A
2121	1	5	8430Q	GE	R
89	1	0	6423C	HS	A
2310	50	2	1623K	GE	R
1437	7	0	6314H	GH	R
2102	1	2	1440T	GE	U
1815	1	0	3496B	DB	U
1104	240	1	4094L	R1	R
501	5	1	5985B	CT	A
1452	1	2	1093M	GE	U
957	1	0	5924T	CT	R
960	1	1	4691X	R1	U
343	30	5	8512B	GE	R
512	1	0	9467G	GE	A
1992	5	0	5088T	DT	U
1936	1	0	8698T	GE	A
1901	1	0	8463K	GE	A
1035	20	1	1889K	GE	U
1923	50	0	6217F	HS	A
1182	60	0	9633B	HS	A
2272	200	4	1850J	GE	R
1287	1	2	4701K	R1	U
931	2	5	8905Q	GE	A
1266	30	5	1944H	GE	U
1106	1	0	6424D	HS	A
314	15	0	9608Q	IF	R
2342	30	5	9398P	GE	A
287	1	5	8830R	GE	A
149	4	0	1375J	GE	U
2291	1	5	5548B	OT	U
808	10	1	5886T	CT	U
1351	90	0	8710K	GE	A
1733	2	1	9143F	GE	U
1127	5	0	8891Y	GE	R
2335	28	5	8774T	GE	A
918	200	5	1953T	GE	R
271	7	0	1474N	GE	A
1375	4	5	9134R	GE	R
1129	150	3	8650G	GE	A
1003	30	0	1444B	GE	R
2045	90	5	8810Q	GE	U
1341	4	0	6412L	HS	A
540	30	4	2507Y	GE	U
933	12	5	2250K	GE	A
1828	90	5	8838E	GE	U
865	20	0	5414Y	PL	A
668	30	0	6353J	HS	A
1659	50	2	2523T	GE	R
30	1	0	6488L	HS	A
644	50	2	4072H	R1	U
1368	1	0	4551M	R1	R
2228	1	1	2319C	GE	U
1753	1	5	5537K	OT	U
855	2	0	4577X	R1	A
648	1	2	4470G	R1	U
315	90	5	9404Y	GE	A
995	28	5	9311C	GE	A
2331	5	0	6227R	HS	A
312	30	5	8589C	GE	R
65	1	0	4848E	R1	U
1016	1	11	9270X	GE	R
338	5	0	1060T	GE	U
471	1	5	8408M	GE	R
768	30	5	2995P	GE	A
770	1	0	3319Q	DT	U
1843	1	0	9443B	GE	A
1133	4	5	9438R	GE	R
1480	1	0	8828P	GE	U
1639	1	5	8228C	GE	U
1556	1	0	5324F	PL	A
1085	1	0	4176T	R1	U
1024	240	1	3117C	GE	A
1556	2	0	3275J	PQ	U
234	6	2	9360P	GE	A
620	3	3	2554K	GE	R
1084	1	2	4931M	R1	U
1299	100	5	8231F	GE	U
8	5	0	5168B	DT	U
2041	1	0	4774G	R1	U
1706	20	0	8306E	GE	R
517	25	5	9106G	GE	R
1129	50	0	6209T	HS	A
2197	30	0	9603K	HS	A
2195	20	0	8524P	GE	R
1604	3	0	5308J	PL	A
1033	28	5	8606Y	GE	A
2144	100	5	2231K	GE	U
1625	10	0	3488N	DB	U
1042	56	5	9093N	GE	A
1831	6	0	6485H	HS	A
92	50	0	5072Y	DT	U
187	60	0	6357N	HS	A
71	60	3	2592K	GE	A
1372	200	2	2100M	GE	U
1059	2	5	8682Y	GE	U
1093	30	5	2011W	GE	R
16	1	3	9355J	GE	R
72	28	5	8702B	GE	R
307	30	3	8887R	GE	R
431	1	0	9579E	HS	A
2154	1	0	4378K	R1	U
1802	14	0	1210Q	GE	A
935	2	0	4571N	R1	A
530	1	1	1888J	SB	U
1677	20	0	3317N	DT	U
1091	30	5	2361G	GE	U
1749	1	5	8486P	GE	U
1725	20	0	8388L	GE	R
1198	2	0	5975L	CT	A
2164	100	2	9394K	GE	R
104	28	5	9317J	GE	A
650	30	5	8450R	GE	U
1604	3	4	1258F	GE	R
2200	3	1	1131M	GE	R
1387	1	0	4743P	R1	U
1242	1	0	4556T	R1	R
1963	1	0	8843K	GE	R
521	3	5	8675N	GE	R
340	30	2	9175X	GE	A
326	100	2	1163F	GE	U
1899	24	0	5090X	DT	R
2035	2	0	1160C	GE	U
1991	28	5	9142E	GE	A
739	1	0	8527T	GE	R
1972	1	5	8761D	GE	U
392	1	5	5550D	OT	U
923	5	5	2129C	GE	A
1990	28	1	9488J	GE	A
2293	10	0	3368G	DT	R
954	50	0	1966L	GE	U
1957	100	3	5337X	PL	A
1693	30	5	8594H	GE	A
374	10	0	2308L	GE	R
776	5	0	1645N	GE	U
1800	1	0	4939Y	R1	R
1517	20	0	3318P	DT	U
1812	3	0	9487H	GE	U
835	28	5	9289X	GE	A
712	1	1	8709J	GE	A
671	5	0	3485K	DB	U
675	60	5	2109B	GE	R
2225	1	0	4643J	R1	U
1059	2	11	9297H	GE	R
1059	2	11	9263M	GE	R
2325	1	0	5390Q	PL	A
95	56	5	9060W	GE	A
483	20	0	8542N	GE	R
1668	21	0	2715X	GE	R
243	10	0	9200F	GE	R
365	25	0	5189D	DT	U
2029	28	5	8185T	GE	A
1962	30	5	1969P	GE	U
1342	5	0	2257T	GE	U
1544	1	2	9030G	GE	A
1586	50	0	1787C	GE	U
544	200	5	1953T	GE	R
477	200	0	5040G	DT	U
1973	7	1	2709N	GE	U
1809	120	2	9380Q	GE	A
2108	28	5	8023G	GE	R
372	10	0	5153F	DT	U
1268	28	5	8623W	GE	R
1673	100	5	1270W	GE	A
2325	2	0	3278M	PQ	U
1321	1	0	4644K	R1	U
1789	200	4	9344T	GE	A
277	24	5	8630F	GE	R
1111	60	0	8785J	GE	A
2308	56	5	9062Y	GE	A
603	120	5	1157X	GE	U
408	28	11	9235C	GE	R
489	20	0	2527B	GE	R
906	60	5	9022W	GE	R
2150	96	0	5018D	DT	U
740	3	0	2448W	GE	R
329	2	5	9448G	GE	A
1389	1	0	9641K	HS	A
1274	30	5	2456G	GE	U
17	140	2	9148L	GE	A
1820	5	0	5973J	CT	A
1447	2	0	5898K	CT	R
826	200	2	2099L	GE	U
1358	1	0	6254E	HS	A
1745	1	0	5899L	CT	R
444	10	0	6338N	HS	A
1141	100	3	8724E	GE	A
982	1	0	9441X	GE	R
1830	50	0	1003T	GE	A
1052	100	5	2186C	GE	U
1722	60	2	9174W	GE	A
629	1	0	5400F	PL	A
20	30	0	4238C	R1	U
1999	28	5	9372G	GE	R
1839	20	0	1214X	GE	U
279	28	5	9367B	GE	R
746	6	0	6302Q	HS	A
1234	1	2	2974M	GE	U
2312	4	0	4943E	R1	R
2006	1	0	4917T	R1	U
428	30	5	1516T	GE	U
1269	1	0	4948K	R1	U
1905	60	2	8361C	GE	A
1839	20	0	5063L	DT	U
1064	30	5	8399C	GE	R
586	1	2	4510J	R1	U
1977	30	5	8394T	GE	R
1068	1	0	4758K	R1	U
1047	25	5	2707L	GE	R
1135	1	1	1886G	GE	U
2142	1	0	3478C	DB	U
383	1	2	4931M	R1	U
426	1	0	5879K	CT	U
1728	1	0	5892D	CT	A
1055	100	5	8505P	GE	A
2245	1	3	1658G	GE	A
759	2	0	4685N	R1	U
1885	1	2	4447C	R1	U
1104	120	1	4333C	R1	R
316	100	3	5361E	PL	A
1745	1	0	8730L	GE	A
76	1	5	8126Q	GE	U
1617	10	1	8269F	GE	U
332	5	5	5948C	CT	A
588	1	0	1630T	GE	U
1872	56	5	8497F	GE	A
1773	5	0	8421F	GE	U
2018	100	5	1165H	GE	A
1412	2	1	4920Y	R1	U
1731	30	5	9055N	GE	R
572	4	2	9463C	GE	A
2005	40	0	3114X	GE	A
2034	2	3	4670T	R1	U
54	2	0	4668Q	R1	U
761	5	5	1466E	GE	U
1570	50	2	1561E	GE	R
964	28	5	9331D	GE	R
2119	1	2	4122Y	R1	U
194	30	5	8010N	GE	U
2150	96	1	1010E	GE	U
1932	90	0	4328T	R1	U
78	2	5	2157M	GE	U
228	5	0	1783W	GE	R
503	1	0	8668F	GE	U
786	1	0	9150N	GE	R
1970	1	3	5319Y	PL	A
1930	100	0	3093T	GE	U
827	1	2	4071G	R1	U
92	50	0	5358B	PL	A
2053	60	5	9202H	GE	A
1089	2	5	8354Q	GE	R
261	100	5	1445C	GE	R
504	60	5	8163P	GE	A
1454	2	0	3482G	DB	U
2135	1	0	1080W	GE	U
1460	3	5	8714P	GE	R
180	100	5	3016R	GE	R
35	4	1	5870Y	CT	U
1302	100	5	2939Q	GE	U
1280	1	1	4001N	R1	U
362	90	5	8746H	GE	R
477	200	2	2419H	GE	U
210	30	5	2166B	GE	R
951	50	3	5325G	PL	A
920	1	2	1288T	GE	U
150	1	5	5508X	OT	R
21	1	0	9136W	GE	A
86	100	5	1835N	GE	A
373	4	0	6323T	HS	A
458	28	5	9376L	GE	R
236	5	0	1784X	GE	R
1174	1	5	8365G	GE	U
1717	2	1	2345K	GE	U
2241	30	5	2366M	GE	U
868	30	5	2012X	GE	R
1782	5	0	5106R	DT	U
252	25	0	5221T	DT	U
2327	10	1	8264Y	GE	U
171	1	5	2763K	GE	U
1635	20	0	5115F	DT	R
683	28	5	9290Y	GE	A
1179	30	3	8561N	GE	R
1184	30	5	9045C	GE	R
402	1	5	5543R	OT	U
791	56	2	1664N	GE	U
395	1	1	4473K	R1	R
2033	6	0	6480C	HS	A
132	5	5	9493P	GE	A
812	10	1	1594X	GE	A
1020	1	5	8285C	GE	U
782	200	0	5038E	DT	U
1581	200	2	2294R	GE	U
316	100	0	5364H	PL	A
340	30	2	9112N	GE	A
1588	10	0	1195X	GE	U
1796	1	0	5976M	CT	A
1602	2	0	5213J	DT	U
997	20	0	1609Q	GE	R
1941	8	5	8417B	GE	R
1662	30	5	9056P	GE	R
627	28	5	8696Q	GE	A
1926	20	0	5198N	DT	R
1715	100	5	1611T	GE	A
1513	1	0	8201P	GE	R
381	1	1	9025B	GE	A
123	1	3	5846Q	CT	A
205	10	0	4690W	R1	U
1545	180	0	9620H	HS	A
1714	1	0	5113D	DT	R
501	5	1	8199M	GE	A
2205	28	0	6257H	HS	A
1236	4	2	2776D	GE	U
299	1	7	5897J	CT	A
1305	2	1	4886E	R1	U
1670	10	1	1595Y	GE	A
1849	20	0	2622B	GE	R
1444	56	5	8664B	GE	A
1488	1	0	4003Q	R1	U
147	200	2	2600W	GE	U
1933	6	0	6481D	HS	A
729	60	5	8583R	GE	R
324	1	0	6467J	GH	R
1556	1	3	5322D	PL	A
170	2	0	5974K	CT	A
1891	4	0	1376K	GE	U
2115	50	0	5218P	DT	R
1366	30	5	8295N	GE	U
2010	200	2	2431Y	GE	U
1075	20	0	5418E	PL	A
1283	1	0	5011R	DT	R
1945	1	2	4935R	R1	U
1762	30	0	6468K	HS	A
395	2	3	9160D	GE	A
865	20	2	5408P	PL	A
563	28	5	9141D	GE	A
214	3	5	9329B	GE	R
1059	2	5	2914J	GE	U
1805	2	5	9397N	GE	R
1596	1	5	5540N	OT	U
2049	100	2	2826R	GE	U
661	200	4	8798C	GE	A
1563	60	5	1446D	GE	R
1504	2	0	8866P	GE	R
625	20	0	5243Y	DT	R
162	10	1	9465E	GE	A
802	30	2	2728N	GE	R
580	1	2	4405W	R1	U
188	1	1	9466F	GE	A
1699	2	5	9078T	GE	A
592	15	4	8180M	GE	A
1447	2	0	8728J	GE	R
130	1	5	9411H	GE	A
1385	56	5	4320J	R1	A
1944	10	0	3374N	DT	U
1496	3	1	2358D	GE	A
1529	28	5	8356T	GE	U
674	28	0	6470M	MD	R
38	56	5	8794W	GE	A
1285	1	0	6493R	HS	A
369	5	0	2766N	GE	U
910	1	0	4772E	R1	U
999	6	0	5942R	CT	R
757	30	5	8734Q	GE	A
2092	4	5	9164H	GE	R
1317	4	2	5936K	CT	A
602	1	2	2360F	GE	U
596	30	5	9043Y	GE	R
1798	3	0	5941Q	CT	R
1399	1	0	6271C	HS	A
2134	20	0	2839K	GE	R
1461	20	0	9323Q	GE	A
776	5	0	3479D	DB	U
1678	20	0	5248F	DT	R
1468	60	2	9127J	GE	A
1352	1	2	2895J	GE	U
569	56	5	9316H	GE	A
1546	30	5	9052K	GE	R
2090	30	5	9020R	GE	R
723	1	0	4180B	R1	U
1478	1	0	4366T	R1	R
1925	1	0	8844L	GE	A
933	8	5	2553J	GE	A
1795	5	2	1531N	GE	U
1699	2	5	8741C	GE	A
2281	50	5	2732T	GE	A
451	30	0	6358P	HS	A
1820	5	0	3026G	GE	A
1759	20	0	8510X	GE	U
1388	1	0	4007X	R1	R
2140	28	5	2791X	GE	U
1434	120	3	8652J	GE	A
1791	15	0	6366C	IF	R
297	30	5	2367N	GE	U
2124	200	2	8448P	GE	A
1647	10	0	4832H	R1	U
1252	84	1	4078P	R1	U
137	25	0	2893G	GE	U
141	20	0	8455B	GE	R
814	1	5	5535H	OT	R
1059	2	11	9266Q	GE	R
317	2	0	4659F	R1	U
376	100	5	2225D	GE	U
430	15	2	8820F	GE	A
1892	3	1	1140B	GE	R
1515	1	0	8808N	GE	A
1722	60	2	9123E	GE	A
452	10	1	1169M	GE	U
1480	1	0	5880L	CT	U
1391	5	0	4658E	R1	U
1474	28	1	9419R	GE	A
2180	1	2	1438Q	GE	U
606	2	0	4668Q	R1	U
1186	28	5	4397K	R1	A
1142	1	0	2122Q	GE	R
2174	1	1	8705E	GE	U
1364	1	3	5302C	PL	A
1463	1	5	8597L	GE	U
1178	1	3	8294M	GE	A
48	1	2	4284L	R1	A
1597	10	0	2647H	GE	U
152	100	5	8535F	GE	U
1059	2	11	9273C	GE	R
2329	100	5	1973W	GE	R
1584	1	0	9578D	HS	A
943	200	2	1153Q	GE	U
776	5	0	5169C	DT	U
1258	1	0	4695D	R1	U
1037	3	0	5316T	PL	A
1691	28	0	5136H	DT	R
1969	15	0	9609R	IF	R
1178	1	3	5979Q	CT	A
1144	3	0	5307H	PL	A
710	5	1	2390T	GE	U
2039	28	5	8534E	GE	U
1194	30	5	8717T	GE	A
1722	60	2	9172R	GE	A
394	5	0	5212H	DT	U
1942	30	5	8008L	GE	R
1600	50	0	5203W	DT	R
902	20	0	8523N	GE	R
2275	200	2	1259G	GE	R
258	1	5	8875D	GE	A
1059	2	11	9277G	GE	R
890	100	2	1070H	GE	A
1002	4	5	9383W	GE	A
1318	2	5	9428F	GE	A
824	6	0	6148N	HS	A
242	60	2	9341P	GE	A
1973	7	0	3321T	DT	U
634	2	0	4899W	R1	U
122	5	0	4654Y	R1	U
1279	5	3	9185K	GE	A
1102	90	5	8884N	GE	U
713	1	0	6265R	HS	A
251	1	5	9057Q	GE	R
1723	1	2	4932N	R1	U
1521	1	0	4773F	R1	U
708	50	2	4073J	R1	U
1312	1	5	5547Y	OT	U
551	10	0	1085D	GE	R
1768	28	5	8363E	GE	A
1506	1	2	5399E	PL	A
630	1	3	9087G	GE	A
1818	2	2	4578Y	R1	A
1927	28	5	8507R	GE	R
946	1	5	8895E	GE	R
224	180	5	8845M	GE	A
1595	10	0	1085D	GE	R
340	30	5	9114Q	GE	A
2105	1	0	1047D	GE	U
2288	1	2	8864M	GE	U
849	2	0	4814J	R1	U
2212	30	5	8879H	GE	A
1232	30	5	8247C	GE	U
991	2	0	5885R	CT	U
2102	1	2	5557L	OT	U
2234	20	0	5241W	DT	R
268	1	5	8895E	GE	R
189	90	5	1149L	GE	U
1008	21	0	9645P	HS	A
2233	2	0	8867Q	GE	R
689	5	1	2977Q	GE	U
1594	30	5	8477E	GE	R
816	4	5	4585H	R1	A
1528	5	5	2349P	GE	A
1201	20	0	5246D	DT	R
1131	1	0	5386L	PL	A
1827	28	2	9198D	GE	A
1238	1	2	4844Y	R1	U
2173	1	2	4936T	R1	U
1614	28	5	4443W	R1	A
1532	1	5	5534G	OT	U
1958	25	3	1896T	GE	R
1206	28	1	9418Q	GE	A
2062	10	1	8412R	GE	A
867	50	3	2415D	GE	U
1750	20	0	8525Q	GE	R
2096	3	5	5521N	OT	A
1069	56	5	9076Q	GE	A
16	1	3	5556K	OT	R
526	5	2	1533Q	GE	U
1922	21	0	9642L	HS	A
137	25	0	5205Y	DT	U
1469	5	0	5148Y	DT	R
2097	20	0	5392T	PL	A
1240	1	0	8698T	GE	A
592	15	5	8181N	GE	A
133	100	0	6151R	HS	A
1087	30	5	8855C	GE	R
754	192	0	5344G	PL	A
691	1	5	2682E	GE	R
1465	20	0	8454Y	GE	A
644	50	3	5325G	PL	A
758	1	0	5041H	DT	U
921	5	0	3491R	DB	U
1836	100	5	1196Y	GE	U
1847	5	0	8783G	GE	U
2235	30	11	9231W	GE	R
1667	25	0	1347X	GE	U
1628	1	0	6336L	IF	R
1620	21	1	1621H	GE	R
2304	1	5	8707G	GE	A
467	5	0	2530E	GE	U
1748	60	5	2920Q	GE	A
299	1	0	9611W	HS	A
850	500	10	8556H	GE	U
979	50	0	5329L	PL	A
2162	60	5	8382E	GE	R
466	28	5	4399M	R1	A
1664	5	0	2981X	GE	U
769	1	0	4768Y	R1	U
1891	4	0	5929C	CT	U
1842	28	5	2857J	GE	R
710	5	0	3313J	DT	U
854	1	11	9215B	GE	R
2126	28	3	5348L	PL	A
31	60	3	8660T	GE	A
1416	1	0	4938X	R1	R
201	2	0	8865N	GE	R
1487	100	0	1983J	GE	A
1076	1	2	4107E	R1	U
1331	200	1	2605D	GE	U
1227	50	3	5353R	PL	A
1220	25	1	2325J	GE	U
1023	1	5	8853Y	GE	U
863	5	1	2286H	GE	U
2223	2	0	4816L	R1	U
440	60	0	4151L	R1	A
53	4	1	8617M	GE	A
1049	2	0	8462J	GE	A
1188	10	0	5903Q	CS	R
2030	60	5	1978D	GE	U
1774	200	4	9345W	GE	A
156	10	0	2369Q	GE	U
1165	11	0	3037W	GE	U
963	30	0	8255L	GE	A
2117	1	4	8786K	GE	A
44	10	0	9199E	GE	R
2076	56	5	1956Y	GE	A
705	30	5	2280B	GE	A
701	240	1	4093K	R1	R
1060	100	2	1779P	GE	R
1888	100	5	1835N	GE	A
1263	4	5	2474F	GE	R
2171	2	5	9295F	GE	A
250	1	0	6455R	HS	A
179	56	5	2849Y	GE	A
928	28	5	8270G	GE	R
337	20	0	5166X	DT	R
1363	60	0	9646Q	HS	A
1365	4	5	8144P	GE	A
1308	5	0	8582Q	GE	R
336	4	5	8667E	GE	R
2200	3	1	5902P	CT	R
1059	2	11	9359N	GE	R
1373	1	0	4343N	R1	U
946	1	5	5553G	OT	R
1483	2	5	2967E	GE	U
1572	1	1	4040P	R1	U
559	60	5	8166T	GE	A
1004	30	5	8480H	GE	U
880	8	5	3092R	GE	A
1698	100	5	8559L	GE	A
106	30	5	9122D	GE	U
393	30	5	9044B	GE	R
63	2	2	3107M	GE	U
268	1	5	5553G	OT	R
715	5	0	5989F	CT	U
425	2	6	9251X	GE	R
2298	1	0	4161B	R1	U
1190	5	1	8016X	GE	U
764	112	5	1330B	GE	A
272	4	3	9117W	GE	A
1029	1	0	8227B	GE	R
1902	20	0	5165W	DT	R
313	4	1	8753Q	GE	A
1738	1	2	4461T	R1	U
933	8	5	3066J	GE	A
753	28	5	1471K	GE	A
866	1	1	9066E	GE	A
981	100	5	2923W	GE	U
853	60	0	6453P	HS	A
1016	1	5	2926B	GE	A
1160	1	1	4134N	R1	A
1245	1	0	4693B	R1	U
611	1	0	4686P	R1	U
971	30	1	1326T	GE	R
799	1	1	2480M	GE	A
715	5	0	2199R	GE	U
2118	50	0	1696G	GE	U
1856	1	3	5421H	PL	A
1915	1	0	2123R	GE	R
2031	30	5	2629J	GE	R
568	1	0	6427G	HS	A
607	14	1	8318T	GE	U
1193	1	0	6371H	HS	A
252	50	3	5375X	PL	A
16	1	7	9356K	GE	R
1451	2	5	8588B	GE	A
642	1	0	4663K	R1	U
2061	28	5	8605X	GE	A
1013	1	5	8229D	GE	U
518	20	0	8387K	GE	R
1843	1	0	5850X	CT	A
2093	1	1	2424N	GE	U
340	30	2	9173T	GE	A
1901	1	0	6288Y	HS	A
592	1	0	6210W	HS	A
1597	1	0	3487M	DB	U
1000	10	5	8467P	GE	R
1441	90	0	9618F	HS	A
687	1	5	8287E	GE	R
925	30	3	2549E	GE	A
1343	2	0	9476R	GE	A
1568	60	0	6429J	HS	A
643	30	5	4233T	R1	A
1307	60	2	2727M	GE	R
1640	100	5	8585W	GE	A
541	60	5	8398B	GE	R
699	20	0	1653B	GE	R
415	60	5	2110C	GE	R
677	4	5	9012H	GE	A
1764	200	1	2642C	GE	U
916	1	0	4016J	R1	U
1111	20	0	1215Y	GE	U
775	8	5	2646G	GE	R
1509	1	1	4889H	R1	U
2234	20	0	2840L	GE	R
1115	60	3	2103Q	GE	R
815	1	0	6279L	HS	A
2141	180	0	6202K	HS	A
227	3	5	8514D	GE	A
1708	56	5	9092M	GE	A
1629	10	0	5935J	CT	U
2087	7	0	6318M	GH	R
1117	2	3	8778B	GE	A
1059	2	5	9013J	GE	U
1310	5	1	2281C	GE	U
931	2	5	8162N	GE	U
2069	1	0	4665M	R1	U
1009	60	5	8398B	GE	R
2326	60	5	1325R	GE	U
1109	1	5	8239P	GE	R
783	1	0	4761N	R1	U
1436	1	0	8834Y	GE	U
47	1	0	4781P	R1	U
1535	30	5	2237R	GE	R
1904	100	5	1862B	GE	R
70	50	5	8019C	GE	A
1666	1	1	4880W	R1	U
1112	5	0	5932F	CT	U
1722	60	2	9111M	GE	A
1886	60	5	1616C	GE	R
24	30	5	8470T	GE	U
1114	3	0	2334W	GE	U
833	10	0	1086E	GE	R
1016	1	5	8573F	GE	U
2277	20	0	5244B	DT	R
2194	56	2	8267D	GE	A
1894	5	3	9207N	GE	A
1379	2	0	4797L	R1	U
366	1	0	1031G	GE	U
2008	30	5	8508T	GE	R
2232	60	5	8371N	GE	A
338	5	0	3494X	DB	U
1306	4	0	6324W	HS	A
1439	1	0	5515G	OT	U
984	28	0	9626P	HS	A
582	90	0	5370P	PL	A
43	200	4	9292C	GE	A
1222	1	1	8346G	GE	U
2196	20	0	8133C	GE	A
1059	2	11	9280K	GE	R
1152	2	1	4922C	R1	U
1549	1	1	4649Q	R1	U
1575	100	5	1682M	GE	U
868	30	11	9243L	GE	R
124	60	5	1443Y	GE	R
2131	28	5	1434L	GE	R
1669	7	0	1811H	GE	A
2133	200	2	2289L	GE	U
1981	28	0	6499C	HS	A
2337	60	0	6186N	HS	A
1822	90	0	9605M	HS	A
704	10	1	1089H	GE	U
531	30	5	1345T	GE	U
698	30	5	8720Y	GE	A
1378	1	0	6290C	HS	A
638	5	0	3451P	DB	U
686	6	0	5119K	DT	R
1578	50	0	3345C	DT	U
882	50	2	2429W	GE	U
237	28	5	2863Q	GE	R
428	30	5	8028M	GE	U
1699	2	5	9427E	GE	A
1028	1	0	8569B	GE	A
2158	10	0	1256D	GE	R
149	4	0	5928B	CT	U
1558	100	5	2440K	GE	U
1854	5	0	4656C	R1	U
870	100	1	1746X	GE	U
184	5	5	5949D	CT	A
2103	30	5	1622J	GE	U
2112	1	0	3196F	GE	U
885	8	5	8259Q	GE	A
599	25	0	5204X	DT	R
\.


--
-- Data for Name: restriction; Type: TABLE DATA; Schema: drugs; Owner: ian
--

COPY restriction (pbscode, comment, code) FROM stdin;
1002R	Herpes simplex keratitis	1715
1003T	Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment\nNOTE: Aciclovir 200 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.	2056
1007B	Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment\nNOTE: Aciclovir 200 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.	2190
1017M	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
1027C	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
1052J	Herpes zoster ophthalmicus\nNOTE: Aciclovir is effective only if commenced within 72 hours of onset of rash.   Aciclovir 800 mg is not PBS-subsidised for herpes simplex or chickenpox.	1152
1052J	Treatment of patients with herpes zoster within 72 hours of the onset of the rash\nNOTE: Aciclovir is effective only if commenced within 72 hours of onset of rash.   Aciclovir 800 mg is not PBS-subsidised for herpes simplex or chickenpox.	1955
1070H	Prophylaxis of thiamine deficiency in an Aboriginal or a Torres Strait Islander person	2384
1085D	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1085D	Septicaemia, proven	1847
1085D	Septicaemia, suspected	1846
1086E	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1086E	Septicaemia, proven	1847
1086E	Septicaemia, suspected	1846
1088G	Serious supra-ventricular cardiac arrhythmias	1731
1088G	Serious ventricular cardiac arrhythmias where treatment is initiated in a hospital (in-patient or out-patient)	1732
1090J	Serious supra-ventricular cardiac arrhythmias	1731
1090J	Serious ventricular cardiac arrhythmias where treatment is initiated in a hospital (in-patient or out-patient)	1732
1104D	Anorectal congenital abnormalities	1025
1104D	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
1104D	Megacolon	1221
1104D	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
1104D	Patients receiving palliative care	1263
1104D	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
1104D	Terminal malignant neoplasia	1400
1115Q	Treatment of corticosteroid-responsive dermatoses	1422
1119X	Treatment of corticosteroid-responsive dermatoses	1422
1121B	Radiation induced mucositis	1669
1127H	Vernal kerato-conjunctivitis	1466
1131M	Primary and relapsing superficial urothelial carcinoma of the bladder	1290
1140B	Treatment of carcinoma in situ of the urinary bladder	1419
1165H	Narcolepsy	1236
1165H	Use in attention deficit hyperactivity disorder, in accordance with State/Territory law	1461
1166J	Neurogenic urinary retention	1239
1166J	Phaeochromocytoma	1285
1208N	Bacterial gastroenteritis in severely immunocompromised patients	1573
1208N	Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients	1572
1208N	Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials	1431
1208N	Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials	1432
1209P	Bacterial gastroenteritis in severely immunocompromised patients	1573
1209P	Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients	1572
1209P	Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials	1431
1209P	Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials	1432
1210Q	Bacterial gastroenteritis in severely immunocompromised patients	1573
1210Q	Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients	1572
1210Q	Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials	1431
1210Q	Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials	1432
1211R	Anovulatory infertility	1026
1211R	Patients undergoing in-vitro fertilisation	1267
1217C	Bacterial keratitis	1031
1255C	Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor	1257
1256D	Cellulitis	3132
1256D	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1256D	Septicaemia, proven	1847
1256D	Septicaemia, suspected	1846
1257E	Cellulitis	3132
1257E	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1257E	Septicaemia, proven	1847
1257E	Septicaemia, suspected	1846
1258F	Anorectal congenital abnormalities	1025
1258F	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
1258F	Megacolon	1221
1258F	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
1258F	Patients receiving palliative care	1263
1258F	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
1258F	Terminal malignant neoplasia	1400
1259G	Anorectal congenital abnormalities	1025
1259G	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
1259G	Megacolon	1221
1259G	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
1259G	Patients receiving palliative care	1263
1259G	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
1259G	Terminal malignant neoplasia	1400
1260H	Anorectal congenital abnormalities	1025
1260H	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
1260H	Megacolon	1221
1260H	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
1260H	Patients receiving palliative care	1263
1260H	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
1260H	Terminal malignant neoplasia	1400
1263L	Anorectal congenital abnormalities	1025
1263L	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
1263L	Megacolon	1221
1263L	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
1263L	Patients receiving palliative care	1263
1263L	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
1263L	Terminal malignant neoplasia	1400
1269T	Moderate to severe androgenisation in non-pregnant women (acne alone is not a sufficient indication of androgenisation)\nCAUTION: This drug should not be used during pregnancy as it may result in feminisation of the male foetus.	1230
1270W	Advanced carcinoma of the prostate	1014
1270W	To reduce drive in sexual deviations in males	1404
1285P	Endometriosis, visually proven	1090
1285P	Hereditary angio-oedema	1151
1285P	Short-term treatment (up to 6 months) of intractable primary menorrhagia (Treatment of this indication is limited to 6 months. See Australian Product Information)	2639
1285P	Short-term treatment (up to 6 months) of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments (Treatment of this indication is limited to 6 months.  See Australian Product Information)	2640
1287R	Endometriosis, visually proven	1090
1287R	Hereditary angio-oedema	1151
1287R	Short-term treatment (up to 6 months) of intractable primary menorrhagia (Treatment of this indication is limited to 6 months. See Australian Product Information)	2639
1287R	Short-term treatment (up to 6 months) of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments (Treatment of this indication is limited to 6 months.  See Australian Product Information)	2640
1299J	Bone pain due to malignant disease	1036
1299J	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1300K	Bone pain due to malignant disease	1036
1300K	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1326T	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.   No applications for increased repeats will be authorised.	1177
1327W	Gastro-oesophageal reflux disease	1533
1327W	Scleroderma oesophagus	1337
1327W	Zollinger-Ellison syndrome	1476
1330B	Hyperkinetic extrapyramidal disorders	1161
1349B	Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has previously been granted an authority prescription for the same eye.   A patient is eligible for a total of 15 subsidised treatments per eye.  This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.   Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin.  Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  The reason treatment is abandoned must be provided.  Where such notification has been made, the treatment so affected will not count towards the maximum.   Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.  Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2685
1349B	Initial PBS-subsidised treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has been authorised by the Angiogram Review Panel to receive treatment with verteporfin in the same eye under the MBS Visudyne Therapy Program.   Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.   The first authority application for each eye must be made in writing, and must include:  (a) a completed authority prescription form; and  (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au], which includes the date of review by the Angiogram Review Panel and the number of treatments administered in that eye under the MBS Visudyne Therapy Program; and  (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).   Written applications for authority to prescribe verteporfin should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Medicare Australia will then contact the prescriber by telephone.  The original documentation must be posted to the above address after approval has been gained.   A patient is eligible for a total of 15 subsidised treatments per eye.  This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.   Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin.  Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  The reason treatment is abandoned must be provided.  Where such notification has been made, the treatment so affected will not count towards the maximum	2684
1972T	Malaria	2142
1349B	Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200).   Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.   The first authority application for each eye must be made in writing, and must include:  (a) a completed authority prescription form; and  (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and  (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).   Written applications for authority to prescribe verteporfin should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Medicare Australia will then contact the prescriber by telephone.  The original documentation must be posted to the above address after approval has been gained.   No more than 15 treatments (1 initial and 14 continuing) per eye will be authorised.   Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin.  Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  The reason treatment is abandoned must be provided.  Where such notification has been made, the treatment so affected will not count towards the maximum	2683
1356J	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1356J	Septicaemia, proven	1847
1356J	Septicaemia, suspected	1846
1382R	Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) where the patient has previously been granted an authority prescription for the same eye.   Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.  Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2677
1382R	Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography.   Where a fluoroscein angiogram cannot be performed due to a contraindication as listed in the TGA-approved product information, details of the contraindication must be provided.  A copy of the report of an alternative method of diagnosis must be included in the application, for example, optical coherence tomography (OCT) or red free photography.   Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.   The first authority application for each eye must be made in writing, and must include:  (a) a completed authority prescription form; and  (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and  (c) a copy of the fluorescein angiogram or alternative method of diagnosis where applicable.   Written applications for authority to prescribe ranibizumab should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Medicare Australia will then contact the prescriber by telephone.  The original documentation must be posted to the above address after approval has been gained	2822
1411G	Phenylketonuria	1286
1417N	Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) agonist therapy\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3247
1434L	Major depressive disorders	1211
1434L	Obsessive-compulsive disorder	1241
1441W	Invasive ocular infection	1188
1441W	Perioperative use in ophthalmic surgery	1714
1441W	Suspected pseudomonal eye infection	1391
1443Y	Acromegaly\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1001
1443Y	Parkinson's disease\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1255
1443Y	Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1844
1443Y	Pathological hyperprolactinaemia where radiotherapy is not indicated\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1843
1443Y	Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1842
1443Y	Pathological hyperprolactinaemia where surgery is not indicated\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1841
1444B	Prevention of the onset of lactation in the puerperium for medical reasons	1289
1445C	Acromegaly\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1001
1445C	Parkinson's disease\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1255
1445C	Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1844
1445C	Pathological hyperprolactinaemia where radiotherapy is not indicated\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1843
1445C	Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1842
1445C	Pathological hyperprolactinaemia where surgery is not indicated\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1841
1757L	Treatment of cryptococcal meningitis	3295
5903Q	Germ cell neoplasms	1139
1446D	Acromegaly\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1001
1446D	Parkinson's disease\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1255
1446D	Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1844
1446D	Pathological hyperprolactinaemia where radiotherapy is not indicated\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1843
1446D	Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1842
1446D	Pathological hyperprolactinaemia where surgery is not indicated\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1841
1451J	Metabolic disorders	1223
1453L	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
1454M	Hormone-dependent breast cancer as an alternative to adjuvant chemotherapy in peri- or pre-menopausal women	3228
1454M	Hormone-dependent locally advanced (equivalent to stage III) or metastatic (equivalent to stage IV) breast cancer in pre-menopausal women	1872
1454M	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	1871
1454M	Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy will be authorised)	1377
1471K	Maintenance therapy in patients with cryptococcal meningitis and immunosuppression	1199
1471K	Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients	3240
1471K	Treatment of cryptococcal meningitis	3295
1471K	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
1471K	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
1471K	Treatment of serious and life-threatening candida infections	3296
1472L	Maintenance therapy in patients with cryptococcal meningitis and immunosuppression	1199
1472L	Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients	3240
1472L	Treatment of cryptococcal meningitis	3295
1472L	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
1472L	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
1472L	Treatment of serious and life-threatening candida infections	3296
1473M	Maintenance therapy in patients with cryptococcal meningitis and immunosuppression	1199
1473M	Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients	3240
1473M	Treatment of cryptococcal meningitis	3295
1473M	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
1473M	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
1473M	Treatment of serious and life-threatening candida infections	3296
1474N	Maintenance therapy in patients with cryptococcal meningitis and immunosuppression	1199
1474N	Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients	3240
1474N	Treatment of cryptococcal meningitis	3295
1474N	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
1474N	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
1474N	Treatment of serious and life-threatening candida infections	3296
1475P	Maintenance therapy in patients with cryptococcal meningitis and immunosuppression	1199
1475P	Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients	3240
1475P	Treatment of cryptococcal meningitis	3295
1475P	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
1475P	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
1475P	Treatment of serious and life-threatening candida infections	3296
1502C	Proctitis	1294
1502C	Ulcerative colitis	1454
1509K	Severe dry eye syndrome, including Sjogren's syndrome	1362
1510L	For use in a hospital	1128
1511M	For use in a hospital	1128
1526H	Serious staphylococcal infections	1345
1527J	Serious staphylococcal infections	1345
1542E	Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1754
1542E	Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1755
1561E	Cataplexy associated with narcolepsy	1041
1561E	Obsessive-compulsive disorder	1241
1561E	Phobic disorders in adults	1287
1572R	Oral candidiasis in severely immunocompromised persons where topical therapy has failed\nCAUTION: Hepatotoxicity has been reported with ketoconazole.	1245
1572R	Systemic or deep mycoses where other forms of therapy have failed\nCAUTION: Hepatotoxicity has been reported with ketoconazole.	1398
1573T	Symptomatic genital candidiasis recurring after treatment of at least 2 episodes with topical therapy\nCAUTION: Hepatotoxicity has been reported with ketoconazole.	1487
1574W	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
1581F	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
1581F	For the treatment of boys over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty. Treatment must not extend beyond 6 months	1116
1581F	For the treatment of infertility in males associated with isolated luteinising hormone deficiency	1117
1581F	For the treatment of infertility in males due to hypogonadotrophic hypogonadism	1118
1581F	For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation	1120
1590Q	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1594X	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
1595Y	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
1596B	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
1597C	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
1606M	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1606M	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1606M	Severe disabling pain associated with proven malignant neoplasia	1357
1606M	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
1606M	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1609Q	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1609Q	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1609Q	Severe disabling pain associated with proven malignant neoplasia	1357
1609Q	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
1609Q	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1611T	Crohn's disease where hypersensitivity to sulfonamides exists	2268
1611T	Crohn's disease where intolerance to sulfasalazine exists	2269
1611T	Ulcerative colitis where hypersensitivity to sulfonamides exists	1708
1611T	Ulcerative colitis where intolerance to sulfasalazine exists	1709
1614Y	Bone pain due to malignant disease	1036
1614Y	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1615B	Bone pain due to malignant disease	1036
1615B	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1616C	Severe acne not responding to other tetracyclines\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1347
1621H	Treatment of anaerobic infections	1416
1623K	For patients requiring doses greater than 20 mg per week	2884
1627P	Severe depression	1355
1628Q	Severe depression	1355
1638F	Prophylaxis in large bowel surgery	1300
1638F	Treatment, in a hospital, of acute anaerobic sepsis	1448
1646P	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1757L	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
1757L	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
1757L	Treatment of serious and life-threatening candida infections	3296
1779P	Treatment of chronic spasticity	1421
1646P	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1646P	Severe disabling pain associated with proven malignant neoplasia	1357
1646P	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
1646P	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1648R	Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated	2631
1648R	Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated	2632
1648R	Reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and where NSAID therapy is essential	2630
1653B	Chronic severe disabling pain associated with proven malignant neoplasia	1061
1653B	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
1653B	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1653B	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1653B	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1654C	Chronic severe disabling pain associated with proven malignant neoplasia	1061
1654C	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
1654C	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1654C	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1654C	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1655D	Chronic severe disabling pain associated with proven malignant neoplasia	1061
1780Q	Treatment of chronic spasticity	1421
1655D	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
1655D	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1655D	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1655D	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1656E	Chronic severe disabling pain associated with proven malignant neoplasia	1061
1656E	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
1656E	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
1656E	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
1656E	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
1658G	Bone pain due to malignant disease in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent	2271
1658G	Chronic arthropathies (including osteoarthritis) with an inflammatory component in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent	2270
1659H	Bone pain due to malignant disease	1036
1659H	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1671Y	Monotherapy for osteoporosis, where other treatment has failed and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval\nNOTE: Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.	2024
1671Y	Monotherapy for osteoporosis, where other treatment is contraindicated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval\nNOTE: Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.	2026
1671Y	Monotherapy for osteoporosis, where other treatment is not tolerated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval\nNOTE: Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.	2025
1671Y	Patients on long-term treatment with corticosteroids\nNOTE: Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.	1262
1671Y	Patients receiving PBS-subsidised therapy with this drug for osteoporosis prior to 1 February 2004\nNOTE: Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.	1976
1674D	Bone pain due to malignant disease	1036
1674D	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1698J	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
1703P	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	1304
1705R	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	1304
1728Y	Ulcerative colitis where hypersensitivity to sulfonamides exists\nNOTE: Not for the treatment of Crohn's disease.	1708
1728Y	Ulcerative colitis where intolerance to sulfasalazine exists\nNOTE: Not for the treatment of Crohn's disease.	1709
1757L	Maintenance therapy in patients with cryptococcal meningitis and immunosuppression	1199
1757L	Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients	3240
1783W	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1783W	Septicaemia, proven	1847
1783W	Septicaemia, suspected	1846
1784X	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1784X	Septicaemia, proven	1847
1784X	Septicaemia, suspected	1846
1785Y	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
1785Y	Septicaemia, proven	1847
1785Y	Septicaemia, suspected	1846
1795L	Bone pain due to malignant disease	1036
1795L	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1798P	Prevention of migraine\nNOTE: Cyproheptadine hydrochloride is not PBS-subsidised for use in hay fever or atopy.	1288
1805B	Neurologically proven epilepsy\nCAUTION: Abuse of clonazepam has been reported. Refer to the current product information.	1574
1806C	Neurologically proven epilepsy\nCAUTION: Abuse of clonazepam has been reported. Refer to the current product information.	1574
1807D	Epilepsy	1093
1808E	Neurologically proven epilepsy\nCAUTION: Abuse of clonazepam has been reported. Refer to the current product information.	1574
1811H	Hairy cell leukaemia	3180
1822X	Angina not responding to other therapy	1023
1824B	Dysmenorrhoea	1087
1824B	Menorrhagia	1222
1834M	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
1835N	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
1850J	Epilepsy	1093
1853M	Epilepsy	1093
1862B	Neurogenic urinary retention	1239
1862B	Phaeochromocytoma	1285
1891M	Infections where resistance to amoxycillin is proven	1837
1891M	Infections where resistance to amoxycillin is suspected	1836
1892N	Infections where resistance to amoxycillin is proven	1837
1892N	Infections where resistance to amoxycillin is suspected	1836
1895R	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1896T	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1897W	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1898X	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
1900B	Major depressive disorders	1211
1903E	Persons at high risk of pneumococcal infections	1282
1903E	Persons with Hodgkin's disease	1284
1903E	Splenectomised persons over 2 years of age	1385
1913Q	Treatment of corticosteroid-responsive dermatoses	1422
1915T	Treatment of corticosteroid-responsive dermatoses	1422
1928L	For local intra-articular or peri-articular infiltration	1102
1953T	Detrusor overactivity	1081
1956Y	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2611
1956Y	CONTINUING TREATMENT  -  (S)MMSE improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2609
1956Y	INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 to 14.  Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease.  Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2608
1956Y	INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2610
1973W	Late stage Parkinson's disease as adjunctive therapy in patients being treated with levodopa - decarboxylase inhibitor combinations	1864
1975Y	Malaria	2142
1981G	Prophylactic treatment of contacts of patients with Haemophilus influenzae type B	1297
1981G	Prophylaxis of meningococcal disease in close contacts and carriers	1303
1982H	Leprosy in adults	1190
1983J	Leprosy in adults	1190
1984K	Prophylactic treatment of contacts of patients with Haemophilus influenzae type B	1297
1984K	Prophylaxis of meningococcal disease in close contacts and carriers	1303
2000G	Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1754
2000G	Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1755
2001H	Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1754
2001H	Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1755
2003K	Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1754
2003K	Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1755
2011W	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
2012X	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
2013Y	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
2019G	Severe forms of disorders of keratinisation	1363
2019G	Severe intractable psoriasis	1366
2020H	Severe forms of disorders of keratinisation	1363
2020H	Severe intractable psoriasis	1366
2027Q	Gyrate atrophy of the choroid and retina	1147
2027Q	Urea cycle disorders	1458
2043M	Severe cardiac arrhythmias	1350
2047R	Bone pain due to malignant disease	1036
2047R	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
2048T	Bone pain due to malignant disease	1036
2048T	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
2059J	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2611
2059J	CONTINUING TREATMENT  -  (S)MMSE improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2609
2059J	INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 to 14.  Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease.  Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2608
2059J	INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2610
2065Q	Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy	1351
2066R	Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy	1351
2080L	Chronic stable plaque type psoriasis vulgaris	1066
2088X	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1123
2123R	Severe disabling pain associated with proven malignant neoplasia	1357
5903Q	Lymphoma	1198
2088X	For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1126
2088X	Malignant neoplasia (late stage)	1216
2091C	Anorectal congenital abnormalities	1025
2091C	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
2091C	Megacolon	1221
2091C	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
2091C	Patients receiving palliative care	1263
2091C	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
2091C	Terminal malignant neoplasia	1400
2095G	Patients established on this drug as a pharmaceutical benefit prior to 1 November 1999	1260
2095G	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding	1720
2095G	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs	1721
2095G	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin	1719
2101N	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
2101N	Androgen deficiency in males with established pituitary or testicular disorders	1022
2101N	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
2103Q	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
2109B	Treatment of hormone-dependent breast cancer\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.	1749
2110C	Treatment of hormone-dependent breast cancer\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.	1749
2114G	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
2114G	Androgen deficiency in males with established pituitary or testicular disorders	1022
2114G	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
2115H	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
2115H	Androgen deficiency in males with established pituitary or testicular disorders	1022
2115H	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
2117K	Treatment of corticosteroid-responsive dermatoses	1422
2118L	Treatment of corticosteroid-responsive dermatoses	1422
2122Q	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2122Q	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2122Q	Severe disabling pain associated with proven malignant neoplasia	1357
2122Q	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
2122Q	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2123R	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2123R	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2123R	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
2123R	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2124T	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2124T	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2124T	Severe disabling pain associated with proven malignant neoplasia	1357
2124T	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
2124T	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2129C	Cranial diabetes insipidus	1678
2130D	Panic disorder where other treatments have failed or are inappropriate	1975
2131E	Panic disorder where other treatments have failed or are inappropriate	1975
2132F	Panic disorder where other treatments have failed or are inappropriate	1975
2136K	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or irbesartan monotherapy	1594
2142R	Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy\nNOTE: Not to be used in combination with lanthanum.	3105
2142R	Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy\nNOTE: Not to be used in combination with lanthanum.	3106
2161R	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan medoxomil monotherapy	2614
2166B	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan medoxomil monotherapy	2614
2170F	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan medoxomil monotherapy	2614
2172H	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours	3188
2179Q	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
2179Q	Septicaemia, proven	1847
2179Q	Septicaemia, suspected	1846
2214M	Crohn's disease where hypersensitivity to sulfonamides exists	2268
2214M	Crohn's disease where intolerance to sulfasalazine exists	2269
2214M	Ulcerative colitis where hypersensitivity to sulfonamides exists	1708
2214M	Ulcerative colitis where intolerance to sulfasalazine exists	1709
2234N	Crohn's disease where hypersensitivity to sulfonamides exists	2268
2234N	Crohn's disease where intolerance to sulfasalazine exists	2269
2234N	Ulcerative colitis where hypersensitivity to sulfonamides exists	1708
2234N	Ulcerative colitis where intolerance to sulfasalazine exists	1709
2236Q	Major depressive disorders	1211
2237R	Major depressive disorders	1211
2240X	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.   No applications for increased repeats will be authorised.	1177
2241Y	Gastro-oesophageal reflux disease	1533
2241Y	Scleroderma oesophagus	1337
2242B	Major depressive disorders	1211
2242B	Obsessive-compulsive disorder	1241
2242B	Panic disorder	1862
2728N	Hormone-dependent advanced breast cancer	1543
2244D	Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2805
2244D	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2806
2246F	Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2805
2246F	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2806
2250K	Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment.  Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.  The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment\nNOTE: Authorities for increased maximum quantities, up to a maximum of 52, may be authorised.	2735
2250K	Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme.  Treatment with oral steroids should not be commenced during the period of initial treatment.   Eosinophilic oesophagitis is demonstrated by the following criteria:  (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and  (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and  (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.   The date of birth of the patient must be included in the authority	2734
2269K	Prophylaxis of endocarditis in patients hypersensitive to penicillin	1302
2270L	Endophthalmitis	1091
2270L	Use initiated in a hospital for infections where vancomycin is an appropriate antibiotic	1464
2274Q	Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment\nNOTE: Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	2194
2276T	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours	3189
2280B	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours	3189
2283E	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours	3189
2285G	Treatment of a dermatophyte infection in an Aboriginal or a Torres Strait Islander person where topical treatment has failed	2865
2285G	Treatment of a dermatophyte infection in a patient aged up to 18 years inclusive where topical treatment and griseofulvin have failed	3244
2287J	Crohn's disease where hypersensitivity to sulfonamides exists	2268
2287J	Crohn's disease where intolerance to sulfasalazine exists	2269
2287J	Ulcerative colitis where hypersensitivity to sulfonamides exists	1708
2287J	Ulcerative colitis where intolerance to sulfasalazine exists	1709
2308L	Antidote to folic acid antagonists	1028
2310N	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
2310N	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
2312Q	For use in combination with another antibiotic in the treatment of proven serious staphylococcal infections	1130
2313R	Severe refractory hypertension. Treatment must be initiated by a consultant physician	2759
2315W	Germ cell neoplasms	1139
2315W	Lymphoma	1198
2316X	Endometrial cancer	1088
2316X	Hormone-dependent breast cancer	1542
2318B	Initiation of thyroid therapy in severely hypothyroid patients	1182
2318B	Management of patients with thyroid cancer	1219
2318B	Replacement therapy for hypothyroid patients who have documented intolerance to thyroxine sodium	1858
2318B	Replacement therapy for hypothyroid patients who have documented resistance to thyroxine sodium	1859
2324H	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
2328M	Invasive ocular infection	1188
2328M	Perioperative use in ophthalmic surgery	1714
2328M	Suspected pseudomonal eye infection	1391
2329N	Invasive ocular infection	1188
2329N	Perioperative use in ophthalmic surgery	1714
2329N	Suspected pseudomonal eye infection	1391
2338C	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
2343H	Severe cardiac arrhythmias	1350
2344J	Severe cardiac arrhythmias	1350
2347M	Phenylketonuria	1286
2349P	Proven chronic lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:  (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or  (b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or  (c) hydrogen breath test\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2760
2350Q	Acute lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.	2762
2357C	Proven chronic lactose intolerance in children aged 1 year and over who are significantly malnourished. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:  (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or  (b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or  (c) hydrogen breath test\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2761
2358D	Acute lactose intolerance in children aged 1 year and over. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.	1790
2375B	Maple syrup urine disease	1220
2379F	Tyrosinaemia	1453
2380G	Maple syrup urine disease	1220
2382J	Phenylketonuria	1286
2387P	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours	3188
2388Q	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours	3188
2432B	Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours	3188
2446R	Acute myelogenous leukaemia	1006
2448W	Acute myelogenous leukaemia	1006
2454E	Bone pain due to malignant disease	1036
2454E	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
2474F	Phenylketonuria	1286
2478K	Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with dasatinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib Authority Application Form for continuing treatment; and  (3) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or  (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with dasatinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 18 months of the commencement of treatment with dasatinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.  For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.  Where a patient has previously received PBS-subsidised treatment with dasatinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.	3039
2480M	Treatment of chronic suppurative otitis media in an Aboriginal or a Torres Strait Islander person aged 1 month or older	2615
2480M	Treatment of chronic suppurative otitis media in a patient less than 18 years of age with a grommet in situ	3192
2480M	Treatment of chronic suppurative otitis media in a patient less than 18 years of age with perforation of the tympanic membrane	3191
2481N	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2481N	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2481N	Severe disabling pain associated with proven malignant neoplasia	1357
5912E	Hairy cell leukaemia	3180
2481N	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
2481N	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2482P	Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with dasatinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib Authority Application Form for continuing treatment; and  (3) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or  (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with dasatinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 18 months of the commencement of treatment with dasatinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.  For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.  Where a patient has previously received PBS-subsidised treatment with dasatinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.	3039
2485T	Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with dasatinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib Authority Application Form for continuing treatment; and  (3) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or  (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with dasatinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 18 months of the commencement of treatment with dasatinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.  For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.  Where a patient has previously received PBS-subsidised treatment with dasatinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.	3039
2502Q	Hypocalcaemia due to renal disease	1165
2502Q	Hypoparathyroidism	1166
2502Q	Hypophosphataemic rickets	1167
2502Q	Treatment for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body	2636
2502Q	Vitamin D-resistant rickets	1467
2522R	Major depression where other antidepressant therapy has failed	1860
2522R	Major depression where other antidepressant therapy is contraindicated	1861
2523T	Major depression where other antidepressant therapy has failed	1860
2523T	Major depression where other antidepressant therapy is contraindicated	1861
2527B	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
2527B	Severe disabling pain not responding to non-narcotic analgesics	1358
2546B	Treatment of biopsy confirmed primary (previously untreated) superficial basal cell carcinoma (sBCC) in patients with normal immune function for whom surgical excision, cryotherapy, or curettage with diathermy are inappropriate and topical drug therapy is required.   The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application\nNOTE: The patient or carer must be able to understand and administer the imiquimod dosing regimen.  No applications for increased maximum quantities and/or repeats will be authorised.  Treatment of recurrent (previously treated) lesions will not be authorised.	2816
2549E	Severe cystic acne not responsive to other therapy	1354
2553J	Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2807
3017T	Primary treatment of ovarian cancer in combination with a platinum compound	1293
3017T	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
2553J	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2809
2553J	Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1687
2553J	Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1688
2553J	Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2808
2553J	Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2810
2554K	Proctitis	1294
2554K	Ulcerative colitis	1454
2555L	Anorectal congenital abnormalities	1025
2555L	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
2555L	Megacolon	1221
2555L	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
2555L	Patients receiving palliative care	1263
2555L	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
2555L	Terminal malignant neoplasia	1400
2556M	Anorectal congenital abnormalities	1025
2556M	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
2556M	Megacolon	1221
2556M	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
2556M	Patients receiving palliative care	1263
2556M	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
2556M	Terminal malignant neoplasia	1400
2557N	Anorectal congenital abnormalities	1025
2557N	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult	1122
2557N	Megacolon	1221
2557N	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function	1254
2557N	Patients receiving palliative care	1263
2557N	Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities	1268
2557N	Terminal malignant neoplasia	1400
2560R	Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2807
2560R	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2809
2560R	Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1687
2560R	Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1688
2560R	Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2808
2560R	Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2810
2591J	Severe cystic acne not responsive to other therapy	1354
2592K	Severe cystic acne not responsive to other therapy	1354
2622B	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2622B	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2622B	Severe disabling pain associated with proven malignant neoplasia	1357
3026G	Locally advanced or metastatic non-small cell lung cancer	1194
2622B	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
2622B	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2626F	Hypertension in a patient not adequately controlled with either ramipril or felodipine monotherapy	2670
2629J	Hypertension in a patient not adequately controlled with either ramipril or felodipine monotherapy	2670
2646G	A child aged less than 7 years with proven glutaric aciduria type 1	2613
2650L	An infant or young child with proven glutaric aciduria type 1	2612
2667J	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
2668K	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
2670M	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
2670M	Androgen deficiency in males with established pituitary or testicular disorders	1022
2670M	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
2676W	Biliary atresia	1034
2676W	Chronic liver failure with fat malabsorption	1059
2676W	Chylothorax	1068
2676W	Chylous ascites	1670
2676W	Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child aged 2 years and over, where the child has been assessed by a suitably qualified allergist or paediatrician.  The date of birth of the patient must be included in the authority application	2813
2676W	Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides.  The date of birth of the patient must be included in the authority application	2812
2676W	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child has been assessed by a paediatric gastroenterologist or specialist allergist.  The date of birth of the patient must be included in the authority application	2815
2676W	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides and soy protein is not tolerated or is likely not to be tolerated.  The date of birth of the patient must be included in the authority application	2814
2676W	Cystic fibrosis	1080
2676W	Enterokinase deficiency	1092
2676W	Initial treatment, for up to 3 months, for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years.  Intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free diet with a soy protein as the principal formula. The date of birth of the patient must be included in the authority application	2811
2676W	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application	2806
2676W	Proven fat malabsorption	1310
2676W	Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months.  The date of birth of the patient must be included in the authority application	2567
2676W	Severe intestinal malabsorption including short bowel syndrome	1364
2681D	Severe dry eye syndrome, including Sjogren's syndrome	1362
2682E	Severe dry eye syndrome, including Sjogren's syndrome	1362
2694T	Alopecia areata	1020
2694T	For local intra-articular or peri-articular infiltration	1102
2694T	Granulomata, dermal	1146
2694T	Keloid	1189
2694T	Lichen planus hypertrophic	1191
2694T	Lichen simplex chronicus	1192
2694T	Lupus erythematosus, chronic discoid	1197
2694T	Necrobiosis lipoidica	1237
2694T	Uveitis	1465
2700D	Ablation of thyroid remnant tissue, in combination with radioactive iodine, in a post thyroidectomy patient without known metastatic disease	3193
2702F	Pelvic inflammatory disease	1279
2703G	Pelvic inflammatory disease	1279
2707L	Bronchiectasis in patients aged 8 years or older	1851
2707L	Chronic bronchitis in patients aged 8 years or older	1852
2707L	Severe acne	1346
2711Q	Bronchiectasis in patients aged 8 years or older	1851
2711Q	Chronic bronchitis in patients aged 8 years or older	1852
2711Q	Severe acne	1346
2714W	Urethritis	1459
2715X	Urethritis	1459
2722G	Endometriosis	1089
2725K	Endometrial cancer	1088
2725K	Hormone-dependent breast cancer	1542
2727M	Endometrial cancer	1088
2727M	Hormone-dependent breast cancer	1542
2732T	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1123
2732T	For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1126
2732T	Malignant neoplasia (late stage)	1216
2732T	Myoclonic epilepsy	1235
2734X	Hormone-dependent advanced breast cancer	1543
2738D	Phenylketonuria	1286
2739E	Phenylketonuria	1286
2745L	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
2746M	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
2804N	Proximal or extensive (greater than 80% nail involvement) onychomycosis due to dermatophyte infection where topical treatment has failed.  This infection must be proven by microscopy or culture and confirmed by an Approved Pathology Authority.  The date of the pathology report must be provided at the time of application and must not be more than 12 months old\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2191
2808T	Parkinson's disease as adjunctive therapy in patients being treated with levodopa - decarboxylase inhibitor combinations\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1863
2809W	Parkinson's disease as adjunctive therapy in patients being treated with levodopa - decarboxylase inhibitor combinations\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1863
2810X	Parkinson's disease as adjunctive therapy in patients being treated with levodopa - decarboxylase inhibitor combinations\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1863
2812B	Treatment of corticosteroid-responsive dermatoses	1422
2813C	Treatment of corticosteroid-responsive dermatoses	1422
2815E	Treatment of corticosteroid-responsive dermatoses	1422
2820K	Treatment of corticosteroid-responsive dermatoses	1422
2833D	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
2834E	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
2839K	Chronic severe disabling pain associated with proven malignant neoplasia	1061
2839K	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
2839K	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2839K	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2839K	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2840L	Chronic severe disabling pain associated with proven malignant neoplasia	1061
2840L	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
2840L	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
3026G	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
3026G	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
3026G	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
2840L	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2840L	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2841M	Chronic severe disabling pain associated with proven malignant neoplasia	1061
2841M	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
2841M	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
2841M	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
2841M	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
2845R	Hypertension in patients who are not adequately controlled with indapamide and/or perindopril	2753
2848X	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
2849Y	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
2850B	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
2851C	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
2856H	Depression where all other anti-depressant therapy has failed or is inappropriate	1609
2857J	Hypertension in a patient who is not adequately controlled with either trandolapril or verapamil hydrochloride sustained release monotherapy	3082
2863Q	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
2881P	Treatment of corticosteroid-responsive dermatoses	1422
2882Q	Treatment of corticosteroid-responsive dermatoses	1422
2887Y	Treatment of corticosteroid-responsive dermatoses	1422
2888B	Treatment of corticosteroid-responsive dermatoses	1422
2920Q	Heterotopic ossification	1153
2920Q	Symptomatic Paget disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy	3257
2920Q	Symptomatic Paget disease of bone when calcitonin has been found to be unsatisfactory due to unacceptable side effects	3258
2926B	Patients who have previously received this product as a pharmaceutical benefit	1769
2926B	Patients who have purchased a meter to be used with this product prior to 1 August 2003	1770
2946C	Familial hypophosphataemia	1099
2946C	Hypercalcaemia	1157
2946C	Hypophosphataemic rickets	1167
2946C	Vitamin D-resistant rickets	1467
2956N	Severe dry eye syndrome, including Sjogren's syndrome	1362
2962X	Initial treatment (up to 6 months) of visually proven endometriosis	1172
2962X	Subsequent treatment (up to 6 months) of visually proven endometriosis, where 2 years or more have elapsed since the end of the previous course and where a recent bone density assessment has been made. The date of the assessment must be provided	1389
2990J	Alopecia areata	1020
2990J	For local intra-articular or peri-articular infiltration	1102
2990J	Granulomata, dermal	1146
2990J	Keloid	1189
2990J	Lichen planus hypertrophic	1191
2990J	Lichen simplex chronicus	1192
2990J	Lupus erythematosus, chronic discoid	1197
2990J	Necrobiosis lipoidica	1237
2990J	Psoriasis	1313
2995P	Symptomatic Paget disease of bone	3256
2995P	Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia	1412
2997R	Symptomatic Paget disease of bone	3256
2997R	Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia	1412
3010K	Acute bacterial enterocolitis	1002
3010K	Complicated urinary tract infection	1070
3016R	Parkinson's disease which is not drug induced	1258
3017T	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
3017T	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
3017T	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
3017T	Locally advanced or metastatic non-small cell lung cancer	1194
3026G	Primary treatment of ovarian cancer in combination with a platinum compound	1293
3026G	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
3036T	Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2647
3036T	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years or older with a bone mineral density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2758
3064G	Constipation in patients with malignant neoplasia	1613
3064G	Hepatic coma or precoma (chronic porto-systemic encephalopathy)	1150
3066J	Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2807
3066J	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2809
3066J	Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1687
3066J	Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1688
3066J	Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2808
3066J	Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2810
3078B	Tyrosinaemia	1453
3079C	Methylmalonic acidaemia	1225
3079C	Propionic acidaemia	1307
3092R	Hypercalcaemia in children under the age of 4 years	1158
3112T	Corneal grafts	1077
3112T	Uveitis	1465
3113W	Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole\nNOTE: Metronidazole has similar efficacy to vancomycin but may have less selective pressure to vancomycin resistant enterococci and is therefore the preferred treatment.	1702
3113W	Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole\nNOTE: Metronidazole has similar efficacy to vancomycin but may have less selective pressure to vancomycin resistant enterococci and is therefore the preferred treatment.	1701
3114X	Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole\nNOTE: Metronidazole has similar efficacy to vancomycin but may have less selective pressure to vancomycin resistant enterococci and is therefore the preferred treatment.	1702
3114X	Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole\nNOTE: Metronidazole has similar efficacy to vancomycin but may have less selective pressure to vancomycin resistant enterococci and is therefore the preferred treatment.	1701
3116B	Hyperphosphataemia associated with chronic renal failure	2212
3117C	Hyperphosphataemia associated with chronic renal failure	2212
3128P	Chylothorax	1068
3128P	Chylous ascites	1670
3128P	Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders	1671
3128P	Hyperlipoproteinaemia type 1	1513
3128P	Intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect, requiring a ketogenic diet	1672
3128P	Long chain fatty acid oxidation disorders	1511
3130R	Prophylaxis of endocarditis in patients hypersensitive to penicillin	1302
3131T	Endophthalmitis	1091
3131T	Use initiated in a hospital for infections where vancomycin is an appropriate antibiotic	1464
3134Y	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1123
3134Y	For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1126
3134Y	Malignant neoplasia (late stage)	1216
3135B	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1123
5179N	Bone pain due to malignant disease	1036
3135B	For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1126
3135B	Malignant neoplasia (late stage)	1216
3136C	Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae	1276
3138E	Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin	1145
3161J	Disabling spasticity	1084
3161J	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1123
3161J	For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1126
3161J	Malignant neoplasia (late stage)	1216
3162K	Disabling spasticity	1084
3162K	For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1123
3162K	For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	1126
3162K	Malignant neoplasia (late stage)	1216
3169T	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
3169T	Schizophrenia	1589
3170W	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
3170W	Schizophrenia	1589
3171X	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
3171X	Schizophrenia	1589
3172Y	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
3172Y	Schizophrenia	1589
3190X	Bone pain due to malignant disease	1036
3190X	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
3323X	Prophylaxis of endocarditis in patients hypersensitive to penicillin	1302
3338Q	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
3357Q	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
3358R	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
3367F	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
3368G	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
4007X	Severe seborrhoeic dermatitis	1371
4008Y	Severe seborrhoeic dermatitis	1371
4010C	Onychomycosis	1243
4011D	Onychomycosis due to dermatophyte infection proven by microscopy or culture and confirmed by an approved pathology provider	1244
4046Y	For the management of actinic keratoses in patients where other standard treatments are inappropriate, and topical drug therapy is required as field treatment for clinically visible and subclinical lesions\nNOTE: Maximum quantity of four tubes (original + 3 repeats) in 12 months.	3227
4049D	For relief of urinary symptoms when antibiotic or other therapy alone is inappropriate	1105
4059P	For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0)	1793
4070F	Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated	1417
4082W	Hypocalcaemia	1164
4082W	Osteoporosis	1247
4082W	Proven calcium malabsorption	1845
4089F	Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids	1368
4090G	Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids	1368
4092J	Severe intractable rhinitis	1367
4093K	Hyperphosphataemia in chronic renal failure	1162
4094L	Hyperphosphataemia in chronic renal failure	1162
4106D	Severe seborrhoeic dermatitis	1371
4115N	Upper and lower respiratory tract infections	1457
4134N	Treatment of solar keratosis on the face and scalp in patients where other standard treatments are inappropriate and topical drug therapy is required as field treatment for clinically visible and subclinical lesions	3073
4142B	Hyperphosphataemia in chronic renal failure	1162
4144D	For the short-term treatment of anxiety	1109
4145E	For the short-term treatment of anxiety	1109
4150K	Patients with refractory phobic or anxiety states\nNOTE: For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.	1277
4150K	Patients with terminal disease\nNOTE: For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.	1278
4151L	Patients with refractory phobic or anxiety states\nNOTE: For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.	1277
4151L	Patients with terminal disease\nNOTE: For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.	1278
4179Y	For use in patients pre- and post-angioplasty	1606
4190M	Patients requiring an NSAID in whom a risk of upper gastrointestinal complications is high or with a history of peptic ulcer disease	1265
4216X	Patients with refractory phobic or anxiety states\nNOTE: For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.	1277
4216X	Patients with terminal disease\nNOTE: For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.	1278
4233T	Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated	1417
4246L	Short-term use when oral laxative therapy has failed or is inappropriate	1379
4284L	Continuing treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Continuing treatment may be prescribed by rheumatologists or consultant physicians, following initial therapy of 3 doses, in patients who satisfy the following criteria:  (1) There is improvement in ESR and/or CRP; and  (2) An ACR20 (American College of Rheumatology) response is achieved by 14 weeks after the commencement of therapy.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form)	1677
4284L	Initial treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Initial treatment may be prescribed by rheumatologists or consultant physicians for the reduction of signs and symptoms and prevention of structural joint damage in adult patients with active rheumatoid arthritis who satisfy all of the following criteria:  (1) (a) Proven raised erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP); and  (1) (b) Proven erosive rheumatoid arthritis without end-stage disease;  (2) Failure of an adequate trial of methotrexate and 2 other disease modifying anti-rheumatic drugs (such as sulfasalazine, hydroxychloroquine, leflunomide or cyclosporin)  -  unless these drugs were contraindicated or intolerance had developed;  (3) No history of active tuberculosis requiring treatment in the last 3 years;  (4) No history of opportunistic infection in the last 2 months;  (5) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form)	1676
4320J	For the treatment of refractory neuropathic pain not controlled by other drugs	2821
4321K	Patients with documented hypomagnesaemia	1272
4322L	For the treatment of refractory neuropathic pain not controlled by other drugs	2821
4323M	For the treatment of refractory neuropathic pain not controlled by other drugs	2821
4324N	For the treatment of refractory neuropathic pain not controlled by other drugs	2821
4332B	Hypocalcaemia	1164
4332B	Osteoporosis	1247
4332B	Proven calcium malabsorption	1845
4333C	Hypocalcaemia	1164
4333C	Osteoporosis	1247
4333C	Proven calcium malabsorption	1845
4348W	For the topical treatment of secondarily infected traumatic skin lesions	1111
4349X	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain where treatment has been initiated by a specialist with appropriate expertise in pain management.	1062
4350Y	For the topical treatment of secondarily infected traumatic skin lesions	1111
4365R	Post-menopausal symptoms in women who have failed to respond using oral or topical oestrogens	1566
4366T	Post-menopausal symptoms in women who have failed to respond using oral or topical oestrogens	1566
4380M	For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day.   Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density T-score of less than -1.0)	3131
4390C	For the treatment of ano-genital warts	1113
4396J	Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated	1417
4397K	Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated	1417
4398L	Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated	1417
4399M	Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated	1417
4443W	For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0)	1793
4444X	For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0)	1793
4463X	Tinea pedis	1402
4473K	Tinea pedis	1402
4522B	For the short-term treatment of insomnia	1110
4551M	For colostomy and ileostomy use	1101
4551M	For use by paraplegic and quadriplegic patients	1125
4551M	For use with surgical appliances	1134
4556T	For colostomy and ileostomy use	1101
4556T	For use by paraplegic and quadriplegic patients	1125
4556T	For use with surgical appliances	1134
4559Y	Primary treatment of histopathologically confirmed superficial basal cell carcinoma where other standard treatments are inappropriate and topical drug therapy is required	2279
4566H	For the treatment of ano-genital warts	1113
4570M	For the treatment of obese patients.  Total treatment will not exceed 12 months from initial application.  Patients are eligible for 1 continuous treatment in a lifetime.  The patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available).   Initial treatment for patients who meet the following criteria to qualify:  (a) Body Mass Index (BMI) greater than or equal to 35 with no known co-morbidities; or  (b) BMI greater than or equal to 30 with 1 or more of the following co-morbidities:  (i) diabetes;  (ii) ischaemic heart disease;  (iii) psychiatric conditions;  (iv) hypertension.  The prescriber must provide the following:  (a) initial body weight; and  (b) BMI.   Continuing treatment for patients who have previously been issued with an authority prescription for orlistat.  After 3 months and up to 6 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 2.5 kg or 2.5% (whichever is the lesser).   Continuing treatment for patients who have previously been issued with an authority prescription for orlistat. After 6 months and up to 12 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 5 kg or 5% (whichever is the lesser)\nNOTE: The patient should be ideally enrolled in an exercise program and be receiving supplemental vitamins.	2208
4571N	Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program\nNOTE: Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.	1270
4572P	Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program\nNOTE: Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.	1270
4573Q	Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program\nNOTE: Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.	1270
4576W	Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program\nNOTE: Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.	1270
4577X	Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program\nNOTE: Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.	1270
4578Y	Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program\nNOTE: Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.	1270
4579B	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4580C	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4584G	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4585H	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4586J	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4591P	To be approved for the treatment of refractory neuropathic pain not controlled by other drugs	1604
4592Q	To be approved for the treatment of refractory neuropathic pain not controlled by other drugs	1604
4593R	To be approved for the treatment of refractory neuropathic pain not controlled by other drugs	1604
4594T	To be approved for the treatment of refractory neuropathic pain not controlled by other drugs	1604
4595W	To be approved for the treatment of refractory neuropathic pain not controlled by other drugs	1604
4596X	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4597Y	Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.   Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats	1792
4646M	For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings	2853
4647N	For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings	2853
4648P	For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings	2853
4938X	Initial treatment of venous ulcers	1972
4939Y	Initial treatment of venous ulcers	1972
4940B	Initial treatment of venous ulcers	1972
4941C	Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated	1973
4942D	Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated	1973
4943E	Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated	1973
5001F	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5002G	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5003H	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5006L	Infections where resistance to amoxycillin is proven	1837
5006L	Infections where resistance to amoxycillin is suspected	1836
5008N	Infections where resistance to amoxycillin is proven	1837
5008N	Infections where resistance to amoxycillin is suspected	1836
5009P	Infections where resistance to amoxycillin is proven	1837
5009P	Infections where resistance to amoxycillin is suspected	1836
5011R	Infections where resistance to amoxycillin is proven	1837
5011R	Infections where resistance to amoxycillin is suspected	1836
5015Y	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5016B	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5023J	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5032W	Radiation induced mucositis	1669
5034Y	For local intra-articular or peri-articular infiltration	1102
5034Y	Keloid	1189
5034Y	Lichen planus hypertrophic	1191
5048Q	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
5049R	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
5057E	Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin	1145
5064M	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5065N	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5066P	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5067Q	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5076E	Bone pain due to malignant disease	1036
5076E	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5077F	Bone pain due to malignant disease	1036
5077F	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5083M	Prophylaxis of endocarditis in patients hypersensitive to penicillin	1302
5090X	Serious staphylococcal infections	1345
5091Y	Serious staphylococcal infections	1345
5096F	Serious staphylococcal infections	1345
5097G	Serious staphylococcal infections	1345
5111B	Treatment of corticosteroid-responsive dermatoses	1422
5112C	Treatment of corticosteroid-responsive dermatoses	1422
5113D	Treatment of corticosteroid-responsive dermatoses	1422
5114E	Treatment of corticosteroid-responsive dermatoses	1422
5115F	Severe disabling pain not responding to non-narcotic analgesics	1358
5116G	Severe disabling pain not responding to non-narcotic analgesics	1358
5117H	Severe disabling pain not responding to non-narcotic analgesics	1358
5118J	For use in a hospital	1128
5119K	For use in a hospital	1128
5123P	Bone pain due to malignant disease	1036
5123P	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5126T	Bone pain due to malignant disease	1036
5126T	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5132D	Severe disabling pain not responding to non-narcotic analgesics	1358
5136H	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5148Y	For local intra-articular or peri-articular infiltration	1102
5150C	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5154G	Treatment, in a hospital, of acute anaerobic sepsis	1448
5155H	Treatment of anaerobic infections	1416
5161P	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5162Q	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5163R	Severe disabling pain not responding to non-narcotic analgesics	1358
5164T	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5165W	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5166X	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5167Y	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5171E	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5176K	Bone pain due to malignant disease	1036
5176K	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5177L	Bone pain due to malignant disease	1036
5177L	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5178M	Bone pain due to malignant disease	1036
5178M	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5179N	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5186Y	Bone pain due to malignant disease	1036
5186Y	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5190E	Severe disabling pain not responding to non-narcotic analgesics	1358
5191F	Severe disabling pain not responding to non-narcotic analgesics	1358
5194J	Severe disabling pain not responding to non-narcotic analgesics	1358
5195K	Severe disabling pain not responding to non-narcotic analgesics	1358
5197M	Severe disabling pain not responding to non-narcotic analgesics	1358
5198N	Severe disabling pain not responding to non-narcotic analgesics	1358
5201R	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5202T	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5203W	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5204X	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5217N	Bone pain due to malignant disease	1036
5217N	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5218P	Bone pain due to malignant disease	1036
5218P	Chronic arthropathies (including osteoarthritis) with an inflammatory component	1054
5224Y	Chronic arthropathies	2046
5227D	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5230G	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
5231H	Short-term treatment of acute pain	1378
5232J	For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed	1497
5232J	For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed	1615
5233K	For local intra-articular or peri-articular infiltration	1102
5233K	Keloid	1189
5233K	Lichen planus hypertrophic	1191
5234L	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5235M	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5236N	For pain where aspirin and/or paracetamol alone are inappropriate or have failed	1537
5237P	Severe disabling pain not responding to non-narcotic analgesics	1358
5238Q	Severe disabling pain not responding to non-narcotic analgesics	1358
5239R	Severe disabling pain not responding to non-narcotic analgesics	1358
5240T	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5241W	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5242X	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5243Y	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5244B	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5245C	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5246D	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5247E	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5248F	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5249G	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5250H	Chronic severe disabling pain not responding to non-narcotic analgesics	1062
5257Q	Serious staphylococcal infections	1345
5258R	Serious staphylococcal infections	1345
5301B	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5301B	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5302C	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5302C	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5303D	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5303D	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5304E	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5304E	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5305F	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5306G	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5307H	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5308J	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5311M	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5311M	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5904R	Antidote to folic acid antagonists	1028
5312N	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5312N	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5313P	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5313P	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5314Q	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5315R	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5316T	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5317W	Continuing supply for palliative care patients where colicky pain is a symptom, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1894
5317W	Initial supply (for up to 4 months) for palliative care patients where colicky pain is a symptom\nNOTE: No applications for increased repeats will be authorised.	1893
5318X	Continuing supply for palliative care patients where colicky pain is a symptom\nNOTE: No applications for repeats will be authorised.	1895
5319Y	Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1891
5319Y	Initial supply (for up to 4 months) for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated\nNOTE: No applications for increased repeats will be authorised.	1890
5320B	Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated\nNOTE: No applications for repeats will be authorised.	1892
5322D	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5322D	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5324F	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5325G	Continuing supply for palliative care patients where nausea and/or vomiting is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1897
5325G	Initial supply (for up to 4 months) for palliative care patients where nausea and/or vomiting is a problem\nNOTE: No applications for increased repeats will be authorised.	1896
5326H	Continuing supply for palliative care patients where nausea and/or vomiting is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1897
5326H	Initial supply (for up to 4 months) for palliative care patients where nausea and/or vomiting is a problem\nNOTE: No applications for increased repeats will be authorised.	1896
5327J	Continuing supply for palliative care patients where nausea and/or vomiting is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1897
5327J	Initial supply (for up to 4 months) for palliative care patients where nausea and/or vomiting is a problem\nNOTE: No applications for increased repeats will be authorised.	1896
5328K	Continuing supply for palliative care patients where nausea and/or vomiting is a problem\nNOTE: No applications for repeats will be authorised.	1898
5329L	Continuing supply for palliative care patients where nausea and/or vomiting is a problem\nNOTE: No applications for repeats will be authorised.	1898
5330M	Continuing supply for palliative care patients where nausea and/or vomiting is a problem\nNOTE: No applications for repeats will be authorised.	1898
5331N	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5331N	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5332P	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5333Q	Continuing supply for palliative care patients where dry mouth is a symptom, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1900
5333Q	Initial supply (for up to 4 months) for palliative care patients where dry mouth is a symptom\nNOTE: No applications for increased repeats will be authorised.	1899
5334R	Continuing supply for palliative care patients where dry mouth is a symptom, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1900
5334R	Initial supply (for up to 4 months) for palliative care patients where dry mouth is a symptom\nNOTE: No applications for increased repeats will be authorised.	1899
5335T	Continuing supply for palliative care patients where dry mouth is a symptom\nNOTE: No applications for repeats will be authorised.	1901
5336W	Continuing supply for palliative care patients where dry mouth is a symptom\nNOTE: No applications for repeats will be authorised.	1901
5337X	Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1903
5337X	Initial supply (for up to 4 months) for palliative care patients for the prevention of epilepsy\nNOTE: No applications for increased repeats will be authorised.	1902
5338Y	Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1903
5338Y	Initial supply (for up to 4 months) for palliative care patients for the prevention of epilepsy\nNOTE: No applications for increased repeats will be authorised.	1902
5339B	Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1903
5339B	Initial supply (for up to 4 months) for palliative care patients for the prevention of epilepsy\nNOTE: No applications for increased repeats will be authorised.	1902
5340C	Continuing supply for palliative care patients for the prevention of epilepsy\nNOTE: No applications for repeats will be authorised.	1904
5341D	Continuing supply for palliative care patients for the prevention of epilepsy\nNOTE: No applications for repeats will be authorised.	1904
5342E	Continuing supply for palliative care patients for the prevention of epilepsy\nNOTE: No applications for repeats will be authorised.	1904
5343F	Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1891
5343F	Initial supply (for up to 4 months) for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated\nNOTE: No applications for increased repeats will be authorised.	1890
5344G	Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated\nNOTE: No applications for repeats will be authorised.	1892
5345H	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5345H	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5346J	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5346J	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5347K	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5347K	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5348L	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5348L	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5349M	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5350N	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5351P	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5352Q	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5353R	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5353R	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5354T	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5355W	Continuing supply for palliative care patients where anxiety is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2200
5355W	Initial supply (for up to 4 months) for palliative care patients where anxiety is a problem\nNOTE: No applications for increased repeats will be authorised.	2199
5356X	Continuing supply for palliative care patients where anxiety is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2200
5356X	Initial supply (for up to 4 months) for palliative care patients where anxiety is a problem\nNOTE: No applications for increased repeats will be authorised.	2199
5357Y	Continuing supply for palliative care patients where anxiety is a problem\nNOTE: No applications for repeats will be authorised.	2201
5358B	Continuing supply for palliative care patients where anxiety is a problem\nNOTE: No applications for repeats will be authorised.	2201
5359C	Continuing supply for palliative care patients where insomnia is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2203
5359C	Initial supply (for up to 4 months) for palliative care patients where insomnia is a problem\nNOTE: No applications for increased repeats will be authorised.	2202
5360D	Continuing supply for palliative care patients where insomnia is a problem\nNOTE: No applications for repeats will be authorised.	2204
5361E	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5361E	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5421H	Initial supply (for up to 4 months) for palliative care patients where dry mouth is a symptom\nNOTE: No applications for increased repeats will be authorised.	1899
5362F	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5362F	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5363G	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5363G	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5364H	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5365J	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5366K	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5368M	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5368M	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5370P	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5371Q	Continuing supply for palliative care patients where anxiety is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2200
5371Q	Initial supply (for up to 4 months) for palliative care patients where anxiety is a problem\nNOTE: No applications for increased repeats will be authorised.	2199
5372R	Continuing supply for palliative care patients where anxiety is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2200
5372R	Initial supply (for up to 4 months) for palliative care patients where anxiety is a problem\nNOTE: No applications for increased repeats will be authorised.	2199
5373T	Continuing supply for palliative care patients where anxiety is a problem\nNOTE: No applications for repeats will be authorised.	2201
5374W	Continuing supply for palliative care patients where anxiety is a problem\nNOTE: No applications for repeats will be authorised.	2201
5375X	Continuing supply for palliative care patients where insomnia is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2203
5375X	Initial supply (for up to 4 months) for palliative care patients where insomnia is a problem\nNOTE: No applications for increased repeats will be authorised.	2202
5376Y	Continuing supply for palliative care patients where insomnia is a problem\nNOTE: No applications for repeats will be authorised.	2204
5377B	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5377B	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5378C	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5378C	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5379D	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5380E	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5381F	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5381F	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5382G	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2206
5382G	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem\nNOTE: No applications for increased repeats will be authorised.	2205
5383H	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5384J	Continuing supply for palliative care patients where severe pain is a problem\nNOTE: No applications for repeats will be authorised.	2207
5385K	Continuing supply for palliative care patients where a painful mouth is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	2346
5385K	Initial supply (for up to 4 months) for palliative care patients where a painful mouth is a problem\nNOTE: No applications for increased repeats will be authorised.	2345
5386L	Continuing supply for palliative care patients where a painful mouth is a problem\nNOTE: No applications for repeats will be authorised.	2347
5387M	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5387M	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5388N	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5847R	Metastatic breast cancer after failure of prior therapy which includes an anthracycline	3107
5389P	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5389P	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5390Q	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5391R	Continuing supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred\nNOTE: Telephone approvals are limited to 1 month's therapy.	2349
5391R	Initial supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Telephone approvals are limited to 1 month's therapy.	2348
5392T	Continuing supply (for up to 1 month) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: No applications for repeats will be authorised.	2350
5393W	Continuing supply (for up to 3 months) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred\nNOTE: Telephone approvals are limited to 1 month's therapy.	2352
5393W	Initial supply (for up to 3 months) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics\nNOTE: Telephone approvals are limited to 1 month's therapy.	2351
5394X	Continuing supply (for up to 3 months) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred\nNOTE: Telephone approvals are limited to 1 month's therapy.	2352
5394X	Initial supply (for up to 3 months) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics\nNOTE: Telephone approvals are limited to 1 month's therapy.	2351
5395Y	Continuing supply (for up to 1 month) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics\nNOTE: No applications for repeats will be authorised.	2353
5396B	Continuing supply (for up to 1 month) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics\nNOTE: No applications for repeats will be authorised.	2353
5397C	Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred, in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent\nNOTE: No applications for increased repeats will be authorised.	2343
5397C	Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent\nNOTE: No applications for increased repeats will be authorised.	2342
5398D	Continuing supply for palliative care patients where severe pain is a problem in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent\nNOTE: No applications for repeats will be authorised.	2344
5399E	Continuing supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred\nNOTE: Telephone approvals are limited to 1 month's therapy.	2349
5399E	Initial supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Telephone approvals are limited to 1 month's therapy.	2348
5400F	Continuing supply (for up to 1 month) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: No applications for repeats will be authorised.	2350
5401G	Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2858
5402H	Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2858
5403J	Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2858
5404K	Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2858
5405L	Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2858
5406M	Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2858
5407N	First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2859
5407N	Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2860
5901N	Treatment of carcinoma in situ of the urinary bladder	1419
5408P	First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2859
5408P	Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2860
5409Q	First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2859
5409Q	Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2860
5410R	First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2859
5410R	Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2860
5411T	First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2859
5411T	Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2860
5412W	First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2859
5412W	Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.  Telephone approvals are limited to 1 month's therapy.	2860
5413X	Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2861
5414Y	Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2861
5415B	Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2861
5416C	Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2861
5417D	Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2861
5418E	Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects\nNOTE: No applications for increased repeats will be authorised.	2861
5419F	Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1888
5419F	Initial supply (for up to 4 months) for palliative care patients where constipation is a problem\nNOTE: No applications for increased repeats will be authorised.	1887
5420G	Continuing supply for palliative care patients where constipation is a problem\nNOTE: No applications for repeats will be authorised.	1889
5421H	Continuing supply for palliative care patients where dry mouth is a symptom, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	1900
5422J	Continuing supply for palliative care patients where dry mouth is a symptom\nNOTE: No applications for repeats will be authorised.	1901
5423K	Initial supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has failed to respond to laxatives\nNOTE: No applications for repeats will be authorised.	3235
5424L	First continuing supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has demonstrated a response to methylnaltrexone\nNOTE: No applications for increased repeats will be authorised.	3236
5424L	Second and subsequent continuing supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has demonstrated a response to methylnaltrexone, and where consultation with a palliative care specialist or service has occurred\nNOTE: No applications for increased repeats will be authorised.	3237
5425M	Continuing supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has demonstrated a response to methylnaltrexone\nNOTE: No applications for repeats will be authorised.	3238
5501M	Herpes simplex keratitis	1715
5502N	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5503P	Severe dry eye syndrome, including Sjogren's syndrome	1362
5504Q	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5505R	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5506T	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5507W	Severe dry eye syndrome, including Sjogren's syndrome	1362
5508X	Severe dry eye syndrome, including Sjogren's syndrome	1362
5509Y	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5510B	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5517J	Severe dry eye syndrome, including Sjogren's syndrome	1362
5518K	Severe dry eye syndrome, including Sjogren's syndrome	1362
5519L	Severe dry eye syndrome, including Sjogren's syndrome	1362
5520M	Severe dry eye syndrome, including Sjogren's syndrome	1362
5521N	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5524R	Severe dry eye syndrome, including Sjogren's syndrome	1362
5525T	Severe dry eye syndrome, including Sjogren's syndrome	1362
5526W	Severe dry eye syndrome, including Sjogren's syndrome	1362
5527X	Severe dry eye syndrome, including Sjogren's syndrome	1362
5528Y	Severe dry eye syndrome, including Sjogren's syndrome	1362
5529B	Vernal kerato-conjunctivitis	1466
5532E	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5535H	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2138
5535H	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2137
5542Q	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2138
5542Q	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2137
5545W	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5553G	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3138
5553G	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3137
5555J	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3138
5555J	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3137
5556K	Severe dry eye syndrome, including Sjogren's syndrome	1362
5558M	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3138
5558M	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3137
5559N	Severe dry eye syndrome, including Sjogren's syndrome	1362
5560P	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5561Q	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	2802
5831X	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information\nNOTE: No applications for repeats will be authorised.	2713
5831X	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated\nNOTE: No applications for repeats will be authorised.	2714
5832Y	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated\nNOTE: A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.	2715
5902P	Primary and relapsing superficial urothelial carcinoma of the bladder	1290
5833B	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
5834C	Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval	2957
5834C	Mesothelioma in combination with cisplatin.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval\nNOTE: No applications for increased maximum quantities for the 500 mg vial will be authorised.	2958
5835D	Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval	2957
5835D	Mesothelioma in combination with cisplatin.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval\nNOTE: No applications for increased maximum quantities for the 500 mg vial will be authorised.	2958
5836E	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information\nNOTE: No applications for repeats will be authorised.	2713
5836E	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated\nNOTE: No applications for repeats will be authorised.	2714
5837F	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information\nNOTE: No applications for repeats will be authorised.	2713
5837F	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated\nNOTE: No applications for repeats will be authorised.	2714
5838G	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated\nNOTE: A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.	2715
5839H	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated\nNOTE: A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.	2715
5840J	B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.   Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.   The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:  (a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and  (b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry	3015
5841K	B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.   Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.   The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:  (a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and  (b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry	3015
5842L	Neoadjuvant treatment of a patient with a WHO performance status of 1 or less, with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx, in combination with cisplatin and fluorouracil\nNOTE: The carcinoma can be considered inoperable for technical or organ preservation reasons.	3051
5843M	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
5843M	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
5843M	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
5843M	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
5843M	Locally advanced or metastatic non-small cell lung cancer	1194
5844N	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
5844N	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
5844N	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
5844N	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
5844N	Locally advanced or metastatic non-small cell lung cancer	1194
5845P	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
5845P	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
5845P	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
5845P	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
5845P	Locally advanced or metastatic non-small cell lung cancer	1194
5846Q	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
5848T	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5849W	Continuing PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with metastatic colorectal cancer who has previously been issued with an authority prescription for bevacizumab and who does not have progressive disease and who remains on first-line chemotherapy\nNOTE: Not for use as monotherapy.	3143
5849W	Initial PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with previously untreated metastatic colorectal cancer with a WHO performance status of 0 or 1\nNOTE: Not for use as monotherapy.	3142
5850X	Continuing PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with metastatic colorectal cancer who has previously been issued with an authority prescription for bevacizumab and who does not have progressive disease and who remains on first-line chemotherapy\nNOTE: Not for use as monotherapy.	3143
5850X	Initial PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with previously untreated metastatic colorectal cancer with a WHO performance status of 0 or 1\nNOTE: Not for use as monotherapy.	3142
5851Y	Induction and consolidation treatment of relapsed acute promyelocytic leukaemia (characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript) in a patient who is arsenic naive at induction	3150
5852B	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
5852B	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
5852B	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
5852B	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
5852B	Locally advanced or metastatic non-small cell lung cancer	1194
5877H	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
5877H	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
5878J	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
5878J	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
5888X	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered.  No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy\nNOTE: No applications for increased maximum quantities will be authorised. Prescribers should advise Medicare Australia of the number of cycles planned when requesting approval for repeats.	2330
5888X	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:  (a) altretamine;  (b) carmustine;  (c) cisplatin when a single dose constitutes a cycle of chemotherapy;  (d) cyclophosphamide at a dose of 1500 mg per square metre per day or greater;  (e) dacarbazine;  (f) procarbazine when a single dose constitutes a cycle of chemotherapy;  (g) streptozocin.  No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy\nNOTE: No applications for increased maximum quantities will be authorised. Prescribers should advise Medicare Australia of the number of cycles planned when requesting approval for repeats.	2071
5889Y	Hairy cell leukaemia	3180
5891C	Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen	1568
5891C	Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane	1795
5891C	Metastatic breast cancer, as monotherapy, where therapy with capecitabine and/or a taxane is contraindicated	1796
5892D	Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen	1568
5892D	Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane	1795
5892D	Metastatic breast cancer, as monotherapy, where therapy with capecitabine and/or a taxane is contraindicated	1796
5893E	Hairy cell leukaemia	1149
5896H	Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2068
5896H	Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2386
5897J	Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2068
5897J	Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2386
5898K	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5899L	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5900M	Metastatic malignant melanoma	3181
5921P	Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide	2416
5921P	Adjuvant treatment of operable breast cancer in combination with cyclophosphamide\nNOTE: A maximum of four cycles of treatment will be authorised under this restriction.	3292
5921P	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5921P	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
5921P	Locally advanced or metastatic non-small cell lung cancer	1194
5921P	Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%.  Docetaxel must be used as first-line chemotherapy and administered in three weekly cycles\nNOTE: A maximum of 10 cycles of treatment with docetaxel will be authorised under this restriction.	2732
5921P	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
5922Q	Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide	2416
5922Q	Adjuvant treatment of operable breast cancer in combination with cyclophosphamide\nNOTE: A maximum of four cycles of treatment will be authorised under this restriction.	3292
5922Q	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5922Q	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
5922Q	Locally advanced or metastatic non-small cell lung cancer	1194
5922Q	Neoadjuvant treatment of a patient with a WHO performance status of 1 or less, with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx, in combination with cisplatin and fluorouracil\nNOTE: The carcinoma can be considered inoperable for technical or organ preservation reasons.	3051
5922Q	Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%.  Docetaxel must be used as first-line chemotherapy and administered in three weekly cycles\nNOTE: A maximum of 10 cycles of treatment with docetaxel will be authorised under this restriction.	2732
5922Q	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
5923R	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5924T	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5936K	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
5936K	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
5936K	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
5936K	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
5936K	Locally advanced or metastatic non-small cell lung cancer	1194
5937L	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
5937L	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
5937L	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
5937L	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
5937L	Locally advanced or metastatic non-small cell lung cancer	1194
5941Q	Acute myelogenous leukaemia	1006
5942R	Acute myelogenous leukaemia	1006
5943T	Relapsed or refractory germ cell tumours following first-line chemotherapy	1325
5943T	Relapsed or refractory sarcomas following first-line chemotherapy	1327
5944W	Relapsed or refractory germ cell tumours following first-line chemotherapy	1325
5944W	Relapsed or refractory sarcomas following first-line chemotherapy	1327
5945X	Hairy cell leukaemia	1149
5945X	Myeloproliferative disease with excessive thrombocytosis	1234
5946Y	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
5947B	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
5948C	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
5949D	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
5953H	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
5953H	Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy	1206
5956L	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
5956L	Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy	1206
5958N	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
5959P	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
5960Q	Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide	1618
5961R	Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide	1618
5967C	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5968D	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5969E	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5970F	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5971G	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5972H	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5973J	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
5973J	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5973J	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
5973J	Locally advanced or metastatic non-small cell lung cancer	1194
5973J	Primary treatment of ovarian cancer in combination with a platinum compound	1293
5973J	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
5974K	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
5974K	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5974K	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
5974K	Locally advanced or metastatic non-small cell lung cancer	1194
5974K	Primary treatment of ovarian cancer in combination with a platinum compound	1293
5974K	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
5975L	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
5975L	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5975L	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
5975L	Locally advanced or metastatic non-small cell lung cancer	1194
5975L	Primary treatment of ovarian cancer in combination with a platinum compound	1293
5975L	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
5976M	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
5976M	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5976M	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
5976M	Locally advanced or metastatic non-small cell lung cancer	1194
5976M	Primary treatment of ovarian cancer in combination with a platinum compound	1293
5976M	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
5977N	For use as a single agent in the treatment of advanced colorectal cancer	3185
5978P	Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma	1745
5978P	Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma	1744
5979Q	Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma	1745
5979Q	Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma	1744
5985B	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	3186
5986C	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5987D	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
5992J	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5992J	Locally advanced or metastatic non-small cell lung cancer	1194
5993K	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
5993K	Locally advanced or metastatic non-small cell lung cancer	1194
5994L	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
5994L	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
5995M	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
5995M	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
5996N	Myeloproliferative disease with excessive thrombocytosis	1234
5997P	Myeloproliferative disease with excessive thrombocytosis	1234
5998Q	Myeloproliferative disease with excessive thrombocytosis	1234
5999R	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
5999R	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
6101D	Schizophrenia in patients who are intolerant of other neuroleptic agents	1827
6101D	Schizophrenia in patients who are non-responsive to other neuroleptic agents	1826
6102E	Schizophrenia in patients who are intolerant of other neuroleptic agents	1827
6102E	Schizophrenia in patients who are non-responsive to other neuroleptic agents	1826
6103F	Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with botulinum toxin type A purified neurotoxin complex as a paediatric patient	3044
6103F	Continuing PBS-subsidised treatment of moderate to severe spasticity of the upper limb in a cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with botulinum toxin type A purified neurotoxin complex as a paediatric patient\nNOTE: Contact Medicare Australia before commencing PBS-subsidised treatment in cerebral palsy patients who have been treated for moderate to severe spasticity of the upper limb with non-PBS-subsidised botulinum toxin prior to the age of 18.	3140
6103F	Treatment of blepharospasm associated with dystonia, including benign blepharospasm and VIIth nerve disorders (hemifacial spasm) in patients 12 years and older	1418
6103F	Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive	3043
6103F	Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.  Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime.  Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture.  Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.  The date of the stroke must be provided.  Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin	3141
6103F	Treatment of moderate to severe spasticity of the upper limb in a cerebral palsy patient aged from 2 to 17 years inclusive\nNOTE: Contact Medicare Australia before commencing PBS-subsidised treatment in cerebral palsy patients who have been treated for moderate to severe spasticity of the upper limb with non-PBS-subsidised botulinum toxin prior to the age of 18.	3139
6103F	Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care	1524
6109M	For use by organ or tissue transplant recipients	1504
6113R	Disorders of erythropoiesis associated with treatment-related chronic iron overload	1085
6120D	Grandfather  -  continuing for patients five years or older  Continuation of treatment of cystic fibrosis in a patient 5 years of age or older, who initiated treatment with dornase alfa at an age of less than 5 years and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use\nNOTE: It is highly desirable that all patients be included in the national cystic fibrosis patient data-base.	3201
6120D	Grandfather  -  for patients less than five years of age who initiated dornase alfa prior to listing  Treatment of cystic fibrosis in a patient less than 5 years of age who initiated treatment with dornase alfa prior to 1 November 2009 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use\nNOTE: It is highly desirable that all patients be included in the national cystic fibrosis patient data-base.	3202
6120D	Treatment of cystic fibrosis in a patient less than 5 years of age who has:  (1) A severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring frequent hospital admissions more frequently than 3 times per year; or  (2) Significant bronchiectasis on chest high resolution computed tomography scan; or  (3) Severe cystic fibrosis bronchiolitis with persistent wheeze non-responsive to conventional medicines; or  (4) Severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy.   In order for the patient to be eligible for participation in the HSD program, the following conditions must be met:  (1) The patient must be assessed at a cystic fibrosis clinic/centre which is under the supervision of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis, and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;  (2) Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented involving the patient, the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team to establish agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. Further reassessments are to be undertaken and documented yearly\nNOTE: It is highly desirable that all patients be included in the national cystic fibrosis patient data-base.	3200
6120D	Use by cystic fibrosis patients who satisfy all of the following criteria:  (1) are 5 years of age or older;  (2) have a FVC greater than 40% predicted for age, gender and height;  (3) have evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);  (4) are participating in a 4 week trial as detailed below or have achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) after a 4 week trial.   In order for patients to be eligible for participation in the HSD program, the following conditions must be met:  (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of dornase alfa under the HSD program is limited to such physicians.  If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;  (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;  (3) Prior to dornase alfa therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;  (4) Initial therapy is limited to 4 weeks' treatment with dornase alfa at a dose of 2.5 mg daily;  (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) are eligible for continued subsidy under the HSD program at a dose of 2.5 mg daily;  (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 2.5 mg daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;  (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that dornase alfa treatment is continuing to produce worthwhile benefits. (Dornase alfa therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;  (8) Other aspects of treatment, such as physiotherapy, must be continued;  (9) Where there is documented evidence that a patient already receiving dornase alfa therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period)\nNOTE: It is highly desirable that all patients be included in the national cystic fibrosis patient data-base.	1507
6125J	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6125J	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
6125J	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
6125J	Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired	1657
6125J	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	2923
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)	2924
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	2925
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	2926
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	2927
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)	2928
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease	2929
6126K	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma	2930
6126K	A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3087
6126K	A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2919
6126K	A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2918
6126K	A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation	2915
6126K	A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation	2916
6126K	A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2917
6126K	A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2922
6127L	For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia	2912
8378Y	Glioblastoma multiforme following radiotherapy	2101
6126K	A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3187
6126K	A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2921
6126K	A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)	2920
6126K	For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia	2912
6126K	Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation	2914
6126K	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy	2913
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	2923
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)	2924
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	2925
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	2926
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	2927
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)	2928
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease	2929
6127L	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma	2930
6127L	A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3087
6127L	A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2919
6127L	A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2918
6127L	A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation	2915
6127L	A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation	2916
6127L	A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2917
6127L	A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2922
6127L	A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3187
6127L	A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2921
6127L	A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)	2920
6127L	Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation	2914
6127L	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy	2913
6134W	Treatment of aciclovir-resistant herpes simplex virus infection in immunocompromised patients with HIV infection	1413
6134W	Treatment of cytomegalovirus retinitis in patients with AIDS	1610
6136Y	Cytomegalovirus retinitis in severely immunocompromised patients	1612
6136Y	Prophylaxis of cytomegalovirus disease in bone marrow transplant patients at risk of cytomegalovirus disease	1830
6136Y	Prophylaxis of cytomegalovirus disease in solid organ transplant patients at risk of cytomegalovirus disease	1831
6137B	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6137B	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6148N	Treatment of chronic granulomatous disease in patients with frequent and severe infections despite adequate prophylaxis with antimicrobial agents	1058
6151R	Treatment of Mycobacterium avium complex infections	1434
6152T	Treatment of Mycobacterium avium complex infections	1434
6153W	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6153W	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6154X	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6154X	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6155Y	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6155Y	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6169Q	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6170R	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6171T	Treatment of opiate dependence in accordance with the law of the relevant State or Territory	1569
6172W	Treatment of opiate dependence in accordance with the law of the relevant State or Territory	1569
6178E	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6181H	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6186N	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6186N	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6189R	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6189R	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6190T	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6190T	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6193Y	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6193Y	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6194B	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6194B	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6195C	Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre	1299
6195C	Treatment of Mycobacterium avium complex infections in HIV-positive patients	1435
6202K	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6202K	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6203L	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6203L	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6204M	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6205N	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6206P	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6499C	Chronic iron overload in adults, adolescents and children 6 years and older associated with disorders of erythropoiesis	2440
6207Q	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6208R	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1651
6208R	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1650
6209T	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1651
6209T	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1650
6210W	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6210W	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6211X	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6211X	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6212Y	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6212Y	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6213B	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6213B	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6215D	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6215D	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6216E	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6217F	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6218G	Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement	1009
6218G	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6218G	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6219H	Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement	1009
6219H	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6219H	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
8018B	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
6221K	Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre	1299
6223M	Bone metastases from breast cancer	1035
6223M	Multiple myeloma	1233
6223M	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6227R	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100 micrograms 3 times daily	2622
6227R	Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2623
6228T	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100 micrograms 3 times daily	2622
6228T	Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2623
6229W	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100 micrograms 3 times daily	2622
6229W	Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2623
6232B	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6232B	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
6232B	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
6232B	Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired	1657
6232B	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
6234D	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6234D	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6243N	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6243N	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6246R	Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement	1009
6291D	A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2921
6246R	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6246R	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6247T	Treatment of cytomegalovirus retinitis in patients with AIDS	1610
6249X	Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive mucocutaneous involvement	1828
6249X	Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive visceral involvement	1829
6250Y	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6250Y	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6251B	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6253D	Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement	1009
6253D	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6253D	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6254E	Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement	1009
6254E	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6254E	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6255F	Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement	1009
6255F	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception	2939
6255F	Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase	1463
6256G	Cytomegalovirus retinitis in severely immunocompromised patients	1612
6257H	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy	2932
6264Q	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6264Q	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6265R	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6265R	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6266T	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6270B	Disorders of erythropoiesis associated with treatment-related chronic iron overload	1085
6291D	A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)	2920
6291D	For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia	2912
6291D	Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation	2914
6271C	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy	2932
6279L	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6280M	Prophylaxis of cytomegalovirus (CMV) infection and disease following renal transplantation in patients at risk of CMV disease	1494
6284R	Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to multiple sclerosis	1638
6284R	Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord disease	1640
6284R	Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord injury	1639
6284R	Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity of cerebral origin	1637
6286W	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6287X	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6288Y	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6289B	Bone metastases from breast cancer	1035
6289B	Multiple myeloma	1233
6289B	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6290C	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	2923
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)	2924
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	2925
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	2926
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	2927
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)	2928
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease	2929
6291D	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma	2930
6291D	A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3087
6291D	A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2919
6291D	A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2918
6291D	A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation	2915
6291D	A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation	2916
6291D	A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2917
6291D	A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2922
6291D	A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3187
6291D	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy	2913
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	2923
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)	2924
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	2925
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	2926
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	2927
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)	2928
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease	2929
6292E	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma	2930
6292E	A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3087
6292E	A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2919
6292E	A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2918
6292E	A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation	2915
6292E	A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation	2916
6292E	A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2917
6292E	A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2922
6292E	A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3187
6292E	A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))	2921
6292E	A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)	2920
6292E	For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia	2912
6292E	Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation	2914
6292E	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy	2913
6293F	Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with clostridium botulinum type A toxin-haemagglutinin complex as a paediatric patient	3045
6293F	Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive	3043
6293F	Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.  Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime.  Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture.  Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.  The date of the stroke must be provided.  Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin	3141
6293F	Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care	1524
6295H	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6296J	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6297K	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6298L	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6298L	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6299M	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6299M	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6300N	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6300N	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6301P	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6301P	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6302Q	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6303R	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6305W	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6307Y	Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment\nNOTE: Treatment must be in accordance with the law of the relevant State or Territory.	1538
6308B	Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment\nNOTE: Treatment must be in accordance with the law of the relevant State or Territory.	1538
6309C	Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment\nNOTE: Treatment must be in accordance with the law of the relevant State or Territory.	1538
6312F	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6313G	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6314H	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6315J	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6499C	Chronic iron overload in paediatric patients aged 2 to 5 years, associated with disorders of erythropoiesis, who are intolerant to desferrioxamine or in whom desferrioxamine has proven ineffective	2441
6316K	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6317L	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6318M	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6319N	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6320P	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6321Q	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6322R	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6323T	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6324W	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6325X	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6326Y	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6327B	Treatment of HIV infection in patients over 12 years of age, weighing 40 kg or more, with CD4 cell counts of less than 500 per cubic millimetre	1822
6327B	Treatment of HIV infection in patients over 12 years of age, weighing 40 kg or more, with viral load of greater than 10,000 copies per mL	1823
6328C	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6329D	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6330E	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6332G	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment	2619
6335K	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6336L	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6337M	Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors	1555
6337M	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy	1228
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	1005
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma	1097
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	1140
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	1168
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	1238
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade)	1240
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma	1249
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease	1324
6337M	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma	1333
6337M	Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	1051
6337M	Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	1046
6337M	Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation	1274
6338N	Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors	1555
6338N	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy	1228
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	1005
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma	1097
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	1140
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	1168
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	1238
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade)	1240
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma	1249
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease	1324
6338N	Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma	1333
6338N	Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	1051
6338N	Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	1046
6338N	Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation	1274
6339P	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6341R	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
6341R	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
6461C	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1651
6345Y	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6352H	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6352H	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
6352H	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
6352H	Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired	1657
6352H	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
6353J	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6353J	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
6353J	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
6353J	Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired	1657
6353J	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
6354K	Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required	1654
6354K	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
6354K	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
6354K	Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired	1657
6354K	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
6356M	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6356M	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6357N	Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome	1620
6357N	Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease	1964
6358P	Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:  (1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or  (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy\nNOTE: Patients should have undergone a liver biopsy at some point since initial diagnosis to obtain histological evidence of chronic hepatitis.  Patients may receive tenofovir treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.	2931
6426F	Acromegaly in a patient controlled on Sandostatin subcutaneous injections.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months of treatment	2624
6461C	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1650
6500D	Chronic iron overload in adults, adolescents and children 6 years and older associated with disorders of erythropoiesis	2440
6358P	Treatment, as sole PBS-subsidised therapy, of chronic hepatitis B in a patient who is nucleoside analogue naive and satisfies all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy\nNOTE: Patients should have undergone a liver biopsy at some point since initial diagnosis to obtain histological evidence of chronic hepatitis.  Patients may receive tenofovir treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.	3203
6358P	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6358P	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia	2923
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)	2924
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours	2925
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours	2926
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma	2927
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)	2928
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease	2929
6363X	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma	2930
6363X	A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3087
6363X	A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2919
6363X	A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2918
6363X	A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	2917
6363X	A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned	3187
6363X	For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia	2912
6364Y	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1651
6364Y	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1650
6365B	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6366C	For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3294
6426F	Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2625
6500D	Chronic iron overload in paediatric patients aged 2 to 5 years, associated with disorders of erythropoiesis, who are intolerant to desferrioxamine or in whom desferrioxamine has proven ineffective	2441
6367D	Continuing PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of severe active polyarticular course juvenile chronic arthritis in patients who have demonstrated an adequate response to treatment with etanercept as manifested by:  (a) an active joint count of fewer than 10 active (swollen and tender) joints; OR  (b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; OR  (c) a reduction in the number of the following active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of the joint assessment must be provided.   Only 6 months of treatment per application will be approved. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria.   Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.   Withdrawal of treatment with etanercept should be considered in patients who have achieved and sustained complete remission of disease for 12 months. Subsequent applications for PBS-subsidised re-treatment with etanercept will be subject to the authority conditions applying to initial treatment and will not be authorised within 12 months of the date on which treatment with etanercept was ceased.   Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application	1781
6367D	Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of patients under 18 years who have severe active polyarticular course juvenile chronic arthritis; AND  (a) whose parent or authorised guardian has signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have demonstrated either:  (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or  (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:   -  oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or   -  oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months. (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)   Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.   Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.   The following criteria must be met in order to demonstrate failure to achieve an adequate response to either of the above treatment regimens:  (a) an active joint count of at least 20 active (swollen and tender) joints; OR  (b) at least 4 active joints from the following list:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, or intolerance develops during the period of use such that permanent withdrawal is necessary and a suitably effective treatment regimen cannot be implemented, this exempts the requirement to demonstrate an inadequate response within the time period specified above for these agents.   The authority application must be in writing and must include the information used to determine the patient's eligibility under the criteria above. The date of the joint assessment must be provided.   Only 16 weeks of treatment will be approved. The assessment of the patient's response to initial treatment should be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated	1779
6369F	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1764
6370G	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1764
6371H	Bone metastases from breast cancer	1035
6371H	Bone metastases from hormone-resistant prostate cancer, with demonstration of biochemical progression of disease despite maximal therapy with hormonal treatments	1797
6371H	Multiple myeloma	1233
6371H	Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1500
6372J	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6372J	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6373K	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6374L	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6375M	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6376N	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6392K	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6427G	Acromegaly in a patient controlled on Sandostatin subcutaneous injections.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months of treatment	2624
8018B	Primary treatment of ovarian cancer in combination with a platinum compound	1293
6394M	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6395N	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6396P	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6397Q	Continuing treatment  Continuing PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with infliximab; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with infliximab.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg.  Up to a maximum of 2 repeats may be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2849
6397Q	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 22 weeks of treatment will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg.  Up to a maximum of 3 repeats may be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.   PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.   In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.   From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.   A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.   For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.   The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.   There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.   If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.   (1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.   From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Rituximab patients:  A further application may be submitted to Medicare Australia 24 weeks after the first infusion.  New baselines may be submitted with this application if appropriate.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements.  However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application.  However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.   In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab.  This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD.  Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.   To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.	3221
6397Q	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with infliximab within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.   A maximum of 22 weeks of treatment will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg.  Up to a maximum of 3 repeats may be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints.  Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.   The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.   From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.   'Grandfather' arrangements will only apply for the first Treatment Cycle.  For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2848
6399T	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6427G	Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2625
8018B	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
6399T	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6400W	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6400W	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6401X	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6401X	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6428H	Acromegaly in a patient controlled on Sandostatin subcutaneous injections.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months of treatment	2624
6464F	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
8015W	Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy will be authorised)	1377
6402Y	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6402Y	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6403B	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6403B	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6404C	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6428H	Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2625
6488L	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6489M	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
8180M	Hairy cell leukaemia	1149
6404C	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6405D	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6405D	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6406E	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6406E	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6455R	Treatment, in combination with other antiretroviral agents, of HIV infection in antiretroviral experienced patients with treatment failure characterised by treatment-limiting toxicity to previous antiretroviral agents. Patients must have failed previous treatment with 3 different antiretroviral regimens.  At least 1 of each of the following classes of antiretroviral drugs must have been attempted:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 1 protease inhibitor	2008
6490N	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6491P	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6407F	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6407F	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6408G	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6408G	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6409H	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6429J	Cessation of treatment (all patients)  Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to scleroderma or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.   Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) [see Note on authority approval requirements].   Approval will only be granted for the 62.5 mg tablet strength.  The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.   Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month	3013
6409H	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6410J	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
6410J	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
6411K	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
6412L	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
6413M	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
8018B	Locally advanced or metastatic non-small cell lung cancer	1194
6414N	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
6415P	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
6416Q	Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective	1912
6416Q	Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy	1911
6417R	Schizophrenia in patients who are intolerant of other neuroleptic agents	1827
6417R	Schizophrenia in patients who are non-responsive to other neuroleptic agents	1826
6418T	Schizophrenia in patients who are intolerant of other neuroleptic agents	1827
6418T	Schizophrenia in patients who are non-responsive to other neuroleptic agents	1826
6423C	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment	2620
6423C	Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2621
6424D	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment	2620
6424D	Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2621
6425E	Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND  (a) after failure of other therapy including dopamine agonists; or  (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or  (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.  In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.  Treatment must cease if IGF1 is not lower after 3 months treatment	2620
6425E	Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.  Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose	2621
6429J	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.   Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3162
6429J	Initial (change or re-commencement for adult patients)  Application for initial treatment with bosentan monohydrate of adult patients with one of the following:  (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR  (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3160
6429J	Initial (change or re-commencement for patients under 18 years of age)  Application for initial treatment with bosentan monohydrate of patients aged less than 18 years with one of the following:  (a) primary pulmonary hypertension, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR  (b) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with a PAH agent other than bosentan monohydrate.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3161
6429J	Initial (new adult patients)  Application for initial PBS-subsidised treatment with bosentan monohydrate of adult patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to scleroderma and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (c) WHO Functional Class IV primary pulmonary hypertension; OR  (d) WHO Functional Class IV pulmonary arterial hypertension secondary to scleroderma.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3156
6429J	Initial (new adult patients)  Application for initial PBS-subsidised treatment with bosentan monohydrate of adult patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to scleroderma and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3155
6451M	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
6429J	Initial (new patients)  Application for initial PBS-subsidised treatment with bosentan monohydrate of a patient who has been assessed by a physician from a designated hospital to have WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment (and signed by the parent or authorised guardian for patients under 18 years of age) indicating that the patient understands and acknowledges that PBS-subsidised treatment with bosentan monohydrate will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3159
6429J	Initial (new patients under 18 years of age)  Application for initial PBS-subsidised treatment with bosentan monohydrate of patients aged less than 18 years who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class IV primary pulmonary hypertension.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a patient and prescriber acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3158
6429J	Initial (new patients under 18 years of age)  Application for initial PBS-subsidised treatment with bosentan monohydrate of patients aged less than 18 years who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate prior vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a patient and prescriber acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3157
6430K	Cessation of treatment (all patients)  Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to scleroderma or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.   Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) [see Note on authority approval requirements].   Approval will only be granted for the 62.5 mg tablet strength.  The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.   Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month	3013
6430K	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.   Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3162
6451M	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
6452N	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
6430K	Initial (change or re-commencement for adult patients)  Application for initial treatment with bosentan monohydrate of adult patients with one of the following:  (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR  (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3160
6430K	Initial (change or re-commencement for patients under 18 years of age)  Application for initial treatment with bosentan monohydrate of patients aged less than 18 years with one of the following:  (a) primary pulmonary hypertension, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR  (b) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with a PAH agent other than bosentan monohydrate.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3161
6430K	Initial (new adult patients)  Application for initial PBS-subsidised treatment with bosentan monohydrate of adult patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to scleroderma and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (c) WHO Functional Class IV primary pulmonary hypertension; OR  (d) WHO Functional Class IV pulmonary arterial hypertension secondary to scleroderma.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3156
6430K	Initial (new adult patients)  Application for initial PBS-subsidised treatment with bosentan monohydrate of adult patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to scleroderma and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3155
6430K	Initial (new patients)  Application for initial PBS-subsidised treatment with bosentan monohydrate of a patient who has been assessed by a physician from a designated hospital to have WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment (and signed by the parent or authorised guardian for patients under 18 years of age) indicating that the patient understands and acknowledges that PBS-subsidised treatment with bosentan monohydrate will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3159
6452N	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
6453P	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
6453P	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
8018B	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
6430K	Initial (new patients under 18 years of age)  Application for initial PBS-subsidised treatment with bosentan monohydrate of patients aged less than 18 years who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class IV primary pulmonary hypertension.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a patient and prescriber acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3158
6430K	Initial (new patients under 18 years of age)  Application for initial PBS-subsidised treatment with bosentan monohydrate of patients aged less than 18 years who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate prior vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) two completed authority prescription forms [see Note for authority approval requirements]; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a patient and prescriber acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3157
6431L	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6432M	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6433N	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
6434P	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6435Q	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6435Q	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6436R	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	2135
6437T	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	2135
6438W	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6439X	Monotherapy in patients with chronic hepatitis B and compensated liver disease who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Have received no prior peginterferon alfa therapy for the treatment of hepatitis B;  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception;  (5) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L).  Treatment is limited to 1 course of treatment for a duration of up to 48 weeks\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2940
6454Q	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
6454Q	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
6455R	Treatment, in combination with other antiretroviral agents, of HIV infection in antiretroviral experienced patients with treatment failure characterised by evidence of HIV replication, despite ongoing therapy. Patients must have failed previous treatment with 3 different antiretroviral regimens.  At least 1 of each of the following classes of antiretroviral drugs must have been attempted:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 1 protease inhibitor	2007
8180M	Myeloproliferative disease with excessive thrombocytosis	1234
6439X	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
6448J	Continuing treatment for all patients  Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:  (a) has demonstrated a response to treatment with infliximab; and  (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with infliximab.   Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.   For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.   Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment.   Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.   Written applications for authorisation must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.   All measurements provided must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with infliximab will be authorised under this criterion.   At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone	2496
6448J	Initial 1 (new patients)  First course of PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND  (a) who has at least 2 of the following:  (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or  (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or  (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND  (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.   The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.   If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.   If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.   The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.   The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.   Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.   At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone	2494
6448J	Initial 2 (change or re-commencement for all patients)  Initial course of PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with infliximab.   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.   A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.   At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone	2495
6449K	Monotherapy in patients with chronic hepatitis B and compensated liver disease who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Have received no prior peginterferon alfa therapy for the treatment of hepatitis B;  (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception;  (5) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L).  Treatment is limited to 1 course of treatment for a duration of up to 48 weeks\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2940
6449K	Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  The treatment course is limited to up to 48 weeks.   Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	2334
6450L	Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:  (1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or  (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy\nNOTE: Patients should have undergone a liver biopsy at some point since initial diagnosis to obtain histological evidence of chronic hepatitis.  Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.	2931
6456T	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with iloprost trometamol of patients who have received approval for initial PBS-subsidised treatment with iloprost trometamol, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of iloprost trometamol treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3171
6456T	Initial (change or re-commencement for all patients)  Application for initial PBS-subsidised treatment with iloprost trometamol of patients with one of the following:  (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised iloprost trometamol after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with iloprost trometamol; OR  (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than iloprost trometamol; OR  (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and  (5) for WHO Functional Class III patients, where this is the first application for iloprost trometamol, assessment details of the PBS-subsidised PAH agent they have failed to respond to.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3170
6456T	Initial (new patients)  Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class IV primary pulmonary hypertension; OR  (c) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR  (d) WHO Functional Class IV drug-induced pulmonary arterial hypertension.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3169
6456T	Initial (new patients)  Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with iloprost and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3168
6457W	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	2135
6458X	Treatment of HIV infection in patients over 12 years of age, weighing 40 kg or more, with CD4 cell counts of less than 500 per cubic millimetre	1822
6458X	Treatment of HIV infection in patients over 12 years of age, weighing 40 kg or more, with viral load of greater than 10,000 copies per mL	1823
6459Y	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1651
6459Y	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1650
6460B	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1651
6460B	Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required	1650
6465G	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6466H	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6467J	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6468K	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6468K	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6469L	Multiple myeloma\nNOTE: Patients receiving thalidomide under the PBS listing must be registered in the Thalidomide Risk Management Program.	1233
6470M	Treatment of opiate dependence within a framework of medical, social and psychological treatment\nNOTE: Treatment must be in accordance with the law of the relevant State or Territory.	2295
6471N	Treatment of opiate dependence within a framework of medical, social and psychological treatment\nNOTE: Treatment must be in accordance with the law of the relevant State or Territory.	2295
6476W	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
6477X	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3167
6477X	Initial (change or re-commencement for all adult patients)  Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients with one of the following:  (a) primary pulmonary hypertension who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR  (b) WHO Functional Class IV primary pulmonary hypertension and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR  (c) WHO Functional Class III primary pulmonary hypertension and who have failed to respond to a prior PBS-subsidised PAH agent.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and  (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3165
6492Q	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6493R	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6494T	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6494T	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
6495W	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
6477X	Initial (change or re-commencement for all patients under 18 years of age)  Application for initial PBS-subsidised treatment with epoprostenol sodium of patients aged less than 18 years with one of the following:  (a) primary pulmonary hypertension who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR  (b) WHO Functional Class IV primary pulmonary hypertension and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR  (c) WHO Functional Class III primary pulmonary hypertension and who have failed to respond to a prior PBS-subsidised PAH agent.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and  (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3166
6477X	Initial (new adult patients)  Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class IV primary pulmonary hypertension.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3163
6477X	Initial (new patients under 18 years of age)  Application for initial PBS-subsidised treatment with epoprostenol sodium of patients aged less than 18 years who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class IV primary pulmonary hypertension.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a patient acknowledgment, signed by the parent or authorised guardian and the prescriber, indicating that they understand and acknowledge that PBS-subsidised treatment with PAH agents will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised under this criterion.  Where fewer than 5 repeats are initially requested, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3164
6478Y	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3167
6495W	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
8002E	Treatment of patients with herpes zoster within 72 hours of the onset of the rash\nNOTE: Famciclovir is effective only if commenced within 72 hours of onset of rash.   Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	1955
8003F	Major depressive disorders	1211
8007K	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.	1177
8008L	Gastro-oesophageal reflux disease	1533
8008L	Scleroderma oesophagus	1337
8008L	Zollinger-Ellison syndrome	1476
6478Y	Initial (change or re-commencement for all adult patients)  Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients with one of the following:  (a) primary pulmonary hypertension who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR  (b) WHO Functional Class IV primary pulmonary hypertension and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR  (c) WHO Functional Class III primary pulmonary hypertension and who have failed to respond to a prior PBS-subsidised PAH agent.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and  (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3165
6478Y	Initial (change or re-commencement for all patients under 18 years of age)  Application for initial PBS-subsidised treatment with epoprostenol sodium of patients aged less than 18 years with one of the following:  (a) primary pulmonary hypertension who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR  (b) WHO Functional Class IV primary pulmonary hypertension and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR  (c) WHO Functional Class III primary pulmonary hypertension and who have failed to respond to a prior PBS-subsidised PAH agent.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and  (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3166
6478Y	Initial (new adult patients)  Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class IV primary pulmonary hypertension.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3163
6478Y	Initial (new patients under 18 years of age)  Application for initial PBS-subsidised treatment with epoprostenol sodium of patients aged less than 18 years who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  WHO Functional Class IV primary pulmonary hypertension.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a patient acknowledgment, signed by the parent or authorised guardian and the prescriber, indicating that they understand and acknowledge that PBS-subsidised treatment with PAH agents will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised under this criterion.  Where fewer than 5 repeats are initially requested, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3164
6480C	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6481D	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6482E	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6483F	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6484G	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6485H	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6486J	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
6496X	Continuing treatment  Continuing PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:  (1) who have a documented history of severe active psoriatic arthritis; and  (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with infliximab; and  (3) who, at the time of application, demonstrate an adequate response to treatment with infliximab.   An adequate response to treatment with infliximab is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 2 repeats may be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2955
6496X	Initial 1  Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have severe active psoriatic arthritis; and  (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and  (3) have failed to achieve an adequate response to:  (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and  (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or  (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats may be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle	3096
6496X	Initial 2  Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and  (3) have not failed treatment with infliximab during the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats may be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2953
6496X	Initial 3  Initial PBS-subsidised supply for continuing treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) were receiving treatment with infliximab prior to 16 March 2006; and  (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with infliximab.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 2 repeats may be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Patients may qualify for PBS-subsidised treatment under this restriction once only	2954
6497Y	Continuing treatment for HER2 positive early breast cancer where the patient has previously received treatment with PBS-subsidised trastuzumab.   The patient is eligible to receive sufficient trastuzumab to complete 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy.   Trastuzumab must not be used in patients with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.  Cardiac function must be tested by a suitable method including, for example, ECHO or MUGA, at 3 monthly intervals during treatment.   Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   The medical practitioner should request sufficient quantity based on the weight of the patient for 3 weeks' supply (equivalent to 1 dose for the 3 weekly dosing regimen, or 3 doses for the once weekly dosing regimen).  Up to a maximum of 3 repeats may be authorised.   Breaks in therapy.  Where a patient has a break in trastuzumab therapy of more than 1 week but less than 6 weeks from when the last dose was due, authority approval will be granted for a new loading dose.  Authority applications for new loading doses may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2599
6497Y	Initial treatment for HER2 positive early breast cancer commencing concurrently with adjuvant chemotherapy following surgery.   The total duration of PBS-subsidised treatment (initial plus continuing) that will be authorised is 52 weeks.   HER2 positivity must be demonstrated by in situ hybridisation (ISH).   Trastuzumab must not be used in patients with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.  Cardiac function must be tested by a suitable method including, for example, ECHO or MUGA, prior to seeking the initial authority approval and then at 3 monthly intervals during treatment.   Authority applications for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Early Breast Cancer - PBS Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes:  (i) a copy of the pathology report from an Approved Pathology Authority confirming the presence of HER2 gene amplification by in situ hybridisation (ISH); and  (ii) a copy of the signed patient acknowledgement form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The medical practitioner should request sufficient quantity based on the weight of the patient to provide for a maximum of 3 weeks' treatment (equivalent to the loading dose for the 3 weekly regimen, and the loading dose and 2 weekly doses for the once weekly regimen)	2419
6498B	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
6498B	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
8018B	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
8019C	Advanced carcinoma of the prostate	1014
8019C	To reduce drive in sexual deviations in males	1404
8023G	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8024H	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8025J	Prophylactic treatment of contacts of patients with Haemophilus influenzae type B	1297
8025J	Prophylaxis of meningococcal disease in close contacts and carriers	1303
8035X	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8035X	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8035X	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8035X	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8035X	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8039D	Detrusor overactivity	1081
8043H	Treatment of corticosteroid-responsive dermatoses	1422
8048N	Patients undergoing percutaneous coronary atherectomy	1717
8048N	Patients undergoing percutaneous coronary balloon angioplasty	1716
8048N	Patients undergoing percutaneous coronary stent placement	1718
8049P	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
8049P	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
8049P	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
8049P	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
8049P	Locally advanced or metastatic non-small cell lung cancer	1194
8050Q	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
8050Q	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
8050Q	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
8050Q	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
8050Q	Locally advanced or metastatic non-small cell lung cancer	1194
8054X	Treatment of corticosteroid-responsive dermatoses	1422
8055Y	Treatment of corticosteroid-responsive dermatoses	1422
8056B	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
8057C	Maple syrup urine disease	1220
8058D	Methylmalonic acidaemia	1225
8058D	Propionic acidaemia	1307
8059E	Methylmalonic acidaemia	1225
8059E	Propionic acidaemia	1307
8061G	Methylmalonic acidaemia	1225
8061G	Propionic acidaemia	1307
8063J	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	1426
8064K	Herpes zoster ophthalmicus\nNOTE: Valaciclovir is effective only if commenced within 72 hours of onset of rash.   Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	1152
8064K	Treatment of patients with herpes zoster within 72 hours of the onset of the rash\nNOTE: Valaciclovir is effective only if commenced within 72 hours of onset of rash.   Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	1955
8071T	Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide	2416
8071T	Adjuvant treatment of operable breast cancer in combination with cyclophosphamide\nNOTE: A maximum of four cycles of treatment will be authorised under this restriction.	3292
8071T	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
8071T	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
8071T	Locally advanced or metastatic non-small cell lung cancer	1194
8071T	Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%.  Docetaxel must be used as first-line chemotherapy and administered in three weekly cycles\nNOTE: A maximum of 10 cycles of treatment with docetaxel will be authorised under this restriction.	2732
8071T	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
8074Y	Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide	2416
8074Y	Adjuvant treatment of operable breast cancer in combination with cyclophosphamide\nNOTE: A maximum of four cycles of treatment will be authorised under this restriction.	3292
8074Y	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
8074Y	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
8074Y	Locally advanced or metastatic non-small cell lung cancer	1194
8074Y	Neoadjuvant treatment of a patient with a WHO performance status of 1 or less, with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx, in combination with cisplatin and fluorouracil\nNOTE: The carcinoma can be considered inoperable for technical or organ preservation reasons.	3051
8074Y	Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%.  Docetaxel must be used as first-line chemotherapy and administered in three weekly cycles\nNOTE: A maximum of 10 cycles of treatment with docetaxel will be authorised under this restriction.	2732
8074Y	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
8076C	Relapsed or refractory germ cell tumours following first-line chemotherapy	1325
8076C	Relapsed or refractory sarcomas following first-line chemotherapy	1327
8077D	Relapsed or refractory germ cell tumours following first-line chemotherapy	1325
8077D	Relapsed or refractory sarcomas following first-line chemotherapy	1327
8078E	Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide	1618
8079F	Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide	1618
8083K	Short-term reduction of intra-ocular pressure in patients already on maximally tolerated anti-glaucoma therapy	1374
8086N	Ulcerative colitis where hypersensitivity to sulfonamides exists\nNOTE: Not for the treatment of Crohn's disease.	1708
8086N	Ulcerative colitis where intolerance to sulfasalazine exists\nNOTE: Not for the treatment of Crohn's disease.	1709
8090T	Symptomatic Paget disease of bone	3256
8092X	Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment\nNOTE: Famciclovir 125 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.	2194
8093Y	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8094B	Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) agonist therapy\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3247
8098F	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
8098F	Androgen deficiency in males with established pituitary or testicular disorders	1022
8098F	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
8099G	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
8099G	Androgen deficiency in males with established pituitary or testicular disorders	1022
8099G	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
8100H	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
8100H	Schizophrenia	1589
8101J	Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule	1751
8101J	Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule	1175
8114C	Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution	2662
8114C	Pathological hyperprolactinaemia where radiotherapy is not indicated	2661
8114C	Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution	2660
8114C	Pathological hyperprolactinaemia where surgery is not indicated	2659
8115D	Prevention of the onset of lactation in the puerperium for medical reasons	1289
8118G	Panic disorder where other treatments have failed or are inappropriate	1975
8121K	Serious staphylococcal infections	1345
8122L	Serious staphylococcal infections	1345
8128T	Treatment of corticosteroid-responsive dermatoses	1422
8131Y	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in combination with GnRH (LH-RH) agonist therapy	3299
8131Y	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in conjunction with surgical orchidectomy	3300
8132B	Bone metastases from breast cancer	1035
8132B	Maintenance treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1205
8132B	Multiple myeloma	1233
8133C	Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment\nNOTE: Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	2056
8134D	Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment\nNOTE: Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	2190
8136F	Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids	1753
8136F	Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids	1752
8141L	Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids	1753
8141L	Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids	1752
8144P	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3233
8146R	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8146R	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8146R	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8146R	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8146R	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8163P	Prophylaxis of migraine in a patient who has experienced an average of 3 or more migraines per month over a period of at least 6 months, and who:  (a) has a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR  (b) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker;  AND  (c) has a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR  (d) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.   Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated	2799
8163P	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs	2797
8164Q	Prophylaxis of migraine in a patient who has experienced an average of 3 or more migraines per month over a period of at least 6 months, and who:  (a) has a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR  (b) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker;  AND  (c) has a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR  (d) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.   Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated	2799
8164Q	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs	2797
8165R	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs	2797
8166T	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs	2797
8170B	Maintenance treatment of bipolar I disorder	2044
8170B	Schizophrenia	1589
8173E	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8174F	Major depressive disorders	1211
8174F	Obsessive-compulsive disorder	1241
8179L	Treatment of hormone-dependent breast cancer in post-menopausal women\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.  This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.	2213
8181N	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
8182P	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
8183Q	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
8184R	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
8185T	Maintenance treatment of bipolar I disorder	2044
8185T	Schizophrenia	1589
8186W	Maintenance treatment of bipolar I disorder	2044
8186W	Schizophrenia	1589
8187X	Maintenance treatment of bipolar I disorder	2044
8187X	Schizophrenia	1589
8191D	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8192E	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8196J	Systemic aspergillosis	1396
8196J	Systemic histoplasmosis	1397
8196J	Systemic sporotrichosis	1399
8196J	Treatment and maintenance therapy in patients with AIDS who have chronic pulmonary histoplasmosis infection	1857
8196J	Treatment and maintenance therapy in patients with AIDS who have disseminated pulmonary histoplasmosis infection	1856
8196J	Treatment of oesophageal candidiasis in immunosuppressed patients	1855
8196J	Treatment of oropharyngeal candidiasis in immunosuppressed patients	1854
8197K	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8198L	Gastro-oesophageal reflux disease	1533
8198L	Scleroderma oesophagus	1337
8199M	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	3186
8200N	Uncomplicated cervicitis due to Chlamydia trachomatis\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1839
8200N	Uncomplicated urethritis due to Chlamydia trachomatis\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1838
8201P	Trachoma\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1405
8208B	Symptomatic Paget disease of bone	3256
8209C	Symptomatic Paget disease of bone	3256
8213G	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8214H	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8215J	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8216K	Treatment of hormone-dependent metastatic breast cancer in post-menopausal patients\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.	1750
8217L	Suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment\nNOTE: Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.	2193
8220P	Major depressive disorders	1211
8221Q	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8222R	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8223T	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8224W	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8225X	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8226Y	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8227B	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8233H	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
8234J	Patients with advanced HIV disease (CD4 cell counts of less than 150 million per litre)	1271
8238N	Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1754
8238N	Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer	1755
8239P	Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids	1753
8239P	Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids	1752
8240Q	Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids	1753
8240Q	Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids	1752
8306E	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8310J	Maple syrup urine disease	1220
8313M	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8245Y	Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women commencing within 6 months of ceasing treatment with tamoxifen citrate\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.  This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.  This drug is not PBS-subsidised for extended adjuvant early breast cancer treatment where the total duration of letrozole (or any other aromatase inhibitor) treatment extends beyond 5 years.	2692
8245Y	Treatment of hormone-dependent advanced breast cancer in post-menopausal women\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.  This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.  This drug is not PBS-subsidised for extended adjuvant early breast cancer treatment where the total duration of letrozole (or any other aromatase inhibitor) treatment extends beyond 5 years.	1608
8245Y	Treatment of hormone-dependent early breast cancer in post-menopausal women\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.  This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.  This drug is not PBS-subsidised for extended adjuvant early breast cancer treatment where the total duration of letrozole (or any other aromatase inhibitor) treatment extends beyond 5 years.	2691
8253J	Treatment of acute myocardial infarction within 6 hours of onset of attack	1480
8254K	Infections where resistance to amoxycillin is proven	1837
8254K	Infections where resistance to amoxycillin is suspected	1836
8255L	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8255L	Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002	1735
8256M	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8256M	Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002	1735
8257N	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8257N	Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002	1735
8258P	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8258P	Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002	1735
8259Q	Biliary atresia	1034
8259Q	Chronic liver failure with fat malabsorption	1059
8259Q	Chylous ascites	1670
8259Q	Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child aged 2 years and over, where the child has been assessed by a suitably qualified allergist or paediatrician.  The date of birth of the patient must be included in the authority application	2813
8259Q	Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides.  The date of birth of the patient must be included in the authority application	2812
8259Q	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child has been assessed by a paediatric gastroenterologist or specialist allergist.  The date of birth of the patient must be included in the authority application	2815
8259Q	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides and soy protein is not tolerated or is likely not to be tolerated.  The date of birth of the patient must be included in the authority application	2814
8259Q	Cystic fibrosis	1080
8259Q	Enterokinase deficiency	1092
8259Q	Initial treatment, for up to 3 months, for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years.  Intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free diet with a soy protein as the principal formula. The date of birth of the patient must be included in the authority application	2811
8259Q	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application	2806
8259Q	Proven fat malabsorption	1310
8259Q	Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months.  The date of birth of the patient must be included in the authority application	2567
8259Q	Severe intestinal malabsorption including short bowel syndrome	1364
8260R	Maple syrup urine disease	1220
8265B	Bone metastases from breast cancer	1035
8265B	Maintenance treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	1205
8265B	Multiple myeloma	1233
8266C	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3280
8267D	Symptomatic Paget disease of bone	3256
8270G	Major depressive disorders	1211
8270G	Obsessive-compulsive disorder	1241
8272J	Eradication of Helicobacter pylori associated with peptic ulcer disease	1096
8280T	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
8280T	Locally advanced or metastatic non-small cell lung cancer	1194
8281W	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
8281W	Locally advanced or metastatic non-small cell lung cancer	1194
8282X	Acute lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.	2762
8315P	Treatment of febrile neutropenia	1427
8316Q	Treatment of febrile neutropenia	1427
8319W	Infections where resistance to amoxycillin is proven	1837
8283Y	Proven chronic lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:  (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or  (b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or  (c) hydrogen breath test\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2760
8284B	For use as a single agent in the treatment of advanced colorectal cancer	3185
8287E	Severe dry eye syndrome, including Sjogren's syndrome	1362
8289G	Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule	1751
8289G	Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule	1175
8293L	Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma	1745
8293L	Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma	1744
8294M	Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma	1745
8294M	Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma	1744
8298R	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3280
8299T	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
8300W	Treatment of mild to moderate Pneumocystis carinii pneumonia in adult patients who are intolerant of trimethoprim/sulfamethoxazole therapy	1433
8301X	Major depressive disorders	1211
8302Y	Major depressive disorders	1211
8305D	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8305D	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8305D	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8305D	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8305D	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8306E	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8306E	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8306E	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8306E	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8319W	Infections where resistance to amoxycillin is suspected	1836
8328H	Pyridoxine non-responsive homocystinuria	1314
8331L	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.   No applications for increased repeats will be authorised.	1177
8332M	Gastro-oesophageal reflux disease	1533
8332M	Scleroderma oesophagus	1337
8332M	Zollinger-Ellison syndrome	1476
8333N	Gastro-oesophageal reflux disease	1533
8333N	Scleroderma oesophagus	1337
8333N	Zollinger-Ellison syndrome	1476
8335Q	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events as adjunctive therapy with low-dose aspirin	1725
8335Q	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding	1726
8335Q	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs	1727
8336R	Trachoma\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1405
8341B	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3233
8348J	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
8348J	Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy	1206
8349K	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8349K	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8349K	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8349K	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8349K	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8350L	Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and anginal pain lasting longer than 20 minutes	1729
8350L	Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and repetitive episodes of angina at rest or during minimal exercise in the previous 12 hours	1730
8350L	Patients with non-Q-wave myocardial infarction	1275
8354Q	Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug	1266
8357W	For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2665
8358X	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1720
8358X	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1721
8358X	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1719
8358X	Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1723
8358X	Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1724
8358X	Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1722
8359Y	Onchocerciasis	1242
8359Y	Strongyloidiasis	1388
8360B	Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide	2417
8360B	Advanced breast cancer after failure of prior therapy which includes an anthracycline	1741
8360B	Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound	1742
8360B	Locally advanced or metastatic non-small cell lung cancer	1194
8360B	Primary treatment of ovarian cancer in combination with a platinum compound	1293
8360B	Treatment of HER2 positive early breast cancer in combination with trastuzumab	2439
8361C	Adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2267
8361C	Advanced breast cancer after failure of prior therapy which includes a taxane and an anthracycline\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1738
8361C	Advanced breast cancer in combination with docetaxel after failure of prior anthracycline-containing chemotherapy\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1614
8361C	Advanced breast cancer where therapy with a taxane and/or an anthracycline is contraindicated\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1739
8361C	Treatment of advanced or metastatic colorectal cancer\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1522
8362D	Adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2267
8362D	Advanced breast cancer after failure of prior therapy which includes a taxane and an anthracycline\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1738
8362D	Advanced breast cancer in combination with docetaxel after failure of prior anthracycline-containing chemotherapy\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1614
8362D	Advanced breast cancer where therapy with a taxane and/or an anthracycline is contraindicated\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1739
8362D	Treatment of advanced or metastatic colorectal cancer\nNOTE: In the adjuvant setting, the recommended treatment duration is 24 weeks.  Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	1522
8363E	Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2647
8367J	Parkinson's disease as adjunctive therapy in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	2067
8369L	Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae	1276
8370M	For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1135
8371N	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate	2798
8372P	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate	2798
8373Q	Initial treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2681
8373Q	Initial treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2643
8374R	Treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician	2682
8374R	Treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician	2644
8375T	Treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician	2682
8375T	Treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician	2644
8378Y	Recurrence of anaplastic astrocytoma following standard therapy	1736
8378Y	Recurrence of glioblastoma multiforme following standard therapy	1737
8379B	Glioblastoma multiforme following radiotherapy	2101
8379B	Recurrence of anaplastic astrocytoma following standard therapy	1736
8379B	Recurrence of glioblastoma multiforme following standard therapy	1737
8380C	Glioblastoma multiforme following radiotherapy	2101
8380C	Recurrence of anaplastic astrocytoma following standard therapy	1736
8380C	Recurrence of glioblastoma multiforme following standard therapy	1737
8381D	Glioblastoma multiforme following radiotherapy	2101
8381D	Recurrence of anaplastic astrocytoma following standard therapy	1736
8381D	Recurrence of glioblastoma multiforme following standard therapy	1737
8382E	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events	1728
8383F	Bacterial keratitis	1031
8384G	Severe dry eye syndrome, including Sjogren's syndrome	1362
8385H	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8385H	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8385H	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8385H	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8385H	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8386J	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8386J	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8386J	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8386J	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8386J	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8387K	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8387K	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8387K	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8589C	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or quinapril hydrochloride monotherapy	1597
8387K	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8387K	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8388L	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8388L	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8388L	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8388L	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8388L	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8389M	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8393R	Parkinson's disease\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1255
8394T	Parkinson's disease\nNOTE: Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.	1255
8398B	Severe cardiac arrhythmias	1350
8399C	Gastro-oesophageal reflux disease	1533
8400D	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or fosinopril sodium monotherapy	1591
8401E	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or fosinopril sodium monotherapy	1591
8403G	Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule	1751
8403G	Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule	1175
8404H	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or irbesartan monotherapy	1594
8405J	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or irbesartan monotherapy	1594
8408M	Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug	1266
8409N	Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug	1266
8410P	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8411Q	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8412R	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
8413T	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
8414W	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
8415X	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
8416Y	Pyridoxine non-responsive homocystinuria	1314
8417B	For infants and very young children with pyridoxine non-responsive homocystinuria	1484
8424J	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8424J	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8424J	Severe disabling pain associated with proven malignant neoplasia	1357
8424J	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8424J	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8430Q	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1759
8430Q	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1758
8431R	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1759
8431R	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1758
8432T	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate\nNOTE: Seretide is not indicated for the initiation of bronchodilator therapy in COPD.	1759
8432T	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate\nNOTE: Seretide is not indicated for the initiation of bronchodilator therapy in COPD.	1758
8432T	Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy\nNOTE: Seretide is not indicated for the initiation of bronchodilator therapy in COPD.	2680
8433W	Maintenance treatment of bipolar I disorder	2044
8433W	Schizophrenia	1589
8434X	Maintenance treatment of bipolar I disorder	2044
8434X	Schizophrenia	1589
8439E	Symptomatic treatment of osteoarthritis	1547
8439E	Symptomatic treatment of rheumatoid arthritis	1848
8440F	Symptomatic treatment of osteoarthritis	1547
8440F	Symptomatic treatment of rheumatoid arthritis	1848
8443J	Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2805
8443J	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2806
8445L	Tyrosinaemia	1453
8446M	Tyrosinaemia	1453
8448P	Primary biliary cirrhosis\nNOTE: Not for use in the treatment of sclerosing cholangitis or cholelithiasis.	1700
8449Q	Hypertension in patients who are not adequately controlled with indapamide and/or perindopril	2753
8453X	Chronic severe disabling pain due to cancer	1499
8454Y	Chronic severe disabling pain due to cancer	1499
8455B	For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1497
8456C	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
8456C	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
8456C	Schizophrenia	1589
8457D	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
8457D	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
8457D	Schizophrenia	1589
8458E	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
8458E	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
8458E	Schizophrenia	1589
8459F	For the treatment of hydatid disease in conjunction with surgery or when a surgical cure cannot be achieved or where surgery cannot be used	1496
8460G	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
8460G	Androgen deficiency in males with established pituitary or testicular disorders	1022
8460G	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
8461H	Symptomatic Paget disease of bone	3256
8462J	Symptomatic Paget disease of bone	3256
8463K	Symptomatic Paget disease of bone	3256
8464L	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8464L	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8464L	Severe disabling pain associated with proven malignant neoplasia	1357
8464L	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8464L	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8465M	Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program. Details of the program must be specified in the authority application	2774
8465M	Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested. Details of the program must be specified in the authority application	2775
8467P	Phenylketonuria	1286
8476D	Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy	1196
8476D	Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy	1206
8477E	Hypertension in patients who are not adequately controlled with 20 mg enalapril maleate	1590
8478F	Chylothorax\nNOTE: Monogen is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1068
8478F	Chylous ascites\nNOTE: Monogen is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1670
8478F	Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders\nNOTE: Monogen is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1671
8478F	Hyperlipoproteinaemia type 1\nNOTE: Monogen is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1513
8478F	Long chain fatty acid oxidation disorders\nNOTE: Monogen is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1511
8479G	Phenylketonuria	1286
8481J	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.  The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	3070
8481J	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
8481J	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
8482K	Symptomatic Paget disease of bone	3256
8489T	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8599N	Ulcerative colitis where hypersensitivity to sulfonamides exists\nNOTE: Not for the treatment of Crohn's disease.	1708
8489T	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8489T	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8489T	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8489T	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8490W	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8490W	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8490W	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8490W	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8490W	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8491X	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8491X	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8491X	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8491X	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8491X	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8492Y	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8518H	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1759
8518H	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1758
8590D	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or quinapril hydrochloride monotherapy	1597
8591E	Phenylketonuria	1286
8492Y	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8492Y	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8492Y	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8492Y	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8493B	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8493B	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8493B	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8493B	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8493B	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8494C	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8494C	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8494C	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8494C	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8494C	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8495D	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8592F	Maple syrup urine disease	1220
8593G	Severe dry eye syndrome, including Sjogren's syndrome	1362
8495D	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8495D	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8495D	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8496E	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8496E	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8496E	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8519J	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate\nNOTE: Seretide is not indicated for the initiation of bronchodilator therapy in COPD.	1759
8519J	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate\nNOTE: Seretide is not indicated for the initiation of bronchodilator therapy in COPD.	1758
8496E	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8497F	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8497F	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8497F	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8497F	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8498G	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8519J	Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy\nNOTE: Seretide is not indicated for the initiation of bronchodilator therapy in COPD.	2680
8520K	Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate	2798
8521L	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8594H	Schizophrenia	1589
8595J	Schizophrenia	1589
8498G	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8498G	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8498G	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8499H	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8499H	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8499H	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8523N	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
8523N	Severe disabling pain not responding to non-narcotic analgesics	1358
8524P	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
8499H	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8500J	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8500J	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8500J	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8500J	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8501K	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8501K	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8501K	Severe disabling pain associated with proven malignant neoplasia	1357
8524P	Severe disabling pain not responding to non-narcotic analgesics	1358
8525Q	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
8525Q	Severe disabling pain not responding to non-narcotic analgesics	1358
8526R	Treatment of acute myocardial infarction within 12 hours of onset of attack	1481
8527T	Treatment of acute myocardial infarction within 12 hours of onset of attack	1481
8530Y	Acute myelogenous leukaemia	1006
8501K	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8501K	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8502L	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8502L	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8502L	Severe disabling pain associated with proven malignant neoplasia	1357
8502L	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8502L	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8503M	Treatment of tapeworm infestation	1525
8504N	Hypertension in patients who are not adequately controlled with 16 mg candesartan cilexetil	1593
8505P	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8506Q	Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.  This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years, i.e. a patient who has received 2 years of tamoxifen therapy may only receive 3 years of PBS-subsidised treatment with exemestane.	1541
8506Q	Treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years' treatment with tamoxifen citrate\nNOTE: This drug is not PBS-subsidised for primary prevention of breast cancer.  This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years, i.e. a patient who has received 2 years of tamoxifen therapy may only receive 3 years of PBS-subsidised treatment with exemestane.	2457
8507R	Gastro-oesophageal reflux disease	1533
8507R	Scleroderma oesophagus	1337
8508T	Gastro-oesophageal reflux disease	1533
8508T	Scleroderma oesophagus	1337
8509W	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.	1177
8511Y	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
8511Y	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
8512B	Major depressive disorders	1211
8512B	Obsessive-compulsive disorder	1241
8513C	Major depressive disorders	1211
8514D	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
8517G	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1759
8517G	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate	1758
8531B	Acute myelogenous leukaemia	1006
8596K	Schizophrenia	1589
8539K	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
8539K	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
8540L	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
8540L	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
8541M	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8541M	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8541M	Severe disabling pain associated with proven malignant neoplasia	1357
8541M	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8541M	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8542N	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8542N	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8542N	Severe disabling pain associated with proven malignant neoplasia	1357
8542N	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8542N	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8543P	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8543P	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8543P	Severe disabling pain associated with proven malignant neoplasia	1357
8565T	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8543P	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8543P	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8545R	Phenylketonuria	1286
8548X	Severe dry eye syndrome, including Sjogren's syndrome	1362
8551C	Myeloproliferative disease with excessive thrombocytosis	1234
8552D	Myeloproliferative disease with excessive thrombocytosis	1234
8553E	Myeloproliferative disease with excessive thrombocytosis	1234
8554F	Phenylketonuria	1286
8555G	Phenylketonuria	1286
8559L	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8561N	Symptomatic treatment of osteoarthritis	1547
8561N	Symptomatic treatment of rheumatoid arthritis	1848
8562P	Symptomatic treatment of osteoarthritis	1547
8562P	Symptomatic treatment of rheumatoid arthritis	1848
8563Q	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8563Q	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8563Q	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8563Q	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8564R	Severe dry eye syndrome, including Sjogren's syndrome	1362
8565T	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8598M	Ulcerative colitis where hypersensitivity to sulfonamides exists\nNOTE: Not for the treatment of Crohn's disease.	1708
8598M	Ulcerative colitis where intolerance to sulfasalazine exists\nNOTE: Not for the treatment of Crohn's disease.	1709
8566W	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8566W	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8567X	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2138
8567X	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2137
8569B	Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen	1568
8569B	Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane	1795
8569B	Metastatic breast cancer, as monotherapy, where therapy with capecitabine and/or a taxane is contraindicated	1796
8570C	Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen	1568
8570C	Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane	1795
8570C	Metastatic breast cancer, as monotherapy, where therapy with capecitabine and/or a taxane is contraindicated	1796
8572E	Hairy cell leukaemia	1149
8574G	Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2805
8574G	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2806
8575H	Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2807
8575H	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2809
8575H	Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1687
8575H	Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1688
8575H	Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2808
8575H	Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2810
8577K	Glucose transport protein defects	1579
8577K	Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance	1581
8577K	Patients with intractable seizures requiring treatment with a ketogenic diet	1578
8577K	Pyruvate dehydrogenase deficiency	1580
8578L	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
8580N	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
8580N	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
8580N	Schizophrenia	1589
8581P	Acute exacerbations of chronic bronchitis	1582
8582Q	Short-term treatment of acute pain\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1378
8583R	Major depressive disorders	1211
8584T	Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs	1587
8585W	Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs	1587
8586X	Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs	1587
8587Y	Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet	1596
8588B	Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs	1587
8599N	Ulcerative colitis where intolerance to sulfasalazine exists\nNOTE: Not for the treatment of Crohn's disease.	1709
8600P	Maintenance of healed gastro-oesophageal reflux disease\nNOTE: No applications for increased maximum quantities will be authorised.	1629
8601Q	Healing of gastro-oesophageal reflux disease\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1628
8604W	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8605X	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8606Y	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8611F	For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	1615
8612G	Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents	2823
8612G	Constipation in patients with malignant neoplasia	1613
8612G	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies	2693
8612G	Patients receiving palliative care	1263
8613H	Phenylketonuria	1286
8614J	Adult patients with severe sepsis who have a high risk of death as determined by acute dysfunction in at least 2 organs or modified Apache II score of at least 25.  Acute organ dysfunction is defined as follows:  (1) For cardiovascular-system dysfunction, an arterial systolic blood pressure of less than or equal to 90 mmHg or mean arterial pressure of less than or equal to 70 mmHg for at least 1 hour despite adequate fluid resuscitation, adequate intravascular volume status or the use of vasopressors in an attempt to maintain a systolic blood pressure of greater than or equal to 90 mmHg or a mean arterial pressure of greater than or equal to 70 mmHg;  (2) For kidney dysfunction, urine output of less than 0.5 mL per kg of body weight per hour for 1 hour despite adequate fluid resuscitation;  (3) For respiratory-system dysfunction, a ratio of PaO2 to FiO2 of less than or equal to 250;  (4) For haematologic dysfunction, a platelet count of less than 80,000 per cubic millimetre or which has decreased by 50 percent in the previous 3 days;  (5) In the case of unexplained metabolic acidosis, a pH of less than or equal to 7.30 or a base deficit of greater than or equal to 5.0 mmol per L in association with a plasma lactate level of greater than 1.5 times the upper limit of the normal value for the reporting laboratory\nNOTE: Medical practitioners should request the appropriate quantity of vials at the time of the authority application, according to the weight of the patient, to achieve a dose of 24 micrograms per kg per hour over a maximum of 96 hours.	1630
8616L	Acute episode of mild to moderate ulcerative colitis\nNOTE: Not for the treatment of Crohn's disease.	1707
8617M	Acute episode of mild to moderate ulcerative colitis\nNOTE: Not for the treatment of Crohn's disease.	1707
8618N	Eczema	1622
8619P	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
8619P	Androgen deficiency in males with established pituitary or testicular disorders	1022
8619P	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
8621R	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.  The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	3070
8621R	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
8621R	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
8622T	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or telmisartan monotherapy	1645
8623W	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or telmisartan monotherapy	1645
8624X	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or eprosartan mesylate monotherapy	1644
8625Y	For maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and a long-acting beta-2 agonist	2673
8625Y	For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with inhaled corticosteroids	2672
8625Y	For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with oral corticosteroids	2671
8625Y	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide	1757
8625Y	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide	1756
8626B	For the long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease	1646
8627C	First-line preventer medication, as the single preventer agent for children aged 2 to 5 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium\nNOTE: Montelukast sodium is not PBS-subsidised for use in a child aged 2 to 5 years with moderate to severe asthma. It is not intended as an alternative for a child aged 2 to 5 years who requires a corticosteroid as a preventer medication.   Montelukast sodium is not subsidised in a child aged 2 to 5 years for use in combination with other preventer medications. PBS subsidy for montelukast sodium will therefore cease for a child aged 2 to 5 years who requires a preventer medication in addition to montelukast sodium.	2617
8628D	First-line preventer medication, as the single preventer agent for children aged 6 to 14 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium	2618
8628D	Prevention of exercise-induced asthma, as an alternative to adding salmeterol xinafoate or eformoterol fumarate, in a child aged 6 to 14 years whose asthma is otherwise well controlled while receiving optimal dose inhaled corticosteroid, but who requires short-acting beta-2 agonist 3 or more times per week for prevention or relief of residual exercise-related symptoms\nNOTE: Montelukast sodium is not PBS-subsidised for use in a patient aged 15 years or older, or for use in addition to a long-acting beta-agonist in any age group, or for use as a single second line preventer, as an alternative to corticosteroids, in a child aged 6 to 14 years with moderate to severe asthma.	3217
8629E	Chylothorax\nNOTE: Caprilon is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet, long chain fatty acid oxidation disorders or hyperlipoproteinaemia type 1.	1068
8629E	Chylous ascites\nNOTE: Caprilon is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet, long chain fatty acid oxidation disorders or hyperlipoproteinaemia type 1.	1670
8629E	Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders\nNOTE: Caprilon is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet, long chain fatty acid oxidation disorders or hyperlipoproteinaemia type 1.	1671
8630F	Glucose transport protein defects	1579
8630F	Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance	1581
8630F	Patients with intractable seizures requiring treatment with a ketogenic diet	1578
8630F	Pyruvate dehydrogenase deficiency	1580
8631G	Tyrosinaemia	1453
8632H	Maple syrup urine disease	1220
8633J	Contraception	1643
8633J	Idiopathic menorrhagia where oral treatments are contraindicated	2690
8633J	Idiopathic menorrhagia where oral treatments are ineffective	2689
8637N	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.   PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.   In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.   From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.   A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.   For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.   The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.   There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.   If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.   (1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.   From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Rituximab patients:  A further application may be submitted to Medicare Australia 24 weeks after the first infusion.  New baselines may be submitted with this application if appropriate.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements.  However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application.  However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.   In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab.  This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD.  Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.   To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.	3224
8637N	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with etanercept within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints.  Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.   The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.   From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.   'Grandfather' arrangements will only apply for the first Treatment Cycle.  For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2845
8637N	Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years; AND  (a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly; AND  (c) who have failed to achieve an adequate response to methotrexate, in combination with 2 other disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; AND  (d) who have subsequently failed to achieve an adequate response following a minimum of 3 months' treatment with:  (i) leflunomide; or  (ii) cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use, the patient is exempted from demonstrating an inadequate response to the above treatment regimens. Details of the contraindication or intolerance, including the degree of toxicity, must be provided at the time of application.   The following criteria must be met in order to demonstrate failure to achieve an adequate response:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).    If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be in writing and must include sufficient information to determine the patient's eligibility according to the above criteria.  The date of joint assessment must be provided.   Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 4 months of treatment may be requested by telephone. Under no circumstances will telephone approvals be granted for initial or continuing authority applications, or for treatment that would otherwise extend the initial treatment period beyond 4 months.   The assessment of the patient's response to the initial course of treatment should be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria	3225
8638P	Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who, at the time of application, demonstrate an adequate response to treatment with etanercept as manifested by:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND 1 or more of the following:  (i) an active joint count of fewer than 10 active (swollen and tender) joints; or  (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or  (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of assessment of the patient must be provided.   Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.   Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application	1910
8665C	Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2386
8669G	Severe disabling pain due to cancer not responding to non-narcotic analgesics	1789
8638P	Continuing treatment  Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with etanercept; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2846
8638P	Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, and who were receiving treatment with etanercept prior to 1 December 2002; AND  (a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.   The authority application must be in writing and must include sufficient information to determine the patient's eligibility. The date of assessment of the patient must be provided	1909
8639Q	Haemodialysis	1148
8640R	Haemodialysis	1148
8641T	Haemodialysis	1148
8642W	Haemodialysis	1148
8643X	Haemodialysis	1148
8644Y	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8644Y	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8644Y	Severe disabling pain associated with proven malignant neoplasia	1357
8644Y	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1358
8644Y	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8646C	Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	3080
8647D	Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	3080
8648E	Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	3080
8649F	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1766
8649F	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1765
8666D	Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2068
8666D	Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2386
8667E	Tyrosinaemia	1453
8650G	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1766
8650G	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1765
8651H	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1766
8651H	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1765
8652J	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate sodium and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1763
8653K	Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate sodium and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1763
8654L	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8655M	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8656N	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	2664
8657P	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2052
8657P	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2049
8657P	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2053
8657P	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2050
8657P	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2051
8657P	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
8657P	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
8657P	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
8658Q	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2052
8658Q	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2049
8658Q	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2053
8658Q	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2050
8658Q	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2051
8658Q	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
8658Q	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
8658Q	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
8659R	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2052
8659R	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2049
8659R	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2053
8659R	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2050
8659R	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2051
8659R	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
8659R	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
8659R	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
8660T	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2052
8660T	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2049
8660T	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2053
8660T	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2050
8660T	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2051
8660T	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
8660T	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
8660T	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
8661W	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2052
8661W	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2049
8661W	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2053
8661W	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2050
8661W	Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application	2051
8661W	Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life	1656
8661W	Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate	1655
8661W	Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate	1658
8662X	Cranial diabetes insipidus	1678
8663Y	Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated\nNOTE: Not to be used in preference to enuresis alarms.  Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.	2642
8663Y	Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm\nNOTE: Not to be used in preference to enuresis alarms.  Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.	2641
8664B	Continuing treatment of amyotrophic lateral sclerosis in patients who have previously been issued with an authority prescription for this drug and who:  (1) are ambulatory, and  (a) have not undergone tracheostomy, and  (b) have not experienced respiratory failure; OR  (2) are not ambulatory, and  (a) have not undergone tracheostomy, and  (b) have not experienced respiratory failure, and  (c) are either able to use upper limbs or able to swallow	1762
8664B	Initial treatment of amyotrophic lateral sclerosis, as diagnosed by a neurologist, in patients with disease duration of 5 years or less and who have at least 60 percent of predicted forced vital capacity within 2 months prior to commencing riluzole therapy and who:  (1) are ambulatory, and  (a) have not undergone tracheostomy, and  (b) have not experienced respiratory failure; OR  (2) are not ambulatory, and  (a) have not undergone tracheostomy, and  (b) have not experienced respiratory failure, and  (c) are either able to use upper limbs or able to swallow.  The date of diagnosis and the date and results of spirometry (in terms of percent of predicted forced vital capacity) must be supplied with the initial authority application	2718
8665C	Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy	2068
8670H	Severe disabling pain due to cancer not responding to non-narcotic analgesics	1789
8672K	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8673L	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8673L	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8674M	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8675N	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8675N	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8676P	Severe dry eye syndrome, including Sjogren's syndrome	1362
8677Q	Pyridoxine non-responsive homocystinuria	1314
8678R	Phenylketonuria	1286
8681X	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8681X	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8681X	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8681X	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8681X	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8683B	Patients undergoing non-urgent percutaneous intervention with intracoronary stenting	1884
8684C	Patients undergoing non-urgent percutaneous intervention with intracoronary stenting	1884
8689H	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Rosiglitazone maleate is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2635
8896F	Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and a CD4 cell count of less than 150 million per litre. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment	2596
8690J	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Rosiglitazone maleate is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2635
8694N	Combination therapy with insulin  Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2638
8694N	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2635
8694N	Triple oral combination therapy with metformin and a sulfonylurea  Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2648
8695P	Combination therapy with insulin  Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2638
8697R	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years who has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician, and where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times.  The name of the specialist consulted must be provided at the time of application for initial supply	1943
8697R	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years who has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times	2333
8896F	Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and other opportunistic infections or AIDS defining tumours. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment	2597
8695P	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2635
8695P	Triple oral combination therapy with metformin and a sulfonylurea  Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2648
8696Q	Combination therapy with insulin  Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2638
8696Q	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2635
8696Q	Triple oral combination therapy with metformin and a sulfonylurea  Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea.    The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2648
8697R	Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times, and where the patient has previously been issued with an authority prescription for this drug	1810
8697R	Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug\nNOTE: The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)	1808
8757X	Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs), in combination with an HMG CoA reductase inhibitor (statin)	2438
8697R	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply\nNOTE: The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)	2331
8697R	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis\nNOTE: The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)	2332
8698T	Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times, and where the patient has previously been issued with an authority prescription for this drug	1810
8698T	Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug\nNOTE: The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)	1808
8698T	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years who has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician, and where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times.  The name of the specialist consulted must be provided at the time of application for initial supply	1943
8698T	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years who has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times	2333
8698T	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply\nNOTE: The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)	2331
8698T	Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis\nNOTE: The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)	2332
8700X	Major depressive disorders	1211
8701Y	Major depressive disorders	1211
8702B	Major depressive disorders	1211
8703C	Major depressive disorders	1211
8707G	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8708H	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8709J	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8710K	Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program	2776
8711L	Cranial diabetes insipidus	1678
8712M	Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated\nNOTE: Not to be used in preference to enuresis alarms.  Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.	2642
8712M	Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm\nNOTE: Not to be used in preference to enuresis alarms.  Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.	2641
8713N	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8713N	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8841H	Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2133
8714P	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8714P	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8715Q	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8715Q	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8716R	Haemodialysis	1148
8717T	Schizophrenia	1589
8718W	Schizophrenia	1589
8719X	Schizophrenia	1589
8720Y	Schizophrenia	1589
8724E	Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1952
8725F	Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1952
8726G	Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule	1751
8726G	Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule	1175
8727H	Phenylketonuria	1286
8728J	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8729K	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
8730L	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
8731M	Crohn's disease where hypersensitivity to sulfonamides exists	2268
8731M	Crohn's disease where intolerance to sulfasalazine exists	2269
8731M	Ulcerative colitis where hypersensitivity to sulfonamides exists	1708
8731M	Ulcerative colitis where intolerance to sulfasalazine exists	1709
8732N	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8733P	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8734Q	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8735R	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated	1734
8736T	Schizophrenia	1589
8737W	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	3223
8737W	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with adalimumab within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2842
8738X	Eradication of Helicobacter pylori associated with peptic ulcer disease	1096
8741C	Continuing treatment  Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with adalimumab; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2843
8744F	Pyridoxine non-responsive homocystinuria	1314
8745G	Maple syrup urine disease	1220
8746H	Phenylketonuria	1286
8748K	Patients hypersensitive to other oral diuretics	1261
8750M	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide\nNOTE: Symbicort 400/12 is not recommended nor PBS-subsidised for use as 'maintenance and reliever' therapy.	1757
8750M	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide\nNOTE: Symbicort 400/12 is not recommended nor PBS-subsidised for use as 'maintenance and reliever' therapy.	1756
8752P	Acute episode of mild to moderate ulcerative proctitis\nNOTE: Not for the treatment of Crohn's disease.	1978
8753Q	Acute episode of mild to moderate ulcerative colitis\nNOTE: Not for the treatment of Crohn's disease.	1707
8754R	Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2805
8754R	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2806
8755T	Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2807
8755T	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2809
8755T	Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1687
8755T	Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1688
8755T	Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2808
8755T	Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2810
8757X	Homozygous sitosterolaemia	1991
8757X	Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) is contraindicated	1989
8757X	Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be discontinued or reduced to a dose of 20 mg or less per day, because the patient developed a clinically important product-related adverse event during treatment with a statin.  A clinically important product-related adverse event is defined as follows:  (i) Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or  (ii) Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or  (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin	2669
9345W	Parkinson disease in patients stabilised on concomitant treatment with levodopa - decarboxylase inhibitor combinations and entacapone	3306
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have coronary heart disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2649
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have diabetes mellitus. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2650
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have family history of coronary heart disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2667
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have heterozygous familial hypercholesterolaemia. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2652
8770N	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
9050H	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have hypertension. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2668
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have peripheral vascular disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2651
8757X	Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have symptomatic cerebrovascular disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated	2653
8760C	For patients unable to take a solid dose form of an ACE inhibitor	1998
8768L	Acute episode of mild to moderate ulcerative colitis\nNOTE: Not for the treatment of Crohn's disease.	1707
8769M	Continuing PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where the patient has previously been issued with an authority prescription for gefitinib.   Applications for continuing treatment may be made in writing or on the telephone by contacting Medicare Australia on 1800 700 270	2524
8769M	Initial PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where:  (1) disease progression has occurred following treatment with at least 1 chemotherapy agent; and  (2) there is evidence that the patient has an activating mutation(s) of the epidermal growth factor receptor (EGFR) gene in tumour material.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Gefitinib (Iressa) PBS Authority Application for Use in the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) details of the prior chemotherapy including the name(s) of drug(s) and date of the most recent treatment cycle; and  (4) details of the patient's WHO performance status; and  (5) a copy of the pathology report providing evidence of the presence of activating mutation(s) of the EGFR gene from an Approved Pathology Authority	3230
8770N	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8775W	Prevention of venous thromboembolic events in patients undergoing major hip surgery\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2005
8775W	Prevention of venous thromboembolic events in patients undergoing total knee replacement\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2006
8778B	Initial 1 (new patients)  First course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND  (a) who has at least 2 of the following:  (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or  (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or  (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND  (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.   The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.   If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.   If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.   The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.   The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.   Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2504
8770N	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8770N	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8771P	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8771P	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8771P	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8771P	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
9350D	Symptomatic Paget disease of bone.  Only 1 treatment each year per patient will be PBS-subsidised	3290
9355J	Severe dry eye syndrome, including Sjogren's syndrome	1362
8772Q	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
8772Q	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
8772Q	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
8772Q	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
8773R	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with anakinra, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with anakinra.   Patients who fail to demonstrate a response to treatment with anakinra under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial anakinra after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	3222
8773R	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with anakinra, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with anakinra within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised anakinra treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised anakinra treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised anakinra treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with anakinra under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial anakinra after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2839
8774T	Continuing treatment  Continuing PBS-subsidised treatment with anakinra, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with anakinra; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with anakinra.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with anakinra must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with anakinra, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with anakinra under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial anakinra after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2840
8778B	Initial 2 (change or re-commencement for all patients)  Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with etanercept.   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.   A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2505
8779C	Continuing treatment for all patients  Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:  (a) has demonstrated a response to treatment with etanercept; and  (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.   Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.   For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.   Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment.   Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.   Written applications for authorisation must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.   All measurements provided must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone	2506
8780D	Schizophrenia	1589
8781E	Schizophrenia	1589
8782F	Schizophrenia	1589
8784H	Chronic arthropathies	2046
8785J	Severe disabling pain not responding to non-narcotic analgesics\nNOTE: Each authority approval will be limited to no more than 240 tablets per month for no more than 6 months.	2064
8786K	Metastatic malignant melanoma	3181
8787L	Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful\nCAUTION: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.	2061
8787L	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
8788M	Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful\nCAUTION: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.	2061
8788M	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
8789N	Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful\nCAUTION: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.	2061
8789N	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
8790P	Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful\nCAUTION: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.	2061
8790P	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
8792R	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
8792R	Schizophrenia	1589
8794W	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
8794W	Schizophrenia	1589
8796Y	For maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and a long-acting beta-2 agonist	2673
8796Y	For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with inhaled corticosteroids	2672
8796Y	For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with oral corticosteroids	2671
8796Y	Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide	1757
8796Y	Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide	1756
8797B	Parkinson disease in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	3305
8797B	Parkinson disease in patients stabilised on concomitant treatment with levodopa - decarboxylase inhibitor combinations and entacapone	3306
8798C	Parkinson disease in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	3305
8798C	Parkinson disease in patients stabilised on concomitant treatment with levodopa - decarboxylase inhibitor combinations and entacapone	3306
8799D	Parkinson disease in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	3305
8799D	Parkinson disease in patients stabilised on concomitant treatment with levodopa - decarboxylase inhibitor combinations and entacapone	3306
8800E	Hairy cell leukaemia	3180
8802G	Short-term (up to 3 weeks) intermittent treatment of atopic dermatitis of the face or eyelids in patients aged at least 3 months who fail to achieve satisfactory disease control with intermittent topical corticosteroid therapy, and where more than 3 months have passed since the initial diagnosis of atopic dermatitis.   Failure to achieve satisfactory disease control with intermittent topical corticosteroid therapy is manifest by:  (i) failure of the facial skin to clear despite at least 2 weeks of topical hydrocortisone 1% applied every day; or  (ii) failure of the facial skin to clear despite at least 1 week of a moderate or potent topical corticosteroid applied every day; or  (iii) clearing of the facial skin with at least 2 weeks of topical hydrocortisone 1% applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions; or  (iv) clearing of the facial skin with at least 1 week of a moderate or potent topical corticosteroid applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions	2456
8802G	Treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months with 1 or more of the following contraindications to topical corticosteroids:  (i) perioral dermatitis;  (ii) periorbital dermatitis;  (iii) rosacea;  (iv) epidermal atrophy;  (v) dermal atrophy;  (vi) allergy to topical corticosteroids;  (vii) cataracts;  (viii) glaucoma;  (ix) raised intraocular pressure	2455
8804J	Phenylketonuria	1286
8805K	Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule	1751
8805K	Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule	1175
8807M	Iron deficiency anaemia, in combination with either epoetin alfa or darbepoetin alfa, in patients undergoing chronic haemodialysis who have had a documented hypersensitivity reaction to iron polymaltose and in whom continued intravenous iron therapy is appropriate	2070
8808N	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered.  No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy\nNOTE: No applications for increased maximum quantities will be authorised. Prescribers should advise Medicare Australia of the number of cycles planned when requesting approval for repeats.	2330
9051J	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
8808N	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:  (a) altretamine;  (b) carmustine;  (c) cisplatin when a single dose constitutes a cycle of chemotherapy;  (d) cyclophosphamide at a dose of 1500 mg per square metre per day or greater;  (e) dacarbazine;  (f) procarbazine when a single dose constitutes a cycle of chemotherapy;  (g) streptozocin.  No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy\nNOTE: No applications for increased maximum quantities will be authorised. Prescribers should advise Medicare Australia of the number of cycles planned when requesting approval for repeats.	2071
8814X	Relief of persistent pain associated with osteoarthritis	2094
8816B	Continuing treatment of narcolepsy, where the patient has previously been issued with an authority prescription for this drug	2090
8816B	Initial treatment, by a qualified sleep medicine practitioner or neurologist, of patients with narcolepsy where:  (i) therapy with dexamphetamine sulfate poses an unacceptable medical risk; or  (ii) intolerance to dexamphetamine sulfate of a severity necessitating treatment withdrawal develops.   The presence of any 1 of the following indicates treatment with dexamphetamine sulfate poses an unacceptable medical risk:  (a) a psychiatric disorder;  (b) a cardiovascular disorder;  (c) a history of substance abuse;  (d) glaucoma;  (e) any other absolute contraindication to dexamphetamine sulfate as specified in the TGA-approved Product Information.   Patients must meet the following definition of narcolepsy:  Excessive daytime sleepiness, recurrent naps or lapses into sleep occurring almost daily for at least 3 months and:  (i) a definite history of cataplexy;  or  a mean sleep latency less than or equal to 10 minutes on a Multiple Sleep Latency Test (MSLT). The MSLT must be preceded by nocturnal polysomnography. Sleep prior to the MSLT must be at least 6 hours in duration;  or  an electroencephalographic (EEG) recording showing the pathologically rapid development of REM sleep; and  (ii) absence of any medical or psychiatric disorder that could otherwise account for the hypersomnia.   The authority application must be made in writing and must include the following:  (a) a completed authority prescription form; and  (b) a completed Modafinil (Modavigil) PBS Authority Application for Use in the Treatment of Narcolepsy - Supporting Information Form [www.medicareaustralia.gov.au]; and  (c) details of the contraindication or intolerance to dexamphetamine sulfate; and  (d) either:  (i) the result and date of the polysomnography test and MSLT conducted by, or under the supervision of, a qualified sleep medicine practitioner; or  (ii) the result and date of the EEG, conducted by, or under the supervision of, a neurologist.   The polysomnography, MSLT or EEG test reports must be provided with the authority application	3145
8819E	Glioblastoma multiforme concomitantly with radiotherapy\nNOTE: Temozolomide is not PBS-subsidised for use in conjunction with PBS-subsidised carmustine.	2100
8820F	Glioblastoma multiforme concomitantly with radiotherapy\nNOTE: Temozolomide is not PBS-subsidised for use in conjunction with PBS-subsidised carmustine.	2100
8821G	Glioblastoma multiforme concomitantly with radiotherapy\nNOTE: Temozolomide is not PBS-subsidised for use in conjunction with PBS-subsidised carmustine.	2100
8822H	Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution	2662
8822H	Pathological hyperprolactinaemia where radiotherapy is not indicated	2661
8822H	Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution	2660
8822H	Pathological hyperprolactinaemia where surgery is not indicated	2659
8823J	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
8824K	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
8826M	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2138
8826M	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops	2137
8829Q	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
8830R	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
8830R	Androgen deficiency in males with established pituitary or testicular disorders	1022
8830R	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
8831T	Severe dry eye syndrome, including Sjogren's syndrome	1362
8832W	Severe dry eye syndrome, including Sjogren's syndrome	1362
8833X	Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	1952
8836C	Obsessive-compulsive disorder	1241
8836C	Panic disorder where other treatments have failed or are inappropriate	1975
8837D	Obsessive-compulsive disorder	1241
8837D	Panic disorder where other treatments have failed or are inappropriate	1975
8839F	Use in attention deficit hyperactivity disorder, in accordance with State/Territory law	1461
8840G	Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2134
8840G	Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2133
8841H	Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2134
8897G	Treatment of immunocompromised patients with herpes zoster within 72 hours of the onset of the rash\nNOTE: Famciclovir is effective only if commenced within 72 hours of onset of rash.   Famciclovir 500 mg is not PBS-subsidised for chickenpox.  Famciclovir 500 mg is not PBS-subsidised for herpes zoster, genital herpes or other herpes simplex infections in immunocompetent patients.	2287
8842J	Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2134
8842J	Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application	2133
8843K	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
8843K	Severe disabling pain not responding to non-narcotic analgesics	1358
8844L	A patient undergoing percutaneous coronary intervention	3075
8845M	Ulcerative colitis where hypersensitivity to sulfonamides exists\nNOTE: Not for the treatment of Crohn's disease.	1708
8845M	Ulcerative colitis where intolerance to sulfasalazine exists\nNOTE: Not for the treatment of Crohn's disease.	1709
8846N	Phenylketonuria	1286
8847P	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
8847P	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
8848Q	Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2717
8848Q	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid\nNOTE: Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.	2716
8849R	Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1 November 2008	3092
8849R	Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1 November 2008	3093
8849R	Major depressive disorders	1211
8849R	Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared	2964
8849R	Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and who has been assessed by a psychiatrist	2965
8849R	Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared	2967
8849R	Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and who has been assessed by a psychiatrist	2968
8855C	Major depressive disorders	1211
8856D	Major depressive disorders	1211
8857E	Major depressive disorders	1211
8859G	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8860H	Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution	2662
8860H	Pathological hyperprolactinaemia where radiotherapy is not indicated	2661
8860H	Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution	2660
8860H	Pathological hyperprolactinaemia where surgery is not indicated	2659
8865N	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8865N	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8865N	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8898H	Glioblastoma multiforme, suspected or confirmed, at the time of initial surgery\nNOTE: Carmustine is not PBS-subsidised for use in conjunction with PBS-subsidised temozolomide.	2462
8865N	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8865N	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8866P	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8866P	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8866P	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8866P	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8866P	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8867Q	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8867Q	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8867Q	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8867Q	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8867Q	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8868R	Major depressive disorders	1211
8869T	Schizophrenia	1589
8870W	Schizophrenia	1589
8871X	Anovulatory infertility\nNOTE: Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.    Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.    Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.    Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.	1878
8871X	For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given	1119
8872Y	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
8872Y	Septicaemia, proven	1847
8872Y	Septicaemia, suspected	1846
8873B	Management of nausea and vomiting associated with radiotherapy being used to treat malignancy	1218
8875D	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8876E	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8877F	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
8878G	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9494Q	Chronic stable plaque type psoriasis vulgaris in a patient who is not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy	3209
8878G	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8878G	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8878G	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8878G	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8879H	Heart failure with a left ventricular ejection fraction of 40% or less occurring within 3 to 14 days following an acute myocardial infarction. Treatment with eplerenone must be commenced within 14 days of an acute myocardial infarction.  The date of the acute myocardial infarction and the date of initiation of eplerenone treatment must be documented in the patient's medical records when PBS-subsidised treatment is initiated	2637
8880J	Heart failure with a left ventricular ejection fraction of 40% or less occurring within 3 to 14 days following an acute myocardial infarction. Treatment with eplerenone must be commenced within 14 days of an acute myocardial infarction.  The date of the acute myocardial infarction and the date of initiation of eplerenone treatment must be documented in the patient's medical records when PBS-subsidised treatment is initiated	2637
8881K	Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)	2431
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have cerebrovascular disease which has become symptomatic. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2658
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have coronary heart disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2654
8899J	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.  The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	3070
9050H	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9495R	Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention in combination with aspirin	3208
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have diabetes mellitus. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2655
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have family history of coronary heart disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2678
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have heterozygous familial hypercholesterolaemia. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2657
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have hypertension. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2679
8891Y	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8891Y	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8881K	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have peripheral vascular disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2656
8882L	Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)	2431
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have cerebrovascular disease which has become symptomatic. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2658
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have coronary heart disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2654
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have diabetes mellitus. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2655
8891Y	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8891Y	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8892B	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9045C	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
9047E	Strongyloidiasis	1388
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have family history of coronary heart disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2678
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have heterozygous familial hypercholesterolaemia. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2657
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have hypertension. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2679
8882L	Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have peripheral vascular disease. Inadequate control with a statin is defined as follows:  (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or  (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated.  The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated	2656
8883M	Major depressive disorders	1211
8885P	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3233
8886Q	Initial treatment of gastric ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.	2273
8887R	Symptomatic treatment of osteoarthritis	1547
8887R	Symptomatic treatment of rheumatoid arthritis	1848
8888T	Symptomatic treatment of osteoarthritis	1547
8888T	Symptomatic treatment of rheumatoid arthritis	1848
8891Y	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8896F	Episodic treatment of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and a CD4 cell count of less than 500 million per litre. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment	2595
9047E	Treatment of hookworm infestation	3241
8892B	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8892B	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8892B	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8892B	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8893C	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8893C	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8893C	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8893C	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8893C	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8894D	Chronic severe disabling pain associated with proven malignant neoplasia	1061
8894D	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
8894D	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
8894D	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
8894D	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
8895E	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3138
8895E	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3137
8896F	Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes in immunocompromised patients. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment	2288
8899J	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
8899J	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
8903N	Adverse effects occurring with all of the base-priced drugs	1666
8903N	Drug interactions expected to occur with all of the base-priced drugs	1668
8903N	Drug interactions occurring with all of the base-priced drugs	1667
8903N	Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance	1406
8905Q	Adverse effects occurring with all of the base-priced drugs	1666
8905Q	Drug interactions expected to occur with all of the base-priced drugs	1668
8905Q	Drug interactions occurring with all of the base-priced drugs	1667
8905Q	Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance	1406
8938K	Adverse effects occurring with all of the base-priced drugs	1666
8938K	Drug interactions expected to occur with all of the base-priced drugs	1668
8938K	Drug interactions occurring with all of the base-priced drugs	1667
8938K	Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance	1406
8939L	Adverse effects occurring with all of the base-priced drugs	1666
8939L	Drug interactions expected to occur with all of the base-priced drugs	1668
8939L	Drug interactions occurring with all of the base-priced drugs	1667
8939L	Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance	1406
8940M	Adverse effects occurring with all of the base-priced drugs	1666
8940M	Drug interactions expected to occur with all of the base-priced drugs	1668
8940M	Drug interactions occurring with all of the base-priced drugs	1667
8940M	Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance	1406
8951D	Adverse effects occurring with all of the base-priced drugs	1666
8951D	Drug interactions expected to occur with all of the base-priced drugs	1668
8951D	Drug interactions occurring with all of the base-priced drugs	1667
8951D	Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance	1406
9004X	Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)	1021
9004X	Androgen deficiency in males with established pituitary or testicular disorders	1022
9004X	Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age	1226
9009E	Locally advanced or metastatic non-small cell lung cancer	1194
9010F	Locally advanced or metastatic non-small cell lung cancer	1194
9012H	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
9012H	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
9019Q	Hypertension in patients receiving concurrent antihypertensive therapy	2385
9020R	Hypertension in patients receiving concurrent antihypertensive therapy	2385
9021T	Phenylketonuria	1286
9022W	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
9023X	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
9024Y	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9025B	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9026C	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9027D	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9028E	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9029F	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9030G	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9031H	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9033K	Initial 1  Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have severe active psoriatic arthritis; and  (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and  (3) have failed to achieve an adequate response to:  (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and  (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or  (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.   From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.   Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].   The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.   Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.   Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.   (1)  Initial treatment.   Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).   All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised.  It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.   Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   Grandfather patients.   Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents.  Approval will be based on the criteria included in the relevant restriction.   (2)  Continuing treatment.   Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   (3)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.   Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.   Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.   (4)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.   (5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity.  Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.	3094
9047E	Treatment of whipworm infestation in an Aboriginal or a Torres Strait Islander person	2446
9033K	Initial 2  Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and  (3) have not failed treatment with adalimumab during the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2945
9034L	Continuing treatment  Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:  (1) who have a documented history of severe active psoriatic arthritis; and  (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with adalimumab; and  (3) who, at the time of application, demonstrate an adequate response to treatment with adalimumab.   An adequate response to treatment with adalimumab is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2947
9034L	Initial 3  Initial PBS-subsidised supply for continuing treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) were receiving treatment with adalimumab prior to 16 March 2006; and  (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Patients may qualify for PBS-subsidised treatment under this restriction once only	2946
9035M	Initial 1  Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have severe active psoriatic arthritis; and  (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and  (3) have failed to achieve an adequate response to:  (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and  (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or  (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.   From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.   Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].   The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.   Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.   Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.   (1)  Initial treatment.   Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).   All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised.  It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.   Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   Grandfather patients.   Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents.  Approval will be based on the criteria included in the relevant restriction.   (2)  Continuing treatment.   Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   (3)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.   Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.   Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.   (4)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.   (5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity.  Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.	3095
9035M	Initial 2  Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and  (3) have not failed treatment with etanercept during the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2949
9048F	Other proven vitamin B12 deficiencies	1250
9048F	Pernicious anaemia	1281
9048F	Prophylaxis after gastrectomy	1298
9049G	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9049G	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9049G	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9050H	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9036N	Continuing treatment  Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:  (1) who have a documented history of severe active psoriatic arthritis; and  (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and  (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.   An adequate response to treatment with etanercept is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2951
9036N	Initial 3  Initial PBS-subsidised supply for continuing treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) were receiving treatment with etanercept prior to 17 March 2005; and  (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Patients may qualify for PBS-subsidised treatment under this restriction once only	2950
9037P	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3276
9037P	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3274
9037P	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3275
9037P	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis.  Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.   From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.   Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.  Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.   Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle.  The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.   Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.   There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.   (1)  Application for approval for initial treatment.   Applications for a course of initial treatment should be made in the following situations:  (i)  patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii)  patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4)  Swapping therapy' below]; or  (iii)  patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).   All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.   Grandfather patients (adalimumab and ustekinumab only).   Applications for patients who commenced treatment with adalimumab prior to 1 March 2009 or ustekinumab prior to 26 November 2009, may be made for initial PBS-subsidised treatment as continuing therapy under the initial treatment restriction (Initial 3).  These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment.  Approval will be based on the criteria included in the relevant restriction.   (2)  Assessment of response to initial treatment.   When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment.  This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   (3)  Application for continuing treatment.   Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent.  Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.   For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   (4)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not.  However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.   Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.   (5)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.   To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.   (6)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity.  Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment.  The PASI assessment must be no older than 1 month at the time of application.	3273
9040T	Type 1 diabetes	2418
9042X	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
9043Y	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
9044B	For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs	1540
9051J	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9051J	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9052K	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9052K	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9052K	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9053L	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9053L	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9053L	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9054M	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9054M	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9054M	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9055N	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9055N	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9055N	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9056P	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are currently receiving treatment with a dihydropyridine calcium channel blocker	2449
9056P	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate	2451
9056P	For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate	2450
9057Q	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3138
9057Q	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3137
9058R	Gonorrhoea	1143
9059T	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.   The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2633
9060W	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.   The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2633
9061X	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.   The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2633
9062Y	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.   The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated.  The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated\nNOTE: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.	2633
9064C	Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3239
9065D	Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3239
9066E	Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3239
9070J	Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder	3084
9070J	Schizophrenia	1589
9071K	Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder	3084
9071K	Schizophrenia	1589
9072L	Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder	3084
9072L	Schizophrenia	1589
9073M	Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder	3084
9073M	Schizophrenia	1589
9075P	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
9075P	Schizophrenia	1589
9076Q	Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2272
9076Q	Schizophrenia	1589
9077R	Initial 1 (new patients)  First course of PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND  (a) who has at least 2 of the following:  (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or  (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or  (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND  (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.   The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.   If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.   If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.   The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.   The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.   Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone\nNOTE: TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept and infliximab only.   A patient is eligible for PBS-subsidised treatment with only 1 of the 3 TNF-alfa antagonists at any 1 time.   From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.   A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.   Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once.  A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.   A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.   A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.   There is no limit to the number of treatment cycles a patient may undertake in their lifetime.   (1)  How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 March 2007.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for etanercept and adalimumab and 18 weeks of treatment for infliximab.   From 1 March 2007, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   (2)  Swapping therapy.   Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.   A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application.   However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.   (3)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.   For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  However, this is not required for any subsequent BASDAI results for these patients, nor for patients who were 'grandfathered' on to TNF-alfa antagonist treatment.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.   (4)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.   A patient who commenced treatment with adalimumab for active ankylosing spondylitis prior to 1 November 2006 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.   Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.   Where pre-TNF-alfa antagonist treatment baselines cannot be provided, the following criteria must be met to demonstrate a response to treatment:  The BASDAI score must be either:  (i) no more than 20% greater than the score included in the initial application for PBS-subsidised treatment; or  (ii) no greater than 2.  AND  One of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L.   'Grandfather' arrangements will only apply for the first treatment cycle.  For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2507
9077R	Initial 2 (change or re-commencement for all patients)  Initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with adalimumab.   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.   A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2508
9094P	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9138Y	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated\nNOTE: A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.	2715
9078T	Continuing treatment for all patients  Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:  (a) has demonstrated a response to treatment with adalimumab; and  (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with adalimumab.   Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.   For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.   Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   The first application for continuing treatment following an initial treatment course must be made following a minimum of 12 weeks of treatment with adalimumab.   Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.   Written applications for authorisation must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.   All measurements provided must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone	2510
9078T	Initial ('grandfather' patients)  Initial PBS-subsidised course of adalimumab treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who was receiving treatment with adalimumab prior to 1 November 2006; AND  (a) is receiving treatment with adalimumab at the time of application; AND  (b) has not received prior PBS-subsidised treatment with infliximab or etanercept; AND  (c) whose current Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score is either:  (i) less than or equal to 5 on a 0-10 scale; OR  (ii) improved by at least 2 from baseline; AND  (d) who has:  (i) an ESR measurement no greater than 25 mm per hour; or  (ii) a CRP measurement no greater than 10 mg per L; or  (iii) an ESR or CRP measurement reduced by at least 20% from pre-treatment baseline.   The BASDAI assessment and ESR and/or CRP measurements provided must be no more than 1 month old at the time of application.  Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a signed patient acknowledgment form included in the supporting information form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to this initial course of therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.   A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.   Patients may only qualify for PBS-subsidised treatment under this criterion once	2509
9079W	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
9080X	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
9085E	Initial 1 (new patients)  First course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND  (a) who has at least 2 of the following:  (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or  (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or  (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND  (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.   The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.   If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.   If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.   The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.   The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.   Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2504
9085E	Initial 2 (change or re-commencement for all patients)  Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with etanercept.   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.   A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2505
9086F	Continuing treatment for all patients  Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:  (a) has demonstrated a response to treatment with etanercept; and  (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.   Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.   For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.   Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment.   Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.   Written applications for authorisation must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.   All measurements provided must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone	2506
9087G	Initial 1  Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have severe active psoriatic arthritis; and  (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and  (3) have failed to achieve an adequate response to:  (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and  (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or  (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.   From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.   Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].   The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.   Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.   Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.   (1)  Initial treatment.   Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).   All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised.  It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.   Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   Grandfather patients.   Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents.  Approval will be based on the criteria included in the relevant restriction.   (2)  Continuing treatment.   Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   (3)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.   Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.   Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.   (4)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.   (5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity.  Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.	3095
9139B	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated\nNOTE: A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.	2715
9087G	Initial 2  Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and  (3) have not failed treatment with etanercept during the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2949
9088H	Continuing treatment  Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:  (1) who have a documented history of severe active psoriatic arthritis; and  (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and  (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.   An adequate response to treatment with etanercept is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2951
9088H	Initial 3  Initial PBS-subsidised supply for continuing treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) were receiving treatment with etanercept prior to 17 March 2005; and  (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Patients may qualify for PBS-subsidised treatment under this restriction once only	2950
9089J	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.   PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.   In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.   From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.   A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.   For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.   The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.   There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.   If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.   (1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.   From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Rituximab patients:  A further application may be submitted to Medicare Australia 24 weeks after the first infusion.  New baselines may be submitted with this application if appropriate.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements.  However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application.  However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.   In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab.  This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD.  Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.   To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.	3224
9089J	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with etanercept within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints.  Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.   The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.   From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.   'Grandfather' arrangements will only apply for the first Treatment Cycle.  For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2845
9089J	Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years; AND  (a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly; AND  (c) who have failed to achieve an adequate response to methotrexate, in combination with 2 other disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; AND  (d) who have subsequently failed to achieve an adequate response following a minimum of 3 months' treatment with:  (i) leflunomide; or  (ii) cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use, the patient is exempted from demonstrating an inadequate response to the above treatment regimens. Details of the contraindication or intolerance, including the degree of toxicity, must be provided at the time of application.   The following criteria must be met in order to demonstrate failure to achieve an adequate response:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).    If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be in writing and must include sufficient information to determine the patient's eligibility according to the above criteria.  The date of joint assessment must be provided.   Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 4 months of treatment may be requested by telephone. Under no circumstances will telephone approvals be granted for initial or continuing authority applications, or for treatment that would otherwise extend the initial treatment period beyond 4 months.   The assessment of the patient's response to the initial course of treatment should be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria	3225
9094P	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9140C	Schizophrenia	1589
9141D	Schizophrenia	1589
9090K	Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who, at the time of application, demonstrate an adequate response to treatment with etanercept as manifested by:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND 1 or more of the following:  (i) an active joint count of fewer than 10 active (swollen and tender) joints; or  (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or  (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of assessment of the patient must be provided.   Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.   Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application	1910
9090K	Continuing treatment  Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with etanercept; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2846
9090K	Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, and who were receiving treatment with etanercept prior to 1 December 2002; AND  (a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.   The authority application must be in writing and must include sufficient information to determine the patient's eligibility. The date of assessment of the patient must be provided	1909
9091L	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3276
9094P	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9095Q	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9142E	Schizophrenia	1589
9144G	Hypertension in a patient who is not adequately controlled with either lercanidipine hydrochloride or enalapril maleate monotherapy	2887
9145H	Hypertension in a patient who is not adequately controlled with either lercanidipine hydrochloride or enalapril maleate monotherapy	2887
9091L	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3274
9091L	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3275
9091L	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis.  Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.   From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.   Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.  Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.   Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle.  The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.   Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.   There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.   (1)  Application for approval for initial treatment.   Applications for a course of initial treatment should be made in the following situations:  (i)  patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii)  patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4)  Swapping therapy' below]; or  (iii)  patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).   All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.   Grandfather patients (adalimumab and ustekinumab only).   Applications for patients who commenced treatment with adalimumab prior to 1 March 2009 or ustekinumab prior to 26 November 2009, may be made for initial PBS-subsidised treatment as continuing therapy under the initial treatment restriction (Initial 3).  These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment.  Approval will be based on the criteria included in the relevant restriction.   (2)  Assessment of response to initial treatment.   When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment.  This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   (3)  Application for continuing treatment.   Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent.  Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.   For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   (4)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not.  However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.   Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.   (5)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.   To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.   (6)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity.  Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment.  The PASI assessment must be no older than 1 month at the time of application.	3273
9092M	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9092M	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9092M	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9092M	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9093N	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9093N	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9093N	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9093N	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9094P	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9146J	Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents	2823
9146J	Constipation in patients with malignant neoplasia	1613
9146J	Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies	2693
9146J	Patients receiving palliative care	1263
9095Q	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9095Q	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9095Q	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9096R	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9096R	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9096R	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9096R	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9097T	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information\nNOTE: No applications for repeats will be authorised.	2713
9097T	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated\nNOTE: No applications for repeats will be authorised.	2714
9098W	Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated\nNOTE: A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.	2715
9099X	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	3223
9099X	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with adalimumab within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2842
9147K	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.  The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	3070
9100Y	Continuing treatment  Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with adalimumab; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2843
9101B	Initial 1  Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have severe active psoriatic arthritis; and  (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and  (3) have failed to achieve an adequate response to:  (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and  (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or  (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.   From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.   Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].   The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.   Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.   Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.   (1)  Initial treatment.   Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).   All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised.  It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.   Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   Grandfather patients.   Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents.  Approval will be based on the criteria included in the relevant restriction.   (2)  Continuing treatment.   Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   (3)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.   Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.   Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.   (4)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.   (5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity.  Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.	3094
9101B	Initial 2  Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and  (3) have not failed treatment with adalimumab during the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2945
9102C	Continuing treatment  Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:  (1) who have a documented history of severe active psoriatic arthritis; and  (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with adalimumab; and  (3) who, at the time of application, demonstrate an adequate response to treatment with adalimumab.   An adequate response to treatment with adalimumab is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2947
9102C	Initial 3  Initial PBS-subsidised supply for continuing treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) were receiving treatment with adalimumab prior to 16 March 2006; and  (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Patients may qualify for PBS-subsidised treatment under this restriction once only	2946
9103D	Initial 1 (new patients)  First course of PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND  (a) who has at least 2 of the following:  (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or  (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or  (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND  (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.   The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.   If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.   If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.   The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.   The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.   Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone\nNOTE: TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept and infliximab only.   A patient is eligible for PBS-subsidised treatment with only 1 of the 3 TNF-alfa antagonists at any 1 time.   From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.   A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.   Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once.  A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.   A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.   A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.   There is no limit to the number of treatment cycles a patient may undertake in their lifetime.   (1)  How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 March 2007.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for etanercept and adalimumab and 18 weeks of treatment for infliximab.   From 1 March 2007, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   (2)  Swapping therapy.   Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.   A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application.   However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.   (3)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.   For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  However, this is not required for any subsequent BASDAI results for these patients, nor for patients who were 'grandfathered' on to TNF-alfa antagonist treatment.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.   (4)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.   A patient who commenced treatment with adalimumab for active ankylosing spondylitis prior to 1 November 2006 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.   Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.   Where pre-TNF-alfa antagonist treatment baselines cannot be provided, the following criteria must be met to demonstrate a response to treatment:  The BASDAI score must be either:  (i) no more than 20% greater than the score included in the initial application for PBS-subsidised treatment; or  (ii) no greater than 2.  AND  One of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L.   'Grandfather' arrangements will only apply for the first treatment cycle.  For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2507
9103D	Initial 2 (change or re-commencement for all patients)  Initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with adalimumab.   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.   A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2508
9104E	Continuing treatment for all patients  Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:  (a) has demonstrated a response to treatment with adalimumab; and  (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with adalimumab.   Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.   For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.   Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   The first application for continuing treatment following an initial treatment course must be made following a minimum of 12 weeks of treatment with adalimumab.   Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.   Written applications for authorisation must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.   All measurements provided must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone	2510
9104E	Initial ('grandfather' patients)  Initial PBS-subsidised course of adalimumab treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who was receiving treatment with adalimumab prior to 1 November 2006; AND  (a) is receiving treatment with adalimumab at the time of application; AND  (b) has not received prior PBS-subsidised treatment with infliximab or etanercept; AND  (c) whose current Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score is either:  (i) less than or equal to 5 on a 0-10 scale; OR  (ii) improved by at least 2 from baseline; AND  (d) who has:  (i) an ESR measurement no greater than 25 mm per hour; or  (ii) a CRP measurement no greater than 10 mg per L; or  (iii) an ESR or CRP measurement reduced by at least 20% from pre-treatment baseline.   The BASDAI assessment and ESR and/or CRP measurements provided must be no more than 1 month old at the time of application.  Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a signed patient acknowledgment form included in the supporting information form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to this initial course of therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.   A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.   Patients may only qualify for PBS-subsidised treatment under this criterion once	2509
9106G	Bronchiectasis in patients aged 8 years or older	1851
9106G	Chronic bronchitis in patients aged 8 years or older	1852
9106G	Severe acne	1346
9107H	Pelvic inflammatory disease	1279
9108J	Urethritis	1459
9109K	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.   No applications for increased repeats will be authorised.	1177
9110L	Gastro-oesophageal reflux disease	1533
9110L	Scleroderma oesophagus	1337
9110L	Zollinger-Ellison syndrome	1476
9111M	Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour who have previously been issued with an authority prescription for this drug.   Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib\nNOTE: Patients who achieve a response to treatment at an imatinib dose of 400 mg per day should be continued at this dose and assessed for response at regular intervals.  Patients who fail to achieve a response to 400 mg per day may have their dose increased to 600 mg per day.  Authority applications for doses higher than 600 mg per day will not be approved.   A response to treatment is defined as a decrease from baseline in the sum of the products of the perpendicular diameters of all measurable lesions of 50% or greater.  (Response definition based on the Southwest Oncology Group standard criteria, see Demetri et al.  N Engl J Med 2002; 347: 472-80.)	3232
9111M	Initial PBS-subsidised treatment, for up to 3 months, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining.   Patients who have not previously been treated with imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour must commence treatment at a dose not exceeding 400 mg per day for at least 3 months.  Authority prescriptions for a higher dose will not be approved during this initial 3 month treatment period.   Patients who have previously been treated with non-PBS-subsidised imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour are eligible to receive up to 3 months treatment at a dose of up to 600 mg per day.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and  (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s), including whether or not there is evidence of metastatic disease; and  (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim must be provided	3231
9124F	Initial treatment in combination with chemotherapy as induction or consolidation of a newly diagnosed patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and  (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and  (d) a signed patient acknowledgement	2766
9112N	Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour who have previously been issued with an authority prescription for this drug.   Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib\nNOTE: Patients who achieve a response to treatment at an imatinib dose of 400 mg per day should be continued at this dose and assessed for response at regular intervals.  Patients who fail to achieve a response to 400 mg per day may have their dose increased to 600 mg per day.  Authority applications for doses higher than 600 mg per day will not be approved.   A response to treatment is defined as a decrease from baseline in the sum of the products of the perpendicular diameters of all measurable lesions of 50% or greater.  (Response definition based on the Southwest Oncology Group standard criteria, see Demetri et al.  N Engl J Med 2002; 347: 472-80.)	3232
9112N	Initial PBS-subsidised treatment, for up to 3 months, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining.   Patients who have not previously been treated with imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour must commence treatment at a dose not exceeding 400 mg per day for at least 3 months.  Authority prescriptions for a higher dose will not be approved during this initial 3 month treatment period.   Patients who have previously been treated with non-PBS-subsidised imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour are eligible to receive up to 3 months treatment at a dose of up to 600 mg per day.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and  (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s), including whether or not there is evidence of metastatic disease; and  (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim must be provided	3231
9113P	Continuing treatment of patients who have received initial treatment with imatinib mesylate as a pharmaceutical benefit for the chronic phase of chronic myeloid leukaemia and who have demonstrated either a major cytogenetic response or less than 1% bcr-abl level in the blood in the preceding 12 months.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or  (b) a peripheral blood level of bcr-abl of less than 1% on the international scale [see Note explaining requirements].  Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A peripheral blood bcr-abl level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with imatinib mesylate, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of bcr-abl transcript in the peripheral blood using the international scale, must be submitted.  For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with bcr-abl specific probe must be submitted.  The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 12 months of the commencement of treatment with imatinib mesylate, at which time patients in whom a major cytogenetic response or peripheral blood bcr-abl level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) within 18 months of the commencement of treatment with imatinib mesylate, in patients who have failed to demonstrate a major cytogenetic response or peripheral blood bcr-abl level of less than 1% at between 10 and 12 months (patients in whom a major cytogenetic response or peripheral blood bcr-abl level of less than 1% is demonstrable by 18 months may also receive authorisation for a further 12 months of treatment); and  (iii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood bcr-abl level of less than 1% has been sustained.   For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of bcr-abl transcript in the peripheral blood using the international scale, must be submitted as described in (i) to (iii) above.  For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with bcr-abl specific probe must be submitted with the authority application.  A copy of the non-informative standard karyotype analysis must be included with the authority application.   Where a patient has previously received PBS-subsidised treatment with imatinib mesylate, no approval will be granted for PBS-subsidised re-treatment in the chronic phase of chronic myeloid leukaemia, where that patient has at any time failed to meet the criteria for continuing treatment.	2488
9113P	Initial treatment of patients in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia.   Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy from the date the first application for initial treatment was approved.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the bcr-abl transcript in either peripheral blood or bone marrow; and  (4) a copy of a signed patient acknowledgement form indicating that the patient understands and acknowledges that PBS-subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia will cease if subsequent testing demonstrates that:  (i) the patient has failed to achieve a major cytogenetic response within the initial 18 months of treatment [see Note defining major cytogenetic response]; or  (ii) the patient has failed to sustain a major cytogenetic response for 12 months from the date of the last pathology report that indicated that a major cytogenetic response had been achieved [see Note defining major cytogenetic response]\nNOTE: Imatinib mesylate in the chronic phase of chronic myeloid leukaemia will only be subsidised for patients who are not receiving concomitant PBS-subsidised interferon alfa therapy.   Patients should be commenced on a dose of imatinib mesylate of 400 mg (base) daily and maintained on a minimum dose of imatinib mesylate of 400 mg (base) daily.  Prescribing of lower doses should be carefully considered.  Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter, irrespective of the daily imatinib mesylate dose received.	2210
9114Q	Continuing treatment of patients who have received initial treatment with imatinib mesylate as a pharmaceutical benefit for the chronic phase of chronic myeloid leukaemia and who have demonstrated either a major cytogenetic response or less than 1% bcr-abl level in the blood in the preceding 12 months.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or  (b) a peripheral blood level of bcr-abl of less than 1% on the international scale [see Note explaining requirements].  Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A peripheral blood bcr-abl level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with imatinib mesylate, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of bcr-abl transcript in the peripheral blood using the international scale, must be submitted.  For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with bcr-abl specific probe must be submitted.  The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 12 months of the commencement of treatment with imatinib mesylate, at which time patients in whom a major cytogenetic response or peripheral blood bcr-abl level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) within 18 months of the commencement of treatment with imatinib mesylate, in patients who have failed to demonstrate a major cytogenetic response or peripheral blood bcr-abl level of less than 1% at between 10 and 12 months (patients in whom a major cytogenetic response or peripheral blood bcr-abl level of less than 1% is demonstrable by 18 months may also receive authorisation for a further 12 months of treatment); and  (iii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood bcr-abl level of less than 1% has been sustained.   For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of bcr-abl transcript in the peripheral blood using the international scale, must be submitted as described in (i) to (iii) above.  For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with bcr-abl specific probe must be submitted with the authority application.  A copy of the non-informative standard karyotype analysis must be included with the authority application.   Where a patient has previously received PBS-subsidised treatment with imatinib mesylate, no approval will be granted for PBS-subsidised re-treatment in the chronic phase of chronic myeloid leukaemia, where that patient has at any time failed to meet the criteria for continuing treatment.	2488
9136W	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information\nNOTE: No applications for repeats will be authorised.	2713
9114Q	Initial treatment of patients in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia.   Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy from the date the first application for initial treatment was approved.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the bcr-abl transcript in either peripheral blood or bone marrow; and  (4) a copy of a signed patient acknowledgement form indicating that the patient understands and acknowledges that PBS-subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia will cease if subsequent testing demonstrates that:  (i) the patient has failed to achieve a major cytogenetic response within the initial 18 months of treatment [see Note defining major cytogenetic response]; or  (ii) the patient has failed to sustain a major cytogenetic response for 12 months from the date of the last pathology report that indicated that a major cytogenetic response had been achieved [see Note defining major cytogenetic response]\nNOTE: Imatinib mesylate in the chronic phase of chronic myeloid leukaemia will only be subsidised for patients who are not receiving concomitant PBS-subsidised interferon alfa therapy.   Patients should be commenced on a dose of imatinib mesylate of 400 mg (base) daily and maintained on a minimum dose of imatinib mesylate of 400 mg (base) daily.  Prescribing of lower doses should be carefully considered.  Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter, irrespective of the daily imatinib mesylate dose received.	2210
9115R	Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of the accelerated phase of chronic myeloid leukaemia	1818
9115R	Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of the blast phase of chronic myeloid leukaemia	1819
9115R	Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to the accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and  (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criteria (1), (2), (3) and (5) above, or details of the dates of assessments in the case of progressive splenomegaly	1816
9115R	Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to myeloid blast crisis is defined as either:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or  (2) Extramedullary involvement other than spleen and liver.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and  (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criterion (1) above, or details of the date of assessment in the case of extramedullary involvement	1817
9116T	Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of the accelerated phase of chronic myeloid leukaemia	1818
9116T	Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of the blast phase of chronic myeloid leukaemia	1819
9116T	Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to the accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and  (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criteria (1), (2), (3) and (5) above, or details of the dates of assessments in the case of progressive splenomegaly	1816
9116T	Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to myeloid blast crisis is defined as either:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or  (2) Extramedullary involvement other than spleen and liver.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and  (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criterion (1) above, or details of the date of assessment in the case of extramedullary involvement	1817
9496T	Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention in combination with aspirin	3208
9117W	Continuing PBS-subsidised treatment, as monotherapy or in combination with a corticosteroid and/or cyclophosphamide, of multiple myeloma in a patient who has previously received 4 treatment cycles of bortezomib and who, at the time of application, has demonstrated at least a partial response to bortezomib.   If serum M protein and urine Bence-Jones protein levels are measurable, partial response (PR) compared with baseline (prior to treatment with bortezomib) is defined as:  (a) at least a 50% reduction in the level of serum M protein (monoclonal protein); or  (b) at least a 90% reduction in 24-hour urinary light chain M protein excretion or to less than 200 mg per 24 hours.   If serum M protein and urine Bence-Jones protein levels are unmeasurable as in non-secretory/oligo-secretory multiple myeloma, partial response compared with baseline is defined as:  (c) at least a 50% reduction in the difference between involved and uninvolved serum free light chain (FLC) levels.   If serum M protein and urine Bence-Jones protein and serum FLC are unmeasurable/unavailable, partial response compared with baseline is defined as:  (d) at least a 50% reduction in bone marrow plasma cells; or  (e) no increase in size or number of lytic bone lesions (development of compression fracture does not exclude response); or  (f) at least a 50% reduction in the size of soft tissue plasmacytoma (by clinical or applicable radiographic examination, i.e. MRI or CT-Scan); or  (g) normalisation of corrected serum calcium to less than or equal to 2.65 mmol per L.   For the purpose of assessing eligibility for continuing PBS-subsidised bortezomib treatment beyond 4 cycles, the patient must have achieved at least a partial response at the completion of cycle 4.  The results of the response assessment must be included in a written application to Medicare Australia for further treatment. Where a response assessment is not submitted to Medicare Australia prior to cycle 5, patients will be deemed to have failed to respond to treatment with bortezomib.  Continuing PBS-subsidised supply will not be approved if there is a gap of more than 6 months between the initial application and subsequent applications.   The same parameters provided for the diagnosis of progressive disease are to be used to demonstrate at least a partial response to treatment.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form; and  (3) diagnostic reports demonstrating the patient has achieved at least a partial response.   Diagnostic reports must be no more than 1 month old at the time of application.   Patients who fail to demonstrate at least a partial response after 8 cycles will not be eligible to receive further PBS-subsidised treatment with bortezomib.   No more than 2 cycles of treatment beyond the cycle at which a confirmed complete response was first achieved will be authorised. Confirmation requires 2 determinations a minimum of 6 weeks apart	3196
9117W	Initial PBS-subsidised treatment, as monotherapy or in combination with a corticosteroid and/or cyclophosphamide, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.   If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.   Thalidomide treatment failure is defined as:  (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or  (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.   Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.   Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or Grade 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.   Any queries concerning additional details about treatment failure may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday.   Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:  (1) less than a 25% reduction in serum or urine M protein; or  (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.   Bortezomib will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised lenalidomide.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.   To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:  (a) the level of serum monoclonal protein; or  (b) Bence-Jones proteinuria  -  the results of 24-hour urinary light chain M protein excretion; or  (c) the serum level of free kappa and lambda light chains; or  (d) bone marrow aspirate or trephine; or  (e) if present, the size and location of lytic bone lesions (not including compression fractures); or  (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or  (g) if present, the level of hypercalcaemia, corrected for albumin concentration.   As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and  (3) duration of thalidomide and daily dose prescribed; and  (4) a signed patient acknowledgment	3195
9118X	Continuing PBS-subsidised treatment, as monotherapy or in combination with a corticosteroid and/or cyclophosphamide, of multiple myeloma in a patient who has previously received 8 treatment cycles with bortezomib and who, at the time of application, has demonstrated at least a partial response to bortezomib but who has not received 2 treatment cycles after first achieving a confirmed complete response.   If serum M protein and urine Bence-Jones protein levels are measurable, partial response (PR) compared with baseline (prior to treatment with bortezomib) is defined as:  (a) at least a 50% reduction in the level of serum M protein (monoclonal protein); or  (b) at least a 90% reduction in 24-hour urinary light chain M protein excretion or to less than 200 mg per 24 hours.   If serum M protein and urine Bence-Jones protein levels are unmeasurable as in non-secretory/oligo-secretory multiple myeloma, partial response compared with baseline is defined as:  (c) the difference between involved and uninvolved serum free light chain (FLC) levels, with at least a 50% reduction in this value.   If serum M protein and urine Bence-Jones protein levels and serum FLC are unmeasurable/unavailable, partial response compared with baseline is defined as:  (d) at least a 50% reduction in bone marrow plasma cells; or  (e) no increase in size or number of lytic bone lesions (development of compression fracture does not exclude response); or  (f) at least a 50% reduction in the size of soft tissue plasmacytoma (by clinical or applicable radiographic examination, i.e. MRI or CT-Scan); or  (g) normalisation of corrected serum calcium to less than or equal to 2.65 mmol per L.   The same parameters provided for the diagnosis of progressive disease are to be used to demonstrate at least a partial response to treatment.   Diagnostic reports must be within 1 month of the date of application.   For the purpose of assessing eligibility for continuing PBS-subsidised bortezomib treatment beyond 8 cycles, the patient must have achieved at least a partial response at the completion of cycle 8.  The results of the response assessment must be included in a written application to Medicare Australia for further treatment. Where a response assessment is not submitted to Medicare Australia prior to cycle 9, patients will be deemed to have failed to respond to treatment with bortezomib.  Continuing PBS-subsidised supply will not be approved if there is a gap of more than 10 months between the initial application and an application following completion of 8 treatment cycles.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form; and  (3) diagnostic reports demonstrating the patient has achieved at least a partial response.   No more than 2 cycles of treatment beyond the cycle at which the complete response was first achieved will be authorised. Confirmation requires 2 determinations a minimum of 6 weeks apart.   Applications for PBS-subsidised treatment with bortezomib that extends beyond 11 cycles will not be approved	3197
9119Y	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
9123E	Continuing treatment in combination with chemotherapy as maintenance of first complete remission of patients with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Imatinib mesylate is available with a lifetime maximum of 24 months for continuing treatment with imatinib mesylate therapy for patients with acute lymphoblastic leukaemia reimbursed through the PBS.   Any queries concerning the arrangements to prescribe imatinib mesylate beyond 24 months may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Allogeneic stem cell transplantation is the preferred therapy for eligible patients achieving a complete remission of Philadelphia positive acute lymphoblastic leukaemia.	3144
9123E	Initial treatment in combination with chemotherapy as induction or consolidation of a newly diagnosed patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and  (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and  (d) a signed patient acknowledgement	2766
9123E	Initial treatment of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript BCR-ABL who was previously treated with imatinib mesylate under the Imatinib Compassionate Program and who meets all the PBS criteria.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and  (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and  (d) a signed patient acknowledgement	2767
9124F	Continuing treatment in combination with chemotherapy as maintenance of first complete remission of patients with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Imatinib mesylate is available with a lifetime maximum of 24 months for continuing treatment with imatinib mesylate therapy for patients with acute lymphoblastic leukaemia reimbursed through the PBS.   Any queries concerning the arrangements to prescribe imatinib mesylate beyond 24 months may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Allogeneic stem cell transplantation is the preferred therapy for eligible patients achieving a complete remission of Philadelphia positive acute lymphoblastic leukaemia.	3144
9136W	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated\nNOTE: No applications for repeats will be authorised.	2714
9124F	Initial treatment of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript BCR-ABL who was previously treated with imatinib mesylate under the Imatinib Compassionate Program and who meets all the PBS criteria.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and  (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and  (d) a signed patient acknowledgement	2767
9125G	Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.   Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Dasatinib will only be subsidised for patients with acute lymphoblastic leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate and who are not appropriate for an allogeneic haemopoietic stem cell transplant.	2771
9125G	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.   Failure of treatment is defined as either:  (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;  (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;  (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2769
9125G	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1 December 2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2770
9126H	Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.   Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Dasatinib will only be subsidised for patients with acute lymphoblastic leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate and who are not appropriate for an allogeneic haemopoietic stem cell transplant.	2771
9126H	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.   Failure of treatment is defined as either:  (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;  (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;  (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2769
9137X	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information\nNOTE: No applications for repeats will be authorised.	2713
9137X	Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated\nNOTE: No applications for repeats will be authorised.	2714
9126H	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1 December 2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2770
9127J	Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.   Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Dasatinib will only be subsidised for patients with acute lymphoblastic leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate and who are not appropriate for an allogeneic haemopoietic stem cell transplant.	2771
9127J	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.   Failure of treatment is defined as either:  (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;  (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;  (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2769
9127J	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1 December 2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2770
9128K	Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program. Details of the program must be specified in the authority application	2774
9128K	Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested. Details of the program must be specified in the authority application	2775
9129L	Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program	2776
9130M	Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval	2957
9130M	Mesothelioma in combination with cisplatin.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval\nNOTE: No applications for increased maximum quantities for the 500 mg vial will be authorised.	2958
9131N	Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval	2957
9131N	Mesothelioma in combination with cisplatin.   Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy.  The patient's BSA must be provided at the time of the authority approval\nNOTE: No applications for increased maximum quantities for the 500 mg vial will be authorised.	2958
9132P	Tyrosinaemia	1453
9133Q	Pyridoxine non-responsive homocystinuria	1314
9134R	Maple syrup urine disease	1220
9135T	Maple syrup urine disease	1220
9147K	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
9147K	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
9148L	Continuing treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer who has previously received treatment with PBS-subsidised lapatinib and who does not have progressive disease.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a statement from the prescribing doctor that the disease has not progressed	2890
9148L	Initial treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer (equivalent to Stage IIIC or Stage IV) who has received prior therapy with an anthracycline and a taxane, each for at least 3 cycles, and whose disease has progressed despite treatment with trastuzumab for metastatic disease.   Authority applications for initial treatment must be made in writing and must include:  (a) a completed authority prescription form;  (b) a pathology report demonstrating HER2 positivity has been demonstrated by in situ hybridisation (ISH);  (c) date of last treatment with a taxane and total number of cycles;  (d) date of last treatment with an anthracycline and total number of cycles;  (e) a signed patient acknowledgment;  (f) dates of treatment with trastuzumab; and  (g) date of demonstration of progression whilst on treatment with trastuzumab\nNOTE: Treatment with trastuzumab for metastatic disease is defined as trastuzumab administered alone or in combination with chemotherapy for at least 6 weeks at standard doses.   If treatment with anthracycline or taxane is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].	2888
9149M	Serious staphylococcal infections	1345
9150N	Serious staphylococcal infections	1345
9151P	Parkinson disease	3216
9152Q	Parkinson disease	3216
9153R	Parkinson disease	3216
9155W	Major depressive disorders	1211
9156X	Major depressive disorders	1211
9157Y	Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment a decrease of at least 30% in iPTH concentrations\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.	3023
9157Y	Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment iPTH greater than 15 pmol per L and an (adjusted) serum calcium concentration of less than 2.6 mmol per L\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.	3024
9158B	Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment a decrease of at least 30% in iPTH concentrations\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.	3023
9167L	Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease	2972
9167L	Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer, after prior treatment with platinum-based chemotherapy:  (1) where:  (a) disease progression occurred following treatment with docetaxel or pemetrexed; or  (b) treatment with docetaxel and pemetrexed was either contraindicated or could not be tolerated; and  (2) who has received treatment with erlotinib under the Erlotinib Access Programme prior to 1 August 2008; and  (3) who does not have progressive disease	2973
9158B	Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment iPTH greater than 15 pmol per L and an (adjusted) serum calcium concentration of less than 2.6 mmol per L\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.	3024
9159C	Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment a decrease of at least 30% in iPTH concentrations\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.	3023
9159C	Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment iPTH greater than 15 pmol per L and an (adjusted) serum calcium concentration of less than 2.6 mmol per L\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.	3024
9160D	Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person	2354
9160D	Treatment of a fungal or a yeast infection in a patient aged up to 18 years inclusive	3243
9161E	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
9161E	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
9161E	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
9167L	Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:  (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or  (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and  (2) further cytotoxic chemotherapy is not appropriate	2971
9168M	Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease	2972
9216C	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9161E	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
9162F	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2938
9162F	CONTINUING TREATMENT  -  (S)MMSE or ADAS-Cog improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:  (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);  (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2934
9162F	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 or more.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.   If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2933
9162F	INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2936
9163G	Chronic stable plaque type psoriasis vulgaris of the scalp	2963
9164H	Pyridoxine non-responsive homocystinuria	1314
9165J	Phenylketonuria	1286
9166K	Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease	2972
9166K	Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer, after prior treatment with platinum-based chemotherapy:  (1) where:  (a) disease progression occurred following treatment with docetaxel or pemetrexed; or  (b) treatment with docetaxel and pemetrexed was either contraindicated or could not be tolerated; and  (2) who has received treatment with erlotinib under the Erlotinib Access Programme prior to 1 August 2008; and  (3) who does not have progressive disease	2973
9166K	Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:  (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or  (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and  (2) further cytotoxic chemotherapy is not appropriate	2971
9168M	Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer, after prior treatment with platinum-based chemotherapy:  (1) where:  (a) disease progression occurred following treatment with docetaxel or pemetrexed; or  (b) treatment with docetaxel and pemetrexed was either contraindicated or could not be tolerated; and  (2) who has received treatment with erlotinib under the Erlotinib Access Programme prior to 1 August 2008; and  (3) who does not have progressive disease	2973
9168M	Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:  (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or  (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and  (2) further cytotoxic chemotherapy is not appropriate	2971
9169N	Treatment of partial epileptic seizures, which are not controlled satisfactorily by other anti-epileptic drugs in a patient unable to take a solid dose form of levetiracetam	3291
9170P	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
9171Q	Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with nilotinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to nilotinib in the preceding 18 months and thereafter at 12 monthly intervals.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib Authority Application Form for continuing treatment; and  (3) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or  (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with nilotinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 18 months of the commencement of treatment with nilotinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.   For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.  Where a patient has previously received PBS-subsidised treatment with nilotinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.	3041
9172R	Continuing PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response, but whose disease remains unresectable.   Maximum dose: 800 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a statement that the disease has not progressed on imatinib therapy	2979
9172R	Initial PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans.   Maximum dose: 800 mg per day.   (1) Where the application for authority to prescribe is being sought on the basis of unresectable tumour, written evidence in support of that claim must be provided; and  (2) Where the application for authority to prescribe is being sought on the basis of locally recurrent disease, the site of the local recurrence must be specified; and  (3) Where the application for authority to prescribe is being sought on the basis of metastatic disease, the site(s) of metastatic disease must be provided.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement	2978
9173T	Continuing PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response, but whose disease remains unresectable.   Maximum dose: 800 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a statement that the disease has not progressed on imatinib therapy	2979
9173T	Initial PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans.   Maximum dose: 800 mg per day.   (1) Where the application for authority to prescribe is being sought on the basis of unresectable tumour, written evidence in support of that claim must be provided; and  (2) Where the application for authority to prescribe is being sought on the basis of locally recurrent disease, the site of the local recurrence must be specified; and  (3) Where the application for authority to prescribe is being sought on the basis of metastatic disease, the site(s) of metastatic disease must be provided.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement	2978
9174W	Continuing PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia who has previously been issued with an authority prescription for imatinib and who has achieved and maintained a complete haematological response.   Maximum dose: 400 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the full blood examination report which demonstrates a complete haematological response, with a normal eosinophil count; and  (d) a statement that the disease has not progressed on imatinib therapy	2981
9183H	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
9174W	Initial PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia requiring treatment and confirmed to carry the FIP1L1-PDGFRA fusion gene.   Maximum dose: 400 mg per day.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and  (d) a copy of the full blood examination report confirming the presence of hypereosinophilic syndrome or chronic eosinophilic leukaemia; and  (e) details of organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and  (f) a signed patient acknowledgement	2980
9175X	Continuing PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia who has previously been issued with an authority prescription for imatinib and who has achieved and maintained a complete haematological response.   Maximum dose: 400 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the full blood examination report which demonstrates a complete haematological response, with a normal eosinophil count; and  (d) a statement that the disease has not progressed on imatinib therapy	2981
9175X	Initial PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia requiring treatment and confirmed to carry the FIP1L1-PDGFRA fusion gene.   Maximum dose: 400 mg per day.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and  (d) a copy of the full blood examination report confirming the presence of hypereosinophilic syndrome or chronic eosinophilic leukaemia; and  (e) details of organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and  (f) a signed patient acknowledgement	2980
9176Y	Continuing PBS-subsidised treatment of a patient with a PDGFRB fusion gene-positive myelodysplastic or myeloproliferative disorder who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.   Maximum dose: 400 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the full blood examination report which demonstrates a complete haematological response; and  (d) a statement that the disease has not progressed on imatinib therapy	3033
9176Y	Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:  (1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and  (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:   -  cytarabine;   -  etoposide;   -  hydroxyurea.   Maximum dose: 400 mg per day.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the pathology report confirming the platelet-derived growth factor receptor (PDGFR) gene re-arrangement; and  (d) a copy of the bone marrow biopsy report which demonstrates the presence of a myelodysplastic or myeloproliferative disorder; and  (e) details of the prior therapy trialled and the response; and  (f) a signed patient acknowledgement	2982
9177B	Continuing PBS-subsidised treatment of a patient with a PDGFRB fusion gene-positive myelodysplastic or myeloproliferative disorder who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.   Maximum dose: 400 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the full blood examination report which demonstrates a complete haematological response; and  (d) a statement that the disease has not progressed on imatinib therapy	3033
9177B	Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:  (1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and  (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:   -  cytarabine;   -  etoposide;   -  hydroxyurea.   Maximum dose: 400 mg per day.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the pathology report confirming the platelet-derived growth factor receptor (PDGFR) gene re-arrangement; and  (d) a copy of the bone marrow biopsy report which demonstrates the presence of a myelodysplastic or myeloproliferative disorder; and  (e) details of the prior therapy trialled and the response; and  (f) a signed patient acknowledgement	2982
9178C	Continuing PBS-subsidised treatment of a patient with aggressive systemic mastocytosis confirmed to carry the FIP1L1-PDGFRA fusion gene, who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.   Maximum dose: 400 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the full blood examination report which demonstrates a complete haematological response; and  (d) a statement that the disease has not progressed on imatinib therapy	3034
9183H	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
9217D	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9178C	Initial PBS-subsidised treatment of a patient with aggressive systemic mastocytosis with eosinophilia where:  (1) there is confirmed evidence of the FIP1L1-PDGFRA fusion gene; and  (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:   -  corticosteroids;   -  hydroxyurea.   Maximum dose: 400 mg per day.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and  (d) a copy of the bone marrow biopsy report and/or other tissue biopsy report confirming the diagnosis of aggressive systemic mastocytosis and a copy of the full blood examination report demonstrating eosinophilia; and  (e) details of symptomatic organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and  (f) details of prior treatment trialled and the response; and  (g) a signed patient acknowledgement	2984
9179D	Continuing PBS-subsidised treatment of a patient with aggressive systemic mastocytosis confirmed to carry the FIP1L1-PDGFRA fusion gene, who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.   Maximum dose: 400 mg per day.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the full blood examination report which demonstrates a complete haematological response; and  (d) a statement that the disease has not progressed on imatinib therapy	3034
9179D	Initial PBS-subsidised treatment of a patient with aggressive systemic mastocytosis with eosinophilia where:  (1) there is confirmed evidence of the FIP1L1-PDGFRA fusion gene; and  (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:   -  corticosteroids;   -  hydroxyurea.   Maximum dose: 400 mg per day.   Applications for authorisation for initial treatment must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and  (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and  (d) a copy of the bone marrow biopsy report and/or other tissue biopsy report confirming the diagnosis of aggressive systemic mastocytosis and a copy of the full blood examination report demonstrating eosinophilia; and  (e) details of symptomatic organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and  (f) details of prior treatment trialled and the response; and  (g) a signed patient acknowledgement	2984
9180E	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.   The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time sitagliptin treatment is initiated.  The HbA1c must be no more than 4 months old at the time sitagliptin treatment is initiated.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of sitagliptin therapy, must be documented in the patient's medical records	3097
9181F	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.   The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time sitagliptin treatment is initiated.  The HbA1c must be no more than 4 months old at the time sitagliptin treatment is initiated.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of sitagliptin therapy, must be documented in the patient's medical records	3097
9182G	Dual oral combination therapy with metformin or a sulfonylurea  Type 2 diabetes, in combination with metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.   The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time sitagliptin treatment is initiated.  The HbA1c must be no more than 4 months old at the time sitagliptin treatment is initiated.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of sitagliptin therapy, must be documented in the patient's medical records	3097
9212W	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9213X	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9184J	B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.   Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.   The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:  (a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and  (b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry	3015
9185K	B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.   Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.   The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:  (a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and  (b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry	3015
9186L	Initial 1  Initial treatment of Crohn disease in a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and  (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;  AND/OR  (b) have evidence of active intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (c) be assessed clinically as being in a high faecal output state;  AND/OR  (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or  (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment of adalimumab will be authorised under his criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2993
9186L	Initial 1  Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:  (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and  (c) has evidence of intestinal inflammation; and  (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (e) has failed to achieve an adequate response to prior systemic drug therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have evidence of intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (b) be assessed clinically as being in a high faecal output state;  AND/OR  (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2990
9186L	Initial 1 (new patients)  Initial treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and  (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (c) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.    If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).    The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   The most recent CDAI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and  (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (iii) the signed patient acknowledgement.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.   A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.   From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.   A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.   Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.   There is no limit to the number of treatment cycles a patient may undertake in their lifetime.   (1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.   From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Adalimumab only:  Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.   (b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.   A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.   (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.    (5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.    A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.    A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.    Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.    'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2986
9186L	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2987
9186L	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   A maximum of 16 weeks of treatment will be approved under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2991
9187M	Initial 1  Initial treatment of Crohn disease in a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and  (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;  AND/OR  (b) have evidence of active intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (c) be assessed clinically as being in a high faecal output state;  AND/OR  (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or  (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment of adalimumab will be authorised under his criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2993
9187M	Initial 1  Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:  (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and  (c) has evidence of intestinal inflammation; and  (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (e) has failed to achieve an adequate response to prior systemic drug therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have evidence of intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (b) be assessed clinically as being in a high faecal output state;  AND/OR  (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2990
9187M	Initial 1 (new patients)  Initial treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and  (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (c) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.    If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).    The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   The most recent CDAI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and  (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (iii) the signed patient acknowledgement.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.   A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.   From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.   A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.   Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.   There is no limit to the number of treatment cycles a patient may undertake in their lifetime.   (1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.   From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Adalimumab only:  Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.   (b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.   A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.   (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.    (5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.    A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.    A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.    Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.    'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2986
9187M	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2987
9187M	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   A maximum of 16 weeks of treatment will be approved under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2991
9188N	Initial 1  Initial treatment of Crohn disease in a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and  (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;  AND/OR  (b) have evidence of active intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (c) be assessed clinically as being in a high faecal output state;  AND/OR  (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or  (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment of adalimumab will be authorised under his criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2993
9188N	Initial 1  Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:  (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and  (c) has evidence of intestinal inflammation; and  (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (e) has failed to achieve an adequate response to prior systemic drug therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have evidence of intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (b) be assessed clinically as being in a high faecal output state;  AND/OR  (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2990
9188N	Initial 1 (new patients)  Initial treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and  (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (c) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.    If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).    The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   The most recent CDAI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and  (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (iii) the signed patient acknowledgement.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.   A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.   From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.   A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.   Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.   There is no limit to the number of treatment cycles a patient may undertake in their lifetime.   (1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.   From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Adalimumab only:  Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.   (b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.   A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.   (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.    (5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.    A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.    A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.    Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.    'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2986
9188N	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2987
9188N	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   A maximum of 16 weeks of treatment will be approved under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2991
9189P	Continuing treatment of Crohn disease in a patient assessed by CDAI.   Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) has demonstrated or sustained an adequate response to treatment with adalimumab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.   The CDAI assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with adalimumab, a CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   A maximum of 24 weeks treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2989
9214Y	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9189P	Continuing treatment of Crohn disease in a patient with extensive small intestine disease.   Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and  (b) has demonstrated or sustained an adequate response to treatment with adalimumab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as:  (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or  (b) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (c) reversal of high faecal output state; or  (d) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or  (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or  (iii) the date of clinical assessment.   All assessments must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   A maximum of 24 weeks treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2994
9189P	Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and  (b) has demonstrated or sustained an adequate response to treatment with adalimumab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as:  (a) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (b) reversal of high faecal output state; or  (c) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.   The patient's assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   A maximum of 24 weeks of treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2992
9189P	Initial 3 (grandfather)  Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with adalimumab.   Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:  (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and  (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with adalimumab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and  (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with adalimumab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) the signed patient acknowledgement.   The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with adalimumab.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   A maximum of 24 weeks treatment will be approved under this criterion.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	2988
9189P	Initial 3  Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with adalimumab.   Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and  (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or  (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and  (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with adalimumab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.   An adequate response to adalimumab treatment is defined as:  (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or  (b) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (c) reversal of high faecal output state; or  (d) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:  (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or  (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or  (3) the date of clinical assessment(s); and  (ii) the signed patient acknowledgement.   The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with adalimumab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   Patients who fail to demonstrate or sustain a response to treatment with adalimumab for Crohn disease as specified in the criteria for continuing treatment with adalimumab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.   A maximum of 24 weeks treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of this application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	2995
9190Q	Initial 1  Initial treatment of Crohn disease in a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and  (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;  AND/OR  (b) have evidence of active intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (c) be assessed clinically as being in a high faecal output state;  AND/OR  (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or  (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment of adalimumab will be authorised under his criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2993
9190Q	Initial 1  Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:  (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and  (c) has evidence of intestinal inflammation; and  (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (e) has failed to achieve an adequate response to prior systemic drug therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have evidence of intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (b) be assessed clinically as being in a high faecal output state;  AND/OR  (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2990
9190Q	Initial 1 (new patients)  Initial treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and  (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (c) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.    If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).    The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   The most recent CDAI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and  (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (iii) the signed patient acknowledgement.   A maximum of 16 weeks treatment will be authorised under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.   A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.   From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.   A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.   Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.   A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.   There is no limit to the number of treatment cycles a patient may undertake in their lifetime.   (1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.   From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Adalimumab only:  Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.   (b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.   A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.   (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.    (5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.    A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.    A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.    Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.    'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2986
9190Q	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2987
9383W	Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders\nNOTE: MCT Pro-Cal is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1671
9190Q	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) two completed authority prescription forms; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   A maximum of 16 weeks of treatment will be approved under this criterion.   Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment	2991
9191R	Continuing treatment of Crohn disease in a patient assessed by CDAI.   Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) has demonstrated or sustained an adequate response to treatment with adalimumab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.   The CDAI assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with adalimumab, a CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   A maximum of 24 weeks treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2989
9191R	Continuing treatment of Crohn disease in a patient with extensive small intestine disease.   Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and  (b) has demonstrated or sustained an adequate response to treatment with adalimumab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as:  (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or  (b) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (c) reversal of high faecal output state; or  (d) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or  (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or  (iii) the date of clinical assessment.   All assessments must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   A maximum of 24 weeks treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2994
9191R	Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and  (b) has demonstrated or sustained an adequate response to treatment with adalimumab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as:  (a) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (b) reversal of high faecal output state; or  (c) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.   The patient's assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   A maximum of 24 weeks of treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2992
9215B	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9383W	Hyperlipoproteinaemia type 1\nNOTE: MCT Pro-Cal is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1513
9191R	Initial 3 (grandfather)  Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with adalimumab.   Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:  (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and  (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with adalimumab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and  (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with adalimumab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) the signed patient acknowledgement.   The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with adalimumab.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   A maximum of 24 weeks treatment will be approved under this criterion.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	2988
9191R	Initial 3  Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with adalimumab.   Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and  (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or  (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and  (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with adalimumab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.   An adequate response to adalimumab treatment is defined as:  (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or  (b) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (c) reversal of high faecal output state; or  (d) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:  (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or  (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or  (3) the date of clinical assessment(s); and  (ii) the signed patient acknowledgement.   The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with adalimumab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.   Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.   Patients who fail to demonstrate or sustain a response to treatment with adalimumab for Crohn disease as specified in the criteria for continuing treatment with adalimumab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.   A maximum of 24 weeks treatment will be authorised under this criterion.  Where fewer than 5 repeats are requested at the time of this application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	2995
9192T	Atypical mycobacterial infections	3017
9192T	Bordetella pertussis	3016
9196B	Haemodialysis	1148
9197C	Major depressive disorders	1211
9197C	Obsessive-compulsive disorder	1241
9197C	Panic disorder	1862
9198D	Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy\nNOTE: Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year.  No applications for increased maximum quantities and/or repeats will be authorised.  Benefit is improved if used in conjunction with a comprehensive support and counselling program.	3042
9199E	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
9199E	Severe disabling pain not responding to non-narcotic analgesics	1358
9200F	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
9200F	Severe disabling pain not responding to non-narcotic analgesics	1358
9201G	For pain where aspirin and/or paracetamol alone are inappropriate or have failed\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.	1537
9201G	Severe disabling pain not responding to non-narcotic analgesics	1358
9202H	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
9202H	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
9202H	Schizophrenia	1589
9203J	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
9203J	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
9203J	Schizophrenia	1589
9204K	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
9204K	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
9204K	Schizophrenia	1589
9205L	Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate	3151
9205L	Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder	2765
9205L	Schizophrenia	1589
9206M	Ulcerative colitis where hypersensitivity to sulfonamides exists\nNOTE: Not for the treatment of Crohn's disease.	1708
9206M	Ulcerative colitis where intolerance to sulfasalazine exists\nNOTE: Not for the treatment of Crohn's disease.	1709
9207N	B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.   Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.   The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:  (a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and  (b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry	3015
9208P	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9209Q	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9210R	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9211T	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9383W	Long chain fatty acid oxidation disorders\nNOTE: MCT Pro-Cal is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1511
9218E	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9219F	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9220G	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9221H	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9222J	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9223K	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9225M	For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3046
9226N	For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3046
9227P	For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3046
9229R	For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3046
9230T	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9231W	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9232X	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9233Y	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9234B	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9235C	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9236D	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9237E	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9238F	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9384X	Tyrosinaemia	1453
9385Y	Gyrate atrophy of the choroid and retina	1147
9385Y	Urea cycle disorders	1458
9386B	Glycogen storage disease	3081
9239G	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9240H	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9241J	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9242K	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9243L	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9244M	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9245N	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9246P	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9247Q	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9248R	For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3047
9249T	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9250W	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9251X	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9252Y	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9253B	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9254C	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9255D	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9256E	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9257F	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9258G	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9387C	Hypertension in a patient who is not adequately controlled with either trandolapril or verapamil hydrochloride sustained release monotherapy	3082
9259H	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9261K	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9263M	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9264N	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9265P	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9266Q	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9267R	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9268T	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9269W	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9270X	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9271Y	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9273C	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9274D	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9275E	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9276F	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9277G	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9278H	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9279J	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9280K	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9281L	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9282M	Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL greater than 1% on the international scale) and who has failed an adequate trial of imatinib.   Failure of an adequate trial of imatinib is defined as:   (i) Lack of response to initial imatinib therapy, defined as either:   -  failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or   -  failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or   -  failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR   (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy; OR   (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing in value by at least 5 fold to a level of greater than 1% confirmed on a subsequent test), during ongoing imatinib therapy; OR   (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib for any phase of chronic myeloid leukaemia.   Accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).   Blast crisis is defined as either:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or  (2) Extramedullary involvement other than spleen and liver; OR   (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia; OR   (vi) Grade 3 or 4 non-haematological toxicity that is imatinib related and necessitates permanent cessation of imatinib. For patients with imatinib related toxicities, leukaemia activity does not need to be demonstrated.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 1% on the international scale. (The date of the relevant pathology report needs to be provided); and  (e) where there has been a loss of response to imatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement; or  (f) details of Grade 3 or 4 non-haematological toxicity\nNOTE: Dasatinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, nilotinib or interferon alfa therapy.   Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% at 18 months and thereafter at 12 monthly intervals, irrespective of the daily dasatinib dose received.   From 1 November 2008, under the PBS, a patient will be able to trial either dasatinib and/or nilotinib within the initial 18 month treatment period, providing the patient's CML is not resistant to the first second-line agent.   Dasatinib is not PBS-subsidised for patients with CML that is resistant to nilotinib.	3078
9283N	Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL greater than 1% on the international scale) and who has failed an adequate trial of imatinib.   Failure of an adequate trial of imatinib is defined as:   (i) Lack of response to initial imatinib therapy, defined as either:   -  failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or   -  failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or   -  failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR   (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy; OR   (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing in value by at least 5 fold to a level of greater than 1% confirmed on a subsequent test), during ongoing imatinib therapy; OR   (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib for any phase of chronic myeloid leukaemia.   Accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).   Blast crisis is defined as either:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or  (2) Extramedullary involvement other than spleen and liver; OR   (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia; OR   (vi) Grade 3 or 4 non-haematological toxicity that is imatinib related and necessitates permanent cessation of imatinib. For patients with imatinib related toxicities, leukaemia activity does not need to be demonstrated.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 1% on the international scale. (The date of the relevant pathology report needs to be provided); and  (e) where there has been a loss of response to imatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement; or  (f) details of Grade 3 or 4 non-haematological toxicity\nNOTE: Dasatinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, nilotinib or interferon alfa therapy.   Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% at 18 months and thereafter at 12 monthly intervals, irrespective of the daily dasatinib dose received.   From 1 November 2008, under the PBS, a patient will be able to trial either dasatinib and/or nilotinib within the initial 18 month treatment period, providing the patient's CML is not resistant to the first second-line agent.   Dasatinib is not PBS-subsidised for patients with CML that is resistant to nilotinib.	3078
9284P	Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL greater than 1% on the international scale) and who has failed an adequate trial of imatinib.   Failure of an adequate trial of imatinib is defined as:   (i) Lack of response to initial imatinib therapy, defined as either:   -  failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or   -  failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or   -  failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR   (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy; OR   (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing in value by at least 5 fold to a level of greater than 1% confirmed on a subsequent test), during ongoing imatinib therapy; OR   (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib for any phase of chronic myeloid leukaemia.   Accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).   Blast crisis is defined as either:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or  (2) Extramedullary involvement other than spleen and liver; OR   (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia; OR   (vi) Grade 3 or 4 non-haematological toxicity that is imatinib related and necessitates permanent cessation of imatinib. For patients with imatinib related toxicities, leukaemia activity does not need to be demonstrated.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 1% on the international scale. (The date of the relevant pathology report needs to be provided); and  (e) where there has been a loss of response to imatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement; or  (f) details of Grade 3 or 4 non-haematological toxicity\nNOTE: Dasatinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, nilotinib or interferon alfa therapy.   Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% at 18 months and thereafter at 12 monthly intervals, irrespective of the daily dasatinib dose received.   From 1 November 2008, under the PBS, a patient will be able to trial either dasatinib and/or nilotinib within the initial 18 month treatment period, providing the patient's CML is not resistant to the first second-line agent.   Dasatinib is not PBS-subsidised for patients with CML that is resistant to nilotinib.	3078
9285Q	Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in chronic or accelerated phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL greater than 1% on the international scale) and who has failed an adequate trial of imatinib.   Failure of an adequate trial of imatinib is defined as:   (i) Lack of response to initial imatinib therapy, defined as either:   -  failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or   -  failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or   -  failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR   (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy; OR   (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing in value by at least 5 fold to a level of greater than 1% confirmed on a subsequent test), during ongoing imatinib therapy; OR   (iv) Development of accelerated phase in a patient previously prescribed imatinib for the chronic phase of chronic myeloid leukaemia.   Accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR   (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase chronic myeloid leukaemia, provided that blast crisis has been excluded on bone marrow biopsy; OR   (vi) Grade 3 or 4 non-haematological toxicity that is imatinib related and necessitates permanent cessation of imatinib. For patients with imatinib related toxicities, leukaemia activity does not need to be demonstrated.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 1% on the international scale. (The date of the relevant pathology report needs to be provided); and  (e) where there has been a loss of response to imatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority; or  (f) details of Grade 3 or 4 non-haematological imatinib related toxicity\nNOTE: Nilotinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, dasatinib or interferon alfa therapy.   Patients should be commenced on a dose of nilotinib of 400 mg twice daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to nilotinib therapy or a peripheral blood BCR-ABL level of less than 1% at 18 months and thereafter at 12 monthly intervals, irrespective of the daily nilotinib dose received.   Nilotinib is not PBS-subsidised for patients with CML that is resistant to dasatinib.  Nilotinib is not TGA-registered and not PBS-subsidised for patients with CML in blast crisis.  Requests for doses of greater than nilotinib 400 mg twice daily will not be approved.   From 1 November 2008, under the PBS, a patient will be able to trial either dasatinib and/or nilotinib within the initial 18 month treatment period, providing the patient's CML is not resistant to the first second-line agent.	3079
9286R	Neurogenic urinary retention	1239
9286R	Phaeochromocytoma	1285
9288W	Symptomatic Paget disease of bone.  Only 1 treatment each year per patient will be PBS-subsidised	3290
9288W	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.  The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.  Only 1 treatment each year for 3 years per patient in a lifetime will be PBS-subsidised	3289
9288W	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in a patient with fracture due to minimal trauma.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.  In all cases, the fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  Only 1 treatment each year for 3 years per patient in a lifetime will be PBS-subsidised\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	3288
9288W	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.  Only 1 treatment each year for 3 years per patient in a lifetime will be PBS-subsidised	3287
9289X	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9289X	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9289X	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9289X	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9290Y	Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3028
9290Y	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:  (1) Adverse effects on growth and weight; and/or  (2) Adverse effects on sleep including insomnia; and/or  (3) Adverse effects on appetite including anorexia\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3027
9290Y	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3026
9290Y	Initial sole PBS-subsidised treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:  (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or  (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or  (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3025
9291B	Neoadjuvant treatment of a patient with a WHO performance status of 1 or less, with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx, in combination with cisplatin and fluorouracil\nNOTE: The carcinoma can be considered inoperable for technical or organ preservation reasons.	3051
9292C	Parkinson disease in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	3305
9292C	Parkinson disease in patients stabilised on concomitant treatment with levodopa - decarboxylase inhibitor combinations and entacapone	3306
9293D	Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful\nCAUTION: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.	2061
9293D	Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.   Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.   Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.   The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders	3083
9294E	Schizophrenia\nCAUTION: Monitor for post-injection syndrome for at least three hours after each injection.	1589
9295F	Schizophrenia\nCAUTION: Monitor for post-injection syndrome for at least three hours after each injection.	1589
9296G	Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	1722
9296G	Treatment following cardiac stent insertion\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	3219
9296G	Treatment of acute coronary syndromes (myocardial infarction or unstable angina)\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	3246
9297H	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9299K	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9299K	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9299K	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9299K	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9299K	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9301M	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9303P	Schizophrenia\nCAUTION: Monitor for post-injection syndrome for at least three hours after each injection.	1589
9304Q	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised ustekinumab treatment within this Treatment Cycle and who wish to re-commence ustekinumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised ustekinumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3251
9304Q	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised ustekinumab treatment within this Treatment Cycle and who wish to re-commence ustekinumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised ustekinumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3249
9304Q	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3250
9304Q	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment	3248
9305R	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with ustekinumab; and  (c) who have demonstrated an adequate response to treatment with ustekinumab.   An adequate response to ustekinumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with ustekinumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 1 repeat will be authorised.   Where fewer than 1 repeat is requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3255
9333F	Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3304
9409F	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9305R	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with ustekinumab; and  (c) who have demonstrated an adequate response to their most recent course of treatment with ustekinumab.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with ustekinumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with ustekinumab.   A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 1 repeat will be authorised.   Where fewer than 1 repeat is requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3253
9305R	Initial treatment [Initial 3, Face, hand, foot (Grandfather patients)]  Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot and were receiving treatment with ustekinumab prior to 26 November 2009; and  (b) whose disease, prior to treatment with ustekinumab, was of a severity as defined in the initiation criterion included in the initial treatment restriction (Initial 1, New patients  -  face, hand, foot); and  (c) who have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) who have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with ustekinumab (face, hand, foot).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition at baseline (prior to initiation of ustekinumab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.   Where fewer than 1 repeat is requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.   A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The most recent PASI assessment must be no more than 1 month old at the time of application.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   The PASI assessment must be performed on the same affected area as assessed at baseline or prior to initiation of ustekinumab treatment.   Patients may qualify for PBS-subsidised treatment under this restriction once only	3254
9305R	Initial treatment [Initial 3, Whole body (Grandfather patients)]  Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis and were receiving treatment with ustekinumab prior to 26 November 2009; and  (b) had a Psoriasis Area and Severity Index (PASI) score of greater than 15 prior to commencing treatment with ustekinumab; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with ustekinumab (whole body).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient's condition at baseline (prior to initiation of ustekinumab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.   Where fewer than 1 repeat is requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The most recent PASI assessment must be no more than 1 month old at the time of application.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.   Patients may qualify for PBS-subsidised treatment under this restriction once only	3252
9306T	CONTINUING TREATMENT  -  Clinician assessed improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.   The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2611
9306T	CONTINUING TREATMENT  -  (S)MMSE improvement.  Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).   The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.   Subsequent applications for continuing treatment can be made by telephone	2609
9332E	Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule	1175
9306T	INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 10 to 14.  Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease.  Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised	2608
9306T	INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE  -  Patients with an (S)MMSE of 9 or less who require a clinician's assessment.  Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).   Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.   This application must be made in writing, but initial supply may be sought by telephone.  For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.  For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.   Patients who qualify under this criterion are from 1 or more of the following groups:  (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;  (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;  (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;  (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;  (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;  (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment	2610
9307W	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
9308X	Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae	1276
9309Y	Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae	1276
9310B	Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated	3234
9311C	Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated	3234
9312D	Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated	3234
9313E	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3233
9314F	Hypertension in a patient who is not adequately controlled with monotherapy	3242
9315G	Hypertension in a patient who is not adequately controlled with monotherapy	3242
9316H	Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated	3234
9317J	Treatment in combination with aspirin following cardiac stent insertion\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	3146
9317J	Treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin\nNOTE: Not for prophylaxis of DVT or peripheral arterial disease.	3245
9318K	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9319L	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9320M	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9321N	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9322P	Prevention of venous thromboembolism in a patient undergoing total knee replacement	3154
9323Q	Prevention of venous thromboembolism in a patient undergoing total knee replacement	3154
9325T	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9326W	Cellulitis	3132
9326W	Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent	1169
9326W	Septicaemia, proven	1847
9326W	Septicaemia, suspected	1846
9327X	Chylothorax	1068
9327X	Chylous ascites	1670
9327X	Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders	1671
9327X	Hyperlipoproteinaemia type 1	1513
9327X	Intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect, requiring a ketogenic diet	1672
9327X	Long chain fatty acid oxidation disorders	1511
9328Y	Infants and children whose vitamin and mineral intake is insufficient due to a specific diagnosis requiring a highly restrictive therapeutic diet, and whose vitamin, mineral and trace element needs cannot be adequately met with other proprietary vitamin and mineral preparations\nNOTE: Paediatric Seravit should only be used under strict supervision of a dietitian and a paediatrician.	3301
9329B	Gyrate atrophy of the choroid and retina	1147
9329B	Urea cycle disorders	1458
9330C	Tyrosinaemia	1453
9331D	Gastro-oesophageal reflux disease	1533
9331D	Scleroderma oesophagus	1337
9332E	Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule	1751
9333F	Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.  A patient must have trialled and failed to achieve satisfactory seizure control with:  (i) at least one first-line anti-epileptic agent; and  (ii) at least two second-line adjunctive anti-epileptic agents\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3303
9334G	Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3304
9334G	Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.  A patient must have trialled and failed to achieve satisfactory seizure control with:  (i) at least one first-line anti-epileptic agent; and  (ii) at least two second-line adjunctive anti-epileptic agents\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3303
9335H	Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3304
9335H	Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.  A patient must have trialled and failed to achieve satisfactory seizure control with:  (i) at least one first-line anti-epileptic agent; and  (ii) at least two second-line adjunctive anti-epileptic agents\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3303
9336J	Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3304
9336J	Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.  A patient must have trialled and failed to achieve satisfactory seizure control with:  (i) at least one first-line anti-epileptic agent; and  (ii) at least two second-line adjunctive anti-epileptic agents\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3303
9337K	Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3304
9337K	Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.  A patient must have trialled and failed to achieve satisfactory seizure control with:  (i) at least one first-line anti-epileptic agent; and  (ii) at least two second-line adjunctive anti-epileptic agents\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3303
9338L	Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3304
9338L	Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.  A patient must have trialled and failed to achieve satisfactory seizure control with:  (i) at least one first-line anti-epileptic agent; and  (ii) at least two second-line adjunctive anti-epileptic agents\nNOTE: No applications for increased maximum quantities will be authorised for the 56 tablet packs of the 150 mg and 200 mg strengths.	3303
9339M	Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2805
9339M	Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	2806
9340N	Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2807
9345W	Parkinson disease in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	3305
9340N	Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2809
9340N	Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1687
9340N	Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	1688
9340N	Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2808
9340N	Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application\nNOTE: Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.	2810
9341P	Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL greater than 1% on the international scale) and who has failed an adequate trial of imatinib.   Failure of an adequate trial of imatinib is defined as:   (i) Lack of response to initial imatinib therapy, defined as either:   -  failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or   -  failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or   -  failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR   (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy; OR   (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing in value by at least 5 fold to a level of greater than 1% confirmed on a subsequent test), during ongoing imatinib therapy; OR   (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib for any phase of chronic myeloid leukaemia.   Accelerated phase is defined by the presence of 1 or more of the following:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or  (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or  (3) Peripheral basophils greater than or equal to 20%; or  (4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or  (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).   Blast crisis is defined as either:  (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or  (2) Extramedullary involvement other than spleen and liver; OR   (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia; OR   (vi) Grade 3 or 4 non-haematological toxicity that is imatinib related and necessitates permanent cessation of imatinib. For patients with imatinib related toxicities, leukaemia activity does not need to be demonstrated.   Applications for authorisation must be in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 1% on the international scale. (The date of the relevant pathology report needs to be provided); and  (e) where there has been a loss of response to imatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement; or  (f) details of Grade 3 or 4 non-haematological toxicity\nNOTE: Dasatinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, nilotinib or interferon alfa therapy.   Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% at 18 months and thereafter at 12 monthly intervals, irrespective of the daily dasatinib dose received.   From 1 November 2008, under the PBS, a patient will be able to trial either dasatinib and/or nilotinib within the initial 18 month treatment period, providing the patient's CML is not resistant to the first second-line agent.   Dasatinib is not PBS-subsidised for patients with CML that is resistant to nilotinib.	3078
9342Q	Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with dasatinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Chronic Myeloid Leukaemia Dasatinib/Nilotinib Authority Application Form for continuing treatment; and  (3) demonstration of continued response to treatment as evidenced by either:  (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or  (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided\nNOTE: Definitions of response.  A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.  A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.   Authority approval requirements.  For the purposes of assessing response to PBS-subsidised treatment with dasatinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:  (i) between 10 and 18 months of the commencement of treatment with dasatinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and  (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.  For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.  Where a patient has previously received PBS-subsidised treatment with dasatinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.	3039
9343R	Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.   Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Dasatinib will only be subsidised for patients with acute lymphoblastic leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate and who are not appropriate for an allogeneic haemopoietic stem cell transplant.	2771
9343R	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.   Failure of treatment is defined as either:  (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;  (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;  (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2769
9343R	Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1 December 2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.   Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.   The first authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and  (c) a signed patient acknowledgement; and  (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided	2770
9344T	Parkinson disease in patients being treated with levodopa - decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect	3305
9344T	Parkinson disease in patients stabilised on concomitant treatment with levodopa - decarboxylase inhibitor combinations and entacapone	3306
9356K	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9357L	Bone metastases from breast cancer	1035
9359N	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9360P	Prophylaxis of invasive fungal infections, including both yeasts and moulds, in a patient who is at high risk of developing these infections, defined as follows:   (1) Neutropenia  Patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome.  Treatment should continue until recovery of the neutrophil count to at least 500 cells per cubic millimetre.  Patients who have had a previous invasive fungal infection should have secondary prophylaxis during subsequent episodes of neutropenia.   (2) Graft versus host disease (GVHD)  Patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant.  No more than 6 months therapy per episode will be PBS-subsidised	3060
9360P	Treatment of fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis and mycetoma in patients intolerant to, or with disease refractory to, alternative therapy	3059
9360P	Treatment of invasive aspergillosis in patients intolerant to, or with disease refractory to, alternative therapy	3058
9361Q	Glioblastoma multiforme concomitantly with radiotherapy\nNOTE: Temozolomide is not PBS-subsidised for use in conjunction with PBS-subsidised carmustine.	2100
9362R	Glioblastoma multiforme following radiotherapy	2101
9362R	Recurrence of anaplastic astrocytoma following standard therapy	1736
9362R	Recurrence of glioblastoma multiforme following standard therapy	1737
9363T	For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients	3061
9363T	For the treatment and maintenance therapy of other serious invasive mycosis	3298
9363T	For the treatment and maintenance therapy of serious Candida infections where the causative species is not susceptible to fluconazole	3297
9363T	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole has failed	3065
9363T	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole is not tolerated	3066
9363T	For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species	3062
9364W	For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients	3061
9364W	For the treatment and maintenance therapy of other serious invasive mycosis	3298
9364W	For the treatment and maintenance therapy of serious Candida infections where the causative species is not susceptible to fluconazole	3297
9364W	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole has failed	3065
9364W	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole is not tolerated	3066
9364W	For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species	3062
9365X	Major depressive disorders	1211
9366Y	Major depressive disorders	1211
9367B	Major depressive disorders	1211
9372G	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy	3076
9373H	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy	3076
9374J	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy	3076
9375K	Hypertension in patients who are not adequately controlled with either amlodipine or valsartan monotherapy	3077
9376L	Hypertension in patients who are not adequately controlled with either amlodipine or valsartan monotherapy	3077
9377M	Hypertension in patients who are not adequately controlled with either amlodipine or valsartan monotherapy	3077
9378N	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
9379P	Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate	3229
9380Q	Continuing treatment, as the sole PBS-subsidised agent, of advanced hepatocellular carcinoma in a patient who has previously been treated with PBS-subsidised sorafenib and who does not have progressive disease\nNOTE: Sorafenib is not PBS-subsidised for adjunctive treatment after resection, ablation or chemoembolization.  Sorafenib is not PBS-subsidised for maintenance therapy after disease progression.   No applications for increased maximum quantities and/or repeats will be authorised.	3072
9380Q	Initial treatment, as the sole PBS-subsidised agent, of advanced (BCLC Stage C) hepatocellular carcinoma in a patient with a WHO performance status of 2 or less and Child Pugh class A\nNOTE: Sorafenib is not PBS-subsidised for adjunctive treatment after resection, ablation or chemoembolization.  Sorafenib is not PBS-subsidised for maintenance therapy after disease progression.   No applications for increased maximum quantities and/or repeats will be authorised.	3071
9381R	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or telmisartan monotherapy	1645
9382T	Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet	1596
9383W	Chylothorax\nNOTE: MCT Pro-Cal is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1068
9383W	Chylous ascites\nNOTE: MCT Pro-Cal is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.	1670
9498X	Treatment of suspected or confirmed malaria due to Plasmodium falciparum\nNOTE: Artemether with lumefantrine is not PBS-subsidised for prophylaxis of malaria.	3210
9391G	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.  The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	3070
9391G	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.  A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body\nNOTE: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride, strontium ranelate and zoledronic acid.	2646
9391G	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.  The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated	2645
9393J	Treatment of severe primary Restless Legs Syndrome in a patient who manifests all 4 diagnostic criteria below and whose baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score is greater than or equal to 21 points prior to initiation of pramipexole.   The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated.   The diagnostic criteria for Restless Legs Syndrome are:  (a) An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and  (b) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and  (c) The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and  (d) The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night.   Pramipexole is not PBS-subsidised for Restless Legs Syndrome secondary to other causes\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3088
9394K	Treatment of severe primary Restless Legs Syndrome in a patient who manifests all 4 diagnostic criteria below and whose baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score is greater than or equal to 21 points prior to initiation of pramipexole.   The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated.   The diagnostic criteria for Restless Legs Syndrome are:  (a) An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and  (b) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and  (c) The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and  (d) The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night.   Pramipexole is not PBS-subsidised for Restless Legs Syndrome secondary to other causes\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3088
9395L	Tyrosinaemia	1453
9396M	Phenylketonuria	1286
9397N	Phenylketonuria	1286
9398P	Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated\nNOTE: Not to be used in preference to enuresis alarms.  Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.	2642
9398P	Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm\nNOTE: Not to be used in preference to enuresis alarms.  Desmopressin nasal spray may be associated with an increased risk of hyponatraemia compared to the oral formulations.	2641
9399Q	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9399Q	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9399Q	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9399Q	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9399Q	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9400R	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9410G	Metastatic colorectal cancer in patients with a WHO performance status of 2 or less\nNOTE: In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.	3184
9499Y	Maple syrup urine disease	1220
9400R	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9400R	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9400R	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9400R	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9401T	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
9401T	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
9401T	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
9401T	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
9401T	Locally advanced or metastatic non-small cell lung cancer	1194
9402W	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
9402W	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
9402W	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
9402W	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
9402W	Locally advanced or metastatic non-small cell lung cancer	1194
9403X	Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy\nNOTE: Not to be used in combination with sevelamer.	3101
9403X	Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy\nNOTE: Not to be used in combination with sevelamer.	3102
9404Y	Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy\nNOTE: Not to be used in combination with sevelamer.	3101
9404Y	Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy\nNOTE: Not to be used in combination with sevelamer.	3102
9405B	Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy\nNOTE: Not to be used in combination with sevelamer.	3101
9405B	Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy\nNOTE: Not to be used in combination with sevelamer.	3102
9406C	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9406C	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9406C	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9423Y	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.	1177
9424B	Gastro-oesophageal reflux disease	1533
9424B	Scleroderma oesophagus	1337
9424B	Zollinger-Ellison syndrome	1476
9406C	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9406C	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9407D	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9407D	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9407D	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9407D	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9407D	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9408E	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9408E	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9408E	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9408E	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9408E	Subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient	2099
9409F	Chronic severe disabling pain associated with proven malignant neoplasia	1061
9409F	Chronic severe disabling pain not responding to non-narcotic analgesics\nNOTE: Authorities for increased maximum quantities and/or repeats will be granted only for:  (i)chronic severe disabling pain associated with proven malignant neoplasia; or   (ii)chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or   (iii)first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or   (iv)subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.	1062
9409F	Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months	2097
9409F	First application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed.  The date of the consultation must be no more than 3 months prior to the application for a PBS authority.  The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application	2189
9571R	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
9411H	Continuing treatment for severe established osteoporosis where the patient has previously been issued with an authority prescription for this drug.   Teriparatide must only be used for a lifetime maximum of 18 months therapy (18 pens).  Up to a maximum of 18 pens will be reimbursed through the PBS.   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3099
9411H	Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant physician, for severe, established osteoporosis in a patient with a very high risk of fracture who:  (a) has a bone mineral density (BMD) T-score of -3.0 or less; and  (b) has had 2 or more fractures due to minimal trauma; and  (c) has experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses.   A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.   If treatment with anti-resorptive therapy is contraindicated according to the relevant TGA-approved Product Information, details of the contraindication must be provided at the time of application.   If an intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use of one anti-resorptive agent, alternate anti-resorptive agents must be trialled so that the patient achieves the minimum requirement of 12 months continuous therapy.  Details of accepted toxicities including severity can be found on the Medicare Australia website at www.medicareaustralia.gov.au and must be provided at the time of application.   Anti-resorptive therapies for osteoporosis and their adequate doses which will be accepted for the purposes of administering this restriction are alendronate sodium 10 mg per day or 70 mg once weekly, risedronate sodium 5 mg per day or 35 mg once weekly, raloxifene hydrochloride 60 mg per day (women only), etidronate 200 mg with calcium carbonate 1.25 g per day, strontium ranelate 2 g per day and zoledronic acid 5 mg per annum.   Authority applications must be made in writing and must include:  Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed during the course of anti-resorptive therapy and the score of the qualifying BMD measurement\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3100
9411H	Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant physician, for severe, established osteoporosis in a patient with a very high risk of fracture who was receiving treatment with teriparatide prior to 1 May 2009.   The authority application must be made in writing and the commencement date of treatment and the number of doses the patient has received of teriparatide must be provided with the application. The patient is eligible to receive a maximum of 18 months therapy of combined PBS-subsidised and non-PBS-subsidised therapy.   Patients may qualify for PBS-subsidised treatment under this restriction once only\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3098
9413K	For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3046
9414L	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
9414L	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
9414L	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
9414L	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
9414L	Locally advanced or metastatic non-small cell lung cancer	1194
9415M	Metastatic breast cancer after failure of prior therapy which includes an anthracycline	3107
9417P	Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3108
9418Q	Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3108
9419R	Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3108
9420T	Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria\nNOTE: RECIST Criteria is defined as follows:  Complete response (CR) is disappearance of all target lesions.  Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.  Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.  Stable disease (SD) is small changes that do not meet above criteria.	3109
9420T	Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who was receiving treatment with sunitinib prior to 1 May 2009	3110
9421W	Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria\nNOTE: RECIST Criteria is defined as follows:  Complete response (CR) is disappearance of all target lesions.  Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.  Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.  Stable disease (SD) is small changes that do not meet above criteria.	3109
9421W	Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who was receiving treatment with sunitinib prior to 1 May 2009	3110
9422X	Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria\nNOTE: RECIST Criteria is defined as follows:  Complete response (CR) is disappearance of all target lesions.  Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.  Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.  Stable disease (SD) is small changes that do not meet above criteria.	3109
9422X	Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who was receiving treatment with sunitinib prior to 1 May 2009	3110
9425C	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3268
9425C	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3266
9425C	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3267
9425C	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis.  Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.   From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.   Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.  Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.   Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle.  The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.   Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.   There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.   (1)  Application for approval for initial treatment.   Applications for a course of initial treatment should be made in the following situations:  (i)  patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii)  patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4)  Swapping therapy' below]; or  (iii)  patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).   All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.   Grandfather patients (adalimumab and ustekinumab only).   Applications for patients who commenced treatment with adalimumab prior to 1 March 2009 or ustekinumab prior to 26 November 2009, may be made for initial PBS-subsidised treatment as continuing therapy under the initial treatment restriction (Initial 3).  These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment.  Approval will be based on the criteria included in the relevant restriction.   (2)  Assessment of response to initial treatment.   When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment.  This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   (3)  Application for continuing treatment.   Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent.  Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.   For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   (4)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not.  However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.   Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.   (5)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.   To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.   (6)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity.  Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment.  The PASI assessment must be no older than 1 month at the time of application.	3265
9426D	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3268
9426D	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3266
9426D	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3267
9426D	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis.  Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.   From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.   Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.  Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.   Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle.  The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.   Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.   There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.   (1)  Application for approval for initial treatment.   Applications for a course of initial treatment should be made in the following situations:  (i)  patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii)  patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4)  Swapping therapy' below]; or  (iii)  patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).   All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.   Grandfather patients (adalimumab and ustekinumab only).   Applications for patients who commenced treatment with adalimumab prior to 1 March 2009 or ustekinumab prior to 26 November 2009, may be made for initial PBS-subsidised treatment as continuing therapy under the initial treatment restriction (Initial 3).  These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment.  Approval will be based on the criteria included in the relevant restriction.   (2)  Assessment of response to initial treatment.   When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment.  This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   (3)  Application for continuing treatment.   Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent.  Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.   For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   (4)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not.  However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.   Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.   (5)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.   To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.   (6)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity.  Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment.  The PASI assessment must be no older than 1 month at the time of application.	3265
9427E	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and  (c) who have demonstrated an adequate response to treatment with adalimumab.   An adequate response to adalimumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3272
9571R	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
9427E	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and  (c) who have demonstrated an adequate response to their most recent course of treatment with adalimumab.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with adalimumab.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3270
9427E	Initial treatment [Initial 3, Face, hand, foot (Grandfather patients)]  Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot and were receiving treatment with adalimumab prior to 1 March 2009; and  (b) whose disease, prior to treatment with adalimumab, was of a severity as defined in the initiation criterion included in the initial treatment restriction (Initial 1, New patients  -  face, hand, foot); and  (c) who have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) who have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with adalimumab (face, hand, foot).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition at baseline (prior to initiation of adalimumab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.   A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The most recent PASI assessment must be no more than 1 month old at the time of application.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment must be performed on the same affected area as assessed at baseline or prior to initiation of adalimumab treatment.   Patients may qualify for PBS-subsidised treatment under this restriction once only	3271
9427E	Initial treatment [Initial 3, Whole body (Grandfather patients)]  Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis and were receiving treatment with adalimumab prior to 1 March 2009; and  (b) had a Psoriasis Area and Severity Index (PASI) score of greater than 15 prior to commencing treatment with adalimumab; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with adalimumab (whole body).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient's condition at baseline (prior to initiation of adalimumab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The most recent PASI assessment must be no more than 1 month old at the time of application.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   Patients may qualify for PBS-subsidised treatment under this restriction once only	3269
9428F	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and  (c) who have demonstrated an adequate response to treatment with adalimumab.   An adequate response to adalimumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3272
9428F	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and  (c) who have demonstrated an adequate response to their most recent course of treatment with adalimumab.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with adalimumab.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3270
9432K	Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared	2964
9428F	Initial treatment [Initial 3, Face, hand, foot (Grandfather patients)]  Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot and were receiving treatment with adalimumab prior to 1 March 2009; and  (b) whose disease, prior to treatment with adalimumab, was of a severity as defined in the initiation criterion included in the initial treatment restriction (Initial 1, New patients  -  face, hand, foot); and  (c) who have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) who have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with adalimumab (face, hand, foot).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition at baseline (prior to initiation of adalimumab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.   A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The most recent PASI assessment must be no more than 1 month old at the time of application.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   The PASI assessment must be performed on the same affected area as assessed at baseline or prior to initiation of adalimumab treatment.   Patients may qualify for PBS-subsidised treatment under this restriction once only	3271
9428F	Initial treatment [Initial 3, Whole body (Grandfather patients)]  Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis and were receiving treatment with adalimumab prior to 1 March 2009; and  (b) had a Psoriasis Area and Severity Index (PASI) score of greater than 15 prior to commencing treatment with adalimumab; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with adalimumab (whole body).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient's condition at baseline (prior to initiation of adalimumab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The most recent PASI assessment must be no more than 1 month old at the time of application.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.   Patients may qualify for PBS-subsidised treatment under this restriction once only	3269
9429G	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and  (c) who have demonstrated an adequate response to treatment with etanercept.   An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3278
9429G	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and  (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3277
9431J	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and  (c) who have demonstrated an adequate response to treatment with etanercept.   An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3278
9431J	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and  (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3277
9432K	Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1 March 2008	2966
9432K	Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1 March 2008	2969
9432K	Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and who has been assessed by a psychiatrist	2965
9432K	Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared	2967
9432K	Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and who has been assessed by a psychiatrist	2968
9433L	Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1 March 2008	2966
9433L	Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1 March 2008	2969
9433L	Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared	2964
9433L	Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and who has been assessed by a psychiatrist	2965
9433L	Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared	2967
9433L	Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and who has been assessed by a psychiatrist	2968
9434M	Maple syrup urine disease	1220
9436P	Maple syrup urine disease	1220
9437Q	Urea cycle disorders\nNOTE: Arginine with carbohydrate is not indicated for the treatment of arginase deficiency and other inborn errors of protein metabolism.	1458
9438R	A child aged from 6 months up to 10 years with proven glutaric aciduria type 1	3134
9439T	Treatment of suspected or confirmed Plasmodium falciparum malaria in a patient aged 3 years or older where quinine containing regimens are inappropriate\nNOTE: Atovaquone with proguanil hydrochloride is not PBS-subsidised for the prophylaxis of malaria.	3135
9440W	Nasal colonisation with Staphylococcus aureus in an Aboriginal or a Torres Strait Islander person\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3136
9441X	Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.   Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle	3050
9442Y	Continuing PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with metastatic colorectal cancer who has previously been issued with an authority prescription for bevacizumab and who does not have progressive disease and who remains on first-line chemotherapy\nNOTE: Not for use as monotherapy.	3143
9442Y	Initial PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with previously untreated metastatic colorectal cancer with a WHO performance status of 0 or 1\nNOTE: Not for use as monotherapy.	3142
9443B	Continuing PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with metastatic colorectal cancer who has previously been issued with an authority prescription for bevacizumab and who does not have progressive disease and who remains on first-line chemotherapy\nNOTE: Not for use as monotherapy.	3143
9443B	Initial PBS-subsidised treatment, in combination with first-line chemotherapy, of a patient with previously untreated metastatic colorectal cancer with a WHO performance status of 0 or 1\nNOTE: Not for use as monotherapy.	3142
9446E	Glucose transport protein defects\nNOTE: KetoCal should only be used under strict supervision of a dietician, together with a metabolic physician and/or neurologist.	1579
9446E	Patients with intractable seizures requiring treatment with a ketogenic diet\nNOTE: KetoCal should only be used under strict supervision of a dietician, together with a metabolic physician and/or neurologist.	1578
9446E	Pyruvate dehydrogenase deficiency\nNOTE: KetoCal should only be used under strict supervision of a dietician, together with a metabolic physician and/or neurologist.	1580
9447F	Schistosomiasis	3147
9448G	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
9449H	Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin	3149
9449H	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.   The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time sitagliptin treatment is initiated.  The HbA1c must be no more than 4 months old at the time sitagliptin treatment is initiated.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of sitagliptin therapy, must be documented in the patient's medical records	3148
9450J	Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin	3149
9450J	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.   The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time sitagliptin treatment is initiated.  The HbA1c must be no more than 4 months old at the time sitagliptin treatment is initiated.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of sitagliptin therapy, must be documented in the patient's medical records	3148
9451K	Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin	3149
9451K	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.   The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time sitagliptin treatment is initiated.  The HbA1c must be no more than 4 months old at the time sitagliptin treatment is initiated.   Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:  (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or  (b) red cell transfusion within the previous 3 months.  A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of sitagliptin therapy, must be documented in the patient's medical records	3148
9452L	For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients	3061
9452L	For the treatment and maintenance therapy of other serious invasive mycosis	3298
9452L	For the treatment and maintenance therapy of serious Candida infections where the causative species is not susceptible to fluconazole	3297
9452L	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole has failed	3065
9452L	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole is not tolerated	3066
9452L	For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species	3062
9453M	Induction and consolidation treatment of relapsed acute promyelocytic leukaemia (characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript) in a patient who is arsenic naive at induction	3150
9454N	Detrusor overactivity in a patient who cannot tolerate oral oxybutynin, or who cannot swallow oral oxybutynin	3152
9455P	Initial 1 (new patients)  First course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND  (a) who has at least 2 of the following:  (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or  (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or  (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND  (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.   The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.   If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.   If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.   The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.   The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.   Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment form.  Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.   A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2504
9455P	Initial 2 (change or re-commencement for all patients)  Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with etanercept.   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.   A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.   Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone	2505
9456Q	Continuing treatment for all patients  Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:  (a) has demonstrated a response to treatment with etanercept; and  (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.   Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.   For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.   Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment.  Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment.   Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.   Written applications for authorisation must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.   All measurements provided must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone	2506
9457R	Initial 1  Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have severe active psoriatic arthritis; and  (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and  (3) have failed to achieve an adequate response to:  (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and  (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or  (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.   From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.   Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].   The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.   Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.   Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.   (1)  Initial treatment.   Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).   All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised.  It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.   Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   Grandfather patients.   Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents.  Approval will be based on the criteria included in the relevant restriction.   (2)  Continuing treatment.   Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.   (3)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.   Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.   Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.   (4)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.   (5)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity.  Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.	3095
9483D	Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be reduced to a dose of 20 mg or less per day, because the patient developed a clinically important product-related adverse event during treatment with a statin.  A clinically important product-related adverse event is defined as follows:  (i) Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or  (ii) Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or  (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin	3194
9483D	Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)	2431
9457R	Initial 2  Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and  (3) have not failed treatment with etanercept during the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2949
9458T	Continuing treatment  Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:  (1) who have a documented history of severe active psoriatic arthritis; and  (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and  (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.   An adequate response to treatment with etanercept is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	2951
9458T	Initial 3  Initial PBS-subsidised supply for continuing treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:  (1) have a documented history of severe active psoriatic arthritis; and  (2) were receiving treatment with etanercept prior to 17 March 2005; and  (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.   Patients may qualify for PBS-subsidised treatment under this restriction once only	2950
9459W	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.   PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.   In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.   From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.   A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.   For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.   The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.   There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.   If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.   (1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.   From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Rituximab patients:  A further application may be submitted to Medicare Australia 24 weeks after the first infusion.  New baselines may be submitted with this application if appropriate.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements.  However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application.  However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.   In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab.  This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD.  Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.   To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.	3224
9459W	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with etanercept within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle\nNOTE: (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints.  Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.   The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.   From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.   'Grandfather' arrangements will only apply for the first Treatment Cycle.  For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2845
9459W	Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years; AND  (a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly; AND  (c) who have failed to achieve an adequate response to methotrexate, in combination with 2 other disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; AND  (d) who have subsequently failed to achieve an adequate response following a minimum of 3 months' treatment with:  (i) leflunomide; or  (ii) cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use, the patient is exempted from demonstrating an inadequate response to the above treatment regimens. Details of the contraindication or intolerance, including the degree of toxicity, must be provided at the time of application.   The following criteria must be met in order to demonstrate failure to achieve an adequate response:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (i) an active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).    If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be in writing and must include sufficient information to determine the patient's eligibility according to the above criteria.  The date of joint assessment must be provided.   Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 4 months of treatment may be requested by telephone. Under no circumstances will telephone approvals be granted for initial or continuing authority applications, or for treatment that would otherwise extend the initial treatment period beyond 4 months.   The assessment of the patient's response to the initial course of treatment should be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria	3225
9486G	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9616D	Treatment, in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir twice daily, of HIV infection in an antiretroviral experienced patient with:  (a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or  (b) CD4 cell counts of less than 500 per cubic millimetre.  A patient must have failed previous treatment with, or have resistance to, 1 antiretroviral regimen	3279
9617E	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and  (c) who have demonstrated an adequate response to treatment with infliximab.   An adequate response to infliximab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 2 repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3264
9460X	Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who, at the time of application, demonstrate an adequate response to treatment with etanercept as manifested by:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND 1 or more of the following:  (i) an active joint count of fewer than 10 active (swollen and tender) joints; or  (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or  (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of assessment of the patient must be provided.   Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.   Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application	1910
9460X	Continuing treatment  Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with etanercept; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2846
9460X	Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, and who were receiving treatment with etanercept prior to 1 December 2002; AND  (a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND  (b) who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.   The authority application must be in writing and must include sufficient information to determine the patient's eligibility. The date of assessment of the patient must be provided	1909
9461Y	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3276
9484E	Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be reduced to a dose of 20 mg or less per day, because the patient developed a clinically important product-related adverse event during treatment with a statin.  A clinically important product-related adverse event is defined as follows:  (i) Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or  (ii) Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or  (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin	3194
9484E	Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)	2431
9493P	Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops	1359
9461Y	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3274
9461Y	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3275
9461Y	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis.  Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.   From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.   Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.  Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.   Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle.  The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.   Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.   There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.   (1)  Application for approval for initial treatment.   Applications for a course of initial treatment should be made in the following situations:  (i)  patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii)  patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4)  Swapping therapy' below]; or  (iii)  patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).   All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.   Grandfather patients (adalimumab and ustekinumab only).   Applications for patients who commenced treatment with adalimumab prior to 1 March 2009 or ustekinumab prior to 26 November 2009, may be made for initial PBS-subsidised treatment as continuing therapy under the initial treatment restriction (Initial 3).  These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment.  Approval will be based on the criteria included in the relevant restriction.   (2)  Assessment of response to initial treatment.   When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment.  This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   (3)  Application for continuing treatment.   Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent.  Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.   For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   (4)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not.  However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.   Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.   (5)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.   To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.   (6)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity.  Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment.  The PASI assessment must be no older than 1 month at the time of application.	3273
9462B	Continuing treatment (Face, hand, foot)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and  (c) who have demonstrated an adequate response to treatment with etanercept.   An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   The most recent PASI assessment must be no more than 1 month old at the time of application.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3278
9462B	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and  (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.   A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.   Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3277
9463C	Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline	2069
9463C	Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy	2141
9463C	Locally advanced or metastatic adenocarcinoma of the pancreas	1193
9463C	Locally advanced or metastatic bladder cancer, in combination with cisplatin	1740
9463C	Locally advanced or metastatic non-small cell lung cancer	1194
9464D	Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3138
9464D	Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or prostaglandin or prostamide analogue monotherapies	3137
9465E	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9466F	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9467G	Prevention of venous thromboembolism in a patient undergoing total hip replacement	3153
9468H	Prevention of venous thromboembolism in a patient undergoing total knee replacement	3154
9469J	Prevention of venous thromboembolism in a patient undergoing total knee replacement	3154
9472M	For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3035
9475Q	Initial PBS-subsidised treatment, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.   Accreditation following completion of injection administration training with Sanofi-Aventis is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector	3182
9476R	Maintenance PBS-subsidised treatment, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.   Accreditation following completion of injection administration training with Sanofi-Aventis is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector	3183
9477T	Initial treatment of peptic ulcer\nNOTE: Helicobacter pylori eradication therapy should be considered.   No applications for increased repeats will be authorised.	1177
9478W	Gastro-oesophageal reflux disease	1533
9478W	Scleroderma oesophagus	1337
9479X	Prevention and treatment of infection in partial or full skin thickness loss due to burns	1865
9479X	Prevention and treatment of infection in partial or full skin thickness loss due to epidermolysis bullosa	1866
9479X	Stasis ulcers	1386
9480Y	Systemic treatment of Pseudomonas aeruginosa infection in a patient with cystic fibrosis	3190
9481B	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy	3076
9482C	Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy	3076
9488J	Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.   Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.   Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3207
9488J	Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a signed patient acknowledgement.   Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib\nNOTE: Any queries concerning the arrangements to prescribe sunitinib malate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.   Any queries concerning patients who are enrolled on the Sunitinib Compassionate Program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Written applications for authority to prescribe sunitinib malate should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Sunitinib malate is not PBS-subsidised for the treatment of patients with resectable malignant gastrointestinal stromal tumours.	3206
9489K	Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.   Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.   Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3207
9489K	Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a signed patient acknowledgement.   Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib\nNOTE: Any queries concerning the arrangements to prescribe sunitinib malate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.   Any queries concerning patients who are enrolled on the Sunitinib Compassionate Program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Written applications for authority to prescribe sunitinib malate should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Sunitinib malate is not PBS-subsidised for the treatment of patients with resectable malignant gastrointestinal stromal tumours.	3206
9490L	Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.   Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.   Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3207
9490L	Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (3) a signed patient acknowledgement.   Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib\nNOTE: Any queries concerning the arrangements to prescribe sunitinib malate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Prescribing information (including Authority Application forms) is available on the Medicare Australia website at www.medicareaustralia.gov.au.   Any queries concerning patients who are enrolled on the Sunitinib Compassionate Program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Written applications for authority to prescribe sunitinib malate should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Sunitinib malate is not PBS-subsidised for the treatment of patients with resectable malignant gastrointestinal stromal tumours.	3206
9491M	Severe dry eye syndrome, including Sjogren's syndrome	1362
9492N	For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3036
9572T	In combination with other antiretrovirals, for the treatment of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1 and:  (a) evidence of HIV replication (viral load greater than 5,000 copies per mL); and/or  (b) CD4 cell counts of less than 500 per cubic millimetre.  A patient must have virological failure of previous treatment with, or have resistance to, 3 different antiretroviral regimens, including regimens with:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 2 protease inhibitors.  A tropism assay to determine CCR5 only strain status is required prior to initiation.  Individuals with CXCR4 tropism demonstrated at any time point are not eligible	3286
9573W	In combination with other antiretrovirals, for the treatment of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1 and:  (a) evidence of HIV replication (viral load greater than 5,000 copies per mL); and/or  (b) CD4 cell counts of less than 500 per cubic millimetre.  A patient must have virological failure of previous treatment with, or have resistance to, 3 different antiretroviral regimens, including regimens with:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 2 protease inhibitors.  A tropism assay to determine CCR5 only strain status is required prior to initiation.  Individuals with CXCR4 tropism demonstrated at any time point are not eligible	3286
9574X	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9575Y	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9576B	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9577C	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9578D	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9579E	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9580F	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9600G	Chronic iron overload in adults, adolescents and children 6 years and older associated with disorders of erythropoiesis	2440
9600G	Chronic iron overload in paediatric patients aged 2 to 5 years, associated with disorders of erythropoiesis, who are intolerant to desferrioxamine or in whom desferrioxamine has proven ineffective	2441
9602J	Patients with chronic hepatitis B who satisfy all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy\nNOTE: PBS-subsidised entecavir monohydrate must be used as monotherapy.	2937
9603K	Patients with chronic hepatitis B who have failed lamivudine therapy and who satisfy all of the following criteria:  (1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or  (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy\nNOTE: Patients should have undergone a liver biopsy at some point since initial diagnosis to obtain histological evidence of chronic hepatitis.  PBS-subsidised entecavir monohydrate must be used as monotherapy.	2935
9604L	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
9626P	Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50 pmol per L, not responding to conventional therapy\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.   "Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.	2893
9605M	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with sildenafil citrate of patients who have received approval for initial PBS-subsidised treatment with sildenafil citrate, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sildenafil citrate treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3175
9605M	Initial (change or re-commencement for all patients)  Application for initial PBS-subsidised treatment with sildenafil citrate of patients with one of the following:  (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sildenafil citrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sildenafil citrate; OR  (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than sildenafil citrate.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3174
9605M	Initial (new patients)  Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3173
9605M	Initial (new patients)  Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3172
9607P	Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy	1256
9608Q	For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3294
9609R	For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement\nNOTE: Supply of these items is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3294
9610T	Treatment, in combination with other antiretroviral agents, and co-administered with 200 mg ritonavir twice daily, of HIV infection in antiretroviral experienced adults with:  (a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or  (b) CD4 cell counts of less than 500 per cubic millimetre.  Patients must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 2 protease inhibitors	2700
9611W	Continuing treatment  Continuing PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult:  (a) who has a documented history of severe active rheumatoid arthritis; and  (b) who has demonstrated an adequate response to treatment with rituximab; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this Treatment Cycle was with rituximab.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].   Patients may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.  The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.   The same indices of disease severity used to establish baseline at the commencement of treatment with each initial application must be used for assessment of all continuing applications.   Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: (3) Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.   To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.  Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints.  Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.   The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.   (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity.  Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.   (5)  Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.   From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.   A patient may only qualify for PBS-subsidised treatment under this criterion once.  A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.   'Grandfather' arrangements will only apply for the first Treatment Cycle.  For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient.  See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.	2852
9611W	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult who:  (a) has a documented history of severe active rheumatoid arthritis; and  (b) has failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist in this Treatment Cycle; and  (c) has not previously failed to respond to PBS-subsidised rituximab in the current Treatment Cycle.   Applications for patients who have demonstrated a response to PBS-subsidised rituximab treatment within this Treatment Cycle and who wish to re-commence rituximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised rituximab treatment has been submitted to Medicare Australia.   A patient may qualify to receive a further course of treatment (1 infusion at week 0 and 1 infusion at week 2) every 24 weeks with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.   The same indices of disease severity used to establish baseline at the commencement of treatment with each initial application must be used for assessment of all continuing applications.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].   Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial rituximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.   Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.   Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle\nNOTE: Any queries concerning the arrangements to prescribe rituximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Written applications for authority to prescribe rituximab should be forwarded to:   Medicare Australia  Prior Written Approval of Specialised Drugs  Reply Paid 9826  GPO Box 9826  HOBART TAS 7001   Further prescribing information is on the Medicare Australia website at www.medicareaustralia.gov.au.	2850
9611W	Initial 3 ('grandfather' patients)  Initial PBS-subsidised supply for continuing treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult who:  (a) has a documented history of severe active rheumatoid arthritis; and  (b) was receiving treatment with rituximab prior to 7 March 2007; and  (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with rituximab.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the signed patient acknowledgement form.   The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.   Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.   Patients can qualify for PBS-subsidised treatment under this criteria once only\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).   Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.   PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.   In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.   From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.   A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.   For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.   The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.   A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.   There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.   If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.   (1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.   (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).   Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.   From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Rituximab patients:  A further application may be submitted to Medicare Australia 24 weeks after the first infusion.  New baselines may be submitted with this application if appropriate.   (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.   It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.   Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.   Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.   (2) Swapping therapy.   Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements.  However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application.  However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.   In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.   To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab.  This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD.  Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.   To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.	2851
9612X	Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.   Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of moderate to severe refractory Crohn disease; and  (b) has demonstrated or sustained an adequate response to treatment with infliximab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.   The PCDAI assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3007
9612X	Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.   Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:  (a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4 July 2007; and  (b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and  (c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with infliximab.  For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and  (ii) the signed patient acknowledgement.   The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	3008
9612X	Initial treatment of Crohn disease in a paediatric patient.   Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:  (a)  has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b)  whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period;  (ii) an 8 week course of enteral nutrition;  (iii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 10 mg per square metre weekly for 3 or more months.   NOTE: Prescribers must be gastoenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and  (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and  (iii) the signed patient acknowledgement.   A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment	3006
9613Y	Continuing treatment of Crohn disease in a patient assessed by CDAI.   Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) has demonstrated or sustained an adequate response to treatment with infliximab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.   The CDAI assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with infliximab, a CDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	2998
9613Y	Continuing treatment of Crohn disease in a patient with extensive small intestine disease.   Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and  (b) has demonstrated or sustained an adequate response to treatment with infliximab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to infliximab treatment is defined as:  (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or  (b) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (c) reversal of high faecal output state; or  (d) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or  (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or  (iii) the date of clinical assessment.   All assessments must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3003
9613Y	Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and  (b) has demonstrated or sustained an adequate response to treatment with infliximab.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to infliximab treatment is defined as:  (a) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (b) reversal of high faecal output state; or  (c) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.   The patient's assessment must be no more than 1 month old at the time of application.   If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3001
9613Y	Initial 1  Initial treatment of Crohn disease in a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and  (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;  AND/OR  (b) have evidence of active intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (c) be assessed clinically as being in a high faecal output state;  AND/OR  (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or  (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment	3002
9613Y	Initial 1  Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.   Initial PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:  (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and  (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and  (c) has evidence of intestinal inflammation; and  (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (e) has failed to achieve an adequate response to prior systemic drug therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have evidence of intestinal inflammation, including:  (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR  (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR  (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;  AND/OR  (b) be assessed clinically as being in a high faecal output state;  AND/OR  (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and  (iii) date of the most recent clinical assessment; and  (iv) the signed patient acknowledgement.   All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.   A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment	2999
9613Y	Initial 1 (new patients)  Initial treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:  (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and  (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (c) has failed to achieve an adequate response to prior systemic therapy including:  (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and  (ii) immunosuppressive therapy including:   -  azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or   -  6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or   -  methotrexate at a dose of at least 15 mg weekly for 3 or more months.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.    If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).    The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   The most recent CDAI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and  (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and  (iii) the signed patient acknowledgement.   A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment	2996
9736K	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where adverse events have occurred with other suitable PBS-listed drugs\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3281
9613Y	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.   Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   A maximum quantity and number of repeats to provide for an initial course of infliximb consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment	2997
9613Y	Initial 2  Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.   Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:  (a) has a documented history of severe refractory Crohn disease; and  (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and  (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.   Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.   Authority applications must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and  (ii). details of prior TNF alfa antagonist treatment including details of date and duration of treatment.   A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.   The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.   This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.   It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment	3000
9613Y	Initial 3 (grandfather)  Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with infliximab.   Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:  (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and  (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and  (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and  (ii) the signed patient acknowledgement.   The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with infliximab.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	3004
9613Y	Initial 3  Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with infliximab.   Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:  (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and  (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or  (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and  (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and  (d) has demonstrated or sustained an adequate response to treatment with infliximab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].   The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.   An adequate response to infliximab treatment is defined as:  (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or  (b) improvement of intestinal inflammation as demonstrated by:  (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR  (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR  (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or  (c) reversal of high faecal output state; or  (d) avoidance of the need for surgery or total parenteral nutrition (TPN).   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:  (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or  (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or  (3) the date of clinical assessment(s); and  (ii) the signed patient acknowledgement.   The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with infliximab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.   The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.   Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.   Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only	3005
9614B	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
9614B	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
9615C	Continuing PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of severe active polyarticular course juvenile chronic arthritis in patients 18 years or older who have demonstrated an adequate response to treatment with etanercept as manifested by:  (a) an active joint count of fewer than 10 active (swollen and tender) joints; OR  (b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; OR  (c) a reduction in the number of the following active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of the joint assessment must be provided.   Only 6 months of treatment per application will be approved. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria.   Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.   Withdrawal of treatment with etanercept should be considered in patients who have achieved and sustained complete remission of disease for 12 months. Subsequent applications for PBS-subsidised re-treatment with etanercept will be subject to the authority conditions applying to initial treatment and will not be authorised within 12 months of the date on which treatment with etanercept was ceased.   Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application.   Where a patient with severe active polyarticular course juvenile chronic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50 mg may be prescribed	2744
9736K	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions are expected to occur with other suitable PBS-listed drugs\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3283
9617E	Continuing treatment (Whole body)  Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:  (a) who have a documented history of severe chronic plaque psoriasis; and  (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and  (c) who have demonstrated an adequate response to their most recent course of treatment with infliximab.   An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.   This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.   The most recent PASI assessment must be no more than 1 month old at the time of application.   Approval will be based on the PASI assessment of response to the most recent course of treatment with infliximab.   A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 2 repeats will be authorised.   Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.   A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3261
9617E	Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3263
9617E	Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]  Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have a documented history of severe chronic plaque psoriasis; and  (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.   Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.   A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.   A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.   Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle	3260
9617E	Initial treatment [Initial 1, Face, hand, foot (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:   (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline	3262
9617E	Initial treatment [Initial 1, Whole body (New patients  -  No prior biological agent)]  Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:  (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and  (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and  (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and  (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:  (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or  (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or  (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or  (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).   The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.   Applications for authorisation must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements.   A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg.  Up to a maximum of 3 repeats will be authorised.   Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.   A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment\nNOTE: TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS   The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab and ustekinumab, for adult patients with severe chronic plaque psoriasis.  Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept, infliximab and ustekinumab.   From 1 March 2010, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept, infliximab or ustekinumab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent.  Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.   A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 March 2010 is considered to be in their first Cycle as of 1 March 2010.   Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.   Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once.  Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  A patient who, prior to 1 March 2010, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2010.   Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.   Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle.  The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.   Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.   Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.   There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.   How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 March 2010.   There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.   (1)  Application for approval for initial treatment.   Applications for a course of initial treatment should be made in the following situations:  (i)  patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii)  patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4)  Swapping therapy' below]; or  (iii)  patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).   All applications for initial treatment will be limited to provide for a maximum of 16 weeks of treatment in the case of adalimumab and etanercept, 22 weeks of treatment in the case of infliximab and 28 weeks of treatment in the case of ustekinumab.   Grandfather patients (adalimumab and ustekinumab only).   Applications for patients who commenced treatment with adalimumab prior to 1 March 2009 or ustekinumab prior to 26 November 2009, may be made for initial PBS-subsidised treatment as continuing therapy under the initial treatment restriction (Initial 3).  These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.   Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment.  Approval will be based on the criteria included in the relevant restriction.   (2)  Assessment of response to initial treatment.   When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment.  This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.   (3)  Application for continuing treatment.   Following the completion of an initial treatment course of a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent.  Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.   For second and subsequent courses of PBS-subsidised treatment with adalimumab, etanercept, infliximab or ustekinumab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.   Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.   (4)  Swapping therapy.   Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.   Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.   Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not.  However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.   Patients who commenced treatment with adalimumab prior to 1 June 2009 or ustekinumab prior to 1 March 2010 access these interchangeability arrangements in the same way as patients who have not.   To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.   To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.   (5)  Baseline measurements to determine response.   Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.   To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.   (6)  Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.   Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity.  Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment.  The PASI assessment must be no older than 1 month at the time of application.	3259
9618F	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
9618F	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
9619G	Bone metastases from breast cancer	1035
9620H	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with lanthanum.	3103
9620H	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with lanthanum.	3104
9621J	Continuing treatment  Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:  (a) who have a documented history of severe active rheumatoid arthritis; and  (b) who have demonstrated an adequate response to treatment with abatacept; and  (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with abatacept.   An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   A maximum of 24 weeks of treatment will be approved under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.   Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.   Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial abatacept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2837
9621J	Initial 1 (new patients)  Application for initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have severe active rheumatoid arthritis; and  (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and  (c) have failed to achieve an adequate response to the following treatments:  (i) methotrexate at a dose of at least 20 mg weekly; and  (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and  (iii) a minimum of 3 months' treatment with:   -  leflunomide; or   -  cyclosporin.   If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.   If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].   The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;  AND either  (i) a total active joint count of at least 20 active (swollen and tender) joints; or  (ii) at least 4 active joints from the following list of major joints:   -  elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or   -  shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.   If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and  (3) a signed patient acknowledgement.   A maximum of 16 weeks of treatment will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.   Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with abatacept.   Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial abatacept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	3220
9736K	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions have occurred with other suitable PBS-listed drugs\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3282
9736K	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3285
9621J	Initial 2 (change or re-commencement)  Application for an initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:  (a) have a documented history of severe active rheumatoid arthritis; and  (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].   Applications for patients who have received PBS-subsidised treatment with abatacept within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.   A maximum of 16 weeks of treatment will be authorised under this restriction.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.   Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.   Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.   Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle.  Patients may re-trial abatacept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle	2835
9621J	Initial 3 ('grandfather' patients)  Initial PBS-subsidised supply for continuing treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult who:  (a) has a documented history of severe active rheumatoid arthritis; and  (b) was receiving treatment with abatacept prior to 1 November 2007; and  (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with abatacept.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the signed patient acknowledgement.   The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.   The assessment of the patient's response to a continuing course of therapy must be made within 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled in order to ensure continuity of treatment for those patients who meet the continuation criterion.   A maxiumum of 24 weeks of treatment with abatacept will be approved under this criterion.   At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion.  Up to a maximum of 5 repeats may be authorised.   Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).   Patients may qualify for PBS-subsidised treatment under this restriction once only.   Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle	2836
9622K	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with sitaxentan sodium of patients who have received approval for initial PBS-subsidised treatment with sitaxentan sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sitaxentan sodium treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3179
9622K	Initial (change or re-commencement for all patients)  Application for initial PBS-subsidised treatment with sitaxentan sodium of patients with one of the following:  (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sitaxentan sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sitaxentan sodium; OR  (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than sitaxentan sodium.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3178
9622K	Initial (new patients)  Application for initial PBS-subsidised treatment with sitaxentan sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3177
9736K	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3284
9622K	Initial (new patients)  Application for initial PBS-subsidised treatment with sitaxentan sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3176
9623L	Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia	1957
9624M	Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug, and who has demonstrated compliance with, and an ability to tolerate, this therapy.   A maximum quantity of 3 infusions will be issued with the continuing authority	2897
9624M	Initial treatment, as monotherapy, by neurologists, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient 18 years of age or older, who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years.   The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient.   A maximum quantity of 6 infusions will be issued with the initial authority	2896
9625N	Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L AND an (adjusted) serum calcium concentration at least 2.6 mmol per L, not responding to conventional treatment\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.   "Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.	2894
9625N	Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50 pmol per L, not responding to conventional therapy\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.   "Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.	2893
9626P	Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L AND an (adjusted) serum calcium concentration at least 2.6 mmol per L, not responding to conventional treatment\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.   "Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.	2894
9627Q	Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L AND an (adjusted) serum calcium concentration at least 2.6 mmol per L, not responding to conventional treatment\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.   "Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.	2894
9627Q	Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50 pmol per L, not responding to conventional therapy\nNOTE: During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved.  During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.   During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability.  Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.   "Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.	2893
9628R	Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.   Genotropin branded products (including MiniQuick) are also available for the treatment of Prader-Willi Syndrome in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit for the treatment of Prader-Willi Syndrome'\nNOTE: These guidelines may be obtained from the Department of Health and Ageing's internet site at http://www.health.gov.au/hGH, or from:   Growth Hormone Program  Access and Systems Branch  Department of Health and Ageing  GPO Box 9848  CANBERRA ACT 2601  Contact telephone number (02) 6289 7274	3133
9629T	Treatment, in combination with other antiretroviral agents, of HIV infection in an antiretroviral experienced patient with:  (a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or  (b) CD4 cell counts of less than 500 per cubic millimetre.   A patient must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 1 protease inhibitor	2956
9630W	Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B who is nucleoside analogue naive and satisfies all of the following criteria:  (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);  (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or  (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;  (3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.  Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy	3052
9631X	Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule\nNOTE: Supply of this item is through an accredited IVF/GIFT clinic. For enquiries relating to the IVF/GIFT Program, medical practitioners should contact Medicare Australia on 1800 700 270.	3293
9632Y	Schizophrenia in patients who are intolerant of other neuroleptic agents	1827
9632Y	Schizophrenia in patients who are non-responsive to other neuroleptic agents	1826
9633B	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
9633B	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
9634C	Patients naive to interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.  For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.  Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).  Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3055
9634C	Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)   Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:  (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);  (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.  The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12\nNOTE: Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:  (a) a nurse educator/counsellor for patients; and  (b) 24 hour access by patients to medical advice; and  (c) an established liver clinic; and  (d) facilities for safe liver biopsy.	3053
9635D	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with sevelamer.	3103
9635D	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with sevelamer.	3104
9636E	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with sevelamer.	3103
9636E	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with sevelamer.	3104
9637F	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6 mmol per L at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with sevelamer.	3103
9637F	Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.  Management includes initiation, stabilisation and review of therapy as required\nNOTE: Not to be used in combination with sevelamer.	3104
9638G	Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective	1912
9638G	Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy	1911
9639H	Treatment, in combination with other antiretroviral agents, of HIV infection in an antiretroviral experienced patient with:  (a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or  (b) CD4 cell counts of less than 500 per cubic millimetre.   A patient must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:  (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and  (ii) at least 1 nucleoside reverse transcriptase inhibitor; and  (iii) at least 1 protease inhibitor	2956
9640J	Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy	1256
9641K	Continuing PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of severe active polyarticular course juvenile chronic arthritis in patients 18 years or older who have demonstrated an adequate response to treatment with etanercept as manifested by:  (a) an active joint count of fewer than 10 active (swollen and tender) joints; OR  (b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; OR  (c) a reduction in the number of the following active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).   All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of the joint assessment must be provided.   Only 6 months of treatment per application will be approved. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria.   Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.   Withdrawal of treatment with etanercept should be considered in patients who have achieved and sustained complete remission of disease for 12 months. Subsequent applications for PBS-subsidised re-treatment with etanercept will be subject to the authority conditions applying to initial treatment and will not be authorised within 12 months of the date on which treatment with etanercept was ceased.   Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application.   Where a patient with severe active polyarticular course juvenile chronic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50 mg may be prescribed	2744
9642L	Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3205
9642L	Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.   If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.   Thalidomide treatment failure is defined as:  (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or  (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.   Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.   Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.   Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:  (1) less than a 25% reduction in serum or urine M protein; or  (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.   Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.   To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:  (a) the level of serum monoclonal protein; or  (b) Bence-Jones proteinuria  -  the results of 24-hour urinary light chain M protein excretion; or  (c) the serum level of free kappa and lambda light chains; or  (d) bone marrow aspirate or trephine; or  (e) if present, the size and location of lytic bone lesions (not including compression fractures); or  (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or  (g) if present, the level of hypercalcaemia, corrected for albumin concentration.   As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and  (3) duration of thalidomide and daily dose prescribed; and  (4) a signed patient acknowledgment\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3204
9643M	Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3205
9643M	Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.   If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.   Thalidomide treatment failure is defined as:  (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or  (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.   Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.   Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.   Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:  (1) less than a 25% reduction in serum or urine M protein; or  (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.   Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.   To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:  (a) the level of serum monoclonal protein; or  (b) Bence-Jones proteinuria  -  the results of 24-hour urinary light chain M protein excretion; or  (c) the serum level of free kappa and lambda light chains; or  (d) bone marrow aspirate or trephine; or  (e) if present, the size and location of lytic bone lesions (not including compression fractures); or  (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or  (g) if present, the level of hypercalcaemia, corrected for albumin concentration.   As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and  (3) duration of thalidomide and daily dose prescribed; and  (4) a signed patient acknowledgment\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3204
9644N	Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3205
9644N	Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.   If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.   Thalidomide treatment failure is defined as:  (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or  (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.   Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.   Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.   Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:  (1) less than a 25% reduction in serum or urine M protein; or  (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.   Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.   To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:  (a) the level of serum monoclonal protein; or  (b) Bence-Jones proteinuria  -  the results of 24-hour urinary light chain M protein excretion; or  (c) the serum level of free kappa and lambda light chains; or  (d) bone marrow aspirate or trephine; or  (e) if present, the size and location of lytic bone lesions (not including compression fractures); or  (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or  (g) if present, the level of hypercalcaemia, corrected for albumin concentration.   As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and  (3) duration of thalidomide and daily dose prescribed; and  (4) a signed patient acknowledgment\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3204
9645P	Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3205
9645P	Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.   If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.   Progressive disease is defined as at least 1 of the following:  (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or  (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or  (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or  (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or  (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or  (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or  (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).   Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein and less than 200 mg per 24 hour Bence-Jones proteinuria.   Thalidomide treatment failure is defined as:  (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or  (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.   Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.   Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.   Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:  (1) less than a 25% reduction in serum or urine M protein; or  (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.   Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.   The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.   To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:  (a) the level of serum monoclonal protein; or  (b) Bence-Jones proteinuria  -  the results of 24-hour urinary light chain M protein excretion; or  (c) the serum level of free kappa and lambda light chains; or  (d) bone marrow aspirate or trephine; or  (e) if present, the size and location of lytic bone lesions (not including compression fractures); or  (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or  (g) if present, the level of hypercalcaemia, corrected for albumin concentration.   As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10 g per L and urinary Bence-Jones protein undetectable or less than 200 mg per 24 hours) must be provided; and  (3) duration of thalidomide and daily dose prescribed; and  (4) a signed patient acknowledgment\nNOTE: Patients receiving lenalidomide via the PBS must be registered in the RevAccess program.	3204
9646Q	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1832
9646Q	Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with viral load of greater than 10,000 copies per mL	1833
9647R	Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy	1256
9648T	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3215
9648T	Initial (change or re-commencement for all patients)  Application for initial treatment with ambrisentan of patients with one of the following:  (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR  (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3214
9648T	Initial (grandfather patients)  Application for initial PBS-subsidised treatment with ambrisentan of patients who were receiving treatment with ambrisentan prior to 1 December 2009 and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease; OR  (c) WHO Functional Class IV primary pulmonary hypertension; OR  (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) for patients who have received less than 6 months of ambrisentan treatment at the time of application  -  a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results of the following 3 tests, where available, at the time treatment with ambrisentan was commenced:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) the date of commencement of ambrisentan treatment; and  (4) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. The number of repeats authorised will be dependent on the duration of prior ambrisentan therapy.  Where patients have received less than 6 months of non-PBS-subsidised treatment with ambrisentan, sufficient repeats to allow the patient to complete a total of 6 months of combined PBS-subsidised and non-PBS-subsidised therapy may be requested.  Where fewer than the maximum allowable number of repeats are requested at the time of application, authority approvals for the remainder of the allowable repeats may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3213
9648T	Initial (new patients)  Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (c) WHO Functional Class IV primary pulmonary hypertension; OR  (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3212
9648T	Initial (new patients)  Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3211
9649W	Continuing treatment (all patients)  Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT.   The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3215
9649W	Initial (change or re-commencement for all patients)  Application for initial treatment with ambrisentan of patients with one of the following:  (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR  (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and  (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and  (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3214
9649W	Initial (grandfather patients)  Application for initial PBS-subsidised treatment with ambrisentan of patients who were receiving treatment with ambrisentan prior to 1 December 2009 and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease; OR  (c) WHO Functional Class IV primary pulmonary hypertension; OR  (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) for patients who have received less than 6 months of ambrisentan treatment at the time of application  -  a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results of the following 3 tests, where available, at the time treatment with ambrisentan was commenced:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) the date of commencement of ambrisentan treatment; and  (4) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. The number of repeats authorised will be dependent on the duration of prior ambrisentan therapy.  Where patients have received less than 6 months of non-PBS-subsidised treatment with ambrisentan, sufficient repeats to allow the patient to complete a total of 6 months of combined PBS-subsidised and non-PBS-subsidised therapy may be requested.  Where fewer than the maximum allowable number of repeats are requested at the time of application, authority approvals for the remainder of the allowable repeats may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3213
9649W	Initial (new patients)  Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (c) WHO Functional Class IV primary pulmonary hypertension; OR  (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3212
9649W	Initial (new patients)  Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:  (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR  (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.   Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.   Applications for authorisation must be in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:  (i) RHC composite assessment; and  (ii) ECHO composite assessment; and  (iii) 6MWT; and  (3) a signed patient and prescriber acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with a PAH agent will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].   Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.   Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].   The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday)	3211
9650X	Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre	1820
9650X	Treatment of HIV infection in patients with viral load of greater than 10,000 copies per mL	1821
9714G	Treatment of infections suspected or proven to be due to a susceptible organism in patients who require a liquid formulation and in whom the syrup formulations are unsuitable	2423
9734H	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where adverse events have occurred with other suitable PBS-listed drugs\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3281
9734H	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions are expected to occur with other suitable PBS-listed drugs\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3283
9734H	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions have occurred with other suitable PBS-listed drugs\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3282
9734H	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3285
9734H	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance\nNOTE: No applications for increased maximum quantities and/or repeats will be authorised.	3284
\.


--
-- PostgreSQL database dump complete
--

